introduct
gut
microbiota
play
crucial
role
regul
physiolog
host
specif
immun
system
recent
evid
suggest
gut
microbiota
involv
liver
diseas
fatti
liver
diseas
alcohol
viral
hepat
howev
remain
unclear
whether
immunolog
respons
modul
gut
microbiota
directli
indirectli
metabolit
short
chain
fatti
acid
scfa
secondari
bile
salt
import
signal
molecul
gut
liver
far
littl
known
influenc
gut
microbiota
diat
liver
injuri
concanavalin
cona
model
mous
model
cell
mediat
autoimmun
hepatit
therefor
investig
role
gut
microbiota
liver
injuri
method
germ
free
antibiot
treat
firxfger
mice
challeng
cona
multipl
paramet
analyz
initi
peak
recoveri
phase
liver
injuri
immunophenotyp
perform
via
flow
cytometri
microbi
composit
fece
analyz
rrna
sequenc
scfa
level
estim
hepat
express
level
receptor
eg
hepat
express
well
sever
regul
bile
acid
metabol
investig
influenc
scfa
immun
cell
composit
analyz
via
fac
analysi
vitro
experi
wo
liver
sinusoid
endotheli
cell
lsec
result
germ
free
well
antibiot
treat
mice
protect
liver
injuri
antibiot
treatment
reduc
frequenc
cell
regulatori
cell
treg
follow
hepat
express
respons
antibiot
treatment
leng
effect
seen
cholesterol
lase
catalyz
convers
cholesterol
primari
bile
acid
opposit
effect
could
determin
case
bile
acid
membran
receptor
vitro
experi
indic
butyr
reduc
product
cell
lsec
conclus
clearli
verifi
link
gut
microbiota
liver
damag
reduct
via
antibiot
absenc
germ
free
mice
gut
microbiota
led
amelior
line
decreas
treg
liver
explain
less
sever
liver
damag
result
indic
analysi
scfa
bile
salt
metabol
need
determin
specif
function
pathogenesi
liver
diseas
disclosur
follow
peopl
noth
disclos
birgit
schiller
claudia
wegscheid
laura
berkhout
agnieszka
e
zarzycka
ulrich
steinhoff
nicol
fischer
gisa
tieg
background
liver
immun
organ
interpos
portal
peripher
venou
circul
immun
aberr
includ
alter
adapt
immun
respons
occur
chronic
liver
diseas
chang
mainli
explor
cell
isol
liver
peripher
venou
blood
associ
liver
diseas
sever
unclear
chang
cell
subset
tsubset
distribut
portal
vs
peripher
venou
blood
patient
chronic
hepat
c
chcv
relat
diseas
sever
method
prospect
studi
cohort
compens
chcv
patient
subject
underw
percutan
liver
biopsi
direct
portal
vein
cannul
direct
pressur
dpp
measur
portal
peripher
blood
sampl
obtain
cell
measur
multicolor
flow
cytometri
categor
central
memori
effector
memori
effector
cell
ishak
fibrosi
score
dppwere
use
marker
liver
diseas
sever
spearman
rho
r
use
correl
diseas
sever
indic
tsubsetabsolut
count
result
patient
enrol
complet
studi
mean
age
found
patient
respect
dpp
rang
mmhg
portal
blood
central
memori
tsubset
none
bset
correl
peripher
bloocf
neither
tsubset
correl
increas
dpp
portal
blood
deriv
central
memori
tsubset
trend
toward
signific
wherea
none
tsubset
show
signific
chang
interestingli
erafolood
tsubset
correl
dpp
effector
memori
tsubset
show
neg
correl
r
conclus
tsubset
show
dynam
chang
across
liver
diseas
sever
diseas
sever
associ
quantit
chang
tsubset
tsubset
distinct
portal
peripher
venou
system
tsubset
chang
appear
confin
peripher
circul
suggest
adapt
immun
cell
aberr
chcv
evolv
liver
diseas
progress
diseas
liver
contribut
chang
affect
cell
transit
portal
system
venou
circul
disclosur
follow
peopl
noth
disclos
ohad
etzion
rabab
ali
christoph
koh
elliot
levi
david
e
kleiner
shakuntala
rampertaap
sergio
weig
varun
k
takyar
ai
thanda
han
shilpa
lingala
nanci
fryzek
vanessa
theo
heller
background
aim
hepatocellular
carcinoma
hcc
often
base
chronic
inflamm
malign
transform
hepatocyt
result
liver
fibrogenesi
process
subset
helper
th
cell
involv
mediat
regul
treg
effect
specif
overexpress
cyclic
adenosin
element
modul
alpha
previous
describ
dispos
toward
th
phenotyp
model
system
lupu
erythematosu
lung
inflamm
addit
increas
thl
respons
associ
poor
prognosi
patient
chronic
liver
diseas
cld
therefor
investig
relev
cell
cld
implic
hepatocellular
carcinoma
hcc
method
transgen
mice
overexpress
cross
nemo
knockout
mice
gener
mice
impact
mediat
cld
progress
examin
proof
impact
matg
cell
adopt
transfer
bone
marrow
deriv
cell
bmdc
perform
comprehens
analysi
phenotyp
nanostr
fac
analysi
includ
result
overexpress
mice
diminish
serum
transaminas
level
associ
reduc
number
infiltr
b
dendrit
cell
consequ
fibrosi
hcc
develop
significantli
reduc
simultan
adopt
transfer
bmdc
mice
clearli
identifi
essenti
improv
cours
cld
surprisingli
scenario
nt
show
thl
phenotyp
product
express
linag
marker
contrast
hepat
characteris
express
marker
like
vitro
stimul
retino
acid
ra
contain
supernat
activ
hsc
polaris
toward
treg
phenotyp
mechanist
administr
specif
retino
acid
receptor
rar
inhibitor
reduc
treg
polaris
find
reveal
prerequisit
induc
treg
conclus
result
demonstr
overexpress
chang
inflammatori
milieu
attenu
initi
progress
cld
unexpect
studi
demonstr
transgen
induc
hsc
shift
chronic
inflamm
liver
toward
protect
treg
respons
disclosur
christian
trautwein
advisori
committe
review
panel
abbvi
msd
bm
gilead
bayer
astrazeneca
speak
teach
falk
msd
abbvi
bm
gilead
follow
peopl
noth
disclos
antj
moh
nadin
hermann
kim
ohl
mark
v
boekschoten
thoma
longerich
klau
tenbrock
francisco
javier
cubero
background
secret
cell
th
implic
autoimmun
inflammatori
diseas
provid
link
innat
adapt
immun
respons
cell
present
around
bile
duct
function
role
mechan
local
poorli
understood
method
primari
human
cholangiocyt
assess
chemokin
cytokin
secret
respons
bacteri
product
cytokin
includ
effect
cholangiocyt
cell
differenti
stabil
assess
use
media
stimul
without
result
ecoli
lp
treatment
cholangiocyt
stimul
secret
abl
attract
th
cell
migrat
assay
cholangiocyt
secret
th
polar
cytokin
includ
treat
cell
show
evid
polaris
th
cell
day
stimul
stimul
cholangiocyt
supernat
treatment
induc
depend
prolifer
cholangiocyt
increas
express
treatment
also
induc
cholangiocyt
secret
could
respons
recruit
neutrophil
macrophag
around
bile
duct
conclus
cholangiocyt
respond
prolifer
secret
th
polar
cytokin
favour
mainten
th
lineag
infiltr
cell
secret
polaris
cytokin
cholangiocyt
respons
lp
e
coli
suggest
presenc
bacteria
product
inflam
portal
tract
may
contribut
mainten
polaris
microenviron
disclosur
david
h
adam
advisori
committe
review
panel
gsk
proximagen
grantresearch
support
takeda
bioti
therapi
novimmun
chemocentryx
novimmun
bioti
therapi
patent
heldfil
bioti
therapi
bioti
therapi
bioti
therapi
bioti
therapi
bioti
therapi
bioti
therapi
bioti
therapi
bioti
therapi
follow
peopl
noth
disclos
hannah
c
jefferi
ricki
h
bhogal
jane
birtwistl
solomon
brown
simon
c
afford
ye
h
oo
backgroundaim
clinic
evid
patient
chronic
liver
diseas
increas
immunoglobulin
compar
healthi
subject
regardless
condit
patient
liver
cirrhosi
whose
risk
sever
bacteri
infect
increas
accord
progress
statu
previous
report
peripher
memori
frequenc
function
significantli
decreas
cirrhot
patient
hepatolog
hypothes
dysregul
b
cell
differenti
viabil
function
involv
excess
product
futil
immunoglobulin
thu
aim
clarifi
b
cell
function
patient
wide
rang
liver
diseas
analyz
profil
serum
immunoglobulin
subtyp
b
cell
gene
signatur
method
retrospect
analyz
igg
iga
igm
level
patient
liver
diseas
medic
record
classifi
depend
etiolog
score
five
etiolog
group
hcv
hbv
alcohol
nafld
other
patient
autoimmun
hepat
diseas
aih
pbc
exclud
use
cryopreserv
serum
also
perform
immunoglobulin
isotyp
bioplex
system
measur
mrna
level
activ
marker
pcr
isol
memori
recov
cirrhot
patient
healthi
subject
addit
examin
express
cytidin
deaminas
aid
crucial
recombin
somat
hypermut
plasma
cell
differenti
result
cirrhot
patient
elev
serum
igg
iga
regardless
underli
etiolog
chang
also
igg
iga
level
increas
progress
stage
patient
advanc
cirrhosi
b
c
tend
increas
frequenc
rel
decreas
compar
healthi
donor
hd
express
activ
marker
memori
cirrhosi
group
compar
hd
howev
aid
level
memori
increas
cirrhot
patient
compar
hd
conclus
cirrhot
patient
wide
rang
etiolog
show
increas
immunoglobulin
statu
enhanc
express
aid
memori
b
cell
disproport
immunoglobulin
profil
may
account
futil
immunoglobulin
statu
advanc
cirrhosi
disclosur
david
e
kaplan
grantresearch
support
bayer
pharmaceut
inovio
pharmaceut
follow
peopl
noth
disclos
hiroyoshi
doi
kenichi
morikawa
junichi
eguchi
takayoshi
ito
tatsuya
kanto
hitoshi
yoshida
interplay
macrophag
cell
shape
inflammatori
respons
appropri
balanc
cell
essenti
resolut
fibrosi
shown
model
organ
reject
transplant
polaris
result
antigen
present
profession
cell
helper
lymphocyt
induc
chronic
liver
fibrosi
carbon
tetrachlorid
inject
mice
defect
last
step
phagocytosi
counterpart
hypothesi
phagocytosi
instrument
antigen
present
correct
cytokin
environ
correct
cell
polaris
occur
increas
damag
observ
mice
lack
phagocyt
cargo
digest
altogeth
imbal
macrophag
polaris
tip
phenotyp
find
prompt
us
investig
respons
order
investig
liver
harvest
distinct
time
point
suspens
analysi
carri
use
qpcr
immunohistochemistri
total
liver
extract
liver
section
respect
studi
show
absenc
correct
phagocyt
cargo
digest
impair
respons
result
defect
product
cytokin
observ
homeostat
condit
also
mrna
express
untreat
mice
lack
phagocyt
cargo
process
vs
wild
type
mice
fold
possibl
point
gener
defect
polaris
mrna
express
untreat
mice
lack
phagocyt
cargo
process
vs
wild
type
mice
fold
also
prolifer
compart
observ
mice
lack
last
step
phagocytosi
recoveri
immunohistochemistri
vs
cellsfield
view
magnif
micegroup
investig
requir
determin
mechan
phagocytosi
act
respons
whether
defect
phagocytosi
correl
uncontrol
expans
specif
subtyp
regener
liver
understand
dynam
control
relationship
may
great
impact
elucid
novel
potenti
therapeut
target
scar
process
disclosur
follow
peopl
noth
disclos
lara
campana
sarah
e
mok
antonella
pellicoro
stuart
j
forb
john
p
iredal
introduct
unregul
inflamm
liver
drive
onset
progress
rang
aetiolog
divers
chronic
liver
diseas
ultim
promot
format
neoplast
tumour
hepatocellular
carcinoma
hcc
key
step
hepat
inflamm
recruit
leukocyt
via
hepat
sinusoid
endotheli
cell
hsec
member
tetraspanin
famili
previous
shown
play
role
leukocyt
recruit
vascular
endothelia
howev
presenc
previous
explor
hepat
sinusoid
endothelium
consequ
understand
express
function
liver
could
identifi
new
therapeut
target
limit
hepat
inflamm
method
use
immunohistochemistri
dual
colour
immunofluoresc
studi
western
blot
determin
express
normal
liver
chronic
liver
diseas
hcc
elisa
studi
use
determin
regul
express
hsec
growth
factor
proinflammatori
cytokin
hepatoma
cell
line
supernat
adhes
assay
use
studi
function
role
adhes
jurkat
cell
human
cell
line
hsec
monolay
result
increas
protein
express
associ
area
fibrosi
neovascularis
particularli
parenchym
liver
diseas
alcohol
liver
diseas
ald
steatohepat
nash
well
hcc
shown
highli
express
hsec
vivo
express
maintain
cultur
hsec
vitro
express
hsec
upregul
stimul
supernat
tumourigen
growth
factor
hepatocyt
growth
factor
hgf
vascular
endotheli
growth
factor
vegf
also
found
molecul
cluster
around
adher
cell
follow
captur
physiolog
flow
hsec
monolay
furthermor
antibodi
significantli
reduc
adher
cell
flow
condit
conclus
demonstr
first
time
express
human
sinusoid
endotheli
cell
neovessel
rang
chronic
liver
diseas
hcc
also
demonstr
hsec
maintain
vitro
upregul
factor
play
import
function
role
cell
adhes
hsec
taken
togeth
find
understand
hepat
inflamm
lymphocyt
recruit
liver
chronic
diseas
carcinogenesi
could
form
basi
potenti
therapeut
target
disclosur
follow
peopl
noth
disclos
daniel
patten
jame
c
wadkin
sivesh
k
kathir
kamarajah
chri
j
weston
shishir
shetti
background
aim
new
daa
treatment
hcv
infect
highli
efficaci
yet
costli
nevertheless
time
move
treat
select
priorit
patient
strategi
includ
treatment
hcv
infect
patient
end
lifetim
model
real
life
hcv
infect
patient
enrol
piter
cohort
use
compar
two
ifn
free
treatment
polici
polici
treat
patient
cohort
fibrosi
stage
polici
treat
first
patient
priorit
easl
hcv
clinic
practic
guidelin
wait
treat
remain
patient
would
reach
stage
dynam
lifetim
hcv
diseas
progress
relat
cost
evalu
adapt
markov
model
lifetim
horizon
health
care
system
perspect
real
life
patient
enter
model
proper
age
fibrosi
stage
follow
model
lifetim
total
medic
cost
qali
increment
ratio
icer
evalu
probabilist
scenario
analys
perform
result
analysi
base
price
hcv
regimen
treat
fibrosi
stage
vs
treat
priorit
patient
first
add
increment
cost
increment
qali
icer
per
qali
gain
mont
carlo
scenario
simul
arrang
plot
report
accept
curv
ceac
icer
increment
cost
increment
qali
polici
vs
polici
remain
cost
effect
simul
assum
scenario
analysi
differ
icer
calcul
fourteen
price
combin
differenti
fibrosi
stage
discount
rate
base
price
treatment
regimen
remain
unvari
time
patient
moder
sever
liver
diseas
stage
wherea
decreas
combin
discount
price
patient
stage
appli
icer
sensit
price
variat
patient
stage
price
level
lower
base
price
appli
patient
respect
polici
result
domin
less
cost
greater
benefit
polici
polici
becom
cost
effect
simul
domin
sensit
analysi
conclus
treat
hcv
infect
fibrosi
stage
appear
improv
health
outcom
cost
effect
increas
significantli
lower
treatment
price
earli
fibrosi
stage
disclosur
maurizia
r
brunetto
advisori
committe
review
panel
gilead
janssen
abbvi
speak
teach
roch
gilead
squibb
abbott
roch
janssen
alfredo
di
leo
advisori
committe
review
panel
thd
speak
teach
abbvi
msd
gilead
roch
italfarmaco
giovanni
raimondo
speak
teach
bm
gilead
roch
merck
janssen
bayer
msd
carlo
ferrari
advisori
committe
review
panel
gilead
roch
abbvi
bm
merck
arrowhead
grantresearch
support
gilead
roch
janssen
gloria
taliani
advisori
committe
review
panel
abbvi
janssen
gilead
bm
merck
roch
speak
teach
roch
merck
bm
gilead
jannsen
abbvi
pierluigi
blanc
consult
abbvi
grantresearch
support
gilead
speak
teach
bm
giovanni
b
gaeta
advisori
committe
review
panel
janssen
merck
abbvi
roch
speak
teach
bm
gilead
merck
luchino
chessa
board
membership
abbvi
speak
teach
bm
jannsen
erica
villa
advisori
committe
review
panel
msd
abbvi
gsk
gilead
speak
teach
novarti
pietro
andreon
advisori
committe
review
panel
gilead
abbvi
intercept
speak
teach
gilead
bm
gabriella
verucchi
advisori
committe
review
panel
gilead
abbvi
janssen
viiv
speak
teach
merck
co
gilead
bristol
meyer
squibb
abbvi
marcello
persico
advisori
committe
review
panel
abbvi
grant
research
support
gilead
massimo
zuin
board
membership
abbvi
speak
teach
roch
massimo
puoti
advisori
committe
review
panel
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
speak
teach
bm
bm
bm
bm
alfredo
alberti
advisori
committe
review
panel
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
abbvi
janssen
grantresearch
support
merck
gilead
merck
gilead
merck
gilead
merck
gilead
abbvi
janssen
speak
teach
novarti
bm
novarti
bm
novarti
bm
novarti
bm
maria
g
rumi
grantresearch
support
msd
speak
teach
msd
bm
gilead
abbvi
follow
peopl
noth
disclos
loreta
kondili
federica
romano
matteo
ruggeri
stefano
rosato
anna
linda
zignego
alessia
ciancio
guglielmo
borgia
teresa
santantonio
antonio
gasbarrini
elk
ern
donatella
ieluzzi
francesco
p
russo
maria
vinci
carmin
coppola
liliana
chemello
salvator
madonia
gerardo
nardon
vincenzo
de
maria
marco
massari
giusepp
montalto
giusepp
foti
americo
cicchetti
antonio
craxi
stefano
vella
background
cur
hcv
treatment
regimen
associ
reduct
rate
liver
cancer
whether
achiev
sustain
virolog
respons
follow
treatment
antivir
daa
regimen
yield
similar
benefit
unknown
object
studi
examin
associ
treatment
complet
daa
sofosbuvir
sof
risk
incid
liver
cancer
data
method
us
administr
claim
data
januari
march
identifi
adult
hcv
patient
dispens
least
week
therapi
evid
subsequ
hcv
treatment
comparison
identifi
adult
patient
diagnos
hcv
without
evid
hcv
treatment
activ
time
sof
approv
includ
patient
minimum
month
enrol
evid
prior
liver
cancer
baselin
hazard
ratio
hr
estim
risk
incid
liver
cancer
associ
complet
therapi
calcul
adjust
baselin
confound
use
cox
proport
hazard
method
result
patient
complet
treatment
like
year
male
cirrhosi
baselin
vs
untreat
hcv
patient
median
shorter
vs
untreat
patient
day
respect
stratifi
baselin
cirrhosi
statu
absolut
cumul
incid
rate
confid
interv
ci
differ
untreat
patient
per
py
respect
among
per
py
respect
among
cirrhot
signific
interact
observ
treatment
effect
baselin
cirrhosi
adjust
age
gender
cirrhosi
baselin
condit
signific
p
associ
observ
sof
complet
liver
cancer
ci
absenc
associ
observ
sof
treatment
regimen
ci
ci
respect
conclus
cohort
studi
complet
treatment
independ
associ
risk
incid
liver
cancer
regardless
ifn
strongest
risk
factor
liver
cancer
baselin
cirrhosi
older
age
male
gender
futur
cohort
studi
examin
liver
cancer
risk
follow
complet
daa
therapi
disclosur
anand
p
chokkalingam
employ
gilead
scienc
stock
sharehold
gilead
scienc
amanda
w
singer
employ
gilead
scienc
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
laura
telep
employ
gilead
scienc
stock
sharehold
gilead
scienc
background
aim
hcv
recombin
strain
st
petersburg
variant
report
sever
countri
preval
may
underestim
vast
major
standard
genotyp
assay
base
core
sequenc
far
data
recombin
viru
israel
clinic
import
hcv
recombin
genotyp
lie
upon
mistakenli
identifi
treat
genotyp
treatment
insuffici
genotyp
studi
report
first
case
recombin
strain
israel
addit
aim
assess
abil
abbott
realtim
hcv
genotyp
ii
ruo
gtii
assay
detect
recombin
strain
comparison
analys
method
store
sera
sampl
chronic
hcv
patient
viral
load
unitml
test
central
laboratori
haifa
western
galile
clalit
health
servic
hcv
genotyp
perform
sampl
use
abbott
gtii
commerci
kit
accord
manufactur
instruct
abbott
gtii
assay
amplifi
detect
portion
core
region
sampl
recombin
strain
detect
analyz
analys
result
genotyp
distribut
addit
sampl
sera
diagnos
recombin
strain
nine
patient
immigr
born
former
ussr
mean
age
year
old
base
analys
perform
sampl
show
sampl
inde
recombin
genotyp
chimera
break
point
meanwhil
follow
patient
reveal
two
patient
relaps
week
pegifn
therapi
two
patient
show
respons
svr
obtain
one
patient
week
daclatasvir
sofosbuvir
therapi
patient
ongo
treat
daa
conclus
found
rate
recombin
hcv
b
hcv
genotyp
genotyp
test
studi
awar
rais
possibl
patient
identifi
hcv
patient
recommend
use
genotyp
assay
amplifi
core
region
hcv
genom
presenc
recombin
viru
may
affect
outcom
antivir
treatment
disclosur
rasha
n
daniel
employ
clalit
health
servic
follow
peopl
noth
disclos
mira
barak
orli
azulay
eli
zuckerman
kidney
transplant
use
antivir
therapi
hbv
hcv
recipi
lower
patient
graft
surviv
recipi
last
two
decad
nucleo
id
analogu
wide
use
hbv
patient
wherea
therapi
use
smaller
proport
hcv
patient
aim
updat
impact
hbv
hcv
patient
graft
surviv
assess
prognost
impact
viral
control
hbv
hcv
method
first
patient
graft
surviv
prospect
record
french
nationwid
databas
kidney
recipi
accord
serolog
statu
second
calcul
base
type
error
power
random
sampl
least
hbv
hcv
patient
record
investig
evalu
influenc
viral
control
viral
control
defin
low
dna
level
upon
antivir
therapi
inact
carrier
hbv
patient
svr
spontan
viral
erad
hcv
recipi
result
recipi
median
age
year
analyz
posit
hcv
antibodi
posit
hbsag
non
infect
patient
hcv
kidney
recipi
significantli
lower
patient
surviv
hbv
p
recipi
p
without
signific
differ
hbv
recipi
also
significantli
lower
graft
surviv
hbv
p
adjust
age
recipi
age
donor
time
cold
ischemia
extent
dr
match
hcv
antibodi
remain
independ
prognost
factor
mortal
hr
ci
p
b
patient
record
investig
viral
control
obtain
almost
hbv
recipi
case
hcv
patient
viral
control
observ
case
among
antivir
therapi
hcv
patient
patient
viral
control
higher
patient
vs
graft
vs
without
multivari
analysi
hcv
infect
remain
independ
associ
mortal
case
viral
replic
wherea
hcv
recipi
neg
pcr
similar
patient
graft
surviv
patient
conclus
control
viral
replic
allow
obtain
similar
patient
graft
surviv
hbv
hcv
recipi
comparison
recipi
convers
uncontrol
hcv
infect
still
associ
decreas
patient
graft
surviv
disclosur
fontain
board
membership
abbvi
gilead
bm
janssen
independ
contractor
gilead
bm
msd
roch
janssen
laurent
alric
board
membership
schere
plough
schere
plough
schere
plough
schere
plough
consult
msd
grantresearch
support
abbvi
speak
teach
roch
bm
gilead
roch
bm
gilead
roch
bm
gilead
roch
bm
gilead
msd
abbvi
stanisla
pol
board
membership
boehring
ingelheim
tibotec
janssen
cilag
gilead
glaxo
smith
kline
roch
msd
novarti
grant
research
support
gilead
roch
msd
speak
teach
boehring
ingelheim
tibotec
janssen
cilag
gilead
roch
msd
novarti
philipp
mathurin
board
membership
msd
bm
gilead
abvi
verlyx
consult
roch
bayer
follow
peopl
noth
disclos
benjamin
legendr
julien
labreuch
alexandr
louvet
corinn
antoin
christoph
legendr
marc
hazzan
nassim
kamar
sebastien
dharanc
guillaum
lassailli
florent
artru
alain
duhamel
background
rel
small
proport
hcv
infect
person
develop
hepat
decompens
hepatocellular
carcinoma
even
sever
year
infect
predict
develop
complic
help
priorit
treatment
decis
method
erchiv
calcul
three
commonli
use
clinic
score
liver
diseas
sever
determin
risk
overal
mortal
hepat
decompens
hd
hepatocellular
carcinoma
hcc
year
diagnosi
hcv
exclud
hd
hcc
baselin
hiv
hbsag
receiv
hcv
treatment
day
result
among
hcv
infect
person
identifi
lowest
cp
meld
score
develop
hd
hcc
die
within
year
hcv
diagnosi
howev
proport
increas
fold
next
stratum
score
year
one
fold
year
stratum
mortal
hd
hcc
highest
higher
strata
year
diagnosi
tabl
conclus
mortal
complic
infrequ
first
year
hcv
diagnosi
person
low
liver
diseas
sever
score
exponenti
increas
increas
time
increas
sever
score
data
may
help
determin
optim
time
initi
treatment
minim
mortal
liver
diseas
complic
tabl
proport
person
die
develop
hepat
decompens
hepatocellular
carcinoma
year
diagnosi
hcv
infect
erchiv
disclosur
adeel
butt
grantresearch
support
gilead
abbvi
follow
peopl
noth
disclos
yanji
ren
background
high
rate
hepat
c
hcv
reinfect
follow
success
treatment
among
men
sex
men
msm
report
europ
data
avail
us
assess
incid
primari
hcv
infect
reinfect
follow
success
treatment
among
hiv
posit
msm
san
diego
method
perform
retrospect
cohort
analysi
hcv
primari
incid
reinfect
incid
success
treatment
among
msm
largest
hiv
clinic
san
diego
ucsd
owen
clinic
incid
hcv
infect
assess
among
msm
neg
test
defin
posit
test
start
defin
posit
hcv
rna
pcr
test
date
sustain
viral
respons
svr
among
msm
treat
hcv
analysi
patient
censor
reinfect
last
neg
test
april
incid
calcul
use
surviv
time
method
result
among
baselin
neg
patient
seroconvers
occur
risk
lead
overal
primari
hcv
incid
per
ci
time
period
among
msm
achiev
svr
follow
hcv
treatment
becam
median
time
year
date
svr
estim
reinfect
rate
py
ci
two
individu
reinfect
occur
inject
drug
use
report
share
syring
equip
sinc
svr
third
individu
histori
drug
use
three
hcv
patient
well
control
hiv
infect
conclus
hcv
reinfect
incid
among
msm
san
diego
fold
higher
primari
hcv
incid
increas
effort
prevent
reinfect
among
msm
requir
disclosur
natasha
k
martin
grantresearch
support
gilead
speak
teach
abbvi
merck
gilead
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
charl
hick
advisori
committe
review
panel
bristol
myer
squibb
gilead
scienc
merck
janssen
virolog
viiv
gsk
follow
peopl
noth
disclos
antoin
chaillon
thoma
c
martin
davey
smith
sanjay
r
mehta
craig
ballard
bradford
colwel
francesca
torriani
luca
hill
christoph
mathew
edward
r
cachay
aim
natur
substitut
rass
report
highli
variabl
preval
across
differ
hcv
genotyp
gt
investig
frequenc
natur
rass
role
treatment
efficaci
larg
databas
includ
main
method
rass
analys
patient
pt
perform
protocol
sampl
rass
defin
major
result
overal
pt
show
natur
rass
independ
cirrhosi
import
differ
gtsubtyp
frequent
show
rass
respect
high
preval
never
found
major
rass
preval
also
show
highest
preval
rass
respect
major
rass
detect
common
major
ra
major
sofosbuvir
ra
never
found
put
rass
exclus
detect
often
associ
p
covari
analysi
notabl
preval
higher
respect
pt
respect
among
pt
resist
test
gene
show
multipl
rass
preval
associ
rass
mainli
pt
show
rass
lastli
pt
treat
hibitor
studi
evalu
potenti
role
natur
among
pt
none
major
rass
baselin
minor
rass
reach
sustain
viral
respons
among
cirrhot
pt
show
major
rass
chang
two
treat
regimen
without
ribavirin
experienc
virolog
failur
contrari
receiv
ribavirin
reach
svr
conclus
natur
rass
common
across
pt
show
resist
though
major
mutat
seem
clinic
relev
thu
qualit
identif
major
natur
rass
rather
requir
properli
guid
therapi
disclosur
laura
nicolini
board
membership
abbvi
speak
teach
abbvi
gilead
msd
pietro
andreon
advisori
committe
review
panel
gilead
abbvi
intercept
speak
teach
gilead
bm
dant
romagnoli
advisori
committe
review
panel
abbvi
massimo
puoti
advisori
committe
review
panel
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
speak
teach
bm
bm
bm
bm
giuliano
rizzardini
grantresearch
support
msd
gilead
speak
teach
bm
msd
gilead
abbvi
janssen
gloria
taliani
advisori
committe
review
panel
abbvi
janssen
gilead
bm
merck
roch
speak
teach
roch
merck
bm
gilead
jannsen
abbvi
massimo
andreoni
advisori
committe
review
panel
gilead
bm
janssen
tibotec
abbvi
viiv
manag
posit
msd
mario
angelico
advisori
committe
review
panel
gilead
janssen
grantresearch
support
roch
speak
teach
gsk
roch
gilead
novarti
bm
bayer
francesca
speak
teach
merck
sharp
dohm
gilead
janssen
abbvi
viiv
roch
diagnostici
bm
follow
peopl
noth
disclos
valeria
cento
maria
chiara
sorbo
ada
bertoli
ilaria
lenci
ennio
polilli
chiara
masetti
laura
gianserra
elisabetta
teti
elisa
biliotti
carlo
f
magni
marianna
aragri
valeria
mich
michela
meli
simona
marenco
vincenza
calvaruso
stefania
paolucci
fausto
baldanti
filomena
morisco
massimo
siciliano
valeria
pace
palitti
bianca
bruzzon
nicola
coppola
tina
ruggiero
miriam
lichtner
barbara
menzaghi
nerio
lapadr
velia
chiara
di
maio
francesco
de
leonardi
martina
milana
pierluigi
cacciator
alessandro
pieri
loredana
sarmati
simona
landonio
antonio
gasbarrini
antonio
craxi
vincenzo
vullo
adriano
pellicelli
sergio
babudieri
caterina
pasquazzi
giustino
parruti
carlo
f
perno
background
aim
hepat
c
viru
hcv
common
caus
cirrhosi
hepatocellular
carcinoma
hcc
indic
liver
transplant
lt
unit
state
recent
advanc
hcv
brought
regimen
sustain
virolog
respons
svr
rate
although
gener
popul
screen
previous
found
strategi
us
popul
must
consid
aim
compar
cost
effect
three
screen
strategi
hcv
screen
sa
screen
base
birth
cohort
screen
bc
screen
base
risk
regardless
age
hr
method
markov
model
estim
natur
histori
hcv
evalu
three
hcv
screen
strategi
sa
bc
hr
lifetim
horizon
us
gener
popul
base
age
risk
statu
cohort
model
health
state
includ
fibrosi
stage
decompens
cirrhosi
hcc
lt
death
probabl
progress
downstream
complic
base
presenc
absenc
viru
svr
hcv
antibodi
preval
high
risk
patient
vari
specif
cohort
treatment
approv
daa
exact
regimen
durat
base
genotyp
stage
liver
diseas
cirrhosi
across
cohort
assum
seen
annual
primari
care
provid
hcv
ab
patient
detect
hcv
rna
chc
patient
awar
infect
svr
rate
transit
probabl
util
cost
deriv
literatur
increment
cost
effect
ratio
compar
sa
two
screen
strategi
sensit
analys
test
impact
key
model
driver
result
screen
strategi
led
identif
new
case
hcv
sa
million
bc
million
hr
million
strategi
screen
cost
billion
lead
million
qali
bc
hr
cost
billion
billion
million
qali
compar
bc
screen
led
addit
million
qali
save
billion
compar
hr
sa
led
million
addit
qali
save
billion
context
sa
strategi
domin
bc
hr
strategi
addit
qali
cost
save
conclus
era
highli
effect
regimen
oral
daa
screen
entir
u
popul
treat
activ
viremia
project
disclosur
deidr
blissett
consult
mapl
health
group
rachel
beckerman
consult
gilead
scienc
follow
peopl
noth
disclos
zobair
younossi
rob
blissett
linda
henri
youssef
younossi
sharon
hunt
introduct
aberr
express
biliari
marker
cytokeratin
epitheli
cell
adhes
molecul
epcam
thought
reflect
abnorm
regener
recruit
hepat
progenitor
cell
aim
describ
express
biliari
marker
hepatocyt
patient
compens
cirrhosi
investig
potenti
influenc
decompens
event
hepatocellular
carcinoma
occurr
patient
method
among
patient
cirrhosi
enrol
french
prospect
anr
cirvir
cohort
select
patient
avail
liver
biopsi
perform
within
year
inclus
liver
biopsi
activ
grade
potenti
steatohepat
epcam
immunostain
assess
independ
pathologist
biopsi
consid
posit
least
foci
hepatocyt
observ
categor
extens
one
sever
cirrhot
nodul
show
posit
stain
hepatocyt
epcam
consid
posit
least
one
foci
hepatocyt
stain
patient
prospect
follow
influenc
biliari
marker
decompens
event
ascit
hepat
encephalopathi
bleed
hepatocellular
carcinoma
occurr
studi
use
univari
analys
cox
multivari
analysi
result
among
patient
elig
studi
men
mean
age
biopsi
show
hepatocyt
patient
among
stain
extens
biopsi
posit
epcam
patient
express
marker
associ
lower
platelet
count
higher
afp
level
histolog
steatohepat
month
patient
experienc
least
one
decompens
event
hcc
diagnos
patient
extens
stain
independantli
associ
occurr
decompens
event
hr
along
low
albumin
level
absenc
sustain
virolog
respons
epcam
express
independantli
associ
hcc
occurr
hr
along
older
age
low
prothombin
time
steatohepat
observ
biopsi
associ
subsequ
decompens
hcc
occurr
conclus
aberr
express
epcam
hepatocyt
assess
liver
biops
patient
compens
cirrhosi
reflect
cirrhosi
stage
prone
develop
cirrhosi
complic
disclosur
nathali
advisori
committe
review
panel
roch
speak
teach
bm
gilead
bayer
advisori
committe
review
panel
roch
gilead
consult
lfb
biomedica
speak
teach
gilead
janssen
bm
roch
abbvi
follow
peopl
noth
disclos
dominiqu
wendum
richard
layes
valeri
bourcier
fatiha
merabten
carol
cagnot
emmanuel
sauc
pierr
bedossa
benoit
terri
janick
selv
paulett
nathali
sturm
christoph
sattonnet
pierr
nahon
mariann
ziol
hepat
c
viru
hcv
screen
taken
new
import
result
updat
guidelin
new
cur
therapi
rew
studi
assess
hcv
homeless
popul
includ
women
shadow
cohort
san
francisco
recruit
studi
homeless
unstabl
hous
women
sampl
systemat
conduct
free
meal
program
homeless
shelter
singl
room
occup
hotel
women
oversampl
studi
inclus
criteria
includ
femal
sex
age
year
lifetim
histori
hous
instabl
slept
public
place
shelter
stay
seri
peopl
place
sleep
paper
estim
preval
correl
hcv
exposur
proport
unawar
statu
assess
correl
outcom
among
women
posit
hiv
coinfect
consist
recruit
strategi
half
sampl
major
women
cohort
born
report
recent
past
inject
drug
use
idu
factor
independ
associ
posit
born
earlier
adjust
odd
ratio
aor
ci
histori
idu
aor
ci
number
psychiatr
diagnos
aor
ci
women
symptom
current
depress
lower
adjust
odd
hcv
seroposit
aor
ci
overal
report
never
hcv
test
among
posit
unawar
statu
factor
independ
associ
women
know
hcv
statu
control
birth
cohort
statu
idu
includ
lower
incom
per
increas
aor
ci
fewer
psychiatr
diagnosi
per
diagnosi
aor
ci
recent
cocain
use
ye
vs
aor
ci
result
fill
import
gap
inform
regard
hcv
among
homeless
women
confirm
need
enhanc
screen
popul
high
proport
histori
drug
use
psychiatr
problem
due
age
risk
profil
high
probabl
women
studi
infect
decad
thu
signific
liver
diseas
associ
mental
ill
hcv
suggest
addit
increas
screen
augment
mental
health
care
support
may
need
enhanc
treatment
success
disclosur
kimberli
page
grantresearch
support
nih
gilead
cdc
follow
peopl
noth
disclos
michel
yu
jennif
cohen
jennif
evan
martha
shumway
elis
riley
introduct
hepascor
serum
test
provid
clinic
use
data
regard
stage
liver
fibrosi
subsequ
clinic
outcom
chronic
liver
diseas
aim
studi
determin
chang
hepascor
result
time
delta
hepascor
could
accur
predict
chang
risk
liver
relat
death
lrd
hepatocellular
carcinoma
hcc
liver
decompens
ld
composit
endpoint
lrd
hcc
ld
hcv
infect
method
chronic
hepat
c
patient
attend
depart
hepatolog
sir
charl
gairdner
hospit
western
australia
two
hepascor
test
perform
studi
abil
baselin
delta
hepascor
test
predict
liver
relat
outcom
assess
use
univari
multivari
cox
regress
auroc
analysi
result
patient
year
follow
develop
hepatocellular
carcinoma
liver
decompens
andor
liver
relat
death
baselin
hepascor
p
delta
hepascor
independ
associ
composit
endpoint
baselin
hepascor
associ
signific
increas
lrd
ld
hcc
patient
baselin
hepascor
subsequ
improv
delta
hepascor
significantli
decreas
risk
lrd
ld
composit
endpoint
compar
baselin
hepascor
stabl
hepascor
valu
delta
deterior
hepascor
valu
delta
optimum
time
interv
hepascor
test
determin
compar
improv
delta
hepascor
stabl
wors
delta
hepascor
combin
baselin
hepascor
delta
hepascor
significantli
predict
improv
liver
relat
outcom
time
test
year
conclus
studi
show
improv
hepascor
valu
significantli
associ
reduc
rate
mortal
morbid
find
implic
patient
manag
follow
hcv
erad
may
determin
time
reduc
need
varic
hcc
screen
disclosur
angu
w
jeffrey
patent
heldfil
uwa
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
yi
huang
bastiaan
de
boer
gerri
c
macquillan
david
j
speer
john
joseph
gari
p
jeffrey
background
global
viral
hepat
strategi
set
goal
elimin
chronic
hepat
c
hcv
attain
goal
health
care
commun
need
treat
larg
number
patient
previous
diagnos
hcv
treatment
defer
due
contraind
potenti
advers
effect
previou
therapi
better
understand
estim
number
person
diagnos
yet
treat
hcv
allow
improv
plan
budget
futur
care
larg
popul
object
analyz
demograph
comorbid
condit
person
treat
vs
treat
hcv
therapi
identifi
signific
predictor
receiv
treatment
hcv
method
retrospect
cohort
studi
kaiser
permanent
southern
california
kpsc
larg
health
mainten
organ
includ
approxim
million
member
inclus
criteria
year
old
diagnosi
code
posit
lab
test
result
hcv
rna
month
continu
membership
index
date
index
date
defin
date
first
treatment
cours
first
hcv
diagnosi
icd
code
posit
hcv
rna
test
exclus
criteria
hcv
diagnosi
andor
diagnosi
hepatocellular
carcinoma
hcc
index
date
diagnosi
code
andor
lab
test
comorbid
ill
repres
rel
absolut
contraind
hcv
treatment
therapi
determin
multivari
logist
regress
use
determin
predictor
treatment
vs
result
patient
receiv
treatment
receiv
treatment
demograph
factor
associ
receiv
treatment
shown
tabl
conclus
larg
epidemiolog
studi
identifi
largest
patient
categori
remain
untreat
hcv
help
budget
plan
futur
treatment
popul
new
well
toler
therapi
factor
associ
receiv
hcv
disclosur
lisa
nyberg
grantresearch
support
merck
gilead
abbvi
craig
cheetham
grantresearch
support
bm
ander
h
nyberg
grantresearch
support
gilead
paid
institut
abbvi
paid
institut
follow
peopl
noth
disclos
xia
li
yang
kevin
chiang
susan
caparosa
zobair
younossi
background
wisteria
floribunda
bind
protein
report
noninvas
marker
liver
fibrosi
predictor
hepatocellular
carcinoma
hcc
chronic
hepat
c
chc
patient
studi
aim
assess
associ
hcc
develop
chc
patient
use
sampl
collect
method
particip
studi
cohort
serum
level
evalu
total
sampl
consist
hcc
case
control
case
control
serial
sampl
collect
variou
time
throughout
associ
hcc
analyz
use
multivari
logist
regress
model
stratifi
accord
time
sampl
collect
hcc
diagnosi
area
receiv
oper
characterist
auroc
curv
use
evalu
predict
accuraci
model
integr
risk
factor
predict
hcc
risk
result
level
sampl
closer
hcc
diagnosi
higher
collect
farther
hcc
diagnosi
howev
level
consist
low
time
control
sampl
analysi
use
sampl
collect
variou
occas
show
level
associ
hcc
risk
manner
adjust
gender
age
serum
alt
ast
afp
hcv
rna
level
hcv
genotyp
adjust
odd
ratio
ci
respect
coi
compar
coi
refer
stratifi
time
sampl
collect
hcc
diagnosi
associ
level
hcc
strongest
period
decreas
longer
time
compar
level
coi
adjust
odd
ratio
ci
level
coi
respect
predict
hcc
within
year
year
year
year
auroc
incorpor
level
predictor
respect
predict
hcc
within
period
conclus
level
significantli
predict
hcc
develop
patient
chronic
hepat
c
associ
predict
accuraci
stronger
sampl
collect
closer
hcc
diagnosi
collect
farther
hcc
diagnosi
disclosur
yong
yuan
employ
bristol
myer
squibb
compani
follow
peopl
noth
disclos
chang
chen
hu
lin
jessica
liu
jen
su
chiang
lu
wang
masaaki
korenaga
masashi
mizokami
chen
lee
yang
purpos
hiv
popul
greater
risk
hcv
due
share
mode
transmiss
compar
hivhcv
like
result
fibrosi
cirrhosi
high
rate
cure
possibl
hivhcv
patient
due
modern
antivir
daa
analysi
evalu
hcv
test
treatment
pattern
set
identifi
opportun
improv
outcom
coinfect
patient
method
use
opera
databas
collabor
caregiv
clinic
state
hiv
individu
initi
hiv
antiretrovir
therapi
art
first
time
identifi
follow
data
freez
death
loss
prospect
collect
data
extract
electron
health
record
result
hiv
patient
evalu
hcv
prior
art
initi
hcv
hcv
viral
load
diagnosi
treatment
record
histori
resolv
hcv
start
art
hcv
abpati
reevalu
hcv
result
new
hcv
diagnos
includ
confirm
seroconvers
baselin
hcv
case
diagnos
daa
era
later
ever
treat
hcv
commonli
hiv
art
initi
daa
era
median
time
hcv
diagnosi
treatment
month
iqr
overal
treat
case
receiv
therapi
includ
treat
later
conclus
patient
hiv
popul
evalu
hcv
hcv
treatment
common
daa
era
major
case
remain
untreat
treatment
delay
also
commmon
given
import
control
hcv
diseas
progress
coinfect
patient
exist
effect
therapi
greater
effort
made
treat
coinfect
patient
continu
monitor
hcv
among
patient
baselin
disclosur
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
follow
peopl
noth
disclos
cassidi
henegar
jennif
fusco
philip
lackey
liver
elastographi
wide
use
assess
liver
fibrosi
patient
chronic
hepat
c
also
recommend
monitor
regress
liver
fibrosi
success
antivir
therapi
studi
earli
chang
liver
stiff
initi
antivir
treatment
studi
popul
compris
patient
chronic
hepat
c
mean
age
sd
year
metavir
fibrosi
stage
n
n
genotyp
gt
n
n
n
mean
bmi
sd
patient
treat
oral
regimen
prior
therapi
week
initi
antivir
treatment
fibrosi
stage
assess
transient
elastographi
use
touch
devic
echosen
pari
franc
classifi
accord
metavir
score
system
valu
liver
stiff
defin
kpa
f
kpa
f
kpa
f
mean
liver
stiff
baselin
kpa
decreas
kpa
perform
week
week
cutoff
valu
appli
baselin
appli
initi
antivir
therapi
follow
result
obtain
within
week
initi
treatment
fibrosi
stage
improv
least
one
stage
patient
remain
stabl
worsen
patient
classifi
baselin
classifi
week
patient
classifi
baselin
classifi
week
patient
baselin
classifi
week
decreas
liver
stiff
correl
baselin
ast
alt
level
studi
mark
decreas
liver
stiff
observ
within
two
week
initi
antivir
therapi
pathophysiolog
point
view
clinic
signific
decreas
liver
fibrosi
within
short
period
time
seem
imposs
therefor
assum
decreas
caus
resolut
inflammatori
activ
within
liver
current
valu
assess
fibrosi
stage
patient
chronic
hepat
c
transient
elastographi
obtain
patient
fibrosi
activ
inflamm
therefor
data
clearli
indic
lower
valu
liver
stiff
appropri
monitor
liver
fibrosi
initi
antivir
therapi
disclosur
michael
gschwantler
advisori
committe
review
panel
janssen
bm
gilead
abbvi
grantresearch
support
abbvi
gilead
speak
teach
janssen
bm
gilead
abbvi
follow
peopl
noth
disclos
stephan
moser
enisa
gutic
michael
schleicher
world
health
assembl
pass
resolut
elimin
viral
hepat
reliabl
diseas
burden
estim
requir
develop
strategi
achiev
goal
polari
observatori
creat
gather
data
model
chang
annual
diseas
burden
estim
hbv
hcv
hdv
diseas
burden
model
develop
countri
estim
preval
hcv
model
took
consider
new
infect
diseas
progress
mortal
cure
delphi
process
use
publish
literatur
follow
interview
local
expert
use
gather
data
countri
literatur
search
use
anoth
countri
global
preval
estim
use
region
averag
countri
without
data
approxim
million
individu
estim
experi
virem
hcv
infect
lower
publish
estim
due
recent
lower
preval
estim
african
countri
larg
increas
treatment
lower
estim
also
attribut
increas
mortal
due
caus
age
popul
alon
approxim
thousand
individu
treat
cure
largest
increas
treatment
unit
state
treat
follow
egypt
european
union
although
increas
treatment
substanti
step
toward
reduc
global
burden
liver
relat
death
current
treatment
rate
suffici
achiev
elimin
disclosur
sarah
blach
employ
center
diseas
analysi
ivan
gamkrelidz
employ
center
diseas
analysi
jessi
gunter
employ
center
diseas
analysi
helen
nde
employ
center
diseas
analysi
devin
employ
center
diseas
analysi
kathryn
l
employ
center
diseas
analysi
homi
razavi
grantresearch
support
gilead
abbvi
manag
posit
center
diseas
analysi
follow
peopl
noth
disclos
chri
est
kimberli
murphi
ken
pasini
sarah
robbin
jonathan
schmelzer
background
aim
analysi
volatil
organ
compound
voc
exhal
breath
identifi
marker
alcohol
nonalcohol
fatti
liver
diseas
aim
pilot
studi
investig
util
breath
test
diagnosi
advanc
fibrosi
patient
chronic
hepat
c
viru
hcv
infect
method
patient
undergo
liver
biopsi
recruit
fibrosi
determin
experienc
pathologist
stage
accord
metavir
score
advanc
fibrosi
defin
exhal
breath
plasma
sampl
collect
within
week
biopsi
isotop
analyz
iri
use
analyz
breath
sampl
aminopyrin
result
patient
includ
mean
age
year
male
advanc
fibrosi
iri
analysi
exhal
breath
reveal
patient
advanc
fibrosi
significantli
lower
valu
compar
without
advanc
fibrosi
min
min
respect
min
min
patient
patient
level
respect
sensit
specif
posit
predict
valu
neg
predict
valu
breath
test
min
min
use
new
valu
compar
standard
valu
shown
tabl
auroc
use
diagnosi
advanc
fibrosi
breath
test
min
min
ci
ci
respect
conclus
aminopyrin
breath
test
potenti
biomark
advanc
fibrosi
warrant
valid
breath
test
good
neg
test
detect
fibrosi
new
min
min
disclosur
follow
peopl
noth
disclos
gamal
shiha
reham
soliman
seham
seif
wale
samir
background
despit
advanc
therapi
chronic
hepat
c
chc
remain
import
worldwid
public
health
problem
aim
studi
extern
valid
longitudin
predict
model
konerman
hepatolog
risk
advers
clinic
outcom
deriv
cohort
advanc
chc
among
patient
pt
earli
advanc
stage
chc
method
adult
chc
seen
hepatolog
clinic
retrospect
analyz
pt
hepat
decompens
hepatocellular
carcinoma
hcc
liver
transplant
lt
hepat
b
hiv
present
exclud
pt
also
exclud
outcom
includ
hepat
decompens
hcc
lt
free
surviv
machin
learn
method
use
predict
outcom
year
result
cohort
pt
mean
age
male
white
genotyp
present
treatment
cirrhosi
pt
develop
outcom
median
follow
year
interquartil
rang
area
receiv
oper
characterist
curv
auroc
year
risk
predict
composit
clinic
outcom
decompens
hcc
lt
death
ci
ci
model
perform
retain
account
achiev
sustain
virolog
respons
baselin
cirrhosi
model
accur
assess
transplant
free
surviv
hcc
figur
mean
aspart
aminotransferas
platelet
ratio
index
mean
maximum
baselin
platelet
count
mean
albumin
contribut
significantli
risk
predict
conclus
accur
assess
risk
clinic
outcom
among
pt
chc
obtain
use
routin
collect
longitudin
data
model
retain
accuraci
across
pt
minim
fibrosi
baselin
differ
treatment
exposur
vari
genotyp
given
worldwid
burden
chc
model
convey
use
prognost
inform
guid
intens
clinic
monitor
urgenc
treatment
disclosur
anna
lok
grantresearch
support
gilead
bm
follow
peopl
noth
disclos
monica
konerman
dongxia
lu
yiwei
zhang
mari
thomson
ji
zhu
aashesh
verma
nizar
talaat
peter
higgin
akbar
k
walje
background
unit
state
us
major
risk
factor
acquir
hepat
c
hcv
well
known
e
intraven
drug
user
idu
blood
transfus
prior
hcv
screen
hiv
infect
men
sex
men
howev
case
identifi
risk
factor
present
studi
examin
associ
sexual
risk
factor
risk
hcv
infect
among
adult
infect
individu
method
nhane
popul
base
repres
survey
individu
us
data
combin
studi
exclud
intraven
drug
user
idu
person
less
year
old
older
year
multivari
analysi
hiv
posit
particip
result
overal
n
overal
preval
ci
peak
preval
estim
observ
among
person
year
age
preval
sexual
risk
factor
associ
hcv
infect
among
individu
hcv
preval
among
individu
sexual
partner
compar
among
individu
partner
hcv
preval
among
herp
hsv
compar
among
infect
hsv
among
individu
sexual
debut
hcv
preval
compar
among
sexual
debut
year
age
preval
among
hsv
posit
sexual
debut
younger
compar
hsv
neg
older
sexual
debut
analys
examin
associ
sexual
risk
factor
hcv
infect
control
age
gender
educ
poverti
ethnic
marit
statu
blood
transfus
drug
use
ivdu
multipl
variabl
model
adjust
hsv
infect
compar
hsv
infect
lifetim
partner
compar
lifetim
partner
final
sexual
debut
carri
compar
sexual
year
age
among
individu
hsv
posit
earli
sexual
debut
year
ci
compar
without
hsv
later
sexual
debut
conclus
examin
risk
factor
among
popul
infect
popul
use
popul
base
us
data
identifi
numer
sexual
risk
factor
associ
hcv
infect
analys
data
suggest
among
individu
engag
higher
risk
sexual
behavior
hcv
may
transmit
sexual
activ
disclosur
follow
peopl
noth
disclos
nall
mora
william
h
adam
stephani
klietherm
lara
r
duga
jennif
e
layden
mitochondria
provid
energi
eukaryot
cell
via
oxid
phosphoryl
regul
cellular
surviv
via
control
apoptosi
mutat
mitochondri
dna
mtdna
relat
mani
human
diseas
mtdna
mutat
acquir
throughout
human
histori
natur
select
allow
subdivid
human
popul
number
discret
mitochondri
clade
haplogroup
defin
basi
specif
mtdna
polymorph
european
mtdna
haplogroup
found
influenc
liver
fibrosi
progress
patient
aid
aim
studi
assess
relationship
mtdna
haplogroup
event
lre
patient
method
studi
clinic
characterist
outcom
patient
baselin
liver
biopsi
simultan
blood
serum
sampl
follow
median
month
year
primari
endpoint
occurr
lre
defin
decompens
hepatocellular
carcinoma
whichev
occur
first
mtdna
genotyp
perform
sequenom
massarray
platform
univari
multivari
fine
gray
proport
hazard
regress
take
account
death
compet
risk
use
test
associ
mtdna
haplogroup
lre
variabl
adjust
alcohol
intak
score
sustain
viral
respons
svr
result
patient
treat
interferon
ribavirin
achiev
svr
total
patient
lre
patient
die
patient
patient
mtdna
haplogroup
h
lre
wherea
patient
haplogroup
lre
haplogroup
h
associ
lower
hazard
lre
univari
analysi
subhazard
ratio
shr
multivari
analysi
adjust
shr
ashr
wherea
haplogroup
associ
signific
higher
hazard
lre
univari
analysi
multivari
analysi
conclus
mtdna
haplogroup
associ
increas
hazard
lre
wherea
haplogroup
h
associ
reduc
hazard
lre
result
suggest
mtdna
haplogroup
factor
influenc
natur
histori
chronic
hepat
c
patient
hiv
infect
disclosur
follow
peopl
noth
disclos
salvador
resino
teresa
pilar
miral
luz
medrano
ana
carrero
cristina
diez
leir
bellon
juan
berengu
background
individu
infect
hepat
c
viru
hcv
spontan
clear
infect
risk
reinfect
data
spontan
clearanc
hcv
reinfect
particularli
reinfect
heterolog
genotyp
human
limit
examin
hcv
larg
cohort
british
columbia
canada
method
analysi
use
data
bc
hepat
tester
cohort
includ
individu
test
hcv
link
data
medic
visit
hospit
prescript
drug
identifi
peopl
hcv
reinfect
underw
follow
test
clear
first
infect
spontan
achiev
sustain
virolog
respons
svr
treatment
examin
hcv
multivari
cox
proport
hazard
model
use
identifi
potenti
predictor
result
half
particip
spontan
clear
reinfect
incid
rate
confid
interv
ci
per
py
proport
incid
rate
per
py
spontan
clear
first
infect
proport
rate
ci
twice
achiev
svr
treatment
proport
rate
ci
adjust
analysi
likelihood
hcv
higher
among
spontan
clear
first
infect
compar
achiev
svr
adjust
hazard
ratio
ahr
ci
lower
reinfect
heterolog
hcv
genotyp
ahr
ci
conclus
abil
spontan
clear
first
infect
markedli
increas
likelihood
clear
subsequ
infect
confer
protect
heterolog
viru
disclosur
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
nazrul
islam
jeanni
shovel
paul
gustafson
mark
gilbert
jason
wong
mark
tyndal
nave
z
janjua
franc
recommend
hepat
c
viru
hcv
screen
still
target
peopl
high
risk
infect
remain
unawar
statu
context
highli
effect
toler
therapi
recommend
patient
near
futur
reassess
hcv
screen
strategi
need
studi
conduct
french
gener
popul
age
year
undiagnos
chronic
hepat
c
chc
markov
model
simul
life
expect
discount
qualiti
adjust
life
year
qali
direct
lifetim
discount
cost
increment
ratio
icer
differ
strategi
death
strategi
target
risk
popul
studi
popul
effect
screen
risk
popul
risk
men
year
peopl
year
peopl
year
peopl
year
assum
reach
target
popul
chc
diagnos
treatment
initi
regardless
fibrosi
either
least
expens
treatment
combin
reli
publish
literatur
nation
preval
survey
characterist
undiagnos
person
term
fibrosi
accord
gender
age
alcohol
consumpt
time
screen
obtain
previous
publish
mathemat
model
whatev
treatment
combin
tabl
consid
treatment
compar
current
screen
strategi
ad
men
age
year
associ
lowest
icer
target
peopl
age
effect
target
men
age
year
remain
univers
screen
even
effect
target
peopl
remain
franc
although
univers
screen
associ
highest
cost
effect
strategi
treatment
initi
regardless
fibrosi
tabl
analysi
consid
either
least
expens
treatment
combin
weakli
domin
strategi
higher
icer
effect
altern
strategi
disclosur
sylvi
consult
msd
abbvi
bm
abbott
janssen
pharmaceut
gilead
heva
public
health
expertis
grantresearch
support
janssen
pharmaceut
msd
arhel
speak
teach
janssen
gilead
bm
advisori
committe
review
panel
roch
gilead
speak
teach
roch
abbvi
gilead
bm
janssen
philipp
mathurin
board
membership
msd
bm
gilead
abvi
verlyx
consult
roch
bayer
daniel
dhumeaux
stock
sharehold
yazdan
yazdanpanah
board
membership
abbvi
bm
gilead
msd
roch
johnson
johnson
viivhealthcar
pfizer
janssen
consult
abbvi
bm
gilead
msd
roch
johnson
johnson
viiv
healthcar
pfizer
janssen
follow
peopl
noth
disclos
alexandr
huneau
adelin
verleen
brouard
josian
pillonel
yann
le
strat
sabrina
cossai
valeri
background
risk
hepatocellular
carcinoma
hcc
peopl
spontan
clear
hcv
infect
sc
achiev
svr
rxsvr
fail
treatment
rxfail
untreat
chronic
hcv
norx
well
establish
evalu
hcc
risk
patient
group
use
bc
hepat
tester
cohort
method
includ
million
individu
test
hcv
hiv
report
case
hbv
hcv
hiv
activ
tb
link
medic
visit
hospit
cancer
prescript
drug
mortal
cumul
incid
function
multivari
cox
proport
hazard
model
use
examin
hcc
risk
four
hcv
group
sc
rxsvr
rxfail
norx
result
elig
individu
sc
treat
rxsvr
rxfail
chronic
hcv
norx
four
group
follow
median
iqr
year
sc
rxsvr
rxfail
norx
rxfail
group
higher
level
cirrhosi
vs
diabet
vs
group
annual
hcc
incid
rate
per
py
sc
rxsvr
rxfail
norx
hcc
incid
rate
higher
among
cirrhosi
group
multivari
model
compar
norx
sc
hazard
ratio
hr
rxsvr
associ
reduc
hcc
risk
rxfail
higher
hcc
risk
expect
cirrhosi
older
age
yr
yr
compar
yr
male
sex
genotyp
vs
infect
problemat
alcohol
use
increas
adjust
hcc
risk
conclus
expect
hcc
risk
sc
low
rxfail
group
highest
hcc
risk
like
reflect
poorer
prognost
profil
treatment
initi
highlight
limit
hcc
prevent
benefit
treat
later
stage
diseas
older
regimen
even
svr
achiev
higher
hcc
risk
rxsvr
compar
sc
suggest
earlier
hcv
treatment
requir
achiev
risk
reduct
observ
sc
disclosur
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
mark
tyndal
mei
chong
darrel
cook
jason
wong
margot
e
kuo
hasina
samji
zahid
butt
amanda
yu
maria
alvarez
ryan
wood
nave
z
janjua
background
hepat
c
viru
hcv
infect
system
diseas
associ
hepat
extrahepat
manifest
ehm
diseas
burden
associ
hepat
manifest
hcv
well
document
howev
econom
impact
ehm
hcv
outsid
unit
state
remain
unknown
object
estim
annual
direct
medic
cost
associ
ehm
hcv
franc
method
previous
valid
econom
model
use
estim
annual
direct
medic
cost
associ
ehm
hcv
preval
nine
ehm
mix
type
cryoglobulinemia
vascul
chronic
kidney
diseas
type
diabet
mellitu
dm
lymphoma
lichen
planu
sjogren
syndrom
porphyria
cutanea
tarda
arthriti
depress
obtain
recent
systemat
review
younossi
et
al
pppi
inpati
outpati
medic
cost
treat
ehm
franc
obtain
literatur
french
databas
pmsi
expert
opinion
unavail
otherwis
prescript
drug
cost
taken
vidal
websit
cost
adjust
euro
overal
nation
direct
medic
cost
associ
ehm
hcv
calcul
multipli
total
pppi
cost
ehm
respect
preval
rate
size
popul
franc
inse
corinn
pioch
sensit
analysi
perform
consid
confid
interv
report
younossi
et
al
result
individu
estim
infect
hcv
franc
mean
averag
pppi
cost
ehm
total
annual
direct
medic
cost
associ
care
patient
ehm
hcv
franc
estim
sensit
analys
suggest
rang
million
euro
total
cost
associ
extrahepat
manifest
hcv
conclus
extrahepat
manifest
hcv
quit
costli
substanti
add
overal
econom
burden
hcv
infect
disclosur
patric
p
cacoub
advisori
committe
review
panel
gilead
abbvi
grantresearch
support
msd
bm
speak
teach
janssen
antoin
lafuma
grantresearch
support
genom
health
gsk
pierr
fabr
ucb
bm
bayer
gilead
biogen
gedeon
richter
urgo
sanofi
diaxonhit
janssen
insm
csl
berh
eisai
msd
follow
peopl
noth
disclos
mathieu
vautier
ann
clair
desboi
mariann
doz
zobair
younossi
purpos
examin
outcom
along
hcv
care
cascad
among
popul
babi
boomer
screen
hcv
infect
academ
primari
care
set
target
underserv
individu
method
program
fund
cdc
implement
babi
boomer
screen
linkag
care
gradi
memori
hospit
primari
care
center
atlanta
ga
usa
twenti
month
complet
screen
program
evalu
record
patient
screen
posit
hcv
antibodi
outcom
report
subset
chronic
hcv
infect
includ
type
initi
linkag
care
number
visit
number
refer
antivir
treatment
reason
number
achiev
rapid
virolog
respons
rvr
end
treatment
respons
etr
sustain
virolog
respons
week
complet
therapi
result
birth
cohort
popul
african
american
uninsur
patient
screen
hcv
antibodi
hcv
rna
test
complet
patient
virem
virem
patient
initi
linkag
care
visit
onsit
primari
hcv
clinic
infecti
diseas
clinic
primari
care
clinic
subsequ
patient
attend
second
specialti
visit
third
visit
fourth
fifth
patient
refer
direct
act
antivir
daa
treatment
reason
includ
lack
advanc
fibrosi
lost
await
newer
medic
substanc
abus
among
patient
result
avail
initi
daa
therapi
achiev
rvr
achiev
etr
achiev
conclus
result
show
follow
highli
success
hcv
screen
linkag
care
program
remain
signific
drop
along
later
stage
hcv
care
cascad
result
number
patient
initi
daa
therapi
despit
fact
excel
outcom
achiev
patient
initi
therapi
find
lost
follow
signific
contributor
suggest
intervent
focus
maintain
patient
care
patient
navig
case
manag
could
improv
treatment
uptak
underserv
popul
high
hcv
preval
disclosur
lesley
miller
advisori
committe
review
panel
bristol
myer
squibb
grantresearch
support
gilead
scienc
fluker
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
cameron
b
bodi
brandi
park
wynnetta
wimberley
ike
okosun
background
aim
new
treatment
allow
increas
number
patient
cure
chronic
hepat
c
viru
hcv
infect
anecdot
mani
patient
complain
sustain
virolog
respons
svr
accompani
weight
gain
aim
studi
analyz
weight
chang
factor
associ
weight
chang
patient
cure
hcv
treatment
sofosbuvir
sof
ledipasvir
ldv
method
data
collect
patient
treat
sofldv
achiev
svr
bodi
weight
measur
record
baselin
within
eight
week
start
treatment
within
four
week
svr
patient
without
document
weight
diuret
furosemid
spironolacton
signific
ascit
andor
like
caus
weight
chang
e
g
malign
exclud
cirrhosi
determin
diagnost
code
diabet
defin
hemoglobin
obes
bodi
mass
index
bmi
weight
chang
analyz
pair
two
interv
baselin
svr
baselin
end
follow
day
baselin
result
patient
patient
male
mean
age
yr
mean
weight
chang
baselin
svr
pound
lb
p
baselin
svr
patient
gain
weight
lost
weight
remain
within
lb
baselin
mean
gain
lb
mean
loss
lb
sixti
patient
gain
lb
gain
lb
lost
lb
diabet
patient
n
gain
significantli
weight
lb
n
lb
p
statist
signific
differ
weight
chang
male
femal
p
patient
without
cirrhosi
p
patient
without
obes
p
patient
treatment
less
week
p
albumin
total
cholesterol
ldl
hdl
triglycerid
differ
significantli
patient
gain
weight
lost
weight
among
patient
second
weight
measur
mean
chang
lb
p
conclus
patient
achiev
svr
sof
ldv
treatment
gain
weight
gain
entir
group
modest
lb
greater
diabet
lb
weight
increas
continu
follow
prevent
excess
weight
gain
patient
receiv
hcv
treatment
especi
diabet
may
benefit
advic
diet
exercis
da
dk
disclosur
kian
bichoupan
consult
janssen
gilead
andrea
branch
grantresearch
support
gilead
galm
follow
peopl
noth
disclos
adiba
azad
sweta
chekuri
thoma
schiano
background
aim
interferon
ifn
direct
antivir
agent
daa
effect
erad
hepat
c
virus
hcv
rapidli
improv
liver
residu
function
howev
whether
daa
prevent
hcc
primarili
secondarili
still
unknown
chronic
hepat
c
chc
caus
dysregul
iron
metabol
lead
moder
iron
overload
featur
hyperferritinemia
iron
overload
also
suspect
one
factor
favor
hepatocellular
carcinoma
hcc
howev
whether
daa
normal
hyperferritinemia
may
ferritin
possibl
predict
factor
hcc
undergo
daa
yet
elucid
method
commit
institut
review
board
prior
inform
consent
genotyp
chc
patient
undergo
daa
daclatasvir
asunaprevir
sofosbuvir
ledipasvir
recruit
laboratori
data
day
pre
end
treatment
eot
analyz
patient
activ
bleed
iron
supplement
renal
diseas
women
menopaus
exclud
analysi
hcc
surveil
patient
follow
accord
guidelin
aasldidsa
hcc
identifi
eot
within
month
defin
earli
emerg
result
eight
case
earli
hcc
emerg
notic
eot
serum
ferritin
decreas
significantli
iul
vs
iul
p
signific
decreas
also
notic
adjust
gender
age
chang
rate
serum
ferritin
aferritin
compar
valu
correl
significantli
chang
rate
alt
p
type
collagen
p
ldl
p
albumin
p
p
tend
correl
chang
rate
afp
p
case
earli
emerg
hcc
significantli
lower
vs
p
multivari
analysi
along
hcc
past
histori
aferritin
p
auc
valu
reduct
signific
predict
factor
earli
emerg
hcc
conclus
hyperferritinemia
normal
rapidli
daa
accord
hcv
erad
improv
clinic
marker
hepat
injuri
hepat
stellat
cell
activ
lipid
protein
metabol
aferritin
one
independ
signific
predict
factor
earli
hcc
emerg
daa
sinc
obes
excess
alcohol
intak
may
also
caus
hyperferritinemia
serum
ferritin
might
use
collect
predict
marker
hcc
patient
achiev
svr
daa
disclosur
follow
peopl
noth
disclos
chu
nobuhiro
nakamoto
aya
ugamura
hirotoshi
ebinuma
hidetsugu
saito
takanori
kanai
hcv
infect
million
subject
worldwid
viru
high
propens
persist
host
lead
cirrhosi
liver
cancer
metabolom
studi
metabol
chang
biolog
system
may
identifi
specif
profil
associ
subtl
alter
induc
diseas
studi
avail
metabolit
chang
liver
injuri
sinc
none
focus
patient
reach
svr
follow
treatment
direct
act
antivir
daa
aim
studi
perform
serum
metabolom
analysi
set
sera
collect
hcv
patient
men
mean
age
success
undergo
differ
daa
regimen
therapi
baselin
week
hcv
genotyp
metavir
score
indic
score
patient
remain
also
analyz
small
group
sera
healthi
subject
order
local
pl
plot
respect
baselin
preliminari
neg
control
group
sampl
analyz
use
proton
nuclear
magnet
reson
spectroscopi
partial
least
squar
pl
canon
analysi
ca
appli
demonstr
signific
discrimin
accuraci
two
patient
highlight
metabol
shift
sever
metabolit
unequivoc
assign
e
amino
acid
organ
acid
creatin
creatinin
lactat
cholin
differ
compar
baselin
baselin
featur
higher
level
format
acet
p
methionin
higher
p
preliminari
analysi
reveal
also
progress
near
healthi
fingerprint
serum
metabolom
analysi
sampl
show
remark
profil
chang
baselin
found
variat
opposit
direct
format
produc
adult
hepatocyt
methionin
metabolit
take
part
biochem
way
e
glucos
metabol
also
involv
acet
amino
acid
go
synthesi
folat
alter
could
impli
metabol
impair
previous
observ
chronic
infect
also
sinc
methionin
major
sourc
methyl
group
understand
variat
could
reveal
import
dysfunct
liver
essenti
pathway
requir
methyl
e
epigenet
regul
dna
chronic
infect
disclosur
follow
peopl
noth
disclos
giorgia
ceccotti
gaia
meoni
leonardo
tenori
laura
gragnani
elisa
fognani
elena
gianni
claudio
luchinat
anna
linda
zignego
background
aim
primari
care
base
model
hcv
care
success
establish
although
widespread
adopt
limit
urgent
need
scale
global
train
provid
hcv
aim
studi
develop
operation
hepcur
hepcur
org
base
applic
app
offer
three
compon
open
access
toolkit
dashboard
enhanc
provid
abil
deliv
hcv
care
link
patient
app
provid
educ
medic
remind
platform
track
adher
symptom
platform
medic
provid
method
hepcur
app
collabor
among
academ
tertiari
care
medic
center
new
york
state
ny
depart
health
doh
commun
health
center
ny
hepcur
platform
captur
unit
state
center
medicaid
medicar
hcv
qualiti
indic
popul
health
manag
nation
hcv
treatment
guidanc
use
provid
decis
support
algorithm
patient
data
case
submit
provid
discuss
weekli
session
expert
result
hepcur
provid
dashboard
http
providershepcureorg
launch
novemb
weekli
session
conduct
sinc
februari
session
archiv
open
access
total
uniqu
attende
weekli
session
attend
mean
attende
week
patient
mobil
app
launch
novemb
increas
patient
engag
download
may
primari
barrier
adopt
lack
deep
integr
exist
electron
health
record
ehr
hepcur
current
work
ny
doh
integr
hepcur
epic
ehr
use
commun
health
center
ny
addit
ny
doh
hcv
qualiti
indic
ehepqu
integr
hepcur
allow
direct
report
conclus
hepcur
platform
bring
hcv
infect
patient
primari
care
provid
expert
hepatologist
togeth
increas
treatment
capac
patient
engag
goal
improv
health
outcom
initi
implement
phase
led
recommend
seri
enhanc
includ
ehr
integr
creat
capac
local
expert
provid
case
base
hub
spoke
model
upgrad
process
along
research
evalu
outcom
provid
patient
use
hepcur
implement
hepcur
resourc
limit
set
without
ehr
also
explor
disclosur
jeffrey
j
weiss
consult
abbvi
inc
follow
peopl
noth
disclos
ponni
v
perumalswami
trang
vu
brook
wyatt
korin
parrella
jason
roger
background
aim
amino
acid
mutat
posit
hcv
core
protein
associ
increas
risk
hepatocellular
carcinoma
hcc
asian
patient
infect
hcv
first
time
studi
evalu
prognost
signific
mutat
unit
state
popul
method
hcv
quasispeci
baselin
serum
sampl
patient
chronic
hcv
infect
enrol
trial
investig
use
miseq
deep
sequenc
relationship
percentag
quasispeci
mutat
posit
incid
hcc
evalu
receiv
oper
characterist
roc
multivari
cox
regress
analys
result
roc
analysi
quasispeci
percentag
posit
posit
optim
sensit
discern
higher
lower
hcc
risk
baselin
quasispeci
patient
later
develop
hcc
median
year
rang
wherea
match
control
remain
median
year
rang
fisher
exact
probabl
test
baselin
quasispeci
patient
develop
hcc
wherea
match
control
analysi
hcc
incid
higher
among
patient
baselin
differ
signific
significantli
lower
among
patient
baselin
addit
cox
regress
model
increas
hcc
risk
associ
presenc
quasispeci
baselin
hazzard
ratio
hr
confid
interv
ci
higher
astalt
ratio
higher
alkalin
phosphatas
p
greater
number
white
blood
cell
associ
reduc
hcc
risk
ci
conclus
pilot
studi
unit
state
patient
add
previou
evid
hcv
core
protein
mutat
associ
hcc
risk
indic
potenti
util
hcv
quasispeci
analysi
biomark
hcc
risk
disclosur
andrea
branch
grantresearch
support
gilead
galm
follow
peopl
noth
disclos
ahm
elshami
matthew
pendleton
franci
j
eng
erin
h
doyl
ali
bashir
background
success
erad
chronic
hepat
c
viru
hcv
reli
effect
screen
program
earli
detect
linkag
care
howev
awar
hcv
screen
guidelin
may
lack
especi
among
urban
popul
high
preval
socioeconom
disadvantag
speak
minor
aim
evalu
rate
hcv
screen
hcv
awar
among
patient
high
risk
chronic
hcv
divers
hospit
method
prospect
cohort
studi
consecut
adult
undergo
outpati
endoscopi
juli
evalu
hcv
screen
rate
among
high
risk
patient
base
us
prevent
servic
task
forc
guidelin
focu
birth
cohort
histori
drug
use
incarcer
blood
transfus
prior
factor
awar
prior
hcv
result
rate
accept
hcv
test
evalu
test
multivari
logist
regress
result
among
patient
high
risk
chronic
hcv
male
birth
cohort
histori
drug
use
histori
incarcer
blood
transfus
hiv
among
cohort
receiv
prior
hcv
test
among
awar
test
result
hcv
posit
patient
like
hcv
neg
patient
awar
result
vs
p
among
high
risk
patient
offer
hcv
test
accept
compar
white
black
asian
hispan
like
accept
test
p
speak
patient
like
accept
test
vs
p
patient
born
less
like
accept
test
vs
multivari
regress
black
asian
hispan
significantli
like
accept
hcv
test
compar
white
tabl
conclus
among
adult
present
outpati
endoscopi
urban
hospit
high
risk
hcv
receiv
prior
test
receiv
prior
test
awar
result
lower
rate
test
accept
among
birth
cohort
concern
given
higher
risk
among
group
predictor
hcv
test
accept
disclosur
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
follow
peopl
noth
disclos
brendan
campbel
yael
bogler
rachel
baden
taft
bhuket
benni
liu
background
relationship
chronic
kidney
diseas
hepat
c
viru
hcv
infect
well
describ
less
known
acut
kidney
injuri
aki
fect
popul
addit
antivir
buvir
sof
wide
use
treatment
hcv
object
cohort
studi
character
rate
aki
patient
versu
patient
without
hcv
examin
rate
exposur
contain
treatment
regimen
method
adult
patient
evid
hcv
infect
identifi
larg
us
administr
medic
claim
databas
claim
incur
januari
march
data
patient
compar
random
sampl
adult
patient
without
evid
hcv
infect
databas
valid
administr
claim
code
use
determin
first
diagnosi
aki
includ
patient
least
month
continu
enrol
medic
plan
prior
cohort
entri
prior
claim
absolut
rate
correspond
exact
poisson
confid
interv
ci
determin
group
adjust
incid
rate
ratio
irr
determin
use
poisson
regress
result
among
identifi
hcv
patient
absolut
aki
rate
per
py
ci
versu
per
py
ci
popul
aki
rate
higher
among
patient
concomit
cirrhosi
concomit
liver
diseas
liver
transplant
per
py
respect
adjust
age
sex
baselin
covari
includ
renal
insuffici
cirrhosi
hcv
infect
found
associ
approxim
increas
risk
aki
ci
p
among
patient
receiv
treatment
absolut
aki
rate
exposur
tain
regimen
per
py
ci
rate
exposur
altern
treatment
per
py
ci
adjust
age
sex
baselin
covari
includ
renal
insuffici
cirrhosi
exposur
regimen
associ
reduc
risk
aki
event
ci
conclus
result
observ
studi
indic
hcv
infect
independ
associ
increas
risk
aki
independ
associ
exposur
sof
risk
aki
result
confirm
futur
investig
disclosur
laura
telep
employ
gilead
scienc
stock
sharehold
gilead
scienc
andrea
brown
employ
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
anand
p
chokkalingam
employ
gilead
scienc
stock
sharehold
gilead
scienc
background
aim
histolog
hepat
fibrosi
import
predict
factor
hepatocellular
carcinoma
hcc
develop
patient
chronic
hepat
c
chc
howev
owe
invas
natur
liver
biopsi
sever
altern
fibrosi
marker
propos
index
combin
standard
biochem
valu
age
recogn
simpl
reliabl
altern
liver
biopsi
assess
hepat
fibrosi
also
use
predict
marker
hcc
develop
recent
advanc
antivir
treatment
improv
rate
sustain
virolog
respons
svr
patient
chc
howev
risk
hcc
develop
persist
even
patient
achiev
svr
achiev
svr
result
alter
standard
biochem
valu
patient
chang
associ
hcc
develop
svr
fulli
clarifi
method
studi
includ
chc
patient
receiv
antivir
therapi
achiev
svr
estim
immedi
treatment
week
end
treatment
last
laboratori
examin
last
visit
multivari
cox
proport
hazard
analysi
use
estim
hazard
ratio
hr
variabl
hcc
develop
cumul
incid
hcc
develop
evalu
use
kaplanmei
plot
analysi
test
result
median
time
year
rang
year
patient
develop
hcc
median
valu
pretreat
last
visit
respect
valu
time
point
significantli
differ
one
anoth
p
time
point
patient
develop
hcc
significantli
higher
develop
hcc
area
receiv
oper
characterist
curv
indic
pretreat
predict
hcc
develop
high
diagnost
accuraci
superior
predict
valu
last
visit
multivari
cox
proport
hazard
analysi
demonstr
pretreat
significantli
associ
hcc
develop
hr
p
cutoff
valu
pretreat
identifi
cumul
incid
hcc
develop
patient
pretreat
respect
p
conclus
although
decreas
time
patient
high
pretreat
remain
high
risk
hcc
develop
achiev
svr
disclosur
follow
peopl
noth
disclos
takuya
genda
ayato
murata
nozomi
amano
sho
sato
hironori
tsuzura
shunsuk
sato
yutaka
narita
yoshio
kanemitsu
yuji
shimada
katsuyori
iijima
akihito
nagahara
sumio
watanab
background
intern
report
hepat
c
viru
hcv
epidem
among
men
sex
men
hiv
msm
associ
recreat
drug
use
sex
caus
concern
howev
littl
known
hcv
epidem
among
msm
san
diego
assess
incid
hcv
among
hiv
msm
san
diego
method
perform
retrospect
cohort
analysi
hcv
incid
among
hiv
msm
attend
largest
hiv
clinic
san
diego
ucsd
owen
clinic
incid
hcv
infect
assess
among
hiv
msm
baselin
neg
test
incid
infect
defin
new
posit
test
start
incid
calcul
use
surviv
time
method
result
among
baselin
neg
patient
hcv
seroconvers
occur
risk
incid
rate
ci
hcv
incid
increas
time
figur
tr
test
individu
test
median
ti
interquartil
rang
iqr
median
test
intervc
year
iqr
incid
case
averag
year
age
year
hiv
diagnosi
hcv
diagno
year
first
hcv
neg
test
hcv
diagno
msm
report
ever
inject
drug
use
h
incid
significantli
higher
p
among
report
idu
ci
compar
report
idu
ci
signific
differ
test
rate
conclus
hcv
denc
among
msm
san
diego
increa
rate
similar
london
major
european
cit
doubl
observ
us
multicent
aid
co
studi
studi
also
document
hcv
infect
among
h
msm
inject
drug
work
determin
epidem
trajectori
prevent
requir
control
demic
need
disclosur
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
natasha
k
martin
grantresearch
support
gilead
speak
teach
abbvi
merck
gilead
follow
peopl
noth
disclos
antoin
chaillon
thoma
c
martin
edward
r
cachay
davey
smith
susan
j
littl
sanjay
r
mehta
richard
l
garfein
purpos
despit
cdc
uspstf
recommend
patient
born
receiv
hcv
antibodi
test
major
us
babi
boomer
screen
date
indic
gap
implement
guidelin
primari
aim
studi
compar
hcv
screen
rate
primari
care
subspecialti
clinic
patient
integr
healthcar
system
compris
babi
boomer
method
identifi
babi
boomer
present
least
one
outpati
visit
intern
famili
medicin
gynecolog
subspecialti
clinic
northshor
univers
healthsystem
juli
patient
electron
medic
record
emr
search
hcv
antibodi
test
result
date
back
frequenc
hcv
antibodi
test
stratifi
age
gender
prior
histori
hcv
infect
provid
specialti
influenc
patient
physician
characterist
frequenc
test
analyz
use
multivari
logist
regress
result
patient
met
hcv
screen
criteria
sampl
period
undergon
hcv
antibodi
test
nineti
screen
patient
hcv
patient
underw
follow
hcv
rna
test
rna
detect
patient
hcv
test
slightli
less
common
men
women
significantli
common
patient
younger
vs
older
age
vs
respect
highest
hcv
screen
rate
observ
gynecolog
clinic
patient
follow
intern
medicin
famili
medicin
subspecialti
includ
gastroenterolog
multivari
analysi
characterist
except
gender
exert
independ
statist
signific
influenc
hcv
antibodi
test
among
patient
posit
hcv
antibodi
test
result
rate
hcv
rna
test
affect
physician
specialti
patient
characterist
conclus
overal
observ
low
adher
hcv
birth
cohort
screen
guidelin
among
differ
outpati
set
integr
healthcar
system
hcv
antibodi
test
result
found
elig
patient
patient
younger
age
like
test
older
patient
signific
variabl
differ
specialti
clinic
screen
rate
vari
studi
identifi
opportun
increas
hcv
antibodi
screen
effort
could
incorpor
practic
pattern
disclosur
jay
l
goldstein
advisori
committe
review
panel
aralez
consult
aralez
amnon
sonnenberg
grantresearch
support
gilead
follow
peopl
noth
disclos
amoah
mohammad
beig
clau
fimmel
background
understand
burden
hospit
inmat
import
make
ration
polici
hcv
treatment
prison
compar
hospit
length
stay
readmiss
hcv
infect
statu
among
inmat
method
lemuel
shattuck
hospit
lsh
provid
inpati
medic
servic
inmat
use
bill
record
develop
databas
inmat
discharg
lsh
data
collect
includ
age
race
gender
date
admiss
discharg
length
stay
lo
report
code
disposit
hospit
die
back
prison
anoth
hospit
identifi
individu
use
code
compar
individu
primari
outcom
lo
odd
readmiss
lsh
logist
regress
adjust
confound
age
sex
race
lo
first
admiss
elixhaus
index
result
inmat
contribut
total
discharg
inmat
male
white
median
age
first
hospit
yr
iqr
hcv
code
associ
hospit
median
lo
day
iqr
inmat
hcv
older
vs
p
longer
mean
lo
day
vs
day
p
multivari
model
hcv
remain
associ
increas
odd
readmiss
ci
conclus
associ
inmat
admiss
increas
lo
increas
odd
readmiss
hospit
treatment
may
avert
observ
increas
hospit
hcv
associ
mani
admiss
modest
reduct
hospit
util
svr
could
help
offset
treatment
cost
factor
associ
readmiss
inmat
n
elixhaus
index
variabl
use
multivari
model
hiv
liver
diseas
remov
index
disclosur
follow
peopl
noth
disclos
alyss
g
wurcel
deirdr
j
burk
brian
engl
kathryn
noonan
tamsin
knox
arthur
kim
benjamin
p
lina
introduct
although
highest
european
screen
rate
franc
patient
nt
take
care
hepat
c
diagnos
drug
inject
main
contamin
rout
hepat
c
viru
hcv
franc
western
europ
sinc
french
guidelin
treat
inmat
drug
user
even
fibrosi
level
access
hcv
screen
care
treatment
drug
user
prison
homeless
low
franc
less
consid
difficult
treat
popul
patient
need
support
especi
intervent
hepat
mobil
team
hmt
creat
juli
increas
screen
care
treatment
hepat
b
c
patient
propos
servic
screen
dri
blood
spot
db
hiv
hbv
hcv
mobil
fibroscan
differ
site
social
screen
diagnosi
epic
score
outreach
center
specif
health
care
worker
free
blood
test
primari
care
social
insur
advanc
specialist
consult
access
obligatori
commiss
individu
session
collect
educ
workshop
staff
train
drug
user
prevent
peer
peer
program
low
cost
specif
patient
mobil
phone
specif
one
day
hospit
antivir
treatment
green
thread
outsid
db
scan
specif
convert
truck
object
increas
screen
care
treatment
access
cure
target
popul
patient
method
target
popul
drug
user
prison
homeless
precari
peopl
migrant
psychiatr
patient
propos
part
servic
medic
social
partner
choos
servic
need
result
juli
decemb
db
peopl
hcv
db
hcv
activ
file
patient
includ
new
patient
screen
db
realiz
blood
test
fibroscan
need
treatment
accord
french
recommend
start
treatment
cure
qualiti
program
patient
free
access
close
outsid
hospit
speed
result
avail
nurs
social
worker
conclus
specif
screen
follow
support
difficult
treat
popul
essenti
increas
medic
manag
cure
hcv
patient
hmt
offer
complement
servic
substitut
exist
servic
new
use
tool
screen
diagnosi
treat
patient
outsid
pathway
care
disclosur
andr
jean
remi
consult
roch
janssen
gilead
speak
teach
bm
follow
peopl
noth
disclos
hakim
bouchkira
patric
lamarr
stephan
montabon
background
aim
evalu
util
liver
stiff
measur
predict
hepatocellular
carcinoma
hcc
develop
surviv
chronic
hepat
c
patient
method
enrol
patient
liver
stiff
measur
use
author
hospit
decemb
decemb
exclud
patient
alreadi
achiev
sustain
virolog
respons
svr
initi
liver
stiff
measur
assess
hcc
develop
overal
surviv
base
liver
stiff
use
method
result
patient
consist
male
femal
median
age
liver
stiff
enrol
kpa
kpa
kpa
kpa
kpa
kpa
respect
mean
period
year
hcc
develop
patient
cumul
incid
rate
hcc
year
respect
cumul
hcc
incid
rate
year
kpa
kpa
kpa
kpa
kpa
kpa
respect
p
studi
period
patient
die
caus
death
liver
cancer
liver
failur
gastrointestin
bleed
other
overal
surviv
rate
year
respect
surviv
rate
kpa
kpa
kpa
kpa
kpa
kpa
respect
p
conclus
liver
stiff
predict
outcom
year
chronic
hepat
c
patient
disclosur
ryosuk
tateishi
grantresearch
support
kyowa
hakko
kirin
co
ltd
speak
teach
taisho
pharmaceut
co
ltd
bayer
yakuhi
ltd
otsuka
pharmaceut
co
ltd
astrazeneca
k
k
eisai
co
ltd
gilead
scienc
co
ltd
msd
kk
sumitomo
dinippon
pharma
co
ltd
covidien
japan
inc
wako
pure
chemic
industri
ltd
yoshinari
asaoka
grantresearch
support
kyowa
hakko
kirin
co
ltd
speak
teach
bayer
pharma
follow
peopl
noth
disclos
ryo
nakagomi
ryota
masuzaki
taijiro
wake
mizuki
nishibatak
naoto
fujiwara
masaya
sato
tatsuya
minami
kenichiro
enooku
hayato
nakagawa
yuji
kondo
kazuhiko
koik
purpos
georgia
first
countri
world
adopt
nation
hcv
elimin
goal
set
abstract
present
result
georgia
first
nation
repres
hepat
c
viru
hcv
seropreval
survey
use
monitor
progress
toward
hcv
elimin
method
nation
repres
seropreval
survey
individu
age
year
conduct
georgia
use
stratifi
cluster
design
give
inform
consent
particip
provid
epidemiolog
data
includ
demograph
medic
histori
knowledg
hcv
transmiss
prevent
method
risk
factor
blood
specimen
collect
particip
test
antibodi
hcv
hcv
rna
data
weight
base
probabl
select
calibr
use
censu
data
sex
age
geographi
descript
statist
comput
result
nation
hcv
seropreval
ci
preval
chronic
hcv
infect
ci
seropreval
ci
capit
citi
tbilisi
ci
urban
area
overal
ci
rural
area
seropreval
highest
among
person
age
year
ci
male
ci
person
report
histori
inject
drug
use
idu
ci
incarcer
ci
blood
transfus
georgia
began
test
donor
blood
hcv
ci
ci
respect
major
respond
demonstr
knowledg
hcv
transmit
infect
blood
ci
share
needl
syring
ci
hcv
prevent
avoid
needl
share
ci
avoid
unsterileus
medic
devic
ci
less
half
seroposit
respond
awar
infect
report
initi
treatment
prior
avail
antivir
drug
regimen
georgia
conclus
hcv
seropreval
georgia
high
overal
exceed
among
person
report
idu
higher
urban
rural
set
among
test
hcv
awar
infect
low
treat
knowledg
current
nationwid
hcv
preval
associ
risk
factor
inform
implement
prevent
screen
treatment
strategi
establish
baselin
track
progress
toward
elimin
time
disclosur
follow
peopl
noth
disclos
liesl
hagan
ana
kasradz
stephani
salyer
amiran
gamkrelidz
maia
alkhazashvili
gvantsa
chanturia
nazi
chitadz
roena
sukhiashvili
marina
shakhnazarova
curti
blanton
steven
russel
giorgi
kuchukhidz
davit
baliashvili
susan
hariri
jan
drobeniuc
paata
imnadz
juliett
morgan
francisco
averhoff
introduct
increas
number
licens
antivir
daa
treatment
chronic
hcv
infect
choos
right
treatment
regimen
right
patient
becom
paramount
believ
baselin
sequenc
presenc
substitut
ra
import
contributor
process
present
studi
irish
cohort
perform
retrospect
analysi
hcv
sampl
receiv
drug
resist
test
irish
nation
viru
refer
laboratori
septemb
may
particular
attent
paid
patient
experienc
virolog
failur
attempt
identifi
predictor
failur
method
sanger
sequenc
data
cover
hcv
proteas
code
region
obtain
sampl
receiv
studi
period
sequenc
data
region
sampl
also
obtain
singl
nucleotid
polymorph
site
examin
allel
discrimin
pcr
result
analysi
viral
sequenc
demonstr
hcv
subtyp
subtyp
subtyp
infect
ra
proven
reduc
suscept
inhibitor
treatment
detect
case
although
vast
major
ra
detect
found
subtyp
virus
subtyp
sampl
also
contain
one
ra
polymorph
found
hcv
subtyp
almost
exclus
clade
versu
clade
virus
among
cohort
patient
experienc
virolog
failur
whilst
treatment
ra
could
detect
patient
sequenc
could
gener
includ
major
patient
found
possess
deleteri
singl
nucleotid
polymorph
snp
rs
site
within
gene
locu
nine
eleven
patient
detect
ra
found
also
either
ct
tt
one
patient
cc
snp
preliminari
data
patient
experienc
treatment
failur
inhibitor
also
indic
presenc
ra
individu
discuss
high
incid
ra
within
hcv
proteas
sequenc
detect
ra
sequenc
appar
risk
treatment
failur
albeit
small
number
patient
ra
present
highlight
import
sequenc
virus
prior
commenc
treatment
proteas
inhibitor
need
identifi
addit
predictor
failur
disclosur
follow
peopl
noth
disclos
jonathan
dean
martha
neari
suzi
coughlan
cillian
f
de
gascun
background
acut
hepat
c
viru
hcv
infect
patient
clear
infect
spontan
immunolog
mechan
spontan
clearanc
chronic
hcv
infect
without
antivir
therapi
describ
rare
case
report
frequenc
clearanc
unknown
influenc
hiv
coinfect
method
hcv
clinic
case
registri
singl
tertiari
care
facil
review
quantit
plasma
hcv
rna
level
measur
year
patient
least
one
hcv
rna
luml
evid
acut
infect
includ
chronic
infect
case
spontan
clearanc
defin
least
one
hcv
rna
luml
undetect
preced
least
one
hcv
rna
luml
antivir
therapi
time
interv
measur
result
among
chronic
patient
confid
interv
experienc
spontan
clearanc
five
patient
suppress
hiv
rna
copiesml
antiretrovir
therapi
median
cell
count
rang
patient
hepat
b
viru
hbsag
three
compens
cirrhosi
one
prior
liver
transplant
hcv
recurr
among
patient
frequenc
spontan
clearanc
c
fect
patient
rate
ci
risk
ratio
spontan
hcv
clearanc
hivhcv
coinfect
hcv
monoinfect
c
rate
spontan
clearanc
chronic
hcv
genotyp
infect
c
c
c
risk
ratio
c
c
conclus
spontan
clearanc
chronic
hcv
infect
without
antivir
therapi
rare
occur
patient
clearanc
significantli
common
patient
patient
compar
disclosur
follow
peopl
noth
disclos
varun
jain
diana
otero
tatjana
gavranc
qing
liu
sonja
marcu
norbert
objectiveaim
major
hcv
posit
individu
england
peopl
inject
drug
pwid
poor
engag
health
servic
go
studi
assess
feasibl
detect
stage
treatment
hcv
relat
chronic
liver
diseas
commun
method
prospect
studi
dec
conduct
larg
substanc
misus
servic
se
england
individu
offer
dri
blood
spot
test
dbst
mobil
transient
elastographi
te
hcv
treatment
includ
daa
qualit
interview
recent
addit
patient
report
outcom
sfldqol
health
econom
result
date
individu
recruit
male
mean
age
yr
sd
high
preval
inject
drug
use
idu
alcohol
use
psychiatr
ill
uptak
dbst
prior
test
main
reason
declin
preval
posit
serolog
markerspcr
hbcab
hcv
antibodi
hcv
pcr
genotyp
logist
regress
independ
predictor
posit
hcv
serolog
ever
inject
ci
posit
hbcab
ci
psychiatr
diagnosi
ci
posit
hcv
pcr
underw
te
mean
lsm
kpa
sd
lsm
kpa
cirrhosi
lsm
kpa
signific
associ
posit
hcv
serolog
lsm
kpa
lsm
posit
compar
lsm
p
none
prior
hcv
treatment
treatment
candid
chaotic
lifestyl
remain
commenc
treatment
characterist
treat
cohort
age
yr
sd
male
substancealcohol
use
undergo
te
genotyp
treatment
receiv
inf
rbv
daa
treatment
outcom
svreotr
nine
treatment
six
nr
includ
four
rr
two
questionnair
done
conclus
preval
posit
hcv
serolog
marker
remain
high
pwid
might
explain
almost
preval
signific
hepat
fibrosi
complianc
difficult
engag
cohort
hcv
treatment
outcom
compar
secondari
care
go
prospect
studi
endors
success
novel
easi
replic
commun
base
hcv
treatment
model
onsit
mobil
te
disclosur
margaret
osullivan
grantresearch
support
gilead
sumita
verma
grantresearch
support
gilead
brighton
hove
commission
dunhil
medic
trust
nation
institut
health
research
janssen
abbvi
bm
follow
peopl
noth
disclos
hugh
william
jone
background
host
immun
respons
hepat
c
viru
hcv
suggest
play
import
role
determin
hcv
outcom
examin
cohort
studi
concurr
hepat
b
hbv
infect
found
signific
predictor
spontan
clearanc
hcv
popul
studi
examin
effect
two
along
factor
spontan
clearanc
hcv
cohort
british
columbia
canada
method
bc
hepat
tester
cohort
includ
individu
test
hcv
link
data
medic
visit
hospit
prescript
drug
hcv
posit
individu
least
one
valid
hcv
pcr
test
hcv
diagnosi
includ
studi
examin
factor
associ
spontan
clearanc
hcv
fit
multivari
logist
regress
full
sampl
cox
proport
hazard
model
seroconvert
e
hcv
neg
individu
subsequ
becam
hcv
posit
result
spontan
clearanc
observ
test
hcv
adjust
potenti
confound
odd
spontan
clearanc
hcv
lower
peopl
primari
immunodefici
adjust
odd
ratio
aor
ci
higher
femal
aor
ci
hbv
aor
ci
hcv
infect
aor
ci
compar
conclus
spontan
clearanc
lower
peopl
primari
immunodefici
higher
among
femal
hbv
hcv
infect
disclosur
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
nazrul
islam
mark
gilbert
paul
gustafson
mark
tyndal
nave
z
janjua
background
surveil
treatment
prison
hepat
c
studi
evalu
impact
rapid
hcv
therapi
hcv
transmiss
prison
new
south
wale
australia
analysi
characteris
hcv
epidemiolog
risk
behaviour
among
prison
two
prison
studi
method
data
analysi
includ
prison
enrol
two
prison
octob
march
prison
age
elig
particip
enrol
particip
receiv
test
hcv
antibodiesrna
complet
detail
survey
includ
inject
behaviour
inject
behaviour
hcv
infect
exposur
statu
evalu
result
march
prison
enrol
prison
prison
b
median
age
year
median
durat
stay
current
prison
time
enrol
year
overal
hcv
antibodi
neg
hcv
antibodi
positivehcv
rna
neg
includ
previou
hcv
treatment
hcv
rna
posit
rna
inject
illicit
drug
current
imprison
report
rna
compar
p
inject
previou
month
report
rna
compar
p
among
inject
previou
month
report
share
inject
equip
conclus
high
proport
prison
hcv
infect
prison
report
inject
risk
behaviour
among
prison
risk
hcv
previou
hcv
exposur
clearanc
like
report
high
risk
inject
previou
exposur
suggest
risk
need
increas
prevent
activ
surveil
hcv
incid
focu
detect
hcv
primari
infect
disclosur
jason
grebe
advisori
committe
review
panel
merck
gilead
grant
research
support
merck
gilead
abbvi
bm
natasha
k
martin
grantresearch
support
gilead
speak
teach
abbvi
merck
gilead
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
andrew
r
lloyd
grantresearch
support
merck
gilead
squibb
gregori
dore
board
membership
gilead
merck
abbvi
squibb
grantresearch
support
gilead
merck
abbvi
squibb
speak
teach
gilead
merck
abbvi
squibb
follow
peopl
noth
disclos
behzad
hajarizadeh
mariann
byrn
philippa
mark
toni
butler
janaki
amin
peter
vickerman
carla
treloar
background
regress
cirrhosi
portal
hypertens
pt
major
goal
treatment
patient
hepat
c
viru
hcv
associ
cirrhosi
improv
turcott
cpt
model
end
stage
liver
diseas
meld
score
consist
observ
current
trial
investig
direct
antivir
agent
daa
treatment
hcv
cirrhosi
howev
persist
pt
report
despit
sustain
virolog
respons
svr
improv
current
studi
prospect
evalu
dynam
liver
spleen
stiff
patient
hcv
associ
cirrhosi
svr
antivir
treatment
method
total
patient
male
hcv
associ
cirrhosi
svr
antivir
treatment
includ
liver
spleen
stiff
assess
baselin
bl
end
treatment
eot
week
eot
transient
elastographi
liver
well
acoust
radiat
forc
impuls
arfi
liver
spleen
biochem
virolog
clinic
data
obtain
parallel
result
signific
reduct
liver
stiff
bl
median
rang
kpa
eot
median
rang
kpa
p
well
bl
median
rang
kpa
p
liver
stiff
assess
significantli
decreas
bl
median
rang
ms
median
rang
ms
spleen
stiff
assess
decreas
significantli
b
eot
improv
liver
stiff
pronounc
bl
eot
eot
addit
signific
improv
bl
median
rang
median
rang
observ
conclus
liver
spleen
elastographi
improv
significantli
patient
hcv
associ
cirrhosi
svr
antivir
therapi
effect
mainli
associ
first
week
treatment
must
discuss
amount
improv
liver
stiff
associ
decreas
hepat
necroinflamm
regress
fibrosi
portal
hypertens
studi
investig
dynam
liver
stiff
may
overestim
degre
put
regress
cirrhosi
disclosur
tania
welzel
advisori
committe
review
panel
novarti
janssen
gilead
abbvi
bm
johann
vermehren
advisori
committe
review
panel
abbvi
abbott
speak
teach
abbvi
squibb
gilead
medtron
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
martin
w
welker
advisori
committe
review
panel
roch
chiesi
consult
amgen
novarti
speak
teach
bayer
bm
gilead
follow
peopl
noth
disclos
viola
knop
daniel
hopp
eva
herrmann
annika
vermehren
mireen
background
hepat
c
viru
hcv
infect
major
caus
chronic
liver
diseas
associ
sever
manifest
sever
studi
demonstr
signific
associ
among
hcv
infect
insulin
resist
chronic
kidney
diseas
ckd
cardiovascular
diseas
cvd
conduct
taiwan
unclear
whether
result
studi
appli
us
popul
given
differ
prevail
genotyp
level
comorbid
observ
differ
natur
histori
hcv
object
assess
risk
ckd
cvd
associ
chronic
hcv
infect
us
method
retrospect
cohort
analysi
truven
health
marketscan
databas
conduct
patient
age
year
newli
diagnos
hcv
infect
identifi
hcv
cohort
outcom
includ
incid
ckd
cvd
coronari
heart
diseas
cerebrovascular
diseas
peripher
arteri
diseas
congest
heart
failur
patient
exclud
experienc
outcom
year
prior
first
diagnosi
hcv
match
hcv
cohort
patient
without
hcv
infect
cohort
use
propens
score
match
continu
studi
outcom
end
enrol
decemb
whichev
come
first
use
cox
proport
hazard
model
compar
risk
develop
ckd
cvd
hcv
cohort
addit
covari
adjust
model
includ
alcoholdrug
abus
disord
hivaid
medic
hepat
b
viru
cirrhosi
result
mean
time
year
overal
incid
rate
ckd
per
hcv
patient
cohort
patient
respect
overal
incid
rate
cvd
per
hcv
patient
cohort
patient
respect
multivari
adjust
model
hcv
infect
associ
fold
higher
incid
ckd
hazard
ratio
hr
confid
interv
ci
almost
two
fold
higher
incid
cvd
conclus
analysi
larg
us
administr
claim
databas
suggest
patient
hcv
infect
greater
risk
develop
ckd
cvd
individu
without
hcv
infect
futur
studi
need
investig
whether
sustain
virolog
respons
antivir
alter
risk
develop
andor
progress
renal
diseas
cardiovascular
outcom
disclosur
haesuk
park
consult
gilead
scienc
david
r
nelson
grantresearch
support
abbvi
bm
gilead
merck
janssen
follow
peopl
noth
disclos
wei
wang
chao
chen
background
hepat
c
b
viru
infect
highli
preval
worldwid
main
caus
liver
diseas
children
adult
vertic
transmiss
hcv
major
rout
hcv
infect
children
spain
mark
increas
immigr
popul
recent
year
may
chang
preval
hcv
hbv
pregnanc
object
determin
preval
epidemiolog
hcv
hbv
pregnant
women
spain
method
prospect
cohort
studi
conduct
nation
spanish
hospit
women
year
old
follow
center
januari
till
octob
enrol
preval
hcv
hbv
hbsag
determin
cohort
pregnant
mother
moreov
studi
epidemiolog
hbvhcv
infect
among
pregnant
mother
result
overal
hbv
preval
women
hcv
women
preval
viral
hepat
higher
among
women
year
age
howev
preval
hbv
hcv
differ
significantli
group
hbv
hcv
preval
pregnant
women
respect
vs
preval
viral
hepat
among
women
fertil
age
respect
p
data
hbvhcv
hbv
hiv
hcvhiv
caucasian
chines
popul
predomin
hbv
preval
wherea
caucasian
latin
gypsi
popul
hcv
relat
countri
origin
vhb
infect
women
spain
eastern
europ
hcv
women
form
spain
asia
mainli
china
eastern
europ
africa
south
america
main
risk
factor
hbv
infect
vertic
transmiss
presenc
tattoo
person
anteced
surgeri
howev
hcv
infect
use
parenter
drug
surgeri
tattoo
person
anteced
transfus
conclus
import
percentag
women
infect
virus
immigr
popul
differ
hbvhcv
preval
pregnant
fertil
age
women
may
due
fertil
age
group
high
number
women
high
risk
infect
relat
hcv
preval
hcv
screen
spain
univers
gestat
therefor
perform
mainli
women
women
year
age
increas
risk
viral
hepat
infect
due
lack
prophylact
care
hbv
lack
hcv
blood
screen
disclosur
follow
peopl
noth
disclos
jose
antonio
javier
salmeron
angel
background
hepat
c
viru
hcv
infect
one
main
caus
chronic
liver
diseas
worldwid
metabol
syndrom
ms
highli
preval
within
va
patient
popul
repres
heterogen
group
patient
potenti
genet
basi
especi
certain
ethnic
patient
popul
increas
preval
disord
increas
likelihood
progress
fibrosi
cirrhosi
hepatocellular
carcinoma
risk
progress
chronic
hcv
infect
cirrhosi
highli
variabl
mani
factor
compon
ms
believ
acceler
diseas
progress
impact
likelihood
sustain
virolog
respons
svr
ms
thought
decreas
efficaci
antivir
therapi
chronic
hepat
c
newer
hepat
c
treatment
regimen
use
within
va
healthcar
system
could
affect
hcv
outcom
patient
ms
aim
evalu
presenc
syndrom
could
overcom
hcv
treatment
resist
era
antivir
daa
method
patient
undergo
hcv
antivir
therapi
antivir
pool
analysi
perform
va
greater
lo
angel
hc
analyz
svr
cohort
veteran
hcv
without
dyslipidemia
hypertens
identifi
code
patient
current
therapi
result
svr
result
hcv
treat
patient
dyslipidemia
hypertens
total
number
daa
treat
patient
conclus
data
suggest
presenc
metabol
syndrom
advers
impact
antivir
treatment
respons
newer
drug
import
attain
svr
revers
progress
fibrosi
remain
evalu
disclosur
alan
j
sheinbaum
advisori
committe
review
panel
gilead
speak
teach
vertex
follow
peopl
noth
disclos
jihan
benhamm
christin
yu
jenna
k
kawamoto
vivek
dixit
nevil
pimston
joseph
r
pisegna
background
hepat
e
viru
hev
endem
primarili
zoonot
infect
us
western
europ
recent
data
nhane
suggest
approxim
popul
expos
evidenc
serolog
test
seri
describ
higher
rate
infect
hcv
andor
hiv
sought
evalu
preval
hev
larg
cohort
hcv
hcvhiv
coinfect
patient
method
serum
sampl
obtain
hcvre
heppro
cohort
longitudin
cohort
develop
hcv
hcv
hiv
coinfect
person
seek
care
clinic
facil
district
columbia
surround
environ
sampl
collect
near
baselin
enrol
period
evalu
hev
igg
evalu
use
sensit
elisa
assay
wantai
beij
china
test
perform
accord
manufactur
instruct
posit
confirm
repeat
duplic
test
recommend
manufactur
parametr
test
perform
use
statistix
result
individu
includ
hcv
hcvhiv
test
igg
mean
age
year
rang
year
male
black
median
rang
lower
hiv
mean
vs
enrolle
overal
igg
detect
confirm
proport
confirm
case
statist
similar
regardless
hiv
statu
hcv
vs
hcvhiv
p
ns
preval
affect
sex
race
ethnic
univari
analysi
hev
igg
significantli
common
older
vs
younger
particip
p
modest
invers
correl
count
hev
igg
odcutoff
ratio
r
subject
aid
definit
hev
igg
od
cutoff
ratio
significantli
lower
mean
higher
count
among
igg
posit
person
p
conclus
hev
exposur
higher
hcv
andor
hiv
report
gener
popul
survey
older
hcv
hcvhiv
person
like
expos
howev
hcvhiv
patient
low
less
robust
immun
respons
evidenc
lower
antibodi
titer
specul
may
lead
increas
proport
fals
neg
result
subgroup
evalu
qualit
profil
antibodi
hev
includ
determin
bind
avid
indic
disclosur
kenneth
e
sherman
advisori
committe
review
panel
janssen
merck
synteract
grantresearch
support
medimmun
inovio
merck
gilead
squibb
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
jason
blackard
advisori
committe
review
panel
nih
south
african
medic
research
council
consult
merck
inc
grantresearch
support
merck
inc
follow
peopl
noth
disclos
susan
rouster
moham
tarek
shata
shyam
kottilil
background
incid
acut
hepat
c
ahc
declin
worldwid
howev
almost
year
identif
hepat
c
viru
hcv
new
case
still
occur
sinc
acut
hcv
infect
gener
asymptomat
seldom
diagnos
thu
specif
mode
transmiss
number
patient
expos
sourc
infect
well
clinic
laboratori
cours
given
case
rare
ascertain
real
time
describ
outbreak
ahc
wherein
paramet
known
case
report
three
patient
present
medic
center
new
onset
jaundic
april
may
tabl
ahc
diagnos
review
patient
histori
identifi
common
potenti
sourc
exposur
ct
scan
iv
contrast
one
commun
imag
center
march
last
patient
undergo
ct
center
march
known
chronic
hepat
c
patient
health
author
notifi
patient
summon
test
ct
contrast
day
found
posit
hcv
rna
seven
treat
medic
center
describ
tabl
patient
close
viral
load
declin
significantli
without
antivir
treatment
patient
number
undergo
workup
lung
mass
defer
treatment
patient
treat
daa
patient
prefer
non
declin
viral
load
respect
conclus
iatrogen
acut
hepat
c
still
occur
due
combin
technic
eg
vial
human
factor
given
ahc
rare
lead
fulmin
hepat
failur
know
exact
date
infect
close
monitor
viral
load
present
uniqu
opportun
follow
patient
viral
load
close
anticip
spontan
viral
clearanc
treatment
offer
viral
load
declin
thu
everi
effort
made
ascertain
date
infect
contact
patient
potenti
expos
aim
quantit
clinic
observ
sever
ahc
lead
greater
chanc
spontan
recoveri
tabl
clinic
data
seven
ahc
patient
treat
szmc
disclosur
follow
peopl
noth
disclos
orlev
eyal
shteyer
inna
gafanovich
dana
g
wolf
heftziba
ivgi
ilana
deri
rima
barsuk
daniela
armoni
michal
c
eliav
yizhak
skorochod
gabriel
breuer
ran
kaspa
yonit
scott
cotler
harel
dahari
yoav
luri
backgroundobject
hepat
c
viru
hcv
infect
major
caus
cirrhosi
worldwid
sever
studi
link
hcv
infect
higher
risk
develop
intrahepat
cholestasi
pregnanc
icp
result
inconsist
conduct
aim
assess
associ
icp
hcv
infect
diagnosi
icp
method
studi
consist
two
literatur
search
perform
use
medlin
embas
incept
januari
first
studi
includ
observ
studi
report
rel
risk
odd
ratio
hazard
ratio
associ
hcv
infect
risk
icp
second
analysi
includ
studi
compar
risk
later
hcv
infect
icp
patient
without
icp
pool
risk
ratio
rr
confid
interv
ci
calcul
use
gener
invers
varianc
method
result
three
studi
includ
first
analysi
pool
rr
icp
pregnant
women
compar
pregnant
women
ci
two
studi
includ
second
analysi
pool
rr
later
hcv
infect
among
icp
patient
compar
patient
ci
conclus
studi
demonstr
increas
risk
icp
among
pregnant
women
also
increas
risk
later
hcv
infect
among
icp
patient
physician
awar
associ
strongli
suggest
test
hepat
c
women
sign
icp
forest
plot
includ
studi
associ
hepat
c
infect
risk
intrahepat
cholestasi
pregnanc
top
forest
plot
includ
studi
associ
intrahepat
cholestasi
pregnanc
risk
later
hepat
c
infect
disclosur
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
sikarin
upala
anawin
sanguankeo
patompong
ungprasert
wisit
cheungpasitporn
introduct
treatment
decis
make
direct
act
antivir
daa
patient
chronic
hepat
c
chc
mainli
base
baselin
hcv
rna
concentr
hcv
genotyp
presenc
absenc
liver
cirrhosi
sinc
estim
liver
fibrosi
histolog
result
low
accept
transient
elastographi
te
serum
score
often
use
addit
clinic
find
assess
diagnost
accuraci
panel
serum
score
comparison
te
method
deutsch
hepat
german
hepat
nation
multicent
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
treatment
valid
data
te
avail
patient
patient
serum
sore
apri
score
forn
index
calcul
diagnost
accuraci
compar
fs
result
result
estim
te
patient
signific
fibrosi
sf
kpa
patient
sf
patient
liver
cirrhosi
patient
liver
cirrhosi
frequent
men
older
higher
bmi
longer
estim
durat
diseas
like
svr
rate
follow
differ
daa
regimen
without
ribavirin
week
patient
sf
sf
cirrhosi
respect
discrimin
sf
auroc
apri
score
forn
index
discrimin
cirrhosi
auroc
apri
score
conclus
nation
multicent
real
world
cohort
signific
fibrosi
cirrhosi
predict
accuraci
serum
score
compar
fs
result
data
support
use
serum
score
te
avail
accur
cirrhosi
estim
svr
rate
patient
cirrhosi
numer
lower
current
daa
regimen
disclosur
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
holger
hinrichsen
advisori
committe
review
panel
bm
janssen
gilead
abbvi
speak
teach
msd
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
heik
employ
efactum
gmbh
simon
advisori
committe
review
panel
abbvi
bm
janssen
msd
speak
teach
abbvi
bm
falk
gilead
janssen
norgin
merz
msd
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
follow
peopl
noth
disclos
wolf
peter
hofmann
mireen
examin
coevolut
hiv
hcv
infect
mental
ill
substanc
use
dispar
time
bc
use
bc
hepat
tester
cohort
includ
million
individu
test
hcv
hiv
report
case
hcv
hiv
hbv
tuberculosi
link
administr
healthcar
databas
classifi
individu
seroconvert
preval
hivhcv
million
elig
individu
preval
hcv
infect
hivhcv
hcv
seroconvert
overal
hiv
monoinfect
individu
live
urban
area
low
inject
drug
use
idu
problem
alcohol
use
materi
privileg
group
hivhcv
hcv
seroconvert
materi
depriv
higher
idu
problem
alcohol
use
major
mental
ill
hiv
hcv
hivhcv
began
increas
rural
area
materi
depriv
idu
opioid
substitut
therapi
increas
overtim
among
seroconvert
multivari
multinomi
regress
model
mirror
descript
trend
overtim
odd
idu
declin
among
hcv
preval
hiv
monoinfect
individu
seroconvert
declin
odd
problem
alcohol
use
observ
seroconvert
coinfect
individu
overtim
figur
result
could
inform
optim
align
prevent
care
support
servic
hiv
hcv
infect
popul
within
context
chang
epidemiolog
dispar
risk
profil
group
adjust
log
odd
ratio
risk
factor
hivhcv
group
time
period
disclosur
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
zahid
butt
nabin
shrestha
margot
e
kuo
dionn
gesink
mark
gilbert
jason
wong
amanda
yu
maria
alvarez
hasina
samji
jane
buxton
jame
c
johnston
victoria
cook
david
roth
theodora
b
consolacion
michel
murti
gina
ogilvi
robert
balshaw
mark
tyndal
nave
z
janjua
chronic
liver
diseas
cirrhosi
lead
caus
death
us
viral
hepat
lead
signific
morbid
mortal
use
nation
databas
updat
estim
viral
hepat
burden
us
method
nation
ambulatori
hospit
ambulatori
medic
care
survey
nationwid
inpati
sampl
vital
statist
us
databas
use
estim
medic
care
mortal
primari
diagnosi
viral
hepat
b
c
rate
shown
per
popul
recent
year
avail
result
hepat
c
contribut
million
ambulatori
visit
hospit
discharg
death
ambulatori
visit
hospit
discharg
rate
higher
middl
compar
older
age
among
men
african
american
compar
women
white
respect
rate
increas
significantli
howev
greater
avail
treatment
option
might
contribut
rise
mortal
rate
higher
middl
compar
older
age
among
men
compar
women
vs
african
american
compar
white
vs
mortal
rate
increas
overal
popul
demograph
subgroup
figur
hepat
b
contribut
ambulatori
visit
hospit
discharg
death
ambulatori
visit
hospit
discharg
rate
higher
middl
compar
older
age
along
mortal
rate
higher
among
men
african
american
compar
women
white
hispan
respect
medic
care
rate
doubl
contrast
mortal
rate
declin
one
third
conclus
viral
hepat
burden
us
today
primarili
reflect
hepat
c
greater
among
men
african
american
disclosur
follow
peopl
noth
disclos
aynur
constanc
e
ruhl
purpos
studi
sought
determin
hepat
c
viru
hcv
estim
ghana
lack
avail
data
assess
led
uncertainti
regard
burden
diseas
method
studi
sampl
consist
individu
current
locat
ashanti
region
ghana
studi
particip
complet
survey
oraquick
rapid
screen
assay
hcv
statu
posit
screen
test
underw
confirmatori
test
cia
hcv
antibodi
assay
confirm
seroposit
age
gender
region
origin
identifi
particip
bayesian
logist
regress
use
obtain
odd
ratio
assess
risk
hcv
preval
estim
median
posterior
estim
report
highest
posterior
densiti
hpd
credibl
interv
result
averag
age
particip
rang
year
subject
women
children
age
compris
sampl
individu
origin
ashanti
region
northern
region
region
ghana
compar
subject
odd
hcv
infect
hpd
hpd
hpd
higher
origin
northern
upper
west
upper
east
region
respect
odd
correspond
hcv
preval
estim
hpd
hpd
hpd
northern
upper
west
upper
east
region
compar
ashanti
adjust
region
origin
lowest
preval
hpd
hpd
age
group
respect
begin
age
preval
increas
hpd
peak
hpd
among
year
old
declin
hpd
individu
older
involv
subject
origin
northern
region
northern
upper
west
upper
east
suggest
preval
may
even
higher
north
preval
estim
hpd
among
year
old
increas
hpd
among
individu
year
old
conclus
signific
age
region
differ
hcv
preval
exist
ghana
higher
preval
among
individu
origin
northern
region
among
individu
age
case
observ
among
particip
less
year
age
find
suggest
either
age
cohort
effect
transmiss
exposur
low
childhood
increas
age
disclosur
follow
peopl
noth
disclos
stephani
klietherm
jason
gantenberg
nall
mora
richard
phillip
ohen
dorca
owusu
jennif
e
layden
background
optim
manag
chronic
liver
diseas
depend
degre
liver
fibrosi
accur
evalu
liver
fibrosi
import
though
liver
stiff
measur
lsm
use
fibroscan
serum
wisteria
floribunda
bind
protein
novel
noninvas
reliabl
techniqu
assess
degre
liver
fibrosi
comparison
two
paramet
yet
avail
literatur
aim
studi
assess
correl
lsm
serum
level
among
japanes
patient
hepat
b
c
nafld
method
total
patient
underw
lsm
hospit
review
patient
whose
lsm
valu
invalid
failur
exclud
among
remain
patient
patient
patient
infect
hbv
patient
infect
hcv
patient
nafld
enrol
studi
serum
wfa
aspart
transaminas
platelet
ratio
index
apri
fibrosi
index
platelet
ratio
index
simultan
measur
calcul
occas
lcm
result
baselin
characterist
elig
patient
male
median
age
year
median
valu
lsm
apri
kpa
coi
respect
posit
correl
lsm
level
p
apri
p
p
observ
multipl
linear
regress
analysi
reveal
level
significantli
associ
factor
effect
p
correl
coeffici
lsm
fibrosi
marker
follow
ascend
order
hbv
p
nafld
p
hcv
p
diagnost
perform
apri
evalu
use
receiv
oper
characterist
curv
analysi
auc
apri
lsm
level
lsm
level
lsm
level
respect
optim
cutoff
valu
best
predict
lsm
level
respect
optim
cutoff
valu
best
predict
lsm
level
distinct
etiolog
hbv
nafld
hcv
respect
conclus
lsm
valu
measur
fibroscan
close
correl
serum
level
compar
either
apri
especi
hepat
c
patient
consider
etiolog
liver
diseas
requir
regard
predict
lsm
cutoff
valu
disclosur
seigo
abiru
grantresearch
support
chugai
pharmaceut
co
ltd
follow
peopl
noth
disclos
shinjiro
uchida
kazumi
yamasaki
kohei
hayashi
yuki
kugiyama
shigemun
bekki
satoru
hashimoto
akira
saeki
shinya
nagaoka
atsumasa
komori
hiroshi
yatsuhashi
background
host
viral
environment
interact
play
major
role
clinic
outcom
hcv
infect
spontan
clearanc
sc
may
associ
immunolog
mechan
well
genet
metabol
factor
relat
serum
lipid
therefor
apolipoprotein
e
apo
isoform
interact
lipoprotein
cholesterol
could
alter
cours
diseas
aim
analyz
anthropometr
metabol
lipid
alter
sc
patient
associ
apo
allel
sc
method
total
posit
patient
includ
patient
classifi
chronic
hepat
ch
least
two
detect
viral
load
vl
sc
two
undetect
vl
last
month
clinic
record
elabor
particip
bodi
mass
index
bmi
evalu
electr
bioimped
inbodi
biochem
test
access
dri
chemistri
assay
vl
determin
taqman
hcv
test
liver
damag
evalu
transit
elastographi
apo
genotyp
identifi
taqman
pcr
result
statist
differ
detect
age
gender
risk
factor
hcv
infect
group
howev
bmi
higher
sc
ch
predomin
ch
patient
normal
weight
sc
vs
total
cholesterol
chol
hypercholesterolemia
mgdl
higher
sc
ch
patient
mgdl
vs
mgdl
p
vs
p
respect
signific
differ
detect
insulin
resist
type
diabet
sc
ch
group
vs
vs
respect
liver
damag
detect
sc
patient
despit
low
level
alt
ast
iuml
apo
allel
frequenc
significantli
higher
sc
patient
compar
ch
group
also
allel
subgroup
total
chol
valu
higher
patient
sc
compar
ch
patient
mgdl
mgdl
vs
mgdl
mgdl
respect
allel
bmi
associ
sc
ci
p
cl
ci
wherea
alt
associ
risk
factor
ch
cl
p
conclus
allel
bmi
independ
factor
sc
cholesterol
level
modul
genet
dietari
factor
may
influenc
natur
histori
outcom
hcv
infect
disclosur
follow
peopl
noth
disclos
karina
sonia
roman
nora
fierro
erika
rafael
maria
elena
arturo
panduro
background
new
treatment
hcv
allow
major
patient
achiev
sustain
virolog
respons
svr
howev
mani
patient
advanc
liver
diseas
continu
impair
liver
function
test
need
predict
clinic
cours
mani
center
routin
perform
ctmri
imag
patient
advanc
liver
diseas
provid
data
use
calcul
liver
spleen
volum
aim
assess
liver
volum
predictor
liver
function
method
studi
group
compris
cirrhot
patient
achiev
svr
impair
liver
function
defin
serum
albumin
gdl
prior
start
treatment
liver
spleen
volum
calcul
ctmri
imag
obtain
within
one
year
start
hcv
treatment
adjust
ideal
bodi
weight
use
vitrea
softwar
demograph
anthropometr
medic
record
data
collect
logist
regress
use
identifi
factor
associ
recoveri
liver
function
defin
albumin
level
gdl
result
median
age
patient
year
iqr
albumin
gdl
meld
score
iqr
liver
volum
ml
spleen
volum
ml
liver
function
return
normal
patient
recoveri
albumin
normal
significantli
relat
higher
liver
volum
odd
ratio
per
mlkg
lower
spleen
volum
everi
mlkg
lower
meld
score
everi
increas
meld
score
patient
albumin
gdl
liver
function
return
normal
strong
trend
toward
associ
recoveri
higher
liver
volum
per
mlkg
lower
spleen
volum
per
mlkg
recoveri
significantli
relat
lower
meld
score
everi
increas
meld
score
qualiti
control
test
perform
liver
explant
spleen
explant
known
volum
reveal
liver
spleen
volum
comput
ctmri
accur
estim
liver
weight
median
error
iqr
spleen
weight
median
error
iqr
valid
approach
conclus
liver
spleen
volum
may
sensit
prognost
indic
liver
function
statu
grow
number
patient
advanc
liver
diseas
achiev
svr
acknowledg
da
dk
disclosur
kian
bichoupan
consult
janssen
gilead
andrea
branch
grantresearch
support
gilead
galm
follow
peopl
noth
disclos
roberta
k
sefcik
jasnit
makkar
joshua
hartman
jame
f
crismal
neal
patel
sweta
chekuri
sara
c
lewi
bachir
taouli
thoma
schiano
background
patient
chronic
hcv
infect
increas
risk
chronic
kidney
diseas
ckd
kidney
failur
hepat
c
viru
hcv
also
common
ckd
patient
gener
popul
purpos
studi
estim
preval
ckd
stage
hcv
infect
patient
look
correl
liver
diseas
sever
patient
method
analyz
estim
glomerular
filtrat
rate
egfr
use
ckdepi
formula
patient
posit
viru
c
serolog
multicent
observ
prospect
nation
cohort
hepath
n
exclus
criteria
kidney
transplant
recipi
result
analysi
includ
patient
pt
hcv
pt
characterist
men
year
hypertens
hcv
sinc
year
abl
hcv
rna
genotyp
respect
cirrhot
patient
child
meld
averag
previous
treat
combin
c
includ
associ
interferon
ribavirin
preval
mlmin
inclus
univari
analysi
risk
factor
sex
age
bmi
durat
infect
hcv
treatment
diabet
hypertens
high
cholesterol
level
educ
histori
heart
diseas
liver
transplant
genotyp
without
influenc
stage
fibrosi
cirrhosi
child
score
multivari
analysi
predictor
irc
tabl
conclus
anr
hepath
cohort
ckd
preval
associ
age
hypertens
diabet
hypercholesterolemia
histori
cardiac
diseas
sever
liver
diseas
cirrhosi
child
meld
score
longitudin
analysi
analyz
effect
combin
renal
function
base
usual
nephropathi
risk
factor
tabl
disclosur
fontain
board
membership
abbvi
gilead
bm
janssen
independ
contractor
gilead
bm
msd
roch
janssen
boffa
advisori
committe
review
panel
msd
otsuka
philipp
mathurin
board
membership
msd
bm
gilead
abvi
verlyx
consult
roch
bayer
fabric
carrat
grantresearch
support
anr
linda
wittkop
speak
teach
janssen
gilead
follow
peopl
noth
disclos
eric
thervet
vincent
bonnemain
laurent
alric
stengel
stanisla
pol
background
sinc
develop
direct
act
antivir
daa
sustain
virolog
respons
svr
rate
chronic
hepat
c
patient
increas
dramat
daa
combin
therapi
howev
presenc
substitut
ra
decreas
suscept
daa
within
viral
quasispeci
prior
therapi
consid
main
respons
treatment
failur
viral
relaps
current
test
ra
prior
daa
therapi
recommend
clinic
guidelin
gt
patient
simeprevir
base
regimen
treatment
present
work
analyz
baselin
preval
ra
among
treatment
patient
geograph
area
massiv
parallel
sequenc
use
platform
method
total
sampl
treatment
chronic
hcv
patient
select
fragment
region
amplifi
sequenc
use
sequenc
platform
compar
consensu
sequenc
provid
lo
alamo
sequenc
databas
cutoff
detect
follow
ra
mutat
consid
present
studi
result
overal
ra
region
detect
patient
patient
present
ra
frequenc
preval
ra
follow
subtyp
preval
substitut
follow
frequenc
ra
rang
patient
b
interestingli
patient
substitut
baselin
associ
reduc
suscept
daclatasvir
ledipasvir
ombitasvir
sampl
observ
minor
mutant
carrier
show
mutat
sequenc
conclus
technolog
good
tool
studi
ra
methodolog
reveal
high
preval
ra
region
spain
howev
clinic
signific
variant
depend
frequenc
type
ra
sens
shown
higher
level
daa
resist
substitut
besid
show
preval
ra
instanc
preval
subtyp
compar
still
unknown
minim
frequenc
minor
ra
clinic
relev
disclosur
maria
buti
advisori
committe
review
panel
gilead
janssen
msd
grantresearch
support
gilead
janssen
speak
teach
gilead
janssen
bm
rafael
esteban
speak
teach
msd
bm
novarti
gilead
glaxo
msd
bm
novarti
gilead
glaxo
janssen
follow
peopl
noth
disclos
qian
chen
maria
eugenia
soria
josep
gregori
celia
peral
francisco
damir
maria
hom
david
tabernero
leonardo
nieto
juan
esteban
josep
quer
introduct
hepat
c
viru
hcv
infect
common
chronic
blood
born
infect
unit
state
account
signific
morbid
mortal
increas
effort
perform
birth
cohort
screen
get
high
risk
group
diagnos
treat
hcv
usual
report
peopl
expos
hcv
develop
chronic
infect
group
conduct
studi
determin
tradit
report
rate
develop
chronic
hcv
consist
rate
chronic
hcv
see
era
birth
cohort
screen
method
health
system
consist
hospit
health
center
electron
medic
record
epic
integr
entir
health
system
januari
therefor
januari
june
abl
collect
data
patient
within
health
system
born
screen
hcv
hcv
antibodi
ab
test
identifi
test
hcv
rna
calcul
percentag
patient
hcv
ab
calcul
percentag
patient
hcv
rna
result
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
chronic
infect
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
first
month
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
conclus
base
larg
health
system
patient
born
develop
chronic
hcv
infect
expos
hcv
therefor
patient
expos
hcv
clear
viru
without
treatment
percentag
clearanc
higher
typic
report
patient
clear
hcv
without
treatment
like
spontan
clearanc
hcv
common
previous
expect
disclosur
gia
tyson
speak
teach
gilead
scienc
shobha
joshi
grantresearch
support
salix
eisai
speak
teach
merck
gilead
squibb
georg
therapondo
grantresearch
support
gilead
conatu
speak
teach
grifol
natali
h
bzowej
grantresearch
support
gilead
scienc
ocera
therapeut
nigel
girgrah
speak
teach
gilead
follow
peopl
noth
disclos
philip
oravetz
susan
montz
aldo
russo
backgroundaim
advent
highli
effect
antivir
therapi
hepat
c
viru
hcv
infect
patient
decompens
cirrhosi
abl
achiev
sustain
virolog
respons
svr
widespread
optim
erad
hcv
would
lead
revers
cirrhosi
thu
obviat
need
liver
transplant
ltx
explant
ltx
recipi
present
opportun
accur
assess
histolog
chang
liver
svr
patient
alreadi
advanc
liver
diseas
method
institut
databas
medic
record
review
identifi
adult
liver
transplant
recipi
hcv
patient
divid
svr
versu
group
latter
defin
viremia
time
ltx
patient
stratifi
presenc
hcc
explant
liver
specimen
retriev
review
singl
pathologist
fibrosi
stage
grade
inflamm
nodul
size
overal
histolog
descript
compar
two
group
result
adult
patient
underw
ltx
primari
diagnosi
hcv
patient
achiev
svr
prior
ltx
remain
patient
select
match
age
meld
categori
year
transplant
date
five
svr
explant
review
character
complet
tabl
patient
exhibit
advanc
stage
fibrosi
vari
degre
inflamm
grade
nodul
size
regardless
recent
achiev
svr
studi
ongo
complet
data
svr
patient
avail
time
present
conclus
although
sampl
size
date
small
mark
regress
cirrhosi
observ
hcv
patient
decompens
liver
diseas
may
cirrhosi
far
advanc
regress
complet
analysi
studi
sampl
may
suggest
hcv
therapi
ltx
candid
individu
patient
postpon
antivir
therapi
may
advantag
particularli
region
high
median
meld
score
tabl
explant
characterist
select
patient
hcv
cirrhosi
svr
disclosur
w
ray
kim
advisori
committe
review
panel
intercept
gilead
scienc
merck
follow
peopl
noth
disclos
allison
kwong
john
higgin
background
approxim
million
american
live
hepat
c
viru
hcv
infect
sinc
incid
acut
hcv
infect
rise
therefor
expect
observ
increas
morbid
mortal
includ
cancer
excess
risk
liver
cancer
among
fect
well
document
howev
excess
risk
extrahepat
cancer
less
document
extrahepat
cancer
lymphoma
thyroid
pancreat
multipl
myeloma
observ
therefor
examin
risk
extrahepat
cancer
well
possibl
mediat
mechan
among
subject
compar
method
surveil
epidemiolog
end
result
seer
databas
use
assess
cancer
risk
among
year
older
unit
state
use
hcv
code
classifi
subject
hcv
posit
claim
includ
follow
studi
includ
cancer
case
well
frequenc
match
control
use
uncondit
logist
regress
calcul
adjust
odd
ratio
or
confid
interv
ci
adjust
match
variabl
includ
age
sex
calendar
year
cancer
examin
mediat
mechan
use
structur
equat
model
sem
result
multivari
model
individu
hcv
infect
higher
likelihood
overal
cancer
ci
lip
cancer
stomach
anorect
intrahepat
cancer
nhl
acut
myeloid
leukemia
skin
cancer
pancreat
cancer
diabet
main
mediat
hcv
infect
might
oper
mediat
includ
pancreat
pancreat
cancer
peptic
ulcer
stomach
cancer
conclus
hcv
potenti
risk
factor
sever
type
cancer
associ
hcv
infect
cancer
partial
mediat
diabet
factor
pancreat
peptic
ulcer
studi
need
identifi
mechan
hcv
infect
may
induc
extrahepat
cancer
disclosur
follow
peopl
noth
disclos
fatma
shebl
background
liver
fibrosi
stage
determin
clinic
outcom
chronic
hcv
infect
achiev
sustain
virolog
respons
svr
therapi
regress
fibrosi
time
studi
aim
assess
effect
hcv
daa
therapi
chang
liver
fibrosi
use
transient
elastographi
fibroscan
method
patient
treat
daa
therapi
chronic
hcv
enrol
prospect
cohort
studi
perform
baselin
fibroscan
repeat
scan
end
treatment
eot
month
primari
outcom
signific
improv
liver
fibrosi
decreas
fibroscan
score
month
treatment
rel
baselin
multivari
logist
regress
analysi
use
control
confound
sign
rank
test
use
assess
chang
liver
stiff
measur
lsm
time
point
result
patient
complet
protocol
signific
baselin
liver
fibrosi
lsm
kpa
svr
rate
primari
outcom
improv
lsm
met
patient
relaps
reach
outcom
baselin
metavir
stage
lsm
kpa
improv
lsm
kpa
cutoff
refer
baselin
lsm
kpa
associ
reach
primari
outcom
remain
signific
control
bmi
elev
alt
ci
subgroup
baselin
lsm
kpa
median
chang
lsm
month
kpa
iqr
p
conclus
treatment
chronic
hcv
daa
lead
clinic
relev
reduct
liver
fibrosi
first
year
measur
fibroscan
even
control
bmi
elev
alt
outcom
like
baselin
signific
liver
fibrosi
experienc
improv
metavir
fibrosi
stage
refer
tapper
eb
castera
l
afdhal
nh
clin
gastroenterol
hepatol
disclosur
gregori
k
robbin
grantresearch
support
gilead
xbiotech
raymond
chung
grantresearch
support
gilead
mass
biolog
abbvi
merck
bm
follow
peopl
noth
disclos
justin
chan
neliswa
gogela
hui
zheng
sara
lammert
tokunbo
ajayi
zachari
fricker
arthur
kim
background
patient
chronic
hepat
c
viru
hcv
infect
advanc
chronic
kidney
diseas
ckd
face
substanti
barrier
treatment
limit
data
current
hcv
treatment
pattern
antivir
daa
therapi
patient
hcv
advanc
ckd
examin
us
administr
claim
data
character
treatment
uptak
among
patient
hcv
advanc
ckd
daa
era
method
patient
chronic
hcv
claim
advanc
ckd
stage
iv
v
end
stage
renal
diseas
enrol
januari
march
includ
differ
treat
untreat
advanc
ckd
popul
baselin
ie
prior
one
year
follow
first
hcv
claim
analyz
test
proport
advanc
ckd
patient
initi
treatment
distribut
treatment
regimen
examin
per
calendar
year
result
adult
patient
chronic
hcv
identifi
receiv
treatment
observ
period
total
hcv
patient
diagnosi
advanc
ckd
age
year
male
claim
dialysi
baselin
advanc
ckd
patient
ever
receiv
treatment
advanc
ckd
claim
prior
treatment
start
compar
untreat
advanc
ckd
patient
advanc
ckd
patient
treat
hcv
like
year
age
male
diagnosi
cirrhosi
less
like
diagnos
anemia
type
diabet
receiv
dialysi
baselin
treatment
uptak
median
durat
year
shown
common
regimen
among
treat
advanc
ckd
patient
ribavirin
rbv
interferon
ifn
aprevir
rbv
ifn
treat
patient
receiv
sofosbuvir
sof
regimen
includ
sof
simeprevir
sof
rbv
ledipasvirsof
conclus
grow
number
patient
chronic
hcv
advanc
ckd
treat
hcv
despit
recogn
treatment
limit
popul
treatment
uptak
increas
greater
avail
daa
major
treat
patient
receiv
regimen
disclosur
amanda
w
singer
employ
gilead
scienc
brian
l
mcnabb
consult
docmatt
employ
gilead
scienc
inc
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
marcu
littman
employ
gilead
scienc
inc
manag
posit
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
van
troostenburg
de
bruyn
consult
king
colleg
london
employ
gilead
scienc
intern
ltd
stock
sharehold
gilead
scienc
anand
p
chokkalingam
employ
gilead
scienc
stock
sharehold
gilead
scienc
specif
marker
predict
develop
complic
patient
post
hepat
c
cirrhosi
sustain
virolog
respons
except
aim
studi
analyz
place
surrog
marker
fibrosi
french
nation
multicent
prospect
cohort
patient
cirrhosi
anr
cirvir
includ
center
order
predict
develop
complic
especi
hcc
studi
case
control
studi
ratio
main
event
collect
month
period
hcc
ascit
digest
hemorrag
fibromet
perform
independ
one
lab
fibroscan
analys
everi
month
month
multivari
analysi
took
account
confound
factor
match
chang
marker
time
condit
logist
regress
model
includ
case
hcc
control
cirrhot
patient
without
liver
relat
event
group
mean
age
year
male
group
compar
comorbid
diabet
kidney
failur
ha
dyslipidemia
viral
factor
except
svr
vs
p
lab
data
bilirubin
gammagt
platelet
tp
result
systemat
adjust
svr
onward
signific
differ
case
control
systemat
found
mean
marker
score
persist
fibrotest
vs
fibromet
fibrosi
vs
vs
fibroscan
vs
p
signific
differ
found
svr
patient
except
fibroscan
kinet
show
clinic
relev
chang
thu
multivari
explor
predict
valu
test
carri
adjust
svr
marker
remain
associ
occurr
complic
conclud
surrog
marker
fibrosi
abl
earli
predict
occurr
complic
especi
hcc
patient
post
hepat
c
cirrhosi
marker
kinet
give
addit
inform
herebi
propos
monitor
accur
patient
high
initi
valu
threshold
remain
determin
disclosur
h
zarski
advisori
committe
review
panel
roch
scher
plough
bm
gilead
novarti
janssen
cilag
roch
scher
plough
bm
novarti
janssen
cilag
consult
gilead
speak
teach
siemen
mari
noell
hilleret
speak
teach
bm
gilead
abbvi
advisori
committe
review
panel
roch
gilead
consult
lfb
biomedica
speak
teach
gilead
janssen
bm
roch
abbvi
follow
peopl
noth
disclos
sandra
candic
trocm
jennif
margier
carol
cagnot
pierr
nahon
introduct
brachial
flow
mediat
dilat
fmd
known
method
assess
endotheli
function
chronic
liver
diseas
endotheli
function
shown
impair
suggest
signific
correl
among
liver
damag
sinusoid
endotheli
function
liver
stiff
aim
method
investig
relationship
endotheli
function
liver
stiff
perform
studi
includ
consecut
hcv
genotyp
patient
underw
complet
clinic
laboratori
screen
hcv
infect
liver
stiff
assess
te
fmd
carotid
thick
evalu
ultrasound
mean
age
year
woman
base
te
score
accord
liver
fibrosi
metavir
score
patient
group
follow
result
show
signific
invers
linear
correl
fmd
te
valu
stiff
p
te
higher
correl
shown
signific
although
tendenc
fmd
enhanc
note
whole
popul
spearman
test
fmd
invers
correl
te
p
age
male
sex
ggt
low
plt
apri
p
directli
unconjug
bilirubin
multivari
regress
analysi
te
p
invers
unconjug
bilirubin
directli
associ
fmd
sub
analysi
conduct
patient
te
patient
te
kpa
multivari
analysi
unconjug
bilirubin
low
albumin
directli
correl
fmd
group
te
kpa
independ
factor
invers
associ
fmd
te
conclus
impair
fmd
significantli
associ
worst
te
chronic
hcv
relat
hepat
patient
sickest
diseas
liver
failur
surprisingli
seem
associ
reconstitut
endotheli
function
disclosur
marcello
persico
advisori
committe
review
panel
abbvi
grant
research
support
gilead
follow
peopl
noth
disclos
tommaso
bucci
mario
masaron
andrea
aglitti
rosa
caruso
pasqualina
di
siervi
mari
francois
tripodi
evid
indic
patient
chronic
hepat
c
chc
increas
risk
neoplasia
data
tertiari
referr
center
suggest
hcv
may
independ
risk
factor
colon
neoplasia
howev
link
colon
cancer
chc
commun
set
extens
studi
goal
studi
determin
patient
chc
undergo
colonoscopi
increas
risk
colon
neoplasia
colonoscopi
data
retrospect
collect
compar
patient
chc
control
underw
screen
surveil
patient
match
age
sex
race
data
base
polyp
size
histolog
collect
regress
analysi
appli
screen
data
consist
patient
chc
control
surveil
data
consist
chc
patient
without
chronic
liver
diseas
analysi
screen
data
indic
patient
chc
greater
number
adenoma
comparison
control
vs
p
respect
trend
toward
advanc
neoplasia
seen
chc
group
vs
p
patient
chc
greater
number
polyp
larger
cm
comparison
control
vs
p
respect
regress
analysi
indic
independ
risk
factor
chc
male
sex
develop
colon
neoplasia
odd
polyp
chc
patient
higher
odd
polyp
control
odd
ratio
confid
interv
ci
surveil
data
total
number
patient
polyp
higher
chc
group
control
vs
p
higher
proport
patient
tubular
adenoma
chc
group
vs
trend
patient
chc
polyp
larger
cm
comparison
control
vs
pn
surveil
data
regress
analysi
reveal
chc
independ
risk
develop
colon
neoplasia
odd
polyp
chc
patient
higher
odd
control
patient
odd
ratio
ci
studi
conclud
associ
hcv
infect
increas
number
polyp
advanc
neoplasia
patient
undergo
screen
colonoscopi
chc
patient
undergo
surveil
greater
odd
polyp
format
control
research
determin
high
risk
popul
undergo
screen
earlier
age
andor
decreas
interv
disclosur
follow
peopl
noth
disclos
matthew
conti
john
e
poulo
valentin
milanov
background
recent
novel
glycobiomark
wisteria
floribunda
agglutinin
bind
protein
avail
evalu
liver
fibrosi
aim
studi
assess
associ
serum
level
progress
fibrosi
hepatocarcinogenesi
cumul
surviv
rate
carcinogenesi
rate
patient
hepat
c
viru
hcv
method
studi
protocol
approv
appropri
institut
ethic
review
committe
serum
level
measur
hiscl
sysmex
co
japan
patient
histopatholog
diagnos
hospit
januari
august
patient
diagnos
class
number
patient
carcinoma
hcc
respect
median
age
male
patient
without
hcc
baselin
analyz
surviv
carcinogenesi
rate
median
month
statist
analys
test
u
test
use
cumul
surviv
rate
carcinogenesi
rate
calcul
kaplanmei
method
result
serum
level
c
significantli
higher
patient
p
serum
level
differ
significantli
patient
hcc
without
hcc
patient
without
hcc
fiveeight
year
surviv
rate
high
group
respect
wherea
intermedi
respect
one
die
patient
low
surviv
rate
differ
significantli
among
three
group
hcc
incid
patient
high
higher
low
cumul
carcinogenesi
rate
patient
high
year
contrast
patient
intermedi
patient
low
cumul
carcinogenesi
rate
differ
significantli
among
three
group
p
patient
without
hcc
die
within
month
diagnos
high
period
die
month
conclus
serum
use
diagnosi
despit
exist
hcc
patient
high
poor
prognosi
assess
serum
would
diagnost
util
predict
carcinogenesi
surviv
patient
advanc
fibrosi
disclosur
yasuhito
tanaka
grantresearch
support
chugai
pharmaceut
co
ltd
msd
abbvi
squibb
speak
teach
squibb
follow
peopl
noth
disclos
takako
inou
yuji
tsuzuki
etsuko
iio
kumiko
ohn
noboru
shinkai
tomoyuki
ohik
takaaki
goto
shigeru
sato
background
aim
erad
hepat
c
viru
hcv
interferon
ifn
therapi
report
reduc
mortal
rate
patient
chronic
hcv
chc
infect
howev
impact
hcv
erad
mortal
includ
caus
death
suffici
investig
chc
patient
advanc
liver
fibrosi
method
enrol
chc
patient
advanc
liver
fibrosi
apri
caus
death
incid
hepatocellular
carcinoma
hcc
mortal
includ
diseas
analyz
result
patient
achiev
sustain
virolog
respons
svr
erad
hcv
therapi
receiv
therapi
patient
cohort
select
svr
group
use
propens
score
match
cohort
median
durat
year
cohort
patient
mortal
rate
diseas
patient
patient
respect
cohort
patient
mortal
rate
diseas
patient
ifn
patient
respect
erad
hcv
reduc
mortal
hazard
ratio
hr
confid
interv
ci
includ
mortal
hr
ci
incid
hcc
hr
ci
conclus
erad
hcv
reduc
mortal
also
mortal
chc
patient
advanc
liver
fibrosi
disclosur
follow
peopl
noth
disclos
toshifumi
tada
takashi
kumada
hidenori
toyoda
natsuko
kobayashi
junko
tanaka
share
needl
ancillari
inject
drug
equip
place
peopl
inject
drug
pwid
risk
hepat
c
viru
hcv
highli
infecti
infect
avail
data
hcv
infect
context
inject
anoth
person
previous
use
needl
limit
goal
estim
probabl
hcv
infect
reinfect
accompani
inject
previous
use
needl
classifi
recept
needl
share
rn
probabilist
exposur
model
link
observ
hcv
infect
outcom
rn
exposur
appli
data
ufo
studi
prospect
observ
cohort
studi
activ
pwid
age
survey
test
quarterli
hcv
san
francisco
california
particip
first
survey
statu
first
survey
statu
select
return
particip
analysi
maximum
likelihood
estim
consid
rn
yield
hcv
infect
rang
among
hcv
suscept
group
tabl
show
probabl
hcv
bootstrap
confid
interv
among
differ
suscept
group
becam
infect
reinfect
least
strength
studi
includ
abil
assess
infect
specif
data
recept
needl
share
contact
vs
share
needl
well
short
recal
hcv
test
period
ascertain
exposur
outcom
event
factor
like
account
higher
infect
estim
found
other
ci
boelen
et
al
analysi
fill
import
gap
inform
due
focu
probabl
hcv
associ
rn
primari
rout
hcv
transmiss
among
pwid
result
inform
model
research
impact
prevent
scale
popul
level
impact
reduc
rn
frequenc
rn
contribut
reduc
spread
hcv
probabl
hcv
acquisit
associ
rn
disclosur
kimberli
page
grantresearch
support
nih
gilead
cdc
follow
peopl
noth
disclos
yuridia
leyva
stephen
shiboski
judith
hahn
jennif
evan
erik
erhardt
background
approxim
hepat
c
viru
hcv
patient
cirrhosi
develop
hepatocellular
carcinoma
hcc
lifetim
aspart
aminotransferas
platelet
ratio
index
apri
score
measur
fibrosi
use
determin
risk
advanc
liver
diseas
apri
score
fluctuat
cours
diseas
appear
random
explor
possibl
specif
pattern
use
diagnost
measur
certain
group
hcv
patient
method
use
veteran
health
administr
hcv
clinic
case
registri
isol
set
hcv
patient
hcv
antibodi
rna
case
propens
match
hcv
antibodi
patient
requir
minimum
two
apri
score
separ
year
prior
exist
evid
cirrhosi
hcc
year
studi
classifi
patient
use
lab
data
base
median
apri
score
year
code
clinic
stage
includ
apri
apri
apri
compens
cirrhosi
decompens
cirrhosi
hcc
transplant
care
death
data
model
analyz
webpag
capabl
display
multipl
interact
figur
patient
subgroup
e
g
age
race
gender
alcohol
abus
etc
comparison
result
base
defin
stage
record
year
illustr
diseas
progress
popul
tree
ring
diagram
span
year
period
overal
subgroup
exampl
analyz
age
group
yo
observ
mani
older
popul
die
earli
studi
middl
popul
distinct
pathway
path
compar
younger
older
base
stage
progress
path
creat
markov
chain
model
use
run
mont
carlo
simul
simul
hcv
progress
advanc
liver
diseas
found
younger
popul
greater
probabl
fluctuat
apri
score
progress
advanc
liver
diseas
use
measur
predict
futur
outcom
conclus
apri
score
power
diagnost
tool
measur
progress
advanc
liver
diseas
pattern
emerg
fluctuat
score
easili
view
tree
ring
diagram
model
progress
markov
process
provid
uniqu
novel
way
predict
futur
liver
diseas
outcom
hcv
patient
accur
predict
outcom
specif
patient
group
ultim
improv
hcv
patient
care
reduc
cost
associ
unnecessari
treatment
disclosur
peter
kuhn
stock
sharehold
epic
scienc
jennif
r
kramer
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
jeremi
mason
peter
richardson
fasiha
kanwal
paul
k
newton
backgroud
aim
geospati
analysi
novel
epidemiolog
approach
use
identifi
map
geograph
diseas
cluster
area
describ
demograph
characterist
area
scant
studi
use
geospati
analysi
hepat
c
hcv
research
sought
determin
geograph
distribut
cirrhosi
case
alabama
zip
code
determin
factor
associ
higher
cirrhosi
rate
method
obtain
data
patient
present
care
uab
liver
center
januari
decemb
perform
analysi
empir
bay
eb
local
moran
lisa
geti
ord
gi
gi
consid
zip
code
area
cluster
identifi
high
risk
cirrhosi
hot
spot
use
two
geospati
metric
e
lisa
gi
eb
rate
code
area
classifi
result
preval
cirrhosi
total
cirrhosi
case
within
cluster
area
case
within
area
cirrhosi
cluster
region
higher
cirrhosi
event
rate
per
person
ci
compar
per
person
ci
cluster
commun
locat
central
alabama
citi
birmingham
centroid
point
strong
cirrhosi
cluster
event
rate
per
person
ci
per
person
ci
birmingham
zip
code
among
highest
alabama
zip
code
patient
live
cirrhosi
cluster
commun
like
black
race
vs
p
report
activ
drug
use
vs
p
tobacco
use
vs
p
compar
patient
live
commun
cluster
commun
higher
educ
p
commun
larger
proport
individu
live
poverti
threshold
vs
pir
pir
p
compar
cluster
commun
conclus
studi
support
use
geospati
analysi
tool
identifi
geograph
distribut
cirrhosi
hot
spot
futur
studi
need
investig
underli
caus
cirrhosi
cluster
metropolitan
birmingham
area
disclosur
moham
g
shoreibah
advisori
committe
review
panel
gilead
follow
peopl
noth
disclos
omar
sim
krishna
v
venkata
justin
x
moor
sumant
arora
omar
massoud
background
fibrosi
assess
prior
hepat
c
hcv
treatment
recommend
howev
access
elastographi
limit
resourc
mani
set
even
countri
studi
aim
assess
whether
routin
blood
test
use
triag
need
fibrosi
assess
cohort
peopl
inject
drug
pwid
method
hcv
treatment
prevent
tap
studi
examin
feasibl
hcv
treatment
pwid
use
oral
sofosbuvirledipasvir
melbourn
haematolog
biochem
fibrosi
assess
use
transient
elastographi
perform
screen
ast
platelet
ratio
index
apri
calcul
compar
valid
fibroscan
score
read
success
iqrmedian
screen
cirrhosi
ishak
defin
fibroscan
score
kpa
neg
npv
posit
predict
valu
ppv
calcul
predict
cirrhosi
high
low
apri
result
particip
screen
date
apri
calcul
valid
fibroscan
avail
among
particip
male
median
age
year
iqr
year
median
bodi
mass
index
iqr
median
apri
iqr
median
fibroscan
score
iqr
liver
stiff
respect
two
individu
discrep
apri
fibroscan
score
male
age
year
old
bmi
alt
respect
use
apri
cut
npv
cirrhosi
ci
ppv
use
apri
cut
npv
cirrhosi
ppv
conclus
low
apri
score
may
accept
commun
screen
test
exclud
cirrhosi
fibroscan
unavail
use
apri
may
facilit
treatment
initi
set
apri
threshold
use
diagnos
cirrhosi
disclosur
joseph
doyl
grantresearch
support
gilead
scienc
squibb
abbvi
david
iser
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
merck
roch
amanda
j
wade
grantresearch
support
abbvi
alex
j
thompson
advisori
committe
review
panel
gilead
abbvi
bm
merck
spring
bank
pharmaceut
arrowhead
roch
grantresearch
support
gilead
abbvi
bm
merck
speak
teach
roch
gilead
abbvi
bm
margaret
hellard
grantresearch
support
gilead
scienc
bm
abbvi
backgroundaim
distribut
hepat
c
viru
hcv
genotyp
vari
accord
ethnic
geograph
differ
world
hcv
genotyp
prevail
type
japan
preval
hcv
rare
mainland
japan
contrast
okinawa
island
locat
south
japan
histori
us
militari
occup
world
war
ii
preval
okinawa
report
higher
mainland
reason
may
influenc
geograph
histor
social
background
aim
elucid
rout
timescal
transmiss
hcv
clarifi
genet
featur
hcv
okinawa
island
use
whole
genom
sequenc
hcv
subsequ
phylogenet
analysi
patientsmethod
studi
patient
hcv
infect
determin
serolog
test
enrol
born
bred
okinawa
island
mean
age
year
male
femal
perform
whole
hcv
genom
sequenc
cover
region
core
use
sever
pair
primer
phylogenet
analys
obtain
sequenc
align
use
mafft
set
global
refer
retriev
hcv
databas
phylogenet
tree
construct
method
bootstrap
time
confirm
reliabl
phylogenet
tree
method
use
mega
result
success
obtain
full
genom
sequenc
hcv
sampl
phylogenet
analys
sequenc
cluster
hcv
group
consist
us
strain
asian
cluster
suggest
possibl
rout
transmiss
us
estim
epidem
period
hcv
okinawa
perform
phylodynam
analysi
use
sampl
time
spread
hcv
estim
around
viet
nam
war
sever
rout
hcv
infect
observ
specif
cluster
consist
okinawa
sampl
observ
phylogenet
tree
conclus
okinawa
hcv
estim
introduc
us
spread
acceler
increas
intraven
drug
user
ivdu
viet
nam
war
present
hcv
infect
risk
via
medic
activ
exceedingli
zero
japan
educ
activ
take
screen
test
hcv
infect
patient
also
need
reduc
chronic
hepat
c
patient
disclosur
follow
peopl
noth
disclos
kunikazu
hoshino
masaya
sugiyama
tatsuji
maeshiro
tomoko
date
hirotaka
shoji
yohei
mano
hiroyoshi
doi
sachiyo
yoshio
tatsuya
kanto
masashi
mizokami
background
aim
era
antivir
daa
sustain
virolog
respons
svr
rate
patient
chronic
hepat
c
chc
remark
increas
howev
whether
daa
therapi
improv
liver
histolog
still
larg
unknown
aim
evalu
impact
daa
therapi
liver
fibrosi
cirrhosi
liver
stiff
measur
lsm
method
one
hundr
chines
patient
genotyp
chc
includ
studi
treat
daa
week
group
includ
ledipasvir
mg
sofosbuvir
mg
daclatasvir
mg
sofosbuvir
mg
paritaprevir
mg
ritonavir
mg
ombitasvir
mg
plu
dasabuvir
mg
age
gender
match
patient
treat
pegyl
interferon
base
therapi
median
treatment
durat
week
enrol
control
group
group
median
durat
group
week
week
respect
lsm
measur
baselin
end
transient
elastographi
te
advanc
liver
fibrosi
cirrhosi
defin
lsm
kpa
result
one
hundr
patient
group
achiev
svr
end
significantli
higher
group
p
median
lsm
decreas
significantli
baselin
group
group
vs
kpa
p
group
vs
kpa
p
median
lsm
also
decreas
significantli
group
vs
kpa
p
group
vs
kpa
median
lsm
reduct
baselin
end
group
kpa
equival
median
lsm
reduct
group
kpa
group
patient
advanc
liver
fibrosi
cirrhosi
baselin
significantli
reduc
p
significantli
reduc
p
end
similarli
patient
advanc
fibrosi
cirrhosi
baselin
group
also
significantli
reduc
p
treatment
signific
chang
treatment
end
conclus
liver
fibrosi
cirrhosi
significantli
regress
treatment
daa
therapi
genotyp
chc
patient
impact
daa
therapi
liver
stiff
equival
treatment
disclosur
follow
peopl
noth
disclos
guofeng
chen
dong
ji
lei
lu
yudong
wang
jing
chen
cheng
wang
qing
shao
bing
li
april
wong
vanessa
wu
georg
lau
fibrosi
blood
test
construct
classic
limit
uniqu
diagnost
target
signific
fibrosi
yet
test
commonli
use
diagnost
target
like
cirrhosi
therefor
aim
improv
accuraci
fibrosi
stage
target
biomark
diagnost
target
use
new
statist
method
method
patient
includ
chronic
hepat
c
chc
deriv
popul
valid
popul
differ
etiolog
chc
chronic
hepat
b
hivchc
nafld
alcohol
liver
diseas
use
metavir
fibrosi
stage
f
liver
biopsi
refer
fibromet
biomark
statist
combin
mani
fibrosi
target
made
possibl
metavir
stage
sever
statist
function
success
use
provid
uniqu
score
rang
classic
fibrosi
score
new
score
call
accuraci
evalu
primarili
obuchowski
index
discrimin
metavir
stage
secondarili
auroc
binari
diagnost
target
correct
classif
rate
fibrosi
classif
fibrosi
class
result
deriv
chc
popul
obuchowski
index
auroc
cirrhosi
significantli
superior
respect
p
classif
accur
classif
p
chc
valid
popul
patient
obuchowski
index
auroc
cirrhosi
significantli
superior
classic
blood
test
apri
test
hepascor
zeng
score
also
global
superior
untarget
fibroscan
accord
obuchowski
index
vs
respect
signific
similarli
auroc
cirrhosi
significantli
differ
fibroscan
classif
remain
accur
classif
p
result
confirm
etiolog
conclus
biomark
improv
accuraci
fibrosi
stage
highli
signific
manner
compar
classic
blood
test
match
liver
elastographi
even
cirrhosi
diagnosi
disclosur
paul
cale
consult
echosen
jerom
boursier
consult
echosen
isabel
speak
teach
abbvi
bm
gilead
follow
peopl
noth
disclos
oberti
freder
valeri
moal
sandrin
bertrai
gill
hunault
mari
christin
rousselet
background
account
econom
burden
extrahepat
manifest
essenti
accur
correct
quantif
benefit
treatment
hcv
hcv
infect
main
caus
cryoglobulinemia
vascul
cryova
evolut
hcv
treatment
allow
chang
manag
cryova
object
estim
effect
cost
treatment
direct
act
antivir
daa
era
compar
era
tertiari
nation
refer
french
center
method
chart
review
patient
treat
perform
patient
divid
two
group
accord
first
hcv
treatment
group
interferon
ifn
ribavirin
rbv
pegifnrbv
group
hcv
treatment
daa
main
characterist
assess
diagnosi
follow
first
session
effect
evalu
three
dimens
clinic
respons
cr
improv
organ
affect
cryova
baselin
absenc
clinic
relaps
immunolog
respons
ir
decreas
absenc
cryoglobulinemia
treatment
sustain
virolog
respons
svr
neg
viremia
cost
analys
resourc
use
patient
collect
includ
hcv
treatment
drug
dialysi
durat
hospit
rehabilit
care
cryova
result
patient
cryova
treat
center
sinc
women
mean
age
cryova
diagnosi
year
metavir
score
main
genotyp
main
cryova
symptom
neuropathi
purpura
arthralgia
glomerulonephr
sicca
syndrom
mean
extrahepat
cryova
manifest
per
patient
cryoglobulinemia
posit
type
ig
mk
mean
level
gl
statist
signific
differ
baselin
characterist
group
cr
improv
ir
svr
hcv
drug
cost
increas
mean
total
cost
increas
less
due
decreas
hospit
cost
treatment
conclus
larg
cohort
patient
improv
antivir
effect
safeti
hcv
drug
daa
era
result
higher
rate
clinic
immunolog
respons
cryova
signific
reduct
hospit
treatment
cost
disclosur
patric
p
cacoub
advisori
committe
review
panel
gilead
abbvi
grantresearch
support
msd
bm
speak
teach
janssen
antoin
lafuma
grantresearch
support
genom
health
gsk
pierr
fabr
ucb
bm
bayer
gilead
biogen
gedeon
richter
urgo
sanofi
diaxonhit
janssen
insm
csl
berh
eisai
msd
follow
peopl
noth
disclos
mathieu
vautier
ann
clair
desboi
mariann
doz
background
hepat
steatosi
defin
featur
fatti
liver
diseas
nafld
associ
chronic
hepat
c
infect
chc
particularli
genotyp
diseas
associ
liver
fibrosi
cirrhosi
previou
studi
suggest
associ
higher
degre
steatosi
chc
patient
advanc
fibrosi
aim
investig
preval
steatosi
steatohepat
nash
chang
obes
becom
preval
presenc
affect
fibrosi
chc
method
conduct
retrospect
review
patient
nativ
liver
biopsi
chc
tertiari
referr
center
repeat
biopsi
without
evid
chc
exclud
variabl
collect
includ
age
sex
score
degre
steatosi
histolog
featur
bmi
hcv
genotyp
lft
platelet
count
presenc
comorbid
alcohol
abus
within
month
biopsi
analysi
perform
use
stata
version
spss
version
result
overal
patient
steatosi
steatosi
overal
popul
nash
patient
nash
statist
signific
higher
preval
genotyp
elev
transaminas
compar
without
nash
addit
hispan
statist
higher
preval
nash
steatosi
compar
race
increas
preval
genotyp
infect
hispan
differ
age
bmi
diabet
hypertens
hyperlipidemia
cv
diseas
presenc
steatosi
associ
higher
rate
advanc
fibrosi
high
percentag
steatosi
presenc
sh
ci
associ
higher
rate
advanc
fibrosi
compar
without
steatosi
conclus
steatosi
highli
preval
chronic
chc
coexist
nash
chc
exist
small
number
undergo
biopsi
higher
rate
nashchc
seen
hispan
genotyp
steatosi
nash
associ
advanc
fibrosi
fold
increas
risk
respect
chc
patient
steatosisnash
may
merit
chc
treatment
sooner
closer
liver
monitor
treatment
due
risk
advanc
fibrosi
steatosisnash
disclosur
hector
e
nazario
speak
teach
merck
gilead
abbvi
janssen
follow
peopl
noth
disclos
alex
myint
priyanka
ancharya
background
us
prevent
servic
task
forc
uspstf
recommend
june
patient
born
receiv
screen
hep
atiti
c
data
evalu
implement
birth
cohort
hcv
screen
clinic
practic
scarc
intervent
improv
yet
common
practic
sought
implement
electron
health
record
ehr
clinic
decis
support
cd
tool
hcv
birth
cohort
screen
clinic
site
medic
center
evalu
effect
method
studi
conduct
gener
intern
medicin
clinic
affili
wake
forest
baptist
medic
center
serv
primarili
underrepres
minor
aa
panicoth
white
larg
uninsur
medicaid
popul
depart
medicin
informat
team
design
clinic
decis
support
tool
identifi
individu
birth
cohort
without
previou
antibodi
ab
ehr
establish
pcp
cd
consist
hcv
screen
remind
user
design
automat
provid
order
ab
data
ab
hcv
rna
test
elig
popul
record
ehr
implement
date
data
analyz
three
differ
time
point
end
histor
period
ehr
cd
implement
cd
period
result
popul
elig
screen
increas
three
period
proport
patient
test
ab
histor
juli
decemb
statist
signific
declin
proport
test
patient
posit
ab
result
cd
period
compar
prior
hcv
rna
confirmatori
test
tend
increas
cd
implement
compar
prior
cd
tool
use
order
ab
patient
screen
cd
period
conclus
within
short
period
time
despit
partial
use
month
cd
implement
modest
increas
hcv
birth
cohort
screen
addit
neg
ab
result
increas
cd
period
given
high
preval
posit
popul
believ
continu
use
cd
ad
educ
reinforc
help
uncov
hcv
infect
otherwis
may
remain
undiagnos
disclosur
follow
peopl
noth
disclos
david
n
fitch
ajay
dharod
claudia
campo
marina
nunez
object
chronic
hepat
c
viru
hcv
infect
associ
incid
variou
cancer
studi
done
us
larg
healthcar
set
aim
assess
incid
common
cancer
site
among
chronic
hcv
versu
surveil
epidemiolog
end
result
seer
gener
popul
method
conduct
cohort
studi
year
old
humana
commerci
insur
medicar
advantag
beneficiari
chronic
hepat
c
viru
hcv
patient
identifi
medic
claim
least
diagnos
within
month
patient
requir
baselin
continu
insur
prior
first
hcv
diagnosi
patient
preval
hcv
cancer
diagnos
period
exclud
patient
healthcar
util
line
reduc
detect
bia
identifi
cancer
outcom
interest
valid
algorithm
diagnos
within
month
incid
rate
hcv
cohort
estim
standard
age
sex
us
censu
popul
compar
rate
cohort
seer
area
also
standard
popul
cohort
includ
patient
hcv
diagnos
start
follow
one
healthcar
util
date
result
hcv
patient
younger
mean
age
compar
patient
mean
age
crude
incid
rate
mostli
similar
hcv
rate
standard
age
sex
incid
rate
increas
substanti
standard
rate
significantli
higher
hcv
vs
rate
ratio
rr
confid
interv
lung
liver
pancreat
cancer
rate
similar
cohort
cancer
rr
ci
colorect
cancer
lymphoma
nhl
breast
prostat
leukemia
bladder
renal
lower
incid
thyroid
cancer
hcv
vs
rr
analys
seer
rate
also
consist
hcv
patient
higher
rate
colorect
lung
liver
renal
pancreat
cancer
nhl
vs
seer
gener
popul
conclus
chronic
hcv
associ
higher
incid
common
cancer
site
versu
seer
gener
popul
adjust
age
sex
confound
comorbid
social
behavior
risk
factor
exclud
disclosur
jean
mari
arduino
employ
merck
co
inc
stock
sharehold
merck
co
inc
jinghua
employ
merck
co
inc
follow
peopl
noth
disclos
phyo
htoo
introduct
aim
accuraci
versant
hcv
genotyp
line
probe
assay
lipa
identifi
subtyp
divers
within
genotyp
report
suboptim
aim
present
studi
character
hcv
subtyp
divers
patient
sampl
previous
label
hcv
genotyp
versant
hcv
genotyp
lipa
method
consecut
sampl
store
uz
gent
rna
bank
genotyp
statu
determin
versant
hcv
genotyp
assay
lipa
hcv
sequenc
refer
method
murphi
et
al
concord
genotyp
group
subtyp
type
method
calcul
result
genotyp
subtyp
obtain
sequenc
consid
refer
genotyp
result
hcv
polymeras
region
success
sequenc
genotyp
sampl
two
genotyp
method
result
concord
genotyp
subtyp
sampl
sampl
incomplet
genotyp
lipa
exact
genotyp
result
unidentifi
subtyp
absenc
discrimin
two
subtyp
method
fail
assign
subtyp
sampl
sampl
misclassifi
lipa
wrong
genotyp
correct
genotyp
associ
wrong
subtyp
circul
hcv
recombin
form
detect
hcv
sequenc
refer
method
sampl
label
lipa
method
conclus
direct
sequenc
hcv
polymeras
region
reveal
presenc
recombin
form
sampl
major
label
genotyp
c
versant
hcv
genotyp
impact
choic
optim
antivir
treatment
regimen
patient
care
find
need
evalu
disclosur
follow
peopl
noth
disclos
han
orlent
wim
schuerman
elizaveta
padalko
isabel
desomber
patrick
descheemaek
han
van
vlierbergh
marijk
reynder
background
cirrhosi
due
hcv
infect
associ
increas
risk
hepatocellular
carcinoma
aim
studi
assess
chang
liver
transient
elastographi
te
score
patient
chronic
hepat
c
chc
achiev
sustain
viral
respons
svr
method
retrospect
prospect
studi
includ
patient
chc
baselin
liver
biopsi
achiev
svr
treatment
daa
regimen
pretreat
te
studi
least
one
follow
te
measur
week
later
post
end
treatment
respons
eotr
estim
stage
liver
fibrosi
base
te
categor
kpa
te
kpa
result
median
age
yo
male
median
bmi
median
baselin
te
entir
cohort
kpa
rang
follow
te
decreas
kpa
rang
median
chang
te
kpa
rang
baselin
entir
cohort
cirrhot
median
te
kpa
follow
median
te
done
cirrhot
popul
median
time
week
post
eotr
decreas
kpa
median
chang
te
cirrhot
patient
kpa
rang
rang
patient
compris
entir
cohort
median
chang
te
kpa
rang
rang
entir
cohort
liver
fibrosi
determin
te
cirrhot
group
patient
drop
stage
liver
fibrosi
patient
patient
correl
score
failur
achiev
improv
fibrosi
stage
patient
baselin
drop
stage
liver
fibrosi
patient
multipl
logist
regress
analysi
factor
associ
liver
fibrosi
found
patient
treatment
like
improv
fibrosi
stage
conclus
liver
fibrosi
stage
determin
te
improv
achiev
svr
daa
treatment
patient
signific
drop
te
measur
post
svr
also
correl
signific
drop
although
cirrhot
patient
signific
drop
median
te
compar
patient
lower
probabl
improv
fibrosi
stage
disclosur
eugen
r
schiff
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
janssen
salix
pharmaceut
pfizer
arrowhead
astrazeneca
cv
consult
acorda
grantresearch
support
bristol
myer
squibb
vie
gilead
merck
conatu
medmira
roch
molecular
janssen
orasur
technolog
discoveri
life
scienc
siemen
beckman
coulter
siemen
ortho
jnh
intercept
beckman
follow
peopl
noth
disclos
ahmad
alawad
masato
yoneda
tiffannia
grant
emmanuel
thoma
hepat
c
hcv
common
infect
us
birth
cohort
bc
b
account
us
chronic
infect
estim
least
hcv
unawar
condit
improv
identif
test
linkag
care
protocol
within
larg
health
care
system
paramount
thu
autom
electron
health
record
test
protocol
identifi
bc
hcv
infect
implement
methodolog
januari
hepc
linkag
care
navig
program
establish
gilead
focu
fund
autom
hcv
bc
test
protocol
primari
care
clinic
creat
went
live
centric
juli
six
discret
clinic
decis
support
option
provid
enter
separ
screen
hcv
ab
reflex
test
biostatistician
extract
hcv
test
data
via
sql
compil
sa
export
excel
analysi
descript
analysi
follow
result
juli
may
test
occur
approxim
primari
provid
locat
provid
overal
bc
patient
visit
period
test
test
hcv
ab
posit
hcv
ab
mean
age
patient
year
women
public
insur
black
baa
men
women
hcv
ab
b
aa
account
hcv
ab
baa
men
baa
women
like
hcv
ab
race
ethnic
overal
hcv
ab
rna
test
found
hcv
rna
posit
overal
hcv
test
conclus
bc
test
rate
medstar
health
less
expect
though
hcv
ab
rate
similar
cdc
bc
estim
perhap
due
low
protocol
adher
test
possibl
lower
infect
risk
region
test
differ
urban
site
interestingli
though
overal
posit
previous
report
medstar
washington
hospit
center
current
rate
alon
remain
high
work
underway
increas
test
educ
implement
geocod
analysi
understand
variabl
test
posit
rate
protocol
potenti
provid
essenti
intellig
magnitud
distribut
hcv
within
differ
region
washington
dc
maryland
significantli
impact
push
elimin
hcv
disclosur
dawn
fishbein
advisori
committe
review
panel
bm
gilead
grant
research
support
gilead
stock
sharehold
gilead
abbvi
follow
peopl
noth
disclos
alexand
geboy
whitney
l
nichol
iden
e
perez
stephen
j
fernandez
peter
basch
background
svr
patient
hcv
associ
reduc
rate
morbid
mortal
method
assess
liver
fibrosi
stage
frequent
use
propos
cure
hcv
follow
daa
therapi
defin
svr
least
week
lead
regress
liver
fibrosi
use
measur
prospect
assess
develop
cirrhosi
relat
complic
baselin
predictor
liver
fibrosi
regress
determin
method
conduct
retrospectiveprospect
studi
hcv
patient
achiev
svr
daa
treatment
abbvi
regimen
baselin
liver
fibrosi
stage
fibrosi
stage
determin
use
elastographi
shear
wave
aixplor
superson
imagin
franc
biopredict
franc
well
apri
score
baselin
month
year
month
end
treatment
result
total
patient
enrol
femal
mean
age
year
bmi
hypertens
dm
dyslipidemia
current
elig
analysi
median
follow
period
month
iqr
patient
cirrhosi
baselin
demonstr
improv
defin
chang
fibrosi
stage
patient
demonstr
improv
chang
fibrosi
score
median
iqr
elastographi
score
decreas
significantli
kpa
kpa
p
baselin
spleen
enlarg
p
bmi
bilirubin
level
hypertens
neg
associ
improv
fibrosi
stage
multivari
analysi
enlarg
spleen
predictor
fibrosi
stage
regress
baselin
age
sex
genotyp
histori
previou
antivir
treatment
comorbid
dm
dyslipidemia
alt
ast
platelet
inr
albumin
creatinin
esophag
varic
apri
predictor
fibrosi
regress
conclus
major
subject
demonstr
improv
liver
fibrosi
stage
method
clinic
paramet
neg
predictor
liver
fibrosi
regress
longer
follow
period
requir
determin
impact
daa
treatment
hcv
patient
disclosur
follow
peopl
noth
disclos
yana
davidov
yeroham
kleinbaum
oranit
ella
veitsman
tania
berdichevski
peretz
weiss
sima
katsherginski
hasid
avishag
keren
tsaraf
ziv
ben
ari
background
hepat
c
hcv
treatment
guidelin
recommend
priorit
patient
advanc
fibrosi
howev
strict
insur
requir
abstin
illicit
drug
use
may
limit
access
treatment
object
aim
identifi
socioeconom
barrier
treatment
initi
hcv
patient
advanc
fibrosi
method
new
patient
evalu
hcv
treatment
univers
kentucki
liver
clinic
juli
june
patient
suggest
stage
fibrosi
includ
cohort
analysi
patient
cirrhosi
compens
demograph
clinic
data
insur
proxim
resid
clinic
drug
alcohol
use
histori
incarcer
collect
compar
patient
treat
versu
treat
delay
treatment
e
treat
start
beyond
initi
visit
multivari
logist
regress
done
evalu
factor
predict
treatment
delay
result
mean
interv
initi
consult
treatment
start
day
month
among
treat
antivir
daa
within
month
delay
mean
month
initi
treatment
receiv
treatment
mean
age
seventi
five
percent
male
estim
live
within
mile
clinic
histori
incarcer
remot
histori
illicit
drug
use
remot
histori
alcohol
abus
treat
group
signific
differ
factor
two
group
howev
differ
insur
type
treat
group
like
insur
treat
group
vs
p
patient
delay
treatment
higher
rate
recent
histori
illicit
drug
use
vs
p
posit
urin
drug
screen
evalu
vs
p
multivari
analysi
insur
type
signific
predictor
treatment
initi
patient
insur
higher
likelihood
start
treatment
within
month
vs
medicaid
ci
p
conclus
despit
emerg
highli
effect
hcv
daa
remain
barrier
treatment
initi
patient
advanc
fibrosi
patient
insur
like
receiv
prompt
treatment
compar
medicaid
disclosur
follow
peopl
noth
disclos
patricia
santo
ronald
racho
moaz
abdelwadoud
megan
cooper
candic
b
jen
rosenau
anna
christina
dela
cruz
background
cdc
publish
guidelin
support
screen
hepat
c
hcv
person
born
estim
adult
infect
hcv
fall
within
cohort
furthermor
project
prevent
health
intervent
would
lead
diagnosi
unknown
case
prevent
death
aim
primari
object
measur
adher
hcv
screen
continu
practic
staf
intern
medicin
resid
measur
effect
intervent
enhanc
hcv
screen
method
perform
retrospect
chart
review
random
sampl
patient
born
order
meet
inclus
criteria
patient
must
hcv
statu
unknown
must
seen
primari
care
provid
time
januari
decemb
initi
data
extract
provid
given
remind
hcv
screen
guidelin
email
lectur
confer
chart
review
patient
done
measur
improv
hcv
screen
rate
intervent
data
analyz
use
test
result
patient
review
intervent
met
inclus
criteria
patient
offer
screen
hcv
intervent
patient
met
inclus
criteria
patient
screen
hcv
screen
rate
increas
percent
intervent
conclus
adher
hcv
screen
guidelin
resid
continu
practic
prior
educ
intervent
low
percent
regular
remind
email
confer
lectur
increas
awar
improv
screen
rate
resid
continu
practic
hcv
screen
rate
improv
increas
awar
hcv
screen
guidelin
regular
remind
educ
hous
staff
hcv
screen
rate
intervent
disclosur
follow
peopl
noth
disclos
ali
aamar
kamraan
madhani
prabhdeep
singh
david
chia
backgroundobject
hepat
c
viru
hcv
infect
one
lead
caus
cirrhosi
result
chronic
inflammatori
respons
viru
patient
may
higher
risk
venou
thromboembol
vte
howev
data
associ
unclear
systemat
review
conduct
aim
summar
avail
evid
method
literatur
search
perform
use
medlin
embas
incept
april
studi
report
rel
risk
odd
ratio
hazard
ratio
compar
risk
vte
among
patient
versu
subject
without
hcv
infect
includ
pool
risk
ratio
rr
confid
interv
ci
calcul
use
gener
invers
varianc
method
result
three
studi
met
elig
criteria
includ
analysi
pool
rr
vte
patient
versu
subject
without
hcv
infect
ci
subgroup
analysi
show
risk
increas
pulmonari
embol
pe
deep
venou
thrombosi
dvt
even
though
without
adequ
power
demonstr
statist
signific
pool
rr
ci
pe
pool
rr
ci
dvt
conclus
studi
demonstr
significantli
increas
risk
vte
among
patient
studi
requir
clarifi
risk
address
clinic
practic
forest
plot
includ
studi
hepat
c
infect
risk
venou
thromboembol
top
pulmonari
embol
middl
deep
venou
thrombosi
bottom
disclosur
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
panadeekarn
panjawatanan
patompong
ungprasert
background
aim
last
two
year
european
medicin
agenc
approv
highli
effect
direct
act
antivir
daa
regimen
treatment
hepat
c
access
revolutionari
daa
sofosbuvir
andor
ledipasvir
daclatasvir
ombitasvirparitaprevir
ritonavir
without
dasabuvir
pervas
remain
countri
level
differ
due
part
variat
nation
level
insur
deal
apart
variabl
patient
level
factor
also
influenc
access
aim
studi
analyz
order
influenc
resid
demograph
clinic
condit
access
daa
use
recent
patient
chart
audit
data
automat
interact
detect
chaid
method
ipso
hcv
therapi
monitor
run
sinc
eu
report
physician
per
quarter
across
itali
spain
franc
unit
kingdom
germani
physician
provid
patient
demograph
diseas
treatment
data
hcv
patient
seen
within
period
eu
therapi
monitor
data
chaid
analysi
use
creat
decis
tree
tree
determin
hierarchi
influenc
viral
load
comorbid
countri
substanc
abus
fibrosi
score
patient
access
daa
result
chaid
analysi
split
data
fibrosi
level
reveal
fibrosi
strongest
impact
daa
access
countri
substanc
abus
statu
case
next
influenti
variabl
treatment
access
focus
patient
germani
spain
abus
substanc
chanc
daa
access
whilst
abus
germani
spain
lower
chanc
respect
similar
trend
persist
throughout
individu
fibrosi
level
cohort
apart
cirrhot
patient
clinic
characterist
greater
influenc
resid
conclus
decis
tree
reveal
treatment
access
significantli
depend
fibrosi
countri
substanc
abus
viral
load
comorbid
play
lesser
role
countri
similar
fibrosi
level
adjud
experi
minor
diverg
substanc
abus
statu
integr
access
decis
differ
treatment
rate
abus
diminish
abus
commonli
deni
risk
yet
deni
access
leav
potenti
futur
strain
payer
system
disclosur
follow
peopl
noth
disclos
jason
katz
sarah
brown
moham
aiyaz
elizabeth
baynton
sabina
heinz
background
sensit
accur
hepat
c
viru
hcv
rna
detect
quantif
essenti
manag
chronic
hepat
c
therapi
current
avail
platform
assay
usual
batch
requir
least
one
full
day
work
complet
analys
object
aim
studi
evalu
abil
newli
develop
aptima
hcv
quant
dx
assay
holog
inc
san
diego
ca
amplif
tma
assay
make
use
fulli
autom
panther
system
elimin
need
batch
process
autom
aspect
nucleic
acid
test
singl
step
accur
detect
quantifi
hcv
rna
larg
seri
patient
infect
differ
hcv
genotyp
result
limit
detect
estim
iuml
specif
assay
confid
interv
coeffici
variat
rang
respect
studi
serum
specimen
patient
infect
hcv
genotyp
show
satisfactori
relationship
hcv
rna
level
measur
aptima
hcv
quant
dx
assay
realtim
pcr
compar
abbott
realtim
hcv
abbott
molecular
de
plain
il
coba
ampliprepcoba
taqman
hcv
test
version
capctm
hcv
roch
molecular
system
pleasanton
ca
assay
conclus
new
aptima
hcv
quant
dx
assay
sensit
reason
specif
reproduc
accur
quantifi
hcv
rna
serum
sampl
patient
chronic
hcv
infect
includ
patient
antivir
treatment
quantif
linear
full
dynam
rang
quantif
cover
valu
observ
untreat
treat
patient
chronic
hcv
infect
aptima
hcv
quant
dx
assay
thu
confid
use
detect
quantifi
hcv
rna
clinic
trial
new
drug
clinic
practic
europ
us
disclosur
stephan
chevaliez
advisori
committe
review
panel
janssen
speak
teach
gilead
bm
abbvi
christoph
hezod
speak
teach
roch
bm
msd
janssen
vie
gilead
pawlotski
advisori
committe
review
panel
abbvi
squibb
gilead
janssen
merck
grantresearch
support
gilead
speak
teach
squibb
gilead
merck
janssen
gilead
follow
peopl
noth
disclos
fabienn
dubernet
claud
dauvilli
background
littl
known
risk
hepat
b
viru
hbv
reactiv
hepat
c
viru
hcv
patient
receiv
interferon
ifn
direct
act
antivir
agent
daa
method
patient
receiv
week
daa
therapi
consecut
enrol
baselin
hbv
dna
hbv
surfac
antigen
hbsag
hbv
surfac
antibodi
alanin
aminotransferas
alt
serial
examin
hbv
reactiv
defin
detect
serum
hbv
dna
follow
baselin
undetect
hbv
dna
increas
iuml
hbv
dna
compar
baselin
detect
hbv
dna
signific
alt
flare
defin
alt
time
upper
limit
normal
uln
alt
time
baselin
level
concomit
hbv
dna
iuml
hepat
decompens
defin
signific
alt
flare
combin
jaundic
coagulopathi
hepat
encephalopathi
ascit
result
patient
enrol
hbv
reactiv
none
signific
alt
flare
hepat
decompens
patient
hbv
reactiv
remain
patient
none
hbv
reactiv
daa
therapi
patient
baselin
hbsag
neg
withwithout
posit
chang
hbv
serolog
marker
conclus
risk
hbv
reactiv
low
patient
receiv
daa
treatment
hbv
reactiv
limit
patient
furthermor
risk
alt
flare
hepat
decompens
also
minim
hbv
reactiv
disclosur
chen
advisori
committe
review
panel
bm
gsk
bm
gsk
medigen
consult
medigen
pharmaessentia
grantresearch
support
vazgenet
independ
contractor
j
j
speak
teach
roch
roch
follow
peopl
noth
disclos
liu
liu
hung
su
fang
yang
chen
kao
introduct
inform
epidemiolog
impact
hcv
genotyp
hcvhiv
patient
spain
scarc
data
avail
number
spread
hcv
lineag
design
set
order
determin
preval
distribut
pattern
hcv
hcvhiv
individu
multicent
retrospect
observ
cohort
studi
conduct
spanish
hospit
descript
epidemiolog
analysi
random
sampl
case
perform
portion
hcv
region
nucleotid
amplifi
sequenc
associ
plasma
sampl
hcv
subtyp
perform
use
comet
hcv
onlin
tool
compar
subtyp
system
base
phylogenet
reconstruct
phylogenet
tree
bootstrap
support
branch
built
raxml
use
detect
cluster
sequenc
result
within
initi
cohort
patient
individu
hiv
hcv
present
vhc
characterist
averag
age
male
inject
drug
user
year
estim
time
infect
stage
hepat
fibrosi
greater
equal
region
preval
hcv
exceed
within
hcv
averag
preval
subtyp
respect
distribut
pattern
hcv
subtyp
detect
proport
patient
hcv
mainli
present
north
spain
subtyp
tend
increas
north
south
presenc
greater
equal
southern
spain
addit
detect
signific
cluster
subtyp
form
sequenc
madrid
one
canari
island
share
recent
common
ancestor
moreov
genet
close
sequenc
along
sequenc
belong
dutch
hcvhiv
individu
studi
publish
also
form
signific
cluster
cluster
suggest
transnat
transmiss
network
hcv
associ
risk
factor
detect
use
methodolog
contrast
signific
cluster
found
among
subtyp
sequenc
conclus
high
percentag
hcvhiv
spanish
patient
high
preval
hcv
predomin
subtyp
especi
northern
spain
convers
subtyp
presenc
similar
greater
subtyp
southern
spain
canari
island
phylogenet
analysi
detect
group
close
relat
subtyp
sequenc
suggest
exist
transmiss
network
hcvhiv
associ
risk
factor
disclosur
miguel
von
wichmann
grantresearch
support
abbott
janssen
msd
squibb
gilead
rafael
granado
advisori
committe
review
panel
abbvi
consult
janssen
speak
teach
abbiv
janssen
gilead
follow
peopl
noth
disclos
enriqu
ortega
gonzalez
maria
alma
bracho
victor
asensi
jose
antonio
mira
marisa
mont
livia
giner
carlo
martin
antonio
francisco
arnaiz
de
la
revilla
juan
berengu
cristina
tural
francisco
vera
juan
lui
jose
antonio
oteo
elisa
antonio
aguilera
lui
morano
jorg
navarro
roberto
oropesa
javier
moreno
purificacion
inner
citi
preval
rate
hcv
thought
high
diagnosi
linkag
care
cdc
estim
babi
boomer
born
account
percent
american
hepat
c
howev
screen
popul
dismal
despit
recommend
cdc
uspstf
cm
institut
provid
primari
healthcar
babi
boomer
via
primari
care
physician
less
popul
risk
screen
prior
intervent
year
cdc
publish
recommend
object
object
studi
improv
hcv
screen
babi
boom
gener
method
use
prong
approach
creat
emr
prompt
primari
care
physician
order
screen
test
patient
visit
also
sent
letter
patient
explain
rational
screen
along
order
form
blood
test
letter
sent
approv
primari
care
physician
address
patient
sign
primari
care
physician
patient
found
posit
hcv
educ
link
care
dedic
coordin
collect
number
complet
order
prompt
letter
use
emr
improv
diseas
awar
also
conduct
cme
event
primari
care
physician
addit
coordin
met
offic
staff
provid
educ
materi
result
ongo
studi
mail
letter
patient
primari
care
physician
first
month
period
screen
rate
increas
compar
previou
month
patient
screen
mail
order
patient
found
hcv
antibodi
patient
test
hcv
rna
posit
hcv
rna
total
screen
addit
patient
screen
emr
identifi
anoth
hcv
antibodi
posit
patient
test
hcv
rna
posit
hcv
rna
total
screen
screen
also
receiv
letter
conclus
use
autom
process
incorpor
electron
medic
record
system
effect
way
increas
screen
rate
viral
infect
combin
target
mail
campaign
expand
abil
primari
care
physician
test
patient
identifi
infect
individu
preval
rate
hcv
babi
boom
gener
institut
appear
lower
previous
report
disclosur
paul
j
thuluvath
advisori
committe
review
panel
abbvi
gilead
grantresearch
support
gilead
abbvi
bm
isai
salix
speak
teach
abbvi
bayeronyx
gilead
follow
peopl
noth
disclos
harri
feldman
asher
horowitz
georg
low
background
adult
born
constitut
largest
group
peopl
unit
state
chronic
hepat
c
infect
hcv
young
adult
particularli
histori
inject
drug
use
increasingli
diagnos
unfortun
young
adult
known
low
level
engag
health
care
system
hcv
test
offer
sought
describ
characterist
young
adult
receiv
hcv
test
c
differ
program
partnership
provid
free
hcv
test
three
commun
organ
method
particip
recruit
conveni
sampl
adult
present
hcv
test
one
three
commun
health
program
philadelphia
pennsylvania
june
decemb
particip
complet
survey
time
hcv
test
includ
question
risk
factor
primari
care
prior
hcv
test
descript
statist
perform
survey
data
comparison
made
young
adult
age
older
adult
result
studi
period
adult
young
adult
present
one
commun
health
program
among
adult
consent
studi
complet
survey
young
adult
compar
older
adult
young
adult
sampl
less
like
incarcer
vs
p
like
tattoo
unregul
set
vs
p
young
adult
also
like
older
adult
use
prescript
drug
vs
p
older
adult
like
use
crack
vs
p
cocain
vs
p
despit
sever
risk
factor
young
adult
less
like
older
adult
insur
vs
primari
care
vs
p
rate
prior
hcv
test
similar
two
group
young
adult
older
adult
report
prior
test
among
previous
test
young
adult
like
test
locat
pcp
offic
vs
among
young
adult
previous
test
either
pcp
offic
elsewher
found
posit
c
differ
conclus
studi
suggest
program
import
site
engag
test
young
adult
risk
hcv
may
access
regular
health
care
epidemiolog
hcv
reveal
rise
case
among
young
adult
support
warrant
promot
test
locat
frequent
group
disclosur
michel
dougherti
employ
open
door
divers
popul
health
dispairit
research
nih
nation
institut
minor
health
health
dispar
nimha
dr
shannon
marquez
pi
grantresearch
support
gilead
scienc
lora
magaldi
grantresearch
support
gilead
scienc
carla
coleman
grantresearch
support
gilead
scienc
stacey
trooskin
advisori
committe
review
panel
gilead
scienc
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
jeffrey
hom
preston
studi
evalu
possibl
regress
liver
fibrosi
lf
cirrhosi
lc
cure
chronic
hepat
c
hcv
past
limit
includ
lack
efficaci
drug
studi
examin
effect
sustain
virolog
respons
svr
new
direct
act
antivir
daa
chang
lf
lc
use
test
aspart
amino
transferas
platelet
ratio
index
apri
method
retrospect
cohort
studi
conduct
use
clinic
data
hcv
patient
januari
april
medstar
washington
hospit
center
compar
score
patient
daa
therapi
achiev
svr
treat
safeti
lab
collect
treatment
group
baselin
week
end
treatment
week
treatment
untreat
patient
equival
time
point
wilcoxon
test
use
assess
correl
covari
multivari
logist
regress
use
assess
correl
apri
result
patient
treat
mean
age
year
male
black
statist
signific
differ
treat
control
regard
sex
raceethn
age
significantli
older
treat
group
p
major
hcv
previous
treatment
naiv
though
latter
less
patient
treat
v
regard
baselin
lflc
patient
treatment
group
v
score
significantli
higher
control
compar
treatment
group
time
respect
regard
apri
baselin
fewer
lflc
patient
treatment
group
v
statist
signific
apri
score
significantli
higher
control
compar
treatment
group
time
p
apri
stage
lc
vs
odd
develop
lc
time
time
higher
treat
oradj
stage
lc
vs
odd
develop
lc
time
time
higher
respect
orsadj
apri
score
valid
marker
liver
diseas
examin
treat
new
daa
achiev
svr
studi
show
apri
score
improv
even
advanc
diseas
compar
treat
period
evid
achiev
svr
may
lead
improv
liver
diseas
disclosur
dawn
fishbein
advisori
committe
review
panel
bm
gilead
grant
research
support
gilead
stock
sharehold
gilead
abbvi
follow
peopl
noth
disclos
whitney
l
nichol
alexand
geboy
sameer
desal
iden
e
perez
backgroundobject
gallston
complic
one
common
hepatobiliari
tract
diseas
sever
epidemiolog
studi
suggest
patient
hepat
c
viru
hcv
infect
might
increas
risk
gallston
howev
data
relationship
remain
inconclus
conduct
aim
summar
avail
evid
method
literatur
search
perform
use
medlin
embas
databas
incept
may
studi
report
rel
risk
odd
ratio
hazard
ratio
compar
risk
gallston
among
patient
versu
subject
without
hcv
infect
includ
pool
odd
ratio
confid
interv
ci
calcul
use
gener
invers
varianc
method
result
eleven
studi
met
elig
criteria
includ
analysi
pool
gallston
patient
versu
subject
without
hcv
infect
ci
subgroup
analysi
show
signific
risk
increas
male
pool
ci
femal
pool
ci
conclus
studi
demonstr
significantli
increas
risk
gallston
among
patient
studi
requir
clarifi
risk
address
clinic
pictur
forest
plot
includ
studi
hepat
c
infect
risk
gallston
disclosur
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
panadeekarn
panjawatanan
natasorn
lekuthai
patompong
ungprasert
background
quantif
hepat
c
viru
core
antigen
hcv
ag
serum
use
estim
viral
replic
newli
develop
fulli
autom
chemiluminesc
enzym
immunoassay
cleia
hcv
ag
avail
japan
aim
studi
compar
new
hcv
ag
assay
convent
one
evalu
clinic
util
method
studi
protocol
approv
appropri
institut
ethic
review
committe
new
hcv
ag
assay
lumipuls
presto
hcv
ag
hcv
ag
fujirebio
inc
compar
two
convent
assay
lumipuls
ortho
hcv
ag
hcv
ag
fujirebio
inc
architect
hcv
ag
abbott
japan
total
frozen
sera
posit
neg
lp
ortho
hcv
ag
hospit
total
fresh
sera
neg
hcv
ag
obtain
day
examin
perform
use
studi
basic
examin
reproduc
stabil
quantit
limit
examin
correl
concord
rate
hcv
ag
convent
assay
perform
specif
test
hcv
ag
examin
total
frozen
sera
hypergammaglobulinemia
neg
hcv
ag
measur
hcv
ag
result
reproduc
stabil
quantit
limit
hcv
ag
support
result
efficaci
case
posit
hcv
ag
correl
found
hcv
ag
architect
hcv
ag
discrep
lumipuls
presto
hcv
ag
discrep
lumipuls
presto
architect
hcv
ag
concord
rate
lumipuls
presto
hcv
ag
lumipuls
presto
architect
hcv
ag
case
neg
hcv
ag
discrep
total
frozen
sampl
fresh
sampl
neg
hcv
ag
neg
hcv
ag
cutoff
valu
fmoll
meanwhil
discrep
assay
cutoff
valu
fmoll
frozen
sampl
hypergammaglobulinemia
neg
hcv
ag
sampl
neg
one
sampl
igg
mgdl
show
hcv
ag
conclus
result
basic
examin
specif
test
reliabl
concord
rate
convent
assay
high
nonspecif
reaction
caus
hypergammaglobulinemia
found
reduc
new
assay
lumipuls
presto
hcv
ag
use
high
clinic
effici
disclosur
yasuhito
tanaka
grantresearch
support
chugai
pharmaceut
co
ltd
msd
abbvi
squibb
speak
teach
squibb
follow
peopl
noth
disclos
takako
inou
tomoyuki
ohik
takaaki
goto
kumiko
ohn
yuji
tsuzuki
shigeru
sato
introduct
hepat
c
viral
infect
hcv
becom
curabl
diseas
due
develop
direct
act
antivir
daa
therefor
world
health
organ
set
target
elimin
hcv
largest
group
risk
hcv
present
peopl
inject
drug
pwid
especi
western
world
due
variou
barrier
risk
group
still
underserv
hcv
goal
studi
case
manag
polici
could
improv
uptak
screen
treatment
hcv
pwid
method
perform
prospect
intervent
cohort
studi
evalu
effect
case
manag
screen
treatment
hcv
pwid
opiat
substitut
treatment
ost
set
limburg
belgium
goal
address
pwid
set
provid
step
continuum
care
propos
meyer
jp
et
al
int
j
drug
polici
cohort
exist
four
group
pwid
firstli
larg
group
receiv
methadon
local
pharmaci
second
larg
group
receiv
methadon
ost
set
thirdli
smaller
group
activ
user
needl
exchang
program
final
small
group
recruit
referr
hospit
former
pwid
result
result
present
figur
group
case
screen
except
pharmaci
group
present
time
year
ost
set
could
explain
lower
screen
rate
howev
address
pwid
pharmaci
group
test
pwid
cohort
approxim
hcv
rna
posit
chronic
infect
pwid
assess
treatment
elig
antivir
treatment
howev
treatment
could
start
within
belgian
reimburs
criteria
requir
metavir
fibrosi
score
rule
therapi
present
treatment
start
conclus
case
manag
effect
way
screen
cohort
individu
hcv
also
improv
treatment
uptak
disclosur
frederik
neven
consult
msd
caf
intercept
gore
bm
abbvi
novarti
durect
ono
pharma
promethera
bioscienc
grant
research
support
fer
roch
astella
novarti
abbvi
geert
robaey
advisori
committe
review
panel
msd
janssen
gilead
abbvi
bm
follow
peopl
noth
disclos
rob
bielen
rita
verrando
jori
pender
el
ori
purpos
introduct
oral
antivir
daa
dramat
chang
landscap
hcv
treatment
mani
patient
elig
therapi
due
absenc
interferon
ribavirin
effect
mirror
result
phase
clinic
trial
object
quantifi
number
hcv
gt
patient
popul
fail
current
approv
oral
daa
includ
vs
failur
time
us
method
use
hepat
c
diseas
burden
simul
model
previous
valid
nhane
cdc
studi
use
project
chang
hcv
preval
us
simul
current
clinic
manag
hcv
includ
screen
use
market
research
data
im
ipso
model
daa
treatment
differ
wave
start
launch
daa
follow
daa
includ
sofosbuvir
simeprevir
ledipasvir
multipl
contain
daa
svr
rate
obtain
trio
target
dataset
within
model
patient
fail
elig
unless
cirrhot
project
number
patient
undergo
treatment
number
patient
fail
daa
result
estim
million
patient
would
receiv
treatment
daa
would
fail
achiev
svr
daa
inhibitor
failur
figur
characterist
patient
fail
daa
cirrhosi
conclus
even
era
highli
efficaci
daa
signific
number
patient
fail
achiev
svr
limit
option
popul
repres
group
signific
unmet
medic
need
safe
effect
therapi
need
popul
prevent
longterm
sequela
hcv
disclosur
jagpreet
chhatwal
consult
merck
co
inc
gilead
complet
heor
solut
grantresearch
support
nihnat
center
advanc
translat
scienc
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
stuart
c
gordon
advisori
committe
review
panel
gilead
abbvi
merck
intercept
consult
cv
caremark
grantresearch
support
cymba
bay
gilead
bm
abbvi
intercept
conatu
exalenz
merck
speak
teach
gilead
intercept
follow
peopl
noth
disclos
qiushi
chen
turgay
ayer
fasiha
kanwal
xiaoji
wang
mark
robert
backgroundaim
spontan
hepat
c
viru
hcv
clearanc
achiev
sustain
virolog
respons
svr
mean
therapi
greatli
reduc
incid
hepatocellular
carcinoma
hcc
develop
current
studi
aim
compar
risk
hcc
two
patient
group
method
total
subject
spontan
hcv
clearanc
sc
patient
svr
group
enrol
analysi
result
nineteen
patient
develop
hcc
fourteen
svr
patient
sc
patient
develop
hcc
cox
regress
analysi
factor
predict
hcc
includ
svr
versu
sc
hazard
ratio
hr
confid
interv
ci
diabet
hr
age
hrci
svr
patient
eleven
patient
fibrosi
stage
patient
develop
hcc
compar
sc
subject
svr
patient
p
higher
risk
hcc
develop
analysi
use
liver
fibrosi
variabl
demonstr
factor
associ
hcc
includ
svr
versu
sc
hr
ci
diabet
age
hrci
conclus
compar
subject
spontan
viral
clearanc
subject
antivir
hcv
viral
clearanc
remain
high
risk
hcc
develop
especi
signific
hepat
fibrosi
result
may
provid
import
inform
regard
priorit
current
direct
antivir
agent
countri
disclosur
yu
advisori
committe
review
panel
abbott
msd
abbvi
gilead
j
j
roch
bm
consult
msd
abbvi
gilead
j
j
roch
bm
grantresearch
support
abbott
roch
msd
abbvi
gilead
vie
gilead
roch
bm
speak
teach
abbott
roch
msd
gilead
bm
gsk
chuang
advisori
committe
review
panel
gilead
abbvi
roch
pharmaessentia
speak
teach
gilead
roch
bm
msd
pharmaessentia
follow
peopl
noth
disclos
huang
dai
huang
lee
background
hiv
hcv
infect
character
chronic
immun
system
activ
lead
immunolog
dysregul
exhaust
studi
assess
evolut
inflamm
paramet
hivhcv
subject
treat
differ
regimen
method
individu
start
treatment
includ
analysi
data
leukocyt
inflamm
marker
cryoglobulin
autoantibodi
collect
baselin
week
end
treatment
descript
statist
wilcoxon
test
use
result
hiv
hcv
patient
male
median
age
year
achiev
treatment
differ
regimen
mainli
sof
ribavirin
combin
daclatasvir
ledipasvir
simeprevir
major
infect
genotyp
cirrhot
none
diagnosi
autoimmun
diseas
subject
kidney
damag
trend
neutrophil
increas
chang
observ
leukocyt
ratio
ferritin
cryoglobulin
posit
decreas
significantli
decreas
significantli
ana
posit
remain
stabl
fluoresc
chang
trend
anti
ring
rod
antibodi
increas
conclus
analysi
show
achiev
svr
partial
improv
immunolog
paramet
within
short
follow
immunolog
respons
term
cryoglobulin
clearanc
signific
ana
show
chang
fluoresc
regist
antibodi
consid
subject
alreadi
present
baselin
increas
virolog
clearanc
even
without
interferon
thu
suggest
virolog
instead
effect
tabl
comparison
disclosur
follow
peopl
noth
disclos
roberto
rossotti
background
patient
live
chc
us
born
popul
age
increas
rate
medic
comorbid
make
chc
manag
challeng
addit
relat
medic
interact
may
complic
use
cytochrom
metabol
daa
object
measur
preval
comorbid
medic
may
barrier
toward
initi
daa
larg
u
cohort
chc
method
identifi
optum
insight
insur
claim
databas
chc
patient
code
treatment
group
consist
patient
receiv
daa
prescript
patient
treat
prior
exclud
studi
medic
comorbid
defin
code
result
total
insur
chc
patient
includ
treat
untreat
patient
major
male
medicar
medic
comorbid
figur
untreat
patient
like
end
stage
renal
diseas
vs
treat
p
congest
heart
failur
vs
treat
p
seizur
disord
vs
treat
p
untreat
patient
also
like
activ
prior
episod
psychosi
vs
treat
p
like
prescrib
medic
potenti
sever
interact
daa
vs
treat
p
includ
anticonvuls
untreat
vs
treat
p
conclus
larg
medicar
us
cohort
chc
patient
preval
certain
major
comorbid
concomit
medic
higher
untreat
chc
patient
compar
treat
patient
presenc
major
comorbid
concomit
medic
major
interact
medic
may
barrier
therapi
treatment
prior
develop
comorbid
relat
medic
may
help
improv
overal
treatment
rate
chc
disclosur
mindi
h
nguyen
advisori
committe
review
panel
squibb
gilead
consult
gilead
scienc
inc
grantresearch
support
gilead
scienc
inc
squibb
follow
peopl
noth
disclos
philip
vutien
nhu
josephin
q
tran
felix
cao
vincent
peichel
background
new
york
citi
nyc
mani
estim
resid
chronic
hepat
c
hcv
like
seek
care
one
nyc
acut
care
hospit
outpati
clinic
data
capac
hospit
provid
hcv
screen
diagnosi
treatment
limit
given
chang
landscap
hcv
treatment
complex
nyc
healthcar
system
understand
gap
relat
hcv
care
need
tailor
intervent
end
nyc
health
depart
conduct
need
assess
hospit
capac
hcv
screen
diagnosi
treatment
method
health
depart
develop
administ
survey
practic
relat
hcv
screen
diagnosi
treatment
capac
nyc
acut
care
hospit
clinic
repres
hospit
recruit
email
site
visit
respons
collect
paper
survey
surveymonkey
com
juli
septemb
descript
analysi
conduct
use
survey
monkey
excel
result
hospit
complet
survey
respons
rate
screen
hospit
respond
question
indic
patient
risk
factor
hcv
infect
eighteen
site
also
report
hospit
electron
health
record
system
screen
alert
patient
born
yet
report
screen
cohort
diagnosi
eleven
site
report
challeng
provid
rna
test
implement
hcv
reflex
test
treatment
except
one
facil
hospit
indic
abl
provid
hcv
treatment
howev
respond
indic
hcv
treatment
avail
primari
care
clinic
hivhcv
patient
respect
patient
care
infecti
diseas
gastroenterolog
clinic
final
hospit
respond
question
indic
denial
medic
coverag
health
insur
barrier
hcv
treatment
conclus
survey
provid
understand
practic
gap
hcv
care
capac
among
acut
care
hospit
clinic
nyc
low
rate
screen
confirmatori
test
along
limit
provid
capac
primari
care
set
barrier
secur
treatment
report
inform
use
guid
work
hcv
clinic
network
develop
intervent
address
gap
disclosur
follow
peopl
noth
disclos
ryan
duerm
shale
maulana
jessi
schwartz
nirah
johnson
eric
j
rude
fabienn
laraqu
background
aim
quantif
hcv
rna
antivir
therapi
essenti
guidanc
treatment
durat
decid
futil
determin
sustain
respons
aim
studi
evalu
perform
recent
pcr
hcv
rna
assay
hcv
use
system
coba
hcv
roch
diagnost
method
analyt
sensit
linear
lower
concentr
luml
assess
coba
hcv
use
standard
traceabl
panel
repres
hcv
genotyp
gt
compar
two
establish
hcv
rna
assay
hcv
test
capctm
hcv
test
use
high
pure
system
hpsctm
ln
addit
pairwis
assay
comparison
perform
use
clinic
serum
sampl
repres
hcv
concord
baselin
sampl
assess
use
million
luml
use
tailor
treatment
durat
patient
receiv
ledipasvirsofosbuvir
result
analyt
sensit
coba
hcv
lu
ml
cl
sampl
repres
gt
luml
gt
respect
coba
hcv
mostli
linear
low
hcv
rna
concentr
mean
observ
log
differ
sampl
contain
differ
expect
observ
result
log
luml
pairwis
comparison
quantifi
gt
sampl
show
excel
agreement
coba
hcv
capctm
mean
differ
cl
coba
hcv
vs
hpsctm
mean
differ
cl
use
concord
baselin
sampl
coba
hcv
vs
capctm
coba
hcv
vs
hpsctm
respect
respect
million
luml
conclus
coba
hcv
highli
sensit
linear
low
end
dynam
rang
gt
coba
hcv
show
excel
correl
high
level
concord
million
capctm
hp
ctm
clinic
sampl
patient
hcv
disclosur
johann
vermehren
advisori
committe
review
panel
abbvi
abbott
speak
teach
abbvi
squibb
gilead
medtron
benjamin
maasoumi
advisori
committe
review
panel
abbott
molecular
grantresearch
support
abbott
molecular
roch
diagnost
speak
teach
msdmerck
roch
diagnost
roch
pharma
fujirebio
bm
abbvi
enriqu
marino
employ
roch
molecular
system
inc
ed
g
marin
employ
roch
molecular
system
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
follow
peopl
noth
disclos
caterina
berkowski
veroniqu
background
simplifi
afford
diagnost
tool
essenti
facilit
global
access
hepat
c
viru
hcv
treatment
studi
evalu
clinic
perform
hcv
core
antigen
hcvcag
detect
altern
rna
test
plasma
monitor
hcv
treatment
efficaci
recent
infect
method
particip
recent
hcv
infect
durat
infect
complet
week
sofosbuvirribavirin
ii
assess
week
end
treatment
etr
week
week
week
hcv
rna
hcvcag
quantifi
ampliprepcoba
taqman
assay
roch
architect
hcv
ag
abbott
diagnost
sensit
specif
hcvcag
assay
calcul
quantifi
hcv
rna
result
longitudin
sampl
treat
particip
avail
hcv
rna
hcvcag
test
includ
baselin
etr
week
overal
hcvcag
demonstr
sensit
ci
specif
ci
compar
hcv
rna
hcvcag
detect
sampl
demonstr
sensit
ci
two
baselin
hcvcag
sampl
quantifi
hcv
rna
ml
etr
rna
hcvcag
detect
sampl
respect
sensit
ci
specif
ci
week
rna
hcvcag
detect
sampl
respect
sensit
ci
specif
ci
ci
two
week
hcvcag
result
quantifi
hcv
rna
conclus
studi
demonstr
core
antigen
provid
high
specif
compar
hcv
rna
potenti
clinic
util
hcv
core
antigen
requir
evalu
particularli
context
low
hcv
rna
level
disclosur
gavin
cloherti
employ
abbott
laboratori
stock
sharehold
abbott
laboratori
jason
grebe
advisori
committe
review
panel
merck
gilead
grant
research
support
merck
gilead
abbvi
bm
gregori
dore
board
membership
gilead
merck
abbvi
squibb
grantresearch
support
gilead
merck
abbvi
squibb
speak
teach
gilead
merck
abbvi
squibb
follow
peopl
noth
disclos
francoi
lamouri
behzad
hajarizadeh
mariann
martinello
angelica
soker
danica
martinez
philip
cunningham
pip
mark
gail
matthew
janaki
amin
tanya
l
appleg
background
phase
studi
combin
sofosbuvir
sof
velpatasvir
vel
voxilaprevir
vox
target
distinct
hcv
protein
respect
demonstr
high
efficaci
genotyp
gt
hcv
infect
patient
durat
week
evalu
effect
baselin
resist
associ
substitut
rass
treatment
outcom
emerg
rass
patient
experi
virolog
failur
method
deep
sequenc
perform
baselin
patient
time
virolog
failur
result
report
use
cutoff
result
baselin
patient
rass
least
one
andor
viral
gene
rass
observ
commonli
patient
patient
previous
receiv
inhibitor
patient
treat
week
achiev
similar
rate
observ
patient
without
rass
patient
achiev
inhibitor
patient
patient
ra
achiev
overal
patient
rass
baselin
achiev
thirteen
patient
nucleosid
inhibitor
ni
rass
includ
achiev
patient
relaps
none
treatment
emerg
rass
one
patient
relaps
confer
phenotyp
chang
vox
conclus
baselin
rass
impact
virolog
respons
patient
follow
treatment
sof
vel
vox
week
respect
viral
relaps
associ
emerg
viral
resist
patient
without
baselin
rass
disclosur
nanci
reau
advisori
committe
review
panel
jannsen
merck
abbvi
intercept
salix
bm
gilead
grantresearch
support
gilead
intercept
vie
mindi
h
nguyen
advisori
committe
review
panel
squibb
gilead
consult
gilead
scienc
inc
grantresearch
support
gilead
scienc
inc
squibb
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
edward
j
gane
advisori
committe
review
panel
abbvi
janssen
gilead
scienc
achillion
merck
speak
teach
abbvi
gilead
scienc
merck
alnylam
hada
employ
gilead
scienc
stock
sharehold
gilead
scienc
evguenia
svarovskaia
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
jenni
c
yang
employ
gilead
scienc
inc
luisa
stamm
employ
gilead
scienc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
michael
miller
employ
gilead
scienc
stock
sharehold
gilead
scienc
hongmei
mo
employ
gilead
scienc
inc
eric
lawitz
advisori
committe
review
panel
abbvi
achillion
pharmaceut
regulu
therav
enanta
idenix
pharmaceut
janssen
merck
co
novarti
gilead
grantresearch
support
abbvi
achillion
pharmaceut
boehring
ingelheim
squibb
gilead
scienc
glaxosmithklin
idenix
pharmaceut
intercept
pharmaceut
janssen
merck
co
novarti
nitto
denko
therav
salix
enanta
speak
teach
gilead
janssen
abbvi
bristol
meyer
squibb
merck
intercept
paul
kwo
advisori
committe
review
panel
abbott
abbvi
bm
gilead
janssen
merck
alnylam
quest
cv
innovio
grantresearch
support
abbvi
bm
gilead
merck
janssen
esai
cepheid
conatu
michael
p
curri
consult
alexion
bristol
meyer
squib
abbvi
grant
research
support
gilead
scienc
conatu
ira
jacobson
consult
abbvi
achillion
bristol
myer
squibb
intercept
gilead
janssen
merck
trek
grantresearch
support
abbvi
bristol
myer
squibb
gilead
janssen
merck
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
background
earli
treatment
acut
hepat
c
viru
hcv
infect
interferon
alfa
monotherapi
highli
effect
associ
frequent
unfavor
side
effect
fulli
publish
studi
yet
explor
safeti
efficaci
requir
treatment
durat
interferon
free
treatment
acut
hepat
c
viru
monoinfect
preliminari
report
suggest
ledipasvirsofosbuvir
therapi
effect
acut
hepat
c
relaps
report
patient
week
treatment
method
german
hepnet
acut
hcv
iv
studi
design
singl
arm
prospect
multicent
pilot
studi
evalu
efficaci
safeti
treatment
sofosbuvir
plu
ledipasvir
sofldv
week
without
ribavirin
patient
acut
genotyp
hcv
monoinfect
report
final
week
post
treatment
result
result
twenti
patient
includ
center
male
mean
age
year
patient
hcv
genotyp
patient
genotyp
main
risk
factor
hcv
infect
sexual
transmiss
medic
proceduresneedl
stick
injuri
median
alanin
aminotransferas
alt
median
bilirubin
level
start
antivir
treatment
ul
rang
moll
rang
respect
alt
level
rapidli
declin
therapi
valu
normal
alreadi
treatment
week
patient
week
patient
hcv
rna
undetect
roch
hcv
test
week
patient
respect
patient
alreadi
complet
remain
neg
conclus
treatment
week
ldvsof
well
toler
highli
effect
hcv
genotyp
monoinfect
patient
acut
hepat
c
virolog
respons
durabl
therapi
least
week
rapid
improv
biochem
diseas
activ
observ
therapi
treatment
acut
hepat
c
could
prevent
spread
hcv
high
risk
popul
may
compar
treatment
chronic
hepat
c
disclosur
katja
deterd
speak
teach
abbvi
msdmerck
gilead
christoph
spinner
advisori
committe
review
panel
gilead
scienc
grantresearch
support
gilead
scienc
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
tania
welzel
advisori
committe
review
panel
novarti
janssen
gilead
abbvi
bm
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
anita
pathil
speak
teach
abbvi
bm
gilead
marku
cornberg
advisori
committe
review
panel
merck
msd
mamni
roch
gilead
novarti
abbvi
janssen
cilag
bm
grantresearch
support
merck
msd
germamni
roch
speak
teach
merck
msd
germamni
roch
gilead
bm
novarti
falk
abbvi
andrea
umgelt
speak
teach
gilead
bm
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
follow
peopl
noth
disclos
guido
gerken
ulrich
spengler
johann
wiegand
julian
schulz
zur
wiesch
carolin
armin
papkalla
kristina
weber
svenja
hardtk
heiko
von
der
leyen
armin
koch
dorothe
von
witzendorff
background
object
select
direct
act
antivir
daa
shown
high
safeti
efficaci
treat
hepat
c
hcv
patient
decompens
cirrhosi
dcc
howev
limit
empir
evid
compar
health
econom
outcom
associ
treat
patient
vs
transplant
lt
object
studi
analyz
vs
post
lt
treatment
daa
regimen
among
patient
dcc
waitlist
wl
lt
method
construct
markov
model
natur
diseas
progress
hcv
patient
decompens
cirrhosi
dcc
waitlist
wl
lt
model
follow
hypothet
cohort
patient
mean
age
lifetim
horizon
us
payer
perspect
estim
health
cost
outcom
base
vs
treatment
oral
daa
health
state
natur
histori
stratifi
meld
score
svr
transit
probabl
util
base
literatur
hepatologist
consensu
svr
rate
sourc
cost
sourc
redbook
medicar
fee
schedul
publish
literatur
result
treatment
arm
mean
time
wl
year
probabl
death
wl
vs
year
arm
model
time
horizon
treatment
arm
yield
patient
svr
patient
hcc
death
vs
arm
treatment
strategi
result
life
year
qali
per
patient
life
year
ly
per
patient
lifetim
cost
vs
arm
therefor
treatment
found
icer
base
determinist
sensit
analysi
result
sensit
util
patient
treatment
svr
rate
lt
cost
conclus
time
antivir
treatment
hcv
patient
dcc
rel
lt
import
area
clinic
polici
research
result
indic
treatment
highli
effect
daa
regimen
strategi
treatment
hcv
patient
dcc
waitlist
lt
disclosur
sammi
saab
advisori
committe
review
panel
bm
gilead
merck
janssen
grantresearch
support
gilead
speak
teach
bm
gilead
merck
janssen
salix
onyx
bayer
janssen
stock
sharehold
achillion
johnson
johnson
bm
gilead
stevan
gonzalez
speak
teach
gilead
salix
abbvi
merck
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
follow
peopl
noth
disclos
ryan
b
perumpail
georg
cholankeril
zobair
younossi
background
proteas
inhibitor
pi
identifi
abbvi
enanta
inhibitor
next
gener
hcv
antivir
agent
daa
achiev
high
sustain
virolog
respons
rate
patient
hcv
genotyp
gt
infect
well
patient
previous
fail
regimen
report
present
character
variant
detect
sampl
subject
enrol
part
studi
treatment
rbv
week
patient
previous
fail
regimen
contain
pi
andor
inhibitor
polymeras
inhibitor
method
next
gener
sequenc
ng
perform
hcv
gene
baselin
sampl
first
avail
sampl
virolog
failur
hcv
rna
iu
ml
sequenc
result
detect
cutoff
examin
presenc
variant
rav
gene
result
ng
cutoff
baselin
sampl
patient
identifi
rav
patient
target
sampl
rav
also
present
use
ng
detect
cutoff
patient
cohort
broad
represent
baselin
variant
key
posit
includ
well
patient
baselin
variant
posit
confer
high
level
resist
current
approv
inhibitor
achiev
patient
experienc
virolog
failur
patient
baselin
rav
patient
baselin
rav
conclus
combin
demonstr
potent
antivir
activ
high
barrier
resist
hcv
fect
patient
previous
fail
regimen
regardless
divers
profil
high
preval
baselin
andor
rav
among
patient
promis
result
support
studi
combin
regimen
larger
cohort
patient
disclosur
teresa
ng
employ
abbvi
patent
heldfil
abbvi
stock
sharehold
abbvi
tami
employ
abbvi
stock
sharehold
abbott
rakesh
tripathi
employ
abbvi
stock
sharehold
abbvi
gretja
schnell
employ
abbvi
inc
stock
sharehold
abbvi
inc
thoma
reisch
employ
abbvi
stock
sharehold
abbvi
jill
beyer
employ
abbvi
stock
sharehold
abbvi
tanya
dekhtyar
employ
abbvi
stock
sharehold
abbvi
armen
asatryan
employ
abbvi
federico
mensa
employ
abbvi
stock
sharehold
abbvi
jen
kort
employ
abbvi
stock
sharehold
abbvi
christin
collin
employ
abbvi
background
aim
chronic
hepat
c
viru
chc
patient
decompens
cirrhosi
dcc
await
transplant
limit
treatment
option
high
risk
comorbid
increas
mortal
new
oral
singl
tablet
regimen
sofosbuvirvelpatasvir
sofvel
shown
excel
efficaci
safeti
popul
markov
model
evalu
health
outcom
sofvel
compar
current
treatment
option
dcc
method
analysi
model
cohort
chc
dcc
genotyp
gt
patient
averag
age
us
payer
perspect
lifetim
horizon
treatment
sofvel
week
w
ribavirin
r
compar
ledipasvirsofosbuvir
ldvsof
sof
daclatasvir
dcv
treatment
nt
sustain
virolog
respons
svr
rate
extrapol
transit
probabl
util
base
literatur
review
consensu
panel
hepatologist
result
sofvel
regimen
result
best
health
outcom
term
lowest
number
hepatocellular
carcinoma
hcc
case
liver
transplant
lt
death
compar
compar
gt
tabl
sofdcv
associ
slightli
fewer
complic
particularli
hcc
lt
conclus
compar
current
avail
option
includ
sofdcv
ldvsof
nt
sofvel
demonstr
better
overal
health
outcom
dcc
patient
lead
fewer
case
complic
sofvel
avail
daili
singl
tablet
regimen
chc
patient
simplifi
treatment
across
gt
tabl
project
health
outcom
patientsforsofvelv
compar
disclosur
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
sammi
saab
advisori
committe
review
panel
bm
gilead
merck
janssen
grantresearch
support
gilead
speak
teach
bm
gilead
merck
janssen
salix
onyx
bayer
janssen
stock
sharehold
achillion
johnson
johnson
bm
gilead
stuart
c
gordon
advisori
committe
review
panel
gilead
abbvi
merck
intercept
consult
cv
caremark
grantresearch
support
cymba
bay
gilead
bm
abbvi
intercept
conatu
exalenz
merck
speak
teach
gilead
intercept
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
kimberli
ann
brown
advisori
committe
review
panel
cldf
gilead
abbvi
janssen
merck
bm
janssen
grantresearch
support
gilead
abbvi
janssen
duke
medic
research
merck
speak
teach
cldf
marcelo
kugelma
advisori
committe
review
panel
merck
abbvi
janssen
salix
consult
abbvi
merck
gilead
janssen
grantresearch
support
roch
intercept
holog
gilead
janssen
roch
anadi
salix
abbvi
speak
teach
abbvi
gilead
merck
janssen
salix
follow
peopl
noth
disclos
zobair
younossi
introduct
phase
portion
phase
studi
assess
regimen
elbasvir
ebr
hcv
inhibitor
combin
grazoprevir
gzr
hcv
proteas
inhibitor
japanes
patient
without
compens
cirrhosi
hcv
genotyp
infect
method
hcv
patient
random
immedi
treatment
ebrgzr
daili
week
defer
treatment
placebo
week
follow
activ
dose
week
compens
cirrhot
patient
assign
receiv
ebrgzr
primari
efficaci
endpoint
sustain
virolog
respons
svr
week
fu
coba
taqman
lower
limit
quantit
log
iuml
ebrgzr
arm
safeti
evalu
comparison
advers
event
laboratori
abnorm
treatment
immedi
defer
treatment
arm
result
patient
random
receiv
ebrgzr
receiv
placebo
male
mean
age
cirrhot
male
mean
age
b
ebrgzr
among
among
cirrhot
ebr
gzr
arm
achiev
patient
withdrew
studi
subject
relaps
cirrhot
arm
experienc
relaps
initi
treatment
period
least
one
ae
occur
patient
ebrgzr
placebo
arm
respect
cirrhot
seriou
ae
occur
ebrgzr
placebo
patient
respect
cirrhot
patient
grade
grade
alt
elev
observ
ebrgzr
arm
placebo
arm
grade
alt
elev
observ
cirrhot
arm
patient
grade
alt
elev
common
ae
nasopharyng
alt
increas
ebrgzr
arm
nasopharyng
alt
ast
increas
cirrhot
arm
data
defer
treatment
data
also
present
meet
conclus
ebrgzr
week
highli
effect
gener
well
toler
compens
cirrhot
japanes
patient
hcv
disclosur
fumitaka
suzuki
speak
teach
bm
yoshiyasu
karino
speak
teach
bm
kk
kazuaki
chayama
advisori
committe
review
panel
mitsubishi
tanab
taisho
toyama
consult
abbvi
grantresearch
support
ajinomoto
vie
aska
asstella
aska
bristol
squibb
daiichi
sankyo
dainippon
sumitomo
daiichi
sankyo
eisai
glaxosmithklin
mitsubishi
tanab
nippon
kayaku
otsuka
sogo
rinsho
taiho
takeda
toray
torii
tsumura
zeria
speak
teach
abbott
abbvi
ajinomoto
astella
astrazeneca
bayer
bristol
squibb
chugai
dainippon
sumitomo
eidia
eisai
gilead
glaxosmithklin
jimro
johnson
johnson
mitsubishi
tanab
norifumi
kawada
grantresearch
support
chugai
speak
teach
msd
bm
gilead
abbvi
yoshito
itoh
grantresearch
support
merk
sharp
dohm
squibb
compani
gela
scienc
inc
abbvi
inc
ono
pharmaceut
co
ltd
eisai
co
ltd
daiichi
sankyo
compani
limit
astella
pharma
inc
takeda
pharmaceut
compani
limit
ajinomoto
pharmaceut
co
ltd
sumitomo
dainippon
pharma
co
ltd
fujifilm
medic
co
ltd
otsuka
pharmaceut
co
ltd
speak
teach
merk
sharp
dohm
squibb
compani
gela
scienc
inc
abbvi
inc
satoshi
mochida
grantresearch
support
chugai
msd
tioray
medic
bm
dainihon
sumitomo
pharm
ajinomoto
phamr
abbvi
health
care
co
eisai
speak
teach
msd
toray
medic
bm
tanab
mitsubishi
dainihon
sumitomo
pharm
ajinomoto
pharm
gilead
abbvi
naoyoshi
yatsuzuka
employ
msd
k
k
tsuo
yodoya
employ
msd
k
k
go
fujimoto
employ
msd
k
k
stock
sharehold
merck
janic
wahl
employ
merck
co
michael
robertson
employ
merck
stock
sharehold
merck
stuart
black
employ
merck
hiromitsu
kumada
speak
teach
squibb
pharma
intern
msd
abbvi
glaxosmithklin
gilead
scienc
diainippon
sumitomo
pharma
follow
peopl
noth
disclos
takeshi
okanou
hidenori
toyoda
hitoshi
yoshiji
shintaro
takaki
background
administr
pangenotyp
combin
sofosbuvir
sof
velpatasvir
vel
mg
week
result
overal
rate
hcvhiv
subject
includ
subject
boost
unboost
antiretrovir
arv
regimen
pharmacokinet
pk
data
collect
evalu
relationship
exposur
extrinsicintrins
variabl
treatment
outcom
compar
pk
hcv
subject
method
studi
popul
includ
hcv
hiv
subject
receiv
sofvel
mg
week
stabl
arv
regimen
includ
variou
combin
abacavir
atazanavir
cobicistat
darunavir
elvitegravir
emtricitabin
lamivudin
lopinavir
raltegravir
rilpivirin
ritonavir
tenofovir
disoproxil
fumar
tdf
pk
sof
vel
tenofovir
tfv
evalu
subject
measur
plasma
concentr
use
previous
establish
popul
pk
model
pk
sof
vel
hcvhiv
subject
compar
across
arv
regimen
treatment
outcom
subject
hcv
monoinfect
pk
tfv
compar
across
arv
regimen
boost
vs
unboost
result
exposur
sof
vel
similar
across
arv
regimen
similar
exposur
observ
hcv
popul
ci
rang
mean
tfv
exposur
similar
follow
administr
sofvel
boost
auctau
h
ngml
unboost
auctau
h
ngml
regimen
similar
mean
tfv
auc
observ
follow
tdf
administr
part
boost
regimen
hiv
subject
mean
tfv
auc
rang
h
ng
ml
conclus
pharmacokinet
result
addit
safeti
efficaci
data
support
use
sofvel
mg
week
subject
hcvhiv
tenofovir
exposur
administ
tdf
consist
observ
follow
administr
boost
regimen
hiv
subject
disclosur
erik
mogalian
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
vinay
daryani
employ
gilead
scienc
inc
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
mcnalli
employ
gilead
scienc
stock
sharehold
gilead
scienc
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
anita
mathia
employ
gilead
scienc
inc
follow
peopl
noth
disclos
liyun
ni
norbert
john
ling
introduct
phase
clinic
studi
conduct
evalu
efficaci
safeti
elbasvir
ebr
hcv
inhibitor
grazoprevir
gzr
hcv
proteas
inhibitor
pi
experienc
japanes
patient
without
compens
cirrhosi
hcv
genotyp
infect
studi
result
show
daili
ebrgzr
week
highli
effect
well
toler
hcv
japanes
patient
preval
hcv
variant
rav
baselin
bl
impact
svr
also
assess
studi
method
popul
sequenc
perform
bl
sampl
patient
sampl
viral
load
log
iuml
patient
met
criteria
virolog
failur
vf
rav
interest
confer
resist
proteas
inhibitor
class
includ
posit
rav
interest
confer
resist
inhibitor
class
includ
posit
addit
select
sampl
analyz
clonal
sequenc
clone
baselin
sampl
patient
sampl
vf
patient
phase
program
analyz
next
gener
sequenc
ng
cutoff
resist
analysi
popul
rap
exclud
earli
discontinu
ed
lost
ltfu
well
patient
placebo
arm
result
patient
receiv
activ
studi
drug
patient
achiev
phase
portion
studi
respect
preval
bl
rav
patient
achiev
includ
patient
bl
rav
preval
bl
rav
achiev
patient
bl
rav
patient
without
bl
rav
achiev
patient
bl
rav
patient
bl
rav
rav
observ
vf
rav
observ
vf
includ
patient
bl
rav
still
present
time
failur
conclus
preval
rav
confer
potenc
loss
variou
pi
baselin
respect
presenc
bl
rav
clinic
remark
impact
japanes
phase
studi
disclosur
yoshito
itoh
grantresearch
support
merk
sharp
dohm
squibb
compani
gela
scienc
inc
abbvi
inc
ono
pharmaceut
co
ltd
eisai
co
ltd
daiichi
sankyo
compani
limit
astella
pharma
inc
takeda
pharmaceut
compani
limit
ajinomoto
pharmaceut
co
ltd
sumitomo
dainippon
pharma
co
ltd
fujifilm
medic
co
ltd
otsuka
pharmaceut
co
ltd
speak
teach
merk
sharp
dohm
squibb
compani
gela
scienc
inc
abbvi
inc
fumitaka
suzuki
speak
teach
bm
yoshiyasu
karino
speak
teach
bm
kk
kazuaki
chayama
advisori
committe
review
panel
mitsubishi
tanab
taisho
toyama
consult
abbvi
grantresearch
support
ajinomoto
vie
aska
asstella
aska
bristol
squibb
daiichi
sankyo
dainippon
sumitomo
daiichi
sankyo
eisai
glaxosmithklin
mitsubishi
tanab
nippon
kayaku
otsuka
sogo
rinsho
taiho
takeda
toray
torii
tsumura
zeria
speak
teach
abbott
abbvi
ajinomoto
astella
astrazeneca
bayer
bristol
squibb
chugai
dainippon
sumitomo
eidia
eisai
gilead
glaxosmithklin
jimro
johnson
johnson
mitsubishi
tanab
naoyoshi
yatsuzuka
employ
msd
k
k
etsuo
yodoya
employ
msd
k
k
go
fujimoto
employ
msd
k
k
stock
sharehold
merck
stuart
black
employ
merck
ernest
employ
merck
janic
wahl
employ
merck
co
michael
robertson
employ
merck
stock
sharehold
merck
hiromitsu
kumada
speak
teach
squibb
pharma
intern
msd
abbvi
glaxosmithklin
gilead
scienc
diainippon
sumitomo
pharma
purpos
direct
act
antivir
daa
combin
proteas
inhibitor
discov
abbvi
enanta
inhibitor
achiev
high
sustain
virolog
respons
rate
across
chronic
hepat
c
viru
hcv
genotyp
infect
phase
studi
favor
safeti
profil
angiotensin
ii
receptor
blocker
arb
use
treatment
hypertens
cardiovascular
indic
commonli
administ
hcv
infect
subject
comorbid
pharmacokinet
safeti
toler
coadminist
losartan
valsartan
evalu
assess
interact
potenti
agent
method
crossov
studi
healthi
adult
subject
receiv
singl
dose
losartan
mg
valsartan
mg
alon
combin
mg
qd
mg
qd
intens
blood
sampl
determin
losartan
losartan
carboxyl
acid
metabolit
valsartan
concentr
perform
pharmacokinet
paramet
maximum
observ
concentr
cmax
area
curv
aucinf
andor
trough
concentr
estim
effect
pharmacokinet
losartan
valsartan
vice
versa
assess
analysi
use
sa
safeti
evalu
assess
advers
event
vital
sign
ecg
clinic
laboratori
test
result
exposur
higher
losartan
administ
multipl
dose
rel
losartan
alon
losartan
activ
carboxyl
metabolit
cmax
higher
aucinf
similar
differ
exposur
valsartan
slightli
higher
administ
exposur
cmax
similar
without
losartan
valsartan
differ
seriou
advers
event
occur
studi
pattern
advers
event
report
clinic
signific
vital
sign
ecg
laboratori
abnorm
observ
studi
conclus
increas
losartan
valsartan
exposur
exposur
affect
losartan
valsartan
consist
losartan
valsartan
label
recommend
similar
magnitud
exposur
increas
caus
drug
special
popul
dose
adjust
requir
coadminist
losartan
valsartan
disclosur
matthew
p
kosloski
employ
abbvi
sandeep
dutta
employ
abbvi
qi
jiang
employ
abbvi
inc
betti
yao
employ
abbvi
armen
asatryan
employ
abbvi
federico
mensa
employ
abbvi
stock
sharehold
abbvi
jen
kort
employ
abbvi
stock
sharehold
abbvi
wei
liu
employ
abbvi
purpos
direct
act
antivir
daa
combin
proteas
inhibitor
discov
abbvi
enanta
inhibitor
demonstr
favor
safeti
profil
high
sustain
virolog
respons
rate
across
chronic
hepat
c
hcv
genotyp
infect
phase
studi
previous
demonstr
dose
adjust
need
administr
combin
subject
mild
moder
sever
renal
impair
renal
diseas
esrd
dialysi
studi
evalu
pharmacokinet
safeti
administ
esrd
subject
dialysi
condit
method
studi
subject
hemodialysi
month
receiv
singl
dose
mg
mg
period
three
hour
prior
initi
hemodialysi
session
period
day
prior
schedul
hemodialysi
washout
day
separ
dose
period
intens
blood
sampl
determin
concentr
perform
hour
follow
dose
pharmacokinet
paramet
maximum
observ
concentr
cmax
area
curv
auct
clearanc
cl
clearanc
due
dialysi
cld
estim
addit
arteri
predialyz
venou
postdialyz
blood
sampl
collect
dialysi
effect
dialysi
pharmacokinet
assess
analysi
safeti
evalu
throughout
studi
assess
advers
event
vital
sign
ecg
clinic
laboratori
test
result
peak
plasma
concentr
reach
dialysi
mean
dialysi
durat
hour
cmax
auct
similar
differ
differ
dialysi
condit
compar
day
arteri
venou
concentr
profil
similar
dialysi
cld
repres
minim
portion
total
drug
clearanc
seriou
advers
event
occur
studi
clinic
signific
vital
sign
ecg
laboratori
measur
observ
cours
studi
conclus
exposur
affect
dialysi
need
administ
subject
renal
impair
without
dialysi
disclosur
matthew
p
kosloski
employ
abbvi
sandeep
dutta
employ
abbvi
weihan
zhao
employ
abbvi
inc
stock
sharehold
abbvi
inc
unit
airlin
american
airlin
procter
gambl
federico
mensa
employ
abbvi
stock
sharehold
abbvi
jen
kort
employ
abbvi
stock
sharehold
abbvi
wei
liu
employ
abbvi
follow
peopl
noth
disclos
david
pugatch
background
aim
sofosbuvir
velpatasvir
sof
vel
oral
singl
tablet
regimen
shown
clinic
trial
set
excel
efficaci
toler
tn
te
patient
chronic
hepat
c
viru
hcv
genotyp
markov
model
evalu
health
outcom
sofvel
compar
current
treatment
option
method
analysi
model
two
cohort
chronic
hcv
patient
nc
cirrhot
cc
averag
age
us
payer
perspect
lifetim
horizon
cohort
tn
sofvel
compar
ldvsof
ribavirin
rbv
elbasvirgrazoprevir
ebrgrz
rbv
treatment
nt
sustain
virolog
respons
svr
rate
extrapol
phase
iii
clinic
trial
stratifi
baselin
resist
associ
variant
ebrgrz
transit
probabl
util
base
literatur
review
consensu
panel
hepatologist
result
initi
sofvel
patient
result
best
health
outcom
term
lowest
number
patient
complic
compar
ebrgrz
ldvsof
nt
tabl
result
consist
across
patient
subpopul
includ
tn
pegintereronribavirin
pr
prproteas
nc
cc
conclus
compar
ebrgrz
ldv
sof
sofvel
demonstr
better
overal
health
outcom
reduct
case
decompens
cirrhosi
dcc
hepatocellular
carcinoma
hcc
liver
transplant
lt
respect
result
highlight
benefit
treat
chronic
hcv
sofvel
versu
current
avail
option
tabl
project
health
outcom
per
patient
sof
vel
vs
compar
regimen
hcv
patient
disclosur
stuart
c
gordon
advisori
committe
review
panel
gilead
abbvi
merck
intercept
consult
cv
caremark
grantresearch
support
cymba
bay
gilead
bm
abbvi
intercept
conatu
exalenz
merck
speak
teach
gilead
intercept
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
robert
wong
advisori
committe
review
panel
gilead
grantresearch
support
gilead
kimberli
ann
brown
advisori
committe
review
panel
cldf
gilead
abbvi
janssen
merck
bm
janssen
grantresearch
support
gilead
abbvi
janssen
duke
medic
research
merck
speak
teach
cldf
marcelo
kugelma
advisori
committe
review
panel
merck
abbvi
janssen
salix
consult
abbvi
merck
gilead
janssen
grantresearch
support
roch
intercept
holog
gilead
janssen
roch
anadi
salix
abbvi
speak
teach
abbvi
gilead
merck
janssen
salix
sammi
saab
advisori
committe
review
panel
bm
gilead
merck
janssen
grantresearch
support
gilead
speak
teach
bm
gilead
merck
janssen
salix
onyx
bayer
janssen
stock
sharehold
achillion
johnson
johnson
bm
gilead
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
follow
peopl
noth
disclos
zobair
younossi
background
gender
differ
safeti
efficaci
report
hcv
treatment
data
larg
cohort
women
hcv
treat
direct
act
antivir
lack
aim
analysi
evalu
influenc
gender
efficaci
safeti
regimen
sofvel
mg
patient
hcv
genotyp
gt
method
secondari
analysi
includ
patient
enrol
astral
receiv
sofvel
mg
daili
week
patient
decompens
liver
diseas
astral
exclud
analysi
astral
hivhcv
studi
patient
enrol
women
men
demograph
sustain
virolog
respons
week
advers
event
ae
assess
gender
use
fisher
exact
test
result
overal
patient
treat
sofvel
phase
iii
astral
trial
overal
women
relaps
rate
men
overal
relaps
rate
demograph
ae
gender
describ
tabl
women
report
higher
rate
nausea
headach
nasopharyng
men
analysi
ae
women
done
howev
treatment
gener
well
toler
women
men
discontinu
rate
low
conclus
pool
analysi
daili
singl
tablet
regimen
sofvel
mg
week
highli
efficaci
regardless
gt
gender
safe
option
women
age
hcv
tabl
disclosur
tram
tran
advisori
committe
review
panel
gilead
bristol
myer
squibb
consult
gilead
abbvi
janssen
merck
grantresearch
support
bristol
myer
squibb
speak
teach
gilead
jordan
j
feld
advisori
committe
review
panel
merck
gilead
abbvi
bristol
myer
squibb
grantresearch
support
abbvi
janssen
gilead
merck
regulu
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
sarjita
naik
employ
gilead
scienc
macki
natha
employ
gilead
scienc
stock
sharehold
gilead
scienc
joseph
llewellyn
employ
gilead
scienc
bruce
kreter
employ
gilead
scienc
stock
sharehold
squibb
merck
pfizer
roch
achillion
celgen
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
shari
rogal
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
edward
eggleton
jie
zhang
background
aim
new
oral
singl
tablet
regimen
sofosbuvir
velpatasvir
sofvel
shown
excel
efficaci
safeti
patient
hepat
c
viru
hcv
genotyp
gt
particular
patient
consid
popul
limit
treatment
option
markov
model
evalu
health
outcom
sofvel
compar
current
recommend
altern
high
util
method
analysi
model
cohort
chronic
hcv
patient
mean
age
year
us
payer
perspect
lifetim
horizon
cirrhot
cc
te
respect
sofvel
compar
sofribavirin
r
treatment
nt
sofvel
compar
sofdaclatasvir
dcv
nt
sustain
virolog
respons
svr
rate
base
phase
iii
clinic
trial
transit
probabl
util
base
literatur
review
consensu
panel
hepatologist
result
sofvel
regimen
result
best
health
outcom
term
lowest
number
decompens
cirrhosi
dcc
hepatocellular
carcinoma
hcc
liver
transplant
lt
compar
compar
tabl
result
consist
across
patient
subpopul
includ
treatment
cirrhot
conclus
result
demonstr
sofvel
highli
effect
hcv
patient
lead
fewest
case
complic
vs
sofr
sofdcv
furthermor
sofvel
provid
option
avail
singl
tablet
regimen
chronic
hcv
simplifi
treatment
across
gt
although
studi
report
efficaci
adher
rate
singl
tablet
regimen
similar
clinic
trial
set
addit
analys
necessari
determin
impact
util
tabl
project
health
outcom
per
patient
sof
vel
vs
compar
regimen
hcv
patient
sofdcv
substitut
sofr
recommend
across
disclosur
stuart
c
gordon
advisori
committe
review
panel
gilead
abbvi
merck
intercept
consult
cv
caremark
grantresearch
support
cymba
bay
gilead
bm
abbvi
intercept
conatu
exalenz
merck
speak
teach
gilead
intercept
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
marcelo
kugelma
advisori
committe
review
panel
merck
abbvi
janssen
salix
consult
abbvi
merck
gilead
janssen
grantresearch
support
roch
intercept
holog
gilead
janssen
roch
anadi
salix
abbvi
speak
teach
abbvi
gilead
merck
janssen
salix
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
robert
wong
advisori
committe
review
panel
gilead
grantresearch
support
gilead
kimberli
ann
brown
advisori
committe
review
panel
cldf
gilead
abbvi
janssen
merck
bm
janssen
grantresearch
support
gilead
abbvi
janssen
duke
medic
research
merck
speak
teach
cldf
sammi
saab
advisori
committe
review
panel
bm
gilead
merck
janssen
grantresearch
support
gilead
speak
teach
bm
gilead
merck
janssen
salix
onyx
bayer
janssen
stock
sharehold
achillion
johnson
johnson
bm
gilead
follow
peopl
noth
disclos
zobair
younossi
background
era
antivir
therapi
daa
chronic
hepat
c
hcv
decis
treat
hcv
liver
transplant
lt
waitlist
candid
controversi
thought
treat
candid
prior
lt
model
diseas
meld
score
may
improv
therebi
place
purgatori
meld
would
reduc
likelihood
receiv
lt
data
report
determin
purgatori
meld
inde
exist
method
use
unit
network
organ
share
uno
databas
compar
hcv
lt
waitlist
candid
month
may
octob
daa
januari
june
fda
approv
daa
agent
novemb
decemb
determin
rate
transplant
death
use
remov
code
deceas
donor
transplant
death
sick
transplant
statist
analys
perform
use
sa
result
overal
total
hcv
waitlist
lt
candid
candid
period
candid
period
compar
period
hcv
waitlist
lt
candid
significantli
lower
rate
remov
due
death
p
sick
transplant
p
tabl
hcv
waitlist
lt
candid
howev
significantli
lower
rate
liver
transplant
p
discuss
although
hcv
lt
waitlist
candid
lower
likelihood
receiv
transplant
likelihood
die
waitlist
significantli
lower
data
need
evalu
determin
role
purgatori
meld
within
popul
tabl
hcv
liver
transplant
waitlist
candid
transplant
death
rate
versu
disclosur
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
sammi
saab
advisori
committe
review
panel
bm
gilead
merck
janssen
grantresearch
support
gilead
speak
teach
bm
gilead
merck
janssen
salix
onyx
bayer
janssen
stock
sharehold
achillion
johnson
johnson
bm
gilead
stevan
gonzalez
speak
teach
gilead
salix
abbvi
merck
rachel
beckerman
consult
gilead
scienc
follow
peopl
noth
disclos
georg
cholankeril
ryan
b
perumpail
eric
r
yoo
menghan
hu
background
assess
risk
factor
develop
hepatocellular
carcinoma
hcc
follow
success
erad
hepat
c
viru
hcv
interferon
therapi
direct
agent
daa
therapi
cohort
studi
method
retrospect
evalu
patient
achiev
svr
oral
daa
regimen
daclatasvirasunaprevir
dcvasv
plu
ribavirin
patient
background
chronic
hepat
cirrhosi
caus
hcv
genotyp
receiv
hcc
surveil
tumor
marker
afp
dcp
ultrasonographi
andor
dynam
comput
tomographi
least
biannual
evid
hcc
develop
prior
hcv
erad
within
year
follow
erad
observ
period
median
month
rang
patient
develop
hcc
hcv
erad
month
hcv
erad
hcc
develop
patient
develop
hcc
cumul
hcc
develop
rate
respect
daa
group
group
treatment
regimen
associ
develop
hcc
hcv
erad
independ
risk
factor
hcc
develop
multivari
analysi
identifi
male
gender
hr
ci
advanc
fibrosi
stage
hr
ci
heavi
alcohol
intak
hr
ci
serum
afp
level
measur
treatment
year
treatment
exclud
analysi
patient
develop
hcc
baselin
afp
level
ngml
daa
group
higher
group
ngml
afp
level
gradual
decreas
group
therapi
similar
year
start
therapi
p
valu
signific
conclus
demonstr
present
studi
rate
hcc
develop
reduc
patient
infect
hcv
genotyp
achiev
svr
regimen
impact
treatment
similar
treatment
regard
hcc
risk
reduct
patient
achiev
svr
disclosur
michio
imamura
grantresearch
support
squibb
speak
teach
squibb
kazuaki
chayama
advisori
committe
review
panel
mitsubishi
tanab
taisho
toyama
consult
abbvi
grantresearch
support
ajinomoto
vie
aska
asstella
aska
bristol
squibb
daiichi
sankyo
dainippon
sumitomo
daiichi
sankyo
eisai
glaxosmithklin
mitsubishi
tanab
nippon
kayaku
otsuka
sogo
rinsho
taiho
takeda
toray
torii
tsumura
zeria
speak
teach
abbott
abbvi
ajinomoto
astella
astrazeneca
bayer
bristol
squibb
chugai
dainippon
sumitomo
eidia
eisai
gilead
glaxosmithklin
jimro
johnson
johnson
mitsubishi
tanab
follow
peopl
noth
disclos
yuko
nagaoki
hiroshi
aikata
tomoki
kobayashi
tomokazu
kawaoka
masataka
tsuge
akira
hiramatsu
yoshiiku
kawakami
background
although
current
direct
act
antivir
daa
taken
big
step
forward
hcv
therapi
experi
patient
vascul
cv
limit
aim
evalu
clinic
immunolog
outcom
subject
treat
oral
daa
week
end
therapi
method
prospect
observ
studi
circul
cryoglobulin
receiv
daa
therapi
patient
group
two
cohort
asymptomat
cryoglobulin
acc
patient
cv
complet
immunolog
respons
cir
defin
complement
normal
cryoglobulin
ativ
week
therapi
among
clinic
remiss
consid
complet
bva
affect
organ
improv
partial
bva
entri
score
result
caucasian
patient
includ
acc
signific
differ
observ
group
regard
age
median
year
antivir
therapi
ldvsof
femal
gender
common
group
vs
cirrhosi
acc
group
vs
patient
show
significantli
elev
rheumatoid
factor
rf
vs
iuml
lower
complement
fraction
vs
gl
slightli
higher
cryoglobulin
among
common
manifest
asthenia
purpura
polyneuropathi
arthralgia
renal
involv
twelv
patient
receiv
glucocorticoid
rituximab
rate
cryoglobulin
improv
equal
group
rf
decreas
greater
vs
iu
cir
achiev
without
signific
differ
group
cryocrit
median
baselin
associ
despit
persist
cryoglobulin
abnorm
patient
patient
achiev
clinic
remiss
complet
partial
median
bva
score
decreas
p
resolut
purpura
arthralgia
plu
improv
renal
neurolog
symptom
respect
glucocorticoid
dosag
could
reduc
patient
conclus
despit
short
patient
hcv
circul
cryoglobulin
achiev
cir
svr
baselin
cryocrit
independ
factor
relat
respons
howev
associ
clinic
improv
signific
proport
patient
disclosur
londono
consult
janssen
gilead
bm
speak
teach
msd
abbvi
xavier
forn
consult
jansen
abbvi
grantresearch
support
jansen
abbvi
follow
peopl
noth
disclos
martin
bonacci
zoe
patricia
gonzalez
manel
ramo
casal
sabela
len
chronic
hepat
c
viru
hcv
infect
preval
patient
advanc
chronic
kidney
diseas
hemodialysi
hd
compar
gener
popul
direct
act
antivir
daa
effect
chronic
hepat
c
howev
treatment
hcv
patient
advanc
ckd
hd
remain
major
challeng
due
lack
report
efficaci
safeti
data
daa
popul
investig
efficaci
safeti
sofosbuvir
sof
ribavirin
rbv
chronic
hcv
infect
ckd
patient
hd
patient
method
patient
ckd
hd
chronic
hcv
infect
prospect
enrol
septemb
receiv
sof
rbv
week
prior
start
treatment
patient
inform
use
sofosbuvir
commerci
approv
individu
sever
renal
impair
patient
consent
use
sof
understand
safeti
efficaci
circumst
unknown
patient
start
sof
mg
daili
rbv
mg
thrice
weekli
per
toler
patient
serial
hb
valu
anaemia
manag
erythropoietin
epo
iron
safeti
efficaci
data
collect
includ
data
patient
complet
therapi
result
patient
enrol
mean
age
yr
hcv
genotyp
present
genotyp
patient
patient
complet
week
therapi
virolog
cure
achiev
patient
complet
week
reach
week
week
svr
wk
mean
drop
haemoglobin
gdl
patient
requir
adjust
ribavirin
dosag
increas
erythropoietin
dose
patient
need
blood
transfus
patient
discontinu
ribavirin
due
persist
low
haemoglobin
conclus
sofosbuvir
plu
ribavirin
therapi
given
week
appear
well
toler
patient
esrd
hd
svr
week
disclosur
follow
peopl
noth
disclos
sumanlata
nayak
manoj
sharma
rajendra
p
mathur
prem
prakash
varma
ekta
gupta
ashok
choudhari
kapil
jamwal
rakhi
maiwal
guresh
kumar
ankit
bhardwaj
shiv
k
sarin
abstract
background
acoust
radiat
forc
impuls
arfi
elastographi
method
measur
liver
stiff
howev
report
evalu
valu
arfi
elastographi
liver
fibrosi
chronic
hepat
c
patient
sustain
virolog
respons
svr
aim
investig
diagnost
perform
arfi
elastographi
effect
durat
erad
hcv
liver
stiff
use
afri
elastographi
hepat
c
viru
hcv
infect
patient
svr
method
prospect
studi
enrol
patient
hcvpatient
svr
women
patient
hcv
women
needl
liver
biopsi
perform
patient
arfi
elastographi
measur
patient
perform
day
liver
biopsi
biopsi
perform
year
end
therapi
result
diagnost
accuraci
express
area
receiv
oper
characterist
curv
arfi
elastographi
hcv
patient
svr
patient
hcv
diagnosi
signific
fibrosi
diagnosi
sever
fibrosi
diagnosi
liver
cirrhosi
respect
respect
mean
ls
valu
assess
use
arfi
elastographi
ms
fibrosi
stage
patient
svr
patient
hcv
infect
mean
ls
valu
assess
use
arfi
elastographi
markedli
lower
patient
svr
compar
patient
hcv
infect
regard
stage
fibrosi
mean
ls
valu
assess
use
arfi
elastographi
compar
among
patient
hcv
patient
svr
observ
period
svr
year
patient
svr
observ
period
svr
year
fibrosi
stage
respect
mean
ls
valu
assess
use
arfi
elastographi
ms
fibrosi
stage
patient
hcv
patient
svr
patient
svr
patient
signific
decreas
ls
valu
observ
accord
observ
period
svr
conclus
liver
stiff
valu
lower
patient
svr
compar
patient
hcv
stage
fibrosi
liver
stiff
valu
affect
durat
svr
disclosur
follow
peopl
noth
disclos
yoshihiko
tachi
introduct
studi
hcv
infect
patient
b
cirrhosi
achiev
week
sofosbuvirvelpatasvir
sofvel
ribavirin
rbv
contrast
regimen
evalu
patient
decompens
cirrhosi
rbv
dose
mgday
weight
base
rbv
dose
mgday
use
studi
analysi
compar
safeti
toler
sofvel
weight
base
ribavirin
dose
safeti
toler
ledipasvirsofosbuvir
ldvsof
rbv
mg
report
studi
method
advers
event
laboratori
abnorm
compar
patient
cirrhosi
pretranspl
treat
sofvel
rbv
week
studi
patient
treat
ldvsof
mg
rbv
week
studi
toler
rbv
assess
review
rbv
dose
modif
dose
reduct
discontinu
result
patient
treat
sofvel
base
rbv
lower
incid
advers
event
compar
patient
treat
ldvsof
mg
rbv
howev
regimen
advers
event
mild
moder
sever
one
patient
treat
sofvel
rbv
one
patient
treat
ldvsof
rbv
treatment
relat
seriou
advers
event
three
patient
receiv
sofvel
rbv
die
one
patient
receiv
ldvsof
rbv
die
death
assess
treatment
relat
tabl
present
summari
postbaselin
hemoglobin
rbv
dose
modif
higher
incid
rbv
dose
reduct
interrupt
modif
among
patient
treat
sofvel
weight
base
rbv
compar
patient
treat
ldvsof
rbv
conclus
higher
incid
hemoglobin
reduct
hcv
infect
patient
cirrhosi
treat
sofvel
weight
base
rbv
compar
patient
treat
ldvsof
mg
rbv
manag
frequent
dose
modif
rbv
without
discontinu
treatment
group
patient
treat
provid
experienc
care
patient
advanc
liver
diseas
manag
rbv
associ
toxic
disclosur
michael
r
charlton
consult
gilead
scienc
grantresearch
support
gilead
scienc
merck
janssen
abbvi
novarti
intercept
robert
brown
advisori
committe
review
panel
vital
therapi
consult
gilead
janssen
abbvi
merck
bm
gregori
everson
advisori
committe
review
panel
rochegenentech
abbvi
galectin
squibb
hepc
connect
biotest
gilead
merck
board
membership
hepquant
llc
psc
partner
hepquant
llc
consult
abbvi
bm
gilead
squibb
grantresearch
support
rochegenentech
abbvi
squibb
merck
psc
partner
gilead
manag
posit
hepquant
llc
hepquant
llc
patent
heldfil
univ
colorado
speak
teach
abbvi
mitchel
l
shiffman
advisori
committe
review
panel
merck
gilead
abbvi
grantresearch
support
conatu
immuron
merck
gilead
galactin
abbvi
ngmbio
intercept
novarti
eisai
shire
speak
teach
merck
gilead
abbvi
intercept
myron
j
tong
speak
teach
bm
gilead
genentech
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
di
employ
gilead
scienc
inc
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
mcnalli
employ
gilead
scienc
stock
sharehold
gilead
scienc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
jacquelin
g
oleari
advisori
committe
review
panel
gilead
intercept
novarti
consult
abbvi
fish
richarson
pc
grantresearch
support
fisher
scientif
speak
teach
gilead
abbvi
merck
astella
stock
sharehold
medfus
michael
p
curri
consult
alexion
bristol
meyer
squib
abbvi
grant
research
support
gilead
scienc
conatu
follow
peopl
noth
disclos
lingl
han
mani
subramanian
introduct
phase
trial
antivir
regimen
ombitasvirparitaprevirritonavir
previr
identifi
abbvi
enanta
dasabuvir
ribavirin
rbv
achiev
high
sustain
virologi
svr
rate
favor
safeti
profil
hcv
patient
includ
compens
cirrhosi
evalu
impact
progress
liver
diseas
year
pt
patient
chronic
hcv
infect
receiv
rbv
method
phase
intern
multicent
open
label
studi
enrol
hcv
patient
without
cirrhosi
compens
cirrhosi
across
center
countri
patient
receiv
rbv
week
base
subtyp
cirrhosi
statu
consist
approv
local
label
first
interim
result
includ
hcv
rna
lloq
week
pt
safeti
clinic
outcom
chang
liver
fibrosi
baselin
evalu
result
patient
receiv
studi
drug
male
white
compens
cirrhosi
patient
reach
time
point
itt
achiev
patient
reach
patient
without
cirrhosi
respect
patient
achiev
mean
score
improv
time
greatest
improv
seen
patient
cirrhosi
mean
kpa
chang
baselin
total
patient
experienc
ae
fatigu
headach
nausea
pruritu
insomnia
occur
patient
major
ae
mildmoder
sever
patient
experienc
seriou
ae
patient
discontinu
studi
drug
due
ae
grade
laboratori
abnorm
rare
clinic
outcom
report
tabl
conclus
data
larg
studi
confirm
efficaci
safeti
result
observ
registr
trial
rbv
hcv
patient
preliminari
data
show
benefici
impact
liver
fibrosi
clinic
outcom
infrequ
updat
safeti
efficaci
clinic
outcom
present
nl
pneumonia
lead
hepat
decompens
multipl
organ
failur
nl
ischem
heart
diseas
ascit
varic
bleed
hepat
encephalopathi
disclosur
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
emili
duma
employ
abbvi
stock
sharehold
abbvi
giovanni
b
gaeta
advisori
committe
review
panel
janssen
merck
abbvi
roch
speak
teach
bm
gilead
merck
sam
lee
employ
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
alma
perez
advisori
committe
review
panel
gilead
la
roch
abbvi
msd
grantresearch
support
janssen
speak
teach
gilead
la
roch
abbvi
janssen
bm
msd
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
rui
marinho
advisori
committe
review
panel
abbvi
msd
bm
janssen
bayer
mariem
charafeddin
employ
abbvi
ltd
stock
sharehold
abbvi
ltd
tami
employ
abbvi
stock
sharehold
abbott
kevin
howieson
employ
abbvi
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
fabien
zoulim
advisori
committe
review
panel
janssen
gilead
novira
abbvi
arbutu
transgen
consult
roch
grantresearch
support
novarti
gilead
scynexi
roch
novira
assemblypharm
janssen
speak
teach
bristol
myer
squibb
gilead
follow
peopl
noth
disclos
adrian
raul
j
andrad
igor
g
bakulin
resat
ozara
li
liu
melanni
co
background
hcv
regimen
contain
ombitasvir
inhibitor
paritaprevir
proteas
inhibitor
identifi
abbvi
enanta
ritonavir
obvptvr
plu
ribavirin
rbv
highli
efficaci
treatment
hcv
genotyp
gt
infect
util
larg
dataset
sequenc
contain
divers
hcv
subtyp
isol
patient
treat
obvptvr
rbv
assess
genet
divers
geograph
region
analyz
patient
demograph
baselin
sequenc
variabl
across
subtyp
report
develop
viral
resist
virolog
failur
vf
patient
method
gene
sequenc
popul
sequenc
ng
baselin
sampl
cirrhot
patient
sequenc
includ
phylogenet
analysi
assess
genet
relationship
among
within
subtyp
countri
preval
baselin
polymorph
variant
rav
analyz
result
sixteen
subtyp
identifi
combin
dataset
subtyp
preval
vari
countri
enrol
studi
subtyp
preval
countri
origin
close
associ
report
distribut
subtyp
africa
europ
north
america
phylogenet
analysi
sequenc
reveal
two
sequenc
cluster
within
subtyp
correl
countri
origin
sampl
one
cluster
contain
sequenc
egypt
middl
east
second
cluster
contain
sequenc
origin
europ
baselin
demograph
analys
also
reveal
distribut
patient
race
significantli
differ
across
subtyp
baselin
amino
acid
variabl
frequent
detect
across
subtyp
impact
treatment
outcom
overal
patient
experienc
vf
infect
infect
predomin
rav
time
failur
conclus
overal
high
respons
rate
observ
among
patient
infect
hcv
subtyp
impact
baselin
polymorph
treatment
outcom
subtyp
distribut
differ
base
patient
demograph
geographi
two
phylogenet
cluster
within
subtyp
found
segreg
countri
origin
suggest
genet
distinct
strain
circul
egypt
versu
europ
disclosur
gretja
schnell
employ
abbvi
inc
stock
sharehold
abbvi
inc
rakesh
tripathi
employ
abbvi
stock
sharehold
abbvi
jill
beyer
employ
abbvi
stock
sharehold
abbvi
thoma
reisch
employ
abbvi
stock
sharehold
abbvi
coleen
hall
employ
abbvi
stock
sharehold
abbvi
yao
yu
employ
abbvi
niloufar
mobasheri
employ
abbvi
stock
sharehold
abbvi
tami
employ
abbvi
stock
sharehold
abbott
christin
collin
employ
abbvi
background
major
metabolit
sofosbuvir
sof
clear
renal
accumul
sever
renal
impair
end
stage
renal
diseas
although
popul
exclud
phase
clinic
trial
patient
mild
moder
renal
impair
enrol
retrospect
analysi
present
safeti
profil
therapi
group
method
safeti
data
patient
without
compens
cirrhosi
enrol
phase
studi
sofrbv
assess
accord
degre
renal
impair
normal
renal
function
estim
glomerular
filtrat
rate
egfr
use
equat
mlmin
mild
renal
impair
egfr
mlmin
moder
renal
impair
egfr
mlmin
result
patient
includ
analysi
mild
moder
renal
impair
baselin
mean
egfr
mlmin
patient
normal
renal
function
mild
moder
renal
impair
respect
baselin
characterist
gener
similar
across
group
except
patient
impair
renal
function
older
tabl
provid
summari
advers
event
ae
patient
receiv
rbv
higher
rate
grade
ae
sae
discontinu
compar
patient
receiv
rbv
differ
pronounc
among
renal
impair
among
patient
receiv
rbv
similar
rate
grade
ae
discontinu
due
ae
across
group
patient
moder
renal
impair
higher
rate
sae
conclus
treatment
regimen
patient
mild
moder
renal
impair
differ
seen
rbv
toler
patient
moder
renal
impair
compar
mild
renal
impair
overal
summari
safeti
patient
treat
tain
regimen
accord
renal
function
presenc
rbv
disclosur
francoi
durand
advisori
committe
review
panel
astella
novarti
bm
speak
teach
gilead
stephen
pianko
advisori
committe
review
panel
roch
novarti
gilead
roch
novarti
consult
gilead
speak
teach
janssen
bm
shampa
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
mcnalli
employ
gilead
scienc
stock
sharehold
gilead
scienc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
eugen
r
schiff
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
janssen
salix
pharmaceut
pfizer
arrowhead
astrazeneca
cv
consult
acorda
grantresearch
support
bristol
myer
squibb
abbvi
gilead
merck
conatu
medmira
roch
molecular
janssen
orasur
technolog
discoveri
life
scienc
siemen
beckman
coulter
siemen
ortho
jnh
intercept
beckman
massimo
colombo
advisori
committe
review
panel
gilead
scienc
abbvi
bm
bayer
merck
speak
teach
gilead
scienc
abbvi
bm
bayer
merck
janssen
sanofi
vertex
follow
peopl
noth
disclos
liyun
ni
daa
outstand
safeti
profil
phase
iii
trial
surveil
gener
addit
safeti
warn
drug
interact
restrict
use
decompens
cirrhosi
aim
evalu
detail
safeti
data
across
broad
spectrum
patient
treat
daa
usual
clinic
practic
method
patient
enrol
treat
accord
region
standard
care
academ
commun
medic
center
north
america
europ
detail
inform
demograph
clinic
cours
advers
event
ae
abstract
medic
record
central
data
core
data
monitor
systemat
review
data
accuraci
result
jan
may
patient
pt
treat
oral
daa
includ
pt
cirrhosi
evid
prior
hepat
decompens
regimen
includ
sofrbv
rbv
therapi
complet
earli
discontinu
due
ae
occur
higher
among
tain
vs
regimen
vs
death
report
pt
varieti
caus
increas
bilirubin
baselin
bilirubin
occur
pt
evalu
data
prematur
discontinu
treatment
sever
baselin
occur
pt
concomit
alt
elev
die
pt
associ
biliari
tract
diseas
sepsi
transplant
multivari
logist
analys
exclud
patient
cirrhosi
prior
hepat
decompens
low
albumin
higher
baselin
bilirubin
associ
treatment
de
novo
hepat
decompens
occur
previous
compens
cirrhot
pt
wherea
secondari
decompens
event
among
prior
histori
decompens
higher
ribavirin
use
associ
secondari
hepat
decompens
latter
group
ci
p
conclus
event
rate
hyperbilirubinemia
decompens
low
even
among
patient
advanc
cirrhosi
infrequ
led
prematur
discontinu
therapi
featur
advanc
cirrhosi
associ
increas
risk
ae
note
ribavirin
independ
increas
risk
hepat
decompens
sever
hyperbilirubinemia
clinic
sequela
usual
occur
absenc
alt
elev
deserv
scrutini
disclosur
michael
w
fri
consult
merck
abbvi
janssen
bristol
myer
squibb
gilead
grantresearch
support
merck
abbvi
janssen
bristol
myer
squibb
gilead
stock
sharehold
target
pharmasolut
k
rajend
reddi
advisori
committe
review
panel
merck
janssen
bm
abbvi
gilead
grantresearch
support
merck
bm
gilead
janssen
abbvi
mitchel
l
shiffman
advisori
committe
review
panel
merck
gilead
abbvi
grantresearch
support
conatu
immuron
merck
gilead
galactin
abbvi
ngmbio
intercept
novarti
eisai
shire
speak
teach
merck
gilead
abbvi
intercept
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
paul
j
pockro
advisori
committe
review
panel
janssen
merck
bm
gilead
abbvi
consult
lumena
beckman
coulter
grantresearch
support
intercept
janssen
bm
gilead
lumena
beckman
coulter
abbvi
rm
merck
speak
teach
abbvi
janssen
gilead
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
jacquelin
g
oleari
advisori
committe
review
panel
gilead
intercept
novarti
consult
abbvi
fish
richarson
pc
grantresearch
support
fisher
scientif
speak
teach
gilead
abbvi
merck
astella
stock
sharehold
medfus
david
r
nelson
grantresearch
support
abbvi
bm
gilead
merck
janssen
joseph
k
lim
consult
bristol
myer
squibb
gilead
grantresearch
support
bristol
myer
squibb
gilead
follow
peopl
noth
disclos
alexand
kuo
luci
akushevich
monika
vainoriu
background
estim
viru
hcv
patient
use
proton
pump
inhibitor
ppi
acid
reduc
agent
concomit
ppi
use
inhibitor
impact
pharmacokinet
pk
antivir
agent
daa
potenti
reduc
efficaci
phase
studi
result
demonstr
effect
ppi
use
pk
combin
elbasvirgrazoprevir
ebrgzr
healthi
volunt
post
hoc
analysi
studi
phase
clinic
program
ebrgzr
assess
sustain
viral
respons
subject
ppi
use
pk
ebrgzr
patient
method
data
deriv
six
phase
ebrgzr
trial
treatment
experienc
subject
without
cirrhosi
analys
done
modifi
full
analysi
set
popul
exclud
administr
discontinu
baselin
ppi
use
defin
consecut
day
use
day
day
bivari
analys
assess
ppi
use
factor
associ
svr
gender
age
continu
dichotom
cirrhosi
statu
prior
treatment
statu
baselin
hcv
rna
continu
dichotom
hcv
genotyp
baselin
resist
associ
variant
variabl
model
result
overal
subject
report
baselin
use
ppi
achiev
patient
without
ppi
use
achiev
ppi
use
predict
factor
achiev
base
univari
analysi
p
bivari
model
none
interact
term
statist
signific
indic
potenti
effect
ppi
consist
across
factor
consid
addit
ppi
usag
statist
signific
effect
regardless
adjust
factor
consid
studi
popul
pk
data
avail
estim
auc
cmax
valu
ebr
compar
among
patient
without
report
ppi
use
tabl
conclus
result
demonstr
ppi
use
ebrgzr
clinic
signific
effect
rate
patient
without
cirrhosi
aucarea
curv
gmgeometr
mean
estim
use
popul
pk
model
disclosur
nanci
reau
advisori
committe
review
panel
jannsen
merck
abbvi
intercept
salix
bm
gilead
grantresearch
support
gilead
intercept
vie
michael
robertson
employ
merck
stock
sharehold
merck
feng
employ
merck
luzelena
caro
employ
merck
co
inc
wendi
w
yeh
employ
merck
nguyen
employ
merck
janic
wahl
employ
merck
co
eliav
barr
employ
merck
stock
sharehold
merck
peggi
hwang
employ
merck
merck
stephani
klopfer
employ
merck
co
inc
background
although
proteas
inhibitor
pi
variant
typic
decreas
frequenc
cessat
pi
therapi
chronic
hepat
c
patient
suscept
pi
patient
previous
fail
respond
pi
therapi
address
method
total
genotyp
chronic
hepat
c
patient
detect
drug
variant
rav
neither
hcv
prior
treatment
determin
invad
assay
treat
daclatasvir
plu
previr
human
hepatocyt
chimer
mice
inject
serum
sampl
obtain
either
patient
daclatasvir
plu
asunaprevir
treat
simeprevir
sofosbuvir
telaprevir
nucleotid
amino
acid
sequenc
region
determin
deep
sequenc
result
sustain
virolog
respons
svr
achiev
daa
patient
wherea
patient
experienc
simeprevir
plu
treatment
failur
p
multivari
logist
regress
analysi
identifi
histori
simeprevir
treatment
odd
ratio
absenc
p
independ
predictor
svr
viral
breakthrough
daclatasvir
asunaprevir
treatment
rav
persist
high
frequenc
contrast
deep
sequenc
analysi
show
frequenc
rav
gradual
decreas
complet
replac
cessat
therapi
mice
inject
serum
patient
daclatasvir
plu
asunaprevir
treat
simeprevir
alon
sofosbuvir
combin
either
simeprevir
telaprevir
simperevir
alon
simperevir
plu
sofosbuvir
treatment
result
rapid
emerg
mutat
significantli
higher
frequenc
mice
inject
serum
daclatasvir
asunaprevir
compar
mice
inject
serum
daa
patient
contrast
sofosbuvir
plu
simeprevir
treatment
sofosbuvir
plu
telaprevir
treatment
reduc
serum
hcv
rna
level
sustain
emerg
rav
suppress
mice
inject
serum
daclatasvir
asunaprevir
conclus
virolog
respons
daclatasvir
plu
asunaprevir
treatment
low
patient
simeprevir
plu
treatment
failur
pi
resist
remain
even
disappear
mutant
strain
sequenc
daa
combin
therapi
without
pi
recommend
patient
fail
pi
treatment
disclosur
michio
imamura
grantresearch
support
squibb
speak
teach
squibb
yuji
ishida
employ
phoenixbio
co
ltd
chise
tateno
board
membership
phoenixbio
co
ltd
kazuaki
chayama
advisori
committe
review
panel
mitsubishi
tanab
taisho
toyama
consult
abbvi
grantresearch
support
ajinomoto
abbvi
aska
asstella
aska
bristol
squibb
daiichi
sankyo
dainippon
sumitomo
daiichi
sankyo
eisai
glaxosmithklin
mitsubishi
tanab
nippon
kayaku
otsuka
sogo
rinsho
taiho
takeda
toray
torii
tsumura
zeria
speak
teach
abbott
abbvi
ajinomoto
astella
astrazeneca
bayer
bristol
squibb
chugai
dainippon
sumitomo
eidia
eisai
gilead
glaxosmithklin
jimro
johnson
johnson
mitsubishi
tanab
follow
peopl
noth
disclos
hiromi
kan
nobuhiko
hiraga
c
nelson
hay
takuro
uchida
eisuk
miyaki
masataka
tsuge
hiromi
hiroshi
aikata
daiki
miki
hidenori
ochi
backgroundpurpos
high
rate
efficaci
observ
phase
trial
week
elbasvirgrazoprevir
ebr
hcv
inhibitor
gzr
hcv
proteas
inhibitor
patient
opioid
agonist
therapi
oat
hcv
reinfect
observ
patient
end
treatment
eot
week
aim
three
year
studi
evalu
hcv
reinfect
inject
risk
behavior
patient
treat
ebrgzr
method
year
observ
cohort
studi
enrol
patient
receiv
least
one
dose
ebr
gzr
phase
trial
everi
month
patient
test
hcv
rna
detect
viral
genotyp
sequenc
perform
patient
complet
questionnair
assess
drug
use
result
patient
treat
patient
enrol
patient
enrol
gener
repres
parent
trial
averag
age
year
male
white
race
sixti
percent
patient
studi
phase
trial
posit
urin
drug
screen
ud
result
enrol
respect
median
time
eot
first
visit
day
rang
addit
reinfect
observ
eot
week
two
viral
recurr
identifi
first
visit
one
patient
baselin
patient
report
drug
use
intranas
cocain
inhal
amphetamin
inhal
cannabinoid
identifi
opiat
cannabinoid
detect
ud
one
patient
baselin
hcv
rna
luml
detect
first
visit
howev
genotyp
unabl
determin
due
low
viral
load
drug
use
report
patient
previou
month
drug
besid
oat
detect
ud
patient
consid
reinfect
addit
pend
patient
report
drug
use
inject
past
month
inject
drug
use
past
month
report
patient
among
report
inject
drug
use
past
month
patient
inject
drug
includ
heroin
amphetamin
cocain
opioid
conclus
hcv
reinfect
among
patient
opioid
agonist
therapi
follow
elbasvirgrazoprevir
treatment
uncommon
despit
ongo
drug
use
addit
ongo
disclosur
gregori
dore
board
membership
gilead
merck
abbvi
squibb
grantresearch
support
gilead
merck
abbvi
squibb
speak
teach
gilead
merck
abbvi
squibb
jason
grebe
advisori
committe
review
panel
merck
gilead
grant
research
support
merck
gilead
abbvi
bm
frederick
altic
grantresearch
support
gileaad
nih
nida
samhsa
hrsa
speak
teach
merck
bristol
myer
squibb
gilead
rush
practic
point
commun
alain
h
litwin
advisori
committe
review
panel
merck
gilead
bm
janssen
grantresearch
support
merck
gilead
olav
dalgard
advisori
committe
review
panel
msd
janssen
cilag
medivir
gilead
abbvi
grantresearch
support
msd
medivir
gilead
abbvi
edward
j
gane
advisori
committe
review
panel
abbvi
janssen
gilead
scienc
achillion
merck
speak
teach
abbvi
gilead
scienc
merck
alnylam
ann
luetkemey
grantresearch
support
gilead
abbvi
bristol
myer
squibb
merck
ronald
nahass
advisori
committe
review
panel
gilead
merck
janssen
bm
grantresearch
support
gilead
merck
janssen
bm
peng
advisori
committe
review
panel
abbvi
bm
gilead
msd
roch
brian
conway
advisori
committe
review
panel
abbvi
gilead
merck
grantresearch
support
abbvi
gilead
merck
pendopharm
jannsen
speak
teach
abbvi
gilead
merck
david
iser
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
merck
roch
huang
employ
merck
stock
sharehold
merck
isaia
n
gendrano
employ
merck
sharp
dohm
corp
stock
sharehold
merck
sharp
dohm
corp
peggi
hwang
employ
merck
merck
michael
robertson
employ
merck
stock
sharehold
merck
janic
wahl
employ
merck
co
eliav
barr
employ
merck
stock
sharehold
merck
heather
l
platt
employ
merck
follow
peopl
noth
disclos
oren
shibolet
michel
kelli
background
ribavirin
rbv
compon
treatment
regimen
certain
patient
popul
hepat
c
viru
hcv
infect
known
caus
decreas
hemoglobin
andor
elev
indirect
bilirubinrbv
typic
administ
daili
dosag
mg
studi
investig
safeti
efficaci
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
plu
dasabuvir
dsv
fix
low
dose
rbv
patient
genotyp
chronic
hcv
infect
without
cirrhosi
method
phase
studi
design
evalu
safeti
efficaci
obvptvrdsv
dose
rbv
mg
qd
week
patient
without
cirrhosi
either
hcv
tn
te
previou
interferon
ifn
pegyl
ifn
rbv
therapi
efficaci
assess
sustain
virolog
respons
week
compar
histor
rate
regimen
coadminist
weight
base
rbv
safeti
assess
patient
receiv
least
dose
studi
drug
result
present
itt
modifi
itt
exclud
discontinu
due
failur
relat
ae
popul
result
total
patient
femal
white
enrol
studi
tn
data
date
may
patient
reach
end
treatment
rate
itt
patient
reach
week
ae
mostli
mild
moder
sever
fatigu
headach
insomnia
frequent
report
one
patient
breakthrough
patient
relaps
patient
discontinu
studi
drug
failur
patient
discontinu
due
drug
relat
ae
subject
requir
rbv
dose
reduct
per
protocol
grade
abnorm
report
patient
treatment
period
grade
grade
elev
total
bilirubin
level
report
full
safeti
data
rate
avail
meet
conclus
preliminari
data
ongo
studi
demonstr
rate
itt
popul
regimen
well
toler
hemoglobin
bilirubin
abnorm
observ
infrequ
preliminari
result
suggest
use
rbv
regimen
may
suffici
patient
achiev
svr
reduc
ae
disclosur
fred
poordad
advisori
committe
review
panel
abbottabbvi
achillion
bm
inhibitex
boehering
ingelheim
pfizer
genentech
idenix
gilead
merck
vertex
salix
janssen
novarti
grantresearch
support
abbvi
anadi
achillion
bm
boehring
ingelheim
genentech
idenix
gilead
merck
pharmassett
vertex
salix
tibotecjanssen
novarti
paul
j
pockro
advisori
committe
review
panel
janssen
merck
bm
gilead
abbvi
consult
lumena
beckman
coulter
grantresearch
support
intercept
janssen
bm
gilead
lumena
beckman
coulter
abbvi
rm
merck
speak
teach
abbvi
janssen
gilead
natarajan
ravendhran
grantresearch
support
bm
gilead
merck
abbvi
salix
speak
teach
onyx
salix
gilead
abbvi
michael
r
lucey
grantresearch
support
abbvi
gilead
michael
epstein
advisori
committe
review
panel
aspir
bariatr
consult
abbvi
eli
lilli
imhealthsci
lesli
bank
grantresearch
support
abbvi
virolog
gilead
merck
bm
speak
teach
abbvi
immunolog
gilead
merck
bm
david
e
bernstein
consult
abbvi
merck
janssen
grantresearch
support
gilead
abbvi
bm
janssen
speak
teach
gilead
preethi
krishnan
employ
abbvi
inc
tami
employ
abbvi
stock
sharehold
abbott
akshanth
r
polep
employ
abbvi
kristina
unnebrink
employ
abbvi
stock
sharehold
abbvi
marisol
martinez
employ
abbvi
stock
sharehold
abbvi
david
r
nelson
grantresearch
support
abbvi
bm
gilead
merck
janssen
follow
peopl
noth
disclos
shahriar
sedghi
robert
reindollar
roger
trinh
rajvineeth
k
pothacamuri
background
previou
multin
phase
studi
demonstr
treatment
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
dasabuvir
dsv
well
toler
achiev
sustain
virolog
respons
week
patient
infect
genotyp
hepat
c
viru
hcv
without
cirrhosi
despit
find
interferon
ifn
peglat
ifn
pegifn
ribavirin
rbv
still
current
standard
care
asian
countri
hcv
infect
high
preval
present
studi
evalu
safeti
efficaci
obvptvr
plu
dsv
adult
chronic
hcv
infect
mainland
china
taiwan
south
korea
method
th
phase
random
studi
safeti
efficaci
obvptvr
dsv
administ
week
evalu
ifnpegifn
rbv
adult
chronic
hcv
infect
patient
arm
receiv
activ
drug
week
period
patient
arm
b
receiv
placebo
period
follow
activ
drug
treatment
week
period
efficaci
assess
compar
arm
rate
histor
svr
rate
telaprevir
plu
pegifn
rbv
safeti
assess
patient
receiv
least
dose
studi
drug
result
total
patient
mainland
china
south
korea
taiwan
random
arm
b
patient
asian
femal
treatment
experienc
data
date
may
south
korean
taiwanes
arm
patient
reach
week
achiev
rate
chines
patient
yet
reach
week
treatment
emerg
advers
event
ae
patient
receiv
activ
drug
mild
sever
common
ae
arm
b
upper
respiratori
tract
infect
headach
dizzi
nine
patient
seriou
ae
treatment
arm
arm
b
one
case
arm
drug
relat
result
alanin
aminotransferas
elev
two
patient
arm
b
discontinu
treatment
conclus
preliminari
data
ongo
studi
demonstr
rate
hcv
korean
taiwanes
patient
treat
obvptvr
dsv
week
regimen
well
toler
mostli
mild
ae
report
rate
entir
studi
report
confer
disclosur
jinlin
hou
consult
roch
novarti
gsk
bm
abbovir
grantresearch
support
roch
novarti
gsk
yan
luo
employ
abbvi
stock
sharehold
abbvi
jeong
heo
advisori
committe
review
panel
abbvi
gilead
grant
research
support
bm
roch
gsk
sillajen
chu
advisori
committe
review
panel
gilead
speak
teach
bm
merck
abbvi
roch
jidong
jia
consult
abbi
bm
gsk
novarti
roch
xinyan
zhang
employ
abbvi
tami
employ
abbvi
stock
sharehold
abbott
niloufar
mobasheri
employ
abbvi
stock
sharehold
abbvi
chuang
advisori
committe
review
panel
gilead
abbvi
roch
pharmaessentia
speak
teach
gilead
roch
bm
msd
pharmaessentia
follow
peopl
noth
disclos
lai
wei
zhongp
duan
mong
cho
jun
cheng
jun
li
common
hcv
genotyp
global
account
largest
proport
infect
europ
latin
america
russia
turkey
east
asia
report
efficaci
week
elbasvirgrazoprevir
mg
proteas
inhibitor
hcv
fect
patient
enrol
clinic
develop
program
analysi
patient
use
data
pool
trial
involv
countri
includ
patient
withwithout
cirrhosi
chronic
kidney
diseas
ckd
hiv
cirrhosi
compens
confirm
either
liver
biopsi
noninvas
test
patient
stage
stage
ckd
hemodialysi
includ
hivhcv
patient
requir
stabl
antiretrovir
regimen
arv
tenofovir
abacavir
emtricitabin
lamivudin
either
raltegrevir
dolutegravir
rilpivirin
hiv
viral
load
undetect
arv
viral
load
luml
primari
endpoint
proport
patient
hcv
rna
lower
limit
quantit
week
treatment
efficaci
data
present
full
analysi
set
fa
includ
patient
receiv
least
one
dose
studi
medic
pp
popul
exclud
nonvirolog
failur
total
patient
includ
analysi
mean
patient
age
year
rang
male
white
asian
black
african
american
baselin
viral
load
luml
evid
cirrhosi
fa
patient
categor
virolog
failur
categor
nonvirolog
failur
withdraw
exclud
nonvirolog
failur
pp
analysi
notabl
differ
subgroup
analys
patient
cirrhot
noncirrhot
patient
baselin
viral
load
luml
patient
baselin
viral
luml
hivhcv
patient
patient
stage
ckd
respect
high
efficaci
achiev
popul
treat
elbasvirgrazoprevir
week
compar
efficaci
across
subgroup
includ
cirrhosi
high
baselin
viral
load
prior
treatment
failur
disclosur
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
lawrenc
serfati
advisori
committe
review
panel
msd
janssen
roch
gilead
bm
abbvi
speak
teach
aptali
john
vierl
advisori
committe
review
panel
abbvi
gilead
hyperion
intercept
janssen
novarti
merck
sundis
hepquant
salix
immuron
exalenz
chronic
liver
diseas
foundat
board
membership
clinic
research
center
america
llc
grantresearch
support
abbvi
eisai
gilead
hyperion
intercept
janssen
novarti
merck
sundis
ocera
mochida
immuron
exalenz
conatu
speak
teach
gala
chronic
liver
diseas
foundat
viral
chronic
liver
diseas
foundat
clinic
care
option
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
jan
sperl
advisori
committe
review
panel
msd
abbvi
gilead
janssen
grantresearch
support
gilead
janssen
speak
teach
msd
bm
abbvi
gilead
janssen
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
hiromitsu
kumada
speak
teach
squibb
pharma
intern
msd
abbvi
glaxosmithklin
gilead
scienc
diainippon
sumitomo
pharma
peggi
hwang
employ
merck
merck
michael
robertson
employ
merck
stock
sharehold
merck
janic
wahl
employ
merck
co
eliav
barr
employ
merck
stock
sharehold
merck
rohit
talwani
employ
merck
heather
l
platt
employ
merck
follow
peopl
noth
disclos
wendi
cheng
background
previou
multin
phase
studi
demonstr
treatment
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
dasabuvir
dsv
ribavirin
rbv
well
toler
achiev
sustain
virolog
respons
week
patient
infect
genotyp
b
hepat
c
viru
hcv
compens
cirrhosi
despit
find
interferon
ifn
peglat
ifn
pegifn
ribavirin
rbv
still
current
standard
care
asian
countri
hcv
infect
high
preval
present
studi
evalu
safeti
efficaci
obvptvr
plu
dsv
coadminist
rbv
adult
chronic
hcv
infect
compens
cirrhosi
mainland
china
south
korea
taiwan
method
phase
studi
safeti
efficaci
obvptvr
plu
dsv
rbv
administ
week
evalu
treatment
experienc
ifnpegifn
rbv
adult
hcv
infect
compens
cirrhosi
fibrosi
stage
efficaci
assess
sustain
virolog
respons
post
treatment
week
compar
histor
svr
rate
telaprevir
plu
pegifn
rbv
safeti
efficaci
assess
patient
receiv
least
dose
studi
drug
result
total
patient
femal
asian
enrol
mainland
china
south
korea
taiwan
patient
chronic
b
hcv
infect
compens
cirrhosi
data
date
may
week
data
avail
patient
achiev
rate
treatment
emerg
advers
event
teae
mild
sever
common
teae
increas
blood
bilirubin
level
pruritu
anemia
asthenia
dizzi
four
patient
seriou
teae
assess
relat
daa
regimen
one
assess
possibl
relat
rbv
one
patient
achiev
discontinu
treatment
due
teae
day
dose
due
elev
alanin
aminotransferas
aspart
aminotransferas
blood
bilirubin
conclus
high
rate
achiev
hcv
asian
patient
compens
cirrhosi
treat
obvptvr
plu
dsv
rbv
week
regimen
well
toler
mostli
mild
teae
report
rate
entir
studi
report
confer
disclosur
yan
luo
employ
abbvi
stock
sharehold
abbvi
chu
advisori
committe
review
panel
gilead
speak
teach
bm
merck
abbvi
roch
jinlin
hou
consult
roch
novarti
gsk
bm
abbovir
grantresearch
support
roch
novarti
gsk
bo
fu
employ
abbvi
niloufar
mobasheri
employ
abbvi
stock
sharehold
abbvi
jeong
heo
advisori
committe
review
panel
abbvi
gilead
grant
research
support
bm
roch
gsk
sillajen
follow
peopl
noth
disclos
lai
wei
wang
seung
woon
paik
jun
cheng
qing
xie
zhongp
duan
kao
background
combin
daclatasvir
dcv
pangenotyp
inhibitor
antivir
andor
feronribavirin
pegifnrbv
assess
multipl
phase
clinic
studi
report
interim
analys
studi
studi
includ
respons
durabl
safeti
resist
method
ongo
observ
studi
monitor
patient
year
receiv
treatment
parent
studi
dcvsofosbuvir
sof
dcvasunaprevir
asv
dcvasvbeclabuvir
bcv
dcvpegifnrbv
dcvasvpegifnrbv
patient
enrol
within
month
parent
studi
complet
protocol
avail
evalu
annual
visit
hcv
rna
level
hepat
diseas
progress
decompens
event
persist
resist
variant
result
analysi
includ
patient
treat
dcv
regimen
treat
regimen
patient
male
age
year
hcv
cirrhot
overal
evalu
patient
achiev
parent
studi
maintain
svr
recent
visit
twelv
patient
relaps
achiev
onbefor
posttreat
week
patient
reinfect
relaps
less
frequent
treatment
regimen
vs
regimen
patient
report
hepat
diseas
progress
event
hcc
cirrhosi
hcccirrhosi
common
patient
achiev
parent
studi
achiev
maintain
among
patient
virolog
failur
monitor
month
posttreat
replac
variant
wildtyp
sequenc
observ
patient
respect
conclus
interim
analysi
indic
achiev
regimen
durabl
posttreat
infrequ
liver
diseas
progress
hcc
develop
patient
treat
regimen
ongo
disclosur
k
rajend
reddi
advisori
committe
review
panel
merck
janssen
bm
abbvi
gilead
grantresearch
support
merck
bm
gilead
janssen
abbvi
stanisla
pol
board
membership
boehring
ingelheim
tibotec
janssen
cilag
gilead
glaxo
smith
kline
roch
msd
novarti
grant
research
support
gilead
roch
msd
speak
teach
boehring
ingelheim
tibotec
janssen
cilag
gilead
roch
msd
novarti
paul
j
thuluvath
advisori
committe
review
panel
abbvi
gilead
grantresearch
support
gilead
abbvi
bm
isai
salix
speak
teach
abbvi
bayeronyx
gilead
hiromitsu
kumada
speak
teach
squibb
pharma
intern
msd
abbvi
glaxosmithklin
gilead
scienc
diainippon
sumitomo
pharma
kazuaki
chayama
grantresearch
support
ajinomoto
astella
asuka
msd
bayer
daiichi
sankyo
dainippon
sumitomo
eisai
nihon
kayaku
nihon
shinyaku
kowa
mitsubishi
tanab
nippon
eli
lili
roch
otsuka
takeda
toray
torii
tsumura
zeria
speak
teach
squibb
abbvi
ajinomoto
abbott
astella
astrazeneca
asuka
chugai
dainippon
sumitomo
johnson
johnson
jimuro
miyarisan
nihon
kayaku
nihon
shinyaku
olympu
msd
jame
levin
advisori
committe
review
panel
gilead
merck
grant
research
support
gilead
merck
bm
abbvi
speak
teach
bm
gilead
merck
abbvi
eric
lawitz
advisori
committe
review
panel
abbvi
achillion
pharmaceut
regulu
therav
enanta
idenix
pharmaceut
janssen
merck
co
novarti
gilead
grantresearch
support
abbvi
achillion
pharmaceut
boehring
ingelheim
squibb
gilead
scienc
glaxosmithklin
idenix
pharmaceut
intercept
pharmaceut
janssen
merck
co
novarti
nitto
denko
therav
salix
enanta
speak
teach
gilead
janssen
abbvi
bristol
meyer
squibb
merck
intercept
maurizia
r
brunetto
advisori
committe
review
panel
gilead
janssen
abbvi
speak
teach
roch
gilead
squibb
abbott
roch
janssen
peng
advisori
committe
review
panel
abbvi
bm
gilead
msd
roch
marcelo
silva
advisori
committe
review
panel
msd
abbvi
grant
research
support
bm
msd
bayer
speak
teach
bm
abbvi
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
jeong
heo
advisori
committe
review
panel
abbvi
gilead
grant
research
support
bm
roch
gsk
sillajen
fiona
mcphee
employ
squibb
rong
yang
employ
bm
stock
sharehold
bm
misti
linaberri
employ
bm
stephani
noviello
consult
employ
squibb
stock
sharehold
j
j
squibb
follow
peopl
noth
disclos
joji
toyota
adrian
gadano
wayn
ghesquier
guido
gerken
zhaohui
liu
purpos
aim
studi
assess
treat
chronic
hepat
c
hcv
infect
patient
stage
compar
treat
patient
develop
cirrhosi
method
markov
model
develop
follow
cohort
patient
lifetim
year
age
two
strategi
compar
treat
patient
independ
fibrosi
stage
versu
treat
cirrhot
patient
analysi
perform
gener
patient
popul
age
distribut
patient
differ
fibrosi
stage
cost
reflect
uk
set
patient
treat
buvir
ldvsof
week
stage
ldvsof
week
cirrhot
stage
model
structur
base
model
submit
nation
institut
health
care
excel
nice
hcv
previou
health
technolog
apprais
sustain
virolog
respons
rate
transit
probabl
cost
util
obtain
literatur
clinic
trial
ldvsof
cost
outcom
discount
recommend
nice
includ
sensit
analysi
well
proport
patient
determinist
probabilist
sensit
analys
conduct
investig
differ
rang
paramet
altern
valu
collect
literatur
onward
transmiss
consid
analysi
result
cost
lower
life
year
qali
gain
higher
treatment
start
earlier
stage
diseas
result
analysi
therefor
show
treat
fibrosi
stage
cost
per
cure
treat
patient
versu
furthermor
treat
patient
earlier
gener
fewer
case
decompens
cirrhosi
hepatocellular
carcinoma
liver
transplant
save
live
result
robust
sensit
analysi
conclus
analysi
demonstr
treat
hcv
earli
fibrosi
stage
includ
uk
therefor
treat
patient
soon
diagnos
hcv
gener
save
also
reduc
burden
hcv
disclosur
lucil
employ
mapi
ine
guerra
consult
gilead
mark
nelson
advisori
committe
review
panel
janssen
msd
bm
abbvi
viiv
gilead
consult
janssen
msd
bm
abbvi
viiv
gilead
grantresearch
support
boehring
ingelheim
janssen
msd
bm
abbvi
viiv
gilead
roch
speak
teach
gsk
janssen
msd
bm
abbott
viiv
gilead
sanjay
bhagani
advisori
committe
review
panel
bm
msd
abbvi
jannsen
gilead
scienc
speak
teach
bm
gilead
scienc
msd
jannsen
abbvi
background
sofosbuvir
sof
ledipasvirsofosbuvir
ldv
sof
approv
treatment
chronic
hcv
infect
adult
safeti
efficaci
sof
ribavirin
rbv
ldvsof
assess
adolesc
receiv
adult
dose
pharmacokinet
pk
lower
dose
sof
ldvsof
evalu
children
confirm
appropri
predict
dose
popul
method
children
weight
kg
screen
receiv
sof
mg
qd
rbv
day
ldvsof
mg
qd
day
intens
pk
assess
done
day
respect
pk
addit
patient
cohort
inadvert
receiv
adult
dose
sof
mg
ldv
sof
mg
day
upon
complet
pk
patient
continu
sofrbv
week
respect
ldvsof
wk
sof
major
circul
metabolit
ldv
pk
paramet
compar
via
anova
exposur
phase
sof
ldvsof
adult
clinic
program
predefin
equival
bound
safeti
assess
throughout
studi
result
patient
complet
pk
assess
screen
median
rang
age
patient
male
femal
sofrbv
weight
kg
median
rang
age
weight
ldvsof
patient
male
femal
respect
studi
treatment
well
toler
sof
ldv
sof
exposur
similar
pediatr
phase
popul
tabl
conclus
studi
treatment
well
toler
sof
mg
rbv
ldvsof
mg
provid
compar
exposur
observ
adult
data
support
ongo
evalu
dose
children
disclosur
kimberli
l
garrison
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
anita
mathia
employ
gilead
scienc
inc
kathryn
kersey
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
bittoo
kanwar
employ
gilead
scienc
regino
p
advisori
committe
review
panel
shire
consult
roch
grantresearch
support
abbvi
gilead
bristol
merck
sucampo
karen
f
murray
grantresearch
support
gilead
stock
sharehold
merck
jessica
wen
grantresearch
support
gilead
bm
abbvi
novarti
kathleen
b
schwarz
advisori
committe
review
panel
alexion
grant
research
support
squibb
gilead
rochegenentech
roch
william
balistreri
grantresearch
support
gilead
follow
peopl
noth
disclos
liyun
ni
anant
jain
john
ling
lin
mari
suzann
whitworth
background
egypt
highest
preval
chronic
hepat
c
viru
hcv
infect
world
patient
infect
genotyp
gt
viru
ledipasvirsofosbuvir
ldvsof
week
result
rate
phase
studi
conduct
franc
aim
ongo
studi
evalu
safeti
efficaci
ldvsof
ribavirin
rbv
tn
te
patient
egypt
chronic
genotyp
gt
hcv
infect
method
tn
patient
random
week
rbv
patient
random
week
random
stratifi
cirrhosi
statu
patient
receiv
week
ldvsofrbv
primari
endpoint
secondari
endpoint
includ
safeti
toler
result
tn
egyptian
patient
enrol
treat
male
mean
rang
age
mean
rang
bmi
compens
cirrhosi
genotyp
patient
enrol
date
male
mean
rang
age
mean
rang
bmi
compens
cirrhosi
genotyp
rate
summar
total
tn
patient
achiev
due
relaps
rebound
earli
studi
discontinu
te
patient
date
achiev
data
group
present
common
ae
patient
treatment
group
headach
fatigu
seriou
ae
report
patient
injuri
road
traffic
accid
arm
fractur
atyp
chest
pain
none
sae
consid
relat
studi
drug
road
traffic
accid
led
treatment
discontinu
conclus
preliminari
result
support
use
ldvsof
week
patient
genotyp
hcv
potenti
util
ldvsof
week
preliminari
rate
nn
patient
hcv
reach
week
patient
nanot
applic
disclosur
imam
wake
advisori
committe
review
panel
janssen
speak
teach
hoffman
l
roch
bm
gilead
abbvi
moham
hassani
grantresearch
support
gilead
sc
abbvi
janssen
speak
teach
abbvi
talaat
zakareya
grantresearch
support
gilead
scienc
inc
radi
hammad
grantresearch
support
gilead
scienc
inc
janssen
pharmaceut
inc
kathryn
kersey
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
benedetta
massetto
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
gamal
e
esmat
advisori
committe
review
panel
msd
bm
compani
msd
bm
compani
abbvi
grantresearch
support
gilead
sc
abbvi
speak
teach
roch
gsk
compani
roch
gsk
compani
gilead
sc
abbvi
follow
peopl
noth
disclos
gamal
shiha
reham
soliman
wael
abdelrazek
rabab
f
omar
wale
samir
sherief
musa
sophia
lu
wahid
h
doss
background
aim
signific
advanc
treatment
chronic
hepat
c
made
direct
act
antivir
daa
regimen
sustain
virolog
respons
svr
rate
may
achiev
patient
data
long
term
virolog
clinic
outcom
regimen
need
recent
report
suggest
hcc
incid
may
reduc
success
daa
therapi
object
ongo
registri
studi
evalu
long
term
outcom
patient
cirrhosi
achiev
svr
follow
treatment
sof
base
regimen
method
patient
compens
decompens
cirrhosi
achiev
svr
receiv
regimen
elig
enrol
patient
may
enrol
within
week
complet
treatment
studi
transfer
anoth
svr
registri
studi
within
year
achiev
svr
follow
treatment
clinic
practic
set
patient
return
visit
everi
week
year
durabl
svr
clinic
outcom
decompens
hcc
transplant
death
laboratori
paramet
relat
diseas
progressionregress
follow
patient
result
patient
enrol
may
mean
age
rang
male
mean
rang
meld
score
baselin
cpt
cpt
b
c
cirrhosi
respect
median
rang
time
sinc
end
treatment
clinic
studi
patient
day
baselin
svr
maintain
patient
hcc
tabl
show
chang
pretreat
cpt
class
start
registri
studi
decompens
cirrhosi
chang
laboratori
paramet
time
event
clinic
sign
week
registri
studi
present
conclus
baselin
registri
studi
svr
maintain
patient
cirrhosi
regimen
patient
decompens
cirrhosi
pretreat
cpt
class
improv
entri
registri
studi
cpt
b
cpt
c
b
unchang
ongo
studi
provid
inform
whether
achiev
svr
follow
treatment
hcv
daa
regimen
improv
longer
term
liver
function
reduc
rate
complic
includ
hcc
tabl
number
patient
cpt
b
c
cirrhosi
prior
treatment
regimen
cpt
class
baselin
registri
studi
disclosur
andrew
j
muir
advisori
committe
review
panel
abbvi
bm
gilead
janssen
merck
consult
shire
inovia
pharmaceut
intercept
portola
pharmaceut
grantresearch
support
abbvi
bm
gilead
janssen
merck
holog
intercept
ngm
biopharm
roch
maria
buti
advisori
committe
review
panel
gilead
janssen
msd
grantresearch
support
gilead
janssen
speak
teach
gilead
janssen
bm
ronald
nahass
advisori
committe
review
panel
gilead
merck
janssen
bm
grantresearch
support
gilead
merck
janssen
bm
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
edward
j
gane
advisori
committe
review
panel
abbvi
janssen
gilead
scienc
achillion
merck
speak
teach
abbvi
gilead
scienc
merck
alnylam
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
alessandra
mangia
advisori
committe
review
panel
gilead
scienc
bm
msd
bohering
bm
board
membership
msd
grant
research
support
janssen
janssen
gilead
speak
teach
roch
jose
l
calleja
advisori
committe
review
panel
gilead
abbvi
speak
teach
abbvi
gilead
janssen
bm
kathryn
kersey
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
marc
advisori
committe
review
panel
bohring
inghelmein
bohring
inghelmein
transgen
board
membership
squibb
gilead
idenix
consult
roch
novarti
tibotec
abott
glaxo
smith
kline
merck
squibb
novarti
tibotec
abott
glaxo
smith
kline
speak
teach
gilead
roch
merck
squibb
bruce
bacon
advisori
committe
review
panel
gilead
squibb
isi
abbvi
janssen
consult
merck
grantresearch
support
merck
gilead
squibb
abbvi
speak
teach
merck
gilead
abbvi
salix
janssen
bradley
freilich
grantresearch
support
schere
plough
vertex
roch
abbott
pharmaset
anadi
abbott
schere
plough
vertex
roch
abbott
pharmaset
anadi
abbott
schere
plough
vertex
roch
abbott
pharmaset
anadi
abbott
schere
plough
vertex
roch
abbott
pharmaset
anadi
abbott
connatu
bristol
myer
jansen
gilead
speak
teach
onyx
onyx
onyx
onyx
gilead
jansen
abbott
michael
p
curri
consult
alexion
bristol
meyer
squib
abbvi
grant
research
support
gilead
scienc
conatu
follow
peopl
noth
disclos
stephani
moodi
paul
marotta
introduct
pivot
studi
modern
direct
act
antivir
daa
svr
rate
hcv
genotyp
howev
data
replic
less
well
control
set
includ
patient
difficult
treat
method
german
hepat
c
registri
nation
multicentr
cohort
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
treatment
result
patient
enrol
data
avail
patient
time
analysi
demograph
male
median
age
year
caucasian
treatment
experienc
liver
cirrhosi
mio
luml
comorbid
report
patient
cohort
cardiovascular
psychiatr
drug
abus
diabet
thyroid
dysfunct
frequent
patient
treat
one
approv
regimen
analys
tabl
overal
multivari
analysi
adjust
age
sex
platelet
cirrhosi
hcv
rna
treatment
regim
associ
choic
antivir
regimen
p
cirrhosi
p
higher
age
p
patient
overal
substanti
differ
patient
advers
event
report
patient
fatigu
headach
nausea
insomnia
frequent
seriou
advers
event
observ
patient
die
conclus
data
real
life
cohort
show
svr
rate
close
obtain
clinic
studi
choic
antivir
therapi
associ
treatment
outcom
addit
higher
age
posit
factor
presenc
cirrhosi
neg
factor
achiev
dropout
rate
low
confirm
good
adher
patient
regimen
tabl
treatment
regimen
data
patient
hcv
itt
disclosur
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
heik
employ
efactum
gmbh
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
chronic
hcv
preval
doc
although
svr
daa
treatment
tx
high
feasibl
svr
patient
pt
doc
unknown
compar
virginia
doc
daa
telemedicin
hcv
pt
indig
clinic
treat
ledipasvirsofosbuvir
method
doc
pt
evalu
via
telemedicin
diseas
sever
appropri
tx
follow
guidelin
decompens
cirrhosi
signific
less
month
exclud
demograph
baselin
lab
hiv
prior
tx
statu
tn
experienc
te
advanc
fibrosi
af
bridg
fibrosiscirrhosi
durat
tx
use
ribavirin
rbv
primari
outcom
record
compar
doc
pt
control
group
indig
tx
clinic
time
period
provid
exclud
gt
n
treat
daa
result
consecut
pt
includ
doc
pt
compar
privat
indig
pt
data
avail
characterist
popul
shown
tabl
doc
younger
male
tn
af
receiv
rbv
week
tx
doc
similar
indig
compar
privat
clinic
even
lost
follow
exclud
multipl
logist
regress
identifi
treatment
clinic
predictor
lack
impact
race
gender
age
durat
prior
tx
histori
rbv
use
hiv
conclus
tx
hcv
doc
telemedicin
daa
feasibl
high
higher
doc
compar
privat
clinic
may
due
directli
observ
therapi
differ
pt
characterist
lower
marker
diseas
sever
addit
data
longer
follow
doc
need
disclosur
richard
k
sterl
advisori
committe
review
panel
merck
baxter
salix
bayer
bm
abbvi
gilead
gsk
jansen
grantresearch
support
merck
rochegenentech
pfizer
gilead
bayer
bm
abbvi
velimir
luket
advisori
committe
review
panel
gsk
grantresearch
support
intercept
lumenashir
merck
gilead
genfit
bm
abvi
ngm
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
reena
cherian
lewi
shawn
ravi
chhatrala
ana
alsaleh
kathleen
genther
carloyn
driscol
kelli
martin
scott
c
matherli
mohammad
siddiqui
r
todd
stravitz
puneet
puri
hannah
lee
paula
g
smith
introduct
ledipasvirsofosbuvir
ldvsof
week
approv
treatment
chronic
hepat
c
studi
week
ldvsof
wk
previous
untreat
patient
without
cirrhosi
although
number
patient
elig
week
accord
summari
product
characterist
smpc
high
larg
proport
patient
still
receiv
longer
treatment
durat
one
reason
might
uncertainti
whether
week
treatment
durat
suffici
harder
cure
popul
hiv
patient
patient
opioid
substitut
treatment
ost
older
patient
yr
aim
analysi
evalu
virolog
respons
rate
wk
treatment
real
world
condit
patient
method
german
hepat
c
registri
nation
multicent
cohort
patient
treat
discret
physician
data
collect
data
system
confirm
plausibl
check
site
monitor
analysi
data
patient
wk
treatment
ldvsof
avail
data
data
cut
includ
baselin
characterist
prior
treatment
histori
safeti
effect
investig
result
femal
pt
treat
week
mean
sd
age
yr
fibrosi
stage
evalu
elastographi
mean
sd
stiff
valu
kpa
pt
reach
svr
time
point
includ
analysi
genotyp
distribut
baselin
viral
load
mio
iuml
treatment
experienc
liver
cirrhosi
treat
week
despit
characterist
overal
svr
rate
itt
pp
pt
hiv
svr
group
itt
pp
viral
relaps
occur
pt
receiv
ost
pt
develop
viral
relaps
pt
discontinu
therapi
lost
follow
thu
itt
pp
compar
itt
pp
without
ost
pt
yr
rate
itt
pp
pt
pretreat
achiev
rate
itt
pp
conclus
real
world
condit
wk
ldvsof
achiev
high
svr
rate
heterogen
group
like
hiv
pt
call
harder
cure
popul
disclosur
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
gerlind
teuber
advisori
committe
review
panel
msd
gilead
abbvi
grantresearch
support
gilead
abbvi
falk
speak
teach
msd
gilead
bm
abbvi
janssen
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
anita
pathil
speak
teach
abbvi
bm
gilead
stefan
christensen
advisori
committe
review
panel
bm
abbvi
janssen
viiv
gilead
msd
speak
teach
gilead
msd
abbvi
bm
janssen
heik
employ
efactum
gmbh
simon
advisori
committe
review
panel
abbvi
bm
janssen
msd
speak
teach
abbvi
bm
falk
gilead
janssen
norgin
merz
msd
clau
niederau
advisori
committe
review
panel
msd
abbvi
jannsen
gilead
consult
msd
grantresearch
support
msd
speak
teach
msd
abbvi
bm
roch
gilead
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
background
hepat
c
viru
hcv
genotyp
gt
account
estim
global
hcv
infect
difficult
cure
antivir
daa
therapi
especi
patient
cirrhosi
prior
treatment
failur
previous
present
safeti
efficaci
asvir
inhibitor
proteas
inhibitor
paritaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
plu
sofosbuvir
sof
ribavirin
rbv
patient
arm
b
investig
safeti
efficaci
treatment
durat
patient
assess
rbv
addit
patient
includ
cirrhosi
method
quartz
multicent
studi
fect
patient
receiv
obvptvr
sof
rbv
arm
c
arm
week
patient
cirrhosi
arm
e
receiv
week
patient
without
cirrhosi
receiv
arm
b
without
arm
af
rbv
week
primari
efficaci
endpoint
percentag
patient
achiev
result
studi
enrol
patient
tabl
show
select
baselin
demograph
efficaci
safeti
data
patient
week
patient
avail
data
hcv
rna
lloq
two
patient
one
arm
c
week
arm
week
experienc
relaps
date
virolog
failur
patient
infect
regardless
cirrhosi
statu
common
ae
fatigu
headach
nausea
diarrhea
seriou
ae
relat
daa
ae
led
discontinu
studi
drug
conclus
well
toler
patient
infect
patient
achiev
complet
resist
safeti
data
present
tabl
baselin
demograph
safeti
disclosur
stephen
shafran
advisori
committe
review
panel
squibb
gilead
scienc
merck
grantresearch
support
abbvi
squibb
gilead
scienc
janssen
merck
speak
teach
pfizer
mariem
charafeddin
employ
abbvi
ltd
stock
sharehold
abbvi
ltd
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
manal
abunimeh
employ
abbvi
bo
fu
employ
abbvi
tami
employ
abbvi
stock
sharehold
abbott
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
edward
j
gane
advisori
committe
review
panel
abbvi
janssen
gilead
scienc
achillion
merck
speak
teach
abbvi
gilead
scienc
merck
alnylam
follow
peopl
noth
disclos
david
shaw
rajvineeth
k
pothacamuri
eric
cohen
background
combin
direct
act
antivir
agent
daa
demonstr
high
rate
sustain
virologi
respons
svr
patient
chronic
hepat
c
viru
hcv
infect
compens
cirrhot
howev
clinic
data
limit
daa
patient
comorbid
renal
dysfunct
phase
studi
assess
safeti
efficaci
obv
ptvr
dsv
rbv
patient
sever
renal
impair
renal
diseas
includ
dialysi
result
first
cohort
previous
present
present
safeti
efficaci
data
second
cohort
arm
includ
patient
compens
cirrhosi
method
particip
either
treatment
tn
treatment
experienc
te
ifnpegifn
rbv
patient
hcv
infect
fibrosi
stage
assign
arm
c
receiv
regimen
rbv
mg
qd
week
fibrosi
stage
assign
arm
treat
regimen
week
patient
hcv
infect
fibrosi
stage
assign
arm
e
treat
regimen
without
rbv
week
efficaci
assess
svr
week
safeti
assess
patient
receiv
least
dose
studi
drug
result
total
patient
chronic
hcv
infect
without
cirrhosi
sever
renal
impair
end
stage
renal
diseas
enrol
cohort
arm
c
arm
arm
e
among
male
black
patient
either
stage
chronic
kidney
diseas
includ
hemodialysi
data
date
may
achiev
patient
arm
c
e
respect
popul
patient
achiev
prematur
discontinu
treatment
treatment
emerg
advers
event
ae
mild
moder
sever
anemia
decreas
hemoglobin
fatigu
frequent
report
ten
patient
experienc
seriou
ae
one
patient
discontinu
treatment
arm
c
conclus
preliminari
data
ongo
studi
demonstr
rate
ae
mild
moder
sever
result
support
use
regimen
patient
advanc
renal
diseas
treatment
option
limit
disclosur
john
vierl
advisori
committe
review
panel
abbvi
gilead
hyperion
intercept
janssen
novarti
merck
sundis
hepquant
salix
immuron
exalenz
chronic
liver
diseas
foundat
board
membership
clinic
research
center
america
llc
grantresearch
support
abbvi
eisai
gilead
hyperion
intercept
janssen
novarti
merck
sundis
ocera
mochida
immuron
exalenz
conatu
speak
teach
gala
chronic
liver
diseas
foundat
viral
chronic
liver
diseas
foundat
clinic
care
option
eric
lawitz
advisori
committe
review
panel
abbvi
achillion
pharmaceut
regulu
therav
enanta
idenix
pharmaceut
janssen
merck
co
novarti
gilead
grantresearch
support
abbvi
achillion
pharmaceut
boehring
ingelheim
squibb
gilead
scienc
glaxosmithklin
idenix
pharmaceut
intercept
pharmaceut
janssen
merck
co
novarti
nitto
denko
therav
salix
enanta
speak
teach
gilead
janssen
abbvi
bristol
meyer
squibb
merck
intercept
k
rajend
reddi
advisori
committe
review
panel
merck
janssen
bm
abbvi
gilead
grantresearch
support
merck
bm
gilead
janssen
abbvi
philipp
j
zamor
advisori
committe
review
panel
bristol
myer
squibb
gilead
grantresearch
support
gilead
abbvi
merck
speak
teach
bristol
myer
squibb
gilead
abbvi
david
e
bernstein
consult
abbvi
merck
janssen
grantresearch
support
gilead
abbvi
bm
janssen
speak
teach
gilead
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
parvez
mantri
consult
salix
gilead
janssen
abbvi
bm
grant
research
support
salix
merck
gilead
mass
biolog
vital
therapi
santari
mass
biolog
squibb
abbiv
shinogi
tacer
intercept
speak
teach
gilead
janssen
salix
paul
j
pockro
advisori
committe
review
panel
janssen
merck
bm
gilead
abbvi
consult
lumena
beckman
coulter
grantresearch
support
intercept
janssen
bm
gilead
lumena
beckman
coulter
abbvi
rm
merck
speak
teach
abbvi
janssen
gilead
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
sonal
kumar
advisori
committe
review
panel
gilead
intercept
abbvi
speak
teach
intercept
gilead
kalyan
r
bhamidimarri
advisori
committe
review
panel
gilead
bristol
myer
squibb
salix
speak
teach
alexion
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
tami
employ
abbvi
stock
sharehold
abbott
wangang
xie
employ
abbvi
thoma
podsadecki
employ
abbvi
stock
sharehold
abbvi
tarek
hassanein
advisori
committe
review
panel
abbvi
pharmaceut
squibb
trek
therapeut
grantresearch
support
abbvi
pharmaceut
obalon
squibb
eiasi
pharmaceut
gilead
scienc
merck
sharp
dohm
ngm
biopharmaceut
ocera
therapeut
salix
pharmaceut
sundis
taigen
biotechnolog
vital
therapi
tobria
shinoghi
co
ltd
la
jolla
pharmaceut
trek
therapeut
novo
nordisk
intercept
speak
teach
baxter
squibb
gilead
scienc
salix
pharmaceut
abbvi
pharmaceut
follow
peopl
noth
disclos
eric
cohen
nyingi
kemmer
giusepp
morelli
michael
bennett
background
aim
octob
fda
releas
warn
use
paritaprevir
ombitasvir
dasabuvir
prod
ribavirin
patient
cirrhosi
consequ
prod
contraind
patient
pugh
class
bc
hepat
impair
hyperbilirubinemia
elev
alt
concentr
observ
therapi
sever
clinic
signific
abnorm
set
report
aim
studi
character
bilirubin
alt
chang
observ
prod
therapi
larg
popul
determin
impact
chang
outcom
earli
discontinu
therapi
method
patient
particip
australian
compassion
access
program
treat
hepat
c
octob
juli
includ
analysi
receiv
least
one
dose
prod
elev
bilirubin
character
accord
common
terminolog
criteria
advers
event
ctcae
result
patient
includ
analysi
major
cirrhosi
cirrhot
patient
complet
respons
data
hyperbilirubinemia
prod
common
elev
valu
occur
subject
tabl
small
proport
patient
mild
elev
prior
comemnc
patient
experienc
elev
bilirubin
mgdl
cirrhot
develop
hyperbilirubinemia
within
first
week
therapi
ceas
therapi
earli
mean
week
instanc
alt
diminish
prod
mean
iul
howev
patient
increas
alt
least
iul
baselin
associ
hyperbilirubinemia
cirrhot
conclus
studi
hcv
genotyp
patient
mostli
cirrhosi
rate
excel
hyperbilirubinemia
occur
commonli
instanc
abnorm
lead
discontinu
significantli
impact
upon
svr
small
proport
patient
bilirubin
exceed
frequent
result
earli
discontinu
maximum
bilirubin
increas
prod
disclosur
john
lubel
advisori
committe
review
panel
gilead
abbvi
bayer
grantresearch
support
bm
msd
abbvi
speak
teach
gilead
abbvi
bm
jansen
roch
stephen
pianko
advisori
committe
review
panel
roch
novarti
gilead
roch
novarti
consult
gilead
speak
teach
janssen
bm
alex
j
thompson
advisori
committe
review
panel
gilead
abbvi
bm
merck
spring
bank
pharmaceut
arrowhead
roch
grantresearch
support
gilead
abbvi
bm
merck
speak
teach
roch
gilead
abbvi
bm
david
iser
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
merck
roch
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
gregori
dore
board
membership
gilead
merck
abbvi
squibb
grantresearch
support
gilead
merck
abbvi
squibb
speak
teach
gilead
merck
abbvi
squibb
katherin
stuart
advisori
committe
review
panel
gilead
bayer
abbvi
grantresearch
support
roch
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
amani
zekri
advisori
committe
review
panel
gilead
bm
msd
abbvi
miriam
levi
advisori
committe
review
panel
bayer
grantresearch
support
gilead
vinc
fragom
advisori
committe
review
panel
roch
msd
jansen
brenda
moral
advisori
committe
review
panel
msd
jansen
roch
abbvi
bm
joe
sasadeusz
advisori
committe
review
panel
merck
gilead
bm
grantresearch
support
roch
gilead
avvbi
speak
teach
gila
merck
bm
merck
amanda
j
wade
grantresearch
support
abbvi
stuart
k
robert
board
membership
abbvi
gilead
follow
peopl
noth
disclos
joann
mitchel
alessia
gazzola
sarah
chiver
gauri
mishra
john
gough
edmund
tse
gerri
c
macquillan
paul
gow
saroj
nazareth
steven
j
bollipo
tracey
l
jone
background
genet
variant
inosin
triphosphatas
gene
confer
reduc
itpas
activ
associ
protect
hemolyt
anemia
peginterferon
ifn
treatment
hepat
c
viru
hcv
studi
patient
treat
ifn
ribavirin
shown
improv
treatment
efficaci
patient
reduc
itpas
activ
ribavirin
import
compon
regimen
current
recommend
combin
sever
regimen
treatment
hcv
infect
present
studi
genet
analys
conduct
interrog
effect
itpa
variant
anemia
platelet
count
virolog
respons
hcv
genotyp
subject
treat
antivir
daa
regimen
ombitasvirparitaprevirritonavir
dasabuvir
without
ribavirin
method
dna
sampl
obtain
appropri
consent
subject
enrol
studi
analyz
itpa
variant
rsl
use
pyrosequenc
result
reduct
itpas
activ
protect
anemia
effect
signific
gender
ad
covari
analys
male
subject
lower
itpas
activ
protect
anemia
hb
chang
gdl
low
itpas
vs
gdl
high
itpas
wherea
signific
associ
note
among
femal
subject
gdl
low
itpas
vs
gdl
high
itpas
ns
itpas
activ
signific
impact
platelet
count
overal
howev
femal
subject
lower
itpas
activ
significantli
higher
incid
thrombocytosi
low
itpas
vs
high
itpas
associ
note
itpas
activ
reduct
hb
level
platelet
count
patient
treat
without
ribavirin
reduct
itpas
activ
impact
virolog
respons
daa
treatment
viral
kinet
baselin
level
conclus
studi
demonstr
genet
variant
itpa
associ
reduc
activ
may
help
predict
anemia
chronic
hepat
c
patient
treat
regimen
contain
ribavirin
may
particularli
help
context
subject
difficult
treat
hcv
infect
patient
cirrhosi
regimen
recommend
contrast
studi
analyz
regimen
studi
show
impact
itpas
activ
reduct
treatment
outcom
relaps
rate
regimen
disclosur
manal
abunimeh
employ
abbvi
jona
soderholm
employ
abbvi
justin
w
davi
employ
abbvi
emili
duma
employ
abbvi
stock
sharehold
abbvi
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
jeffrey
f
ware
employ
abbvi
patent
heldfil
abbvi
stock
sharehold
abbvi
martin
lag
advisori
committe
review
panel
msd
abbvi
gilead
medivir
bm
speak
teach
msd
abbvi
gilead
medivir
bm
follow
peopl
noth
disclos
aparna
vasanthakumar
decreas
estim
glomerular
filtrat
rate
egfr
report
patient
hcv
infect
receiv
antivir
agent
ebrgzr
safe
efficaci
patient
chronic
kidney
diseas
stage
ckd
studi
aim
analysi
evalu
impact
ebrgzr
egfr
patient
less
sever
ckd
analyz
pool
dataset
patient
receiv
ebrgzr
mg
without
ribavirin
rbv
week
patient
receiv
rbv
patient
includ
cirrhot
hiv
creatinin
valu
assess
baselin
timepoint
egfr
calcul
use
modifi
diet
renal
diseas
equat
baselin
end
treatment
week
patient
evalu
ckd
egfr
egfr
tabl
demograph
similar
group
except
higher
proport
patient
ckd
group
vs
patient
ckd
egfr
ml
baselin
show
decreas
egfr
treatment
ebrgzr
affect
egfr
patient
egfr
treatment
durat
rbv
cirrhosi
hiv
coinfect
advers
affect
renal
outcom
patient
demograph
chang
egfr
disclosur
k
rajend
reddi
advisori
committe
review
panel
merck
janssen
bm
abbvi
gilead
grantresearch
support
merck
bm
gilead
janssen
abbvi
david
roth
advisori
committe
review
panel
merck
sharp
dome
consult
merck
sharp
dome
peggi
hwang
employ
merck
merck
barbara
haber
employ
merck
co
inc
nguyen
employ
merck
eliav
barr
employ
merck
stock
sharehold
merck
janic
wahl
employ
merck
co
wayn
greav
employ
merck
follow
peopl
noth
disclos
annett
bruchfeld
introduct
high
price
direct
act
antivir
daa
prevent
access
treatment
gener
version
sofosbuvir
daclatasvir
ledipasvir
mass
produc
price
current
us
retail
price
patient
legal
right
import
month
treatment
australia
uk
new
zealand
mani
countri
provid
person
use
worldwid
sever
thousand
patient
treat
legal
import
direct
act
antivir
hepat
c
buyer
club
establish
russia
usa
australia
se
asia
uk
analysi
assess
efficaci
safeti
gener
daa
access
via
person
import
rule
fixhepc
buyer
club
method
sofosbuvir
sof
ledipasvir
ldv
daclatasvir
dcv
import
gener
compani
india
china
bangladesh
select
daa
treatment
durat
depend
baselin
hcv
genotyp
fibrosi
stage
provis
patient
safeti
gener
daa
evalu
qualiti
use
high
precis
liquid
chromatograhi
hplc
nuclear
magnet
reson
nmr
patient
evalu
treatment
svr
advers
event
record
analysi
includ
data
patient
two
clinic
fixhepc
buyer
club
patient
treat
usa
europ
australia
new
zealand
se
asia
summari
svr
rate
compar
equival
data
origin
phase
trial
sofldv
sofdcv
result
patient
treat
receiv
sofldv
sofdcv
sof
rbv
overal
patient
male
mean
age
year
cirrhosi
genotyp
aselin
hcv
rna
luml
first
four
week
treatment
viral
decay
kinet
hcv
rna
first
week
treatment
similar
result
origin
phase
studi
sofdcv
sofldv
base
current
avail
data
percentag
hcv
rna
lloq
end
treatment
eot
svr
genotyp
rate
sof
ldv
sofdcv
svr
rate
consist
result
origin
trial
daa
combin
conclus
analysi
treatment
legal
import
gener
daa
achiev
overal
rate
rate
compar
seen
phase
trial
brand
treatment
mass
treatment
current
gener
daa
feasibl
option
high
price
prevent
access
brand
treatment
disclosur
follow
peopl
noth
disclos
jame
freeman
richard
salli
adam
kennedi
greg
jeffrey
anna
savag
andrew
hill
purpos
among
patient
chronic
hcv
littl
inform
benefit
achiev
svr
term
liver
function
comparison
assess
liver
function
recent
devis
albi
method
patient
median
year
ci
classifi
achiev
svr
relaps
respons
nr
receiv
interferon
base
therapi
result
differ
liver
function
group
evid
end
treatment
improv
fall
rapidli
nr
relaps
cohort
figur
surviv
better
svr
svr
respect
year
p
fibrosi
assess
index
progress
significantli
r
nr
group
hcc
major
caus
death
great
major
occur
among
group
overal
die
overal
record
die
liver
failur
conclus
within
timefram
studi
svr
associ
improv
liver
function
less
progress
fibrosi
improv
surviv
appear
larg
result
reduct
hcc
develop
johnson
pj
et
al
j
clin
oncol
chang
albi
score
accord
treatment
respons
lower
score
vertic
axi
indic
better
liver
function
disclosur
follow
peopl
noth
disclos
philip
j
johnson
emili
de
groot
sarah
berhan
toshifumi
tada
takashi
kumada
hidenori
toyoda
background
aim
clinic
trial
regimen
perform
similarli
patient
hivhcv
hcv
recent
report
suggest
hcv
monoinfect
patient
achiev
similar
svr
rate
base
regimen
real
world
cohort
rwc
observ
clinic
trial
howev
yet
demonstr
hivhcv
patient
aim
studi
compar
efficaci
singl
tablet
regimen
ledipasvir
sofosbuvir
ldvsof
hcv
genotyp
patient
hiv
hcv
clinic
trial
effect
rwc
method
analysi
data
three
clinic
trial
ldvsof
hivhcv
patient
compar
four
rwc
rwc
select
base
willing
particip
least
hivhcv
patient
clinic
trial
includ
data
erad
anr
softrih
studi
rwc
includ
ascend
portug
veteran
affair
usc
repres
divers
patient
popul
europ
u
includ
academ
center
urban
primari
care
set
veteran
health
administr
baselin
characterist
efficaci
analyz
result
clinic
trial
enrol
patient
follow
baselin
characterist
male
black
cirrhosi
rwc
studi
enrol
patient
follow
overal
baselin
characterist
male
black
cirrhosi
report
demograph
patient
enrol
clinic
trial
treat
week
ldvsof
overal
rate
rwc
patient
treat
week
ldvsof
rbv
overal
individu
studi
result
present
tabl
conclus
real
world
data
hivhcv
patient
correl
close
data
seen
clinic
trial
svr
rate
high
across
popul
includ
black
race
treatment
experienc
patient
cirrhosi
analysi
demonstr
svr
rate
rwc
generaliz
clinic
trial
tabl
clinic
trial
rwc
ldvsof
rbv
hiv
hcv
patient
evalu
virolog
efficaci
contain
patient
treat
week
disclosur
susanna
naggi
advisori
committe
review
panel
merck
grant
research
support
tacer
gilead
abbvi
bm
jenssen
merck
eric
rosenth
board
membership
gilead
msd
abbvi
justin
mcginni
consult
gilead
grantresearch
support
abbvi
sarjita
naik
employ
gilead
scienc
macki
natha
employ
gilead
scienc
stock
sharehold
gilead
scienc
joseph
llewellyn
employ
gilead
scienc
richard
haubrich
employ
gilead
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
luisa
stamm
employ
gilead
scienc
curti
cooper
advisori
committe
review
panel
gilead
abbvi
merck
grantresearch
support
merck
gilead
abbvi
speak
teach
merck
abbvi
gilead
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
follow
peopl
noth
disclos
sarah
kattakuzhi
object
japan
dual
oral
therapi
daclatasvir
dcv
asunaprevir
asv
first
interferon
ifn
therapi
approv
patient
hepat
c
viru
hcv
genotyp
infect
juli
combin
therapi
dcv
asv
primarili
use
patient
without
variant
rav
prior
treatment
studi
examin
characterist
patient
without
baselin
rav
fail
achiev
hcv
erad
dcvasv
therapi
identifi
new
baselin
rav
close
associ
failur
combin
therapi
method
total
patient
hcv
genotyp
infect
rav
prior
dcvasv
therapi
enrol
rav
evalu
use
direct
sequenc
method
result
patient
age
rang
year
median
patient
femal
patient
cirrhosi
one
hundr
eighti
patient
prior
therapi
receiv
treatment
sustain
virolog
respons
week
achiev
patient
rate
patient
cirrhosi
hcv
rna
logiuml
lower
patient
chronic
hepat
hcv
rna
logiu
ml
vs
vs
respect
patient
andor
rav
significantli
lower
rate
compar
patient
without
rav
vs
p
coexist
rav
close
associ
treatment
failur
rav
without
rav
although
patient
advers
event
result
cessat
dcvasv
therapi
patient
receiv
dcvasv
six
week
alt
elev
achiev
multivari
analysi
show
andor
rav
odd
ratio
confid
interv
coexist
discontinu
therapi
result
advers
event
grade
higher
alt
elev
significantli
associ
virolog
failur
pretreat
coexist
rav
present
patient
virolog
failur
conclus
patient
without
rav
virolog
effect
dcvasv
therapi
associ
baselin
andor
rav
coexist
rav
result
indic
coexist
baselin
rav
affect
antivir
effect
dcvasv
therapi
disclosur
follow
peopl
noth
disclos
seiichi
mawatari
akihiro
moriuchi
sho
ijuin
haruka
saka
oki
taniyama
kazuaki
tabu
akihiko
oshig
kohei
oda
tsutomu
tamai
akio
ido
background
treatment
direct
antivir
agent
daa
achiev
high
sustain
virolog
respons
svr
rate
across
broad
rang
patient
chronic
hepat
c
viru
hcv
infect
presenc
baselin
variant
rav
associ
reduc
svr
rate
depend
daa
regimen
data
retreat
daa
failur
howev
aasld
guidelin
recommend
switch
anoth
daa
drug
class
addit
ribavirin
treatment
extens
week
addit
test
rav
recommend
prior
initi
retreat
method
patient
failur
current
approv
daa
combin
therapi
drawn
larg
resist
databas
compris
patient
post
failur
serum
sampl
analyz
presenc
rav
direct
sequenc
gene
patient
urgent
reason
retreat
base
rav
analysi
guidelin
recommend
result
total
patient
failur
differ
daa
combin
analyz
current
approv
daa
therapi
affect
treatment
failur
includ
ledipasvirsofosbuvir
rbv
simeprevirsofosbuvir
daclatasvirsofosbuvir
sofosbuvirrbv
genotyp
paritaprevirombitasvir
dasabuvir
rav
detect
genotyp
gt
failur
patient
includ
patient
rav
retreat
initi
patient
cirrhosi
major
retreat
patient
fail
simeprevirsofosbuvir
retreat
either
ledipasvirsofosbuvir
regimen
chosen
far
patient
complet
patient
achiev
svr
conclus
retreat
start
small
subgroup
daa
failur
mainli
due
lack
approv
regimen
use
individu
treatment
approach
base
rav
analysi
switch
anoth
regimen
differ
daa
target
svr
achiev
major
daa
failur
disclosur
johann
vermehren
advisori
committe
review
panel
abbvi
abbott
speak
teach
abbvi
squibb
gilead
medtron
joerg
petersen
advisori
committe
review
panel
squibb
gilead
novarti
merck
squibb
gilead
novarti
merck
grant
research
support
roch
glaxosmithklin
roch
glaxosmithklin
speak
teach
abbott
tibotec
merck
abbott
tibotec
merck
holger
hinrichsen
advisori
committe
review
panel
bm
janssen
gilead
abbvi
speak
teach
msd
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
follow
peopl
noth
disclos
julia
dietz
simon
susser
thoma
von
hahn
ulrich
spengler
christoph
p
berg
introduct
antivir
therapi
hepat
c
hcv
potenti
improv
liver
function
patient
decompens
hcv
cirrhosi
candid
liver
transplant
howev
data
treatment
outcom
popul
limit
method
prospect
collect
data
patient
satisfi
current
minimum
criterion
transplant
decompens
cirrhosi
australia
meld
commenc
combin
therapi
sofosbuvir
daclatasvir
sofdac
without
ribavirin
riba
week
australian
patient
suppli
program
toscar
analys
outcom
includ
death
transplant
result
studi
includ
patient
mf
mean
standard
deviat
sd
age
year
mean
sd
child
pugh
score
cp
follow
least
week
commenc
treatment
genotyp
predominantli
patient
receiv
sofdac
two
receiv
sofdacriba
patient
fail
previou
therapi
patient
complet
week
therapi
three
transplant
follow
achiev
patient
genotyp
genotyp
genotyp
genotyp
patient
relaps
one
patient
lost
follow
patient
fail
complet
therapi
due
death
transplant
advers
event
overal
mean
meld
cp
score
patient
studi
fell
p
respect
baselin
patient
complet
treatment
mean
meld
cp
fell
p
p
respect
die
transplant
due
liver
failur
mean
meld
increas
death
transplant
mean
cp
remain
unchang
overal
patient
achiev
improv
meld
cp
score
treatment
patient
meld
entri
die
requir
rescu
liver
transplant
whilst
treatment
compar
patient
meld
p
conclus
rate
hcv
posit
patient
advanc
liver
diseas
treat
sofosbuvir
daclatasvir
withwithout
ribavirin
reduc
compar
patient
group
although
treatment
improv
meld
cp
score
patient
signific
proport
die
requir
rescu
transplant
meld
may
better
delay
treatment
period
disclosur
geoff
mccaughan
advisori
committe
review
panel
gilead
abbvi
stuart
k
robert
board
membership
abbvi
gilead
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
carolin
talli
advisori
committe
review
panel
bm
speak
teach
gilead
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
alex
j
thompson
advisori
committe
review
panel
gilead
abbvi
bm
merck
spring
bank
pharmaceut
arrowhead
roch
grantresearch
support
gilead
abbvi
bm
merck
speak
teach
roch
gilead
abbvi
bm
susan
mason
advisori
committe
review
panel
janssen
msd
bm
gilead
scienc
grantresearch
support
janssen
msd
speak
teach
ashm
brenda
moral
advisori
committe
review
panel
msd
jansen
roch
abbvi
bm
peter
w
angu
advisori
committe
review
panel
gilead
scienc
bm
bayer
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
phoeb
thwait
paul
gow
alan
j
wigg
gari
p
jeffrey
joann
mitchel
background
aim
interferon
ifn
antivir
treatment
daa
effect
cure
hcv
infect
outcom
patient
unknown
auric
austrian
ribavirin
rbv
interferon
free
cohort
clinicaltri
gov
real
world
studi
includ
patient
advanc
liver
diseas
without
evid
hepatocellular
carcinoma
hcc
treat
ifnrbv
free
daa
combin
studi
patient
outcom
evalu
least
week
treatment
free
follow
method
patient
auric
sustain
virolog
respons
week
follow
relaps
lost
follow
time
abstract
submiss
patient
complet
least
week
treatment
free
follow
mean
age
genotyp
gt
child
pugh
score
cp
treatment
sofosbuvir
sof
daclatasvir
dcv
previr
smv
sofledipasvir
smvdcv
result
svr
durabl
follow
cp
improv
patient
c
c
b
worsen
b
b
c
eleven
patient
liver
relat
event
ascit
hepat
encephalopathi
one
varic
hemorrhag
five
patient
transplant
end
therapi
eot
due
decompens
liver
cirrhosi
occurr
de
novo
hcc
one
die
due
thrombot
complic
three
patient
delist
due
clinic
improv
seven
addit
patient
die
five
relat
liver
diseas
three
due
nonhepat
diseas
report
previous
hcc
diagnos
patient
mean
age
cp
baselin
overal
platelet
count
plt
serum
albumin
alb
improv
baselin
bl
eot
furthermor
eot
plt
bl
vs
vs
svr
alb
vs
gl
vs
p
conclus
clinic
condit
laboratori
marker
liver
function
improv
patient
cirrhosi
success
daa
therapi
howev
morbid
mortal
rate
remain
substanti
furthermor
unexpectedli
high
rate
hcc
observ
shortli
eot
implic
need
vigor
surveil
achiev
svr
patient
cirrhosi
disclosur
rudolf
e
stauber
advisori
committe
review
panel
gilead
msd
bm
grantresearch
support
abbvi
hermann
laferl
advisori
committe
review
panel
janssen
grant
research
support
gilead
abbvi
roch
speak
teach
gilead
andrea
maieron
advisori
committe
review
panel
msd
jannsen
bm
ingelheim
gilead
abbvi
grantresearch
support
roch
speak
teach
roch
msd
jannsen
gilead
abbvi
marku
advisori
committe
review
panel
bayer
intercept
gilead
janssen
bm
abbvi
consult
bayer
shionogi
ono
pharma
eli
lilli
abbvi
grantresearch
support
bayer
gilead
msd
abbvi
speak
teach
bayer
gilead
msd
abbvi
ivo
graziadei
advisori
committe
review
panel
gilead
abbvi
msd
janssen
bm
speak
teach
gilead
abbvi
msd
bm
michael
h
trauner
consult
albireo
falk
phenex
gilead
novarti
msd
grantresearch
support
falk
albireo
intercept
harald
hofer
advisori
committe
review
panel
gilead
abbvi
speak
teach
janssen
bm
gilead
abbvi
peter
ferenc
advisori
committe
review
panel
idenix
gilead
msd
janssen
salix
abbvi
bm
wilson
therapeut
patent
heldfil
madau
rottapharm
speak
teach
gilead
roch
follow
peopl
noth
disclos
karin
kozbial
stephan
moser
remi
schwarzer
ramona
al
zoairi
heinz
zoller
sandra
beinhardt
albert
stattermay
rafael
stern
petra
e
michael
p
strasser
background
program
antivir
daa
chronic
hepat
c
viru
hcv
infect
provid
access
daa
pend
approv
provid
data
effect
safeti
regimen
collect
data
nationwid
program
promot
italian
medicin
agenc
provid
access
regimen
ombitasvir
paritaprevir
pharmacokinet
enhanc
ritonavir
dasabuvir
obvptvr
dsv
ribavirin
rbv
infect
regimen
obvptvr
rbv
infect
patient
cirrhosi
high
risk
decompens
method
hcv
patient
cirrhosi
high
risk
decompens
receiv
obvptvr
mg
dasabuvir
mg
week
patient
receiv
obvptvr
mg
week
primari
efficaci
endpoint
sustain
virolog
respons
week
univari
multivari
logist
regress
use
identifi
baselin
characterist
associ
advers
event
record
throughout
studi
result
overal
rate
among
cirrhot
patient
receiv
obvptvr
dsv
rbv
therapi
week
logist
regress
analys
identifi
bilirubin
mgd
ci
margin
albumin
gdl
ci
associ
patient
discontinu
treatment
due
advers
event
conclus
find
suggest
safeti
effect
obvptvr
dsv
rbv
use
patient
hcv
genotyp
infect
cirrhosi
high
risk
decompens
similar
report
clinic
trial
disclosur
alessio
aghemo
advisori
committe
review
panel
abbvi
gilead
grantresearch
support
gilead
speak
teach
abbvi
gilead
msd
janssen
bm
alfredo
alberti
advisori
committe
review
panel
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
abbvi
janssen
grantresearch
support
merck
gilead
merck
gilead
merck
gilead
merck
gilead
abbvi
janssen
speak
teach
novarti
bm
novarti
bm
novarti
bm
novarti
bm
andrea
antinori
consult
bristol
myer
squibb
gilead
merck
abbi
viiv
grantresearch
support
gilead
bristol
myer
squibb
viiv
giovanni
b
gaeta
advisori
committe
review
panel
janssen
merck
abbvi
roch
speak
teach
bm
gilead
merck
edoardo
g
giannini
advisori
committe
review
panel
glaxosmithklin
gilead
consult
grantresearch
support
glaxosmithklin
speak
teach
glaxosmithklin
msd
roch
gilead
bayer
bm
janssen
novarti
massimo
puoti
advisori
committe
review
panel
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
gsk
abbott
janssen
msd
roch
gilead
scienc
novarti
speak
teach
bm
bm
bm
bm
giovanni
raimondo
speak
teach
bm
gilead
roch
merck
janssen
bayer
msd
francesca
speak
teach
merck
sharp
dohm
gilead
janssen
abbvi
viiv
roch
diagnostici
bm
erica
villa
advisori
committe
review
panel
msd
abbvi
gsk
gilead
speak
teach
novarti
follow
peopl
noth
disclos
salvator
petta
marco
marzioni
pierluigi
russo
antonio
ascion
raffael
bruno
savino
bruno
antonio
chirianni
manuela
merli
vincenzo
messina
simona
montilla
carlo
f
perno
maria
rendina
anna
linda
zignego
luca
pani
antonio
introduct
retreat
option
experienc
patient
new
direct
act
antivir
daa
yet
well
defin
aim
studi
analyz
retreat
patient
fail
first
cours
regimen
contain
new
dda
patient
method
two
cohort
patient
treat
new
daa
real
life
hcv
infect
avdlib
patient
avdlib
patient
constitut
sinc
januari
septemb
overal
patient
expos
sofosbuvir
sof
contain
regimen
sof
ribavirin
rbv
gifn
rbv
sof
simeprevir
sim
rbv
sofdaclatasvir
dac
rbv
sof
ledipasvir
ldv
rbv
expos
exviera
regimen
result
among
patent
relaps
ifn
free
regimen
male
fibrosi
stage
patient
patient
hcv
genotyp
repartit
respect
relaps
one
receiv
second
cours
dda
record
patient
treatment
relaps
follow
one
patient
receiv
viekiraxrbv
week
cours
sof
peginfrbv
failur
patient
receiv
sofdacrbv
mostli
week
sofpegifnrbv
sofrbv
failur
patient
receiv
sofl
week
sofrbv
sofpegrbv
failur
patient
receiv
sofsim
rbv
week
sofpegrbv
sofl
failur
one
patient
receiv
sofelbasvirgrazoprevirrbv
week
sofl
failur
rav
high
level
among
inhibitor
found
time
viral
failur
two
patient
svr
avail
patient
achiev
svr
result
remain
patient
avail
time
meet
conclus
studi
show
retreat
patient
previous
fail
daa
first
cours
therapi
highli
effici
svr
observ
patient
retreat
sof
viekirax
least
week
avail
second
line
daa
therapi
ideal
daa
alreadi
administ
solut
cure
hcv
infect
patient
disclosur
bertrand
hanslik
board
membership
msd
janssen
mayoli
gilead
intercept
speak
teach
roch
aptali
bm
echosen
marc
advisori
committe
review
panel
bohring
inghelmein
bohring
inghelmein
transgen
board
membership
squibb
gilead
idenix
consult
roch
novarti
tibotec
abott
glaxo
smith
kline
merck
squibb
novarti
tibotec
abott
glaxo
smith
kline
speak
teach
gilead
roch
merck
squibb
follow
peopl
noth
disclos
deni
ouzan
guillaum
gaell
le
folgoc
christoph
renou
michel
antoni
patrick
delasal
thierri
fontang
patricia
cerdan
pierr
toulemond
sylvain
beorchia
nathali
boyer
philipp
halfon
background
normal
alt
level
coincid
virolog
suppress
patient
treat
daa
aim
analysi
character
baselin
bl
factor
patient
persist
elev
alt
end
treatment
eot
method
patient
safeti
analysi
set
phase
ion
trial
sof
vel
trial
includ
analysi
treat
least
week
bl
eot
data
avail
elev
alt
defin
alt
greater
upper
limit
normal
uln
defin
central
laboratori
result
overal
patient
receiv
least
week
treatment
elev
alt
bl
major
alt
normal
initi
ldv
sofvel
elev
alt
eot
compar
patient
alt
normal
patient
continu
elev
alt
eot
higher
rate
cirrhosi
condit
cholelithiasi
hepat
steatosi
diabet
mellitu
hypertens
like
take
block
agent
diabet
medic
higher
bmi
hemoglobin
valu
baselin
multivari
regress
analysi
present
well
analys
use
aasld
threshold
alt
valu
efficaci
similar
group
nearli
patient
elev
bl
alt
reach
hcv
rna
lloq
week
treatment
achiev
patient
alt
normal
patient
elev
alt
eot
conclus
ldvsof
sofvel
highli
efficaci
patient
elev
alt
bl
regardless
whether
alt
normal
eot
patient
elev
alt
level
prior
hcv
treatment
rapid
sustain
normal
transaminas
evalu
hepatobiliari
metabol
condit
may
contribut
liver
inflamm
resolv
viral
suppress
baselin
characterist
patient
elev
baselin
alt
treat
ldvsof
sofvel
disclosur
tania
welzel
advisori
committe
review
panel
novarti
janssen
gilead
abbvi
bm
paul
kwo
advisori
committe
review
panel
abbott
abbvi
bm
gilead
janssen
merck
alnylam
quest
cv
innovio
grantresearch
support
abbvi
bm
gilead
merck
janssen
esai
cepheid
conatu
ira
jacobson
consult
abbvi
achillion
bristol
myer
squibb
intercept
gilead
janssen
merck
trek
grantresearch
support
abbvi
bristol
myer
squibb
gilead
janssen
merck
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
shampa
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
mcnalli
employ
gilead
scienc
stock
sharehold
gilead
scienc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
follow
peopl
noth
disclos
jie
zhang
keyur
patel
background
hcv
genotyp
still
challeng
genotyp
current
standard
therapi
relaps
rate
still
consid
high
particularli
patient
cirrhosi
combin
daclatasvir
sofosbuvir
without
ribavirin
week
shown
slightli
improv
svr
rate
lower
relaps
rate
use
dose
ribavirin
goal
studi
explor
efficaci
week
versu
week
rin
cirrhot
patient
hcv
genotyp
explor
import
initi
ribavirin
dose
method
subject
screen
studi
random
two
arm
week
versu
week
ratio
use
ivr
baselin
demograph
viral
paramet
similar
arm
mean
age
year
male
patient
treatment
naiv
patient
experienc
pegrbv
therapi
cirrhosi
confirm
patient
fibroscan
result
patient
random
studi
patient
complet
cours
therapi
patient
still
treatment
patient
complet
therapi
achiev
eot
viral
neg
group
one
patient
relaps
patient
adher
medic
regimen
reciev
mg
day
ribvirian
group
patient
finish
studi
ribavirin
dose
start
mgday
patient
mgday
patient
three
patient
group
requir
decreas
ribavirin
dose
due
anemia
start
dose
ribavirin
impact
conclus
combin
daclatasvirsofosbuvirribavirin
recommend
hcv
genotyp
patient
cirrhot
patient
studi
show
treatment
achiev
one
relaps
treatment
achiev
signific
differ
svr
two
arm
mgday
ribavirin
achiev
viral
respons
ribavirin
treatment
well
toler
patient
cirrhosi
disclosur
tarek
hassanein
advisori
committe
review
panel
abbvi
pharmaceut
squibb
trek
therapeut
grantresearch
support
abbvi
pharmaceut
obalon
squibb
eiasi
pharmaceut
gilead
scienc
merck
sharp
dohm
ngm
biopharmaceut
ocera
therapeut
salix
pharmaceut
sundis
taigen
biotechnolog
vital
therapi
tobria
shinoghi
co
ltd
la
jolla
pharmaceut
trek
therapeut
novo
nordisk
intercept
speak
teach
baxter
squibb
gilead
scienc
salix
pharmaceut
abbvi
pharmaceut
follow
peopl
noth
disclos
yasmeen
esshaki
catherin
hill
rene
pozza
jennif
higham
b
k
luvisa
anna
mari
hefner
introduct
one
quarter
hcv
infect
patient
us
serv
mainstream
healthcar
system
includ
nativ
american
incarcer
homeless
data
efficaci
daa
therapi
vulner
popul
limit
aim
determin
efficaci
daa
therapi
predictor
treatment
respons
among
nativ
american
infect
chronic
hcv
method
nativ
american
patient
chronic
hcv
treat
specialti
clinic
primari
care
clinician
echo
extens
commun
healthcar
outcom
echo
model
complet
treatment
directli
act
antivir
daa
therapi
identifi
data
demograph
baselin
laboratori
valu
treatment
regimen
genotyp
viral
load
systemat
abstract
standard
databas
patient
data
psychiatr
diseas
hcv
risk
factor
concomit
nonalcohol
fatti
liver
diseas
nafld
also
collect
result
nativ
american
patient
includ
elig
analysi
major
patient
infect
hcv
genotyp
genotyp
common
subtyp
genotyp
repres
cohort
patient
cirrhosi
treatment
regimen
includ
sofosbuvir
sof
ledipasvir
ldv
sofribavirin
rbv
simeprevir
sim
sof
simsofrbv
sof
peg
rbv
sofldvrbv
paritaprevirritonavirombitasvirdasabuvir
rbv
among
patient
data
activ
use
marijuana
opiat
benzodiazepin
amphetamin
barbitur
diagnos
nonalcohol
fatti
liver
diseas
nafld
overal
patient
achiev
miss
patient
exclud
increas
among
miss
patient
activ
drug
user
psychiatr
diseas
cirrhosi
nineteen
patient
relaps
cirrhot
previous
treat
similar
cirrhot
vs
patient
activ
drug
user
vs
nonform
user
concomit
nafld
hcv
vs
fld
hcv
patient
conclus
overal
high
cure
rate
hcv
nativ
american
treat
daa
regimen
patient
cirrhosi
concomit
nafld
even
activ
drug
use
achiev
high
rate
given
efficaci
daa
treatment
vulner
understudi
popul
step
need
taken
increas
treatment
avail
disclosur
jorg
mera
advisori
committe
review
panel
gilead
board
membership
cdchrsa
grantresearch
support
aid
educ
train
center
indian
health
servic
oklahoma
univers
health
scienc
center
terri
box
advisori
committe
review
panel
gilead
abbvi
salix
bm
grantresearch
support
gilead
merck
intercept
bm
abbvi
salix
boehring
ingelheim
ikaria
speak
teach
gilead
merck
abbvi
intercept
salix
john
scott
advisori
committe
review
panel
tacer
therapeut
grantresearch
support
merck
robert
gish
advisori
committe
review
panel
gilead
abbvi
arrowhead
loni
merck
consult
eiger
genentech
merck
speak
teach
gilead
abbvi
merck
stock
sharehold
arrowhead
richard
manch
speak
teach
gilead
abbvi
merck
bm
salix
bayer
intercept
anita
kohli
advisori
committe
review
panel
gilead
alexion
speak
teach
merck
follow
peopl
noth
disclos
kartik
joshi
karla
thornton
paulina
deme
miranda
l
sedillo
crystal
david
whitney
essex
jennif
shade
background
daa
regimen
associ
hepat
decompens
hd
especi
patient
cirrhosi
larg
scale
studi
avail
quantifi
risk
method
erchiv
databas
analyz
treat
paritaprevirritonavir
ombitasvir
dasabuvir
prod
regimen
hepat
decompens
hd
worsen
renal
function
compar
receiv
sofosbuvirsimeprevir
sofsim
sofosbuvir
ledipasvir
sofldv
regimen
particip
follow
week
exclud
hiv
hbsag
diagnosi
hd
hepatocellular
carcinoma
result
person
prod
sofsim
sofldv
cirrhosi
present
baselin
respect
hd
event
prod
sofsim
sofldv
group
incid
rate
ci
treatment
initi
prod
group
sofsim
group
sofldv
group
among
baselin
cirrhosi
rate
respect
among
without
cirrhosi
baselin
rate
respect
advanc
fibrosi
associ
increas
risk
hd
group
death
proport
person
egfr
increas
higher
among
prod
group
presenc
cirrhosi
appear
affect
conclus
overal
incid
hd
person
treat
prod
regimen
treatment
week
complet
treatment
compar
treat
sofldv
regimen
lower
among
treat
sofsim
regimen
risk
predominantli
observ
cirrhosi
baselin
disclosur
adeel
support
gilead
abbvi
kristen
support
merck
gilead
obaid
shaikh
grantresearch
support
gilead
scienc
shinongi
pharmaceut
merritt
speak
teach
simpli
speak
kenneth
e
sherman
advisori
committe
review
panel
janssen
merck
synteract
grantresearch
support
medimmun
inovio
merck
gilead
myer
squibb
follow
peopl
noth
disclos
yanji
ren
introduct
treatment
hcv
genotyp
still
challeng
compar
hcv
genotyp
sustain
virolog
respons
svr
rate
first
approv
ifn
free
regimen
sofosbuvir
sof
ribavirin
rbv
satisfactori
patient
cirrhosi
treatment
option
includ
pegyl
interferon
pegifn
sofrbv
week
sofledipasvir
ldv
sofdaclatasvir
dcv
week
data
larg
cohort
still
limit
method
deutsch
hepat
german
hepat
nation
multicent
cohort
includ
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
monitor
analysi
base
patient
observ
least
week
initi
antivir
treatment
result
patient
enrol
treatment
initi
patient
male
median
age
year
treatment
experienc
liver
cirrhosi
platelet
mio
iuml
mio
iuml
total
patient
reach
data
miss
patient
anoth
patient
includ
per
protocol
analysi
treatment
regimen
svr
shown
tabl
conclus
sofrbv
sofldv
highlight
need
better
option
patient
pegifn
base
therapi
still
often
use
combin
sofrbv
associ
high
svr
compens
diseasehowev
side
effect
consid
alreadi
use
patient
svr
around
even
patient
tabl
overview
svr
differ
treatment
group
disclosur
marku
cornberg
advisori
committe
review
panel
merck
msd
germamni
roch
gilead
novarti
abbvi
janssen
cilag
bm
grantresearch
support
merck
msd
germamni
roch
speak
teach
merck
msd
germamni
roch
gilead
bm
novarti
falk
abbvi
joerg
petersen
advisori
committe
review
panel
squibb
gilead
novarti
merck
squibb
gilead
novarti
merck
grant
research
support
roch
glaxosmithklin
roch
glaxo
smithklin
speak
teach
abbott
tibotec
merck
abbott
tibotec
merck
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
stefan
christensen
advisori
committe
review
panel
bm
abbvi
janssen
viiv
gilead
msd
speak
teach
gilead
msd
abbvi
bm
janssen
heik
employ
efactum
gmbh
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
clau
niederau
advisori
committe
review
panel
msd
abbvi
jannsen
gilead
consult
msd
grantresearch
support
msd
speak
teach
msd
abbvi
bm
roch
gilead
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
follow
peopl
noth
disclos
andrea
schober
guenther
schmutz
ralph
link
buescher
introduct
antivir
daa
regimen
improv
efficaci
chronic
hcv
treatment
phase
trial
suggest
lower
respons
rate
patient
liver
cirrhosi
howev
limit
inform
efficaci
daa
therapi
patient
advanc
cirrhosi
extent
liver
function
improv
cirrhot
patient
receiv
therapi
unknown
method
deutsch
hepat
german
hepat
nation
multicent
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
treatment
patient
advanc
liver
cirrhosi
defin
least
one
follow
criteria
fibroscan
thrombocyt
albumin
sign
liver
decompens
analyz
result
patient
advanc
liver
cirrhosi
median
rang
patient
fu
week
includ
major
patient
infect
otyp
present
patient
respect
patient
receiv
differ
treatment
regimen
overal
svr
achiev
patient
itt
svr
rate
accord
regimen
rang
daa
therapi
lead
svr
rate
itt
genotyp
n
n
respect
liver
function
paramet
includ
albumin
bilirubin
prothrombin
time
improv
major
patient
antivir
median
platelet
count
clinic
marker
portal
hypertens
increas
baselin
l
p
creatinin
level
stabl
antivir
treatment
sae
report
patient
die
observ
period
conclus
cohort
confirm
daa
treatment
feasibl
patient
advanc
liver
cirrhosi
lead
restor
liver
function
broad
spectrum
individu
treatment
regimen
appli
reflect
individu
treatment
cohort
disclosur
katja
deterd
speak
teach
abbvi
msdmerck
gilead
joerg
petersen
advisori
committe
review
panel
squibb
gilead
novarti
merck
squibb
gilead
novarti
merck
grant
research
support
roch
glaxosmithklin
roch
glaxosmithklin
speak
teach
abbott
tibotec
merck
abbott
tibotec
merck
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
simon
advisori
committe
review
panel
abbvi
bm
janssen
msd
speak
teach
abbvi
bm
falk
gilead
janssen
norgin
merz
msd
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
tim
zimmermann
advisori
committe
review
panel
abbvi
speak
teach
bm
marku
cornberg
advisori
committe
review
panel
merck
msd
mamni
roch
gilead
novarti
abbvi
janssen
cilag
bm
grantresearch
support
merck
msd
germamni
roch
speak
teach
merck
msd
germamni
roch
gilead
bm
novarti
falk
abbvi
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
heik
employ
efactum
gmbh
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
background
data
use
direct
act
antivir
daa
treatment
chronic
hepat
c
scarc
report
result
ombitasvirparitaprevirritonavir
obvptvr
dasabuvir
dsv
combin
hcv
patient
method
anr
hepath
therapeut
option
hepat
b
c
french
cohort
multicent
observ
cohort
aim
includ
patient
http
clinicaltrialsgov
select
cohort
particip
hcv
genotyp
genotyp
infect
initi
combin
ptvr
mgd
obv
mgd
without
dsv
mgd
n
without
n
ribavirin
rbv
gd
octob
mean
age
year
cirrhosi
fibrosi
present
patient
respect
durat
therapi
mainli
week
main
endpoint
criteria
sustain
virolog
respons
defin
undetect
hcv
rna
week
last
treatment
intak
find
popul
characterist
present
tabl
obtain
patient
interpret
real
life
set
combin
associ
high
rate
higher
patient
infect
genotyp
result
patient
treat
includ
cohort
present
failur
associ
factor
analyz
popul
descript
disclosur
fontain
board
membership
abbvi
gilead
bm
janssen
independ
contractor
gilead
bm
msd
roch
janssen
christoph
hezod
speak
teach
roch
bm
msd
janssen
abbvi
gilead
advisori
committe
review
panel
roch
gilead
consult
lfb
biomedica
speak
teach
gilead
janssen
bm
roch
abbvi
stanisla
pol
board
membership
boehring
ingelheim
tibotec
janssen
cilag
gilead
glaxo
smith
kline
roch
msd
novarti
grant
research
support
gilead
roch
msd
speak
teach
boehring
ingelheim
tibotec
janssen
cilag
gilead
roch
msd
novarti
background
advent
new
antivir
dramat
increas
svr
rate
hepat
c
hcv
fewer
advers
effect
howev
erad
viru
could
associ
better
prognosi
patient
aim
assess
impact
basal
comorbid
overal
benefit
hcv
patient
treat
therapi
method
multicent
studi
includ
prospect
hcv
patient
cirrhosi
treat
therapi
basal
comorbid
evalu
charlson
comorbid
index
cci
charlson
b
modifi
charlson
comorbid
index
mcci
berkman
c
circom
index
jepsen
liver
relat
seriou
advers
event
collect
within
first
year
treatment
result
advers
event
found
overal
cohort
death
month
cci
vs
mcci
vs
circom
vs
higher
patient
suffer
advers
event
age
platelet
count
creatinin
albumin
total
bilirubin
well
presenc
cirrhosi
also
relat
advers
event
algorithm
predict
identifi
group
construct
use
crt
grow
method
figur
group
subsequ
introduc
curv
advers
event
logrank
p
mortal
logrank
p
conclus
hcv
patient
show
higher
basal
comorbid
show
risk
suffer
poor
prognosi
rapid
object
algorithm
includ
charlson
comorbid
index
help
identifi
patient
increas
rate
mortal
advers
event
within
first
month
antivir
therapi
thu
could
determin
overal
benefit
daa
therapi
beyond
erad
viru
disclosur
xavier
forn
consult
jansen
abbvi
grantresearch
support
jansen
abbvi
jose
l
calleja
advisori
committe
review
panel
gilead
abbvi
speak
teach
abbvi
gilead
janssen
bm
javier
crespo
advisori
committe
review
panel
abbvi
janssen
bm
grantresearch
support
msd
gilead
maria
buti
advisori
committe
review
panel
gilead
janssen
msd
grantresearch
support
gilead
janssen
speak
teach
gilead
janssen
bm
follow
peopl
noth
disclos
javier
ampuero
carlota
jimeno
rosa
quil
niev
palomo
guillermo
ontanilla
jose
miguel
susana
llerena
patricia
cordero
francisco
javier
serrano
ortega
marta
hernandez
martin
bonacci
mois
diago
blanca
figueruela
raul
j
andrad
manuel
de
la
mata
isabel
carmona
j
navarro
juan
manuel
pascasio
javier
salmeron
manuel
introduct
recent
cohort
analys
claim
hiv
independ
impair
respons
antivir
daa
therapi
chronic
hepat
c
hcv
real
life
cohort
aim
studi
therefor
compar
rate
hivhcv
hcv
subject
nation
german
hcv
cohort
method
deutsch
hepat
german
hepat
nation
multicent
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
hcv
treatment
result
overal
hivhcv
hcv
subject
includ
analysi
baselin
characterist
group
shown
tabl
overal
rate
across
genotyp
itt
analysi
compar
hcv
hivhcv
individu
vs
vs
respect
neither
treatment
durat
ribavirin
use
differ
group
also
differ
hcv
rate
observ
cirrhot
patient
without
hiv
vs
also
subset
patient
receiv
week
ledipasvirsofosbuvir
differ
rate
note
hiv
hcv
patient
vs
number
treatment
discontinu
low
group
accordingli
conclus
analysi
larg
nation
patient
cohort
find
differ
hcv
cure
rate
hivhcv
hcv
patient
therefor
support
current
hcv
guidelin
longer
see
need
consid
hiv
individu
special
patient
popul
neukam
k
et
al
hiv
coinfect
impair
respons
hcv
therapi
easl
abstract
disclosur
k
rockstroh
advisori
committe
review
panel
abbvi
cipla
bm
merck
roch
tibotec
abbvi
bionor
tobira
viiv
abbott
gilead
janssen
consult
novarti
grantresearch
support
gilead
merck
speak
teach
bm
merck
siemen
tibotec
gilead
janssen
viiv
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
heik
employ
efactum
gmbh
marku
cornberg
advisori
committe
review
panel
merck
msd
germamni
roch
gilead
novarti
abbvi
janssen
cilag
bm
grantresearch
support
merck
msd
germamni
roch
speak
teach
merck
msd
germamni
roch
gilead
bm
novarti
falk
abbvi
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
follow
peopl
noth
disclos
thoma
lutz
christian
cord
heribert
hillenbrand
arend
moll
axel
baumgarten
background
aim
retreat
option
antivir
daa
genotyp
patient
limit
te
patient
genotyp
gt
hcv
cirrhosi
tn
te
patientswith
hcv
without
cirrhosi
relaps
follow
sofrbv
treatment
hase
boson
studi
offer
retreat
sofpegifnrbv
week
method
thirti
patient
receiv
sof
week
pegifn
administ
mg
sc
weekli
inject
rbv
administ
oral
mg
divid
daili
dose
primaryendpoint
result
patient
male
one
hcv
infect
cirrhosi
patient
complet
treatment
period
per
protocol
overal
achiev
among
patient
hcv
infect
achiev
rate
higher
among
without
cirrhosi
cirrhosi
among
previous
treat
week
week
tabl
singl
patient
relaps
week
visit
prior
retreat
patient
nucleosid
inhibitor
rass
achiev
retreatmentth
common
advers
event
fatigu
headach
nausea
myalgia
pyrexia
ill
pruritu
rash
patient
experienc
ae
lead
studi
drug
discontinu
one
patient
experienc
sae
shoulder
pain
one
day
treatment
complet
assess
relat
studi
drug
investig
conclus
sofpegifnrbv
provid
high
rate
patient
hcv
infect
relaps
follow
sofrbv
therapi
howev
pegifn
base
regimen
favor
patient
highli
effect
well
toler
ifn
free
regimen
treatment
hcv
need
rate
patient
cirrhosi
statu
prior
regimen
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
stephen
pianko
advisori
committe
review
panel
roch
novarti
gilead
roch
novarti
consult
gilead
speak
teach
janssen
bm
lesli
bank
grantresearch
support
abbvi
virolog
gilead
merck
bm
speak
teach
abbvi
immunolog
gilead
merck
bm
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
stephen
ryder
advisori
committe
review
panel
abbvi
gilead
msd
mb
norgin
matthew
cramp
advisori
committe
review
panel
gilead
abbvi
bm
merck
janssen
grantresearch
support
gilead
abbvi
bm
merck
janssen
speak
teach
gilead
abbvi
bm
merck
janssen
daniel
forton
advisori
committe
review
panel
gilead
merck
abbvi
speak
teach
janssen
bm
barbara
leggett
advisori
committe
review
panel
msd
msd
msd
msd
bm
abbvi
speak
teach
roch
roch
roch
roch
gilead
alnoor
ramji
advisori
committe
review
panel
bm
merck
gilead
janssen
lupin
boehring
ingelheim
grantresearch
support
bm
abbvi
merck
gilead
vertex
novarti
boehring
ingelheim
michael
j
ryan
advisori
committe
review
panel
gilead
speak
teach
gilead
amani
zekri
advisori
committe
review
panel
gilead
bm
msd
abbvi
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
benedetta
massetto
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
eric
yoshida
advisori
committe
review
panel
gilead
scienc
inc
grantresearch
support
abbvi
merck
inc
springbank
jannsen
inc
gilead
scienc
inc
intercept
speak
teach
gilead
scienc
inc
merck
canada
celgen
canada
merck
inc
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
follow
peopl
noth
disclos
michael
schultz
jane
collier
matthew
priest
blair
e
burman
kuldeep
cheent
gerri
c
macquillan
paul
richardson
nigel
stace
donald
l
zogg
eleanor
barn
franc
chen
mani
subramanian
introduct
hcv
infect
associ
increas
risk
chronic
kidney
diseas
ckd
manag
hcv
patient
advanc
ckd
remain
challeng
previous
report
treatment
hcv
patient
ombitasvir
paritaprevir
identifi
abbvi
enanta
pharmacokinet
enhanc
ritonavir
dasabuvir
obvptvr
dsv
rbv
associ
overal
chang
renal
function
howev
observ
mean
gain
egfr
follow
treatment
patient
baselin
bl
egfr
ml
ml
analysi
investig
bl
patient
characterist
laboratori
predictor
egfr
improv
obvptvr
dsv
rbv
method
renal
function
categor
egfr
use
mdrd
equat
patient
group
accord
bl
egfr
analysi
includ
patient
treat
obvptvr
dsv
rbv
trial
iv
exclud
patient
dialysi
bl
factor
associ
increas
egfr
examin
stepwis
logist
regress
primari
model
exclud
two
studi
includ
bl
urinalysi
addit
model
includ
studi
explor
degre
chang
egfr
result
bl
characterist
shown
tabl
primari
model
increas
egfr
associ
bl
proteinuria
ci
p
histori
diabet
ci
bmi
ci
p
black
race
ci
conclus
bl
proteinuria
histori
diabet
lower
bmi
nonblack
race
identifi
predictor
egfr
increas
obvptvr
dsv
rbv
treatment
longer
need
confirm
benefici
effect
renal
function
possibl
clinic
outcom
associ
erad
hcv
treatment
baselin
characterist
exclud
disclosur
david
e
bernstein
consult
abbvi
merck
janssen
grantresearch
support
gilead
abbvi
bm
janssen
speak
teach
gilead
paul
martin
advisori
committe
review
panel
bm
grantresearch
support
merck
gilead
janssen
abbvi
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
marc
advisori
committe
review
panel
bohring
inghelmein
bohring
inghelmein
transgen
board
membership
squibb
gilead
idenix
consult
roch
novarti
tibotec
abott
glaxo
smith
kline
merck
squibb
novarti
tibotec
abott
glaxo
smith
kline
speak
teach
gilead
roch
merck
squibb
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
paul
j
pockro
advisori
committe
review
panel
janssen
merck
bm
gilead
abbvi
consult
lumena
beckman
coulter
grantresearch
support
intercept
janssen
bm
gilead
lumena
beckman
coulter
abbvi
rm
merck
speak
teach
abbvi
janssen
gilead
loi
larsen
employ
abbvi
stock
sharehold
abbvi
diana
l
shuster
employ
abbvi
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
bori
renjifo
employ
abbvi
stock
sharehold
abbvi
ira
jacobson
consult
abbvi
achillion
bristol
myer
squibb
intercept
gilead
janssen
merck
trek
grantresearch
support
abbvi
bristol
myer
squibb
gilead
janssen
merck
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
follow
peopl
noth
disclos
albert
tran
introduct
hepat
c
viral
infect
hcv
remain
one
main
caus
chronic
liver
diseas
worldwid
becom
curabl
diseas
due
develop
direct
act
antivir
daa
therefor
set
target
elimin
hcv
complet
reach
target
peopl
inject
drug
pwid
need
treat
largest
risk
group
hcv
western
world
furthermor
treatment
hcv
pwid
recommend
treatment
guidelin
aim
studi
uptak
outcom
treatment
hcv
pwid
gener
popul
method
perform
belgian
retrospect
cohort
studi
hospit
patient
treat
hospit
ombitasvirparitaprevir
ritonavir
dasabuvir
decemb
novemb
includ
regimen
chosen
base
belgian
reimburs
criteria
center
experienc
treat
hcv
infect
pwid
case
antivir
treatment
start
data
collect
central
databas
pwid
subdivid
activ
user
defin
drug
use
therapi
daa
former
pwid
pwid
defin
someon
use
intraven
drug
least
result
studi
popul
consist
patient
pwid
subdivid
activ
user
former
pwid
treat
one
daa
regimen
ribavirin
pwid
activ
former
younger
predominantli
male
lower
bmi
abus
alcohol
use
benzodiazepin
infect
genotyp
activ
pwid
less
treatment
experienc
use
less
comed
differ
fibrosi
score
group
pwid
similar
rate
trend
toward
psycholog
complaint
pwid
similar
rate
treatment
complet
svr
achiev
irrespect
activ
substanc
abus
conclus
although
daa
safe
effect
also
activ
drug
user
pwid
still
highli
underrepres
belgian
treatment
cohort
even
era
new
daa
therapi
heart
hcv
epidem
effort
necessari
reach
group
disclosur
christoph
moreno
consult
abbvi
janssen
gilead
bm
msd
grant
research
support
janssen
gilead
roch
astella
abbvi
thoma
vanwollegem
advisori
committe
review
panel
gilead
abbvi
bm
grantresearch
support
bm
gilead
roch
wim
verlinden
grantresearch
support
gilead
squibb
mulkay
grantresearch
support
gilead
bm
frederik
neven
consult
msd
caf
intercept
gore
bm
abbvi
novarti
durect
ono
pharma
promethera
bioscienc
grant
research
support
fer
roch
astella
novarti
abbvi
geert
robaey
advisori
committe
review
panel
msd
janssen
gilead
abbvi
bm
follow
peopl
noth
disclos
rob
bielen
han
van
vlierbergh
stefan
bourgeoi
jochen
decaesteck
mike
cool
chantal
de
galocsi
lode
van
overbek
filip
janssen
christoph
van
steenkist
francoi
dheyger
wilfri
cool
background
whether
alcohol
use
neg
impact
hepat
c
viru
hcv
treatment
outcom
era
direct
antivir
agent
daa
unknown
alcohol
use
disord
identif
test
consumpt
questionnair
recommend
administ
annual
va
sinc
screen
unhealthi
alcohol
use
studi
examin
associ
level
drink
ascertain
screen
questionnair
administ
within
one
year
prior
daa
respons
daa
nation
veteran
affair
va
healthcar
system
method
patient
initi
hcv
daa
period
januari
june
complet
questionnair
within
one
year
prior
initi
therapi
compris
final
studi
sampl
daa
includ
sofosbuvir
sof
ledipasvirsofosbuvir
ldvsof
dasabuvir
prod
sustain
virolog
respons
svr
defin
viral
load
limit
quantif
perform
week
end
treatment
score
categor
abstin
drink
unhealthi
drink
men
women
rate
svr
confid
interv
calcul
perform
multipl
logist
regress
model
without
imput
miss
svr
data
result
sampl
mostli
male
black
cirrhosi
mean
age
year
distribut
hcv
genotyp
alcohol
abstin
report
drink
unhealthi
drink
signific
differ
svr
rate
abstin
svr
ci
drink
svr
ci
unhealthi
drink
svr
categori
entir
sampl
among
subgroup
defin
hcv
genotyp
cirrhosi
hiv
statu
categori
significantli
associ
svr
adjust
import
predictor
svr
multivari
logist
model
conclus
substanti
proport
patient
treat
daa
report
abstin
alcohol
base
screen
questionnair
perform
within
year
prior
initi
daa
howev
rate
svr
high
even
among
person
unhealthi
alcohol
use
score
associ
svr
disclosur
follow
peopl
noth
disclos
judith
tsui
emili
william
pamela
green
kristin
berri
feng
su
georg
n
loannou
introduct
insulin
resist
ir
common
complic
patient
chronic
hcv
chang
ir
treatment
direct
act
antivir
daa
known
aim
assess
impact
respons
daa
ir
statu
patient
chronic
hcv
method
five
hundr
eighteen
patient
pegyl
interferon
peg
ribavirin
rbv
experienc
posit
hcv
rna
month
enrol
patient
uncontrol
diabet
comorbid
hepat
extrahepat
malign
decompens
liver
diseas
prior
daa
exclud
homeostat
model
assess
homa
calcul
week
treatment
ir
defin
homa
patient
treat
accord
treat
physician
choic
receiv
one
follow
daa
protocol
week
ombitasvirritonavir
paritaprevirrbv
sofosbuvir
sof
simeprevir
sofravidasvir
sofpegrbv
week
sofrbv
result
patient
age
year
mostli
male
fibrosi
ir
sustain
virolog
respons
week
achiev
patient
signific
differ
homa
respond
respect
homa
improv
significantli
patient
svr
median
decreas
iqr
vs
number
patient
ir
decreas
significantli
patient
achiev
svr
tabl
much
p
treatment
protocol
associ
compar
homa
improv
signific
predictor
includ
age
year
ci
serum
albumin
gdl
ci
liver
stiff
kpa
ci
ir
ci
conclus
insulin
resist
improv
significantli
patient
achiev
svr
differ
daa
regimen
number
patient
ir
therapi
ir
insulin
resist
svr
sustain
virolog
respons
patient
ir
respond
vs
pre
treatment
post
treatment
p
disclosur
wael
grantresearch
support
gilead
scienc
inc
imam
wake
advisori
committe
review
panel
janssen
speak
teach
hoffman
l
roch
bm
gilead
abbvi
follow
peopl
noth
disclos
mostafa
g
elhelbawi
ayman
alsebaey
moham
saad
hashem
hassan
el
shennawi
background
import
subgroup
peopl
inject
drug
pwid
receiv
opioid
substitut
therapi
ost
direct
observ
physician
nurs
drug
treatment
facil
pharmaci
daili
basi
patient
suffer
psychiatr
comorbid
reluct
unabl
go
special
hepat
center
hypothesi
chronic
hepat
c
patient
could
optim
manag
modern
regimen
appli
togeth
ost
direct
observ
physician
nurs
drug
treatment
facil
method
pwid
chronic
hepat
c
borderlin
complianc
malefemal
mean
age
year
genotyp
gt
start
treatment
chronic
hepat
c
ambulatorium
suchthilf
wien
drug
treatment
facil
vienna
austria
four
patient
coinfect
hiv
liver
cirrhosi
patient
receiv
antivir
treatment
togeth
ost
direct
observ
physician
nurs
without
cirrhosi
treat
sofosbuvirledipasvir
eight
week
patient
individu
treatment
regimen
select
accord
gt
fibrosi
stage
pretreat
current
reimburs
polici
insur
result
follow
concept
directli
observ
therapi
adher
antivir
therapi
excel
two
schedul
date
date
ingest
antivir
therapi
combin
ost
miss
patient
till
patient
malefemal
mean
age
year
liver
cirrhosi
present
patient
complet
treatment
period
virolog
heal
hepat
c
infect
sustain
virolog
respons
could
confirm
patient
rate
conclus
directli
observ
therapi
chronic
hepat
c
regimen
drug
treatment
facil
repres
promis
new
concept
treatment
patient
borderlin
complianc
receiv
ost
concept
chronic
hepat
c
cure
group
patient
unabl
treat
hepatolog
center
stress
success
treatment
patient
benefici
also
gener
popul
transmiss
viru
may
prevent
disclosur
michael
gschwantler
advisori
committe
review
panel
janssen
bm
gilead
abbvi
grantresearch
support
abbvi
gilead
speak
teach
janssen
bm
gilead
abbvi
follow
peopl
noth
disclos
stephan
moser
angelika
katharina
marchart
gerhard
rechberg
dori
kalchbrenn
sabrina
ambrosch
julian
luhn
enisa
gutic
han
haltmay
purpos
clinic
trial
antivir
daa
display
efficaci
rate
chronic
hepat
c
chc
unclear
whether
similar
result
seen
routin
practic
goal
verifi
efficaci
safeti
daa
treatment
chc
multicent
patient
cohort
japan
method
prospect
enrol
consecut
chc
patient
week
daclatasvir
asunaprevir
dcvasv
week
sofosbuvir
ledipasvir
sofldv
genotyp
diseas
week
sofosbuvir
ribavirin
sofrbv
genotyp
diseas
initi
period
septemb
april
result
patient
male
patient
mean
age
rang
year
addit
patient
pretreat
regimen
liver
cirrhosi
observ
patient
patient
histori
hepatocellular
carcinoma
among
patient
treat
dcvasv
treatment
discontinu
rate
due
advers
event
common
reason
discontinu
increas
alanin
transaminas
level
sustain
viral
respons
rate
svr
rate
patient
without
cirrhosi
respect
absenc
variant
treat
simeprevir
found
significantli
associ
svr
p
among
patient
treat
sofldv
treatment
discontinu
necessari
two
patient
due
esophag
pneumonia
respect
rate
one
patient
cirrhosi
variant
relaps
therapi
among
patient
treat
sofrbv
treatment
discontinu
rate
rate
patient
achiev
svr
complet
treatment
patient
cirrhot
rbv
dose
reduc
patient
cirrhosi
found
significantli
associ
conclus
cohort
includ
substanti
proport
cirrhot
patient
gener
exhibit
high
respons
rate
hcv
variant
associ
among
patient
treat
dcvasv
cirrhosi
associ
reduct
svr
rate
among
patient
treat
regimen
disclosur
follow
peopl
noth
disclos
tatsuya
ide
yuichiro
eguchi
masaru
harada
yuichi
honma
shinji
iwan
michiaki
okada
teruko
miyajima
ichiro
ogata
kei
reiichiro
kuwahara
keisuk
amano
takuji
torimura
introduct
daa
therapi
patient
advanc
liver
diseas
effect
safe
howev
impact
natur
histori
health
econom
benefit
treat
advanc
pt
popul
remain
unclear
studi
assess
healthcar
resourc
util
clinic
cost
perspect
month
mth
post
daa
therapi
compar
untreat
hcv
patient
accept
onto
uk
transplant
wait
list
method
nh
england
expand
access
program
eap
enabl
provis
week
therapi
sofosbuvir
sof
inhibitor
ledipasvir
daclatasvir
clinician
discret
ribavirin
rbv
cohort
hcv
posit
patient
advanc
decompens
liver
diseas
child
pugh
cp
patient
fulfil
nhsbt
criteria
liver
transplant
lt
treat
atk
colleg
hospit
kch
median
cp
rang
data
collect
clinic
intervent
support
ancillari
therapi
prospect
durat
therapi
mth
post
addit
similar
data
collect
compar
retrospect
control
cohort
untreat
hcv
kch
patient
meet
nhsbt
criteria
median
rang
inclus
onto
lt
wait
list
lt
death
major
within
mth
result
daa
therapi
minim
blood
product
phone
call
support
need
phone
call
nurs
specialist
consult
mean
min
respect
kch
eap
patient
achiev
svr
patient
mth
complet
resolut
decompens
present
treatment
initi
ascit
encephalopathi
svr
transplant
delist
die
due
overdos
progress
compar
transplant
delist
death
control
cohort
clinic
deterior
worsen
meld
necessit
control
cohort
patient
priorit
whilst
wait
list
reflect
durat
emerg
admiss
encephalopathi
sepsissbp
varic
bleed
itu
mean
day
patient
svr
vs
control
cohort
ward
mean
vs
day
respect
overal
mean
cost
savingof
per
success
treat
patient
identifi
discuss
earli
analysi
health
resourc
usag
pt
patient
treat
sof
inhibitor
rbv
demonstr
benefit
surviv
qualiti
life
health
resourc
util
challeng
cohort
full
health
resourc
usag
data
pt
eap
patient
present
longer
term
impact
success
daa
therapi
natur
histori
still
unclear
disclosur
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
michael
heneghan
consult
novarti
speak
teach
falk
pharma
william
irv
advisori
committe
review
panel
novarti
msd
janssen
cilag
bristol
myer
squibb
grantresearch
support
gsk
pfizer
janssen
cilag
gilead
scienc
abbvi
speak
teach
janssen
cilag
roch
ivana
carey
grantresearch
support
gilead
roch
speak
teach
bm
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
follow
peopl
noth
disclos
suman
verma
matthew
sadler
aisl
b
considin
kate
child
abid
suddl
thank
nation
strategi
plan
tackl
hepat
c
spain
around
infect
patient
cure
mainli
gener
popul
howev
plan
also
consid
prioriti
infect
patient
prison
accordingli
plan
project
northern
region
spain
cantabria
inhabit
focus
region
prison
el
dueso
object
perform
systemat
screen
evalu
infect
relat
virus
evalu
efficaci
safeti
antivir
regimen
includ
impact
rate
reinfect
shortlong
term
method
project
plan
start
follow
consecut
phase
viral
test
character
treatment
hcv
infect
inmat
patient
month
new
entri
prison
test
immedi
treatment
initi
first
week
list
variabl
analyz
includ
demograph
clinic
virolog
variabl
includ
baselin
resist
deep
analysi
nucleotid
sequenc
quasispeci
complex
region
endotheli
dysfunct
neurocognit
function
test
treatment
month
efficaci
safeti
qol
throughout
studi
rate
persist
hcv
infect
reinfect
result
inmat
includ
full
test
virus
major
inmat
male
median
age
yr
seventi
patient
posit
hcv
rna
posit
hcv
genotyp
seven
patient
none
fibrosi
distribut
mean
meld
score
virem
patient
treat
rbv
wk
patient
wk
patient
patient
achiev
eot
respons
seriou
ae
report
patient
discontinu
due
ae
baselin
ra
found
patient
frequent
hcv
viral
divers
region
high
irrespect
hcv
genotyp
avail
treat
inmat
includ
remain
variabl
studi
conclus
spanish
prison
hcv
preval
time
describ
gener
popul
show
differ
profil
hcv
genotyp
high
viral
divers
elimin
program
natur
intend
pilot
experi
could
extend
prison
disclosur
javier
crespo
advisori
committe
review
panel
abbvi
janssen
bm
grantresearch
support
msd
gilead
follow
peopl
noth
disclos
susana
llerena
carmen
cobo
silvia
alvarez
angel
miguel
soler
jose
ramon
palla
santiago
echevarria
ana
saez
jesu
aguero
natalia
chueca
raul
pellon
juan
crespo
antonio
cuadrado
federico
garcia
background
aim
present
studi
investig
associ
theinosinetriphosphatas
itpa
activ
degre
anemia
occur
daa
therapi
patient
cirrhosi
method
multicentr
prospect
studi
enrol
patient
cirrhosi
treat
daa
rbv
median
age
year
iqr
male
median
bml
iqr
withchild
b
cirrhosi
transplant
hiv
hcv
genotyp
identifi
median
baselin
hemoglobin
level
gdl
iqr
patient
treat
sofosbuvir
sof
plu
rbv
withombitasvir
paritaprevir
ritonavirand
dasabuvirplu
rbv
virplu
rbv
sofledipasvir
plu
rbv
sofdaclatasvir
plu
rbv
whit
ombitasvir
paritaprevir
ritonavir
plu
rbv
median
dose
rbvmg
kg
iqr
patient
screen
itpa
singl
nucleotid
polymorph
use
direct
sequenc
predict
itpa
activ
base
accord
previou
studi
thompson
result
fifti
patient
group
normal
itpas
activ
group
moder
activityand
group
minim
activ
three
group
declin
hemoglobin
evalu
baselin
day
delta
day
delta
treatment
group
delta
respect
sd
decay
sever
observ
group
respect
also
preval
event
reduct
rbv
dose
orus
erythropoietin
andor
blood
transfus
frequent
observ
group
day
day
group
respect
group
logist
regress
analysi
includ
itpa
activ
age
sex
dose
ribavirin
andegfridentifi
itpa
activ
dose
ribavirina
independ
predictor
event
ic
ic
p
respect
conclus
studi
suggest
polymorph
itpa
gene
influenc
sever
anemia
first
month
treatment
cirrhosi
thu
itpa
polymorph
may
drive
use
rbv
patient
cirrhot
andor
non
respond
patient
disclosur
vincenzo
messina
advisori
committe
review
panel
abbvi
grant
research
support
janssen
roch
marcello
persico
advisori
committe
review
panel
abbvi
grant
research
support
gilead
giovanni
b
gaeta
advisori
committe
review
panel
janssen
merck
abbvi
roch
speak
teach
bm
gilead
merck
ivan
gentil
consult
abbvi
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
nicola
coppola
stefania
de
pascali
giovanni
di
caprio
salvator
martini
giorgio
de
stefano
mario
starac
gianfranca
stornaiuolo
vincenzo
sangiovanni
maria
stanzion
rosa
zampino
federica
calo
luca
rinaldi
alessandro
federico
antonio
riccardo
buonomo
guglielmo
borgia
pietro
filippini
background
aim
hepat
due
hepat
b
viru
hbv
reactiv
report
chronic
hepat
c
chc
patient
coinfect
hbv
treat
either
therapi
direct
act
antivir
daa
compar
rate
hepat
due
hbv
reactiv
hcv
sustain
virolog
respons
svr
chc
patient
hbv
treat
therapi
versu
daa
method
systemat
search
english
literatur
jan
dec
pubm
embas
ovid
cochran
databas
conduct
march
two
independ
review
systemat
identifi
studi
examin
efficaci
safeti
hcv
antivir
therapi
hbvhcv
patient
conduct
use
random
effect
model
assess
primari
outcom
hbv
reactiv
rate
incid
hepat
due
hbv
reactiv
secondari
outcom
hcv
svr
rate
week
patient
treat
interferon
week
patient
treat
daa
case
report
includ
systemat
review
exclud
done
stata
result
search
yield
studi
involv
chc
patient
major
studi
use
interferon
studi
report
svr
rate
studi
report
hbv
reactiv
studi
report
occurr
hepat
due
hbv
reactiv
exclud
result
case
report
overal
svr
rate
hbvhcv
patient
svr
rate
lower
patient
treat
interferon
treat
daa
p
overal
hbv
reactiv
rate
differ
hbv
reactiv
observ
patient
treat
interferon
treat
daa
overal
incid
hepat
due
hbv
reactiv
patient
treat
interferon
vs
treat
daa
case
hbv
reactiv
occur
interferon
treatment
week
month
case
observ
daa
treatment
week
treatment
conclus
chc
patient
hbv
hcv
svr
rate
higher
treat
daa
treat
interferon
though
differ
hbv
reactiv
rate
daa
interferon
base
therapi
incid
hepat
due
hbv
reactiv
higher
daa
treatment
hbv
reactiv
occur
much
earlier
patient
treat
daa
treat
interferon
disclosur
jinlin
hou
consult
roch
novarti
gsk
bm
abbovir
grantresearch
support
roch
novarti
gsk
follow
peopl
noth
disclos
cheng
wang
bing
li
jing
chen
huim
liu
dong
ji
qing
shao
xiaoyong
zhang
vanessa
wu
yudong
wang
lei
lu
jian
sun
guofeng
chen
georg
lau
background
associ
found
hcv
infect
system
atherosclerosi
endotheli
dysfunct
hypertens
carotid
thick
cimt
current
one
wide
use
noninvas
measur
atherosclerosi
ankl
brachial
index
abi
sensit
tool
peripher
arteri
diseas
also
use
assess
system
atherosclerosi
aim
analyz
impact
free
treatment
cardiovascular
risk
hcv
patient
method
recruit
prospect
consecut
patient
elig
antivir
measur
cardiovascular
risk
accord
carotid
thick
cimt
consid
patholog
b
index
abi
consid
patholog
classifi
patient
two
group
accordingli
improvementworsen
cv
risk
group
show
patholog
cimt
abi
treatment
b
cv
risk
group
show
normal
cimt
abi
treatment
addit
obtain
biochem
paramet
baselin
week
finish
treatment
result
obtain
patient
pair
cv
risk
assess
treatment
baselin
patient
show
patholog
abi
decreas
week
pn
also
found
improv
cimt
baselin
vs
week
show
patholog
cimt
combin
test
patient
show
patholog
cimt
abi
baselin
valu
decreas
week
pn
patient
respond
treatment
term
cv
risk
wors
baselin
profil
solubl
biomark
tabl
conclus
preliminari
result
ongo
studi
show
patient
basal
condit
greater
improv
cardiovascular
risk
assess
index
carotid
thick
baselin
characterist
data
shown
mean
sd
variabl
analyz
u
test
disclosur
follow
peopl
noth
disclos
javier
ampuero
raquel
millan
maria
del
carmen
rico
merced
romera
carlota
jimeno
antonio
manuel
background
aim
liver
stiff
ls
transient
elastographi
te
veloc
shear
wave
vs
acoust
radiat
forc
impuls
arfi
report
correl
fibrosi
stage
variou
liver
diseas
aim
present
studi
evalu
effect
antivir
daa
ls
vs
chronic
hepat
c
chc
method
ls
kpa
vs
ms
measur
patient
chc
chang
ls
vs
assess
patient
treat
daa
patient
treat
daclatasvir
dcv
asunaprevir
asv
sofosbuvir
sof
ledipasvir
ldv
hcv
genotyp
sof
ribavirin
rbv
genotyp
result
dcvasv
sofldv
sofrbv
treatment
achiev
high
rate
sustain
virolog
respons
svr
respect
ls
significantli
decreas
vs
significantli
decreas
end
treatment
eot
ls
vs
significantli
decreas
month
eot
p
p
month
eot
compar
baselin
patient
dcvasv
ls
decreas
tendenc
vs
significantli
decreas
eot
compar
baselin
patient
sof
ldv
ls
significantli
decreas
vs
significantli
decreas
month
eot
compar
baselin
patient
sofrbv
fibrosi
stage
deduc
vs
valu
accord
valu
fibrosi
stage
patient
dcvasv
cutoff
valu
determin
roc
analysi
patient
underw
liver
biopsi
two
point
greater
reduct
deduc
stage
observ
patient
dcvasv
whose
pretreat
deduc
stage
higher
platelet
count
lower
total
bilirubin
level
lower
gamma
globulin
level
significantli
associ
greater
reduct
deduc
fibrosi
stage
ls
vs
baselin
predict
svr
treatment
conclus
reduct
ls
observ
patient
daa
attribut
regress
liver
fibrosi
inflamm
reduct
vs
slower
ls
find
may
attribut
stronger
associ
ls
inflamm
compar
vs
signific
reduct
deduc
fibrosi
stage
observ
milder
fibrosi
indic
higher
platelet
count
lower
total
bilirubin
level
gamma
globulin
level
te
arfi
use
evalu
effect
daa
chc
disclosur
kentaro
yoshioka
consult
sanwa
kagaku
kk
follow
peopl
noth
disclos
naoto
kawab
toshiki
kan
tomoki
takamura
sayuri
nomura
senju
hashimoto
michihito
murao
takuji
nakano
kazunori
nakaoka
masashi
ohki
ochi
yuka
takamitsu
kurashita
aiko
fukui
toru
nishikawa
keisuk
osakab
naohiro
ichino
background
aim
peopl
inject
drug
pwid
drive
forc
chronic
hepat
c
chc
western
world
treatment
uptak
low
direct
act
antivir
daa
cure
patient
outreach
treatment
program
drug
treatment
center
dtc
feasibl
shorter
treatment
durat
desir
four
week
daa
trial
disappoint
far
hypothesis
maintain
ribavirin
rbv
week
daa
regimen
ad
alpha
peg
could
give
high
cure
rate
drug
user
method
studi
conduct
one
dtc
thirti
two
patient
random
either
ldvsofrbv
ldvsofrbvpeg
week
rbv
dose
weight
base
peg
ug
weekli
main
inclus
criteria
treatment
patient
chc
genotyp
opium
substitut
therapi
ost
p
age
year
weight
kg
viral
load
luml
liver
stiff
measur
lsm
kpa
subject
allow
kind
concomit
drug
alcohol
use
compliant
ost
program
primari
endpoint
sustain
virolog
respons
week
end
treatment
svr
intent
treat
itt
popul
result
forti
seven
person
screen
initi
treatment
date
submiss
svr
itt
popul
interferon
arm
interferon
free
arm
one
virolog
relap
detect
remain
three
failur
due
lost
prematur
withdrawel
therapi
pp
far
interferon
arm
interferon
free
arm
full
svr
data
present
meet
conclus
week
sofosbuvir
ledipasvir
ribavirin
without
interferon
highli
effect
cure
chc
hard
reach
easi
treat
popul
drug
user
ost
one
virolog
relaps
detect
pp
patient
deliv
treatment
dtc
concurr
ost
feasibl
svr
rate
suggest
short
regiment
evalu
larger
trial
disclosur
ann
l
advisori
committe
review
panel
gilead
scienc
abbvi
grantresearch
support
gilead
scienc
speak
teach
bm
peer
b
christensen
advisori
committe
review
panel
roch
grant
research
support
abbvi
gilead
merck
sharp
dohm
roch
scheer
msd
follow
peopl
noth
disclos
ing
birkemos
dort
kinggaard
holm
belinda
k
moessner
henrik
krarup
background
hcv
affect
approxim
million
person
southeast
asia
one
preval
genotyp
treatment
data
limit
especi
new
direct
act
antivir
daa
agent
ldvsof
fdc
week
shown
effect
multipl
hcv
genotyp
includ
goal
examin
treatment
outcom
divers
popul
method
prospect
enrol
patient
four
medic
center
california
texa
usa
patient
receiv
ldv
mg
singl
tablet
regimen
oral
day
week
cirrhosi
week
cirrhosi
experienc
cirrhosi
noncirrhosi
patient
prior
solid
organ
transplant
exclud
primari
outcom
sustain
virolog
respons
week
therapi
secondari
outcom
advers
event
ae
patient
gave
written
consent
result
overal
mean
age
male
patient
asian
group
includ
patient
includ
patient
statist
signific
differ
baselin
clinic
laboratori
characterist
cirrhosi
statu
prior
treatment
histori
two
group
baselin
hcv
rna
level
log
iu
ml
distribut
subtyp
baselin
platelet
count
overal
group
group
two
patient
decompens
patient
liver
cancer
prior
treatment
group
current
avail
patient
group
group
patient
complet
intend
treatment
durat
two
sae
h
bleed
gastric
ulcer
leg
fractur
due
mechan
fall
patient
achiev
ae
includ
fatigu
insomnia
headach
nausea
conclus
largest
clinic
trial
date
ldvsof
fdc
oral
daili
daa
gener
ldvsof
fdc
week
safe
effect
patient
without
cirrhosi
prior
treatment
failur
ldvsof
fdc
week
also
safe
effect
patient
cirrhosi
andor
prior
treatment
failur
includ
patient
hepat
decompens
liver
cancer
svr
disclosur
mindi
h
nguyen
advisori
committe
review
panel
squibb
gilead
consult
gilead
scienc
inc
grantresearch
support
gilead
scienc
inc
squibb
huy
n
trinh
grantresearch
support
gilead
intercept
abbvi
merk
speak
teach
gilead
stock
sharehold
gilead
son
advisori
committe
review
panel
gilead
asian
health
foundat
speak
teach
gilead
asian
health
foundat
thuan
nguyen
speak
teach
gilead
abbvi
background
new
york
citi
nyc
health
depart
establish
care
coordin
protocol
heath
promot
manual
person
infect
hepat
c
viru
hcv
complex
diseas
often
occur
patient
substanc
abus
hiv
mental
ill
make
treatment
support
set
critic
project
inspir
round
ii
healthcar
innov
award
center
medicaid
medicar
servic
design
health
depart
implement
test
comprehens
care
coordin
protocol
health
promot
curriculum
adapt
hiv
tailor
hcv
primari
aim
demonstr
model
servic
deliveri
payment
reduc
morbid
death
chronic
ill
reduc
cost
associ
complic
use
chronic
hcv
infect
case
studi
method
establish
care
coordin
protocol
health
promot
materi
use
hivaid
adapt
use
patient
hcv
infect
overal
goal
improv
hcv
cure
rate
patient
protocol
includ
comprehens
assess
care
plan
health
promot
treatment
readi
counsel
alcohol
drug
counsel
medic
adher
support
health
promot
session
design
provid
inform
hcv
infect
treatment
hcv
liver
health
alcohol
drug
use
avoid
robust
monitor
evalu
framework
use
evalu
program
includ
monthli
data
feedback
report
fidel
analysi
clinic
outcom
analysi
comparison
control
group
cost
analysi
result
inspir
implement
outpati
clinic
serv
high
need
patient
high
level
fidel
protocol
among
particip
enrol
april
reach
key
mileston
within
day
enrol
includ
complet
comprehens
assess
attend
first
clinic
appoint
hcv
care
receiv
medic
evalu
particip
initi
treatment
receiv
alcohol
counsel
health
promot
treatment
readi
counsel
medic
coordin
particip
receiv
first
health
promot
session
within
day
enrol
project
implement
two
major
medic
center
start
mani
treatment
expect
vast
major
cure
next
year
plan
dissemin
care
coordin
protocol
health
promot
materi
develop
cost
care
coordin
calcul
integr
payment
model
disclosur
follow
peopl
noth
disclos
mari
p
bresnahan
mari
ford
payal
desai
nicolett
g
gantt
fabienn
laraqu
background
aim
current
antivir
therapi
hcv
genotyp
gt
cirrhosi
achiev
suboptim
sustain
virolog
respons
svr
rate
daclatasvir
dcv
sofosbuvir
sof
ribavirin
rbv
recommend
option
due
lower
svr
rate
sofldv
patient
cirrhosi
aim
evalu
efficaci
safeti
sofdcv
sofldv
rbv
cohort
patient
cirrhosi
patient
method
multicent
observ
studi
two
differ
databas
commun
madrid
region
registri
patient
treat
sof
plu
inhibitor
dcv
ldv
rbv
may
octob
includ
result
patient
includ
male
age
year
decompens
fibroscan
kpa
meld
score
receiv
sofdcv
sofldv
receiv
rbv
addit
rbv
extens
week
higher
sofldv
group
vs
vs
p
higher
percentag
decompens
patient
treat
dcv
vs
patient
reach
week
overal
sofdcv
sofldv
rate
summar
tabl
failur
observ
relaps
virolog
failur
death
previou
treatment
impact
svr
platelet
factor
associ
rr
ci
patient
meld
albumin
mgdl
type
inhibitor
impact
vs
rr
ci
vs
rr
ci
respect
patient
present
seriou
advers
event
sae
includ
death
discontinu
percentag
sae
death
higher
decompens
patient
vs
p
vs
cohort
present
meet
conclus
sofldvrbv
achiev
high
rate
patient
compens
cirrhosi
similar
sofdcv
low
rate
seriou
advers
event
disclosur
sonia
alonso
consult
abbvi
gilead
speak
teach
abbvi
bayer
msd
javier
crespo
advisori
committe
review
panel
abbvi
janssen
bm
grantresearch
support
msd
gilead
antonio
olveira
consult
msd
speak
teach
abbvi
gilead
msd
jose
l
calleja
advisori
committe
review
panel
gilead
abbvi
speak
teach
abbvi
gilead
janssen
bm
juan
arena
advisori
committe
review
panel
abbvi
speak
teach
msd
bm
gilead
rafael
granado
advisori
committe
review
panel
abbvi
consult
janssen
speak
teach
abbiv
janssen
gilead
martin
prieto
advisori
committe
review
panel
gilead
abbvi
bristol
xavier
forn
consult
gilead
abbvi
jansen
juan
turn
advisori
committe
review
panel
gilead
abbvi
janssen
bm
speak
teach
msd
gilead
janssen
bm
abbvi
rafael
esteban
speak
teach
msd
bm
novarti
gilead
glaxo
msd
bm
novarti
gilead
glaxo
janssen
follow
peopl
noth
disclos
mar
inmaculada
fernandez
diego
yolanda
real
francisco
gea
benjamin
polo
lorduy
jose
antonio
carrion
maria
jose
devesa
carm
baliella
angel
castro
manuel
juan
manuel
pascasio
javier
salmeron
ester
badia
jose
moreno
jose
lui
montero
conrado
sofosbuvir
sof
inhibitor
shown
efficaci
treat
hepat
c
hcv
recurr
liver
transplant
lt
durat
treatment
util
ribavirin
rbv
clear
popul
aim
assess
patient
treat
sof
regimen
without
rbv
week
lt
b
octob
octob
liver
transplant
recipi
hcv
recurr
enrol
prospect
multicentr
anr
cupilt
cohort
present
studi
select
patient
receiv
sof
inhibitor
rbv
follow
least
week
treatment
discontinu
primari
efficaci
end
point
sustain
virolog
respons
week
end
treatment
identifi
four
group
patient
accord
treatment
regimen
durat
week
logist
regress
adjust
use
c
among
patient
fulfil
inclus
criteria
main
characterist
follow
genotyp
genotyp
treat
fibrosi
stage
patient
cirrhosi
group
patient
child
pugh
cpt
cpt
b
patient
cpt
c
one
hundr
patient
treat
week
without
rbv
rbv
patient
treat
week
without
rbv
rbv
mean
rbv
dose
mgd
rate
fibrosi
stage
previous
treat
patient
higher
week
treatment
group
week
without
rbv
group
week
rbv
group
week
without
rbv
group
week
rbv
group
respect
patient
treatment
failur
multivari
analysi
factor
fibrosi
stage
previou
treatment
hcv
genotyp
hcv
viral
load
baselin
influenc
rate
among
four
studi
group
howev
risk
failur
higher
group
other
genotyp
group
p
rate
haematolog
advers
event
higher
rbv
group
anemia
p
blood
transfus
inhibitor
without
rbv
regimen
week
effici
treat
hcv
recurr
liver
transplant
includ
previous
treat
patient
patient
week
treatement
suggest
disclosur
paulin
speak
teach
novarti
astella
gilead
carolin
jezequel
speak
teach
gilead
msd
christoph
duvoux
advisori
committe
review
panel
novarti
roch
novarti
roch
novarti
roch
novarti
roch
chiesi
speak
teach
astella
astella
astella
astella
victor
de
ledinghen
board
membership
janssen
gilead
bm
abbvi
intercept
pharma
superson
imagin
grantresearch
support
superson
imagin
speak
teach
abbvi
merck
bm
gilead
vincent
leroy
board
membership
abbvi
bm
gilead
consult
janssen
msd
speak
teach
abbvi
bm
gilead
janssen
msd
vincent
di
martino
advisori
committe
review
panel
gilead
franc
abbvi
bm
franc
board
membership
msd
franc
consult
gilead
franc
speak
teach
janssen
bm
franc
gilead
franc
dumorti
board
membership
novarti
astella
roch
gilead
consult
novarti
grantresearch
support
novarti
astella
roch
msd
gsk
gilead
helen
montialoux
consult
gilead
pascal
lebray
grantresearch
support
speak
teach
gilead
gilead
gilead
gilead
daniel
consult
gilead
abbvi
bm
msd
christoph
moreno
consult
abbvi
janssen
gilead
bm
msd
grant
research
support
janssen
gilead
roch
astella
abbvi
habersetz
board
membership
gilead
bm
speak
teach
gilead
bm
consult
astella
bm
gilead
janssen
abbvi
novarti
roch
pageaux
board
membership
astella
bm
speak
teach
gilead
bm
novarti
msd
follow
peopl
noth
disclos
audrey
coilli
clair
sylvi
radenn
nassim
kamar
loui
dalteroch
valeri
filomena
conti
rodolph
anti
christin
silvain
camil
besch
philipp
clair
francoz
armand
abergel
marylin
alexandra
rohel
alpha
diallo
emili
rossignol
danjou
aureli
veisling
background
approxim
canadian
mani
live
remot
area
without
access
hcv
healthcar
specialist
telemedicin
tm
provid
healthcar
margin
patient
compar
patient
characterist
antivir
daa
treatment
outcom
hcv
tm
patient
ottawa
hospit
viral
hepat
outpati
clinic
resid
eastern
ontario
method
cohort
databas
analysi
perform
patient
follow
ottawa
hospit
region
viral
hepat
program
januari
may
tm
patient
compar
examin
baselin
characterist
clinic
outcom
result
tm
patient
younger
vs
year
like
indigen
vs
inject
drug
vs
incarcer
vs
histori
like
genotyp
infect
vs
group
compar
gender
male
cirrhot
stage
tm
patient
underw
transient
elastographi
assess
region
outreach
fibroscan
blitz
compar
patient
tm
patient
complet
daa
therapi
frequent
prescrib
daa
regimen
tm
patient
svr
rate
tm
group
group
conclus
tm
program
success
engag
retain
remot
popul
enrich
characterist
associ
barrier
success
hcv
treatment
tm
patient
abl
engag
hcv
care
achiev
high
svr
rate
compar
obtain
tradit
model
care
disclosur
curti
cooper
advisori
committe
review
panel
gilead
abbvi
merck
grantresearch
support
merck
gilead
abbvi
speak
teach
merck
abbvi
gilead
follow
peopl
noth
disclos
holli
hatashita
parmvir
parmar
daniel
j
corsi
background
treatment
hepat
c
viru
hcv
infect
pegyl
interferon
ribavirin
poor
respons
patient
human
immunodefici
viru
hiv
improv
significantli
direct
act
antivir
daa
compar
hcv
patient
howev
suggest
treatment
outcom
among
black
person
treat
ledipasvirsofosbuvir
ldvsof
may
inferior
assess
treatment
respons
ldvsof
cohort
black
hivhcv
person
newark
new
jersey
methodolog
retrospect
chart
review
conduct
black
genotyp
hivhcv
patient
treat
ldvsof
univers
hospit
infecti
diseas
practic
januari
februari
data
collect
includ
demograph
hcv
treatment
histori
durat
ldvsof
regimen
treatment
respons
result
total
hivhcv
black
patient
receiv
treatment
ldvsof
studi
period
preliminari
data
present
patient
studi
popul
male
mean
age
year
cirrhosi
null
respond
prior
hcv
treatment
pegyl
interferon
ribavirin
boceprevirtelaprevir
patient
genotyp
baselin
median
count
median
hcv
viral
load
luml
median
fibrosur
score
median
creatinin
clearanc
patient
chang
art
prior
begin
ldv
sof
treatment
due
drug
interact
patient
receiv
week
ldvsof
respect
week
treatment
cirrhosi
two
patient
prematur
discontinu
treatment
due
logist
issu
mean
apri
score
baselin
respect
patient
experienc
side
effect
result
discontinu
overal
svr
relaps
cirrhot
svr
rate
genotyp
prior
null
respond
among
cirrhot
conclus
real
world
cohort
black
genotyp
hiv
hcv
patient
ldvsof
high
rate
extrem
well
toler
data
support
high
efficaci
ldvsof
highli
patient
popul
addit
studi
perform
assess
ribavirin
ad
ldvsof
patient
cirrhosi
disclosur
jihad
slim
speak
teach
bm
merck
abbvi
jansen
viiv
gilead
shobha
swaminathan
advisori
committe
review
panel
gilead
scienc
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
jaspreet
banga
sobia
nizami
mario
portilla
sandhya
nagarakanti
background
antivir
regimen
ombitasvir
obv
paritaprevir
identifi
abbvi
enanta
ritonavir
ptvr
dasabuvir
dsv
ribavirin
rbv
approv
europ
treatment
patient
chronic
hepat
c
genotyp
infect
date
data
well
data
outcom
pro
regimen
limit
goal
studi
investig
pro
treatment
regimen
obvptvr
dsv
rbv
method
patient
particip
cohort
studi
real
austria
includ
analysi
patient
receiv
regimen
obvptvr
dsv
rbv
accord
local
label
effect
assess
qualiti
life
hrqol
healthdiseas
awar
work
product
assess
standard
questionnair
wpai
hep
c
result
march
total
patient
receiv
regimen
obvptvr
dsv
rbv
baselin
characterist
shown
tabl
assess
hrqol
show
major
differ
index
score
total
popul
baselin
bl
mean
sd
n
end
treatment
eot
mean
sd
n
patient
avail
data
time
point
n
mean
chang
index
score
sd
indic
reduct
hrqol
due
treatment
analysi
total
activ
impair
score
wpai
reveal
signific
differ
bl
mean
sd
n
eot
mean
sd
n
well
suggest
treatment
advers
affect
total
activ
patient
upcom
result
includ
data
present
meet
conclus
studi
treatment
obv
ptvr
dsv
rbv
advers
impact
hrqol
total
activ
patient
set
austria
confirm
previou
result
toler
regimen
baselin
characterist
disclosur
michael
gschwantler
advisori
committe
review
panel
janssen
bm
gilead
abbvi
grantresearch
support
abbvi
gilead
speak
teach
janssen
bm
gilead
abbvi
peter
ferenc
advisori
committe
review
panel
idenix
gilead
msd
janssen
salix
abbvi
bm
wilson
therapeut
patent
heldfil
madau
rottapharm
speak
teach
gilead
roch
bernhard
j
bauer
advisori
committe
review
panel
abbvi
bm
speak
teach
abbvi
msd
gilead
bm
hermann
laferl
advisori
committe
review
panel
janssen
grant
research
support
gilead
abbvi
roch
speak
teach
gilead
thoma
bamberg
advisori
committe
review
panel
abbvi
msd
bm
grantresearch
support
gilead
speak
teach
abbvi
bm
gilead
rudolf
e
stauber
advisori
committe
review
panel
gilead
msd
bm
grantresearch
support
abbvi
ivo
graziadei
advisori
committe
review
panel
gilead
abbvi
msd
janssen
bm
speak
teach
gilead
abbvi
msd
bm
jan
hetting
employ
abbvi
gmbh
austria
astrid
teskey
employ
abbvi
gmbh
andrea
maieron
advisori
committe
review
panel
msd
jannsen
bm
bvdhringer
ingelheim
gilead
abbvi
grantresearch
support
roch
speak
teach
roch
msd
jannsen
gilead
abbvi
background
highest
preval
chronic
hepat
c
viru
hcv
genotyp
seen
among
southeast
asian
popul
previou
therapi
offer
high
cure
rate
sofosbuvirledipasvir
sofldv
first
treatment
approv
hcv
offer
safe
highli
efficaci
treatment
option
howev
larg
studi
evalu
real
world
outcom
regimen
lack
aim
evalu
real
world
treatment
outcom
larg
gastroenterolog
practic
unit
state
method
retrospect
cohort
studi
evalu
adult
age
chronic
hcv
treat
sofldv
without
ribavirin
commun
gastroenterolog
clinic
us
novemb
may
rate
undetect
viru
week
treatment
end
treatment
eot
stratifi
presenc
cirrhosi
prior
treatment
treatment
vs
treatment
experienc
multivari
logist
regress
model
evalu
predictor
treatment
failur
relaps
result
among
patient
chronic
hcv
treat
sofldv
without
ribavirin
male
mean
age
start
treatment
year
sd
cirrhosi
treatment
experienc
relaps
prior
treatment
pegyl
interferon
ribavirin
overal
undetect
viru
week
treatment
undetect
viru
eot
achiev
tabl
one
patient
detect
viru
eot
two
patient
viral
relaps
week
despit
achiev
undetect
viru
eot
resist
test
treatment
failur
patient
attempt
unsuccess
due
lack
conform
primer
defin
possibl
resist
mutat
achiev
femal
vs
male
cirrhot
vs
patient
without
cirrhosi
signific
predictor
treatment
failur
relaps
identifi
regress
model
conclus
among
larg
real
world
cohort
asian
chronic
hcv
patient
unit
state
oral
sofldv
without
ribavirin
safe
effect
treatment
real
world
set
similar
report
clinic
trial
treatment
outcom
among
asian
hcv
genotyp
patient
treat
sofosbuvirledipasvir
disclosur
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
huy
n
trinh
grantresearch
support
gilead
intercept
abbvi
merk
speak
teach
gilead
stock
sharehold
gilead
huy
nguyen
advisori
committe
review
panel
gilead
bm
speak
teach
gilead
jenni
c
yang
employ
gilead
scienc
inc
robert
gish
advisori
committe
review
panel
gilead
abbvi
arrowhead
loni
merck
consult
eiger
genentech
merck
speak
teach
gilead
abbvi
merck
stock
sharehold
arrowhead
follow
peopl
noth
disclos
nguyen
andrew
huynh
mytop
ly
khanh
k
nguyen
ruel
garcia
brian
levitt
eduardo
dasilvera
background
addit
ribavirin
newer
daa
regimen
unclear
benefit
determin
svr
rate
person
treat
paritaprevirritonavir
ombitasvir
dasabuvir
prod
regimen
without
ribavirin
compar
sofosbuvirledipasvir
sofldv
regimen
set
method
erchiv
databas
nation
cohort
veteran
identifi
hcv
genotyp
infect
person
initi
regimen
exclud
hiv
coinfect
posit
hbsag
miss
hcv
rna
result
identifi
person
prod
ribavirin
sofldv
ribavirin
among
hcv
genotyp
infect
person
ribavirin
prescrib
prod
sof
ldv
svr
rate
rang
regardless
treatment
regimen
presenc
cirrhosi
hcv
subtyp
except
hcv
genotyp
without
cirrhosi
prod
without
ribavirin
svr
minor
clinic
insignific
differ
svr
rate
treat
without
ribavirin
treatment
group
regardless
presenc
cirrhosi
baselin
multivari
logist
regress
analysi
except
cirrhot
treat
prod
small
number
evalu
ribavirin
use
associ
achiev
svr
group
conclus
prod
sofldv
regimen
associ
high
rate
svr
actual
clinic
set
compar
clinic
trial
result
meaning
differ
svr
rate
observ
prescrib
prescrib
ribavirin
sofldv
prod
genotyp
prod
paritaprevir
ritonavir
ombitasvir
dasabuvir
disclosur
adeel
butt
grantresearch
support
gilead
abbvi
kristen
mark
grantresearch
support
merck
gilead
obaid
shaikh
grantresearch
support
gilead
scienc
shinongi
pharmaceut
merritt
speak
teach
simpli
speak
kenneth
e
sherman
advisori
committe
review
panel
janssen
merck
synteract
grantresearch
support
medimmun
inovio
merck
gilead
squibb
follow
peopl
noth
disclos
peng
yan
background
ledipasvirsofosbuvir
ldvsof
directli
act
combin
therapi
approv
treatment
hepat
c
infect
howev
ledipasvir
note
drug
interact
acid
suppress
medic
notabl
proton
pump
inhibitor
ppi
drug
class
result
potenti
decreas
serum
concentr
ledipasvir
due
exclus
acid
suppress
medic
registr
trial
unclear
ldvsof
ppi
impact
sustain
virolog
respons
week
method
use
veteran
affair
va
informat
comput
infrastructur
vinci
abl
queri
pharmaci
databas
prescript
ldvsof
dispens
va
system
octob
decemb
addit
queri
pharmaci
databas
ppi
identifi
ldvsof
cohort
ppi
usag
defin
activ
ppi
prescript
overlap
treatment
period
ldvsof
includ
refil
primari
outcom
defin
hcv
rna
drawn
complet
therapi
result
initi
prescript
ldv
sof
data
avail
veteran
veteran
complet
cours
ldvsof
studi
period
receiv
ppi
cohort
predominantli
male
averag
age
year
caucasian
african
american
alaskan
nativepacif
island
asian
nativ
american
differ
demograph
base
ppi
exposur
patient
receiv
ldv
sof
alon
rate
patient
receiv
ldvsof
concomit
ppi
rate
p
stratifi
analysi
stage
liver
diseas
durat
ldv
sof
therapi
dose
ppi
activ
ppi
refil
genotyp
present
conclus
larg
cohort
veteran
complet
cours
ldvsof
treatment
chronic
hcv
infect
concomit
prescript
ppi
acid
suppress
medic
result
lower
investig
dose
per
packag
insert
need
confirm
medic
result
higher
relaps
rate
disclosur
susanna
naggi
advisori
committe
review
panel
merck
grant
research
support
tacer
gilead
abbvi
bm
jenssen
merck
follow
peopl
noth
disclos
austin
w
chan
william
e
bryan
moham
hashem
mari
l
townsend
laura
ann
wang
steve
choi
background
aim
approxim
adult
germani
chronic
infect
hcv
hcv
genotyp
gt
proport
approx
effect
safeti
antivir
daa
regimen
contain
daclatasvir
dcv
patient
report
german
hepat
method
prospect
cohort
studi
enrol
approx
hcv
patient
receiv
regimen
feb
feb
amongst
patient
enrol
effect
assess
sustain
virolog
respons
week
result
feb
patient
treat
dcvsof
rbv
patient
treatment
experienc
cirrhot
patient
reach
least
w
post
treatment
follow
treatment
durat
week
patient
respect
patient
receiv
diverg
treatment
durat
ribavirin
prescrib
patient
receiv
week
treatment
receiv
week
treatment
svr
rate
subgroup
report
tabl
date
patient
avail
week
data
patient
finish
treatment
plan
achiev
result
rate
patient
treatment
accord
week
dcvsof
result
mitt
decompens
cirrhosi
close
n
discontinu
therapi
occur
patient
virolog
breakthrough
due
advers
event
unplan
event
ltfu
lack
adher
patient
die
dcvsofrbv
gastrointestin
bleed
caus
unknown
conclus
larg
cohort
hcv
patient
treatment
dcvsof
rbv
achiev
high
rate
sustain
virolog
respons
tabl
mitt
rate
subpopul
percentag
present
subgroup
patient
includ
pt
pt
pt
treatment
disclosur
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
marku
cornberg
advisori
committe
review
panel
merck
msd
germamni
roch
gilead
novarti
abbvi
janssen
cilag
bm
grantresearch
support
merck
msd
germamni
roch
speak
teach
merck
msd
germamni
roch
gilead
bm
novarti
falk
abbvi
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
tim
zimmermann
advisori
committe
review
panel
abbvi
speak
teach
bm
tina
nakonz
employ
squibb
conrad
fischer
independ
contractor
bm
germani
intercept
pharma
germani
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
follow
peopl
noth
disclos
andrea
schober
kilian
weigand
background
aim
chronic
infect
hepat
c
viru
cihcv
known
caus
form
kidney
diseas
erad
hcv
may
improv
renal
disfunct
patient
aim
studi
determin
preval
renal
insuffici
effect
treatment
direct
act
antivir
daa
renal
dysfunct
present
cohort
patient
cihcv
method
design
prospect
studi
patient
patient
cihcv
initi
therapi
daa
april
includ
prospect
collect
demograph
clinic
laboratori
variabl
fibrosi
measur
biopsi
fibroscan
kpa
kpa
cirrhosi
kpa
treatment
daa
given
accord
easl
guidelin
sustain
virolog
respons
undetect
viral
load
coba
taqman
week
end
treatment
renal
function
calcul
estim
glomerular
filtrat
rate
egfr
equat
week
end
treatment
function
defin
accord
kdigo
classif
primari
endpoint
proport
patient
chronic
renal
insuffici
cri
defin
gfr
mlmin
chang
gfr
week
end
treatment
patient
cri
baselin
result
individu
includ
mean
age
year
male
pr
ip
first
gener
genotyp
other
genotyp
genotyp
baselin
viral
load
uiml
diabet
fibrosi
stage
cirrhosi
cri
baselin
finish
treatment
week
subgroup
egfr
improv
significantli
obtain
median
mlmin
vs
mlmin
p
conclus
preval
cri
patient
cihcv
high
patient
cihcv
cri
egfr
improv
significantli
disclosur
rafael
granado
advisori
committe
review
panel
abbvi
consult
janssen
speak
teach
abbiv
janssen
gilead
follow
peopl
noth
disclos
miriam
serrano
maria
martin
antoni
adrov
miriam
moreno
melisa
hernandez
maria
pena
background
aim
regimen
ombitasvirparitaprevirritonavir
dasabuvir
weight
base
ribavirin
rbv
approv
treatment
hepat
c
viru
hcv
genotyp
infect
potent
regimen
rbv
dose
reduct
expect
improv
toler
minim
impact
efficaci
object
analys
predict
efficaci
percent
sustain
virolog
respons
svr
safeti
event
incid
rate
total
bilirubin
tbil
elev
hemoglobin
hgb
reduct
regimen
low
dose
mg
rbv
ldr
compar
regimen
weight
base
mg
daili
rbv
wbr
method
efficaci
safeti
data
avail
six
phase
two
phase
studi
wbr
multipl
linear
logist
regress
mlr
model
develop
sa
establish
relationship
trough
concentr
ctrough
valu
daa
rbv
infect
subject
n
subject
includ
achiev
separ
mlr
model
relationship
safeti
incid
rate
sever
area
plasma
curv
auc
valu
develop
r
use
data
infect
subject
six
phase
studi
one
phase
studi
n
relev
covari
includ
model
base
statist
clinic
signific
final
model
use
predict
grade
tbil
elev
grade
hgb
reduct
ldr
compar
wbr
result
ctrough
valu
daa
rbv
along
age
sex
cirrhosi
presenc
vs
absenc
baselin
viral
load
genotyp
vs
cc
associ
svr
expect
chang
ldr
compar
wbr
across
femal
cc
cirrhot
male
subpopul
safeti
analys
paritaprevir
rbv
auc
valu
baselin
tbil
associ
tbil
elev
rbv
auc
baselin
hgb
sex
cirrhosi
associ
hgb
reduct
predict
probabl
grade
tbil
elev
grade
hgb
reduct
ldr
significantli
lower
observ
wbr
respect
conclus
analys
demonstr
lower
rbv
dose
mg
weight
base
dose
regimen
would
improv
toler
minim
effect
chang
hcv
infect
disclosur
akshanth
r
polep
employ
abbvi
balakrishna
hosman
consult
abbvi
lin
employ
abbvi
mukul
minocha
employ
abbvi
stock
sharehold
abbvi
haoyu
wang
employ
abbvi
stock
sharehold
abbvi
amit
khatri
employ
abbvi
inc
patent
heldfil
abbvi
inc
stock
sharehold
abbvi
inc
rajeev
menon
employ
abbvi
patent
heldfil
abbvi
stock
sharehold
abbvi
background
chronic
hepat
c
viru
hcv
infect
particular
signific
renal
diseas
esrd
clinic
trial
patient
sever
esrd
week
treatment
ombitasvir
obv
paritaprevir
ptv
discov
abbvi
enanta
ritonavir
r
dasabuvir
dsv
ribavirin
rbv
hcv
genotyp
gt
infect
led
sustain
viral
respons
week
patient
studi
drug
discontinu
due
advers
event
ae
howev
rbv
commonli
associ
hemoglobin
declin
dose
interrupt
assess
safeti
efficaci
treatment
obvptvr
dsv
patient
esrd
chronic
hcv
infect
method
phase
studi
enrol
patient
either
gt
infect
without
cirrhosi
renal
diseas
egfr
mlmin
includ
hemodialysi
patient
arm
receiv
obvptvr
mg
daili
dsv
mg
twice
daili
week
arm
receiv
obvptvr
mg
daili
week
primari
endpoint
percentag
patient
hcv
rna
luml
patient
receiv
dose
studi
drug
includ
safeti
efficaci
analys
result
total
patient
enrol
patient
male
infect
infect
patient
dialysi
patient
avail
data
achiev
patient
patient
achiev
elect
undergo
renal
transplant
withdrew
consent
treatment
week
one
patient
discontinu
studi
drug
achiev
safeti
summar
tabl
conclus
antivir
regimen
obvptvr
dsv
week
treatment
patient
sever
renal
diseas
hcv
infect
appear
safe
effect
patient
esrd
includ
hemodialysi
complet
data
avail
present
discontinu
studi
drug
still
achiev
studi
drug
due
renal
failur
transplant
alt
return
normal
rang
within
day
without
dose
interrupt
disclosur
edward
j
gane
advisori
committe
review
panel
abbvi
janssen
gilead
scienc
achillion
merck
speak
teach
abbvi
gilead
scienc
merck
alnylam
ricard
consult
abbvi
speak
teach
gilead
abbvi
squibb
merck
sharp
dohm
janssen
stuart
k
robert
board
membership
abbvi
gilead
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
niloufar
mobasheri
employ
abbvi
stock
sharehold
abbvi
manal
abunimeh
employ
abbvi
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
kosh
agarw
advisori
committe
review
panel
gilead
bm
novarti
janssen
abbvi
consult
msd
janssen
achillion
intercept
grantresearch
support
roch
gilead
bm
arbutu
speak
teach
astella
gilead
bm
gsk
follow
peopl
noth
disclos
eric
cohen
richard
skoien
stephen
riordan
backgroundaim
asunaprevir
asv
administr
daclatasvir
dcv
genotyp
ichron
hepat
c
patient
japan
alanin
aminotransferas
alt
elev
frequent
advers
event
howev
precis
mechan
elucid
ursodeoxychol
acid
udca
use
hepatoprotect
medicin
case
liver
dysfunct
ln
studi
investig
signific
serum
asv
concentr
relationship
alt
elev
patient
method
patient
genotyp
chronic
hepat
c
treat
asv
twice
dcv
daili
pharmacokinet
pk
asv
investig
case
trough
concentr
asv
trough
week
measur
intens
pk
studi
perform
case
hour
asv
administr
measur
day
trough
week
measur
case
measur
hplc
case
administr
udca
continu
start
combin
therapi
case
improv
alt
iul
maintain
treatment
period
classifi
stabl
rel
group
relaps
rel
group
result
intens
pk
studi
median
c
max
ngml
max
hour
mean
trough
week
wide
distribut
ngml
individu
differ
case
small
mean
sd
mean
valu
median
trough
cirrhot
case
cp
score
cp
score
case
ngml
median
trough
significantli
correl
type
index
liver
stiff
measur
fibroscan
tm
p
maximum
valu
period
alt
elev
iul
week
udca
group
iul
week
udca
group
median
trough
ngml
rel
rel
group
udca
case
udca
case
ns
udca
case
probabl
alt
elev
treatment
trough
ngml
case
trough
ngml
case
trough
affect
svr
ngml
svr
case
ngml
case
ns
conclus
asv
concentr
correl
hepat
reserv
degre
fibrosi
alt
elev
combin
therapi
asv
dcv
patient
genotyp
hcv
infect
associ
serum
asv
concentr
udca
reduc
alt
elev
disclosur
shuhei
hige
speak
teach
bm
abbi
msd
yoshiyasu
karino
speak
teach
bm
kk
follow
peopl
noth
disclos
itaru
ozeki
ryoji
tatsumi
masakatsu
yamaguchi
mutsuumi
kimura
tomohiro
arakawa
tomoaki
nakajima
yasuaki
kuwata
takahiro
sato
takumi
ohmura
joji
toyota
background
avail
effect
daa
treatment
chronic
hcv
infect
result
major
increas
number
patient
suscept
benefit
new
therapeut
approach
mani
patient
advanc
liver
diseas
requir
rapid
access
antivir
treatment
therefor
innov
strategi
need
optim
patient
manag
cope
larg
cohort
patient
acceler
treatment
initi
object
studi
compar
manag
select
hcv
patient
treat
daa
hepatologist
physician
special
nurs
tertiari
care
center
method
patient
candid
daa
regimen
prospect
alloc
treatment
supervis
either
hepatologist
physician
group
p
special
nurs
group
n
key
exclus
criteria
child
c
cirrhosi
hepatocellular
carcinoma
sever
comorbid
cirrhosi
defin
fibroscan
score
kpa
fibrotest
score
patient
receiv
regimen
accord
intern
guidelin
includ
mainli
result
patient
male
median
age
year
daa
treatment
initi
cirrhosi
present
patient
child
b
median
meld
score
patient
renal
failur
diabet
hypertens
hcv
genotyp
predomin
follow
genotyp
patient
treat
week
week
signific
differ
baselin
characterist
treatment
durat
group
p
n
overal
rate
group
p
vs
group
n
prematur
treatment
discontinu
occur
group
p
vs
group
n
sever
advers
event
observ
group
p
vs
group
n
death
treatment
period
report
group
p
vs
group
n
loss
follow
overal
popul
significantli
frequent
group
p
group
n
conclus
studi
larg
cohort
strongli
show
daa
regimen
safe
success
manag
special
nurs
strategi
may
acceler
daa
treatment
access
hcv
patient
disclosur
advisori
committe
review
panel
roch
gilead
consult
lfb
biomedica
speak
teach
gilead
janssen
bm
roch
abbvi
daniel
dhumeaux
stock
sharehold
christoph
hezod
speak
teach
roch
bm
msd
janssen
abbvi
gilead
follow
peopl
noth
disclos
giovanna
scoazec
muriel
ann
varaut
arian
mallat
aim
antivir
daa
therapi
develop
hepat
c
hcv
treatment
increas
efficaci
aim
describ
pattern
hcv
manag
liver
infecti
diseas
id
specialist
method
institut
review
board
approv
survey
email
member
american
associ
studi
liver
diseas
aasld
infecti
diseas
societi
america
idsa
respons
anonym
respons
mail
receiv
treat
hcv
patient
aasld
respond
treat
hcv
idsa
respond
vs
p
therapi
choic
treatment
patient
genotyp
ledipasvirsofosbuvir
sofosbuvirribavirin
daclatasvirsofosbuvir
ledipasvirsofosbuvir
respect
hcv
treatment
failur
encount
particip
frequent
liver
id
specialist
vs
p
liver
specialist
treat
hcv
decompens
cirrhosi
id
specialist
vs
p
hcv
recurr
liver
transplant
lt
vs
p
year
experi
treat
hcv
affect
approach
hcv
treatment
failur
hepat
fibrosi
assess
method
hcv
treatment
liver
biopsi
obtain
respond
insur
coverag
major
limit
factor
prevent
initi
daa
practition
discuss
knowledg
largest
survey
pattern
hcv
manag
liver
id
specialist
major
respond
adher
aasldidsa
hcv
treatment
guidelin
liver
specialist
treat
decompens
cirrhot
post
lt
patient
liver
biopsi
larg
replac
method
assess
hepat
fibrosi
id
specialist
identifi
group
could
expand
hcv
treatment
workforc
less
idsa
respond
treat
hcv
essenti
identifi
barrier
id
specialist
treat
hcv
augment
hcv
care
capac
survey
rais
import
issu
need
consensu
amongst
insur
program
improv
hcv
treatment
access
global
scale
hcv
practic
pattern
specialti
valu
number
fisher
exact
test
disclosur
follow
peopl
noth
disclos
maen
masadeh
huafeng
shen
yazan
hasan
andrew
johann
antonio
j
sanchez
introduct
agent
daa
hcv
improv
treatment
chronic
hepat
c
due
higher
efficaci
better
toler
substanti
reduct
contraind
despit
major
progress
relaps
still
occur
assess
influenc
tradit
risk
factor
treatment
outcom
method
gecco
cohort
multicent
cohort
site
germani
patient
start
follow
daa
regimen
includ
analysi
pegyl
interferon
pegifn
avirin
rbv
sofosbuvir
sof
sof
rbv
sof
simeprevir
smv
sof
daclatasvir
dcv
rbv
sofledipasvir
ldv
paritaprevirritonavir
prtr
ombitasvir
obv
rbv
dasabuvir
dsv
treatment
outcom
measur
sustain
virolog
respons
week
end
therapi
itt
proport
patient
gecco
also
part
german
hepat
c
registri
result
analysi
base
patient
gecco
cohort
risk
factor
associ
lower
rate
presenc
liver
cirrhosi
vs
cellspl
vs
although
presenc
liver
cirrhosi
strongli
correl
cell
count
p
without
cirrhosi
also
associ
lower
svr
rate
figur
age
sex
mio
luml
alt
level
cdc
stage
specif
antiretrovir
therapi
hcv
treatment
regimen
associ
statist
lower
svr
rate
conclus
despit
consider
improv
efficaci
treatment
chronic
hepat
c
daa
low
cell
liver
cirrhosi
remain
risk
factor
treatment
failur
associ
presenc
liver
cirrhosi
low
cell
count
may
explain
portal
hypertens
splenomegali
consecut
lymphopenia
disclosur
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
patrick
ingiliz
consult
gilead
abbvi
janssen
cilag
speak
teach
bm
msd
gilead
abbvi
thoma
lutz
advisori
committe
review
panel
gilead
msd
abbvi
bm
janssen
cilag
grantresearch
support
gilead
glaxosmithklin
msd
abbvi
janssen
cilag
speak
teach
viiv
bm
knud
schew
advisori
committe
review
panel
abbvi
gilead
msd
bm
janssen
cilag
hexal
speak
teach
msd
hexal
gilead
k
rockstroh
advisori
committe
review
panel
abbvi
cipla
bm
merck
roch
tibotec
abbvi
bionor
tobira
viiv
abbott
gilead
janssen
consult
novarti
grantresearch
support
gilead
merck
speak
teach
bm
merck
siemen
tibotec
gilead
janssen
viiv
christoph
boeseck
consult
abbvi
viiv
speak
teach
msd
gilead
bm
heiner
w
busch
speak
teach
tibotec
msd
janssen
bm
gilead
abbott
stefan
christensen
advisori
committe
review
panel
bm
abbvi
janssen
viiv
gilead
msd
speak
teach
gilead
msd
abbvi
bm
janssen
follow
peopl
noth
disclos
florian
berger
julian
schulz
zur
wiesch
guenther
schmutz
axel
baumgarten
background
new
regimen
gener
direct
antivir
agent
daa
demonstr
high
efficaci
among
patient
regist
trial
nevertheless
littl
known
impact
therapi
liver
stiff
measur
lsm
liver
function
set
aim
evalu
impact
svr
lsm
clinic
liver
paramet
index
gener
daa
therapi
popul
hcv
infect
patient
metavir
liver
fibrosi
patient
method
hcv
patient
mf
bmi
liver
fibrosi
undergo
antivir
therapi
daa
consecut
enrol
april
decemb
three
tertiari
center
hepatolog
southern
itali
decompens
cirrhosi
exclud
genotyp
patient
treat
basi
easlaisf
guidelin
sofosbuvir
sof
ribavirin
rbv
ombitasvirparitaprevirritonavir
everi
patient
clinic
biochem
imag
data
lsm
ultrasonographi
meld
score
collect
baselin
therapi
start
end
therapi
eot
week
sustain
virolog
respons
result
patient
metavir
lsm
kpascal
reach
patient
patient
lsm
patient
child
meld
score
significantli
decreas
eot
p
interestingli
signific
differ
variabl
found
eot
pn
univari
analysi
clinic
liver
function
paramet
baselin
glucos
p
type
diabet
p
alt
p
plt
p
found
associ
signific
eot
lsm
improv
multipl
regress
age
sex
bmi
glucos
diabet
alt
meld
child
platelet
level
plt
independ
variabl
alt
plt
directli
diabet
invers
associ
signific
lsm
reduct
conclus
virolog
respons
regimen
associ
fibrosi
regress
recoveri
liver
function
detect
earli
eot
respons
achiev
wherea
differ
eot
week
found
svr
patient
diabet
seem
neg
influenc
lsm
improv
investig
advis
assess
long
term
effect
svr
disclosur
marcello
persico
advisori
committe
review
panel
abbvi
grant
research
support
gilead
follow
peopl
noth
disclos
mario
masaron
andrea
aglitti
rosa
caruso
alessandro
federico
marcello
dallio
silvia
camera
nicola
caporaso
filomena
morisco
purpos
evalu
success
rate
insur
approv
singl
center
set
hepat
c
therapi
involv
ledipasvirsofosbuvir
compar
ibd
therapi
involv
adalimumab
method
pharmaceut
record
review
patient
prescrib
ledipasvirsofosbuvir
adalimumab
juli
novemb
data
extract
includ
type
insur
insur
approv
fibrosi
stage
base
fibroscan
patient
prescrib
ledipasvirsofosbuvir
data
type
ibd
sever
anemia
locat
extraintestin
manifest
perian
complic
collect
patient
prescrib
adalimumab
result
patient
prescrib
therapi
ledipasvirsofosbuvir
base
therapi
overal
approv
rate
comparison
ammong
patient
prescrib
adalimumab
approv
patient
deni
still
pend
approv
among
patient
prescrib
ledipasvirsofosbuvir
insur
compani
patient
medicar
privat
insur
medicaid
approv
rate
medicar
patient
privat
insur
medicaid
patient
amongst
privat
insur
privat
approv
rate
privat
b
approv
rate
privat
insur
approv
adalimumab
group
patient
medicar
medicaid
patient
privat
privat
b
privat
insur
patient
medicaid
medicar
approv
patient
deni
one
privat
b
crohn
diseas
diagnos
absenc
anemia
extraintestin
manifest
wherea
second
patient
insur
privat
b
ulcer
coliti
diagnos
presenc
moder
anemia
manifest
conclus
evalu
insur
approv
rate
ledipasvirsofosbuvir
base
hepat
c
therapi
adalimumab
base
ibd
therapi
approv
rate
therapi
base
ledipasvirsofosbuvir
medicaid
patient
low
approv
rate
overal
approv
rate
adalimumab
base
therapi
medicar
medicaid
patient
approv
patient
deni
privat
insur
tabl
show
approv
rate
percentag
ledipasvirsofosbuvir
base
insur
type
disclosur
follow
peopl
noth
disclos
mohammad
arsalan
siddiqui
hani
eraqi
sadiq
omar
syedmoham
jafri
background
aim
phase
studi
daa
patient
chronic
hepat
c
cirrhosi
includ
patient
year
itali
restrict
prescript
regimen
patient
sever
fibrosi
cirrhosi
skew
usag
daa
toward
advanc
age
fascia
contain
patient
frequent
candid
olt
evalu
safeti
efficaci
daa
regimen
use
ongo
dataset
region
databas
includ
hcv
patient
present
treatment
liver
centr
throughout
sicili
order
evalu
appropri
prioriti
patient
method
march
may
patient
regist
met
aifa
criteria
treatment
start
daa
regimen
patient
elderli
age
year
regimen
choic
use
ribavirin
base
viral
genotyp
stage
diseas
accord
guidelin
result
cohort
elderli
patient
higher
preval
women
vs
p
pr
patient
vs
p
genotyp
vs
p
fibrosi
vs
p
hcc
previou
treat
vs
p
diabet
vs
p
arteri
hypertens
vs
p
hearth
diseas
vs
p
kidney
diseas
vs
p
vs
p
compar
patient
year
hiv
vs
p
previou
olt
vs
p
less
frequent
elderli
may
patient
conclud
treatment
patient
conclud
week
itt
rate
etr
elderli
rate
svr
elderli
two
patient
die
elder
liver
failur
varic
bleed
conclus
use
daa
regimen
practic
safe
effect
elderli
patient
cirrhosi
sever
fibrosi
due
hcv
younger
popul
lifetim
util
hcv
erad
elder
term
reduct
event
overal
surviv
need
evalu
observ
cohort
disclosur
gaetano
bertino
grantresearch
support
abbvi
giovanni
raimondo
speak
teach
bm
gilead
roch
merck
janssen
bayer
msd
follow
peopl
noth
disclos
vincenza
calvaruso
iren
cacciola
maurizio
russello
antonio
davi
gaetano
scifo
riccardo
volp
arturo
montineri
tullio
prestileo
salvator
madonia
giusepp
malizia
antonio
digiacomo
antonio
magro
anna
licata
bruno
cacopardo
antonino
salvo
luigi
guarneri
ignazio
scalisi
giovanni
mannino
pietro
colletti
fabio
cartabellotta
vincenzo
portelli
antonio
craxi
vito
di
marco
background
aim
despit
high
hcv
preval
person
oat
rare
engag
hcv
care
program
refer
patient
offsit
telemedicin
videoconferenc
permit
direct
interact
patient
specialist
distinct
locat
might
use
hcv
treatment
oat
patient
method
hcv
rna
posit
patient
undergo
hcv
evalu
via
telemedicin
onsit
physician
assist
hepatologist
pretreat
lab
visit
perform
onsit
direct
act
antivir
daa
procur
specialti
pharmaci
methadon
use
directli
observ
therapi
charg
submit
electron
third
parti
payer
patient
satisfact
assess
telemedicin
satisfact
questionnair
tsq
result
hcv
patient
male
hispan
receiv
hcv
evalu
via
telemedicin
patient
well
stabil
methadon
except
hcv
genotyp
fibrosi
assess
patient
underw
fibrosur
reveal
mild
stage
moder
stage
sever
stage
patient
daa
begun
complet
patient
hcv
rna
undetect
patient
treatment
complet
pt
week
pt
pt
sixteen
patient
undergo
evalu
await
daa
remain
untreat
date
insur
mandat
fibrosi
drug
use
restrict
prevent
patient
ultim
receiv
therapi
auditori
visual
commun
issu
identifi
select
tsq
result
illustr
tabl
medic
adher
excel
conclus
hcv
care
feasibl
reimburs
model
hcv
treatment
deliveri
oat
program
excel
initi
patient
accept
strengthen
time
patient
adher
antivir
efficaci
excel
telemedicin
virtual
integr
care
oat
clinic
select
tsq
result
disclosur
andrew
h
talal
advisori
committe
review
panel
merck
co
abbvi
gilead
grantresearch
support
merck
co
intercept
gilead
abbott
molecular
abbvi
conatu
marianthi
markat
grantresearch
support
abbvi
follow
peopl
noth
disclos
phylli
andrew
anthoni
mcleod
yang
chen
clewert
sylvest
lawrenc
brown
background
antivir
safe
effect
advanc
hepat
c
cirrhosi
impact
svr
morbid
mortal
advanc
diseas
unknown
examin
outcom
ukeld
albi
score
hcv
patient
advanc
cirrhosi
treat
uk
hcv
earli
access
program
either
sofosbuvirledipasvir
sofosbuvirdaclatasvir
result
patient
pugh
score
baselin
averag
time
week
svr
achiev
patient
whilst
relaps
svr
predict
death
year
overal
progress
transplant
overal
associ
signific
improv
ukeld
versu
year
albi
score
versu
year
seen
patient
relaps
strikingli
cumul
probabl
hcc
incid
year
signifcantli
higher
relaps
group
versu
svr
group
fisher
exact
test
svr
signific
predictor
diagnosi
hcc
independ
meld
ukeld
albi
multivari
analysi
conclus
data
suggest
rapid
benefit
daa
treatment
advanc
hcv
cirrhosi
reduct
transplant
rate
may
becom
evid
longer
strongli
predict
fall
ukeld
group
unclear
whether
lower
incid
hcc
svr
group
repres
inhibit
tumour
initi
reduc
growth
radiolog
undetect
lesion
either
scenario
improv
liver
function
svr
widen
treatment
option
time
hcc
diagnosi
fig
cumul
hcc
surviv
end
daa
treatment
hcv
cirrhosi
disclosur
janet
catt
advisori
committe
review
panel
bristol
myer
squibb
vie
gilead
william
rosenberg
advisori
committe
review
panel
janssen
merk
gilead
merk
gilead
gsk
abbvi
board
membership
iqur
limit
iqur
limit
consult
siemen
grantresearch
support
gilead
merk
speak
teach
siemen
roch
follow
peopl
noth
disclos
andrea
affronti
meena
ju
dougla
macdonald
purpos
direct
act
antivir
therapi
daa
expans
set
urgenc
valid
best
practic
screen
treatment
hepat
c
hcv
deutsch
gesellschaft
international
zusammenarbeit
giz
gmbh
german
develop
cooper
implement
screen
treatment
model
hivhcv
person
nepal
individu
live
hcv
genotyp
genotyp
kinkel
h
method
pivot
hcv
screen
treatment
within
exist
opioid
substitut
treatment
ost
site
screen
patient
hcv
viral
load
gt
astplatelet
ratio
index
apri
fibroscan
enrol
hcv
individu
treatment
ongo
studi
patient
diseas
optim
predictor
baselin
hcv
viral
load
iu
ml
cirrhosi
age
bodi
mass
index
favor
snp
receiv
sir
vs
sdaclatasvir
sd
r
cirrhot
includ
sledipasvir
sl
sd
r
cirrhot
result
demonstr
optim
complet
rapid
virolog
respons
rvrc
without
signific
toxic
among
first
patient
treat
hiv
tenofovir
disoproxil
fumar
tdf
antiretrovir
regimen
treatment
regimen
sd
sl
r
patient
compens
cirrhosi
sir
apri
compar
fibroscan
sensit
specif
neg
predict
valu
advanc
fibrosi
conclus
optim
outcom
drug
toler
demonstr
effect
commun
hcv
screen
treatment
set
simpl
individu
therapi
excel
earli
outcom
across
gt
set
encompass
inject
drug
user
support
simpl
hcv
diagnostictreat
model
implement
ost
site
result
valuabl
extend
hcv
treatment
set
refer
kinkel
h
et
al
preval
hepat
b
c
infect
assess
among
peopl
inject
drug
three
region
nepal
plo
one
disclosur
follow
peopl
noth
disclos
holli
murphi
sameer
dixit
andrew
trotter
apurva
rai
ujjwal
karmacharya
patricia
kramarz
philipp
creac
h
background
treatment
chronic
hepat
c
viru
hcv
infect
direct
act
antivir
daa
base
combin
therapi
lead
high
sustain
respons
rate
howev
variant
rav
frequent
associ
treatment
failur
studi
analyz
preval
characterist
rav
patient
larg
european
resist
databas
method
collect
serum
sampl
european
patient
infect
hcv
genotyp
gt
rav
shown
associ
treatment
failur
confer
fold
chang
drug
suscept
analyz
within
overal
patient
individu
display
virolog
failur
sofosbuvir
sof
sofsimeprevir
smv
sofdaclatasvir
dcv
sofledipasvir
ldv
paritaprevir
ptv
ombitasvir
omv
dasabuvir
dsv
result
patient
rate
rav
individu
preval
rav
variabl
due
frequent
natur
occurr
rav
domin
rav
observ
baselin
failur
treatment
led
signific
select
infect
patient
howev
current
unclear
whether
variant
impact
efficaci
salvag
therapi
dcv
ldv
omv
contain
regimen
rav
occur
frequent
depend
inhibitor
differ
pattern
variant
observ
variant
characterist
typic
rav
pattern
partial
overlap
observ
failur
proteas
inhibitor
smv
ptv
patient
increas
individu
dcvsof
failur
ldvsof
select
rav
interestingli
identifi
patient
virolog
failur
least
subsequ
antivir
therapi
conclus
virolog
failur
associ
appear
characterist
rav
daa
target
region
genotyp
typic
rav
pattern
exist
differ
daa
drug
class
hcv
genotypessubtyp
may
enabl
select
effect
salvag
regimen
howev
patient
show
failur
least
antivir
drug
regimen
disclosur
johann
vermehren
advisori
committe
review
panel
abbvi
abbott
speak
teach
abbvi
squibb
gilead
medtron
georgio
grammatiko
grantresearch
support
gilead
peter
ferenc
advisori
committe
review
panel
idenix
gilead
msd
janssen
salix
abbvi
bm
wilson
therapeut
patent
heldfil
madau
rottapharm
speak
teach
gilead
roch
maria
buti
advisori
committe
review
panel
gilead
janssen
msd
grantresearch
support
gilead
janssen
speak
teach
gilead
janssen
bm
beat
mullhaupt
advisori
committe
review
panel
norgin
consult
msd
intercept
grantresearch
support
gillead
speak
teach
bayer
bm
msd
gilead
bela
hunyadi
advisori
committe
review
panel
abbvi
squibb
accelsior
gilead
scienc
msd
merck
roch
hungari
board
membership
abbvi
squibb
accelsior
gilead
scienc
msdmerck
roch
hungari
consult
abbvi
squibb
accelsior
gilead
scienc
msdmerck
roch
hungari
grantresearch
support
abbvi
squibb
accelsior
gilead
scienc
msdmerck
roch
hungari
speak
teach
abbvi
squibb
accelsior
gilead
scienc
msdmerck
roch
hungari
holger
hinrichsen
advisori
committe
review
panel
bm
janssen
gilead
abbvi
speak
teach
msd
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
joerg
petersen
advisori
committe
review
panel
squibb
gilead
novarti
merck
squibb
gilead
novarti
merck
grant
research
support
roch
glaxosmithklin
roch
glaxosmithklin
speak
teach
abbott
tibotec
merck
abbott
tibotec
merck
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
thoma
von
hahn
speak
teach
abbvi
janssen
thoma
lutz
advisori
committe
review
panel
gilead
msd
abbvi
bm
janssen
cilag
grantresearch
support
gilead
glaxosmithklin
msd
abbvi
janssen
cilag
speak
teach
viiv
bm
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
follow
peopl
noth
disclos
julia
dietz
simon
susser
peiffer
sandra
passmann
dani
perner
caterina
berkowski
andrea
schober
gisela
felten
andrea
zipf
ulrich
spengler
gabi
knecht
background
pharmacokinet
studi
shown
solubl
ledipasvir
compon
ldvsof
combin
decreas
ph
increas
henc
prescrib
inform
caution
concomit
use
acid
reduc
therapi
art
recent
retrospect
analysi
cohort
reveal
reduct
among
patient
receiv
concomit
ldvsof
therapi
art
howev
studi
limit
dose
durat
frequenc
art
use
aim
aim
evalu
impact
art
svr
among
patient
receiv
ldvsof
without
ribavirin
genotyp
chc
method
retrospect
data
analysi
use
data
va
corpor
data
warehous
larg
cohort
veteran
affair
patient
manual
chart
review
data
valid
patient
complet
antivir
therapi
post
treatment
week
viral
load
avail
includ
analysi
descript
statist
student
conduct
continu
variabl
util
categor
variabl
multivari
logist
linear
regress
use
assess
rate
group
control
covari
interest
result
patient
undergo
ldvsof
antivir
therapi
chc
patient
exclud
due
miss
baselin
laboratori
variabl
achiev
patient
receiv
art
without
patient
receiv
art
treatment
prescrib
dose
higher
recommend
packag
insert
achiev
group
receiv
art
like
advanc
liver
diseas
compar
group
defin
score
vs
code
cirrhosi
vs
code
decompens
liver
diseas
vs
subgroup
analysi
patient
receiv
least
week
overlap
ldvsof
reduc
univari
analysi
control
differ
baselin
treatment
characterist
statist
differ
found
group
ci
statist
differ
rate
remain
subgroup
receiv
week
acid
suppress
medic
control
group
ci
conclus
use
art
within
guidelin
provid
prescrib
inform
ldvsof
impact
among
patient
chronic
infect
genotyp
hcv
disclosur
prashant
k
pandya
grantresearch
support
intercept
pharmaceut
conatu
galectin
speak
teach
gilead
abbvi
follow
peopl
noth
disclos
patrick
spoutz
monica
schaefer
mark
patterson
background
antivir
daa
therapi
virolog
failur
hepat
c
viru
occur
fewer
case
pauciti
data
guid
therapeut
decis
daa
therapi
util
failur
aasld
european
associ
studi
liver
easl
made
recommend
includ
switch
differ
daa
class
base
resist
testingbaselin
failur
rav
current
studi
analyz
popul
hcv
therapi
outcom
regimen
chosen
base
upon
genotyp
resist
test
regimen
failur
sofldv
method
data
deriv
two
referr
site
one
academ
one
teach
patient
adher
sofldv
virolog
failur
stop
therapi
advers
event
fail
reason
patient
genotyp
sequenc
analys
within
day
virolog
failur
patient
given
regimen
base
provid
choic
resist
test
util
result
result
includ
rav
detect
failur
salvag
regimen
see
tabl
prior
fail
sofldv
prior
pegrbv
virolog
failur
pi
failur
black
cirrhot
bridg
fibrosi
use
ppi
least
therapi
deni
use
dose
sofldv
failur
detect
rav
detect
rav
interim
analysi
achiev
one
patient
lost
achiev
respons
treat
efficaci
conclus
salvag
regimen
chosen
base
resist
test
perform
ldvsof
failur
success
efficaci
interim
analysi
brian
pearlman
grantresearch
support
merck
bi
bm
j
j
abbvi
gilead
speak
teach
gilead
abbvi
follow
peopl
noth
disclos
andrew
hind
michael
perri
limit
clinic
trial
data
shown
high
efficaci
ledipasvirsofosbuvir
ldvsof
treatment
patient
infect
hepat
c
viru
hcv
genotyp
gt
infect
patient
although
data
limit
cirrhot
patient
studi
assess
safeti
efficaci
ledipasvirsofosbuvir
ldvsof
without
ribavirin
rbv
infect
patient
compens
decompens
cirrhosi
method
ongo
observ
cohort
includ
hcv
treatment
patient
without
decompens
cirrhosi
week
treatment
regimen
ldvsof
rbv
patient
dose
physician
discret
mg
daili
patient
prior
daa
failur
exclud
analysi
compens
cirrhosi
metavir
ascertain
fibroscan
decompens
cirrhosi
child
pugh
score
ascertain
establish
clinic
biochem
radiolog
criteria
primari
efficaci
endpoint
drug
discontinu
andor
occurr
grade
advers
event
result
total
adult
patient
mean
age
year
hcv
rna
luml
enrol
femal
pegyl
interferon
rbv
patient
complet
week
therapi
hcv
rna
undetect
luml
patient
reach
undetectablebelow
rang
hcv
rna
virolog
breakthrough
observ
patient
overal
patient
complet
week
post
treatment
follow
achiev
svr
compens
cirrhosi
decompens
cirrhosi
patient
fail
therapi
relaps
one
decompens
cirrhosi
compens
cirrhosi
includ
treatment
treatment
experienc
four
patient
fail
therapi
receiv
concomit
rbv
advers
event
grade
drug
discontinu
relat
side
effect
two
patient
decompens
child
b
child
c
cirrhosi
die
underli
diseas
progress
therapi
conclus
interim
analysi
cohort
show
ldvsof
without
rbv
highli
effect
favor
safeti
profil
hcv
patient
underli
cirrhosi
rate
high
patient
categori
regardless
presenc
decompens
cirrhosi
prior
treatment
experi
treatment
gener
side
effect
disclosur
faisal
sanai
advisori
committe
review
panel
merck
sharp
dohm
bristol
myer
squibb
janssen
pharmaceut
gilead
scienc
abbvi
grant
research
support
roch
pharmaceut
bristol
myer
squibb
speak
teach
roch
pharmaceut
janssen
pharmaceut
gilead
scienc
bayer
schere
abbvi
ibrahim
h
altraif
advisori
committe
review
panel
gilead
consult
msd
abbvi
bristol
myer
grantresearch
support
roch
janssen
speak
teach
gsk
follow
peopl
noth
disclos
adnan
alzanbagi
moham
babatin
abdullah
alghamdi
hamdan
alghamdi
kahlid
alswat
abdulrahman
aljumah
abduljaleel
al
alwan
ayman
abdo
wale
k
abdullah
alaseeri
yaser
dahlan
ashwaq
alsahafi
hammad
alothmani
haziz
albiladi
background
rate
hepat
c
viru
hcv
posit
higher
patient
hemodialysi
gener
popul
sever
studi
report
hcv
infect
associ
poor
prognosi
hemodialysi
patient
therapi
show
lower
sustain
virolog
respons
rate
svr
hemodialysi
patient
patient
requir
dialysi
combin
oral
administ
daclatasvir
dcv
plu
asunaprevir
asv
effect
patient
infect
hcv
genotyp
expect
safe
chronic
hemodialysi
patient
drug
mainli
metabol
liver
studi
evalu
safeti
efficaci
dcv
plu
asv
combin
therapi
hemodialysi
patient
infect
hcv
method
nineteen
hemodialysi
patient
infect
hcv
genotyp
infect
treat
dcv
plu
asv
combin
therapi
decemb
januari
sixteen
patient
nine
men
seven
women
follow
week
end
treatment
svr
week
discontinu
therapi
dose
reduct
owe
advers
event
evalu
result
patient
three
treat
regimen
median
patient
age
year
rang
year
patient
older
age
year
seven
patient
compens
liver
cirrhosi
despit
two
patient
variant
rav
hcv
region
baselin
patient
achiev
one
patient
cirrhosi
discontinu
treatment
week
owe
onset
acut
pneumonia
anoth
patient
requir
asv
dose
reduct
owe
mild
hepat
disord
patient
recov
discontinu
dose
reduct
later
achiev
conclus
dcv
plu
asv
combin
therapi
hemodialysi
patient
infect
hcv
high
antivir
activ
toler
even
older
patient
patient
liver
cirrhosi
rav
disclosur
follow
peopl
noth
disclos
shiho
miyas
keiko
mizob
natsumi
tsukano
hirohumi
iwashita
shigetoshi
fujiyama
introduct
pivot
trial
report
outcom
novel
antivir
daa
therapi
elderli
patient
investig
effect
safeti
daa
regimen
patient
yr
age
vs
younger
patient
yr
method
deutsch
hepat
multicent
cohort
includ
approxim
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
analysi
includ
patient
initi
treatment
observ
least
week
initi
antivir
treatment
primari
effect
endpoint
result
patient
initi
treatment
yr
age
tabl
iit
pp
patient
yr
patient
yr
respect
cirrhot
patient
yr
itt
pp
compar
elderli
patient
yr
age
frequenc
advers
event
ae
patient
yr
yr
age
respect
proport
seriou
ae
higher
patient
yr
compar
patient
yr
overal
patient
die
year
age
conclus
despit
higher
proport
sae
daa
therapi
gener
safe
effect
elderli
patient
yr
overal
treatment
outcom
similar
observ
younger
patient
tabl
characterist
patient
initi
daa
therapi
disclosur
tania
welzel
advisori
committe
review
panel
novarti
janssen
gilead
abbvi
bm
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
albrecht
stoehr
advisori
committe
review
panel
abbvi
viiv
board
membership
msd
speak
teach
janssen
msd
gilead
abbvi
bm
viiv
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
tim
zimmermann
advisori
committe
review
panel
abbvi
speak
teach
bm
simon
advisori
committe
review
panel
abbvi
bm
janssen
msd
speak
teach
abbvi
bm
falk
gilead
janssen
norgin
merz
msd
holger
hinrichsen
advisori
committe
review
panel
bm
janssen
gilead
abbvi
speak
teach
msd
thoma
berg
advisori
committe
review
panel
gilead
bm
roch
tibotec
vertex
jannsen
novarti
abbott
merck
abbvi
consult
gilead
bm
roch
tibotec
vertex
janssen
grantresearch
support
gilead
bm
roch
tibotec
vertex
jannssen
merckmsd
boehring
ingelheim
novarti
abbvi
speak
teach
gilead
bm
roch
tibotec
vertex
janssen
merckmsd
novarti
merck
bayer
abbvi
heik
employ
efactum
gmbh
stefan
zeuzem
consult
abbvi
squibb
co
gilead
merck
co
janssen
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
introduct
aasldidsa
guidelin
hepat
c
viru
hcv
infect
state
test
hcv
rna
consid
end
antivir
treatment
eot
regimen
howev
remain
rather
unclear
respect
result
interpret
aim
studi
analyz
frequenc
predict
valu
detect
hcv
rna
result
eot
ledipasvir
sof
sofosbuvir
sof
rbv
larg
real
world
cohort
hcv
genotyp
infect
patient
method
deutsch
hepat
german
hepat
nation
multicent
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
subset
patient
fulfil
follow
inclus
criteria
chronic
hcv
genotyp
infect
b
complet
full
cours
antivir
treatment
either
week
c
avail
data
hcv
rna
measur
either
roch
coba
ampliprepcoba
taqman
capctm
abbott
realtim
hcv
assay
art
result
number
patient
fulfil
inclus
criteria
valid
hcv
rna
result
respect
eot
overal
svr
rate
among
patient
patient
treat
among
treat
without
rbv
hcv
rna
detect
patient
eot
almost
half
patient
even
viral
load
limit
quantif
howev
two
patient
detect
eot
result
fail
achiev
svr
rate
one
patient
detect
quantifi
hcv
rna
result
quantifi
viral
load
eot
detect
hcv
rna
eot
far
frequent
art
use
capctm
detect
hcv
rna
patient
hcv
rna
detect
patient
art
use
eot
conclus
almost
one
three
hcv
genotyp
patient
detect
even
quantifi
hcv
rna
result
end
therapi
art
use
howev
svr
rate
remain
high
patient
therefor
treatment
extend
disclosur
benjamin
maasoumi
advisori
committe
review
panel
abbott
molecular
grantresearch
support
abbott
molecular
roch
diagnost
speak
teach
msdmerck
roch
diagnost
roch
pharma
fujirebio
bm
abbvi
stefan
mauss
advisori
committe
review
panel
bm
abbvi
viiv
gilead
speak
teach
bm
abbvi
janssen
gilead
msd
peter
buggisch
advisori
committe
review
panel
janssen
abbvi
bm
speak
teach
falk
msd
gilead
merz
pharma
klau
h
boeker
consult
janssen
speak
teach
msd
roch
gilead
bm
falk
foundat
novarti
abbvi
rainer
speak
teach
roch
pharma
ag
gilead
abbvi
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
heik
employ
efactum
gmbh
hartwig
h
klinker
advisori
committe
review
panel
abbvi
bm
gilead
hexal
janssen
msd
grantresearch
support
abbvi
bm
gilead
janssen
msd
arrowhead
novarti
speak
teach
abbvi
bm
gilead
janssen
msd
eckart
schott
advisori
committe
review
panel
gilead
roch
bayer
bm
abbvi
janssen
msd
speak
teach
gilead
novarti
roch
msd
bayer
falk
bm
janssen
abbvi
christoph
sarrazin
advisori
committe
review
panel
squibb
janssen
merckmsd
gilead
roch
abbvi
janssen
merckmsd
consult
merckmsd
merckmsd
grantresearch
support
abbott
roch
merckmsd
gilead
janssen
abbott
roch
merckmsd
qiagen
speak
teach
gilead
novarti
abbott
roch
merckmsd
janssen
siemen
falk
abbvi
squibb
achillion
abbott
roch
merckmsd
janssen
heiner
wedemey
advisori
committe
review
panel
transgen
msd
roch
gilead
abbott
bm
falk
abbvi
novarti
gsk
roch
diagnost
eiger
consult
myrgmbh
grantresearch
support
msd
novarti
gilead
roch
abbott
roch
diagnost
speak
teach
bm
msd
novarti
itf
abbvi
gilead
dietrich
huepp
advisori
committe
review
panel
roch
msd
novati
gilead
bm
janssen
abbvi
johann
vermehren
advisori
committe
review
panel
abbvi
abbott
speak
teach
abbvi
squibb
gilead
medtron
german
hepat
grantresearch
support
abbvi
deutschland
gmbh
co
kg
squibb
gmbh
co
kgaa
gilead
scienc
gmbh
gmbh
msd
sharp
dohm
gmbh
roch
pharma
ag
aim
hepat
c
viru
hcv
one
import
agent
chronic
hepat
liver
cirrhosi
hepatocellular
carcinoma
far
daa
combin
therapi
one
effect
treatment
chronic
hepat
c
patient
effect
therapi
might
involv
immun
respons
compos
innat
immun
respons
adapt
immun
respons
aim
studi
examin
effect
daa
combin
therapi
innat
immun
respons
nk
cell
activ
frequenc
dim
bright
nk
cell
subset
peripher
blood
chronic
hepat
c
patient
patient
method
chronic
hepat
c
patient
hcv
genotyp
combin
therapi
daa
perform
asunaprevir
daclatasvir
fifteen
sofosbuvir
ledipasvir
five
ombitasvir
paritaprevir
ritonavir
three
ten
patient
male
thirteen
patient
femal
end
therapi
eot
nk
cell
activ
frequenc
nk
cell
nk
cell
peripher
blood
estim
cr
releas
assay
flowcytometri
statist
analysi
perform
anova
studi
approv
ethic
committe
institut
written
inform
consent
obtain
patient
procedur
studi
conduct
accord
declar
helsinki
result
analysi
anova
show
nk
cell
activ
significantli
improv
eot
compar
therapi
p
also
show
frequenc
dim
nk
cell
peripher
blood
significantli
increas
eot
compar
therapi
p
conclus
combin
therapi
daa
chronic
hepat
c
patient
improv
nk
cell
activ
increas
frequenc
nk
cell
peripher
blood
reveal
reduct
hcv
load
chronic
hepat
c
patient
could
restor
nk
cell
activ
reduc
hcv
therefor
result
studi
impli
daa
combin
therapi
might
abl
reduc
risk
hcc
chronic
hepat
c
patient
restor
activ
innat
immun
respons
disclosur
follow
peopl
noth
disclos
ikuo
nakamura
yoshihiro
furuichi
katsutoshi
sugimoto
yoshiyuki
kobayashi
background
egypt
hcv
infect
account
hcv
infect
larg
egyptian
phase
trial
enrol
previous
treat
pegifn
rbv
patient
infect
hcv
without
cirrhosi
arm
compens
cirrhosi
arm
bc
patient
receiv
antivir
agent
regimen
ombitasvir
obv
inhibitor
paritaprevir
ptv
proteas
inhibitor
ritonavir
r
pharmacokinet
enhanc
plu
ribavirin
rbv
method
patient
receiv
obvptvr
mg
daili
plu
rbv
overal
patient
without
cirrhosi
alloc
treatment
arm
patient
compens
cirrhosi
random
treatment
arm
b
treatment
arm
c
patient
follow
week
primari
object
assess
safeti
sustain
virolog
respons
week
post
treatment
assess
chang
liver
biomark
cirrhot
patient
baselin
bl
week
ptw
arm
b
arm
c
result
among
patient
compens
cirrhosi
rate
arm
itt
mitt
popul
exclud
failur
arm
rate
itt
mitt
popul
respect
advers
event
mainli
mildmoder
sever
patient
discontinu
due
advers
event
liver
biomark
includ
fibrosi
liver
function
show
improv
bl
arm
b
arm
c
tabl
final
data
liver
biomark
chang
present
conclus
hcv
egyptian
patient
compens
cirrhosi
treatment
obvptvr
rbv
week
well
toler
result
high
svr
rate
improv
bl
liver
biomark
ptw
patient
determin
magnitud
durabl
chang
disclosur
imam
wake
advisori
committe
review
panel
janssen
speak
teach
hoffman
l
roch
bm
gilead
abbvi
gamal
e
esmat
advisori
committe
review
panel
msd
bm
compani
msd
bm
compani
abbvi
grantresearch
support
gilead
sc
abbvi
speak
teach
roch
gsk
compani
roch
gsk
compani
gilead
sc
abbvi
moham
hassani
grantresearch
support
gilead
sc
abbvi
janssen
speak
teach
abbvi
marisol
martinez
employ
abbvi
stock
sharehold
abbvi
roula
b
qaqish
stock
sharehold
abbvi
coleen
hall
employ
abbvi
stock
sharehold
abbvi
niloufar
mobasheri
employ
abbvi
stock
sharehold
abbvi
follow
peopl
noth
disclos
rabab
f
omar
naglaa
allam
moham
mohey
ayman
yosri
gamal
shiha
reham
soliman
background
although
novel
antivir
daa
achiev
high
sustain
virolog
respons
svr
rate
chronic
hepat
c
hcv
global
access
daa
limit
due
high
price
reduc
price
offer
voluntari
licens
avail
countri
repres
worldwid
epidem
price
activ
pharmaceut
ingredi
api
steadi
high
demand
volum
key
determin
total
product
cost
medicin
aim
studi
calcul
current
feasibl
price
daa
assum
larg
volum
demand
competit
manufactur
method
data
price
volum
api
export
india
analys
onlin
databas
http
wwwinfodriveindiacom
linear
regress
model
calcul
weight
shipment
size
given
lack
export
data
velpatasvir
api
cost
calcul
analysi
chemic
synthesi
cost
raw
materi
cost
api
requir
combin
estim
cost
formul
excipi
packag
profit
margin
ad
result
export
volum
india
sofosbuvir
kg
equival
treatment
cours
daclatasvir
kg
cours
ledipasvir
kg
cours
api
price
decreas
throughout
time
frame
mean
api
price
june
sofosbuvir
daclatasvir
ledipasvir
api
cost
velpatasvir
estim
us
price
time
higher
target
price
sofosbuvir
time
daclatasvir
time
higher
sofosbuvirledipasvir
conclus
hcv
daa
product
cost
fall
rapidli
treatment
sofosbuvir
manufactur
estim
daclatasvir
sofosbuvirledipasvir
velpatasvir
target
price
includ
profit
margin
gener
supplier
price
show
potenti
mass
treatment
hepat
c
access
program
similar
use
peopl
hivaid
calcul
target
price
current
price
daa
treatment
cours
price
usd
disclosur
anton
pozniak
advisori
committe
review
panel
viiv
merck
janssen
gilead
bm
grantresearch
support
viiv
merck
janssen
gilead
bm
speak
teach
viiv
merck
janssen
gilead
bm
cco
webmd
follow
peopl
noth
disclos
andrew
hill
dzintar
gotham
melissa
barber
joseph
fortunak
background
hivhcv
coinfect
patient
high
preval
medic
psychiatr
diseas
may
limit
access
hcv
therapi
recent
trial
daa
therapi
hivhcv
coinfect
patient
demonstr
high
svr
rate
similar
observ
hcv
monoinfect
howev
generaliz
result
question
due
clinic
trial
set
exclus
certain
antiretrovir
goal
analysi
describ
preval
medic
psychiatr
diseas
ddi
interact
hivhcv
coinfect
subject
enrol
gilead
trial
method
integr
analysi
data
hivhcv
coinfect
patient
enrol
phase
registr
trial
sofosbuvir
sof
ribavirin
rbv
week
ledipasvir
ldv
sof
rbv
week
sofvelpatasvir
vel
week
perform
patient
sever
medic
psychiatr
condit
exclud
trial
assess
demograph
medic
histori
concomit
medic
safeti
efficaci
present
result
total
patient
includ
analysi
major
enrol
unit
state
across
studi
high
preval
hypertens
reflux
diseas
gerd
hyperlipidemia
high
proport
psychiatr
comorbid
includ
depress
anxieti
prior
ongo
substanc
abus
report
patient
rate
similar
describ
recent
analysi
hivhcv
coinfect
patient
us
meyer
n
et
al
icaac
studi
conduct
europ
smaller
proport
report
medic
psychiatr
comorbid
overal
svr
rate
rang
base
treatment
regimen
similar
observ
hcv
monoinfect
patient
conclus
use
daa
regimen
result
abil
success
treat
hivhcv
coinfect
patient
complex
comorbid
clinic
trial
generaliz
real
world
practic
disclosur
mark
sulkowski
advisori
committe
review
panel
merck
abbvi
janssen
gilead
trek
cocryst
grantresearch
support
merck
abbvi
janssen
gilead
curti
cooper
advisori
committe
review
panel
gilead
abbvi
merck
grantresearch
support
merck
gilead
abbvi
speak
teach
merck
abbvi
gilead
molina
board
membership
gilead
bm
janssen
merck
abbott
boehring
grantresearch
support
merck
speak
teach
merck
gilead
bm
susanna
naggi
advisori
committe
review
panel
merck
grant
research
support
tacer
gilead
abbvi
bm
jenssen
merck
anu
osinusi
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
luisa
stamm
employ
gilead
scienc
benedetta
massetto
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
john
mcnalli
employ
gilead
scienc
stock
sharehold
gilead
scienc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
john
g
mchutchison
employ
gilead
stock
sharehold
gilead
david
l
wyle
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
abbvi
grantresearch
support
gilead
merck
bristol
myer
squibb
abbvi
tacer
k
rockstroh
advisori
committe
review
panel
abbvi
cipla
bm
merck
roch
tibotec
abbvi
bionor
tobira
viiv
abbott
gilead
janssen
consult
novarti
grantresearch
support
gilead
merck
speak
teach
bm
merck
siemen
tibotec
gilead
janssen
viiv
dougla
dieterich
advisori
committe
review
panel
gilead
bm
abbvi
janssen
merck
achillion
follow
peopl
noth
disclos
k
c
huang
background
phase
iii
registr
trial
ritonavir
boost
paritaprevir
ombitasvir
dasabuvir
prod
ribavirin
safe
well
toler
excel
efficaci
rate
howev
data
safeti
efficaci
prod
therapi
cirrhot
patient
limit
method
octob
juli
compassion
access
program
support
abbvi
pti
ltd
conduct
australia
across
treatment
center
patient
includ
receiv
least
one
dose
prod
primari
hcv
viral
load
lloq
least
week
post
treatment
drug
discontinu
rate
due
advers
event
frequenc
natur
seriou
advers
event
particular
focu
death
hepat
decompens
grade
biochem
abnorm
collect
result
current
analysi
patient
cirrhosi
cpb
complet
treatment
outcom
data
avail
overal
svr
rate
similar
cirrhot
patient
respect
patient
infect
genotyp
receiv
ribavirin
baselin
featur
fulli
character
patient
shown
tabl
similar
previou
report
baselin
viral
load
meld
score
liver
stiff
influenc
svr
earli
cessat
therapi
occur
patient
patient
lower
hyperbilirubinaemia
therapi
common
patient
develop
hyperbilirubinaemia
date
death
report
patient
requir
hospit
admiss
patient
develop
hepat
decompens
grade
laboratori
abnorm
occur
patient
conclus
set
treatment
prod
genotyp
hcv
infect
achiev
excel
rate
includ
cirrhosi
hepat
decompens
occur
infrequ
baselin
paramet
disclosur
john
lubel
advisori
committe
review
panel
gilead
abbvi
bayer
grantresearch
support
bm
msd
abbvi
speak
teach
gilead
abbvi
bm
jansen
roch
stephen
pianko
advisori
committe
review
panel
roch
novarti
gilead
roch
novarti
consult
gilead
speak
teach
janssen
bm
alex
j
thompson
advisori
committe
review
panel
gilead
abbvi
bm
merck
spring
bank
pharmaceut
arrowhead
roch
grantresearch
support
gilead
abbvi
bm
merck
speak
teach
roch
gilead
abbvi
bm
david
iser
speak
teach
abbvi
bristol
myer
squibb
gilead
janssen
merck
roch
simon
strasser
advisori
committe
review
panel
abbvi
msd
squibb
gilead
norgin
bayer
healthcar
speak
teach
roch
product
australia
bayer
healthcar
squibb
msd
gilead
abbvi
gregori
dore
board
membership
gilead
merck
abbvi
squibb
grantresearch
support
gilead
merck
abbvi
squibb
speak
teach
gilead
merck
abbvi
squibb
katherin
stuart
advisori
committe
review
panel
gilead
bayer
abbvi
grantresearch
support
roch
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
amani
zekri
advisori
committe
review
panel
gilead
bm
msd
abbvi
miriam
levi
advisori
committe
review
panel
bayer
grantresearch
support
gilead
vinc
fragom
advisori
committe
review
panel
roch
msd
jansen
brenda
moral
advisori
committe
review
panel
msd
jansen
roch
abbvi
bm
joe
sasadeusz
advisori
committe
review
panel
merck
gilead
bm
grantresearch
support
roch
gilead
avvbi
speak
teach
gila
merck
bm
merck
amanda
j
wade
grantresearch
support
abbvi
stuart
k
robert
board
membership
abbvi
gilead
follow
peopl
noth
disclos
joann
mitchel
alessia
gazzola
sarah
chiver
gauri
mishra
john
gough
edmund
tse
gerri
c
macquillan
paul
gow
saroj
nazareth
steven
j
bollipo
tracey
l
jone
introduct
sustain
virolog
respons
svr
due
antivir
therapi
associ
chang
biochem
marker
liver
function
far
littl
known
effect
svr
liver
fibrosi
therefor
investig
effect
daa
base
hcv
therapi
fibrosi
measur
transient
elastographi
te
method
period
month
treat
total
patient
daa
base
therapi
patient
baselin
evalu
includ
te
svr
total
patient
follow
least
week
post
treatment
includ
te
te
result
classifi
reliabl
reliabl
iqrm
reliabl
iqrm
patient
devid
two
group
cirrhosi
non
cirrhosi
accord
te
result
cut
patient
correct
te
result
includ
result
patient
total
femal
median
age
femal
iqr
male
iqr
distribut
genotyp
follow
considd
previou
treatment
includ
pi
base
regim
patient
includ
evalu
achiev
svr
baselin
bl
te
result
shown
tabl
subgroup
cirrhot
patient
correct
te
kpa
show
regress
fibrosi
accord
te
evalu
proven
regress
bl
te
measur
iqr
fup
te
result
show
iqr
conclus
svr
hcv
patient
due
daa
therapi
appear
induc
regress
fibrosi
patient
moreov
signific
proport
patient
te
proven
cirrhosi
notic
stage
migrat
work
underlin
downstag
fibrosi
even
cirrhot
patient
could
happen
howev
histolog
verif
lack
one
might
wonder
whether
subgroup
cirrhot
fibrosi
regress
te
declin
translat
less
liver
relat
endpoint
therefor
longer
observ
patient
plan
te
result
differ
patient
popul
bl
baselin
te
transient
elastographi
fup
follow
disclosur
stephani
hametn
speak
teach
msd
bm
gilead
scienc
abbvi
alexand
ziachehabi
advisori
committe
review
panel
msd
grant
research
support
gilead
speak
teach
msd
andrea
maieron
advisori
committe
review
panel
msd
jannsen
bm
bdhringer
ingelheim
gilead
abbvi
grantresearch
support
roch
speak
teach
roch
msd
jannsen
gilead
abbvi
follow
peopl
noth
disclos
remi
schwarzer
rainer
background
given
potenti
side
effect
rbv
assess
impact
hrql
asian
patient
hcv
method
short
administ
treatment
clinic
trial
sofosbuvir
sof
regimen
ledipasvir
ldv
sof
sofrbv
south
korea
hong
kong
taiwan
hrql
score
compar
patient
receiv
ldvsof
sofrbv
result
patient
enrol
sofrbv
hcv
genotyp
ldvsof
genotyp
patient
cirrhot
report
overt
fatigu
rate
sofrbv
ldvsof
baselin
score
similar
two
group
howev
soon
treatment
number
hrql
declin
receiv
sofrbv
point
end
treatment
p
contrast
improv
hrql
score
receiv
ldvsof
observ
start
improv
continu
throughout
treatment
end
treatment
p
notabl
hrql
decrement
observ
ldvsof
treatment
cessat
receiv
rbv
decrement
observ
hrql
impair
resolv
p
contrast
complet
ldv
sof
hrql
improv
p
multivari
analysi
use
rbv
independ
associ
mild
impair
hrql
beta
rang
point
physic
mental
summari
score
util
p
conclus
use
rbv
associ
mild
impair
hrql
asian
patient
hcv
ldvsof
lead
improv
hrql
treatment
acheiv
svr
figur
averag
hrql
score
asian
patient
disclosur
chuang
advisori
committe
review
panel
gilead
abbvi
roch
pharmaessentia
speak
teach
gilead
roch
bm
msd
pharmaessentia
henri
chan
advisori
committe
review
panel
gilead
janssen
squibb
roch
novarti
pharmaceut
abbvi
speak
teach
echosen
lim
advisori
committe
review
panel
bayer
healthcar
gilead
scienc
grantresearch
support
bayer
healthcar
bm
gilead
scienc
novarti
peng
advisori
committe
review
panel
abbvi
bm
gilead
msd
roch
chu
advisori
committe
review
panel
gilead
speak
teach
bm
merck
abbvi
roch
lai
advisori
committe
review
panel
squibb
gilead
scienc
inc
consult
squibb
gilead
scienc
inc
speak
teach
squibb
gilead
scienc
inc
stock
sharehold
gilead
scienc
follow
peopl
noth
disclos
zobair
younossi
maria
stepanova
han
chien
sang
hoon
ahn
jeong
chang
seung
woon
paik
lee
kao
sharon
hunt
assess
efficaci
safeti
clinic
outcom
therapi
advanc
liver
diseas
current
monitor
platform
navigator
hcv
patient
treat
oral
daa
vast
geograph
area
northeast
itali
time
analysi
treat
patient
includ
male
mean
age
cirrhosi
child
child
b
child
c
extrahepat
diseas
fibrosi
diabet
present
cvd
obes
nephropathi
patient
treat
accord
guidelin
monitor
monthli
therapi
everi
month
thereaft
efficaci
safeti
analysi
describ
tabl
efficaci
excel
group
significantli
affect
comorbid
howev
reduc
around
patient
child
b
cirrhosi
toler
safeti
excel
patient
child
cirrhosi
reduc
child
b
patient
particularli
treat
ribavirin
conclus
result
confirm
excel
efficaci
safeti
daabas
oral
hcv
treatment
compens
diseas
result
child
b
cirrhosi
appear
somehow
compromis
lower
toler
rbv
contain
regimen
disclosur
anna
maria
cattelan
advisori
committe
review
panel
abbot
consult
bm
viiv
patrizia
burra
grantresearch
support
novarti
astella
kedrion
grifol
biotest
gilead
alfawassermann
antonio
carlotto
advisori
committe
review
panel
abbvi
paolo
ang
advisori
committe
review
panel
sequana
medic
nanoantibiot
franco
capra
independ
contractor
msd
speak
teach
gilead
scienc
giada
carolo
board
membership
abbvi
speak
teach
bm
alfredo
alberti
advisori
committe
review
panel
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
merck
roch
gilead
abbvi
janssen
grantresearch
support
merck
gilead
merck
gilead
merck
gilead
merck
gilead
abbvi
janssen
speak
teach
novarti
bm
novarti
bm
novarti
bm
novarti
bm
follow
peopl
noth
disclos
marta
milan
piergirogio
scotton
luca
g
cavallaro
monica
basso
sandro
panes
diego
tempesta
sara
piovesan
david
campagnolo
francesco
p
russo
alessandro
vario
paolo
fabri
tosca
bertin
maurizio
carrara
liliana
chemello
pierangelo
rover
salvator
lobello
silvia
adami
giovanna
scroccaro
introduct
hepat
c
viru
hcv
genotyp
gt
repres
total
global
hcv
infect
clinic
trial
show
efficaci
oral
antivir
therapi
studi
assess
effect
safeti
sofosfuvirledipasvir
sofl
paritaprevirritonavirombitasvir
without
ribavirin
patient
chronic
hcv
infect
materi
method
retrospect
multicentr
prospect
collect
data
nation
studi
includ
naiv
treatment
experienc
patient
hcv
gt
infect
treat
sofl
patient
least
svr
select
analysi
result
cohort
shown
separ
result
total
cohort
includ
patient
svr
data
global
respect
patient
treat
sofl
patient
male
mean
age
year
patient
child
b
c
patient
receiv
ribavirin
week
respect
four
patient
experienc
virolog
failur
relaps
approxim
patient
report
least
one
seriou
advers
event
sae
one
patient
experienc
hepat
decompens
ascit
patient
discontinu
therapi
patient
die
treatment
subcohort
sofl
bilirubin
mgdl
baselin
factor
associ
lack
respons
none
baselin
factor
investig
significantli
associ
sae
multivari
analysi
patient
treat
without
riba
patient
male
mean
age
year
child
b
patient
receiv
ribavirinth
week
respect
one
patient
experienc
virolog
failur
relaps
sae
report
patient
one
patient
hepat
decompens
encephalopathi
patient
die
treatment
baselin
factor
significantli
associ
failur
achiev
treatment
multivari
analysi
bilirubin
mgdl
albumin
gdl
p
baselin
albumin
p
platelet
significantli
associ
develop
sae
conclus
two
regimen
evalu
sofosfuvirledipasvir
ombitasvirparitaprevirritonavir
without
rbv
achiev
high
rate
efficaci
svr
respect
clinic
practic
good
safeti
profil
associ
minimum
rate
treatment
discontinu
disclosur
javier
crespo
advisori
committe
review
panel
abbvi
janssen
bm
grantresearch
support
msd
gilead
jose
l
calleja
advisori
committe
review
panel
gilead
abbvi
speak
teach
abbvi
gilead
janssen
bm
javier
consult
gilead
janssen
abbvi
maria
buti
advisori
committe
review
panel
gilead
janssen
msd
grantresearch
support
gilead
janssen
speak
teach
gilead
janssen
bm
rosa
morilla
advisori
committe
review
panel
bristol
gilead
abbvi
speak
teach
roch
janssen
msd
juan
turn
advisori
committe
review
panel
gilead
abbvi
janssen
bm
speak
teach
gilead
abbvi
janssen
msd
bm
federico
speak
teach
gilead
scienc
sl
abbvi
spain
slu
juan
arena
advisori
committe
review
panel
abbvi
speak
teach
msd
bm
gilead
martin
prieto
advisori
committe
review
panel
gilead
abbvi
bristol
juan
ruano
advisori
committe
review
panel
gilead
speak
teach
gilead
abbvi
bm
janssen
follow
peopl
noth
disclos
sacristran
belen
javier
ampuero
francisco
gea
sabela
len
joaquin
cabeza
jose
ramon
salcin
juan
manuel
pascasio
diego
francisco
jorquera
carmen
navascu
esther
molina
xavier
torra
silvia
montoliu
jose
moreno
miguel
angel
serra
raul
j
andrad
conrado
miguel
miguel
simon
lucia
bonet
juan
de
la
vega
mois
diago
jose
ramon
fernandez
gloria
inmaculada
fernandez
background
data
describ
clinic
outcom
antivir
daa
therapi
among
patient
infect
hepat
c
viru
hcv
gener
healthcar
set
limit
examin
outcom
among
patient
chronic
hepat
cohort
studi
chec
observ
studi
conduct
us
healthcar
organ
method
patient
began
daa
regimen
januari
includ
analysi
examin
frequenc
treatment
complet
sustain
viral
respons
svr
week
vs
svr
sociodemograph
clinic
factor
conduct
multivari
analysi
identifi
factor
independ
associ
svr
result
patient
began
initi
daa
regimen
studi
period
treatment
experienc
cirrhosi
black
race
hcv
genotyp
mix
genotyp
infect
overal
patient
receiv
sofosbuvir
sof
regimen
without
ledipasvir
ldv
e
sof
simeprevir
daclatasvir
ribavirin
rbv
receiv
sof
ldv
rbv
patient
receiv
regimen
patient
avail
svr
data
achiev
svr
among
patient
frequenc
svr
rang
sof
without
ldv
rbv
sof
ldv
rbv
among
sof
regimen
without
ldv
rbv
sof
ldv
rbv
frequenc
svr
among
patient
infect
respect
multivari
analysi
control
variabl
sole
factor
independ
associ
svr
receipt
sof
ldv
rbv
aor
vs
sof
regimen
without
ldv
rbv
neither
age
sex
raceethn
previou
treatment
statu
presenc
cirrhosi
genotyp
comorbid
score
bodi
mass
index
hiv
coinfect
associ
svr
patient
initi
treatment
either
complet
treatment
yet
svr
data
avail
still
receiv
treatment
close
studi
period
stop
treatment
earli
conclus
among
patient
receiv
daa
gener
healthcar
set
half
cirrhosi
previou
treatment
frequenc
treatment
complet
svr
high
receipt
regimen
sof
ldv
associ
lower
likelihood
achiev
svr
disclosur
stuart
c
gordon
advisori
committe
review
panel
gilead
abbvi
merck
intercept
consult
cv
caremark
grantresearch
support
cymba
bay
gilead
bm
abbvi
intercept
conatu
exalenz
merck
speak
teach
gilead
intercept
mark
schmidt
grantresearch
support
takeda
pharmaceut
intercept
pharmaceut
incyt
pharmaceut
gilead
pharmaceut
follow
peopl
noth
disclos
philip
r
spradl
jian
xing
lorale
b
rupp
ann
c
moorman
mei
lu
eyasu
h
teshal
joseph
boscarino
yihe
daida
scott
holmberg
introduct
hepat
c
viru
hcv
infect
approxim
time
common
among
us
veteran
receiv
care
veteran
affair
va
medic
center
among
gener
popul
infect
classifi
genotyp
histor
hcv
therapi
less
success
veteran
gener
popul
comorbid
psychiatr
disord
regular
alcoholtobacco
use
may
account
differ
ombitasvir
paritaprevirritonavir
dasabuvir
ribavirin
rbv
approv
us
hcv
adult
without
cirrhosi
studi
prospect
evalu
safeti
efficaci
hcv
us
veteran
includ
patient
ongo
psychiatr
disord
current
past
alcoholtobacco
use
method
phase
trial
conduct
hcv
us
veteran
without
cirrhosi
us
va
medic
center
particip
receiv
rbv
except
individu
receiv
treatment
durat
week
except
patient
cirrhosi
week
sustain
virolog
respons
resist
variant
advers
event
ae
assess
result
select
baselin
demograph
present
tabl
current
alcohol
consumpt
tobacco
use
report
baselin
patient
respect
addit
patient
report
ongo
psychiatr
disord
achiev
patient
ongo
psychiatr
disord
inten
popul
miss
data
imput
failur
total
patient
experienc
ae
commonli
fatigu
headach
nausea
seriou
ae
observ
patient
consid
case
patient
discontinu
treatment
due
ae
conclus
hcv
us
veteran
rbv
associ
high
rate
well
toler
presenc
psychiatr
disord
alcohol
consumpt
appear
impact
avail
safeti
efficaci
resist
result
present
disclosur
michael
fuch
grantresearch
support
intercept
galectin
conatu
abbvi
gilead
timothi
r
morgan
grantresearch
support
merck
abbvi
genentech
gilead
bristol
myer
squibb
mariem
charafeddin
employ
abbvi
ltd
stock
sharehold
abbvi
ltd
michael
kozal
grantresearch
support
glaxosmithklin
bristol
myer
squib
merck
abbvi
gilead
viiv
vertex
pathogenica
pfizer
holog
tiam
cytodyn
patent
heldfil
stanford
univers
susanna
naggi
advisori
committe
review
panel
merck
grant
research
support
tacer
gilead
abbvi
bm
jenssen
merck
ramsey
cheung
grantresearch
support
gilead
scienc
abbvi
tami
employ
abbvi
stock
sharehold
abbott
yao
yu
employ
abbvi
kristin
richard
employ
abbvi
stock
sharehold
abbvi
daniel
e
cohen
employ
abbvi
stock
sharehold
abbvi
follow
peopl
noth
disclos
norbert
warren
n
schmidt
victoria
mullal
alexand
monto
dori
h
toro
purpos
hepat
c
viru
hcv
caus
inflamm
hepatocyt
time
lead
cirrhosi
addit
effect
liver
caus
extrahepat
complic
insulin
resist
studi
demonstr
associ
hcv
progress
insulin
resist
diabet
well
improv
glycem
control
upon
virolog
respons
howev
clinic
impact
improv
glycem
control
diabet
patient
achiev
sustain
virolog
respons
week
unknown
object
primari
object
studi
determin
impact
antihyperglycem
medic
need
patient
achiev
hcv
antivir
daa
secondari
object
determin
impact
antihyperglycem
medic
need
patient
relaps
determin
impact
hemoglobin
patient
achiev
methodolog
patient
diagnosi
diabet
complet
cours
hcv
daa
februari
octob
identifi
use
code
medic
dispens
histori
retrospect
patient
data
collect
electron
medic
record
endpoint
chang
antihyperglycem
medic
categor
chang
escal
baselin
end
hcv
treatment
baselin
month
patient
achiev
secondari
endpoint
includ
chang
antihyperglycem
medic
relaps
chang
baselin
month
achiev
descript
statist
use
endpoint
pair
use
data
result
patient
patient
met
inclus
criteria
major
patient
male
mean
age
primarili
black
advanc
fibrot
liver
diseas
present
patient
patient
achiev
antihyperglycem
baselin
month
compar
hcv
daa
relaps
avail
data
patient
achiev
show
statist
signific
decreas
percentag
point
ci
conclus
studi
found
clinic
meaning
antihyperglycem
well
signific
decreas
c
diabet
patient
abl
achiev
hcv
daa
demonstr
addit
potenti
benefit
close
diabet
hcv
treatment
warrant
prospect
larger
studi
need
valid
result
disclosur
follow
peopl
noth
disclos
sheena
b
leclerc
yngve
corinna
kristina
pascuzzi
christoph
burant
kelsey
rife
backgroundaim
ddi
repres
main
limit
current
daa
hcv
determin
preval
use
ddi
potenti
chc
patient
pt
greec
method
consecut
chc
pt
yr
seen
outpati
liver
clinic
tertiari
greek
center
pt
center
includ
hiv
coinfect
pt
exclud
demograph
habit
lab
test
hcv
liver
diseas
characterist
record
classifi
nono
clear
data
ddi
potenti
ddi
contraind
daa
accord
hep
drug
interact
checker
liverpool
univ
result
least
one
present
pt
pt
chronic
contraind
due
ddi
present
pt
pt
simeprevir
smv
pt
sofosbuvir
sof
daclatasvir
dcv
ledipasvirsofosbuvir
ldv
sof
p
contraindicationspotenti
ddi
frequent
present
proteas
inhibitor
inh
contain
agent
inh
p
sof
p
vs
inh
p
vs
inh
tabl
contraind
potenti
ddi
frequent
present
pt
age
yr
p
p
daa
genotyp
g
daa
p
except
ldvsof
tabl
multivari
analys
presenc
contraindicationspotenti
ddi
agent
independ
associ
fibrosi
conclus
contraindicationspotenti
ddi
current
daa
frequent
present
inh
also
present
inh
sof
probabl
ddi
higher
pt
prioriti
daa
therapi
eg
advanc
liver
diseas
therefor
caution
care
select
appropri
daa
regimen
warrant
clinic
practic
tabl
patient
contraind
due
ddi
potenti
ddi
hcv
daa
fibrosi
stage
unknown
pt
genotyp
g
unknown
pt
disclosur
georg
v
papatheodoridi
advisori
committe
review
panel
merck
sharp
dohm
novarti
abbvi
boerhing
ingelheim
squibb
gilead
roch
janssen
glaxosmith
klein
grantresearch
support
roch
gilead
squibb
abbvi
janssen
speak
teach
merck
sharp
dohm
squibb
gilead
roch
janssen
abbvi
spilio
manolakopoulo
advisori
committe
review
panel
novarti
abbvi
msd
bm
gilead
jannsen
consult
gilead
bm
abbvi
jannsen
msd
grantresearch
support
bm
gilead
speak
teach
abbvi
msd
gilead
bm
gsk
jannsen
christo
tsoula
employ
gilead
scienc
stock
sharehold
gilead
scienc
follow
peopl
noth
disclos
john
gouli
christo
k
trianto
kalliopi
zachou
margarita
papatheodoridi
argyro
koukoufiki
anastasia
kourik
konstantino
zisimopoulo
georg
n
daleko
background
patient
decompens
hcv
limit
treatment
option
poor
prognosi
recent
fda
approv
treatment
ldvsofrbv
gt
decompens
patient
base
studi
dataset
import
show
generaliz
clinic
trial
data
data
uk
expand
access
program
eap
compar
clinic
trial
data
decompens
hcv
patient
method
data
trial
compar
data
uk
eap
collect
month
hcv
patient
treat
ldvsofrbv
uk
eap
cohort
select
base
size
avail
compar
data
svr
relaps
rate
meld
improv
safeti
present
result
high
svr
rate
observ
uk
eap
meld
improv
month
similar
within
cpt
class
eap
among
achiev
svr
vs
vs
respect
ldvsofrbv
gener
safe
death
rate
low
attribut
treatment
frequent
observ
patient
see
tabl
conclus
hcv
gt
patient
decompens
cirrhosi
achiev
high
cure
rate
compar
meld
improv
ldvsofrbv
clinic
trial
safeti
consist
known
diseas
progress
popul
advanc
liver
diseas
impact
svr
meld
improv
clinic
outcom
unknown
disclosur
michael
r
charlton
consult
gilead
scienc
grantresearch
support
gilead
scienc
merck
janssen
abbvi
novarti
intercept
michael
p
mann
consult
roch
bm
gilead
boehring
ingelheim
novarti
enyo
pharma
eiger
gsk
merckmsd
janssen
medgen
biotest
abbvi
grantresearch
support
merckmsd
roch
gilead
novarti
boehring
ingelheim
bm
abbvi
janssen
speak
teach
merckmsd
roch
bm
gilead
janssen
gsk
novarti
abbvi
nika
saje
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
philip
troke
employ
gilead
scienc
ltd
stock
sharehold
gilead
scienc
ltd
jame
g
spellman
employ
gilead
scienc
stock
sharehold
gilead
scienc
amanda
copan
employ
gilead
scienc
sarah
arterburn
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
diana
brainard
employ
gilead
scienc
stock
sharehold
gilead
scienc
william
irv
advisori
committe
review
panel
novarti
msd
janssen
cilag
bristol
myer
squibb
grantresearch
support
gsk
pfizer
janssen
cilag
gilead
scienc
abbvi
speak
teach
janssen
cilag
roch
graham
r
foster
advisori
committe
review
panel
glaxosmithklin
novarti
boehring
ingelheim
tibotec
gilead
janssen
idenix
glaxosmithklin
novarti
roch
tibotec
chughai
gilead
merck
janssen
idenix
bm
alnylam
board
membership
boehring
ingelheim
grantresearch
support
roch
chughai
springbank
speak
teach
roch
gilead
tibotec
merck
bm
boehring
ingelheim
gilead
janssen
follow
peopl
noth
disclos
michel
c
cheung
background
aim
improv
cognit
function
liver
transplant
lt
relat
decreas
cerebr
white
matter
lesion
induc
microvascular
lesion
leukoaraiosi
secondari
cerebr
edema
system
inflamm
howev
studi
address
chang
acut
set
immedi
lt
cirrhosi
well
acut
liver
failur
evalu
chang
cerebr
hemodynam
popul
therefor
aim
investig
chang
cerebr
hemodynam
cirrhot
patient
lt
method
prospect
cohort
studi
perform
transcrani
doppler
ultrasonographi
tcd
measur
pulsatil
index
pi
resist
index
ri
index
bhi
middl
cerebr
arteri
pre
pi
ri
bhi
evalu
cerebrovascular
structur
integr
reactiv
respect
neuropsychometr
test
criteria
use
hepat
encephalopathi
character
address
system
inflamm
measur
plasma
level
descript
statist
wilcoxon
test
use
result
patient
includ
male
median
follow
lt
month
median
age
year
main
etiolog
hepat
c
viru
patient
b
meld
score
phe
cff
previou
lt
patient
ascit
decreas
pi
ri
observ
patient
except
lt
increas
bhi
chang
cerebr
hemodynam
parallel
system
inflamm
tabl
clinic
improv
cognit
observ
patient
overt
lt
conclus
result
show
improv
cerebr
hemodynam
lt
cirrhosi
indic
less
arteri
cerebr
vasoconstrict
decreas
piri
seem
influenc
system
inflamm
could
explain
improv
cognit
function
lt
tcd
could
consid
use
tool
assess
chang
cerebr
hemodynam
pre
cirrhosi
tabl
chang
cerebr
hemodynam
inflammatori
marker
lt
result
express
mean
sd
median
iqr
disclosur
follow
peopl
noth
disclos
ricardo
astrid
carlo
francisco
javier
cubero
octavio
elena
aldo
torr
background
biomark
profil
diagnost
acut
reject
ar
could
enhanc
diagnosi
manag
liver
transplant
lt
recipi
aim
identifi
diagnost
genom
mrna
signatur
ar
distinct
patient
caus
graft
dysfunct
normal
function
method
lt
recipi
undergo
liver
biopsi
caus
blood
collect
mrna
express
plu
peg
microarray
two
independ
pathologist
hepatologist
confirm
follow
phenotyp
tx
normal
function
ar
hepat
c
recurr
mix
blood
analysi
discoveri
train
set
gener
lock
classif
model
phenotyp
test
second
valid
set
use
leaveon
loocv
addit
subset
biopsi
tissu
underw
discoveri
comparison
ar
vs
vs
result
lt
recipi
tx
ar
age
year
male
mean
year
lt
analyz
predict
accuraci
signatur
differenti
ar
tx
well
high
vari
base
cv
vs
loocv
model
tabl
biopsi
tissu
mrna
profil
differenti
ar
mix
hcvar
accuraci
biolog
function
canon
pathway
map
blood
graft
profil
suggest
sever
immuneinflammatori
gene
differenti
express
recipi
ar
vs
etiolog
conclus
identifi
blood
graft
mrna
signatur
distinguish
ar
major
caus
graft
injuri
lt
recipi
high
accuraci
biomark
may
use
manag
lt
recipi
diagnos
ar
immun
monitor
guid
immunosuppress
modif
sampl
recent
complet
prospect
multicent
studi
niaid
use
extern
valid
signatur
test
predict
valu
prior
ar
predict
accuraci
blood
mrna
profil
acut
reject
lt
recipi
disclosur
josh
levitski
consult
transplant
genom
incorpor
sunil
kurian
stock
sharehold
transplant
genom
inc
daniel
r
salomon
grantresearch
support
transplant
genom
inc
michael
abecassi
consult
transplant
genom
inc
stock
sharehold
transplant
genom
inc
follow
peopl
noth
disclos
tom
whisen
anthoni
j
demetri
background
primari
scleros
cholang
psc
recur
postliv
transplant
lt
patient
given
lack
diseas
alter
therapi
recurr
psc
common
caus
graft
loss
need
patient
method
data
scientif
registri
transplant
recipi
databas
transplant
util
evalu
outcom
patient
psc
underw
patient
year
old
transplant
acut
liver
failur
graft
surviv
day
exclud
predictor
popul
well
predictor
graft
loss
follow
evalu
cox
proport
hazard
analysi
result
patient
underw
primari
lt
studi
period
psc
significantli
common
patient
psc
compar
patient
without
psc
v
p
among
patient
psc
baselin
characterist
similar
patient
without
except
significantli
younger
like
male
like
receiv
donor
cardiac
death
organ
dcd
experi
acut
reject
multivari
analys
age
hr
p
male
sex
hr
p
donor
risk
index
dri
per
increas
hr
p
deceas
donor
hr
dcd
hr
p
acut
reject
hr
p
independ
predictor
mean
age
year
mean
lab
meld
except
median
time
sinc
initi
lt
iqr
month
median
iqr
month
year
graft
surviv
significantli
higher
patient
psc
compar
patient
vs
respect
p
age
p
dri
increas
hr
deceas
donor
p
independ
predict
graft
loss
common
caus
death
follow
infect
follow
malign
graft
failur
conclus
lt
recipi
psc
requir
commonli
patient
transplant
diseas
donor
characterist
includ
dri
dcd
well
reject
may
play
import
role
predict
graft
loss
fortun
graft
surviv
follow
patient
psc
significantli
higher
patient
without
psc
may
provid
prolong
surviv
popul
disclosur
robert
brown
advisori
committe
review
panel
vital
therapi
consult
gilead
janssen
abbvi
merck
bm
elizabeth
c
verna
grantresearch
support
salix
merck
follow
peopl
noth
disclos
shria
kumar
dustin
carpent
mariana
c
chile
sumit
mohan
jean
c
emond
aim
braden
scale
valid
measur
pressur
ulcer
risk
assess
hospit
patient
unit
state
us
requir
center
medicar
medicaid
servic
prior
find
shown
braden
scale
predict
clinic
outcom
cirrhosi
aim
evalu
associ
pressur
ulcer
risk
accord
braden
scale
earli
outcom
mortal
liver
transplant
lt
method
perform
retrospect
cohort
studi
lt
recipi
singl
center
patient
categor
braden
score
admiss
low
risk
pressur
ulcer
mild
moder
risk
high
risk
perform
logist
regress
evalu
associ
braden
scale
categori
mortal
discharg
rehabilit
facil
statu
discharg
rehospit
linear
regress
evalu
length
hospit
stay
lo
result
patient
studi
mean
age
patient
male
white
hepat
c
nearli
patient
receiv
model
liver
diseas
meld
except
hepatocellular
carcinoma
hcc
adjust
differ
age
gender
race
liver
diseas
etiolog
diabet
dialysi
bodi
mass
index
hcc
meld
score
albumin
donor
risk
index
braden
score
categori
significantli
like
discharg
discharg
rehabilit
facil
p
tabl
braden
score
patient
also
trend
longer
lo
braden
score
categori
associ
mortal
readmiss
rate
conclus
standard
measur
pressur
ulcer
risk
perform
inpati
us
predict
earli
disabl
lt
consider
braden
scale
lt
evalu
may
facilit
prognost
disabl
earli
use
direct
intervent
optim
function
statu
multipl
regress
model
evalu
braden
scale
postliv
transplant
outcom
adjust
age
gender
race
liver
diseas
etiolog
diabet
dialysi
bodi
mass
index
hcc
meld
score
albumin
donor
risk
index
describ
adjust
linear
regress
disclosur
tram
tran
advisori
committe
review
panel
gilead
bristol
myer
squibb
consult
gilead
abbvi
janssen
merck
grantresearch
support
bristol
myer
squibb
speak
teach
gilead
vinay
sundaram
advisori
committe
review
panel
gilead
intercept
speak
teach
salix
abbvi
gilead
abbvi
bm
follow
peopl
noth
disclos
jane
lim
sentia
iriana
shahzad
ahm
daniel
tholey
nichola
nissen
iren
k
kim
andrew
klein
alagappan
annamalai
barri
schlanski
unfavor
microbiota
chang
dysbiosi
associ
cirrhosi
progress
howev
impact
liver
transplant
lt
microbiota
unclear
aim
defin
impact
lt
gut
microbiota
composit
compar
healthi
control
hc
method
outpati
cirrhot
list
lt
enrol
studi
visit
mth
stabl
immunosuppress
visit
pt
underw
stool
collect
microbiota
use
pyrosequenc
analysi
perform
microbi
divers
highermor
divers
chang
lefs
cirrhosi
dysbiosi
ratio
prepost
lt
cirrhosi
dysbiosi
ratio
studi
rel
abund
benefici
autochthon
potenti
pathogen
bacteria
low
scorewors
patient
compar
cohort
hc
result
enrol
pt
year
men
hcv
meld
seen
beforeaft
lt
hc
age
year
pt
rifaximin
lactulos
ciprofloxacin
sbp
prophylaxi
patient
receiv
lt
month
enrol
seen
mth
post
lt
time
visit
bactrim
stabl
tacrolimu
dose
none
patient
recent
infect
hcv
erad
activ
reject
requir
recurr
cirrhosi
vs
microbiota
signific
increas
divers
pre
vs
post
p
lt
signific
improv
cirrhosi
dysbiosi
ratio
pre
post
lefs
signific
reduct
potenti
pathogen
genera
escherichia
shigella
salmonella
signific
increas
potenti
benefici
taxa
ie
ruminococcacea
lachnospiracea
clostridi
famili
comparison
hc
hc
highest
divers
p
best
dysbiosi
ratio
compar
pt
group
vs
hc
expect
greater
dysbiosi
seen
pre
lt
pt
compar
hc
pathogen
genera
escherichia
shigella
salmonella
lower
autochthon
taxa
vs
hc
lt
pt
increas
bacteroidacea
compar
hc
increas
pathogen
genera
either
group
despit
increas
significantli
level
benefici
clostridi
famili
remain
significantli
lower
post
lt
compar
hc
conclus
liver
transplant
significantli
improv
gut
microbi
divers
dysbiosi
level
healthi
control
signific
increas
autochthon
taxa
suppress
pathogen
one
rel
abund
indic
restor
impair
axi
disclosur
jasmohan
bajaj
consult
valeant
norgin
intercept
abbott
grant
research
support
institut
receiv
grant
fund
salix
grifol
dougla
heuman
consult
bayer
grifol
genzym
grantresearch
support
exilixi
novarti
bayer
bristol
myer
squibb
scynexi
ocera
mannkind
salix
globeimmun
roch
sciclon
wyeth
otsuka
ikaria
ucb
celgen
centocor
millenium
osiri
abbvi
gilead
speak
teach
otsuka
astella
stock
sharehold
gener
electr
patrick
gillevet
stock
sharehold
biospherex
llc
metabiom
corp
follow
peopl
noth
disclos
masoumeh
sikaroodi
melani
white
andrew
fagan
hochong
gill
diabet
import
risk
factor
poor
outcom
follow
liver
transplant
benefit
improv
glycaem
control
outcom
establish
aim
studi
assess
whether
good
glycaem
control
protect
deleteri
effect
diabet
liver
transplant
outcom
retrospect
analys
data
adult
liver
transplant
recipi
includ
individu
diabet
transplant
singl
tertiari
referr
centr
januari
septemb
divid
recipi
diabet
poor
hbalc
accept
glycaem
control
hbalc
mean
durat
month
recipi
diabet
year
older
overweight
mortal
unaffect
presenc
diabet
howev
recipi
diabet
increas
rate
allcaus
allograft
failur
rr
v
nd
ci
presenc
diabet
associ
reduc
risk
reject
rr
vs
nd
ci
howev
reject
rate
higher
diabet
recipi
compar
vs
incid
infect
increas
recipi
diabet
rr
vs
nd
ci
risk
infect
greatest
compar
incid
acut
kidney
injuri
increas
recipi
diabet
rr
vs
nd
ci
p
accept
glycaem
control
protect
diabet
recipi
like
itu
within
day
transplant
better
glycaem
control
length
stay
intens
care
itu
hospit
significantli
affect
presenc
diabet
howev
recipi
increas
durat
stay
hospit
compar
vs
day
trend
toward
increas
length
stay
itu
compar
better
glycaem
control
vs
day
conclus
diabet
associ
increas
incid
allograft
failur
infect
aki
follow
liver
transplant
good
glycaem
control
may
protect
deleteri
effect
diabet
infect
associ
reduc
risk
readmiss
itu
reduc
length
stay
hospit
disclosur
michael
heneghan
consult
novarti
speak
teach
falk
pharma
nigel
heaton
speak
teach
astella
stephani
amiel
advisori
committe
review
panel
medtron
follow
peopl
noth
disclos
charlott
boughton
omar
mustafa
abid
suddl
john
g
ogradi
background
everolimu
evr
combin
tacrolimu
ltac
provid
signific
improv
renal
function
adult
liver
transplant
recipi
ltxr
compar
tacrolimu
limit
studi
use
evr
pediatr
ltxr
pltxr
method
studi
evalu
renal
function
efficaci
safeti
toler
evr
combin
cyclosporin
lcsa
ltac
pltxr
elig
pltxr
year
liver
graft
receiv
evr
start
dose
bid
thereaft
adjust
maintain
trough
level
ngml
ltac
ngml
ngml
lcsa
ngml
ngml
steroid
primari
object
renal
function
assess
egfr
schwartz
formula
baselin
bl
analysi
safeti
data
data
monitor
committe
februari
result
stop
studi
enrol
discontinu
studi
medic
result
baselin
mean
sd
age
egfr
respect
egfr
increas
compar
bl
vs
respect
mean
egfr
chang
numer
greater
pltxr
vs
urinari
proteincreatinin
ratio
urinari
protein
excret
decreas
bl
incid
composit
efficaci
failur
treat
biopsi
proven
acut
reject
tbpar
graft
loss
death
low
due
occurr
singl
tbpar
graft
loss
death
occur
studi
period
seriou
infect
occur
pltxr
pltxr
seriou
aesinfect
lead
discontinu
studi
drug
increas
rate
lymphoprolif
diseas
observ
subject
vs
neg
effect
growth
develop
observ
conclus
although
studi
demonstr
good
efficaci
renal
function
evr
ltaclcsa
pltxr
safeti
find
popul
particularli
remain
better
establish
disclosur
rainer
ganschow
grantresearch
support
novarti
astella
ericzon
advisori
committe
review
panel
astella
pfizer
grantresearch
support
novarti
anil
dhawan
advisori
committe
review
panel
promethera
consult
alexion
grantresearch
support
astella
speak
teach
ctr
martzloff
employ
novarti
pharma
ag
jose
aguilar
employ
novarti
pharma
ag
jennif
ng
employ
novarti
pharma
ag
patricia
lopez
manag
posit
novarti
follow
peopl
noth
disclos
khalid
sharif
background
conflict
data
marijuana
mj
use
progress
liver
diseas
liver
transplant
outcom
research
among
mj
user
limit
aim
determin
preval
factor
associ
mj
use
assess
impact
mj
use
time
waitlist
deathdelist
time
transplant
method
retrospect
cohort
adult
evalu
transplant
ucsf
mj
use
defin
psychosoci
assess
urin
toxicolog
statist
includ
poisson
regress
cox
regress
model
result
adult
evalu
list
median
follow
year
preval
mj
use
current
user
prior
user
multivari
analysi
statist
signific
predictor
mj
use
includ
age
year
white
race
tobacco
use
alcohol
use
illicit
drug
use
meld
among
list
patient
mj
use
associ
deathdelist
unadjust
surviv
analysi
figur
adjust
analysi
among
list
patient
mj
use
signific
predictor
deathdelist
wherea
age
year
ci
hbvhcv
cirrhosi
ci
meld
ci
hcc
ci
similarli
among
list
patient
mj
use
predictor
receiv
transplant
wherea
alcohol
use
ci
prescript
opiatebenzodiazepin
use
meld
ci
hcc
ci
conclus
almost
half
evalu
candid
current
prior
user
mj
howev
mj
use
associ
wors
outcom
waitlist
mj
use
penal
transplant
center
ucsf
longer
consid
mj
use
contraind
liver
transplant
disclosur
john
p
robert
consult
medsleuth
stock
sharehold
gilead
alexion
follow
peopl
noth
disclos
prashant
kotwani
varun
saxena
bilal
hame
antiphospholipid
antibodi
frequent
present
patient
liver
diseas
associ
morbid
graft
loss
result
vascular
thrombosi
risk
increas
patient
thrombot
event
high
titer
circul
plasmapheresi
immunosuppress
propos
adequ
therapi
vascular
complic
aim
evalu
impact
plasmapheresi
anticoagul
patient
transplant
endstag
liver
diseas
high
risk
vascular
complic
patient
method
patient
transplant
liver
diseas
screen
lupu
anticoagul
activ
patient
increas
level
anticardiolipin
igm
igg
isotyp
anti
glycoprotein
andor
lupu
anticoagul
activ
fulfil
high
thrombot
risk
criteria
randomli
divid
group
group
patient
standard
low
dose
aspirin
low
weight
heparin
group
b
patient
hour
plasmapheresi
fresh
frozen
plasma
follow
post
olt
anticoagul
least
month
clinic
doppler
us
evalu
perform
immedi
post
olt
differ
first
month
etiolog
sever
cirrhosi
immunosuppress
differ
group
immunosuppress
regimen
includ
steroid
cya
tacrolimu
mycophenol
result
patient
group
develop
relat
complic
cerebrovascular
ischemia
humer
thrombosi
hepat
arteri
thrombosi
intestin
ischemia
retin
arteri
thrombosi
portal
vein
thrombosi
catastroph
antiphospholipid
syndrom
cap
result
graft
loss
irrevers
neurolog
damag
death
group
b
patient
develop
complic
cap
hepat
arteri
thrombosi
result
death
thrombot
complic
rate
vs
p
differ
observ
develop
cap
renal
microangiopathi
tendenc
higher
apl
relat
death
among
patient
standard
therapi
vs
p
conclus
signific
caus
thrombot
complic
mortal
plasmapheresi
anticoagul
may
effect
strategi
prevent
associ
vascular
complic
high
risk
patient
disclosur
follow
peopl
noth
disclos
alejandra
villamil
juan
c
bandi
felix
nunez
eduardo
g
mullen
leticia
yamamoto
eduardo
de
santiban
adrian
gadano
background
recurr
primari
biliari
cholang
pbc
report
approxim
recipi
liver
transplant
lt
caus
late
graft
dysfunct
result
death
although
sever
factor
immunosuppress
use
ursodeoxychol
acid
udca
report
associ
recurr
pbc
rpbc
confirmatori
data
still
scarc
method
retrospect
review
liver
transplant
recipi
male
femal
age
year
pbc
conduct
episod
protocol
liver
biopsi
perform
averag
number
per
year
recipientth
first
appear
histolog
rpbc
scheuer
classif
regard
date
rpbc
risk
factor
surviv
analyz
use
cox
regress
hazard
model
subhazard
rpbc
calcul
use
fine
gray
model
death
without
rpbc
regard
compet
risk
result
deceas
donor
lt
lt
left
lobe
right
lobe
posterior
lobe
mean
age
donor
year
blood
rel
initi
immunosuppress
tacrolimu
cyclosporin
median
lt
year
follow
least
year
udca
continu
corticosteroid
antimetabolit
overal
patient
surviv
year
respect
rpbc
diagnos
median
interv
lt
year
univari
analysi
donor
age
hr
hla
hla
b
dr
mismatch
hr
p
risk
factor
patient
surviv
multivari
analysi
show
hla
mismatch
independ
factor
patient
death
hr
rpbc
hla
mismatch
hr
igm
hr
hr
use
cyclosporin
hr
consid
risk
factor
use
cyclosporin
independ
factor
rpbc
multivari
analysi
hr
use
udca
antimetabolit
continu
corticosteroid
found
associ
rpbc
conclus
hla
mismatch
associ
poor
patient
surviv
use
cyclosporin
associ
rpbc
preemptiv
use
udca
associ
occurr
rpbc
investig
need
evalu
factor
associ
diseas
progress
rpbc
disclosur
follow
peopl
noth
disclos
noriyo
yamashiki
akira
mori
yoshihid
ueda
atsushi
yoshizawa
hironori
haga
toshimi
kaido
hideaki
okajima
shinji
uemoto
background
sinc
develop
model
liver
diseas
meld
score
increas
number
simultan
transplant
slk
previou
research
suggest
patient
cirrhosi
kidney
dysfunct
undergo
first
liver
transplant
alon
lta
decreas
patient
surviv
receiv
slk
transplant
howev
uncertain
benefit
seen
requir
second
liver
transplant
method
scientif
registri
transplant
recipi
underw
second
liver
transplant
analyz
surviv
estim
use
analysi
log
rank
test
cox
proport
hazard
regress
analysi
perform
determin
relationship
recipi
donor
variabl
patient
surviv
result
patient
median
month
rang
median
age
year
major
men
white
underw
lta
alon
receiv
slk
total
patient
die
studi
period
receiv
slk
lta
patient
undergo
slk
significantli
older
like
black
higher
meld
score
serum
creatinin
bilirubin
less
like
icu
lower
inr
univari
analysi
transplant
surviv
greater
underw
slk
median
month
month
year
year
year
surviv
probabl
compar
underw
lta
median
month
statist
signific
adjust
confound
slk
patient
less
like
die
liver
transplant
underw
lta
hr
p
patient
underw
lta
serum
creatinin
greater
mgdl
patient
transplant
surviv
significantli
greater
slk
patient
compar
lta
month
year
year
year
versu
respect
p
conclus
outcom
follow
liver
improv
time
although
continu
wors
primari
liver
transplant
adjust
confound
among
patient
requir
second
liver
transplant
slk
outcom
better
lta
effect
pronounc
transplant
patient
impair
renal
function
given
implic
organ
alloc
futur
research
need
determin
factor
relat
discrep
disclosur
follow
peopl
noth
disclos
sonali
paul
joel
adler
jame
f
markmann
heidi
yeh
liver
transplant
lt
effect
therapi
treatment
chronic
liver
diseas
hepat
liver
failur
howev
unbal
organ
avail
increas
number
potenti
candid
undergo
lt
serious
limit
therapeut
approach
fact
prompt
need
expand
inclus
criteria
graft
lt
graft
accept
transplant
present
steatosi
liver
steatosi
consid
primari
factor
graft
failur
lt
mechan
involv
process
fulli
character
although
macrovesicular
steatosi
consid
key
factor
determin
outcom
lt
recent
find
shown
cholesterol
accumul
control
hepat
ischemiareperfus
injuri
sensit
inflammatori
cytokin
oxid
stress
henc
aim
character
level
cholesterol
express
regulatori
enzym
order
optim
select
criteria
liver
graft
predict
outcom
lt
method
graft
biopsi
collect
donor
recipi
liver
transplant
total
donor
biopsi
analyz
stardl
chop
pdk
r
mrna
express
free
cholesterol
analyz
hplc
graft
reject
clinic
outcom
lt
follow
first
year
patient
result
meld
score
recipi
stardl
mrna
level
donor
biopsi
correl
month
lt
meld
score
r
mrna
level
donor
biopsi
correl
month
lt
stardl
mrna
level
donor
biopsi
correl
total
cholesterol
triglycerid
level
graft
clinic
data
mrna
profil
statist
relat
patient
surviv
follow
lt
meld
score
significantli
increas
patient
bad
prognosi
exhibit
higher
r
mrna
level
donor
liver
biopsi
stardl
mrna
level
free
cholesterol
content
donor
biopsi
show
trend
increas
patient
die
first
year
lt
moreov
percentag
patient
enhanc
r
mrna
level
significantli
increas
third
tertil
indic
bad
prognosi
patient
r
express
beyond
specif
threshold
final
multivari
analysi
confirm
elev
hazard
risk
patient
elev
mrna
level
r
donor
biopsi
level
chop
less
impact
conclus
determin
cholesterol
regulatori
enzym
hmgcoa
mrna
level
could
good
predictor
outcom
lt
disclosur
follow
peopl
noth
disclos
anna
bauli
juan
c
valdecasa
jose
fuster
antoni
rimola
jose
carmen
background
countri
deceas
organ
donat
scarc
big
gap
demand
suppli
organ
live
donor
liver
transplant
ldlt
play
import
role
meet
unmet
need
studi
analyz
outcom
ldlt
patient
high
model
liver
diseas
meld
score
studi
conduct
analys
effect
meld
score
outcom
follow
ldlt
method
outcom
patient
underw
ldlt
juli
march
analys
retrospect
recipi
abo
blood
group
incompat
transplant
acut
liver
failur
paediatr
age
group
exclud
studi
hcc
patient
actual
diseas
meld
consid
analysi
worst
meld
score
within
month
ldlt
consid
patient
group
low
meld
high
meld
score
compar
outcom
one
year
continu
variabl
analys
use
independ
student
test
categor
variabl
compar
use
chi
squar
test
cumul
overal
surviv
rate
calcul
use
method
two
tail
p
valu
consid
signific
statist
data
gener
use
spss
chicago
inc
usa
result
ldlt
recipi
low
meld
group
mean
meld
high
meld
group
mean
meld
higher
preval
hepat
c
viru
hcv
vs
hepatocellular
carcinoma
hcc
vs
low
meld
group
alcohol
liver
diseas
vs
high
meld
group
signific
differ
mean
length
intens
care
unit
vs
hospit
stay
vs
low
high
meld
group
signific
differ
observ
oper
time
graft
weight
grwr
type
graft
harvest
group
howev
patient
high
meld
score
requir
significantli
transfus
fresh
frozen
plasma
vs
p
similarli
signific
differ
rate
sepsi
vs
hepat
arteri
thrombosi
vs
biliari
complic
vs
acut
cellular
reject
vs
signific
differ
observ
surviv
vs
two
group
one
year
conclus
high
meld
score
advers
affect
outcom
ldlt
view
shortag
deceas
organ
ldlt
justifi
high
meld
recipi
disclosur
follow
peopl
noth
disclos
neeraj
saraf
sanjay
k
yadav
narendra
choudhari
sanjiv
saigal
prashant
bhangui
sanjay
goja
amit
rastogi
arvind
soin
background
although
screen
liver
transplant
olt
candid
coronari
arteri
diseas
cad
recommend
lack
data
effect
screen
strategi
centr
adopt
cardiac
risk
assess
protocol
stratifi
patient
risk
group
base
age
cardiac
object
assess
safeti
efficaci
cardiac
risk
stratif
protocol
patient
undergo
olt
assess
method
consecut
patient
year
undergo
olt
assess
period
prospect
includ
patient
stratifi
one
cardiac
risk
group
receiv
standardis
investig
tabl
primari
outcom
cardiac
event
result
patient
includ
median
age
iqr
male
median
meld
score
iqr
common
indic
olt
hepat
c
alcohol
hepatocellular
carcinoma
nafld
document
cardiac
risk
factor
includ
diabet
smoke
hypertens
hypercholesterolemia
famili
person
histori
ischem
heart
diseas
ihd
obes
patient
risk
factor
patient
identifi
low
risk
lr
intermedi
risk
ir
high
risk
hr
lr
patient
sever
pulmonari
hypertens
pht
echo
coronari
angiogram
ca
reject
patient
ir
hr
induc
ischemia
dse
proceed
ca
reject
due
sever
cad
hr
patient
normal
dse
progress
ct
coronari
angiogram
ctca
patient
signific
cad
detect
ctca
reject
list
critic
stenosi
detect
ca
list
without
ca
reject
indic
overal
patient
list
olt
due
abnorm
cardiac
investig
two
cardiac
event
record
event
rate
ir
group
cardiac
arrest
death
cirrhot
cardiomyopathi
neither
patient
cad
identifi
prior
olt
conclus
cardiac
risk
stratif
base
tradit
cardiac
risk
factor
select
use
dse
ca
ctca
safe
feasibl
approach
result
low
cardiac
event
rate
addit
rf
includ
hypertens
smoke
rel
cad
hypercholesterolemia
disclosur
peter
w
angu
advisori
committe
review
panel
gilead
scienc
bm
bayer
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
marcu
robertson
william
wchung
tessa
v
ohalloran
omar
farouqu
mark
horrigan
paul
gow
background
number
women
undergo
liver
transplant
lt
increas
model
care
need
racialethn
dispar
outcom
identifi
predominantli
male
cohort
racialethn
influenc
graft
outcom
women
unknown
method
use
unit
state
scientif
registri
transplant
recipi
srtr
databas
examin
associ
raceethn
graft
loss
women
death
retranspl
covari
includ
recipi
donor
characterist
factor
medic
result
elig
cohort
includ
caucasian
hispan
african
american
aa
asian
women
median
year
graft
surviv
year
lower
among
aa
women
compar
caucasian
hispan
asian
p
risk
graft
loss
higher
aa
women
age
lt
compar
aa
women
age
risk
increas
increas
age
age
year
among
caucasian
women
figur
risk
graft
loss
chronic
reject
higher
younger
compar
older
aa
women
hr
ci
p
signific
risk
differ
older
aa
caucasian
women
howev
caus
graft
loss
significantli
differ
younger
older
aa
women
younger
aa
younger
caucasian
women
p
valu
conclus
aa
women
especi
age
year
higher
risk
graft
loss
compar
older
aa
women
women
racialethn
group
graft
loss
chronic
reject
frequent
young
aa
women
explain
medic
studi
racial
differ
drug
metabol
therefor
need
better
understand
mechan
underli
differenti
rate
reject
graft
loss
disclosur
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
follow
peopl
noth
disclos
shravan
dave
jennif
l
dodg
monika
sarkar
background
although
nash
progress
cirrhosi
earli
adulthood
thought
nash
rare
indic
liver
transplant
lt
young
adult
aim
studi
estim
frequenc
lt
perform
nash
young
adult
year
compar
indic
assess
chang
frequenc
year
evalu
outcom
method
perform
retrospect
cohort
analysi
young
adult
receiv
first
lt
us
use
unit
network
organ
share
databas
incid
rate
ratio
irr
calcul
indic
analysi
use
assess
surviv
outcom
lt
nash
compar
transplant
done
metabol
diseas
result
total
young
adult
underw
lt
mean
age
time
lt
year
male
common
indic
lt
autoimmunecholestat
diseas
follow
acut
liver
failur
alf
incid
lt
perform
nash
increas
indic
irr
significantli
higher
nash
compar
indic
lt
young
adult
demonstr
nash
rapidli
increas
indic
lt
increas
per
year
irr
ci
figur
graft
surviv
rate
lower
rate
higher
nash
compar
metabol
liver
diseas
vs
respect
graft
surviv
vs
respect
conclus
nash
rapidli
grow
indic
lt
among
young
adult
us
account
approxim
transplant
lt
nash
young
adult
associ
lower
graft
surviv
higher
rate
compar
metabol
diseas
disclosur
naim
alkhouri
advisori
committe
review
panel
gilead
scienc
alexion
bm
intercept
grantresearch
support
alexion
speak
teach
abbvi
bm
gilead
alexion
intercept
follow
peopl
noth
disclos
danni
issa
kymberli
watt
ghassoub
rifai
rocio
lopez
iliana
doycheva
background
women
await
liver
transplant
lt
experi
higher
rate
waitlist
mortal
wlm
men
hypothes
sarcopenia
contribut
gender
dispar
method
includ
adult
newli
list
lt
lt
center
abdomin
ct
scan
within
month
list
skelet
muscl
index
smi
defin
total
abdomin
skelet
muscl
area
normal
height
compet
risk
regress
deceas
donor
lt
compet
risk
evalu
associ
femal
sex
wlm
use
smi
defin
sarcopenia
women
result
lt
candid
women
women
vs
men
similar
age
race
like
nash
cholestat
diseas
less
like
hcc
shorter
lighter
similar
bmi
p
compar
men
women
similar
median
meld
lower
creatinin
mgdl
p
median
iqr
smi
women
men
median
mo
followup
women
men
wlm
univari
compet
risk
regress
femal
vs
male
sex
associ
increas
risk
wlm
hr
ci
adjust
smi
complet
mitig
gender
dispar
femal
sex
hr
ci
chang
adjust
meld
black
race
rate
wlm
significantli
higher
among
sarcopen
women
compar
women
conclus
data
suggest
presenc
sarcopenia
account
gender
dispar
lt
waitlist
mortal
sarcopen
women
especi
risk
death
waitlist
receiv
target
intervent
prevent
revers
sarcopenia
await
lt
figur
unadjust
surviv
among
men
sarcopen
women
await
lt
disclosur
follow
peopl
noth
disclos
jennif
c
lai
elizabeth
j
carey
aldo
j
conni
w
wang
srinivasan
dasarathi
michael
dunn
background
biliari
tract
complic
anastomot
strictur
leak
known
occur
orthotop
liver
transplant
olt
ercp
first
line
therapi
manag
complic
pancreat
pep
common
complic
ercp
patient
previous
shown
low
risk
pep
thu
exclud
trial
studi
pep
prophylaxi
rectal
indomethacin
demonstr
benefit
pep
reduct
popul
object
studi
determin
incid
pep
procedur
complic
patient
examin
effect
rectal
indomethacin
method
conduct
retrospect
cohort
studi
patient
undergo
ercp
hospit
univers
pennsylvania
januari
decemb
june
mg
rectal
indomethacin
routin
administ
follow
ercp
examin
procedur
complic
includ
bleed
cholang
pep
moder
sever
pep
determin
cotton
et
al
criteria
patient
contact
within
hour
procedur
outcom
assess
comparison
baselin
characterist
multivari
logist
regress
model
adjust
confound
use
determin
associ
indomethacin
pep
moder
sever
pep
result
case
pep
case
bleed
case
cholang
case
perfor
identifi
follow
procedur
patient
receiv
indomethacin
compar
unexpos
signific
differ
group
respect
pd
cannul
endotrach
intub
type
anesthesia
receiv
pep
occur
indomethacin
patient
compar
unexpos
group
adjust
pd
cannul
biliari
sphincterotomi
rectal
indomethacin
associ
decreas
pep
ci
p
unexpos
group
develop
moder
sever
pep
compar
patient
indomethacin
group
differ
complic
seen
two
cohort
conclus
conclus
demonstr
patient
low
risk
complic
includ
pancreat
bleed
cholang
rectal
indomethacin
significantli
decreas
rate
pancreat
rate
moder
sever
pancreat
advers
effect
bleed
patient
may
benefit
routin
usag
rectal
indomethacin
follow
ercp
disclosur
michael
l
kochman
consult
boston
scientif
dark
canyon
laboratori
employ
merck
grantresearch
support
boston
scientif
patent
held
file
cook
medic
stock
sharehold
merck
follow
peopl
noth
disclos
nikhil
r
thiruvengadam
vandana
khungar
christin
c
hsu
ranjeeta
bahirwani
kimberli
ford
aim
patient
chronic
hepat
c
viru
hcv
infect
remain
increas
risk
develop
chronic
kidney
diseas
ckd
assess
effect
sustain
virolog
respons
svr
therapi
avt
hepat
c
pre
post
liver
transplant
lt
renal
outcom
method
medic
record
consecut
liver
transplant
lt
recipi
review
patient
hcv
cirrhosi
identifi
exclud
patient
graft
loss
day
prior
renal
transplant
simultan
liver
kidney
transplant
hepat
b
prior
avt
miss
data
avt
document
svr
patient
includ
final
analysi
serial
estim
glomerular
filtrat
rate
egfr
calcul
use
mdrd
studi
equat
post
lt
incid
esrd
compar
year
lt
patient
receiv
avt
achiev
svr
patient
fail
treatment
lt
recipi
hepat
c
categor
base
time
avt
treatment
within
year
lt
beyond
year
lt
result
hepat
c
treat
group
svr
treatment
failur
group
similar
baselin
demograph
clinic
characterist
except
svr
group
lower
viral
load
less
like
treat
inhibitor
frequenc
esrd
among
patient
svr
significantli
lower
compar
achiev
svr
versu
p
among
patient
svr
incid
esrd
patient
treat
prior
lt
within
year
lt
beyond
year
lt
respect
achiev
svr
variabl
strongli
associ
prevent
declin
egfr
end
follow
hr
p
figur
achiev
svr
prior
lt
led
least
frequenc
declin
egfr
compar
treat
lt
figur
year
follow
conclus
achiev
svr
lt
recipi
hcv
significantli
decreas
risk
develop
esrd
avt
prior
lt
strongli
consid
await
liver
transplant
preserv
renal
function
disclosur
sanjaya
k
satapathi
advisori
committe
review
panel
gilead
abbvi
board
membership
intercept
grantresearch
support
genfit
gilead
biotest
conatu
intercept
satheesh
nair
advisori
committe
review
panel
jansen
grantresearch
support
gilead
speak
teach
abbvi
valeant
bm
intercept
follow
peopl
noth
disclos
kiran
joglekar
manish
talwar
jason
vanatta
jame
eason
purpos
investig
differ
rel
influenc
hla
recipientdonor
characterist
transplant
graft
failur
gf
liver
diseas
spectrum
method
perform
retrospect
analysi
uno
databas
adult
liver
transplant
recipi
year
psc
pscaih
aih
pbc
aih
pbc
complet
recipientdonor
hla
serotyp
exclud
multiorgan
transplant
retranspl
cox
proport
hazard
regress
use
investig
influenc
hla
recipientdonor
serotyp
match
gf
control
age
sex
raceethn
medic
condit
transplant
icu
hospit
neither
total
bilirubin
creatinin
albumin
donor
age
vs
deceas
vs
live
donor
donor
cardiac
death
statu
graft
type
splitwhol
univari
analys
adjust
multipl
comparison
p
multivari
model
consid
signific
result
time
period
psc
pscaih
aih
pbcaih
pbc
patient
complet
hla
recipientdonor
data
transplant
gf
note
graft
surviv
lower
aih
compar
pbc
vs
group
similar
hla
serotyp
match
characterist
signific
multivari
model
adjust
p
list
tabl
signific
find
note
pscaih
pbc
conclus
certain
recipientdonor
hla
serotyp
match
statu
patient
transplant
liver
diseas
significantli
associ
gf
use
larg
uno
dataset
investig
need
elucid
impact
potenti
role
hla
serotyp
liver
transplant
optim
outcom
recipi
liver
diseas
adjust
hazard
ratio
graft
failur
hla
characterist
disclosur
andrew
j
muir
advisori
committe
review
panel
abbvi
bm
gilead
janssen
merck
consult
shire
inovia
pharmaceut
intercept
portola
pharmaceut
grantresearch
support
abbvi
bm
gilead
janssen
merck
holog
intercept
ngm
biopharm
roch
follow
peopl
noth
disclos
yuval
patel
jacquelin
b
henson
juliu
wilder
jiayin
zheng
chow
carl
l
berg
introduct
patient
undergo
liver
transplant
lt
decis
concern
renal
function
usual
reli
calcul
gfr
egfr
use
creatinin
base
equat
hypothes
current
equat
suboptim
make
clinic
decis
method
compar
calcul
protocol
measur
gfr
use
iothalam
clearanc
year
compar
examin
differ
calcul
protocol
measur
gfr
pre
lt
initi
evalu
post
lt
mo
year
year
examin
perform
stage
iii
ckd
stage
iv
ckd
among
patient
risk
intrins
renal
diseas
age
dm
htn
result
pair
measur
patient
correl
egfr
mgfr
overal
moder
r
poor
stage
iii
r
r
stage
iv
ckd
r
r
amongst
patient
risk
intrins
renal
diseas
r
r
differ
egfr
mgfr
patient
given
time
point
stage
iv
ckd
n
equat
overestim
renal
function
overal
median
differ
mlmin
mlmin
min
stage
iv
ckd
differ
highest
time
initi
evalu
prior
lt
mlmin
mlmin
mlmin
within
first
day
lt
mlmin
mlmin
epi
mlmin
median
differ
decreas
year
lt
figur
conclus
calcul
gfr
use
creatinin
base
equat
substanti
overestim
renal
function
time
clinic
meaning
decis
matter
either
pre
lt
eg
slkt
vs
lt
immedi
lt
eg
cni
minim
correl
improv
year
post
lt
howev
impact
intervent
less
help
time
median
iqr
differ
calcul
gfr
measur
gfr
disclosur
stevan
gonzalez
speak
teach
gilead
salix
abbvi
merck
josh
levitski
consult
transplant
genom
incorpor
goran
klintmalm
grantresearch
support
astella
novarti
opsona
follow
peopl
noth
disclos
sumeet
k
asrani
linda
w
jen
jame
f
trotter
michael
emmett
mitra
k
nadim
background
although
surgeri
potenti
cur
treatment
intrahepat
cholangiocarcinoma
ihcc
outcom
still
unsatisfactori
aim
establish
preoper
prognost
score
identifi
patient
need
therapeut
option
method
total
patient
collect
prospect
maintain
institut
databas
among
patient
underw
hepatectomi
enrol
preoper
avail
predictor
inflamm
paramet
tumor
marker
evalu
remain
inoper
patient
use
control
perform
surviv
analysi
result
overal
median
surviv
time
mst
surviv
month
multivari
analys
use
preoper
predictor
identifi
nlr
crp
iu
ml
independ
associ
poorer
overal
surviv
given
result
preoper
prognost
score
defin
follow
none
factor
presenc
one
factor
presenc
factor
mst
surviv
score
month
compar
month
score
month
score
p
p
respect
moreov
surviv
patient
score
inoper
control
patient
almost
mst
month
year
surviv
respect
conclus
preoper
prognost
score
icc
simpl
use
identifi
patient
need
therapeut
option
disclosur
follow
peopl
noth
disclos
tomoaki
yoh
satoru
seo
kojiro
taura
kentaro
yasuchika
toshimi
kaido
shinji
uemoto
background
liver
transplant
lt
success
treatment
option
liver
lt
infecti
cardiovascular
complic
contribut
reduc
graft
patient
surviv
condit
associ
increas
von
willebrand
factor
antigen
previous
also
correl
surviv
cirrhot
patient
evalu
predict
marker
lt
method
conduct
prospect
studi
patient
first
lt
treat
univers
hospit
heidelberg
patient
seen
lt
outpati
clinic
depart
novemb
august
screen
includ
patient
least
year
age
time
inclus
patient
first
lt
elig
measur
patient
follow
prospect
regard
primari
endpoint
name
surviv
summari
six
patient
die
receiv
median
patient
significantli
higher
patient
aliv
end
median
roc
analysi
auc
reveal
optim
predict
primari
endpoint
sensit
specif
surviv
longer
patient
compar
higher
p
accord
logrank
test
associ
surviv
multivari
analysi
alkalin
phosphatas
alp
meld
score
donor
age
cold
ischemia
time
score
combin
alp
show
impress
capabl
roc
analysi
auc
distinguish
patient
regard
primari
endpoint
conclus
marker
predict
outcom
patient
lt
diagnost
perform
increas
combin
alp
newli
develop
score
disclosur
christian
rupp
grantresearch
support
squibb
gmbh
co
kgaa
karl
heinz
weiss
advisori
committe
review
panel
bayer
health
care
bm
consult
wilson
therapeut
univar
grantresearch
support
novarti
speak
teach
bayer
health
care
norgin
orphan
europ
daniel
gotthardt
advisori
committe
review
panel
novarti
abbvi
bm
gilead
intercept
consult
pfizer
roch
grantresearch
support
novarti
speak
teach
gilead
msdmerck
follow
peopl
noth
disclos
andrea
wannhoff
conrad
rauber
kilian
friedrich
wolfgang
stremmel
schemmer
peter
purpos
studi
identifi
clinic
risk
factor
genet
variant
associ
recurr
fatti
liver
diseas
nafld
transplant
lt
preval
recurr
nafld
high
liver
transplant
occur
make
import
clinic
issu
cohort
patient
underw
liver
transplant
april
august
methodist
univers
hospit
transplant
institut
middl
age
patient
mean
year
old
mostli
white
among
patient
patient
liver
biopsi
within
year
transplant
histolog
slide
blindli
rescor
patient
recurr
nafld
perform
candid
gene
approach
use
dna
extract
donor
recipi
liver
tissu
fix
formalin
embed
paraffin
use
taqman
snp
genotyp
assay
focus
polymorph
gene
known
associ
nafld
pathogenesi
combin
public
health
inform
extract
patient
medic
record
investig
associ
nafld
recurr
univari
analysi
found
higher
triglycerid
lower
creatinin
level
diabet
develop
calcineurin
inhibitor
use
associ
nafld
recurr
multivari
logist
analysi
tabl
show
patient
strongli
suscept
recurr
diseas
receiv
liver
donor
ci
high
triglycerid
level
ci
prescrib
calcineurin
inhibitor
transplant
ci
conclus
recurr
nafld
transplant
like
develop
recipi
receiv
liver
donor
polymorph
use
immunosuppress
ca
calcineurin
inhibitor
predictor
associ
recurr
nafld
transplant
disclosur
sanjaya
k
satapathi
advisori
committe
review
panel
gilead
abbvi
board
membership
intercept
grantresearch
support
genfit
gilead
biotest
conatu
intercept
follow
peopl
noth
disclos
nhu
josephin
q
tran
alexand
j
koval
david
e
kleiner
dave
bridg
background
donat
cardiac
death
dcd
liver
allograft
use
increas
avail
donor
pool
bridg
gap
number
donor
recipi
concern
exist
regard
primari
ischem
biliari
complic
aim
compar
direct
cost
hospit
resourc
util
dcd
versu
donat
brain
death
dbd
liver
transplant
lt
recipi
studi
design
retrospect
observ
studi
compar
clinic
outcom
patient
compar
report
recipi
dcd
graft
age
sex
meld
score
match
recipi
dbd
graft
institut
januari
octob
wilcoxon
ranksum
test
test
use
compar
continu
categor
variabl
respect
continu
outcom
compar
use
wilcoxon
test
binari
outcom
compar
use
mcnemar
test
patient
graft
surviv
compar
use
cluster
test
result
donor
characterist
dcd
dbd
younger
year
age
p
lt
signific
differ
observ
total
length
stay
icu
length
stay
number
compar
direct
cost
lt
discharg
signific
differ
observ
two
group
vs
p
signific
differ
found
patient
graft
surviv
dcd
recipi
compar
dbd
recipi
p
respect
conclus
unlik
previou
report
increas
financi
resourc
use
immedi
period
decreas
patient
graft
surviv
associ
dcd
allograft
signific
differ
dcd
allograft
match
recipi
cohort
report
support
use
dcd
allograft
could
help
expand
donor
pool
liver
transplant
clinic
outcom
among
use
dbd
dcd
donor
liver
transplant
dbd
donat
brain
death
dcd
donat
cardiac
death
lt
liver
transplant
icu
intens
care
unit
lo
length
stay
disclosur
follow
peopl
noth
disclos
jiten
p
kothadia
hrishikesh
samant
fang
qiu
rajani
rangray
timothi
mccashland
marco
olivera
background
liver
transplant
lt
recipi
increas
incid
non
melanoma
skin
cancer
nmsc
american
associ
studi
liver
diseas
aasld
recommend
lt
recipi
seen
dermatologist
annual
skin
exam
aim
determin
qualiti
improv
qi
program
improv
adher
aasld
recommend
skin
cancer
screen
lt
recipi
method
systemat
method
provid
educ
face
face
interact
commun
tool
use
lt
recipi
seen
clinic
fill
questionnair
determin
seen
dermatologist
within
past
year
lt
coordin
review
questionnair
visit
patient
seen
dermatolog
within
year
referr
place
electron
health
record
patient
live
local
advis
contact
primari
care
provid
setup
local
dermatolog
referr
document
chart
referr
rate
review
monthli
qi
meet
rate
compar
implement
program
januari
patient
transplant
januari
includ
chart
retrospect
review
data
collect
data
analysi
conduct
use
spss
version
studi
approv
institut
review
board
result
one
hundr
patient
review
mean
age
year
old
patient
male
half
patient
transplant
hepat
c
twenti
three
percent
patient
histori
nmsc
referr
rate
implement
qi
program
increas
significantli
tabl
patient
refer
dermatolog
initi
program
document
dermatolog
visit
three
visit
found
new
nmsc
three
prior
histori
nmsc
refer
dermatolog
program
start
document
dermatolog
visit
three
diagnos
new
nmsc
exam
patient
prior
histori
nmsc
multivari
analysi
qi
program
factor
associ
increas
skin
cancer
screen
referr
conclus
nmsc
common
lt
patient
center
qi
program
lead
signific
increas
dermatolog
referr
rate
lt
recipi
howev
effort
requir
improv
rate
skin
exam
referr
improv
qi
program
implement
disclosur
fredric
gordon
advisori
committe
review
panel
gilead
consult
gilead
abbvi
grantresearch
support
gilead
abbvi
speak
teach
gilead
abbvi
follow
peopl
noth
disclos
carmi
punzalan
dawn
melanson
amanda
keough
amir
qamar
background
impact
sever
hypoalbuminemia
concurr
ascit
surviv
among
patient
await
liver
transplant
lt
may
accur
captur
model
liver
diseas
meld
score
accur
assess
prognosi
import
priorit
need
lt
aim
evalu
addit
predict
valu
sever
hypoalbuminemia
concurr
ascit
lt
waitlist
surviv
among
us
adult
method
retrospect
evalu
adult
age
list
lt
use
unit
network
organ
share
registri
data
effect
sever
hypoalbuminemia
presenc
ascit
lt
waitlist
surviv
stratifi
liver
diseas
etiolog
presenc
hepatocellular
carcinoma
hcc
evalu
kaplan
meier
multivari
cox
proport
hazard
model
result
among
patient
list
lt
sever
hypoalbuminemia
ascit
time
lt
list
significantli
higher
rate
sever
hypoalbuminemia
seen
men
hcv
patient
patient
diabet
overal
waitlist
surviv
significantli
lower
among
patient
sever
hypoalbuminemia
compar
normal
albumin
vs
p
lower
among
ascit
compar
ascit
vs
p
stratifi
etiolog
neg
impact
sever
hypoalbuminemia
signific
among
patient
nonalcohol
steatohepat
nash
waitlist
surviv
nash
vs
hcv
p
lower
waitlist
surviv
associ
sever
hypoalbuminemia
ascit
seen
among
patient
without
hcc
multivari
regress
sever
hypoalbuminemia
associ
significantli
higher
waitlist
mortal
compar
patient
normal
albumin
even
correct
score
presenc
hcc
hr
ci
p
compar
patient
without
ascit
ascit
time
lt
list
significantli
higher
waitlist
mortal
hr
ci
p
conclus
among
us
adult
await
lt
sever
hypoalbuminemia
presenc
ascit
time
lt
list
associ
significantli
higher
waitlist
mortal
independ
score
higher
waitlist
mortal
seen
worsen
hypoalbuminemia
predictor
liver
transplant
waitlist
mortal
disclosur
catherin
frenett
advisori
committe
review
panel
freseniu
gilead
bayer
speak
teach
bayer
valeant
gilead
bristol
meyer
squibb
btg
wako
diagnost
intercept
walid
ayoub
consult
gilead
abbvi
bm
grifol
speak
teach
intercept
intercept
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
follow
peopl
noth
disclos
joseph
ahn
taft
bhuket
benni
liu
introduct
intestin
permeabl
ip
increas
advanc
stage
liver
diseas
associ
develop
system
inflamm
complic
howev
littl
known
modif
gut
liver
axi
liver
transplant
lt
aim
quantifi
compar
ip
lt
recipi
cirrhot
patient
healthi
control
patient
method
lt
recipi
match
cirrhot
healthi
subject
underw
ip
quantif
test
subject
diseas
potenti
alter
ip
evid
activ
alcohol
consumpt
exclud
studi
result
lt
recipi
cirrhot
child
healthi
control
enrol
median
time
lt
month
median
excret
compar
cirrhot
control
overal
p
lt
recipi
vs
cirrhot
lt
vs
control
p
figur
ip
increas
time
lt
recipi
median
valu
month
month
month
lt
differ
significantli
associ
laboratori
paramet
immunosuppress
medic
type
level
ip
found
except
etiolog
previou
liver
diseas
higher
ip
case
etiolog
median
month
ci
among
lt
recipi
develop
infecti
complic
die
correl
found
ip
valu
p
conclus
lt
recipi
increas
ip
probabl
due
multifactori
chronic
alter
axi
studi
need
assess
clinic
impact
increas
ip
patient
figur
excret
liver
transplant
patient
compar
cirrhot
healthi
control
disclosur
follow
peopl
noth
disclos
francesca
r
ponziani
venanzio
valenza
margherita
lorusso
myrto
elisa
carvelli
rosalba
paon
massimo
siciliano
alfonso
w
avolio
antonio
grieco
salvator
agn
maurizio
pompili
antonio
gasbarrini
gabriel
sganga
background
biliari
complic
liver
transplant
caus
impair
hepat
arteri
perfus
frequent
associ
poor
outcom
aim
present
studi
determin
preval
hepat
arteri
stenosi
prognost
implic
hepat
arteri
collater
liver
transplant
recipi
biliari
strictur
patient
method
liver
graft
recipi
transplant
center
radiolog
document
biliari
strictur
high
qualiti
imag
hepat
arteri
contrast
enhanc
arteri
phase
comput
tomographi
cathet
angiographi
avail
recipi
cholangiogram
classifi
accord
local
biliari
strictur
anastomot
hepat
arteri
stenosi
without
collater
assess
hepat
arteriogram
clinic
demograph
biochem
recipi
donor
data
retrospect
analyz
correl
radiolog
find
result
preval
hepat
arteri
stenosi
liver
transplant
recipi
biliari
strictur
biliari
strictur
associ
hepat
arteri
stenosi
patient
significantli
higher
patient
anastomot
strictur
patient
patholog
hepat
arteriogram
p
neither
locat
bile
duct
strictur
presenc
hepat
arteri
stenosi
predict
outcom
contrast
arteri
collater
associ
significantli
better
overal
graft
surviv
transplant
recipi
biliari
complic
conclus
impair
hepat
arteri
perfus
frequent
associ
strictur
may
also
implic
pathogenesi
anastomot
strictur
despit
neg
prognost
impact
biliari
strictur
hepat
arteri
stenosi
outcom
hepat
arteri
collater
appear
protect
effect
disclosur
follow
peopl
noth
disclos
viveiro
rafael
rehwald
armin
finkenstedt
maria
effenberg
benedikt
schaefer
livia
dorn
stefan
schneeberg
herbert
tilg
bernhard
glodni
heinz
zoller
martin
freund
background
liver
transplant
lt
accept
indic
select
patient
hilar
cholangiocarcinoma
cca
long
term
outcom
thought
compar
patient
undergo
lt
hepatocellular
carcinoma
hcc
aim
studi
compar
surviv
subject
cca
hcc
within
milan
criteria
ii
evalu
factor
associ
mortal
cca
method
data
extract
uno
databas
adult
transplant
cca
hcc
identifi
propens
score
match
use
match
cca
hcc
patient
basi
univari
analysi
perform
assess
differ
cca
hcc
multivari
analysi
perform
assess
factor
associ
mortal
patient
cca
result
patient
hcc
within
milan
criteria
patient
cca
underw
lt
mean
age
year
male
median
month
significantli
shorter
cca
group
vs
month
adjust
age
gender
race
previou
lt
meld
propens
score
cca
patient
higher
risk
die
hcc
p
year
surviv
shorter
patiet
cca
compar
hcc
vs
p
multivari
analysi
dialysi
icu
stay
higher
meld
region
longer
hospit
stay
lack
mycofenol
mofetil
upon
discharg
found
significantli
increas
risk
mortal
cca
conclus
cca
patient
surviv
lower
hcc
studi
need
optimis
cca
select
lt
post
liver
transplant
surviv
disclosur
follow
peopl
noth
disclos
k
v
narayanan
menon
rocio
lopez
carlo
j
mangesh
pagadala
introduct
intraven
contrast
enhanc
imag
invalu
diagnos
patholog
follow
liver
transplant
includ
vascular
infecti
complic
given
potenti
risk
contrast
nephropathi
associ
intraven
iodin
ct
contrast
altern
contrast
modal
abdomin
imag
need
examin
especi
set
renal
insuffici
recent
document
renal
safeti
gadolinium
enhanc
mri
imag
transplant
cohort
even
presenc
renal
insuffici
aim
purpos
studi
examin
renal
safeti
mri
gadolinium
abdomin
imag
patient
follow
liver
transplant
method
studi
involv
retrospect
analysi
post
liver
transplant
patient
underw
abdomin
mri
gadolinium
absenc
renal
replac
therapi
singl
academ
center
case
serum
creatinin
note
prior
within
week
mri
serum
creatinin
valu
mri
compar
use
pair
addit
case
analyz
develop
nephrogen
system
fibrosi
nsf
report
complic
gadolinium
set
renal
insuffici
result
mean
age
year
sd
male
serum
creatinin
valu
rang
mgdl
median
iqr
case
valu
mgdl
median
iqr
median
time
mri
follow
transplant
day
comparison
pre
post
mri
serum
creatinin
valu
demonstr
clinic
signific
differ
mean
chang
ci
post
mri
subgroup
analysi
renal
insuffici
defin
serum
creatinin
mgdl
also
show
clinic
signific
differ
mean
chang
ci
post
mri
addit
case
nsf
note
conclus
observ
suggest
mri
gadolinium
imag
modal
patient
follow
liver
transplant
importantli
renal
safeti
modal
extend
case
baselin
renal
insuffici
defin
cr
mgdl
contrast
enhanc
ct
may
contraind
due
risk
contrast
nephropathi
therefor
gadolinium
enhanc
iv
contrast
imag
provid
invalu
imag
modal
diagnosi
patholog
follow
liver
transplant
especi
set
renal
insuffici
disclosur
follow
peopl
noth
disclos
mari
flynn
mehul
parikh
sebastian
perez
sonali
sakaria
ram
subramanian
hyperdynam
cardiovascular
state
often
present
advanc
cirrhosi
thought
revers
liver
transplant
wish
examin
extent
physiolog
influenc
long
term
outcom
patient
undergo
major
oper
retrospect
collect
data
patient
underw
liver
transplant
indic
oper
period
exclud
patient
age
receiv
graft
live
donor
patient
receiv
organ
simultan
patient
previous
undergon
liver
transplant
primari
outcom
time
either
death
advanc
univari
model
multivari
model
use
anova
test
compar
cox
proport
hazard
model
stepwis
fashion
surviv
analysi
treat
time
risk
time
date
transplant
date
outcom
censorship
last
known
follow
covari
includ
demograph
data
echocardiogram
analyz
data
liver
transplant
patient
white
male
averag
age
year
sd
averag
meld
transplant
sd
prior
transplant
averag
left
ventricular
eject
fraction
lvef
sd
median
calcul
right
ventricular
systol
pressur
echo
mmhg
patient
averag
day
follow
unadjust
patient
reach
composit
outcom
univari
analysi
greatest
predictor
death
graft
failur
presenc
lvef
hr
ci
p
predict
rvsp
rang
hr
ci
p
refer
group
tricuspid
regurgit
jet
echo
two
factor
remain
highli
signific
full
model
lvef
hr
p
rvsp
mmhg
hr
p
age
race
sex
bmi
presenc
hcc
meld
transplant
confer
elev
hazard
death
even
univari
model
elev
estim
lvef
rvsp
screen
echocardiogram
predict
wors
outcom
post
transplant
retrospect
cohort
studi
patient
receiv
organ
result
seem
suggest
use
current
screen
method
may
group
patient
could
identifi
prior
transplant
may
higher
risk
studi
area
need
unravel
physiolog
epidemiolog
underpin
find
disclosur
ahmet
gurakar
advisori
committe
review
panel
bm
gilead
follow
peopl
noth
disclos
nikhilesh
r
mazumd
stuart
russel
aliaksei
pustavoitau
andrew
cameron
benjamin
philosoph
behnam
saberi
background
patient
undergo
liver
transplant
olt
coronari
arteri
diseas
cad
associ
high
mortal
risk
rel
contraind
procedur
evalu
cad
commonli
accomplish
dobutamin
stress
echocardiographi
dse
follow
coronari
angiographi
ca
ischemia
detect
cardiac
ct
angiographi
ctca
allow
detect
signific
coronari
arteri
stenos
howev
effect
screen
tool
uncertain
transplant
set
aim
assess
feasibl
outcom
ctca
olt
candid
high
risk
cad
method
patient
undergo
olt
assess
consid
cad
age
diabet
patient
prospect
includ
period
patient
dse
follow
ctca
patient
receiv
heart
rate
control
nitroglycerin
per
standard
ctca
protocol
primari
outcom
cardiac
event
result
patient
includ
median
age
year
iqr
male
common
indic
olt
assess
hepatocellular
carcinoma
hepat
c
alcohol
nafld
document
cardiac
risk
factor
includ
diabet
smoke
hypertens
hypercholesterolemia
famili
person
histori
ischaem
heart
diseas
ihd
obes
patient
risk
factor
ctca
complet
patient
abandon
patient
due
tachycardia
normal
show
stenosi
plaqu
show
least
one
obstruct
lesion
stenosi
patient
abnorm
ctca
result
refer
cardiolog
clinic
patient
reject
transplant
due
sever
cad
proceed
ca
patient
limit
diseas
list
proceed
pci
list
combin
coronari
arteri
bypass
graft
surgeri
olt
patient
list
without
investig
mean
coronari
arteri
calcium
score
hu
significantli
differ
nafld
patient
patient
underw
olt
cardiac
event
cardiac
arrest
reperfus
patient
normal
dse
ctca
conclus
ctca
feasibl
patient
undergo
assess
olt
identifi
cad
signific
proport
high
cardiac
risk
patient
normal
dse
small
number
case
impact
select
transplant
find
suggest
ctca
may
play
use
role
screen
olt
candid
occult
coronari
arteri
diseas
disclosur
peter
w
angu
advisori
committe
review
panel
gilead
scienc
bm
bayer
grantresearch
support
gilead
scienc
follow
peopl
noth
disclos
marcu
robertson
william
w
chung
omar
farouqu
mark
horrigan
paul
gow
background
preval
obes
us
increas
past
decad
nash
complic
obes
sinc
number
adult
await
liver
transplant
lt
nash
almost
tripl
criteria
list
obes
patient
lt
variabl
across
lt
center
due
concern
obes
relat
complic
aim
studi
evalu
earli
outcom
obes
patient
undergo
liver
transplant
use
nation
databas
method
retrospect
cohort
studi
use
nation
inpati
sampl
largest
public
avail
inpati
databas
us
patient
princip
procedur
icd
code
lt
includ
exclus
criteria
primari
outcom
mortal
secondari
outcom
morbid
measur
intens
care
unit
icu
admiss
shock
failur
resourc
util
measur
length
hospit
stay
lo
total
hospit
charg
patient
classifi
obes
use
icd
code
multivari
logist
regress
odd
ratio
mean
adjust
age
sex
race
median
incom
patient
zip
code
charlson
comorbid
index
hospit
region
urban
locat
size
teach
statu
result
total
patient
underw
liver
transplant
studi
time
frame
obes
mean
age
year
femal
overal
mortal
obes
vs
tabl
show
adjust
odd
ratio
adjust
mean
p
valu
multivari
analysi
mortal
obes
patient
undergo
liver
transplant
differ
term
morbid
differ
odd
shock
icu
admiss
dysfunct
compar
obes
resourc
util
obes
patient
display
total
decreas
lo
total
hospit
charg
compar
differ
signific
multivari
analysi
conclus
obes
gener
associ
increas
risk
mortal
icu
admiss
shock
failur
resourc
util
patient
undergo
liver
transplant
disclosur
michael
l
schilski
advisori
committe
review
panel
gilead
gmpo
wilson
diseas
associ
grantresearch
support
wilson
therapeut
speak
teach
gilead
robert
brown
advisori
committe
review
panel
vital
therapi
consult
gilead
janssen
abbvi
merck
bm
follow
peopl
noth
disclos
paul
kroner
carolina
r
hurtado
raffi
karagozian
background
recent
studi
describ
strong
associ
earli
postlt
outcom
aim
confirm
find
multicent
la
fe
hospit
toronto
gener
hospit
retrospect
cohort
follow
method
tac
csa
trough
level
obtain
first
postlt
day
collect
high
defin
median
tac
csaco
ngml
ngml
ngml
respect
andor
peak
tac
ngml
optim
defin
median
tac
level
ngml
ngml
ngml
respect
low
defin
threshold
optim
exclus
criteria
lack
avail
data
determin
earli
switch
agent
endpoint
includ
surviv
sever
hcv
recurr
de
novo
diabet
mellitu
dm
de
novo
arteri
hypertens
aht
de
novo
malign
dnm
cardiovascular
event
cve
chronic
renal
impair
cri
defin
establish
egfr
ml
recurr
hepatocellular
carcinoma
hcc
moderatesever
acut
reject
acr
within
day
postlt
result
patient
male
median
age
lt
year
median
follow
yr
analyz
tac
csa
use
patient
respect
tac
median
level
ngml
ngml
ngml
respect
baselin
renal
impair
ri
frequent
group
respect
p
patient
surviv
yr
respect
sever
hcv
recurr
de
novo
dm
aht
dnm
cve
cri
hcc
recurr
acr
occur
respect
patient
die
due
recurr
primari
diseas
dnm
hcc
recurr
infect
cve
other
level
associ
surviv
time
point
adjust
baselin
featur
associ
found
either
level
hcv
recurr
dnm
cve
cri
hcc
recurr
analysi
also
perform
accord
calcineurin
inhibitor
fk
signific
differ
conclus
seri
contrast
previous
describ
one
studi
associ
found
earli
defin
cni
trough
level
first
postop
day
lt
outcom
measur
surviv
lt
outcom
strategi
aim
reduc
event
like
focu
addit
variabl
disclosur
gonzalo
sapisochin
grantresearch
support
bayer
eberhard
l
renner
advisori
committe
review
panel
vertex
canada
novarti
astella
canada
roch
canada
gambro
abbvi
bm
gilead
grantresearch
support
novarti
canada
gilead
speak
teach
novarti
astella
canada
roch
canada
martin
prieto
advisori
committe
review
panel
gilead
bristol
abbvi
marina
berengu
advisori
committe
review
panel
novarti
astella
gilead
bm
msd
grantresearch
support
gilead
follow
peopl
noth
disclos
tommaso
di
maira
max
marquez
francia
diaz
le
lilli
eva
montalva
rafa
introduct
renal
failur
first
year
post
liver
transplant
lt
predict
kidney
diseas
excess
risk
mortal
nephrotox
effect
administ
calcineurin
inhibitor
major
concern
goal
proof
concept
studi
develop
joint
model
investig
relationship
longitudin
exposur
tacrolimu
risk
renal
failur
first
year
post
lt
method
patient
transplant
retrospect
studi
longitudin
data
use
investig
variabl
trough
tacrolimu
concentr
first
month
lt
identifi
longitudin
cluster
use
kml
r
packag
joint
mix
effect
model
longitudin
exposur
tacrolimu
ie
concentr
first
year
event
develop
softwar
event
target
defin
acut
renal
failur
increas
serum
creatinin
first
year
accord
first
rifl
criteria
take
refer
serum
creatinin
valu
month
result
surviv
without
renal
failur
observ
three
month
lt
longitudin
cluster
analysi
perform
valu
measur
transplant
reveal
two
patient
patient
classifi
lowest
cluster
correspond
valu
lower
ngml
tend
less
event
renal
impair
addit
joint
model
approach
found
beyond
increas
tacrolimu
residu
concentr
associ
higher
risk
serum
creatinin
increas
compar
ml
hr
visual
predict
check
vpc
appli
curv
show
model
develop
appropri
describ
surviv
without
renal
failur
time
beyond
conclus
result
obtain
new
model
approach
provid
new
argument
reconsid
target
tacrolimu
concentr
lt
joint
model
test
larger
cohort
improv
take
account
renal
failur
reject
order
optim
tacrolimu
target
target
could
disclosur
paul
carrier
speak
teach
roch
msd
janssen
mari
essig
board
membership
gilead
astella
roch
grantresearch
support
gilead
speak
teach
novarti
pierr
marquet
advisori
committe
review
panel
astella
franc
sandoz
franc
consult
chiesi
veroniqu
board
membership
gilead
schere
plough
msd
speak
teach
gilead
schere
plough
msd
janssen
bristol
meyer
squibb
gilead
abbvi
follow
peopl
noth
disclos
annick
rousseau
marylin
premaud
nonalcohol
fatti
liver
diseas
nafld
exist
two
predomin
histolog
subtyp
nonalcohol
fatti
liver
nafl
nonalcohol
steatohepat
nash
nafl
character
benign
steatosi
nash
diagnos
steatosi
accompani
necroinflammatori
activ
fibrosi
nash
import
caus
cirrhosi
lead
list
diagnosi
among
new
liver
transplant
lt
waitlist
registr
howev
littl
known
regard
diseas
recurr
progress
lt
patient
transplant
nafld
thu
aim
current
studi
systemat
evalu
diseas
recurr
fibrosi
progress
patient
lt
nash
method
patient
lt
nash
suspect
nash
author
institut
includ
diseas
recurr
evalu
either
histolog
aliv
patient
perform
evalu
hepat
steatosi
control
attenu
paramet
cap
fibrosi
liver
stiff
measur
lsm
previous
describ
cutoff
cap
lsm
use
de
ledinghen
et
al
j
gastroenterol
hepatol
wong
et
al
j
gastro
fail
offer
liver
biopsi
chart
deceas
patient
review
liver
biopsi
done
year
includ
result
patient
met
entri
criteria
fibroscan
liver
biopsi
steatosi
detect
patient
defin
recurr
nafld
patient
lsm
measur
consist
either
fibrosi
fibrosi
advanc
fibrosi
note
cohort
patient
graft
cirrhosi
clinic
compens
patient
liver
biopsi
recurr
nafld
recurr
nash
bridg
fibrosi
note
patient
patient
cirrhosi
liver
biopsi
interestingli
serum
alt
ast
level
correl
diseas
recurr
nash
fibrosi
stage
lt
recipi
transplantedfor
nafld
three
patient
develop
clinic
signific
graft
cirrhosi
die
complic
relat
endstag
liver
diseas
conclus
recurr
nafld
common
diagnos
base
serum
aminotransferas
although
advanc
fibrosi
occur
nearli
quarter
patient
mortal
relat
graft
cirrhosi
rare
disclosur
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
velimir
luket
advisori
committe
review
panel
gsk
grantresearch
support
intercept
lumenashir
merck
gilead
genfit
bm
abvi
ngm
richard
k
sterl
advisori
committe
review
panel
merck
baxter
salix
bayer
bm
abbvi
gilead
gsk
jansen
grantresearch
support
merck
rochegenentech
pfizer
gilead
bayer
bm
abbvi
follow
peopl
noth
disclos
chandra
bhati
maria
rivera
michael
idowu
carloyn
driscol
divyanshoo
r
kohli
r
todd
stravitz
hochong
gill
scott
c
matherli
puneet
puri
hannah
lee
mohammad
siddiqui
background
studi
intens
care
unit
icu
outcom
patient
undergo
liver
transplant
lt
import
order
develop
system
patient
high
risk
mortal
readili
identifi
identif
predictor
mortal
help
guid
focu
critic
care
resourc
aim
studi
identifi
modifi
factor
predict
mortal
creat
new
model
patient
patient
method
consecut
patient
admit
unit
state
tertiari
care
center
surgic
icu
lt
follow
admiss
lt
hospit
discharg
death
predictor
mortal
defin
receiv
oper
characterist
roc
analysi
perform
assess
predict
mortal
logist
regress
analysi
done
develop
novel
model
use
characterist
result
total
patient
underw
lt
patient
complet
data
set
includ
age
year
male
mostli
hepat
c
viru
alcohol
relat
cirrhosi
die
hospit
higher
serum
creatinin
cr
acut
renal
failur
arf
significantli
common
patient
die
lt
respect
howev
analysi
neither
serum
cr
arf
perform
independ
reliabl
predictor
mortal
auc
respect
bodi
mass
index
need
renal
replac
therapi
encephalopathi
ascit
significantli
associ
mortal
occurr
infect
arf
significantli
common
subject
die
respect
trend
toward
signific
higher
estim
blood
loss
howev
variabl
readili
identifi
subject
exclud
multivari
model
adjust
infect
subject
arf
time
like
die
ci
multivari
logist
regress
model
z
predict
mortal
defin
follow
xarf
excel
perform
auc
conclus
arf
presenc
infect
excel
predictor
mortal
follow
lt
earli
identif
factor
guid
target
critic
care
resourc
hope
improv
immedi
outcom
disclosur
follow
peopl
noth
disclos
christina
c
lindenmey
ahyoung
kim
fadi
niyazi
rocio
lopez
neal
mehta
vedha
sanghi
aanchal
kapoor
carlo
j
background
perform
earli
post
liver
transplant
lt
meld
even
dynam
chang
time
predict
mortal
lt
still
controversi
aim
assess
abil
absolut
calcul
day
lt
predict
mortal
method
data
consecut
patient
underw
lt
two
center
review
patient
receiv
lt
hcc
exclud
well
surviv
least
one
month
meld
calcul
patient
day
lt
result
one
hundr
patient
includ
mostli
male
mean
age
year
main
indic
transplant
decompens
liver
cirrhosi
n
donor
live
deceas
patient
surviv
year
respect
mean
surviv
month
univari
analysi
absolut
day
significantli
predict
mortal
multivari
analysi
meld
day
significantli
associ
ci
p
year
mortal
ci
p
area
curv
meld
day
predict
mortal
year
p
year
cutoff
day
meld
could
predict
mortal
sensit
specif
year
year
respect
conclus
failur
meld
score
declin
first
postop
month
less
signific
predictor
earli
late
mortal
disclosur
wael
grantresearch
support
gilead
scienc
inc
imam
wake
advisori
committe
review
panel
janssen
speak
teach
hoffman
l
roch
bm
gilead
abbvi
follow
peopl
noth
disclos
talaat
zakareya
moham
abbasi
hussein
elsiesi
faisal
abal
khail
moham
al
sebayel
background
aim
nonalcohol
steatohepat
nash
current
second
lead
indic
lt
project
lead
indic
next
year
given
hispan
patient
disproportion
affect
nash
therebi
potenti
compris
greater
proport
lt
recipi
import
investig
perform
popul
aim
evalu
relationship
hispan
ethnic
mortal
method
perform
retrospect
cohort
studi
adult
lt
recipi
hispan
patient
compar
white
black
patient
nash
defin
use
diagnost
code
free
text
cryptogen
cirrhosi
plu
diabet
dm
hypertens
associ
raceethn
surviv
evalu
use
cox
regress
result
lt
recipi
includ
median
time
year
iqr
year
white
hispan
black
asian
comparison
made
amongst
white
hispan
black
lt
recipi
hcv
common
indic
lt
across
three
group
white
hispan
black
nash
third
lead
indic
three
group
white
hispan
higher
proport
compar
black
hispan
lt
recipi
like
govern
provid
health
insur
medicar
medicaid
higher
preval
bmi
dm
hcc
longer
median
wait
list
time
vs
day
white
black
univari
cox
regress
hispan
ethnic
signific
predictor
mortal
hr
black
race
associ
increas
mortal
hr
howev
adjust
factor
known
affect
mortal
hispan
ethnic
associ
decreas
mortal
hr
ci
black
race
remain
predictor
death
hr
nash
lt
recipi
associ
hispan
ethnic
mortal
persist
hr
ci
black
race
associ
differ
mortal
nash
subgroup
hr
ci
conclus
hispan
patient
better
surviv
white
patient
despit
higher
incid
dm
govern
fund
insur
longer
wait
list
time
despit
higher
risk
nash
ethnic
proport
hispan
lt
recipi
nash
similar
white
patient
may
indic
decreas
access
transplant
disclosur
john
p
robert
consult
medsleuth
stock
sharehold
gilead
alexion
follow
peopl
noth
disclos
esteban
figueroa
daniel
brandman
background
liver
transplant
lt
recipi
autoimmun
liver
diseas
psc
pbc
aih
increas
risk
acut
cellular
reject
acr
mani
case
graft
failur
due
recurr
diseas
describ
experi
dual
immunosuppress
steroid
free
transplant
protocol
analyz
effect
diseas
recurr
acr
patient
graft
surviv
complic
sepsi
de
novo
malign
method
conduct
retrospect
chart
review
patient
underw
lt
aih
psc
pbc
april
april
singl
transplant
center
includ
patient
immunosuppress
protocol
includ
rabbit
globulin
mgkg
day
lt
day
dose
solumedrol
mg
iv
day
lt
follow
mycophenol
mofetil
mg
bid
tacrolimu
sirolimuseverolimu
indefinit
result
overal
surviv
respect
median
year
overal
patient
figur
free
surviv
figur
compar
among
diseas
categori
multivari
forward
condit
stratifi
cox
regress
model
steroid
use
acr
predict
overal
patient
graft
surviv
acr
pbc
psc
note
lt
recipi
episod
requir
iv
solumderol
episod
requir
iv
thymoglobulin
rest
manag
optim
immunosuppress
overal
recurr
autoimmun
liver
diseas
note
lt
recipi
episod
sepsi
occur
patient
pbc
aih
risk
malign
low
patient
develop
de
novo
cancer
conclus
dual
immunosuppress
protocol
use
lt
recipi
autoimmun
liver
diseas
accept
rate
surviv
acr
without
predispos
patient
advers
effect
steroid
therapi
patient
fig
graft
surviv
fig
psc
pbc
aih
compar
disclosur
sanjaya
k
satapathi
advisori
committe
review
panel
gilead
abbvi
board
membership
intercept
grantresearch
support
genfit
gilead
biotest
conatu
intercept
satheesh
nair
advisori
committe
review
panel
jansen
grantresearch
support
gilead
speak
teach
abbvi
valeant
bm
intercept
follow
peopl
noth
disclos
olli
jone
faisal
kamal
jason
vanatta
jame
eason
background
cardiovascular
cv
event
major
caus
earli
mortal
despit
preval
cirrhot
cardiomyopathi
liver
transplant
recipi
current
screen
emphas
evalu
ischem
heart
diseas
systol
function
pulmonari
hypertens
mount
evid
suggest
diastol
dysfunct
common
patient
popul
echocardiograph
paramet
may
predict
outcom
aim
evalu
impact
diastol
dysfunct
cv
event
mortal
length
stay
lo
immedi
period
index
hospit
method
adult
lt
recipi
ucsf
includ
transthorac
echocardiogram
tte
electrocardiogram
ekg
perform
within
month
prior
lt
patient
acut
liver
failur
hiv
infect
undergo
exclud
covari
includ
diagnosi
meld
metabol
diabetesdm
hypertensionhtn
cardiac
qt
interv
tte
paramet
cv
event
defin
arrhythmia
myocardi
infarct
stroke
death
logist
regress
use
assess
relationship
diastol
dysfunct
cv
event
result
patient
includ
median
age
male
white
chronic
viral
hepat
common
etiolog
liver
diseas
nashcryptogen
cirrhosi
account
percent
recipi
underw
lt
hcc
median
calcul
meld
iqr
preval
diastol
dysfunct
median
qtc
iqr
patient
without
diastol
dysfunct
similar
regard
age
gender
race
etiolog
liver
diseas
meld
dm
htn
histori
smoke
p
percent
patient
cv
event
die
median
lo
day
iqr
diastol
dysfunct
associ
cv
event
ci
mortal
lo
conclus
retrospect
studi
lt
recipi
singl
center
preval
diastol
dysfunct
tte
similar
studi
diastol
dysfunct
associ
cv
event
mortal
lo
exist
data
conflict
result
possibl
underpow
detect
effect
disclosur
john
p
robert
consult
medsleuth
stock
sharehold
gilead
alexion
follow
peopl
noth
disclos
sean
rudnick
atif
qasim
daniel
brandman
background
endogen
peptid
plasma
includ
messeng
hormon
cytokin
involv
physiolog
diseas
process
liver
detail
analysi
plasma
peptidom
hold
promis
sourc
biomark
use
diagnosi
stage
diseas
well
monitor
postop
complic
liver
failur
partial
hepatectomi
phx
hypothes
alter
plasma
peptid
profil
may
reflect
liver
regener
follow
phx
method
test
hypothesi
perform
comprehens
plasma
peptidom
analys
partial
hepatectom
microminipig
smallest
pig
world
recent
establish
model
biomed
research
five
microminipig
underw
phx
gener
anesthesia
plasma
sampl
collect
minut
hour
phx
use
magnet
bead
purif
success
ms
base
analysi
plasma
sampl
well
liquid
chromatographi
follow
tandem
ms
identifi
endogen
circul
peptid
specif
phase
postop
cours
phx
result
identifi
peptid
might
biolog
relev
notabl
peptid
fragment
nucleosom
compon
includ
histon
detect
soon
phx
presenc
fragment
may
trigger
liver
regener
acut
phase
phx
endogen
peptid
deriv
phosphoprotein
detect
peptid
valid
protein
level
plasma
liver
addit
differ
epitop
protein
includ
albumin
hemoglobin
subunit
show
differ
pattern
chang
phx
mani
biomark
discoveri
effort
search
variat
total
abund
particular
protein
howev
consid
data
differ
epitop
protein
could
sensit
biomark
variou
process
healthi
andor
diseas
liver
includ
liver
regener
phx
conclus
endogen
plasma
peptid
clearli
reflect
postop
cours
phx
pig
molecul
could
becom
sensit
biomark
monitor
postop
complic
futur
studi
need
valid
find
clinic
set
disclosur
follow
peopl
noth
disclos
kohta
iguchi
etsuro
hatano
takashi
nirasawa
noriyuki
iwasaki
motohiko
sato
gen
yamamoto
yosuk
kasai
satoru
seo
kojiro
taura
masaya
ikegawa
shinji
uemoto
background
employ
trajectori
liver
transplant
recipi
return
work
may
influenc
outcom
especi
patient
experi
job
loss
test
associ
new
unemploy
surviv
method
liver
transplant
recipi
age
year
transplant
may
subsequ
return
work
identifi
unit
network
organ
share
registri
surviv
time
work
resumpt
analyz
use
curv
multivari
cox
proport
hazard
model
unemploy
work
resumpt
classifi
temporari
patient
later
return
work
continu
patient
remain
unemploy
death
censor
result
liver
recipi
identifi
studi
period
return
work
median
day
includ
analysi
employ
trajectori
includ
continu
employ
unemploy
report
return
work
temporari
unemploy
continu
unemploy
plot
demonstr
wors
surviv
continu
unemploy
group
rel
temporarili
unemploy
continu
employ
patient
p
figur
multivari
analysi
unemploy
covari
found
becom
unemploy
associ
greater
mortal
hazard
ci
p
adjust
patient
demograph
clinic
characterist
time
transplant
initi
return
work
conclus
although
liver
transplant
recipi
return
work
better
outcom
studi
demonstr
employ
discontinu
pose
risk
surviv
popul
disclosur
follow
peopl
noth
disclos
eliza
w
beal
dmitri
tumin
michael
nau
joseph
tobia
hay
jr
khalid
mumtaz
sylvest
black
background
weight
gain
metabol
syndrom
occur
liver
transplant
lt
though
mechan
poorli
understood
hypothes
may
relat
reduc
metabol
rate
follow
lt
particularli
exercis
purpos
studi
compar
energi
expenditur
rest
exercis
lt
recipi
control
method
fourteen
subject
steatohepat
post
thirteen
subject
fatti
liver
diseas
nafld
perform
exercis
test
subject
underw
analysi
bodi
composit
rest
energi
expenditur
ree
exercis
energi
expenditur
vo
max
max
test
conduct
use
protocol
assess
respiratori
exchang
ratio
peak
heart
rate
subject
stratifi
sex
transplant
statu
match
bmi
age
male
femal
analyz
separ
due
inher
differ
metabol
rate
result
baselin
demograph
significantli
differ
group
tabl
femal
significantli
lower
mean
ree
kcaldaykg
nafld
femal
adjust
total
bodi
mass
lean
bodi
mass
vs
max
ml
kgmin
also
lower
femal
compar
nafld
femal
vs
p
among
male
mean
ree
lower
patient
compar
nafld
differ
statist
signific
adjust
either
total
bodi
mass
vs
lean
bodi
mass
vs
vo
max
lower
male
nafld
male
though
statist
signific
vs
discuss
lt
recipi
particularli
femal
lower
ree
exercis
energi
expenditur
compar
nafld
control
despit
similar
metabol
risk
factor
may
relat
hormon
factor
well
loss
hepat
innerv
follow
lt
individu
aggress
diet
exercis
program
account
lower
calori
expenditur
rest
exercis
institut
optim
weight
manag
tabl
comparison
group
disclosur
mari
e
rinella
advisori
committe
review
panel
abbvi
intercept
consult
fibrogen
ngm
shire
josh
levitski
consult
transplant
genom
incorpor
follow
peopl
noth
disclos
ajay
singhvi
h
steven
sadowski
ayelet
cohen
alysen
demzik
lisa
b
vanwagn
background
stenosi
portal
vein
pv
rare
complic
liver
transplant
lt
pediatr
patient
shown
advers
affect
graft
outcom
increas
lifespan
pediatr
patient
transplant
import
take
proactiv
measur
ensur
graft
surviv
studi
review
safeti
efficaci
percutan
transhepat
balloon
angioplasti
ptba
treatment
portal
vein
stenosi
pv
post
liver
transplant
method
januari
april
pediatr
patient
receiv
liver
transplant
tertiari
referr
transplant
center
review
record
found
children
evalu
pv
lt
use
percutan
transhepat
portal
venographi
ptpv
result
patient
median
age
year
iqr
diagnos
pv
use
ptpv
treat
ptba
two
patient
exclud
analysi
one
pv
receiv
surgic
shunt
surgeri
instead
ptba
patient
also
underw
intravascular
ultrasonographi
ivu
median
time
lt
ptba
month
iqr
half
patient
transplant
due
biliari
atresia
transhepat
approach
use
patient
mean
pv
pressur
gradient
mm
hg
sd
vein
complet
occlus
mean
pv
pressur
gradient
mm
hg
sd
mean
percentag
improv
pressur
gradient
across
stenot
region
pv
sd
averag
fluoroscopi
time
minut
sd
median
platelet
ast
alt
ggt
level
time
ptba
iqr
iqr
iqr
ptba
time
month
visit
iqr
iqr
iqr
iqr
month
ptba
mean
percentag
increas
platelet
level
sd
mean
percentag
decreas
ast
alt
ggt
bilirubin
sd
sd
sd
sd
patient
requir
intervent
stent
portal
venou
patenc
maintain
median
month
iqr
conclus
percutan
transhepat
angioplasti
portal
vein
stenosi
pediatr
liver
transplant
safe
effect
treatment
patenc
improv
clinic
outcom
lead
increas
longev
graft
improv
qualiti
life
disclosur
follow
peopl
noth
disclos
kushal
b
naik
clifford
hawkin
ann
e
gill
nitika
gupta
background
postop
care
fragment
defin
readmiss
hospit
hospit
patient
underw
initi
surgic
procedur
sever
surgic
popul
postop
fragment
associ
increas
risk
short
advers
outcom
object
studi
evalu
whether
care
fragment
associ
reduc
surviv
olt
method
retrospect
cohort
review
perform
use
healthcar
cost
util
project
hcup
state
inpati
databas
florida
california
patient
underw
olt
includ
follow
year
primari
exposur
postop
care
fragment
defin
readmiss
hospit
within
day
discharg
patient
transfer
back
index
hospit
within
hour
consid
group
primari
outcom
surviv
gamma
share
frailti
model
use
risk
adjust
adjust
patient
demograph
clinic
transplant
encount
variabl
result
total
patient
receiv
olt
readmit
cohort
fragment
postop
care
mortal
patient
care
fragment
vs
fragment
care
group
women
group
vs
p
differ
charlson
comorbid
index
age
race
etiolog
liver
diseas
group
signific
differ
note
characterist
index
inpati
stay
group
time
liver
transplant
patient
ultim
fragment
care
longer
preoper
length
stay
lo
vs
day
p
longer
postop
lo
vs
day
p
higher
cost
index
hospit
vs
p
adjust
factor
well
age
gender
charlson
comorbid
index
reason
transplant
patient
care
fragment
remain
heighten
risk
mortal
compar
without
fragment
care
hr
c
conclus
postop
care
fragment
follow
olt
associ
significantli
increas
risk
mortal
given
complex
care
patient
popul
effort
made
ensur
inpati
care
first
day
follow
transplant
occur
index
transplant
center
disclosur
follow
peopl
noth
disclos
veronica
loy
anai
kothari
emili
weng
yoshiki
ezur
paul
kuo
ami
lu
scott
cotler
introduct
biliari
strictur
expect
complic
liver
transplant
lt
occur
liver
transplant
recipi
ltr
suspect
abnorm
note
liver
enzym
addit
work
usual
entail
addit
imag
follow
confirmatori
endoscop
retrograd
cholangiopancreatographi
ercp
diagnost
accuraci
liver
enzym
imag
modal
us
mri
detect
biliari
strictur
ltr
unknown
aim
current
studi
evalu
diagnost
accuraci
liver
enzym
imag
modal
predict
biliari
strictur
method
retrospect
studi
evalu
adult
patient
lt
subsequ
ercp
suspect
biliari
strictur
presenc
biliari
strictur
confirm
via
blind
review
three
expert
intervent
endoscopist
unanim
agre
presenc
biliari
strictur
defin
previous
tabibian
et
al
ann
hepatol
optim
liver
enzym
predict
biliari
strictur
determin
use
youden
index
final
diagnost
accuraci
us
mri
predict
biliari
strictur
evalu
result
total
subject
male
age
year
met
inclus
criteria
mean
time
ercp
year
transplant
subject
biliari
strictur
blind
review
warm
ischemia
time
associ
presenc
biliari
strictur
p
invers
relationship
biliari
strictur
durat
lt
ercp
p
relationship
biliari
strictur
type
donat
live
donor
vs
deceas
donor
observ
optim
determin
biliari
strictur
rise
liver
enzym
compar
baselin
follow
alkalin
phatas
ap
ast
alt
ul
respect
use
alt
elev
highli
sensit
neg
predict
valu
limit
specif
contrast
increas
ap
iul
highest
specif
much
lower
sensit
imag
modal
demonstr
even
lower
accuraci
predict
presenc
biliari
strictur
mri
us
conclus
imag
modal
us
mri
reliabl
predict
presenc
biliari
strictur
ltr
although
imag
modal
rise
liver
enzym
modest
accuraci
predict
biliari
strictur
rise
serum
alt
without
altern
explan
offer
high
neg
predict
valu
disclosur
follow
peopl
noth
disclos
divyanshoo
r
kohli
ravi
vachhani
doumit
bouhaidar
tilak
shah
andrew
moweri
mohammad
siddiqui
background
sinc
avail
entecavir
tenofovir
number
chronic
hepat
b
viru
hbv
patient
progress
diseas
lead
liver
transplant
lt
plateau
proport
hepatocellular
carcinoma
hcc
continu
rise
unclear
trend
affect
men
women
raceethn
group
equal
aim
evalu
trend
lt
list
waitlist
surviv
probabl
receiv
lt
among
adult
chronic
hbv
us
method
use
unit
network
organ
share
registri
data
retrospect
evalu
us
adult
age
chronic
hbv
without
hcc
list
lt
compar
trend
lt
list
year
lt
list
stratifi
time
period
era
vs
era
vs
era
overal
waitlist
surviv
odd
receiv
lt
evalu
multivari
logist
regress
model
stratifi
presenc
hcc
adjust
sex
race
ethnic
age
meld
score
bodi
mass
index
uno
region
result
overal
adult
chronic
hbv
list
lt
major
asian
men
recent
era
men
account
asian
account
lt
waitlist
registr
although
total
number
hbv
patient
list
lt
remain
stabl
proport
hbv
patient
hcc
increas
era
era
compar
era
hbv
patient
era
less
like
die
wait
lt
without
hcc
hcc
asian
hbv
also
lower
odd
waitlist
death
compar
white
without
hcc
p
hcc
p
compar
women
hbv
men
hbv
lower
odd
waitlist
death
seen
cohort
evalu
odd
receiv
lt
hbv
patient
latter
time
period
less
like
receiv
lt
compar
white
hbv
trend
toward
higher
odd
receiv
lt
among
asian
among
cohort
compar
women
hbv
trend
toward
higher
odd
lt
seen
among
men
hcc
cohort
conclus
recent
era
major
lt
list
attribut
asian
men
account
lt
list
us
respect
nearli
half
hbv
patient
list
lt
concurr
hcc
disclosur
ramsey
cheung
grantresearch
support
gilead
scienc
abbvi
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
follow
peopl
noth
disclos
kelli
young
benni
liu
taft
bhuket
michel
tana
malign
liver
transplant
lt
lead
caus
mortal
data
limit
small
sampl
size
predominantli
studi
aim
determin
incid
risk
factor
de
novo
malign
lt
larg
databas
method
scientif
registri
transplant
recipi
srtr
databas
compris
adult
liver
transplant
recipi
across
unit
state
analyz
median
year
result
liver
transplant
recipi
includ
mean
age
year
male
caucasian
mean
bodi
mass
index
bmi
diabet
previou
malign
year
cancer
surviv
malign
skin
cancer
hematolog
malign
solid
malign
hepatocellular
carcinoma
cholangiocarcinoma
recurr
exclud
analysi
univari
analysi
age
male
gender
previou
malign
transplant
alcohol
liver
diseas
nash
obes
diabet
donor
bmi
donor
age
mtor
exposur
year
associ
increas
risk
howev
multivari
analysi
age
decad
hr
ci
p
male
gender
hr
ci
p
caucasian
race
hr
ci
multiorgan
transplant
hr
ci
previou
malign
hr
ci
p
psc
hr
ci
independ
predictor
malign
hr
ci
p
hispan
hr
ci
p
asian
hr
ci
p
race
associ
fewer
malign
compar
caucasian
bmi
hr
ci
diabet
hr
ci
also
associ
fewer
malign
donor
factor
age
gender
ethnic
bmi
recipi
creatinin
predict
malign
neither
calcineurin
inhibitor
mtor
inhibitor
exposur
within
first
year
post
transplant
associ
malign
transplant
mv
analysi
conclus
liver
transplant
recipi
probabl
de
novo
malign
respect
increas
age
male
gender
caucasian
race
transplant
psc
predict
higher
risk
malign
lt
patient
characterist
screen
vigilantli
malign
disclosur
follow
peopl
noth
disclos
mamatha
bhat
kristin
mara
ross
dierkhis
kymberli
watt
purpos
shear
wave
elastographi
vtq
virtual
touch
quantif
novel
noninvas
tool
assess
liver
fibrosi
measur
liver
stiff
vtq
also
possibl
evalu
liver
function
hepatectomi
present
studi
demonstr
associ
shear
wave
veloc
swv
liver
function
test
investig
whether
swv
would
avail
predict
factor
postop
complic
patient
method
clinic
cours
patient
underw
hepatectomi
hepatocellular
carcinoma
depart
januari
march
review
patient
underw
vtq
undergo
hepatectomi
vtq
perform
five
time
differ
area
right
hepat
lobe
mean
swv
calcul
patient
postop
hepat
failur
defin
accord
intern
studi
group
liver
surgeri
result
base
hepat
fibrosi
stage
swv
ms
ms
ms
ms
ms
respect
swv
cirrhosi
significantli
faster
p
swv
show
correl
albumin
p
prothrombin
time
p
astplt
ratio
index
apri
p
indocyanin
green
p
postop
hepat
failur
develop
patient
six
patient
death
univari
analysi
swv
alt
platelet
count
apri
oper
time
intraop
blood
loss
shown
significantli
risk
postop
hepat
failur
multivari
analysi
use
logist
regress
model
involv
seven
signific
factor
determin
univari
analysi
confirm
two
signific
independ
variabl
apri
intraop
blood
loss
p
valu
swv
swv
tendenc
risk
postop
hepat
failur
conclus
shear
wave
elastographi
may
use
tool
evalu
liver
function
hepatectomi
predict
possibl
postop
hepat
failur
disclosur
follow
peopl
noth
disclos
seikan
hai
etsuro
hatano
tadamichi
hirano
yuichi
kondo
nobuhiro
aizawa
hiroko
iijima
jiro
fujimoto
background
aim
recent
report
singl
inject
stem
cell
deriv
human
exfoli
decidu
teeth
shed
popul
msc
condit
medium
shed
markedli
improv
condit
injur
liver
rat
model
acut
liver
failur
alf
induc
anoth
studi
identifi
set
macrophag
induc
monocyt
chemoattract
secret
ectodomain
sialic
show
promot
function
recoveri
rat
spinal
cord
injuri
studi
investig
role
therapeut
potenti
treat
alf
method
rat
alf
induc
intraperiton
inject
inject
mixtur
equival
volum
pb
inject
tail
vein
assess
surviv
rate
serum
transaminas
level
liver
histopatholog
gene
express
real
addit
bone
marrow
cell
rat
isol
differenti
bone
marrow
macrophag
macrophag
factor
incub
dmem
dmem
incub
cell
morpholog
mrna
express
pattern
examin
supernat
use
macrophag
cm
subsequ
apoptosi
model
primari
hepatocyt
made
use
lp
evalu
abil
hepatocyt
macrophag
cm
result
found
singl
intraven
inject
separ
inject
administ
h
inject
markedli
decreas
ast
alt
level
improv
surviv
rate
compar
group
p
rat
also
exhibit
significantli
lower
number
tunel
apoptot
cell
higher
number
prolifer
hepatocyt
rat
mrna
level
marker
significantli
elev
group
compar
control
addit
promot
differenti
bone
macrophag
vitro
cm
suppress
induc
primari
hepatocyt
apoptosi
p
conclus
uniqu
combin
amelior
rat
alf
induct
macrophag
disclosur
hidemi
goto
grantresearch
support
msd
roch
bayer
eisai
ajinomoto
otsuka
astra
tanab
takeda
follow
peopl
noth
disclos
takanori
ito
akihito
yamamoto
yoji
ishizu
teiji
kuzuya
takashi
honda
tetsuya
ishikawa
masatoshi
ishigami
yoshiki
hirooka
receptor
dsdna
receptor
absent
melanoma
involv
assembl
inflammasom
trigger
activ
product
inflammatori
cytokin
hypothes
inflammasom
activ
chronic
liver
injuri
creat
inflammatori
environ
promot
develop
hepatocellular
carcinoma
hcc
object
investig
function
inflammasom
hcc
initi
promot
mice
explor
inhibit
therapeut
tool
mous
model
hcc
evalu
express
inflammasom
compon
human
hcc
patient
method
evalu
develop
hcc
mice
wt
mice
defici
studi
initi
promot
phase
hcc
use
combin
den
carbon
tetrachlorid
administr
inhibit
mice
perform
use
antibodi
last
analyz
pbmc
isol
patient
hcc
patient
advanc
liver
diseas
without
hcc
control
result
month
singl
den
inject
mice
show
strike
reduct
tumor
incid
number
size
compar
wt
mice
liver
injuri
express
inflammatori
mediat
liver
tissu
also
reduc
mice
contrast
tumor
develop
liver
injuri
mice
significantli
differ
wt
control
den
administr
augment
concentr
free
dsdna
serum
wt
mice
hcc
initi
acut
hepatocyt
damag
liver
inflamm
decreas
mice
time
b
blockad
amelior
hepatocyt
damag
express
inflammatori
prolif
marker
liver
tissu
wt
mice
highlight
role
model
mice
also
reduc
hepatocyt
damag
express
inflammatori
prolif
marker
liver
tissu
hcc
promot
addit
treatment
increas
protein
express
inflammasom
compon
liver
wt
mice
last
express
upregul
pbmc
patient
hcc
show
posit
associ
sever
liver
damag
patient
conclus
promot
develop
hcc
mice
increas
respons
tumor
initi
promot
express
hcc
patient
suggest
inflammasom
may
also
play
import
role
human
hcc
disclosur
jose
consult
sequana
medic
sequana
medic
sequana
medic
sequana
medic
stock
sharehold
sequana
medic
sequana
medic
sequana
medic
sequana
medic
follow
peopl
noth
disclos
claudia
martinez
cardona
beatriz
victoria
bachil
francisco
algaba
isabel
alba
moratalla
paula
paula
pinero
romero
oriol
juanola
juarez
pedro
zapat
ruben
franc
liver
fibrosi
excess
accumul
extracellular
matrix
ecm
protein
includ
collagen
occur
type
chronic
liver
diseas
enzym
lysyl
oxidas
lox
famili
catalyz
coval
crosslink
collagen
fiber
specif
lysyl
oxidas
observ
regul
ecm
stiff
stabil
sever
liver
diseas
associ
collagen
scar
format
therefor
inhibit
liver
fibrosi
propos
potenti
target
therapeut
intervent
show
mous
model
liver
fibrosi
treatment
novel
antibodi
ab
target
catalyticsit
inhibit
extracellular
activ
significantli
improv
liver
resolut
comparison
mice
treat
isotyp
control
ab
siriu
red
stain
reveal
reduc
collagen
deposit
histopatholog
score
monitor
matrix
proteas
activ
situ
zymographi
uncov
acceler
augment
collagen
degrad
mice
began
alreadi
fibrot
phase
accompani
increas
infiltr
macrophag
local
specif
area
fibrot
fiber
induc
select
ablat
negat
activ
collagenolyt
activ
observ
treat
mice
furthermor
provid
evid
specif
mmp
e
effici
collagenas
involv
degrad
collagen
follow
treatment
ab
altogeth
result
demonstr
inhibit
ecm
crosslink
reduc
amount
fibrosi
liver
break
ground
arriv
collagenolyt
macrophag
thu
constitut
promis
therapeut
strategi
disclosur
follow
peopl
noth
disclos
mordehay
klepfish
milena
vugman
chen
varol
irit
sagi
accumul
evid
suggest
offspr
obes
mother
wors
obes
fatti
liver
diseas
nafld
mechan
development
program
nafld
appear
involv
innat
immun
system
studi
shown
hedgehog
hh
morphogen
involv
embryogenesi
regul
immun
cell
develop
addit
hh
signal
shown
play
import
role
fat
distribut
obes
nafld
investig
interact
hh
signal
pathway
matern
obes
regul
immun
develop
offspr
program
nafld
method
adult
femal
mice
shown
increas
hh
signal
vivo
subject
either
control
diet
week
mice
embryon
day
foetal
liver
analys
result
interestingli
foetal
liver
embryo
obes
mother
obem
consist
upregul
inflammatori
marker
tumour
necrosi
marker
liver
injuri
transform
growth
tgfp
muscl
actin
asma
collagen
type
flow
cytometri
result
show
increas
percentag
neutrophil
natur
killer
nk
cell
foetal
liver
obem
compar
embryo
lean
mother
conem
conem
also
increas
percentag
neutrophil
nk
cell
compar
conem
howev
obem
show
statist
differ
compar
conem
neutrophil
nk
cell
popul
conclus
matern
obes
increas
liver
inflamm
injuri
accompani
alter
hepat
immun
earli
stage
hh
signal
pathway
interact
matern
diet
alter
foetal
liver
develop
disclosur
follow
peopl
noth
disclos
jiawei
li
anisha
solanki
paul
cordero
vi
nguyen
cansev
katar
manlio
vinciguerra
tessa
crompton
jude
oben
introduct
cellular
adhes
molecul
carcinoembryon
cell
adhes
molecul
member
immunoglobulin
superfamili
express
epithelia
endothelia
especi
leukocyt
receptor
long
cytoplasm
domain
contain
immun
receptor
inhibit
motif
itim
pivot
neg
regul
leukocyt
activ
specif
suppress
activ
nk
cell
cell
myeloid
cell
control
inflamm
role
ceacaml
liver
damag
model
resembl
autoimmun
hepat
unknown
therefor
studi
role
ceacaml
liver
inflamm
method
use
concanavalin
inject
induc
liver
damag
immun
cell
popul
character
flow
cytometri
alanin
aminotransferas
activ
alt
measur
coba
analyz
cytokin
level
determin
elisa
flow
cytometri
result
upon
cona
inject
mice
develop
sever
liver
injuri
increas
plasma
transaminas
activ
compar
wt
anim
effect
cell
intrins
independ
liver
sinc
mice
receiv
cell
mice
sensit
toward
cona
challeng
compar
anim
receiv
wt
cell
furthermor
mice
show
significantli
reduc
plasma
cytokin
level
reduc
secret
cell
nkt
cell
moreov
treg
accumul
blunt
liver
mice
upon
cona
stimul
although
treg
mice
still
suppress
vitro
suppress
assay
howev
treg
fail
prevent
liver
injuri
show
reduc
prolifer
upon
adopt
transfer
conclus
result
disclos
previous
undescrib
protect
role
ceacaml
model
liver
injuri
result
reduct
liver
patholog
concanavalin
hepat
specif
protect
injuri
reli
ceacaml
express
cell
nkt
cell
modul
cytokin
product
aid
treg
prolifer
disclosur
follow
peopl
noth
disclos
andrea
k
horst
claudia
wegscheid
christoph
schaefer
gisa
tieg
global
hepat
e
viru
hev
may
caus
mani
million
infect
annual
result
death
mostli
due
fulmin
liver
failur
hev
infect
present
signific
public
health
problem
asia
africa
hev
caus
larg
waterborn
epidem
acut
jaundic
develop
countri
seropreval
antibodi
highest
clinic
attack
rate
among
young
adult
better
understand
secondari
spread
hev
infect
often
occur
endem
set
develop
countri
rhesu
macaqu
homolog
strain
hev
genotyp
l
assess
host
immun
respons
contribut
protect
subsequ
reinfect
recoveri
initi
hev
infect
rhesu
macaqu
homolog
hev
genotyp
l
follow
l
day
three
naiv
monkey
use
control
initi
igg
concentr
previous
infect
monkey
rang
uml
nine
rhesu
macaqu
monkey
infecti
dose
mid
anim
mid
hev
evid
viral
replic
assess
detect
hev
rna
stool
serum
pcr
evid
hepat
measur
serum
alanin
aminotransferas
alt
activ
igg
antibodi
concentr
igg
hev
avid
index
analyz
serum
sampl
seven
monkey
igg
conc
uml
initi
titer
primari
infect
develop
infect
shed
viru
fece
five
anim
igg
conc
uml
reinfect
evidenc
hev
rna
stool
day
five
anim
develop
infect
lower
avid
index
averag
anim
averag
avid
index
becom
infect
none
monkey
show
elev
alt
activ
three
control
monkey
primari
infect
significantli
lower
igg
avid
index
averag
p
conclus
studi
indic
antibodi
avid
index
import
factor
protect
reinfect
experiment
infect
rhesu
macaqu
studi
provid
evid
protect
hev
reinfect
disclosur
follow
peopl
noth
disclos
youkyung
choi
xiugen
zhang
coleen
tran
brianna
skinner
background
aim
mice
lack
regulatori
cell
treg
mutat
transcript
factor
display
autoimmun
includ
lymphocyt
hepat
infiltr
biochem
hepat
develop
antibodi
ama
analog
drawn
primari
biliari
cholang
mutat
autoimmun
regul
gene
air
impair
thymic
present
otherwis
antigen
develop
cell
associ
hepat
autoimmun
human
mice
method
cell
prepar
thymus
pup
transfer
cell
defici
host
day
later
host
replet
lymphocyt
provid
treg
mice
treg
noth
defici
air
confirm
commerci
pcr
anim
sacrif
onset
system
diseas
assess
technician
blind
treatment
week
sacrific
anim
assess
serum
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
activ
ama
titr
elisa
spleen
weight
proxi
generalis
autoimmun
leucocyt
content
liver
spleen
flow
cytometri
histolog
immunohistochemistri
result
anim
replet
treg
aliv
well
six
week
wherea
anim
receiv
treg
control
demonstr
overt
autoimmun
transfer
either
treg
prevent
splenomegali
reduc
serum
alt
reduc
serum
tnfa
compar
mice
receiv
defici
cell
without
subsequ
treg
replet
assess
flow
cytometri
number
cell
per
gram
liver
spleen
reduc
transfer
either
treg
number
b
cell
unchang
trend
reduct
serum
ldh
ama
titr
transfer
develop
infiltr
contain
numer
cell
abolish
either
treg
signific
differ
treg
recipi
group
conclus
result
suggest
treg
air
defici
anim
suffici
control
generalis
hepat
autoimmun
dysfunct
result
contrast
work
describ
revers
hepat
autoimmun
older
air
balbc
anim
adopt
transfer
wildtyp
treg
differ
implic
host
genet
factor
includ
hla
type
environment
influenc
disclosur
gideon
hirschfield
advisori
committe
review
panel
intercept
pharma
gsk
consult
cymabay
novarti
grantresearch
support
falk
pharma
bioti
takeda
follow
peopl
noth
disclos
gwilym
webb
fabrina
gaspal
nichola
mccarthi
peter
j
lane
background
aim
mice
lack
regulatori
cell
treg
mutat
transcript
factor
display
autoimmun
includ
lymphocyt
hepat
infiltr
biochem
hepat
develop
antibodi
ama
analog
drawn
human
primari
biliari
cholang
pbc
secondari
pair
implic
perpetu
effector
cell
respons
maintain
cell
memori
investig
whether
antibodi
blockad
would
amelior
liver
diseas
treg
defici
mous
model
also
assess
human
diseas
dysregul
method
cell
prepar
thymus
pup
transfer
cell
defici
host
day
later
host
commenc
block
antibodi
ip
twice
weekli
control
anim
sacrif
onset
system
diseas
week
assess
serum
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
ama
titr
lymphocyt
content
liver
flow
cytometri
histolog
liver
section
human
explant
liver
section
stain
serum
measur
pbc
patient
healthi
control
captur
elisa
result
anim
receiv
aliv
well
six
week
wherea
anim
receiv
treg
control
demonstr
overt
autoimmun
cull
end
experi
administr
reduc
spleen
weight
reduc
alt
reduc
ldh
compar
control
assess
flow
cytometri
number
cell
per
gram
liver
spleen
reduc
b
cell
number
alter
develop
infiltr
contain
numer
cell
abolish
blockad
stain
present
within
posit
infiltr
case
human
pbc
autoimmun
hepat
sever
case
steatohepat
absent
almost
normal
liver
significantli
differ
pbc
patient
control
conclus
data
suggest
blockad
murin
model
treg
defici
effect
reduc
hepat
autoimmun
express
appar
human
autoimmun
liver
diseas
aih
pbc
normal
liver
howev
express
also
seen
inflammatori
state
interact
warrant
explor
model
mediat
diseas
disclosur
gideon
hirschfield
advisori
committe
review
panel
intercept
pharma
gsk
consult
cymabay
novarti
grantresearch
support
falk
pharma
bioti
takeda
follow
peopl
noth
disclos
gwilym
webb
fabrina
gaspal
gari
reynold
peter
j
eddow
peter
j
lane
background
aim
forkhead
box
ml
foxml
transcript
factor
belong
fox
famili
protein
share
homolog
wing
helix
dna
bind
domain
shown
foxml
regul
cell
cycl
progress
liver
regener
play
import
role
develop
hepatocellular
carcinoma
howev
despit
numer
evid
liver
regener
carcinogenesi
role
liver
injuri
develop
chronic
liver
diseas
fulli
understood
studi
elucid
issu
develop
novel
transgen
murin
model
enabl
us
control
hepat
foxml
express
method
use
system
gener
transgen
tg
mice
condit
express
foxml
protein
hepatocyt
cross
mice
mice
mice
design
tg
mice
tg
control
mice
design
wt
mice
treat
doxycyclin
time
birth
induc
foxml
express
liver
result
first
demonstr
foxml
protein
express
induc
liver
mice
fed
high
fat
diet
suggest
possibl
involv
foxml
progress
chronic
liver
diseas
next
confirm
overexpress
foxml
protein
liver
tg
mice
western
blot
immunohistochem
analysi
week
age
tg
mice
elev
serum
alt
level
compar
wt
mice
ul
tg
vs
ul
wt
p
tg
mice
also
show
fold
increas
number
tunel
posit
hepatocyt
compar
wt
mice
p
enhanc
liver
injuri
tg
mice
associ
increas
gene
express
tnfa
p
p
p
consist
data
vivo
knockdown
foxml
mous
hepatoma
cell
line
result
signific
reduct
gene
express
suggest
possibl
mechan
foxml
regul
express
hepatocyt
conclus
current
studi
demonstr
transgen
express
foxml
hepatocyt
caus
hepatocyt
death
mice
data
suggest
foxml
may
play
role
pathogenesi
hepat
inflamm
develop
chronic
liver
diseas
disclosur
hayato
hikita
grantresearch
support
squibb
tetsuo
takehara
grantresearch
support
chugai
pharmceut
co
msd
k
k
squibb
mitsubishi
tanab
pharma
corpar
toray
industri
inc
janssen
pharmaceut
co
abbvi
speak
teach
msd
k
k
squibb
gilead
scienc
abbvi
follow
peopl
noth
disclos
tomohid
kurahashi
yuichi
yoshida
satoshi
ogura
mayumi
egawa
kunimaro
furuta
yoshihiro
kamada
shinichi
kiso
tomohid
tatsumi
cell
liver
damag
kill
macrophag
becom
activ
releas
cytokin
phagocytos
dead
cell
debri
facilit
liver
repair
mechan
liver
injuri
stimul
macrophag
activ
liver
fulli
understood
demonstr
previous
activ
transcript
factor
hepat
stellat
cell
hsc
requir
macrophag
clear
region
necrot
cell
produc
inflammatori
cytokin
liver
injuri
suggest
commun
hsc
macrophag
critic
macrophag
activ
liver
injuri
support
show
necrot
hepatocyt
directli
activ
liver
macrophag
vitro
wherea
treatment
hepat
macrophag
condit
medium
hsc
treat
necrot
hepatocyt
activ
hepat
macrophag
remain
identifi
mediat
releas
hsc
modul
hepat
macrophag
function
current
studi
test
hypothesi
eicosanoid
requir
activ
liver
macrophag
hsc
treat
necrot
hepatocyt
treatment
liver
macrophag
condit
medium
hsc
expos
necrot
hepatocyt
activ
macrophag
measur
increas
inflammatori
cytokin
howev
pretreat
hsc
phospholipas
inhibitor
methyl
arachidonyl
fluorophosphon
prevent
macrophag
activ
treatment
primari
mous
hsc
cell
human
hsc
cell
line
necrot
hepatocyt
increas
prostaglandin
e
synthas
mrna
level
addit
necrot
hepatocyt
stimul
primari
mous
hsc
produc
conclus
studi
expand
upon
previou
vivo
studi
demonstr
necrot
cell
stimul
hsc
produc
arachidon
acid
metabolit
regul
liver
macrophag
activ
character
pathway
could
provid
groundwork
novel
therapi
aim
manipul
macrophag
phenotyp
order
allevi
liver
injuri
facilit
liver
repair
disclosur
follow
peopl
noth
disclos
katherin
roth
ryan
albe
bryan
l
coppl
high
mobil
group
releas
damag
associ
molecular
pattern
damp
liver
ischemia
reperfus
ir
exacerb
organ
damag
inflammatori
respons
neutrophil
extracellular
trap
net
recent
found
also
exacerb
steril
inflammatori
injuri
liver
ir
howev
role
intracellular
net
format
understood
sought
determin
role
intracellular
neutrophil
net
format
liver
ir
myloid
cell
specif
knockout
ko
control
mice
subject
warm
liver
ir
liver
damag
assess
alt
level
histolog
protein
cytokin
mrna
innat
immun
cell
popul
evalu
ko
mice
significantli
decreas
serum
transaminas
salt
fig
less
necrosi
inflammatori
cytokin
product
compar
control
ir
suggest
less
degre
liver
injuri
myeloid
cell
absent
significantli
less
net
format
identifi
sinusoid
ischem
liver
lobe
ko
mice
compar
flox
control
mice
confoc
immunofluoresc
imag
associ
significantli
less
net
marker
serum
level
myeloperoxidas
mpo
complex
tissu
level
citrullin
histon
ko
mice
compar
flox
control
mice
vitro
net
format
observ
ko
neutrophil
harvest
ko
mice
stimul
pma
posit
control
damp
histon
confirm
confoc
immunofluoresc
imag
addit
gene
delet
neutrophil
complet
block
citrullin
histon
key
step
net
format
compar
control
neutrophil
respons
variou
stimul
fig
b
conclus
studi
demonstr
domin
role
intracellular
net
format
lack
neutrophil
lead
diminish
net
format
protect
liver
organ
damag
cell
death
liver
ir
serum
transaminas
salt
level
ko
control
flox
mice
liver
ir
data
repres
mice
per
group
p
b
citrullin
histon
complet
block
ko
neutrophil
respons
pma
damp
indic
net
format
disclosur
follow
peopl
noth
disclos
hai
huang
hamza
yazdani
samer
tohm
patricia
loughran
allan
tsung
liver
equip
uniqu
repertoir
innat
adapt
immun
cell
respond
viral
infect
bacteri
product
rel
contribut
microbi
product
cytokin
innat
immun
cell
activ
inflamm
sever
liver
diseas
current
known
aim
studi
analyz
innat
immun
cell
activ
function
three
compart
liver
axi
system
blood
portal
vein
blood
liver
method
isol
lymphocyt
monocyt
liver
portal
vein
system
blood
hepat
c
patient
examin
multicolor
flow
cytometri
addit
plasma
marker
monocytemacrophag
activ
intestin
barrier
integr
ifabp
inflamm
studi
elisa
result
monocyt
natur
killer
nk
cell
mucos
associ
invari
mait
cell
activ
liver
system
portal
vein
blood
indic
increas
express
nk
mait
cell
display
cytotox
phenotyp
liver
two
compart
shown
ex
vivo
express
degranul
marker
consist
find
innat
immun
cell
activ
liver
level
higher
system
portal
plasma
level
compart
correl
activ
intrahepat
monocyt
addit
observ
higher
level
hcv
infect
patient
compar
healthi
control
level
similar
system
portal
plasma
correl
liver
inflamm
assess
histolog
activ
index
level
ifabp
marker
intestin
barrier
loss
increas
patient
compar
healthi
control
moreov
higher
portal
system
plasma
howev
innat
immun
cell
activ
degranul
differ
system
portal
vein
blood
likewis
vitro
function
respons
monocyt
lipopolysaccharid
mait
cell
well
microorgan
differ
system
portal
vein
blood
overal
degre
innat
immun
cell
activ
correl
stage
liver
diseas
assess
direct
portal
vein
pressur
ishak
fibrosi
score
conclus
innat
immun
cell
activ
inflamm
compartment
liver
patient
compens
liver
diseas
activ
intrahepat
monocyt
shed
result
higher
level
plasma
marker
system
portal
plasma
disclosur
follow
peopl
noth
disclos
fabian
j
bolt
ashley
okeef
ohad
etzion
rabab
ali
elisavet
serti
jake
liang
theo
heller
barbara
rehermann
background
primari
biliari
cholang
pbc
progress
cholestat
liver
diseas
mostli
affect
women
though
autoimmun
postul
pathogenesi
pbc
mechan
underli
develop
pbc
larg
unknown
studi
therefor
investig
gender
differ
murin
cholang
induc
repeat
inject
synthet
rna
resembl
human
pbc
method
male
mice
given
repeat
intraperiton
inject
poli
c
twiceweek
week
liver
histolog
assess
mice
sacrif
follow
singl
inject
poli
c
serum
antibodi
detect
elisa
hepat
mrna
level
measur
hepat
protein
level
measur
western
blot
result
femal
mice
given
repeat
inject
poli
c
week
develop
overt
inflammatori
infiltr
surround
bile
duct
portal
area
wherea
male
mice
show
minim
patholog
chang
serum
level
increas
follow
chronic
poli
c
treatment
femal
male
mice
femal
mice
hepat
tnfa
ifnp
mrna
level
swiftli
elev
follow
singl
inject
poli
c
peak
level
hr
reach
nearli
basal
level
respect
contrast
peak
level
tnfa
ifnp
mrna
male
mice
reach
femal
peak
respect
hepat
express
level
major
receptor
rna
differ
male
femal
mice
prior
inject
poli
c
turn
hepat
mrna
level
elev
transient
hr
follow
singl
poli
c
inject
valu
femal
reach
almost
fold
higher
male
moreov
hepat
protein
level
significantli
higher
femal
mice
compar
male
mice
inject
poli
c
conclus
find
clearli
indic
femal
mice
exclus
develop
autoimmun
cholangiopathi
induc
poli
c
acut
reaction
poli
c
liver
appear
potenti
femal
phenomena
like
initi
express
hepat
level
follow
synergist
enhanc
therefor
hypothes
gender
differ
innat
immun
respons
rna
play
pivot
role
pathogenesi
autoimmun
cholangiopathi
includ
pbc
disclosur
follow
peopl
noth
disclos
shunin
someya
kenichi
ikejima
akira
uchiyama
kumiko
arai
kazuyoshi
kon
tomonori
aoyama
shunhei
yamashina
sumio
watanab
background
notch
signal
known
key
regul
cell
prolifer
differenti
apoptosi
immun
cell
function
interact
notch
receptor
ligand
crucial
regul
innat
adapt
immun
liver
inflamm
studi
design
dissect
innat
immun
network
regul
notchl
receptor
ligand
jaggedl
liver
injuri
method
myeloid
specif
notchl
knockout
flox
notchl
notchlflfl
mice
inject
intraperiton
pb
acetaminophen
ugg
p
experi
notch
lflfl
mice
inject
recombin
jaggedl
p
pb
sacrif
indic
time
vitro
studi
bone
macrophag
bmm
isol
notchlflfl
mice
treat
treat
l
ugml
pb
incub
lp
ngml
result
notchlflfl
mice
receiv
resist
liver
injuri
increas
notchl
target
gene
express
akt
phosphoryl
significantli
decreas
serum
alt
level
compar
control
disrupt
notchl
mice
diminish
phosphoryl
akt
cyclindl
enhanc
hmgbl
activ
significantli
increas
alt
level
liver
damag
acetaminophen
challeng
mice
unlik
treat
mice
significantli
increas
macrophag
neutrophil
accumul
hepatocellular
apoptosi
furthermor
treatment
bmm
activ
notchl
phosphoryl
akt
wherea
notchl
knockdown
bmm
result
reduc
phosphoryl
augment
hmgbl
releas
express
well
activ
follow
lp
stimul
conclus
studi
demonstr
jaggedlnotchl
signal
regul
innat
immun
respons
liver
injuri
notchl
activ
inhibit
hmgbl
releas
activ
activ
pathway
novel
find
underscor
critic
role
notchl
signal
cascad
regul
innat
immun
respons
liver
injuri
might
impli
novel
therapeut
potenti
lethal
hepat
disclosur
follow
peopl
noth
disclos
longfeng
jiang
michael
ke
shi
yue
youd
yan
qilong
ying
jun
li
bibo
ke
background
primari
biliari
cholang
pbc
progress
autoimmun
cholestat
liver
diseas
consid
immun
reaction
previou
studi
exhibit
major
contribut
cell
cytokin
pathogenesi
pbc
dendrit
cell
dc
profession
antigen
present
cell
compos
distinct
subset
uniqu
function
phenotyp
characterist
play
differ
role
elicit
key
immun
respons
dc
identifi
liver
section
pbc
patient
embed
damag
bile
duct
transcript
factor
necessari
develop
dendrit
cell
previou
studi
suggest
import
role
dc
defens
intracellular
pathogen
via
cell
secret
aim
assess
role
depend
dc
pbc
develop
method
util
induc
murin
model
pbc
immun
mice
xenobiot
acid
conjug
bovin
serum
albumin
bsa
took
advantag
ko
transgen
mice
lack
transcript
factor
result
lack
cdl
l
dc
subset
analysi
includ
histolog
assess
ama
serum
titer
flow
cytometri
immunohistochemistri
immun
cell
liver
well
hepat
cytokin
profil
result
histopatholog
assess
demonstr
infiltr
lymphocyt
mononuclear
cell
wt
mice
wherea
ko
mice
minor
abnorm
observ
histolog
find
associ
increas
level
alkalin
phosphatas
total
bile
acid
serum
wt
mice
compar
ko
mice
flow
cytometri
analysi
reveal
significantli
decreas
ratio
hepat
cell
mice
furthermor
quantit
pcr
studi
reveal
higher
express
level
cytokin
wt
mice
compar
ko
mice
indic
tissu
inflamm
process
liver
induct
autoimmun
cholang
conclus
result
indic
critic
role
dc
specif
dc
subset
pathogenesi
particularli
break
immun
toler
mechan
pbc
may
pave
road
new
immun
base
cell
specif
target
therapeut
endeavor
disclosur
follow
peopl
noth
disclos
debbi
reuveni
patrick
leung
oren
shibolet
eric
gershwin
ehud
zigmond
macrophag
central
player
inflamm
lead
liver
injuri
report
process
initi
macrophag
polar
toward
ml
phenotyp
previou
data
shown
bone
marrow
bm
macrophag
bmm
recruit
injur
liver
particip
inflamm
natur
peroxisom
receptor
gamma
ligand
implic
compound
found
pgj
inhibit
bmm
migrat
inflammatori
cytokin
product
still
unclear
whether
involv
inflamm
regul
bmm
polar
evalu
role
axi
ml
polar
bmm
also
explor
whether
mirna
involv
process
sinc
mirna
report
key
regul
immun
cell
function
mice
lethal
irradi
receiv
bm
transplant
enhanc
green
fluoresc
protein
transgen
mice
follow
four
week
carbon
tetrachlorid
administr
bm
reconstruct
analysi
perform
detect
amount
type
bmm
express
ml
marker
mirna
measur
western
blot
cytometr
bead
array
high
content
analysi
transcript
factor
assay
kit
use
test
activ
vivo
suppress
ml
polar
bmm
reduc
popul
type
bmm
express
injur
liver
vitro
bmm
challeng
upon
lp
polar
phenotyp
inhibit
process
via
sinc
agonist
caus
suppress
polar
bmm
wherea
specif
antagonist
sirna
attenu
inde
increas
ppari
activ
type
bmm
bioinformat
analysi
http
wwwtargetscanorg
http
wwwmicrornaorg
show
target
respect
use
mimic
inhibitor
three
mirna
confirm
three
mirna
regul
correspond
predict
target
gene
respect
meanwhil
three
mirna
express
decreas
damag
liver
type
bmm
renew
furthermor
result
specif
agonist
antagonist
sirna
indic
mirna
depend
conclus
data
suggest
axi
inhibit
polar
bmm
toward
phenotyp
mirna
depend
manner
disclosur
follow
peopl
noth
disclos
weiyang
li
lei
tian
na
chang
jieshi
xie
lin
yang
liy
li
introduct
aim
human
alcohol
hepat
ah
monocyt
activ
directli
ethanol
indirectli
via
inflammatori
factor
lp
tnfa
henc
number
liver
increas
monocyt
especi
intermedi
inflammatori
type
express
famili
integrin
activ
form
elicit
bind
monocyt
endotheli
adhes
receptor
bring
extravas
tissu
known
induc
shed
form
recent
discov
solubl
thought
inhibit
extravas
leukocyt
conceal
endotheli
adhes
receptor
known
whether
tissu
inflamm
moder
mechan
intact
mediat
ah
therefor
measur
monocyt
express
activ
inact
plasma
level
monocyt
abil
shed
patient
materi
method
flow
cytometri
detect
surfac
express
activ
inact
monocyt
subset
patient
sever
ah
healthi
control
quantifi
plasma
macrophag
activ
marker
patient
sever
ah
diagnosi
day
day
healthi
control
immunosorb
assay
likewis
vitro
shed
pbmc
respons
ethanol
lp
tnfa
measur
result
patient
ah
monocyt
subset
higher
surfac
express
activ
control
p
wherea
differ
express
inact
increas
activ
express
highest
subset
intermedi
inflammatori
monocyt
ah
vs
control
plasma
concentr
increas
patient
compar
control
vs
correl
monocyt
activ
measur
plasma
plasma
chang
period
spontan
product
vitro
elev
two
fold
ah
compar
control
vs
stimul
either
lp
tnfa
ethanol
increas
shed
patient
ah
control
p
conclus
sever
ah
shed
like
result
monocyt
activ
suggest
mechan
oper
within
pictur
florid
hepat
inflamm
disclosur
follow
peopl
noth
disclos
sidsel
stoey
thoma
sandahl
annelouis
hansen
bent
deleuran
thoma
hendrik
vilstrup
tue
w
kragstrup
background
steril
inflamm
tissu
damag
ubiquit
immun
respons
occur
highest
amplitud
liver
major
clinic
consequ
alcohol
steatohepat
ash
nash
lack
effect
therapi
key
requir
sustain
steril
inflamm
high
degre
cellular
oxid
stress
activ
pathway
cardiac
glycosid
digoxin
identifi
potent
suppressor
mechan
hepat
protect
well
defin
aim
assess
whether
digoxin
therapeut
effect
nash
ash
mice
investig
molecular
mechan
mous
human
cell
method
male
mice
place
high
fat
diet
hfd
without
digoxin
ip
mg
kg
twice
week
digoxin
ip
daili
mice
result
therapeut
serum
level
achiev
human
ngml
plasma
alt
liver
histolog
leukocyt
profil
mitochondri
ro
gene
transcriptom
microarray
analyz
chronic
plu
bing
model
ash
perform
identif
digoxin
interact
protein
maintain
cellular
redox
homeostasi
suppress
hifla
activ
investig
proteom
report
luciferas
assay
result
digoxin
reduc
histolog
injuri
neutrophil
infiltr
inflammasom
activ
serum
alt
valu
start
digoxin
time
hfd
alt
ul
hfd
vs
ul
hfddig
p
start
digoxin
week
hfd
neutrophil
hfd
vs
hfddig
monocyt
hfd
vs
hfddig
alt
ul
hfd
vs
ul
hfddig
p
without
reduct
food
intak
low
dose
digoxin
mgkg
also
show
signific
protect
effect
injuri
oxid
stress
steril
inflamm
nash
ald
model
microarray
transcriptom
analysi
reveal
digoxin
treatment
result
signific
ro
metabol
antioxid
signal
pathway
gene
express
hfd
liver
tissu
broad
mass
proteom
screen
reveal
digoxin
bind
pyruv
kinas
independ
kinas
activ
result
chromatin
remodel
transactiv
conclus
data
identifi
novel
mediat
therapeut
target
regul
liver
steril
inflamm
demonstr
protect
role
digoxin
ash
nash
disclosur
follow
peopl
noth
disclos
xinshou
ouyang
han
georg
lau
dechun
feng
rebecca
cardon
cai
rafaz
hoqu
yonglin
chen
yang
irma
wang
bin
gao
natali
j
torok
richard
kibbey
wajahat
z
mehal
background
metabol
syndrom
result
steril
inflamm
liver
depend
activ
inflammasom
cytosol
protein
complex
compris
protein
adaptor
protein
asc
protein
activ
inflammatori
glycogen
synthas
import
metabol
regul
compos
two
isoform
aim
identifi
role
isoform
inhibit
inflammasom
activ
metabol
liver
injuri
method
inflammasom
activ
lpsatp
glucos
primari
mous
macrophag
effect
specif
inhibit
isoform
inflammasom
activ
assay
quantifi
p
supernat
activ
cell
lysat
molecular
mechan
investig
protein
assay
confoc
imag
use
forc
gene
express
system
endogen
protein
tag
mous
macrophag
vivo
role
inhibit
metabol
liver
injuri
demonstr
use
high
fat
diet
hfd
induc
nash
diabet
model
mice
result
pharmacolog
inhibit
total
suppress
inflammasom
activ
respons
atp
urat
crystal
microbi
alkaloid
toxin
staurosporin
inhibit
inhibit
inflammasom
activ
respons
dna
affect
inflammasom
activ
inhibit
suppress
high
glucos
mediat
inflammasom
activ
inhibit
block
inflammasom
reduc
activ
asc
speck
format
inhibit
block
inflammasom
activ
without
affect
level
reactiv
oxygen
speci
ro
pull
endogen
show
directli
bind
asc
inhibit
reduc
asc
protein
macrophag
also
result
signific
reduct
matur
b
secret
respons
inflammasom
activ
predict
inhibit
attenu
urat
periton
suppress
secret
serum
alt
ast
level
ficient
mice
conclus
result
demonstr
critic
role
mediat
masom
activ
liver
injuri
thu
defin
new
therapeut
target
steril
inflamm
liver
disclosur
follow
peopl
noth
disclos
han
ziwen
liang
wajahat
z
mehal
xinshou
ouyang
sever
coronaviru
cov
infect
led
global
epidem
respiratori
failur
one
caus
fulmin
liver
failur
case
sever
clinic
ill
caus
strong
host
inflammatori
respons
viru
particularli
true
mous
liver
damag
follow
infect
murin
hepat
viru
strain
previous
shown
macrophag
activ
drive
much
host
inflamm
ubiquitin
specif
peptidas
pathway
link
type
inflammatori
respons
gener
ask
whether
modul
liver
macrophag
kupffer
cell
kc
inflammatori
respons
found
mice
increas
number
kc
kc
regulatori
phenotyp
character
increas
phagocyt
activ
express
cytokin
respons
lp
respons
kc
lp
induc
cytokin
pattern
cytokin
express
replic
vivo
follow
infect
suscept
mice
mice
decreas
level
cytokin
increas
cytokin
express
liver
compar
mice
contrast
mice
kc
base
criteria
much
express
liver
follow
infect
base
data
hypothes
kc
deleteri
pathogenesi
kc
might
protect
elimin
kc
would
benefici
mice
detriment
mice
surprisingli
deplet
kc
clodron
treatment
led
improv
surviv
mice
day
p
expect
kc
deplet
elimin
cytokin
storm
mice
howev
see
evid
increas
inflamm
liver
damag
group
anim
decreas
earli
viral
replic
liver
log
depend
macrophag
number
sinc
macrophag
constitut
minor
cell
liver
homogen
replic
macrophag
hepatocyt
similar
studi
first
time
illustr
effect
infect
liver
outlin
potenti
new
target
treatment
sever
cov
infect
independ
host
inflammatori
respons
disclosur
follow
peopl
noth
disclos
agata
bartczak
max
xuezhong
yujia
li
kim
tsoi
oyedel
adeyi
ian
mcgilvray
purpos
chronic
alcohol
abus
lead
liver
inflamm
fibrosi
cirrhosi
inflamm
contribut
alcohol
liver
diseas
ald
particularli
alcohol
steatohepat
ash
monocyt
chemoattract
chemokin
motif
ligand
rant
interact
respect
receptor
drive
inflammatori
respons
ash
aim
hypothes
dual
inhibit
cenicriviroc
cvc
attenu
featur
ald
method
use
diet
model
chronic
alcohol
feed
vv
alcohol
week
prevent
cohort
cvc
vehicl
solutol
steril
water
inject
c
daili
entir
length
alcohol
feed
week
treatment
cohort
cvc
vehicl
inject
last
week
alcohol
feed
week
liver
injuri
serum
alt
h
e
steatosi
stain
triglycerid
assess
cytokin
express
analyz
qpcr
elisa
liver
immun
cell
infiltr
fac
result
mice
receiv
alcoholcvc
prevent
cohort
significantli
lower
serum
alt
level
compar
alcoholvehicl
control
entir
cours
alcohol
feed
sacrific
alcoholcvc
group
significantli
reduc
inflammatori
cytokin
level
steatosi
compar
alcoholvehicl
group
mice
alcohol
diet
show
signific
induct
serum
alt
week
introduct
cvc
treatment
rapidli
normal
alt
level
baselin
liver
inflammatori
cytokin
significantli
reduc
cvc
treatment
compar
alcoholvehicl
mice
mice
cvc
treatment
group
show
lower
liver
triglycerid
lipid
accumul
upon
alcohol
administr
final
cvc
prevent
treatment
cohort
significantli
lower
serum
level
compar
alcoholvehicl
group
cvc
administr
prevent
treatment
cohort
significantli
prevent
macrophag
infiltr
liver
restor
reduct
hepat
nk
b
cell
count
conclus
block
cvc
attenu
chronic
macrophag
infiltr
liver
therebi
lower
inflamm
alcohol
hepat
inhibit
prevent
liver
damag
improv
histolog
attenu
steatosi
serum
mous
model
ald
data
indic
therapeut
potenti
cvc
human
aldash
disclosur
eric
lefebvr
employ
tobira
therapeut
inc
san
francisco
ca
usa
pamela
vig
employ
tobira
stock
sharehold
tobira
gyongyi
szabo
advisori
committe
review
panel
alcohol
research
health
niaaa
bile
acid
council
galaxi
project
natur
review
gastro
hepatolog
nih
exrna
program
prevent
cancer
foundat
yale
univers
liver
center
trek
therapeut
univers
colorado
alcohol
center
univers
southern
california
liver
center
univers
pittsburgh
mstp
eab
cytatx
glymps
bio
janssen
research
develop
board
membership
acer
hepatolog
consult
novarti
orbim
roviant
salix
tobira
verlyx
grantresearch
support
bm
gilead
genfit
genentech
univers
florida
intercept
tobira
takeda
vertex
follow
peopl
noth
disclos
aditya
ambad
karen
kodi
patrick
p
low
donna
catalano
benedek
gyongyosi
background
primari
biliari
cholang
pbc
chronic
autoimmun
liver
diseas
character
presenc
antibodi
ama
hepat
antigen
specif
cell
result
progress
cholestasi
eventu
lead
cirrhosi
monocyt
plastic
cell
massiv
recruit
inflam
tissu
differenti
antigen
present
cell
apc
express
monocyt
crucial
emigr
cell
bone
marrow
circul
monocyt
isol
pbc
patient
found
sensit
tlr
signal
result
secret
cytokin
interleukin
cytokin
belong
famili
posit
cell
detect
portal
area
liver
tissu
advanc
stage
pbc
thu
previou
studi
suggest
involv
cell
pbc
pathogenesi
howev
solid
data
evalu
import
function
context
still
miss
method
util
induc
murin
model
pbc
immun
mice
xenobiot
acid
conjug
bovin
serum
albumin
bsa
knockout
ko
mice
mice
apc
restrict
defici
compar
wild
type
wt
control
mice
respect
analysi
includ
histolog
assess
ama
serum
titer
flow
cytometri
immunohistochemistri
immun
cell
liver
fibrosi
evalu
hepat
cytokin
profil
result
histopatholog
evalu
reveal
hepat
infiltr
lymphocyt
mononuclear
cell
wt
mice
compar
mice
exhibit
liver
abnorm
immunofluorec
microscopi
flow
cytometri
analys
show
massiv
accumul
macrophag
around
portal
triad
wt
mice
flow
cytometri
analysi
reveal
significantli
increas
ratio
hepat
cell
wt
mice
hepat
express
level
cytokin
includ
ama
titer
serum
elev
wt
mice
siriu
red
stain
liver
section
exhibit
collagen
deposit
wt
mice
find
support
signatur
liver
mice
exhibit
significantli
milder
diseas
phenotyp
assess
histolog
flow
cytometri
hepat
cytokin
profil
compar
litterm
conclus
result
indic
major
role
apc
deriv
pathogenesi
progress
pbc
may
pave
road
develop
new
therapeut
modal
disclosur
follow
peopl
noth
disclos
debbi
reuveni
patrick
leung
oren
shibolet
eric
gershwin
ehud
zigmond
background
aim
injur
cell
releas
endogen
molecul
call
alarmin
activ
immun
respons
studi
alarmin
transloc
nucleu
cytoplasm
activ
innat
immun
system
liver
failur
elev
plasma
level
observ
point
sensit
marker
hepatotox
fatti
liver
diseas
nafld
common
chronic
liver
diseas
goe
steatosi
hepatocellular
carcinoma
earli
phase
nafld
effect
neutrophil
cell
suppress
liver
damag
remain
elus
henc
aim
investig
relationship
involv
method
analyz
serum
level
earli
nafld
patient
healthi
donor
hd
elisa
laboratori
clinic
data
collect
immunohistochemistri
ihc
use
show
local
liver
biopsi
flow
cytometri
analysi
fac
use
studi
neutrophil
prolifer
cfse
dilut
phenotyp
mitogen
activ
cell
perform
neutrophil
pbmc
stain
cfse
activ
antibodi
hd
patient
result
conclus
interestingli
nafld
patient
level
higher
hd
addit
serum
concentr
posit
correl
absolut
rel
number
circul
neutrophil
ihc
found
resid
nuclei
healthi
hepatocyt
wherea
cytoplasm
local
steatot
hepatocyt
suggest
forthcom
releas
damag
tissu
demonstr
neutrophil
abl
suppress
prolifer
helper
cytotox
cell
inhibit
express
activ
marker
hd
nafld
patient
moreov
found
hd
nafld
patient
neutrophil
enhanc
particular
result
hd
demonstr
potenti
suppress
activ
neutrophil
cell
mayb
establish
protect
inflammatori
respons
earli
nafld
patient
whose
level
higher
hd
neutrophil
show
profil
hd
neutrophil
stimul
vitro
instead
neutrophil
nafld
patient
stimul
nt
increas
suppress
activ
cell
allow
progress
liver
diseas
preliminari
data
lead
us
consid
one
main
actor
suppress
cell
prolifer
alreadi
earli
phase
nafld
disclosur
follow
peopl
noth
disclos
laura
antonucci
cristiana
porcu
barbara
barbaro
stefania
straino
caterina
mucciant
eugenio
gaudio
clara
balsano
acetaminophen
apap
liver
injuri
number
one
caus
acut
liver
failur
unit
state
although
great
deal
research
focus
develop
therapi
limit
liver
injuri
apap
overdos
mani
patient
benefit
type
therapi
liver
injuri
often
extens
time
reach
clinic
patient
would
like
benefit
therapi
aim
stimul
liver
repair
mechan
regul
liver
repair
apap
overdos
howev
fulli
understood
particular
mechan
regul
clearanc
necrot
cell
liver
known
greater
understand
mechan
could
lead
new
therapi
stimul
liver
repair
patient
suffer
acut
liver
failur
present
studi
test
hypothesi
plasmin
critic
clearanc
necrot
cell
liver
test
hypothesi
mice
treat
mgkg
apap
tranexam
acid
inhibit
convers
plasminogen
plasmin
vehicl
steril
salin
tranexam
acid
effect
increas
alt
hour
treatment
similarli
area
necrosi
hour
treatment
differ
tranexam
mice
strike
contrast
wherea
necrosi
larg
absent
mice
given
apap
area
necrosi
mice
treat
apap
tranexam
acid
indic
plasmin
inhibit
prevent
remov
necrot
cell
liver
treat
mice
macrophag
number
differ
two
group
indic
defect
result
improp
recruit
macrophag
similarli
opson
necrot
cell
affect
necrot
cell
similarli
coat
complement
factor
two
group
determin
whether
plasmin
direct
effect
macrophag
function
bone
macrophag
treat
plasmin
plasmin
increas
phagocytosi
upregul
matrix
metalloproteinas
mrna
collect
studi
demonstr
plasmin
critic
remov
necrot
cell
liver
apap
treatment
plasmin
may
promot
clearanc
necrot
cell
directli
stimul
macrophag
phagocytosi
greater
understand
mechan
plasmin
promot
macrophag
phagocytosi
could
lead
new
treatment
stimul
remov
dead
cell
liver
process
essenti
liver
repair
disclosur
follow
peopl
noth
disclos
nikita
joshi
ryan
albe
jame
p
luyendyk
bryan
l
coppl
backgroundaim
alter
immun
common
find
patient
cirrhosi
presenc
subclin
system
inflamm
may
contribut
portal
hypertens
develop
liver
failur
cirrhot
patient
suscept
bacteri
infect
aim
studi
compar
respons
peripher
blood
monocyt
bm
lp
stimul
patient
undergo
placement
tip
method
patient
male
age
year
cirrhosi
portal
hypertens
indic
tip
placement
bleed
andor
refractori
ascit
enrol
etiolog
hcv
hbv
alcohol
multifactori
meld
score
time
tip
procedur
blood
drawn
peripher
vein
portal
vein
deploy
prosthesi
week
tip
placement
sampl
peripher
vein
repeat
healthi
subject
hs
serv
control
peripher
blood
blood
mc
isol
ficol
allow
adher
plastic
dish
transfer
new
dish
cell
incub
without
lp
cytokin
express
measur
quantit
real
time
pcr
result
unstimul
condit
express
level
compar
cirrhot
patient
hs
portal
bm
express
significantli
higher
peripher
bm
cirrhot
patient
hs
upon
lp
stimul
mark
increas
three
cytokin
observ
bm
isol
differ
site
howev
mrna
level
beta
higher
sampl
collect
tip
peripher
portal
collect
peripher
vein
tip
placement
latter
also
significantli
lower
observ
hs
tip
level
lp
stimul
significantli
higher
cirrhot
patient
hs
tip
mrna
reduc
reach
valu
similar
peripher
bm
hs
contrast
express
significantli
lower
sampl
cirrhot
patient
regardless
tip
placement
size
collect
hs
express
slightli
significantli
higher
sampl
cirrhot
patient
conclus
cirrhosi
portal
hypertens
differenti
affect
cytokin
express
bm
reduct
portal
pressur
tip
result
induc
bm
phenotyp
similar
one
observ
peripher
bm
hs
data
suggest
effect
manag
portal
hypertens
may
impact
immun
respons
patient
cirrhosi
disclosur
giacomo
laffi
speak
teach
bayer
fabio
marra
consult
bayer
healthcar
abbvi
astrazeneca
grant
research
support
viiv
speak
teach
gilead
follow
peopl
noth
disclos
benedetta
piombanti
elisa
vivoli
valentina
l
cacciato
francesco
vizzutti
roberto
g
romanelli
andrea
cappon
backgroundaim
suppressor
cell
mdsc
compris
heterogen
popul
myeloid
cell
recogn
suppressor
cell
function
mice
cell
identifi
surfac
marker
howev
marker
describ
mdsc
myeloid
cell
display
marker
recent
report
cell
cell
repres
authent
monocyt
mdsc
liver
addit
increas
number
monocyt
mdsc
observ
liver
murin
model
liver
diseas
nafld
studi
aim
understand
biolog
mdsc
accumul
nafld
liver
method
mice
fed
normal
diet
diet
nafld
model
month
differ
subtyp
cell
sort
liver
cell
fac
cell
surfac
marker
analyz
flowcytometri
observ
effect
steatosi
hepatocyt
cell
expos
oleic
acid
palmit
acid
rna
extract
liver
cell
gene
express
examin
analysi
protein
level
analyz
immunohistochemistri
elisa
migratori
capac
monocyt
mdsc
examin
vitro
migrat
assay
final
bone
marrow
cell
mice
cultur
day
induct
monocyt
mdsc
analyz
flowcytometri
result
among
cell
liver
monocyt
mdsc
subset
cell
express
surfac
mrna
protein
level
higher
liver
nafld
mice
control
mice
result
confirm
use
cell
supplement
fatti
acid
vitro
migrat
assay
show
monocyt
mdsc
migrat
respons
manner
addit
increas
number
monocyt
mdsc
observ
cultur
grown
presenc
manner
conclus
pathway
might
contribut
migrat
monocyt
mdsc
steatot
liver
addit
increas
level
steatot
liver
might
contribut
induct
monocyt
mdsc
result
suggest
target
key
molecul
ration
strategi
regul
immun
environ
nafld
disclosur
teru
kumagi
grantresearch
support
ea
pharma
co
ltd
follow
peopl
noth
disclos
masanori
abe
liy
yao
yoshiko
nakamura
teruki
miyak
yusuk
imai
takao
watanab
yohei
koizumi
osamu
yoshida
yoshio
tokumoto
masashi
hirooka
yoichi
hiasa
object
singl
nucleotid
polymorph
interleukin
interferon
ifn
gene
strongli
associ
sustain
virolog
respons
rate
treat
patient
chronic
hepat
c
pegyl
interferon
ribavirin
combin
therapi
moreov
genotyp
potenti
associ
outcom
direct
antivir
agent
treatment
patient
decompens
cirrhosi
liver
transplant
although
express
dendrit
cell
dc
function
relev
innat
immun
respons
clarifi
fulli
method
knockout
ko
mice
gener
wt
ko
mice
inject
acid
poli
c
via
tail
vein
h
inject
immun
cell
dc
natur
killer
nk
cell
cell
liver
evalu
cell
sort
fac
analysi
bone
dendrit
cell
bmdc
gener
bone
marrow
cell
cultur
media
contain
day
bmdc
pretreat
recombin
protein
neutral
antibodi
cell
stimul
poli
c
result
determin
whether
associ
immun
cell
activ
vivo
wt
ko
mice
stimul
poli
c
number
immun
cell
liver
analyz
ko
mice
number
dc
nk
cell
significantli
decreas
stimul
poli
c
compar
wt
mice
investig
effect
ifn
induct
bmdc
deriv
wt
mice
stimul
poli
c
presenc
absenc
pretreat
pretreat
significantli
enhanc
poli
c
duce
ifnp
induct
invers
pretreat
significantli
suppress
induct
addit
induct
poli
c
significantli
reduc
primari
mous
hepatocyt
deriv
ko
mice
compar
wt
mice
next
evalu
effect
dc
matur
upon
stimul
poli
c
bmdc
deriv
ko
mice
exhibit
lower
express
level
activ
marker
dc
mhc
class
ii
compar
wt
mice
conclus
result
suggest
play
import
role
immun
respons
expect
therapeut
potenti
hepat
bc
viru
infect
also
cancer
immunotherapi
hepatocellular
carcinoma
disclosur
shuichi
kaneko
grantresearch
support
md
co
inc
chugai
pharma
co
inc
toray
co
inc
daiichi
sankyo
co
inc
dainippon
sumitomo
co
inc
ajinomoto
co
inc
bristol
myer
squibb
inc
pfizer
co
inc
astella
inc
takeda
co
inc
otsuka
aapharmaceut
co
inc
eizai
co
inc
bayer
japan
eli
lilli
japan
follow
peopl
noth
disclos
yuika
innami
masao
honda
kazuhisa
murai
tetsuro
shimakami
takayoshi
shirasaki
seishi
murakami
object
liver
failur
aclf
character
rapid
deterior
liver
function
cirrhosi
often
precipit
organ
failur
aclf
associ
sever
immunodysfunct
immun
activ
paresi
often
dysregul
immun
state
lead
sever
monocyt
dysfunct
may
precipit
bacteri
infect
although
aclf
diseas
entiti
attract
much
attent
littl
known
molecular
mechan
respons
alter
monocyt
function
condit
design
studi
patient
biopsi
proven
alcohol
liver
diseas
n
decompens
cirrhosi
alcohol
hepat
aclf
control
blood
obtain
admiss
biochem
test
gene
express
pbmc
flow
cytometri
function
monocyt
assay
plasma
use
determin
cytokinechemokin
level
addit
isol
monocyt
donor
aclf
patient
determin
gene
express
nextgen
sequenc
character
key
molecular
factor
associ
monocyt
dysfunct
use
pathway
analysi
addit
function
assay
perform
healthi
aclf
monocyt
presenc
absenc
normal
aclf
serum
result
observ
decreas
express
within
classic
monocyt
subset
elev
number
produc
intermedi
monocyt
aclf
function
analysi
total
pbmc
isol
monocyt
show
sever
impair
phagocytosi
oxid
burst
aclf
increas
gene
express
pbmc
elev
plasma
level
aclf
associ
decreas
surviv
month
pathway
analysi
reveal
signific
downregul
gene
associ
immunolog
process
monocyt
phagocytosi
interact
respons
bacteri
infect
importantli
cultur
healthi
monocyt
aclf
serum
induc
aclf
dysfunct
phenotyp
convers
cultur
healthi
plasma
revers
aclf
phenotyp
restor
phagocytosi
final
data
indic
central
role
molecular
pathway
associ
aclf
conclus
aclf
associ
sever
immun
dysfunct
induc
aclf
signatur
healthi
monocyt
use
aclf
media
revers
monocyt
dysfunct
aclf
monocyt
use
normal
serum
contain
medium
suggest
circul
factor
promot
syndrom
associ
sever
immun
dysfunct
poor
surviv
aclf
express
analysi
suggest
crucial
role
driver
condit
disclosur
frederik
neven
consult
msd
caf
intercept
gore
bm
abbvi
novarti
durect
ono
pharma
promethera
bioscienc
grant
research
support
fer
roch
astella
novarti
abbvi
follow
peopl
noth
disclos
hanneli
korf
johanni
du
plessi
johann
van
pelt
schalk
van
der
merw
elien
de
smidt
introduct
neutrophil
dysfunct
close
correl
suscept
bacteri
infect
observ
cirrhosi
arc
primarili
thought
consequ
defect
phagocytosi
reactiv
oxygen
speci
ro
product
emerg
evid
suggest
type
iii
interferon
possess
properti
interplay
neutrophil
health
arc
examin
aim
explor
whether
neutrophil
produc
respond
health
arc
method
whole
blood
healthi
control
hc
patient
arc
median
child
pugh
score
cultur
without
e
coli
patient
superimpos
alcohol
hepat
df
rna
extract
isol
neutrophil
total
leukocyt
fraction
quantit
pcr
receptor
endogen
control
perform
patient
whole
blood
incub
examin
express
neutrophil
phagocytosi
ro
product
also
assess
fac
result
notabl
find
seen
neutrophil
mrna
express
amongst
patient
group
emerg
e
induct
group
group
although
lower
level
hc
e
neutrophil
express
group
significantli
less
hc
group
p
observ
e
product
leukocyt
fraction
also
compromis
group
group
significantli
higher
score
ast
compar
group
respect
profound
differ
observ
group
seen
neutrophil
leucocyt
express
receptor
express
addit
significantli
alter
neutrophil
phagocytosi
burst
cell
surfac
receptor
express
conclus
first
time
identifi
neutrophil
produc
innat
type
iii
interferon
reveal
previous
unknown
defici
product
arc
confirm
respons
bacteri
infect
elucid
mechan
may
import
implic
therapeut
develop
era
resist
disclosur
debbi
l
shawcross
advisori
committe
review
panel
norgin
grant
research
support
norgin
speak
teach
norgin
follow
peopl
noth
disclos
jennif
ryan
antonio
riva
gavin
wright
alex
evan
roger
william
shilpa
chokshi
background
cell
intrins
innat
immun
provid
rapid
first
line
defens
thwart
invad
viral
pathogen
product
antivir
cytokin
inflammatori
chemokin
howev
presenc
mani
signal
pathway
liver
role
hbv
pathogenesi
unknown
recent
identif
intracellular
dna
sens
pathway
involv
numer
divers
diseas
process
includ
viral
pathogenesi
carcinogenesi
suggest
role
process
hbv
infect
dna
genom
method
order
character
hbv
intrins
innat
immun
respons
role
dna
rna
sens
pathway
liver
recognit
hbv
util
vivo
vitro
model
includ
analysi
gene
express
liver
biopsi
hbv
infect
patient
addit
mrna
protein
express
measur
hbv
stimul
dna
treat
hepatoma
cell
line
ntcp
heparg
primari
human
hepatocyt
phh
specif
rna
dna
depend
innat
inflammatori
pathway
signal
studi
well
addit
pathway
involv
product
interferon
chemokin
may
drive
subsequ
liver
diseas
sirna
experi
util
determin
signal
pathway
involv
hbv
recognit
microarray
analys
use
character
global
transcriptom
chang
hbv
infect
primari
human
hepatocyt
uv
inactiv
hbv
util
determin
effect
observ
viral
replic
result
hbv
foreign
dna
result
rapid
innat
immun
respons
hepatocyt
character
product
inflammatori
chemokin
mrna
protein
level
analysi
liver
biopsi
patient
support
correl
among
hepat
express
specif
antivir
gene
includ
addit
hbv
elicit
much
broader
rang
gene
express
alter
demonstr
microarray
analysi
induct
chemokin
includ
mediat
predominantli
pathway
follow
hbv
stimul
conclus
hbv
stimul
pathway
predominantli
activ
inflammatori
respons
would
promot
develop
hepat
hcv
stimul
much
stronger
interferon
antivir
respons
understand
mechan
underli
inflammatori
antivir
respons
may
provid
new
strategi
trigger
cytopath
clearanc
cccdna
ultim
cure
patient
hbv
infect
addit
data
offer
addit
insight
hbv
driven
hepatocarcinogenesi
disclosur
eugen
r
schiff
advisori
committe
review
panel
bristol
myer
squibb
gilead
merck
janssen
salix
pharmaceut
pfizer
arrowhead
astrazeneca
cv
consult
acorda
grantresearch
support
bristol
myer
squibb
vie
gilead
merck
conatu
medmira
roch
molecular
janssen
orasur
technolog
discoveri
life
scienc
siemen
beckman
coulter
siemen
ortho
jnh
intercept
beckman
follow
peopl
noth
disclos
masato
yoneda
satoru
saito
emmanuel
thoma
background
aim
factor
hif
recent
identifi
import
regul
immun
inflamm
play
role
pathogenesi
steatohepat
nash
macrophag
activ
determin
event
diseas
progress
upregul
nash
hepatocyt
induc
steatosi
also
found
induc
autophagi
fibroblast
howev
role
macrophag
metabol
stress
explor
studi
hypothes
modul
macrophag
autophagi
respons
free
fatti
acid
method
macrophag
treat
free
fatti
acid
ffa
oleic
acid
plu
palmit
acid
differ
time
period
rna
level
target
gene
examin
qpcr
protein
level
autophagi
relat
molecul
mtor
examin
test
emsa
silenc
overexpress
achiev
use
sirna
respect
cell
supernat
collect
test
elisa
cytokin
chemokin
result
ffa
treatment
cell
mrna
level
show
rapid
increas
follow
upregul
target
gene
protein
level
activ
also
increas
upon
ffa
treatment
macrophag
autophagi
indic
increas
protein
level
decreas
mtor
level
event
parallel
induct
cytokin
cell
silenc
sirna
result
downregul
express
increas
product
cytokin
decreas
suggest
regul
autophagi
well
inflamm
macrophag
convers
overexpress
augment
express
reduc
increas
level
macrophag
provid
addit
evid
regul
autophagi
inflamm
macrophag
conclus
result
indic
upregul
play
protect
role
inflamm
nash
regul
autophagi
pathway
respons
free
fatti
acid
stimul
find
highlight
complex
role
macrophag
regul
metabol
stress
nash
disclosur
gyongyi
szabo
advisori
committe
review
panel
alcohol
research
health
niaaa
bile
acid
council
galaxi
project
natur
review
gastro
hepatolog
nih
exrna
program
prevent
cancer
foundat
yale
univers
liver
center
trek
therapeut
univers
colorado
alcohol
center
univers
southern
california
liver
center
univers
pittsburgh
mstp
eab
cytatx
glymps
bio
janssen
research
develop
board
membership
acer
hepatolog
consult
novarti
orbim
roviant
salix
tobira
verlyx
grantresearch
support
bm
gilead
genfit
genentech
univers
florida
intercept
tobira
takeda
vertex
follow
peopl
noth
disclos
xiaoj
wang
ambika
pandita
abhishek
satishchandran
karen
kodi
aditya
ambad
liver
contain
two
distinct
popul
macrophag
macrophag
mdm
kupffer
cell
mdm
primarili
resid
within
around
vessel
wherea
kupffer
cell
resid
within
sinusoid
mdm
replenish
myeloid
progenitor
bone
marrow
wherea
kupffer
cell
replenish
local
prolifer
matur
kupffer
cell
beyond
observ
littl
inform
whether
function
differ
macrophag
cell
type
present
studi
determin
whether
two
macrophag
popul
produc
differ
level
cytokin
activ
bacteri
lipopolysaccharid
lp
mdm
kupffer
cell
purifi
liver
mice
use
magnet
bead
digest
liver
collagenas
dendrit
cell
remov
neg
select
magnet
bead
next
mdm
purifi
liver
digest
use
magnet
bead
label
antibodi
final
kupffer
cell
purifi
remain
digest
use
magnet
bead
analysi
content
flow
cytometri
indic
mdm
kupffer
cell
greater
pure
basal
level
tumor
necrosi
mrna
higher
mdm
compar
kupffer
cell
treatment
kupffer
cell
lp
increas
respect
treatment
mdm
lp
increas
respect
indic
lp
upregul
cytokin
greater
extent
mdm
lastli
basal
level
induc
nitric
oxid
synthas
higher
mdm
compar
kupffer
cell
suggest
mdm
skew
toward
macrophag
phenotyp
collect
result
indic
mdm
kupffer
cell
mdm
may
main
sourc
cytokin
vivo
liver
exposur
bacteri
product
lp
disclosur
follow
peopl
noth
disclos
bryan
l
coppl
ryan
albe
carli
gerhardt
cheryl
rockwel
background
nafld
one
common
caus
chronic
liver
diseas
long
term
outcom
nafld
gener
popul
set
well
studi
object
compar
risk
death
caus
well
cardiovascular
caus
nafld
subject
accord
presenc
absenc
metabol
syndrom
ms
condit
method
use
survey
nation
health
nutrit
examin
nhane
iii
linkag
nation
death
index
ndi
death
certif
record
follow
decemb
examin
associ
compon
ms
mortal
adult
age
nafld
ms
defin
guidelin
nafld
identifi
hepat
ultrasound
presenc
mild
moder
sever
grade
steatosi
absenc
caus
liver
diseas
excess
alcohol
use
cox
proport
hazard
model
use
estim
hazard
ratio
hr
confid
interv
ci
result
studi
includ
particip
median
follow
year
year
period
subject
die
cardiovascular
diseas
liver
diseas
preval
nafld
without
ms
preval
nafld
one
ms
two
ms
three
ms
four
ms
comparison
absenc
ms
condit
hr
mortal
ci
one
ms
condit
two
ms
condit
three
ms
condit
four
ms
condit
age
histori
cardiovascular
diseas
mutual
adjust
model
dm
independ
associ
increas
risk
death
caus
cardiovascular
caus
mortal
cardiovascular
diseas
caus
mortal
addit
nafld
four
ms
fold
increas
risk
death
caus
compar
nafld
without
ms
conclus
ncreas
number
metabol
condit
associ
increas
risk
mortal
nafld
dm
import
predictor
nafld
disclosur
follow
peopl
noth
disclos
pegah
golabi
munkhzul
otgonsuren
aimal
arsalla
madelin
erario
manirath
srishord
zobair
younossi
background
nafld
preval
estim
high
usa
larg
prospect
studi
lack
correl
demograph
clinic
novel
radiograph
data
histopatholog
method
adult
patient
prospect
enrol
predominantli
time
referr
routin
colon
cancer
screen
screen
evid
nafld
fibroscan
livermultiscan
lm
mr
elastographi
mre
prior
histori
liver
diseas
alcohol
ingest
greater
accept
rang
nafld
consid
exclusionari
patient
exceed
cutoff
valu
imag
test
offer
liver
biopsi
liver
biopsi
read
expert
pathologist
use
brunt
criteria
result
date
particip
enrol
result
avail
interim
analysi
mean
age
year
mean
bmi
male
diabet
preval
nafld
defin
proton
densiti
fat
fraction
pdff
among
complet
radiograph
studi
fig
pdff
valu
nafld
patient
distribut
follow
biopsi
perform
date
normal
nash
among
nash
patient
diabet
diabet
diabet
diabet
patient
diabet
nafld
compar
higher
fibroscantm
lsm
cap
steatosi
grade
p
fibrosi
stage
among
nash
vs
nash
nafld
mean
fibroscantm
lsm
vs
kpa
lif
vs
mre
vs
kpa
mri
vs
conclus
adult
patient
without
known
liver
diseas
interim
result
novel
radiograph
studi
liver
biopsi
confirm
high
preval
nafld
usa
disclosur
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
follow
peopl
noth
disclos
angelo
h
pared
katharin
k
robert
induruwa
n
pathirana
allyson
e
cochet
pedro
manibusan
christoph
j
lisanti
ryan
schwope
alan
georg
katherin
cebe
jame
k
aden
jennif
dustin
thoma
background
aim
pauciti
data
regard
incid
nonalcohol
fatti
liver
diseas
nafld
popul
aim
determin
nafld
incid
mortal
cardiovascular
cv
event
us
commun
method
use
rochest
epidemiolog
project
databas
construct
commun
cohort
subject
diagnos
nafld
olmst
counti
mn
nafld
defin
use
diagnost
code
algorithm
subject
follow
april
mortal
cv
outcom
myocardi
infarct
angina
atrial
fibril
cerebrovascular
diseas
compar
match
control
group
identifi
gener
popul
multivari
cox
regress
analysi
perform
determin
impact
nafld
mortal
cv
event
result
total
subject
nafld
median
age
femal
identifi
incid
rate
increas
per
without
consider
figur
compar
control
nafld
subject
like
diabet
vs
p
hypertens
vs
p
hyperlipidemia
vs
p
nafld
subject
higher
mortal
vs
cv
event
vs
adjust
presenc
diabet
hypertens
hyperlipidemia
addit
age
sex
nafld
independ
associ
mortal
hr
ci
p
cv
event
hr
ci
p
conclus
mostli
white
popul
nafld
incid
increas
consider
nafld
independ
predictor
overal
mortal
cv
event
disclosur
gregori
j
gore
advisori
committe
review
panel
conatu
bayer
patrick
kamath
advisori
committe
review
panel
sequana
medic
follow
peopl
noth
disclos
alina
allen
joseph
j
larson
terri
therneau
introduct
fatti
liver
diseas
nafld
common
liver
diseas
global
patient
nafld
inflamm
liver
steatohepat
nash
wherea
fatti
liver
without
inflamm
fatti
liver
nafl
nash
nafl
previous
consid
potenti
progress
fibrosi
develop
cirrhosi
aim
investig
risk
factor
progress
fibrosi
patient
nafld
impact
subsequ
mortal
materi
method
identifi
patient
undergon
liver
biopsi
find
nafld
karolinska
univers
hospit
stockholm
sweden
patient
perform
two
liver
biopsi
year
part
complet
data
possibl
risk
factor
includ
age
sex
presenc
diseas
bmi
biochem
paramet
identifi
cohort
divid
two
group
one
fibrosi
progress
one
without
fibrosi
progress
follow
death
end
studi
period
biopsi
central
read
one
expert
liver
pathologist
defin
nash
base
flip
algorithm
score
fibrosi
use
nash
crn
system
differ
paramet
two
cohort
analyz
use
continu
variabl
fischer
exact
test
categor
variabl
result
patient
serial
biopsi
median
interv
year
rang
year
patient
fibrosi
progress
median
age
baselin
year
male
median
bmi
diabet
mellitu
type
found
signific
risk
factor
progress
fibrosi
among
patient
fibrosi
progress
nafl
nash
baselin
differ
fibrosi
progress
rate
patient
nafl
nash
baselin
vs
stage
per
year
second
biopsi
patient
follow
median
year
rang
patient
fibrosi
progress
die
follow
versu
patient
without
fibrosi
progress
conclus
patient
nafl
nash
progress
fibrosi
patient
progress
fibrosi
higher
risk
futur
mortal
disclosur
follow
peopl
noth
disclos
olof
elfwen
per
stal
rolf
w
hultcrantz
hann
hagstrom
introduct
fatti
liver
diseas
nafld
affect
around
global
popul
highli
associ
metabol
syndrom
mani
patient
develop
type
diabet
mellitu
nafld
patient
develop
like
progress
steatohepat
nash
liver
fibrosi
need
diagnost
tool
identifi
nafld
patient
highest
risk
develop
aim
studi
find
predict
factor
risk
develop
nafld
patient
materi
method
cohort
patient
nafld
diagnos
analyz
data
develop
collect
electron
paper
patient
chart
biomark
clinic
paramet
baselin
compar
patient
develop
patient
hazard
ratio
hr
develop
number
baselin
variabl
calcul
use
multivari
cox
regress
final
model
adjust
sex
age
hypertens
bmi
triglycerid
glucos
well
histolog
score
fat
lobular
inflamm
balloon
fibrosi
portal
inflamm
result
exclud
patient
baselin
patient
outcom
data
leav
patient
final
analysi
baselin
patient
mean
age
year
women
patient
gener
overweight
mean
bmi
mean
year
rang
individu
develop
age
time
biopsi
ahr
ci
p
serum
triglycerid
ahr
ci
p
higher
stage
fibrosi
ahr
ci
associ
increas
risk
develop
conclus
age
fibrosi
stage
triglycerid
predict
paramet
develop
nafld
disclosur
follow
peopl
noth
disclos
nikla
k
bjorkstrom
per
stal
rolf
w
hultcrantz
hann
hagstrom
background
nonalcohol
fatti
liver
diseas
nafld
common
caus
liver
diseas
us
affect
third
adult
preval
nafld
appear
vari
race
ethnic
variat
may
mere
reflect
differ
risk
factor
obes
dyslipidemia
diabet
hypertens
e
metabol
syndrom
use
data
nash
crn
cohort
studi
assess
variat
common
risk
factor
clinic
featur
sever
nafld
race
ethnic
method
niddk
nash
crn
multicent
cohort
studi
aim
help
elucid
pathogenesi
natur
histori
therapi
nafld
analysi
adult
subject
select
enrol
nash
crn
liver
biopsi
clinic
assess
laboratori
result
within
month
base
upon
patient
categor
white
nhw
hispan
white
hw
asian
black
compar
regard
clinic
laboratori
histolog
featur
result
subject
nhw
hw
asian
black
patient
frequent
women
rang
group
except
asian
men
slightli
outnumb
women
preval
diabet
hypertens
coronari
arteri
diseas
cad
highest
black
lowest
hw
mean
weight
kilogram
group
lowest
asian
intermedi
hw
highest
nhw
black
p
normal
bodi
mass
index
bmi
frequent
asian
least
frequent
black
nafld
activ
score
na
increas
increas
bmi
categori
nhw
asian
black
chang
bmi
hw
frequenc
gg
genotyp
highest
black
follow
asian
nhw
other
lowest
hispan
proport
patient
definit
nash
vs
borderlin
nafld
without
nash
significantli
differ
among
group
conclus
signific
differ
clinic
featur
associ
nafld
base
race
ethnic
femal
predomin
group
except
asian
mean
weight
patient
nafld
lowest
asian
hispan
white
intermedi
white
highest
black
although
black
repres
small
percentag
cohort
high
percentag
diabet
hypertens
cad
gg
genotyp
suggest
presenc
cumul
risk
factor
burden
develop
nafld
group
disclosur
rohit
loomba
advisori
committe
review
panel
galm
inc
tobira
inc
arrowhead
research
inc
consult
gilead
inc
corgenix
inc
janssen
janssen
inc
zafgen
inc
celgen
inc
alnylam
inc
inanta
inc
deutrx
inc
grant
research
support
daiichi
sankyo
inc
aga
merck
inc
promedior
inc
kinem
inc
immuron
inc
adheron
inc
follow
peopl
noth
disclos
niharika
samala
erin
k
hallinan
david
e
kleiner
jay
h
hoofnagl
background
urgent
need
develop
comprehens
rigor
model
current
futur
burden
diseas
due
nafld
impact
health
care
resourc
util
guid
polici
decis
health
care
drug
develop
aim
develop
comprehens
model
burden
diseas
financi
impact
method
preval
nafld
histolog
subtyp
nafl
nash
comput
robust
nation
data
trend
obes
separ
appli
preval
rate
nafl
nash
publish
literatur
data
two
data
set
integr
develop
comprehens
model
nafld
us
popul
transit
rate
toward
cirrhosi
end
stage
liver
diseas
cancer
correct
comput
comprehens
literatur
search
compet
mortal
background
caus
estim
assess
impact
nafld
excess
caus
cardiovascular
death
model
result
valid
base
upon
nation
surveil
data
annual
hcc
incid
attribut
nash
analyt
approach
similar
previous
publish
studi
popul
health
burden
jama
result
current
trend
continu
total
nafld
case
increas
million
million
increas
total
nash
case
increas
million
million
increas
preval
nafld
popul
age
year
increas
next
year
among
total
nash
case
approxim
classifi
increas
number
incid
hcc
case
project
increas
nearli
compar
case
preval
number
compens
decompens
cirrhosi
case
project
increas
case
respect
project
direct
healthcar
cost
end
stage
liver
diseas
increas
usd
liver
relat
mortal
estim
death
increas
death
conclus
project
increas
flatten
obes
preval
disproportion
increas
nash
next
year
translat
substanti
increas
burden
cirrhosi
end
stage
liver
diseas
hcc
result
commensur
increas
health
care
cost
disclosur
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
homi
razavi
grantresearch
support
gilead
abbvi
manag
posit
center
diseas
analysi
follow
peopl
noth
disclos
chri
est
background
aim
nonalcohol
fatti
liver
diseas
nafld
includ
nonalcohol
fatti
liver
nafl
nonalcohol
steatohepat
nash
latter
character
presenc
hepat
steatosi
inflamm
accompani
hepatocyt
injuri
without
fibrosi
human
matrix
shown
contribut
regress
experiment
liver
fibrosi
ectop
express
rodent
actual
acceler
tissu
fibrosi
human
nash
studi
recent
shown
signific
upregul
express
advanc
stage
nash
j
mod
hum
pathol
studi
conduct
evalu
signific
express
diagnost
marker
earli
nash
method
eleven
sampl
histolog
proven
earli
nash
nafl
specimen
examin
along
five
normal
liver
specimen
discrimin
cell
type
express
dual
immunohistochem
stain
perform
use
antibodi
recogn
specif
marker
either
kupffer
cell
kc
capillari
endotheli
cell
hepat
stellat
cell
hepat
progenitor
cell
hpc
precis
local
examin
immunoelectron
microscopi
iem
serum
level
measur
fluoresc
base
immunoassay
express
also
examin
use
western
blot
analys
result
express
normal
nafl
liver
specimen
observ
number
kc
sinusoid
endotheli
cell
blood
vessel
extrem
weak
immunoreact
earli
stage
nash
local
predominantli
kc
monocyt
partial
local
hpc
immunoreact
product
visual
iem
ablumin
portion
cell
membran
kupffer
cell
monocyt
hpc
serum
concentr
patient
earli
stage
nash
ngml
show
higher
tendenc
compar
healthi
person
ngml
conclus
increas
express
associ
diseas
progress
earli
stage
nash
result
show
hpc
express
might
contribut
repair
regener
earli
nash
liver
serum
level
use
marker
detect
hpc
respons
earli
stage
nash
promis
biomark
therapeut
target
nash
disclosur
wataru
ando
grantresearch
support
tosoh
corpor
follow
peopl
noth
disclos
hiroaki
yokomori
yutaka
inagaki
masaya
oda
isao
okazaki
background
aim
compar
diagnost
perform
transient
elastographi
te
superson
imag
ssi
acoust
radiat
forc
impuls
imag
arfi
stage
fibrosi
identifi
clinic
factor
affect
liver
stiff
measur
lsm
prospect
nafld
cohort
method
subject
nafld
includ
subject
liver
stiff
measur
use
te
ssi
arfi
within
month
liver
biopsi
diagnost
perform
stage
liver
fibrosi
evalu
use
receiv
oper
characterist
roc
analysi
anthropometr
data
use
ct
bioelectr
imped
analysi
evalu
covari
influenc
lsm
regress
analys
result
lsm
modal
correl
fibrosi
stage
p
exhibit
similar
perform
stage
fibrosi
p
area
roc
curv
te
kpa
ssi
ms
kpa
arfi
ms
signific
fibrosi
advanc
fibrosi
cirrhosi
arfi
tend
specif
ssi
tend
sensit
differenti
fibrosi
stage
best
diagnost
perform
anthropometr
data
correl
failur
unreli
lsm
especi
ssi
regress
analysi
anthropometr
data
might
confound
lsm
use
ssi
serum
liver
marker
might
confound
lsm
use
te
arfi
conclus
diagnost
perform
individu
lsm
modal
stage
fibrosi
nafld
significantli
differ
te
arfi
might
fit
better
suspicion
advanc
fibrosi
te
ssi
might
advantag
suspicion
mild
fibrosi
anthropometr
evalu
may
help
predict
lsm
reliabl
especi
ssi
keyword
steatosi
fibrosi
veloc
elastometri
fatti
liver
disclosur
follow
peopl
noth
disclos
kim
myoung
seok
lee
young
ho
jung
ho
kim
sae
kyung
joo
yong
jin
jung
fatti
liver
diseas
common
contribut
prematur
death
examin
whether
us
fatti
liver
index
usfli
ruhl
aliment
pharmacol
ther
fatti
liver
index
fli
serum
marker
steatosi
associ
increas
overal
mortal
us
prospect
survey
year
data
method
studi
fast
viral
hepat
neg
adult
particip
third
u
nation
health
nutrit
examin
survey
nhane
high
steatosi
probabl
defin
base
publish
particip
passiv
follow
mortal
identifi
death
certif
underli
contribut
caus
diagnos
linkag
nation
death
index
record
hazard
rate
ratio
hr
mortal
calcul
use
cox
proport
hazard
regress
adjust
common
mortal
risk
factor
result
preval
intermedi
high
steatosi
probabl
use
usfli
marker
respect
death
caus
liver
diseas
includ
primari
liver
cancer
high
usfli
associ
increas
liver
diseas
mortal
analysi
hr
ci
multivari
adjust
risk
increas
figur
high
fli
also
associ
increas
liver
diseas
mortal
figur
associ
higher
usfli
fli
cardiovascular
diseas
cancer
diabet
mortal
analys
figur
conclus
u
popul
higher
steatosi
probabl
use
usfli
fli
independ
associ
increas
liver
diseas
mortal
mortal
outcom
liver
health
manag
steatosi
risk
stratif
merit
studi
disclosur
follow
peopl
noth
disclos
aynur
constanc
e
ruhl
background
aim
satur
fatti
acid
sfa
import
risk
factor
develop
nash
via
endoplasm
reticulum
stress
oxid
stress
major
sourc
hepat
sfa
adipos
tissu
hepat
lipogenesi
de
novo
diet
report
indic
amount
sfa
deriv
adipos
tissu
de
novo
lipogenesi
increas
nash
chang
dietari
sfa
absorpt
unclear
thu
aim
clarifi
chang
absorpt
dietari
palmit
acid
common
dietari
sfa
induc
hepat
inflamm
also
assess
associ
pathogenesi
nash
patient
method
studi
includ
control
well
patient
brunt
stage
defin
earli
advanc
nash
respect
palmit
label
administ
directli
duodenum
use
gastrointestin
endoscopi
avoid
delay
result
deliveri
via
stomach
breath
level
measur
quantifi
metabol
sfa
everi
min
administr
next
min
express
locat
sfa
transport
assess
jejun
biopsi
sampl
western
blot
immunohistochem
stain
associ
breath
level
hepat
steatosi
fibrosi
insulin
resist
evalu
laboratori
test
elastographi
liver
histolog
result
significantli
excret
minut
patient
control
p
earli
phase
min
patient
compar
control
p
western
blot
reveal
higher
level
glycosyl
microsom
triglycerid
transfer
protein
mttp
patient
control
immunohistochem
stain
reveal
strong
glycosyl
express
blood
vessel
excret
patient
earli
phase
auc
mi
laboratori
valu
type
iv
collagen
correl
control
attenu
paramet
cap
liver
stiff
measur
lsm
determin
elastographi
addit
auc
min
significantli
increas
brunt
stage
stage
amount
excret
late
phase
auc
mi
insu
lin
conclus
dietari
palmit
acid
absorpt
upregul
jejunum
appar
associ
clinicopatholog
featur
patient
disclosur
teru
kumagi
grantresearch
support
ea
pharma
co
ltd
follow
peopl
noth
disclos
hiroki
utsunomiya
yasunori
yamamoto
eiji
takeshita
yoshio
tokumoto
fujimasa
tada
teruki
miyak
masashi
hirooka
masanori
abe
bunzo
matsuura
yoshio
ikeda
yoichi
hiasa
background
aim
nonalcohol
fatti
liver
diseas
nafld
associ
increas
risk
coronari
arteri
diseas
cad
underli
mechan
link
nafld
cad
entir
clear
nitrotyrosin
identifi
marker
inflamm
nitric
oxid
product
aim
assess
role
nitrotyrosin
potenti
link
hepat
steatosi
atherosclerosi
method
prospect
enrol
patient
undergo
elect
coronari
angiographi
suspicion
cad
inform
consent
patient
underw
hepat
ultrasound
us
addit
clinic
data
fast
serum
obtain
coronari
angiographi
ca
result
obtain
us
imag
read
central
radiologist
nafld
defin
presenc
hepat
steatosi
us
absenc
caus
liver
diseas
excess
alcohol
use
accord
ca
find
patient
divid
nafld
cad
nafld
minim
lumin
irregular
mli
stenosi
coronari
arteri
nafld
without
cad
concentr
nitrotyrosin
nm
endotheli
nitric
oxid
synthas
eno
pgml
determin
serum
use
elisa
assay
result
nitrotyrosin
level
highli
express
nafld
patient
cad
nafld
mli
compar
patient
nafld
without
cad
p
multivari
analysi
show
nitrotyrosin
ci
age
ci
histori
hyperlipidemia
ci
independ
associ
increas
risk
cad
nafld
patient
furthermor
nitrotyrosin
neg
associ
high
densiti
lipoprotein
p
posit
associ
triglycerid
level
level
eno
significantli
associ
cad
nafld
conclus
increas
level
serum
nitrotyrosin
nafld
may
associ
risk
cad
sinc
eno
level
increas
sourc
nitrotyrosin
potenti
patholog
product
induc
nitric
oxid
synthas
ino
disclosur
brian
p
lam
advisori
committe
review
panel
bm
speak
teach
gilead
stock
sharehold
gilead
vertex
follow
peopl
noth
disclos
elzafir
elsheikh
azza
karrar
sean
c
felix
hussain
allawi
mehmet
sayin
thoma
jeffer
zahra
younoszai
munkhzul
otgonsuren
andrei
racila
jason
poff
bryan
raybuck
lynn
gerber
zobair
younossi
background
overal
mortal
patient
nafld
increas
except
nafld
patient
signific
fibrosi
howev
predictor
signific
fibrosi
nafld
wide
examin
conduct
studi
determin
predictor
nafld
high
risk
fibrosi
stage
nafld
patient
gener
unit
state
popul
use
nation
health
nutrit
examin
survey
nhane
conduct
method
nafld
defin
unit
state
fatti
liver
index
us
fli
inclus
age
ethnic
ggt
waist
circumfer
fast
insulin
glucos
includ
age
year
attend
medic
examin
fast
particip
exclud
test
posit
viral
hepat
signific
alcohol
use
miss
data
either
us
fli
data
use
nafld
fibrosi
score
nf
determin
risk
fibrosi
stage
result
fast
person
age
year
attend
medic
examin
person
met
inclus
exclus
criteria
nafld
subject
nafld
older
vs
p
like
male
vs
p
mexican
american
vs
p
lower
incom
vs
p
signific
independ
predictor
nafld
age
year
male
sex
mexican
american
ethnic
high
bmi
diabet
mellitu
dm
control
uncontrol
metabol
syndrom
tabl
among
nafld
popul
high
probabl
fibrosi
stage
nf
signific
independ
predictor
high
risk
stage
fibrosi
subject
nafld
age
year
high
bmi
dm
control
uncontrol
tabl
conclus
older
obes
diabet
patient
nafld
higher
risk
stage
fibrosi
target
addit
intervent
disclosur
helen
te
advisori
committe
review
panel
intercept
grantresearch
support
abbvi
gilead
conatu
ramsey
cheung
grantresearch
support
gilead
scienc
abbvi
mindi
h
nguyen
advisori
committe
review
panel
squibb
gilead
consult
gilead
scienc
inc
grantresearch
support
gilead
scienc
inc
squibb
follow
peopl
noth
disclos
michael
h
le
pardha
devaki
nghiem
b
ha
dae
jun
background
microrna
mir
small
rna
molecul
involv
regul
gene
express
implic
pathogenesi
nonalcohol
steatohepat
nash
object
determin
util
noninvas
marker
liver
histolog
lesion
method
differenti
mir
analysi
perform
plasma
sampl
subject
suspect
nash
snash
fail
screen
phase
trial
evalu
inhibitor
apoptosi
kinas
mean
age
year
male
mean
bmi
control
mean
bmi
mir
isol
control
use
total
rna
isol
kit
norgen
corp
canada
complementari
dna
gener
use
quantimir
kit
mir
measur
qpcr
use
mirnom
profil
system
bioscienc
mountain
view
calcul
differenti
mir
express
perform
use
method
either
spliceosom
rna
c
elegan
control
statist
analys
perform
use
signific
analysi
microarray
sam
method
mir
minimum
differ
express
subject
control
select
correl
mir
express
fibrosi
stage
nafld
activ
score
na
determin
use
random
decis
forest
method
perform
mir
panel
distinguish
snash
subject
control
determin
result
sampl
snash
control
pass
standard
among
biopsi
snash
subject
na
stage
fibrosi
use
sam
mir
differenti
express
snash
subject
control
mir
significantli
use
minimum
chang
select
criteria
highest
mir
associ
nash
pathogenesi
sever
novel
mir
identifi
one
mir
distinguish
snash
subject
control
area
roc
curv
auroc
strongli
correl
fibrosi
spearman
na
panel
mir
auroc
differenti
snash
subject
control
sensit
specif
conclus
exploratori
studi
panel
mir
differenti
snash
subject
healthi
control
correl
fibrosi
stage
na
although
valid
find
necessari
mir
potenti
util
noninvas
diagnosi
nash
disclosur
biao
li
employ
gilead
scienc
inc
zhaoshi
jiang
employ
gilead
scienc
inc
stock
sharehold
gilead
sciec
inc
ren
xu
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
constantin
djedjo
employ
gilead
scienc
scott
patterson
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
robert
p
myer
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
zachari
goodman
grantresearch
support
gilead
scienc
galectin
therapeut
intercept
alexion
conatu
cempra
nitto
denko
tobira
exalenz
michael
r
charlton
consult
gilead
scienc
grantresearch
support
gilead
scienc
merck
janssen
abbvi
novarti
intercept
nezam
h
afdhal
advisori
committe
review
panel
trio
helath
care
board
membership
journal
viral
hepat
ligand
consult
merck
echosen
bm
achillion
glaxosmithklin
gilead
abbvi
roivant
shionogi
employ
springbank
grantresearch
support
gilead
stock
sharehold
springbank
gilead
rohit
loomba
advisori
committe
review
panel
galm
inc
tobira
inc
arrowhead
research
inc
consult
gilead
inc
corgenix
inc
janssen
janssen
inc
zafgen
inc
celgen
inc
alnylam
inc
inanta
inc
deutrx
inc
grant
research
support
daiichi
sankyo
inc
aga
merck
inc
promedior
inc
kinem
inc
immuron
inc
adheron
inc
follow
peopl
noth
disclos
nandita
sarkar
annapoorna
gururajan
background
oral
avail
agonist
farnesoid
x
receptor
fxr
key
regul
bile
acid
glucos
lipid
homeostasi
first
clinic
studi
administ
nafld
patient
aim
method
perform
singl
center
proof
concept
phase
ila
studi
evalu
efficaci
safeti
toler
nafld
patient
patient
enrol
diagnosi
nafld
base
liver
biopsi
hepat
steatosi
ultrasound
magnet
reson
spectroscopi
mr
continu
attenu
paramet
cap
patient
treat
mg
oral
daili
week
serum
liver
enzym
insulin
sensit
index
clix
hepat
fat
proton
mr
proton
densiti
fat
fraction
cap
assess
evalu
chang
hepat
energi
metabol
kupffer
cell
function
perform
phosphoru
mr
superparamagnet
iron
oxid
splo
magnet
reson
imag
respect
readout
includ
serum
lipid
marker
bile
acid
ba
metabolismsign
result
patient
alloc
treatment
signific
decreas
alt
ggt
observ
week
treatment
tabl
chang
serum
alkalin
phosphatas
hdlldl
cholesterol
triglycerid
seen
insulin
sensit
assess
clix
improv
patient
vs
howev
hepat
steatosi
measur
cap
well
extend
serum
lipid
ba
profil
includ
chang
ratio
significantli
decreas
patient
indic
reduc
hepat
inflammatori
stress
show
differ
seriou
advers
event
occur
short
interv
cardiac
arrhythmia
record
patient
led
termin
studi
conclus
fxr
agonist
improv
insulin
sensit
decreas
serum
ggt
alt
level
week
treatment
nafld
patient
compound
show
improv
fxr
efficaci
safeti
profil
appear
justifi
clinic
paramet
liver
enzym
metabol
marker
disclosur
stefan
traussnigg
grantresearch
support
phenex
pharmaceut
harald
hofer
advisori
committe
review
panel
gilead
abbvi
speak
teach
janssen
bm
gilead
abbvi
martin
hornberg
employ
phenex
pharmaceut
ag
manfr
birkel
employ
phenex
pharmaceut
ag
clau
kremos
consult
gilead
scienc
manag
posit
phenex
pharmaceut
ag
stock
sharehold
phenex
pharmaceut
ag
michael
h
trauner
consult
albireo
falk
phenex
gilead
novarti
msd
grantresearch
support
falk
albireo
intercept
follow
peopl
noth
disclos
christian
kienbach
emina
halilbas
christian
rechl
petra
e
ghazaleh
gouya
michael
wolzt
background
aim
increasingli
recogn
nonalcohol
fatti
liver
diseas
nafld
may
present
individu
use
individu
patient
level
data
two
random
trial
compar
obes
patient
nonalcohol
steatohepat
nash
regard
clinic
histolog
characterist
baselin
determin
advanc
fibrosi
respons
therapi
method
two
trial
combin
nash
patient
receiv
placebo
activ
treatment
includ
vitamin
e
pioglitazon
cholic
acid
subject
divid
bodi
mass
index
bmi
obes
bmi
bmi
result
compar
obes
patient
patient
like
older
mean
age
versu
versu
less
diabet
versu
higher
level
versu
lower
level
versu
p
differ
baselin
histolog
obes
nash
patient
except
balloon
less
common
nonobes
patient
versu
logist
regress
analys
determin
advanc
fibrosi
patient
includ
aspart
aminotransferas
ast
odd
ratio
confid
interv
ci
diabet
ci
platelet
count
ci
similar
obes
nash
among
treat
patient
pair
biopsi
chang
sever
lobular
inflamm
steatosi
balloon
fibrosi
significantli
differ
nonobes
obes
nash
patient
tabl
nafld
activ
score
ci
platelet
count
ci
baselin
associ
respons
nash
patient
conclus
phenotyp
differ
obes
patient
nash
nonobes
patient
display
similar
degre
histolog
sever
respons
therapi
high
index
suspicion
nash
need
recogn
patient
chang
histolog
featur
patient
nonalcohol
steatohepat
compar
obes
patient
disclosur
w
ray
kim
advisori
committe
review
panel
intercept
gilead
scienc
merck
follow
peopl
noth
disclos
donghe
kim
ajitha
mannalithara
prowpanga
udompap
background
aim
nafld
increasingli
report
caus
hcc
worldwid
studi
determin
tempor
trend
preval
nafld
patient
pt
hcc
undergo
liver
resect
lr
past
year
clinic
characterist
outcom
patient
method
retrospect
analysi
pt
undergo
lr
hcc
surgic
team
hcc
confirm
histolog
nafld
diagnos
base
past
present
exposur
obes
diabet
without
caus
chronic
liver
diseas
liver
assess
histolog
fibrosi
stage
metavir
result
patient
includ
mean
age
yr
male
cirrhosi
liver
diseas
etiolog
hcv
hbv
nafld
alcohol
liver
diseas
ald
mix
nafldald
caus
pt
nafld
older
yr
vs
ald
hcv
hbv
p
mainli
male
preval
nafld
steadili
increas
hbv
increas
hcv
decreas
ald
remain
stabl
vs
hcc
develop
absenc
bridg
fibrosiscirrhosi
pt
nafld
vs
hbv
ald
hcv
p
nafld
tumor
less
well
differenti
larger
ald
hcv
mm
vs
mm
mm
respect
p
similar
hbv
mm
within
nafld
group
tumor
characterist
differ
pt
except
much
higher
proport
singl
nodul
vs
respect
p
pt
nafld
underw
major
hepatectomi
vs
ald
hcv
hbv
whole
cohort
patient
tumor
recurr
nafld
alcohol
hcv
hbv
die
nafld
hbv
hcv
ald
mean
time
recurr
yr
without
signific
differ
accord
etiolog
factor
associ
hcc
recurr
tumor
size
number
nodul
satellit
nodul
p
micro
macrovascular
invas
p
respect
satellit
nodul
microvascular
invas
male
sex
etiolog
liver
diseas
independ
associ
recurr
conclus
past
year
strong
increas
nafld
among
resect
hcc
nafld
pt
older
overwhelmingli
male
larger
tumor
develop
mostli
earli
fibrosi
surviv
recurr
rate
similar
etiolog
justifi
cur
therapeut
approach
lr
disclosur
olivi
rosmorduc
advisori
committe
review
panel
syrtex
ipsen
speak
teach
bayer
vlad
ratziu
advisori
committe
review
panel
galm
abbott
genfit
enterom
gilead
consult
tobira
intercept
exalenz
follow
peopl
noth
disclos
raluca
pai
laetitia
fartoux
clair
goumard
olivi
scatton
dominiqu
wendum
background
aim
chronic
hepat
b
comorbid
nonalcohol
fatti
liver
diseas
chbnafld
common
increas
rapidli
greater
china
region
howev
clinic
signific
comorbid
patient
remain
elus
aim
investig
preval
metabol
syndrom
compon
diseas
progress
chb
nafld
compar
chb
nafld
method
total
patient
liver
biopsi
prove
chb
nafld
chbnafld
includ
studi
patient
baselin
liver
cirrhosi
hepatocellular
carcinoma
hcc
histori
alcohol
abus
liver
diseas
exclud
seven
hundr
patient
follow
mean
year
demograph
data
baselin
compon
metabol
syndrom
liver
cirrhosi
relat
complic
hcc
death
note
cox
proport
hazard
model
use
evalu
risk
develop
hcc
mortal
surviv
curv
produc
differ
among
three
group
compar
test
result
preval
hypertens
obes
diabet
mellitu
hyperlipidaemia
chbnafld
group
baselin
significantli
higher
chb
group
respect
hypertens
obes
diabet
mellitu
hyperlipidaemia
p
comparison
significantli
lower
nafld
group
respect
hypertens
obes
diabet
mellitu
hyperlipidaemia
p
comparison
patient
chb
group
nafld
group
chbnafld
group
develop
liver
cirrhosi
end
percentag
patient
progress
liver
cirrhosi
chbnafld
group
significantli
higher
chb
group
p
nafld
group
p
thirteen
patient
chb
group
nafld
group
chbnafld
group
progress
hcc
patient
chbnafld
significantli
higher
cumul
hazard
progress
hcc
chb
group
hazard
p
nafld
group
hazard
p
overal
surviv
among
chb
group
nafld
group
chbnafld
group
equival
p
conclus
preval
metabol
syndrom
chbnafld
significantli
lower
nafld
chb
patient
comorbid
nafld
higher
risk
progress
liver
cirrhosi
hcc
patient
chb
nafld
disclosur
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
jiangao
fan
guofeng
chen
dong
ji
dewei
ye
lei
lu
april
wong
yudong
wang
jing
chen
cheng
wang
qing
shao
bing
li
vanessa
wu
georg
lau
background
treatment
diabet
patient
full
agonist
peroxisom
receptor
gamma
ppari
improv
insulin
sensit
associ
weight
gain
heart
failur
peripher
oedema
bone
loss
endotrophin
fragment
chain
procollagen
type
vi
involv
adipos
tissu
extracellular
matrix
ecm
remodel
metabol
control
establish
serum
assay
endotrophin
assess
novel
ecm
marker
adipokin
could
identifi
type
diabet
nash
patient
respond
optim
ppari
agonist
improv
risk
benefit
ratio
method
ballet
trial
aim
compar
effect
safeti
partial
ppari
agonist
balaglitazon
pioglitazon
patient
stabl
insulin
therapi
month
per
protocol
patient
stratifi
tertil
baselin
level
therapi
correl
achiev
glucos
control
tertil
end
month
treatment
period
result
endotrophin
significantli
associ
therapeut
respons
balaglitazon
pioglitazon
studi
end
subject
two
highest
tertil
show
signific
reduct
fast
serum
glucos
compar
baselin
odd
ratio
reduct
two
upper
tertil
p
p
respect
endotrophin
level
correl
adipos
tissu
mass
insulin
resist
fatti
liver
index
compos
triglycerid
bmi
ggt
waist
circumfer
notabl
advers
event
moder
sever
lower
extrem
oedema
occur
lower
tertil
conclus
elev
serum
level
endotrophin
predict
respons
two
insulin
sensit
lower
identifi
patient
profit
agonist
treatment
disclosur
morten
karsdal
manag
posit
nordic
bioscienc
stock
sharehold
nordic
bioscienc
kim
henriksen
employ
nordic
bioscienc
stock
sharehold
nordic
bioscienc
federica
genoves
employ
nordic
bioscienc
diana
j
leem
employ
nordic
bioscienc
patent
heldfil
nordic
bioscienc
mett
j
nielsen
grantresearch
support
nordic
bioscienc
bent
rii
board
membership
nordic
bioscienc
employ
nordic
bioscienc
manag
posit
nordic
bioscienc
stock
sharehold
nordic
bioscienc
clau
christiansen
board
membership
nordic
biosic
stock
sharehold
bent
christiansen
follow
peopl
noth
disclos
detlef
schuppan
background
accord
recent
report
sever
steatosi
like
affect
liver
elast
e
measur
transient
elastographi
te
subject
fatti
liver
diseas
nafld
howev
littl
known
impact
control
attenu
paramet
cap
assess
te
measur
liver
e
subject
nafld
method
two
hundr
eleven
subject
nafld
includ
prospect
analysi
patient
underw
acoust
radiat
forc
impuls
elastographi
arfi
te
cap
measur
logist
regress
analysi
discrimin
function
analysi
use
calcul
two
kind
e
area
roc
curv
auroc
use
determin
optim
sensit
specif
e
valu
detect
advanc
fibrosi
cirrhosi
result
diagnos
advanc
fibrosi
auroc
te
e
optim
sensit
se
specif
sp
log
odd
optim
se
sp
formula
calcul
use
discrimin
function
analysi
diagnos
cirrhosi
te
e
optim
se
sp
log
odd
optim
se
sp
formula
calcul
use
discrimin
function
analysi
auroc
te
e
significantli
differ
te
e
howev
specif
te
markedli
improv
adjust
cap
without
diminish
sensit
te
optim
valu
conclus
signific
posit
correl
e
fibrosi
stage
subject
nafld
although
e
superior
e
diagnos
advanc
fibrosi
cirrhosi
measur
e
might
obviat
need
liver
biopsi
nafld
acoust
radiat
forc
impuls
arfi
sonograph
transient
sonoelastograph
te
control
attenu
paramet
disclosur
follow
peopl
noth
disclos
dong
hyeon
lee
kim
yong
jin
jung
background
aim
onset
progress
liver
damag
fatti
liver
diseas
nafld
tightli
associ
insulin
resist
ir
dysfunct
adipos
tissu
macrophag
activ
key
step
chronic
low
inflammatori
state
ir
hepat
damag
aim
studi
elucid
pathway
link
ir
circul
hepat
macrophag
activ
liver
damag
patient
nafld
materi
method
glycerol
infus
studi
subject
evalu
lipolysi
adipos
calcul
ffa
insulin
in
in
solubl
marker
hepat
macrophag
activ
measur
immunosorb
assay
elisa
mrna
express
liver
evalu
qpcr
use
supermix
biorad
histolog
score
accord
kleiner
hepat
fat
assess
liver
biopsi
viscer
fat
vf
subcutan
fat
sf
measur
standard
nuclear
magnet
reson
nmr
result
show
signific
associ
featur
liver
damag
liver
biopsi
includ
hepat
fat
na
score
respect
fibrosi
plasma
level
significantli
associ
fast
plasma
level
ffa
lipolysi
r
circul
increas
proport
liver
fat
viscer
subcutan
fat
pn
hepat
express
linear
correl
plasma
level
nafld
subject
hepat
express
significantli
higher
hepat
fat
content
hepat
express
higher
nafld
patient
moder
sever
fibrosi
conclus
specul
nafld
patient
hepat
macrophag
activ
directli
stimul
increas
flux
ffa
due
thu
directli
link
ir
dysfunct
adipos
tissu
liver
damag
disclosur
holger
j
moller
grantresearch
support
danish
council
strateg
research
independ
contractor
nl
patent
heldfil
aarhu
univers
stock
sharehold
affinicon
ap
amalia
gastaldelli
consult
sanofi
grantresearch
support
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
hen
advisori
committe
review
panel
ipsen
consult
novarti
grantresearch
support
abbvi
intercept
novo
nordisk
foundat
follow
peopl
noth
disclos
chiara
rosso
konstantin
kazankov
milena
marietti
melania
gaggini
emma
buzzigoli
gian
paolo
caviglia
maria
lorena
abat
antonina
smedil
giorgio
maria
saracco
hendrik
vilstrup
elisabetta
bugianesi
background
aim
reliabl
biomark
need
diagnosi
monitor
patient
steatohepat
nash
studi
set
determin
perform
new
score
develop
echosen
differenti
nash
simpl
steatosi
base
singl
fibroscan
examin
liver
stiff
control
attenu
paramet
cap
method
patient
suspect
nafld
prospect
underw
fibroscan
examin
within
week
standard
care
liver
biopsi
lb
march
januari
seven
uk
center
lb
read
blind
manner
two
expert
pathologist
nash
diagnos
use
flip
algorithm
nash
sever
grade
accord
na
score
develop
score
diagnos
nash
cohort
split
randomli
train
valid
set
sampl
split
repeat
time
lead
select
optimum
model
test
extern
valid
cohort
consist
nafld
patient
singl
liver
centr
franc
patient
underw
fibroscan
examin
within
day
lb
read
pathologist
result
patient
bmi
kg
studi
follow
patient
exclud
score
develop
lb
interpretablediagnost
nafld
fibroscan
possibl
fibroscan
unreli
accord
boursier
criteria
patient
median
bmi
age
year
male
na
score
nash
extern
valid
cohort
median
bmi
age
year
male
na
score
nash
reliabl
fibroscan
examin
perform
score
shown
tabl
conclus
novel
score
base
measur
liver
stiff
cap
singl
fibroscan
examin
abl
correctli
classifi
patient
withwithout
nash
well
correctli
stage
sever
promis
marker
detectingstag
diseas
activ
patient
nash
nash
score
perform
auc
area
roc
curv
cc
correctli
classifi
patient
maxim
neg
posit
predict
valu
disclosur
quentin
anste
advisori
committe
review
panel
intercept
consult
genfit
eli
lilli
pfizer
inventiva
imperi
innov
grantresearch
support
abbvi
gsk
victor
de
ledinghen
board
membership
janssen
gilead
bm
abbvi
intercept
pharma
superson
imagin
grantresearch
support
superson
imagin
speak
teach
abbvi
merck
bm
gilead
magali
sasso
employ
echosen
celin
fournier
manag
posit
echosen
miett
employ
echosen
follow
peopl
noth
disclos
peter
j
eddow
indra
neil
guha
david
sheridan
emmanouil
tsochatzi
jeremi
cobbold
michael
e
allison
valeri
paradi
pierr
bedossa
philip
n
newsom
background
nonalcohol
fatti
liver
diseas
nafld
lead
caus
chronic
liver
diseas
us
nafld
result
progress
liver
fibrosi
cirrhosi
howev
risk
fibrosi
progress
well
determin
risk
unselect
unref
patient
nafld
remain
larg
unknown
aim
examin
proport
patient
nafld
develop
advanc
fibrosi
defin
time
identifi
predictor
progress
among
patient
low
defin
intermedi
defin
fibrosi
baselin
method
identifi
cohort
patient
nafld
nation
va
databas
use
previous
valid
algorithm
base
persist
alt
elev
valu
iuml
month
apart
absenc
hepat
b
hepat
c
excess
alcohol
use
calcul
annual
use
laboratori
result
ast
alt
platelet
test
perform
within
month
event
multipl
test
per
year
patient
use
median
defin
annual
valu
analysi
includ
nafld
patient
least
annual
valu
exclud
patient
advanc
fibrosi
cirrhosi
baselin
defin
basi
cirrhosi
code
use
km
curv
surviv
function
estim
compar
risk
fibrosi
progress
among
patient
cox
proport
hazard
model
examin
risk
factor
fibrosi
progress
result
analysi
includ
cohort
patient
nafld
mean
follow
sd
year
patient
male
white
among
patient
first
baselin
progress
advanc
fibrosi
year
progress
year
among
patient
first
intermedi
rang
progress
advanc
fibrosi
year
year
respect
multivari
model
patient
baselin
higher
risk
fibrosi
progress
patient
hazard
ratio
confid
interv
age
sex
race
bodi
mass
index
diabet
hypertens
dyslipidemia
significantli
associ
fibrosi
progress
overal
analys
stratifi
baselin
degre
fibrosi
conclus
larg
nation
cohort
unselect
patient
nafld
baselin
degre
fibrosi
strong
predictor
risk
progress
among
intermedi
fibrosi
larg
fraction
patient
progress
high
risk
fibrosi
disclosur
hashem
b
consult
gilead
wako
follow
peopl
noth
disclos
aaron
p
thrift
xiaoy
yu
fasiha
kanwal
coronari
heart
diseas
chd
lead
caus
mortal
patient
nonalcohol
fatti
liver
diseas
nafld
risk
factor
chd
sever
underli
liver
diseas
unknown
aim
current
studi
evalu
relationship
sever
liver
histolog
framingham
risk
score
fr
patient
nafld
niddk
nash
crn
cohort
method
analysi
adult
patient
enrol
liver
biopsi
framingham
risk
score
fr
within
month
enrol
perform
fraction
logist
regress
model
fr
outcom
e
probabl
chd
use
evalu
relationship
fr
diabet
statu
coronari
arteri
diseas
bodi
mass
index
therapi
histolog
featur
result
total
patient
met
criteria
includ
analysi
unadjust
regress
analysi
strong
relationship
observ
fr
metabol
medic
comorbid
includ
diabet
use
therapi
p
waist
circumfer
per
cm
p
known
histori
coronari
arteri
diseas
p
patient
nafld
higher
fr
directli
relat
histolog
featur
includ
balloon
per
score
fibrosi
per
stage
p
portal
inflamm
per
score
p
lower
fr
associ
higher
steatosi
fr
per
score
p
definit
nash
associ
higher
fr
per
categori
multipl
fraction
regress
model
independ
relationship
higher
fr
includ
circumfer
use
therapi
known
histori
cad
increas
sever
fibrosi
definit
nash
decreas
sever
steatosi
remain
signific
conclus
patient
nafld
increasingli
higher
risk
chd
associ
metabol
also
worsen
histolog
includ
presenc
nash
sever
fibrosi
howev
fr
went
increas
steatosi
disclosur
naga
p
chalasani
consult
abbvi
lilli
ds
biopharma
tobira
nusirt
domain
grantresearch
support
intercept
gilead
galectin
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
mohammad
siddiqui
mark
l
van
natta
patricia
h
belt
jeann
clark
jame
tonascia
cynthia
guy
bilal
hame
background
aim
potent
select
fxr
agonist
obetichol
acid
oca
shown
significantli
improv
fibrosi
flint
studi
week
multicent
trial
steatohepat
nash
patient
aim
analysi
explor
whether
specif
subgroup
may
respond
differ
oca
treatment
respect
fibrosi
improv
method
flint
studi
patient
nash
random
mg
oca
placebo
pbo
week
treatment
patient
baselin
end
studi
biopsi
includ
analysi
oca
pbo
fibrosi
improv
defin
stage
improv
week
treatment
base
nash
crn
score
criteria
evalu
central
pathologist
subgroup
categori
age
sex
bodi
mass
index
bmi
baselin
diabet
statu
baselin
weight
loss
week
evalu
treatment
effect
within
subgroup
assess
univari
multivari
analys
order
determin
whether
effect
treatment
vari
significantli
among
subgroup
interact
treatment
subgroup
assess
result
subgroup
evalu
analysi
higher
percentag
patient
show
improv
fibrosi
vs
patient
tabl
critic
interact
treatment
subgroup
significantli
differ
within
subgroup
categori
similar
result
observ
na
improv
point
without
worsen
fibrosi
data
shown
conclus
overal
patient
subgroup
evalu
analysi
achiev
fibrosi
improv
specif
subgroup
respond
differ
oca
treatment
interact
treatment
subgroup
found
evalu
larger
number
patient
warrant
disclosur
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
rohit
loomba
advisori
committe
review
panel
galm
inc
tobira
inc
arrowhead
research
inc
consult
gilead
inc
corgenix
inc
janssen
janssen
inc
zafgen
inc
celgen
inc
alnylam
inc
inanta
inc
deutrx
inc
grant
research
support
daiichi
sankyo
inc
aga
merck
inc
promedior
inc
kinem
inc
immuron
inc
adheron
inc
manal
f
abdelmalek
consult
bhv
pharma
taiwanj
pharma
grant
research
support
tobira
gilead
scienc
nihniddk
genfit
pharmaceut
immuron
galm
taiwanj
pharma
intercept
ngm
pharmaceut
bm
pharma
arisaph
speak
teach
alexion
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
brent
tetri
advisori
committe
review
panel
nimbu
therapeut
bristol
myer
squibb
janssen
conatu
allergan
zafgen
pfizer
novarti
galm
recepto
consult
medimmun
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
loi
lee
employ
intercept
pharmaceut
beatric
ferguson
employ
intercept
pharmaceut
reshma
shringarpur
employ
intercept
stock
sharehold
intercept
david
shapiro
employ
intercept
pharmaceut
manag
posit
intercept
pharmaceut
stock
sharehold
intercept
pharmaceut
naga
p
chalasani
consult
abbvi
lilli
ds
biopharma
tobira
nusirt
domain
grantresearch
support
intercept
gilead
galectin
follow
peopl
noth
disclos
bilal
hame
arthur
j
mccullough
background
fatti
liver
diseas
nafld
relat
insulin
resist
metabol
syndrom
diseas
commonli
found
progress
steatohepat
also
evidenc
major
caus
cryptogen
cirrhosi
sever
recent
studi
show
vitamin
play
import
role
pathogenesi
treatment
chronic
liver
diseas
mani
caus
includ
nafld
howev
studi
specif
involv
role
vitamin
replac
nafld
extrem
limit
object
demonstr
effect
vitamin
replac
liver
enzym
inflammatori
marker
nafld
patient
method
random
control
trial
conduct
liver
clinic
vajira
hospit
januari
decemb
sixti
elig
nafld
particip
alt
elev
vitamin
insuffici
randomli
split
two
group
patient
per
group
assign
receiv
either
vitamin
replac
placebo
week
studi
particip
ask
maintain
lifestyl
medic
experi
well
serum
calcium
level
monitor
everi
four
week
side
effect
hypervitaminosi
serum
alt
inflammatori
marker
homeostasi
model
assess
homa
includ
compar
vitamin
replac
period
evalu
effect
vitamin
result
begin
studi
statist
differ
two
group
patient
baselin
characterist
includ
gender
age
bmi
underli
diseas
except
alt
inflammatori
marker
end
studi
alt
ul
p
pgml
p
ferritin
ngml
p
decreas
significantli
vitamin
group
cap
dbm
hscrp
mgl
liver
stiff
kpa
tend
decreas
placebo
group
ferritin
ngml
hscrp
mgl
cap
dbm
liver
stiff
kpa
increas
although
statist
insignific
addit
decreas
serum
alt
vitamin
group
significantli
greater
placebo
group
ul
vs
ul
respect
p
furthermor
patient
vitamin
group
experi
side
effect
hypervitaminosi
conclus
vitamin
replac
could
significantli
reduc
liver
inflamm
well
contribut
decreas
steatosi
quantif
nafld
patient
alt
elev
without
evid
advers
effect
disclosur
follow
peopl
noth
disclos
suparuede
boonyagard
karjpong
techathuvanan
background
growth
hormon
gh
defici
may
relat
metabol
syndrom
associ
nonalcohol
fatti
liver
diseas
nafld
growth
produc
hepatocyt
secret
stimul
gh
aim
determin
associ
level
sever
nafld
method
use
third
nation
health
nutrit
examin
survey
nhane
iii
data
includ
adult
age
year
gradabl
ultrasonographi
us
imag
hepat
steatosi
identifi
nafld
presenc
moder
sever
hepat
steatosi
us
without
chronic
liver
diseas
chronic
hepat
b
chronic
hepat
c
iron
overload
excess
alcohol
consumpt
control
nafld
control
avail
serum
data
nafld
control
group
stratifi
base
bodi
mass
index
bmi
lean
bmi
obes
result
serum
level
nafld
group
significantli
lower
mean
ngml
compar
control
mean
ngml
p
level
obes
nafld
significantli
lower
mean
ngml
obes
control
mean
ngml
p
level
invers
associ
sever
hepat
steatosi
us
graph
significantli
lower
sever
steatosi
compar
mild
moder
steatosi
lean
nafld
group
vs
mild
vs
moder
multivari
logist
regress
analysi
associ
level
nafld
remain
signific
adjust
age
sex
bmi
insulin
resist
protein
triglycerid
lipoprotein
lipoprotein
adjust
odd
confid
conclus
low
level
serum
associ
nafld
correl
sever
hepat
steatosi
especi
lean
nafld
patient
graph
serum
level
sever
hepat
steatosi
us
p
vs
normal
vs
mild
disclosur
joseph
k
lim
consult
bristol
myer
squibb
gilead
grantresearch
support
bristol
myer
squibb
gilead
follow
peopl
noth
disclos
ye
eun
kwak
albert
c
stephen
djedjo
brian
kirbi
andrew
billin
john
gosink
qinghua
song
roopali
srihari
krysia
grycz
jonna
weston
g
mani
subramanian
william
j
watkin
robert
p
myer
gilead
scienc
inc
foster
citi
ca
usa
background
farnesoid
x
receptor
fxr
agonist
develop
treatment
nonalcohol
steatohepat
nash
cholestat
liver
disord
oral
increas
plasma
fibroblast
growth
factor
decreas
improv
liver
histolog
rodent
primat
model
nash
studi
evalu
safeti
pharmacokinet
pk
pharmacodynam
pd
effect
healthi
volunt
data
pd
marker
pkpd
pdpd
relationship
effect
serum
cholesterol
present
herein
method
random
studi
subject
receiv
singl
multipl
dose
qd
day
mg
fast
match
placebo
washout
singl
multipl
dose
period
plasma
elisa
serum
measur
hour
day
singl
day
multipl
dose
administr
day
pd
paramet
cmax
cmin
calcul
normal
day
valu
chang
serum
cholesterol
also
assess
result
pd
respons
observ
day
day
compar
dose
mg
significantli
increas
reduc
exposur
compar
placebo
tabl
chang
invers
correl
r
p
exposur
show
chang
chang
invers
associ
auctau
r
p
effect
serum
cholesterol
day
mild
significantli
differ
placebo
conclus
oral
administr
result
increas
level
decreas
confirm
biolog
activ
data
support
evalu
patient
nash
cholestat
liver
disord
chang
pd
marker
baselin
multipl
dose
administr
day
data
present
fold
chang
geometr
mean
cv
day
p
compar
placebo
disclosur
constantin
djedjo
employ
gilead
scienc
brian
kirbi
employ
gilead
scienc
andrew
billin
employ
gilead
scienc
john
gosink
employ
gilead
scienc
inc
krystyna
grycz
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
william
watkin
employ
gilead
scienc
robert
p
myer
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
follow
peopl
noth
disclos
qinghua
song
roopali
srihari
jonna
weston
mani
subramanian
background
aim
investig
whether
fatti
liver
diseas
nafld
associ
increas
risk
colorect
neoplasia
crn
method
data
comprehens
health
screen
program
includ
particip
without
malign
chronic
liver
diseas
heavi
drink
underw
screen
colonoscopi
abdomin
ultrasonographi
samsung
medic
center
april
decemb
analyz
advanc
crn
defin
cancer
adenoma
least
mm
diamet
dysplasia
villou
tubulovil
histolog
characterist
combin
thereof
presenc
nafld
diagnos
abdomin
ultrasonographi
exclus
secondari
caus
sever
hepat
fibrosi
patient
nafld
determin
nafld
fibrosi
score
nf
result
nafld
patient
higher
preval
crn
vs
p
advanc
crn
vs
p
individu
without
nafld
adjust
age
sex
smoke
alcohol
bodi
mass
index
famili
histori
colon
cancer
use
aspirin
metabol
factor
includ
fast
blood
glucos
use
diabet
medic
total
cholesterol
triglycerid
use
dyslipidem
medic
systol
blood
pressur
use
antihypertens
medic
nafld
patient
show
higher
risk
crn
odd
ratio
confid
interv
ci
p
advanc
crn
ci
p
compar
individu
without
nafld
addit
nafld
patient
intermedi
high
nf
higher
preval
crn
vs
p
advanc
crn
vs
p
patient
low
nf
model
nafld
patient
intermedi
high
nf
higher
risk
crn
ci
p
advanc
crn
ci
p
patient
low
nf
conclus
nafld
associ
increas
risk
crn
independ
tradit
risk
factor
also
nf
abl
stratifi
risk
crn
among
nafld
patient
find
indic
nafld
nf
use
evalu
individu
risk
crn
disclosur
follow
peopl
noth
disclos
joon
seong
ahn
dong
hyun
sinn
yang
min
sung
noh
hong
jung
lee
seung
woon
paik
hee
jung
son
gwak
backgroundaim
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
activ
macrophag
hepat
stellat
cell
critic
step
promot
liver
fibrosi
share
homolog
macrophag
factor
promot
differenti
viabil
macrophag
common
receptor
receptor
aim
explor
feasibl
fibrosi
marker
patient
nafld
method
enrol
liver
nafld
patient
variou
fibrosi
stage
comprehens
evalu
serum
level
macrophag
relat
marker
solubl
cytokineschemokin
hyaluron
acid
type
iv
collagen
fibrosi
score
apri
index
nafld
fibrosi
score
perform
receiv
oper
characterist
roc
multivari
regress
analys
assess
diagnost
perform
variou
markersindic
order
clarifi
sourc
perform
immunohistochem
immunofluoresc
stain
frozen
liver
specimen
obtain
nafld
patient
result
significantli
increas
progress
fibrosi
independ
marker
liver
cirrhosi
odd
diagnosi
liver
cirrhosi
area
curv
auc
sensit
specif
respect
superior
compar
serum
biomark
fibrosi
index
combin
serum
type
iv
collagen
age
independ
factor
liver
fibrosi
base
fibrosi
score
pgml
type
iv
collagen
ngml
age
year
practic
tool
predict
stage
fibrosi
nafld
patient
auc
sensit
specif
signific
fibrosi
fibrosi
stage
advanc
fibrosi
fibrosi
stage
liver
cirrhosi
respect
immunostain
reveal
almost
posit
cell
liver
tissu
fibroblast
posit
cell
conclus
serum
increas
progress
liver
fibrosi
mainli
due
accumul
sourc
liver
fibroblast
novel
fibrosi
score
consist
serum
type
iv
collagen
age
feasibl
diagnost
marker
liver
fibrosi
nafld
patient
disclosur
kazuaki
chayama
advisori
committe
review
panel
mitsubishi
tanab
taisho
toyama
consult
abbvi
grantresearch
support
ajinomoto
vie
aska
asstella
aska
bristol
squibb
daiichi
sankyo
dainippon
sumitomo
daiichi
sankyo
eisai
glaxosmithklin
mitsubishi
tanab
nippon
kayaku
otsuka
sogo
rinsho
taiho
takeda
toray
torii
tsumura
zeria
speak
teach
abbott
abbvi
ajinomoto
astella
astrazeneca
bayer
bristol
squibb
chugai
dainippon
sumitomo
eidia
eisai
gilead
glaxosmithklin
jimro
johnson
johnson
mitsubishi
tanab
follow
peopl
noth
disclos
hirotaka
shoji
sachiyo
yoshio
yohei
mano
erina
kumagai
hiroyoshi
doi
masaya
sugiyama
masaaki
korenaga
taeang
arai
norio
itokawa
masanori
atsukawa
hiroshi
aikata
hideyuki
hyogo
tomohiko
ohashi
kiyoaki
ito
masashi
yoneda
yuichi
nozaki
takumi
kawaguchi
takuji
torimura
masanori
abe
yoichi
hiasa
toshiya
kamiyama
akinobu
taketomi
masashi
mizokami
tatsuya
kanto
backgroundaim
metabol
syndrom
ms
individu
compon
associ
nonalcohol
fatti
liver
diseas
nafld
sever
progress
sought
evalu
nafld
patient
discrimin
age
effect
compon
ms
combin
risk
sever
hepat
fibrosi
method
consid
consecut
nafld
patient
fulli
evalu
compon
msviscer
obes
ifgdiabet
hdl
triglycerid
arteri
hypertens
result
multivari
logist
regress
analysi
associ
viscer
obes
ci
ifg
diabet
ci
p
low
hdl
cholesterol
mgdl
ci
triglycerid
arteri
hypertens
signific
interact
found
age
viscer
obes
stratifi
patient
age
confirm
interact
third
age
tertil
viscer
obes
consist
lower
dle
year
age
tertil
risk
fibrosi
mostli
driven
viscer
obes
ifgdiabet
higher
three
metabol
risk
factor
lower
middl
age
tertil
respect
final
among
patient
higher
age
tertil
obes
affect
fibrosi
sever
risk
sever
fibrosi
higher
low
hdl
ifgdiabet
withwithout
viscer
obes
conclus
nafld
metabol
profil
risk
sever
fibrosi
chang
accord
age
low
hdl
mostli
obes
ifgdiabet
domin
patient
lower
middl
age
tertil
hdl
ifgdiabet
viscer
obes
highest
age
tertil
disclosur
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
follow
peopl
noth
disclos
salvator
petta
moham
eslam
luca
valenti
elisabetta
bugianesi
marco
barbara
calogero
camma
marianna
porzio
chiara
rosso
silvia
fargion
antonio
craxi
background
aim
polymorph
c
c
transmembran
superfamili
member
one
genet
factor
predispos
develop
fatti
liver
diseas
nafld
aim
evalu
influenc
recipi
donor
genotyp
develop
steatosi
liver
transplant
lt
recipi
method
studi
group
includ
adult
lt
recipi
transplant
occurr
steatosi
evalu
liver
biopsi
first
year
analyz
phospholipas
genotyp
recipi
donor
clinic
laboratori
data
patient
steatosi
grade
compar
patient
without
steatosi
grade
result
steatosi
grade
found
patient
patient
develop
steatosi
grade
distribut
donor
genotyp
differ
significantli
patient
steatosi
cccttt
without
steatosi
cccttt
distribut
recipi
genotyp
similar
patient
steatosi
cccttt
without
steatosi
cccttt
multivari
analysi
donor
genotyp
ci
donor
genotyp
ci
bmi
year
lt
ci
independ
risk
factor
develop
steatosi
effect
donor
pnpla
g
allel
donor
allel
synerg
ci
presenc
donor
risk
allel
ci
presenc
one
risk
allel
g
allel
allel
conclus
donor
genotyp
independ
risk
factor
steatosi
liver
transplant
recipi
effect
donor
genotyp
synerg
effect
donor
genotyp
disclosur
eva
honsova
speak
teach
novarti
pavel
trunecka
advisori
committe
review
panel
astella
pharma
ltd
speak
teach
novarti
pharma
r
follow
peopl
noth
disclos
irena
hejlova
magdalena
neroldova
jaroslav
hubacek
dana
dlouha
libor
kolesar
milan
jirsa
eva
sticova
vera
lanska
juliu
spicak
background
fibroblast
growth
factor
hormon
import
regul
glucos
lipid
metabol
analog
improv
insulin
sensit
lipid
profil
contribut
nonalcohol
steatohepat
nash
pathogenesi
preclin
model
well
obes
human
type
diabet
pegyl
recombin
human
extend
elimin
enabl
daili
weekli
regimen
studi
method
healthi
obes
bmi
subject
random
subcutan
sc
placebo
pbo
singl
ascend
dose
sad
multipl
ascend
dose
mad
studi
primari
endpoint
safeti
toler
pk
pharmacodynam
sad
subject
receiv
dose
mg
pbo
mad
subject
receiv
mg
qd
mg
qd
mg
qd
mg
qd
mg
qd
mg
qw
pbo
subject
sad
mad
receiv
ident
diet
h
prior
rna
express
analyz
mad
abdomin
adipos
tissu
biopsi
pathway
analysi
conduct
metabolom
profil
perform
mad
serum
result
studi
subject
mean
age
mean
bmi
male
hispan
death
sae
discontinu
due
ae
chang
ae
among
mad
subject
receiv
common
ae
inject
site
erythema
ae
mild
show
linear
pk
averag
elimin
h
accumul
fold
qd
dose
neglig
qw
dose
day
associ
improv
bodi
weight
insulin
sensit
triglycerid
lipid
adiponectin
tabl
well
increas
express
gene
involv
mitochondri
oxid
phosphoryl
metabolit
associ
branch
chain
amino
acid
catabol
conclus
singl
multipl
sc
dose
qd
qw
day
healthi
subject
well
toler
associ
improv
bodi
weight
insulin
resist
triglycerid
ldl
adiponectin
gene
express
metabolom
analys
suggest
may
improv
mitochondri
function
amino
acid
homeostasi
may
perturb
nash
benefici
effect
key
driver
nash
pathogenesi
support
evalu
phase
studi
nash
chang
disclosur
edgar
charl
employ
bm
linda
morrow
stock
sharehold
profil
institut
clinic
research
eli
lilli
yi
luo
employ
squibb
rose
christian
employ
squibb
follow
peopl
noth
disclos
marcu
hompesch
chunyu
kate
wu
background
aim
cirrhosi
one
lead
caus
death
worldwid
diagnosi
usual
made
late
stage
acut
decompens
liver
cancer
develop
ideal
diagnosi
made
earli
stage
cirrhosi
occur
current
analyt
imag
method
inaccur
earli
detect
hepat
fibrosi
aim
studi
investig
use
te
earli
detect
silent
chronic
liver
diseas
hepat
fibrosi
presum
healthi
subject
gener
popul
method
descript
studi
subject
age
yr
randomli
identifi
peopl
attend
primari
care
center
barcelona
metro
area
april
januari
patient
known
liver
diseas
exclud
subject
invit
particip
phone
call
accept
medic
examin
lab
test
liver
stiff
measur
lsm
te
perform
day
singl
experienc
oper
accord
publish
data
lsm
kpa
use
cutoff
fibrosi
liver
biopsi
suggest
subject
abnorm
lsm
result
subject
femal
caucasian
mean
age
yr
includ
among
metabol
syndrom
ms
excess
alcohol
consumpt
less
found
hbv
hcv
high
aminotransferas
level
percentag
subject
increas
lsm
accord
cutoff
use
respect
multivari
analysi
age
sex
high
aminotransferas
presenc
ms
associ
increas
lsm
liver
biopsi
perform
elig
patient
histolog
diagnosi
nafldnash
normal
liver
degre
fibrosi
respect
signific
relationship
lsm
degre
fibrosi
kpa
respect
p
percentag
patient
signific
fibrosi
relat
lsm
cutoff
cutoff
kpa
respect
lsm
greatest
accuraci
diagnosi
signific
fibrosi
kpa
sensit
specif
auroc
conclus
high
percentag
presum
healthi
adult
spanish
popul
use
cutoff
lsm
extrapol
biopsi
data
liver
fibrosi
case
relat
nafld
te
good
method
screen
liver
fibrosi
gener
popul
disclosur
rosa
maria
morilla
advisori
committe
review
panel
bristol
gilead
abbvi
speak
teach
roch
janssen
msd
pere
gine
advisori
committe
review
panel
fer
ikaria
promethera
novarti
salix
grantresearch
support
sequana
medic
grifol
follow
peopl
noth
disclos
caballeria
guillem
pera
ingrid
arteaga
llui
rodriguez
alba
carmen
exposito
dolor
miranda
carmen
sanchez
rosa
prat
marta
urquizu
angel
salgado
magda
alemani
alba
martinez
nuria
fabrella
isabel
graupera
pere
toran
juan
caballeria
background
aim
posit
phenotyp
macrophag
display
properti
implic
tissu
repair
type
macrophag
may
contribut
progress
fibrosi
stage
nonalcohol
fatti
liver
diseas
activ
score
na
fatti
liver
diseas
nafld
measur
level
macrophag
activ
marker
solubl
nash
investig
relationship
progress
liver
histolog
nafld
evalu
posit
macrophag
play
role
pathogenesi
nafld
immunohistochem
stain
perform
tissu
repeat
liver
biopsi
target
method
serum
liver
biopsi
obtain
patient
fatti
liver
diseas
nafld
patient
undergon
repeat
liver
biopsi
patient
divid
five
group
base
fibrosi
stage
na
mean
age
year
men
stage
grade
measur
elisa
human
elisa
kit
quantikain
immunohistochem
stain
done
repeat
biopsi
randomli
select
patient
nash
primari
antibodi
mous
monoclon
anti
human
leica
dilut
result
level
correl
fibrosi
stage
p
level
significantli
elev
advanc
fibrosi
stage
group
vs
p
auc
level
correl
na
p
howev
spite
low
na
level
significantli
elev
nash
among
patient
underw
repeat
biopsi
patient
improv
fibrot
degre
improv
na
level
significantli
reduc
patient
improv
fibrot
degre
na
convers
level
elev
patient
whose
fibrosi
na
worsen
posit
macrophag
exist
liver
sinusoid
relationship
amount
posit
macrophag
progress
liver
histolog
nafld
conclus
level
reflect
progress
fibrosi
inflamm
liver
tissu
could
use
biomark
nash
nafld
disclosur
follow
peopl
noth
disclos
miwa
kawanaka
ken
nishino
tomohiro
tanikawa
takahito
oka
noriyo
urata
jun
nakamura
mitsuhiko
suehiro
hirofumi
kawamoto
norikuni
kawanaka
nafld
usual
link
obes
howev
recent
data
shown
presenc
nafld
also
patient
normal
bmi
defin
new
concept
fld
share
mani
metabol
characterist
overweight
nafld
although
lower
preval
metabol
syndrom
met
liver
damag
report
evalu
liver
cardiovascular
damag
studi
consecut
patient
biopsi
proven
nafld
italian
liver
unit
method
biochem
paramet
carotid
atherosclerot
lesion
ultrasonographi
genotyp
liver
histolog
record
subject
divid
accord
bmi
defin
waist
circumfer
wc
surrog
marker
viscer
obes
cm
femal
cm
male
result
patient
femal
mean
age
significantli
lower
preval
hypertens
vs
diabet
vs
met
vs
lower
total
cholesterol
vs
triglycerid
vs
overweightobes
nafld
patient
femal
mean
age
carotid
thick
vs
preval
nash
vs
signific
fibrosi
higher
vs
significantli
lower
preval
carotid
plaqu
similar
preval
g
allel
carriag
differ
two
group
allel
preval
lean
nafld
vs
lean
nafld
steatosi
grade
lobular
inflamm
balloon
score
fibrosi
multivari
analysi
overal
seri
wc
higher
cm
femal
cm
male
significantli
associ
femal
gender
met
nash
fibrosi
diabet
logist
regress
analys
mutual
adjust
bmi
wc
overal
seri
nafld
indic
wc
predict
better
bmi
presenc
nash
p
vs
fibrosi
p
vs
diabet
p
vs
hypertens
vs
plaqu
p
vs
wc
stronger
risk
factor
nash
lean
subject
overweight
subject
conclus
find
indic
nafld
normal
bmi
one
third
carotid
atherosclerosi
sever
liver
damag
evalu
bmi
wc
allow
better
definit
sever
liver
cardiovascular
damag
lean
patient
nafld
disclosur
follow
peopl
noth
disclos
anna
ludovica
fracanzani
salvator
petta
rosa
lombardi
giuseppina
pisano
maurizio
russello
laura
mensi
vito
di
marco
calogero
camma
paola
dongiovanni
luca
valenti
antonio
craxi
silvia
fargion
background
impact
alcohol
liver
injuri
fatti
liver
diseas
nafld
unclear
alcohol
may
increas
fibrosi
progress
chronic
liver
diseas
hepat
c
yet
moder
consumpt
may
protect
cardiovascular
diseas
lead
caus
death
nafld
patient
aim
determin
associ
quantiti
pattern
alcohol
consumpt
liver
fibrosi
patient
nafld
method
patient
nafld
consum
gram
alcoholweek
seen
tertiari
hepatolog
clinic
undergo
bariatr
surgeri
underw
detail
evalu
includ
assess
pattern
type
durat
alcohol
consumpt
liver
biopsi
score
accord
nash
crn
score
system
fibrosi
stage
result
patient
includ
mean
age
year
femal
obes
diabet
mean
fibrosi
stage
advanc
fibrosi
patient
abstain
previous
drunk
alcohol
current
consum
alcohol
median
consumpt
gweek
median
interquartil
rang
total
lifetim
alcohol
consumpt
amongst
drinker
kilogram
median
durat
year
patient
consum
alcohol
bing
pattern
lifetim
abstin
associ
higher
mean
fibrosi
stage
compar
drank
gweek
gweek
abstin
also
associ
higher
mean
fibrosi
stage
comparison
drinker
howev
protect
effect
lost
bing
drinker
alcohol
consumpt
g
week
compar
lifelong
abstin
associ
lower
odd
advanc
fibrosi
ci
adjust
age
diabet
bmi
sex
total
lifetim
consumpt
drinker
lower
odd
advanc
fibrosi
compar
abstain
adjust
ci
wherea
protect
associ
note
bing
drinker
neither
averag
lifetim
intak
per
week
cumul
intak
smoke
statu
associ
advanc
fibrosi
p
conclus
weekli
alcohol
intak
gram
less
pattern
associ
lower
fibrosi
stage
patient
nafld
given
possibl
protect
effect
moder
alcohol
consumpt
cardiovascular
outcom
patient
nafld
without
cirrhosi
may
benefit
modest
alcohol
consumpt
disclosur
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
tim
mitchel
gari
p
jeffrey
gerri
c
macquillan
georg
gara
helena
ching
jeffrey
hamdorf
etiolog
steatohepat
nash
due
part
insulin
resist
oxid
stress
remogliflozin
etabon
remo
inhibitor
shown
previou
clinic
studi
reduc
improv
glycem
control
post
hoc
analysi
examin
whether
improv
glycem
control
associ
chang
insulin
sensit
extent
remo
may
affect
marker
fibrosi
nafld
fibrosi
score
method
random
trial
conduct
subject
type
diabet
subject
equal
random
remo
treatment
mg
bid
placebo
pioglitazon
qd
serum
alanin
aminotransferas
alt
homeostat
model
assess
homa
insulin
sensit
beta
cell
function
homa
assess
baselin
week
week
week
assess
glucos
insulin
perform
baselin
week
use
oral
glucos
toler
test
ogtt
subgroup
subject
nafld
fibrosi
score
determin
baselin
week
result
week
remo
improv
insulin
sensit
beta
cell
function
manner
statist
signific
decreas
baselin
auc
hour
weight
mean
plasma
glucos
follow
ogtt
observ
remo
treatment
group
subject
elev
baselin
alt
remo
treatment
result
signific
reduct
alt
week
baselin
score
indic
broad
rang
fibrosi
stage
remo
dose
effect
reduc
score
reduct
compar
placebo
treatment
remo
score
consist
predict
improv
fibrosi
stage
similar
result
note
score
conclus
previou
studi
use
mous
model
fatti
liver
diseas
remo
significantli
improv
steatohepat
compar
inhibitor
remo
also
display
signific
activ
vitro
vivo
clinic
studi
show
abil
remo
revers
insulin
resist
associ
signific
lower
alt
improv
score
remo
safe
potent
late
stage
clinic
compound
taken
togeth
clinic
data
highli
suggest
remo
may
use
treatment
nash
disclosur
bill
wilkison
manag
posit
bhv
pharma
bentley
cheatham
stock
sharehold
bhv
pharma
follow
peopl
noth
disclos
susan
walker
background
aim
diabet
mellitu
dm
frequent
seen
patient
fatti
liver
diseas
nafld
risk
factor
develop
hepatocellular
carcinoma
ectop
fat
deposit
liver
pancrea
muscl
caus
factor
dm
howev
remain
unclear
ectop
fat
deposit
associ
dm
patient
nafld
recent
mri
use
proton
densiti
develop
allow
us
quantifi
accur
fat
content
variou
organ
aim
studi
investig
associ
ectop
fat
deposit
dm
patient
nafld
use
materi
method
studi
enrol
nafld
patient
year
femalemal
patient
year
femalemal
control
group
nafld
patient
classifi
nafld
patient
dm
group
nafld
patient
without
dm
dm
group
valu
measur
liver
pancrea
muscl
differ
pdff
valu
evalu
anova
follow
scheff
post
hoc
test
use
valu
differenti
group
dm
group
evalu
use
receiv
oper
characterist
roc
analysi
addit
analysi
employ
identifi
import
factor
groupresult
valu
significantli
higher
dm
group
compar
control
group
signific
differ
valu
dm
group
vs
n
vs
n
howev
valu
significantli
higher
group
compar
dm
group
vs
p
roc
analysi
reveal
use
marker
differenti
group
dm
group
p
sensit
specif
posit
neg
predict
valu
respect
addit
analysi
reveal
valu
initi
diverg
variabl
presenc
diabet
mellitu
nafld
patient
conclus
first
show
ectop
fat
deposit
muscl
associ
dm
patient
nafld
use
thu
muscl
steatosi
may
import
therapeut
target
patient
nafld
disclosur
follow
peopl
noth
disclos
takumi
kawaguchi
tatsuyuki
tonan
kiminori
fujimoto
toshi
abe
takuji
torimura
background
although
obes
import
risk
factor
nonalcohol
fatti
liver
diseas
nafld
signific
number
patient
normal
bodi
mass
index
bmi
also
develop
nafld
high
ratio
whr
indic
central
fat
distribut
associ
metabol
syndrom
cardiovascular
diseas
turn
may
relat
nafld
object
determin
associ
central
bodi
fat
distribut
lean
nafld
unit
state
popul
use
larg
databas
method
use
data
third
nation
health
nutrit
examin
survey
nhane
iii
gradabl
hepat
ultrasonographi
us
hepat
steatosi
adult
age
year
nafld
defin
presenc
hepat
steatosi
us
absenc
chronic
liver
diseas
posit
hepat
b
surfac
antigen
posit
hepat
c
antibodi
iron
overload
excess
alcohol
consumpt
control
group
defin
normal
serum
aminotransferas
level
without
hepat
steatosi
chronic
liver
diseas
lean
group
nafld
control
defin
bmi
less
whr
bioelectr
imped
analysi
bia
resist
predict
total
bodi
fat
mass
homeostat
model
assess
insulin
resist
triglycerid
tg
lipoprotein
cholesterol
lipoprotein
cholesterol
record
result
adult
age
year
gradabl
us
imag
identifi
nafld
control
identifi
differ
bmi
group
mean
vs
whr
significantli
higher
group
group
mean
vs
p
although
differ
bia
resist
mean
vs
predictor
total
bodi
fat
mass
multivari
logist
regress
show
lean
nafld
independ
associ
higher
whr
adjust
odd
confid
p
adjust
age
sex
bmi
tg
conclus
increas
central
fat
distribut
associ
risk
nafld
irrespect
total
bodi
fat
mass
individu
normal
bmi
disclosur
joseph
k
lim
consult
bristol
myer
squibb
gilead
grantresearch
support
bristol
myer
squibb
gilead
follow
peopl
noth
disclos
ye
eun
kwak
albert
epidem
problem
obes
bariatr
surgeri
becom
increas
treatment
option
benefici
impact
diabet
steatohepat
nash
increas
rate
candid
sever
comorbid
morbid
mortal
patient
sever
liver
diseas
poorli
known
preliminari
studi
suggest
liver
injuri
could
increas
complic
howev
morbid
obes
patient
liver
injuri
frequent
vari
true
impact
nash
unknown
aim
evalu
impact
liver
histolog
morbid
mortal
bariatr
surgeri
method
patient
oper
bariatr
surgeri
includ
prospect
follow
lill
bariatr
cohort
chru
de
lill
clinic
biolog
histolog
data
well
morbid
within
day
collect
studi
histolog
data
could
impact
morbid
signific
fibrosi
metavir
cirrhosi
nash
sever
nafld
distribut
type
surgeri
differ
group
complic
studi
surgic
procedur
gastric
band
sleev
gastrectomi
bypass
result
patient
includ
characterist
age
women
bmi
nash
cirrhosi
ast
iul
alt
ggt
main
procedur
bypass
gastric
band
rate
complic
frequent
infect
hemorrhag
rhabdomyolysi
univari
analysi
histolog
lesion
associ
morbid
cirrhosi
vs
whatev
procedur
fibrosi
bypass
vs
nash
vs
na
vs
associ
morbid
infect
frequent
complic
incid
increas
accord
sever
fibrosi
multivari
analysi
data
associ
morbid
age
bmi
p
fibrosi
steatosi
term
mortal
patient
die
among
die
within
day
overal
year
surviv
conclus
morbid
associ
higher
age
bmi
fibrosi
steatosi
even
morbid
higher
patient
fibrosi
sever
liver
diseas
benefit
strategi
prove
excel
surviv
year
disclosur
emmanuel
leteurtr
speak
teach
novarti
philipp
mathurin
board
membership
msd
bm
gilead
abvi
verlyx
consult
roch
bayer
follow
peopl
noth
disclos
guillaum
lassailli
robert
caiazzo
charlott
vanveuren
vivian
gnemmi
helen
verkindt
gregori
baud
florent
artru
valeri
alexandr
louvet
sebastien
dharanc
pattou
background
previous
show
presenc
reticuloendotheli
system
re
cell
iron
stain
associ
sever
histolog
featur
diseas
includ
advanc
fibrosi
increas
apoptosi
increas
balloon
definit
diagnosi
nonalcohol
steatohepat
nash
patient
nonalcohol
fatti
liver
diseas
nafld
aim
studi
aim
map
transcriptom
liver
nash
patient
hepat
iron
phenotyp
iron
hepatocellular
hc
iron
re
iron
mix
hcre
iron
nash
crn
util
rna
sequenc
goal
identifi
specif
pathway
gene
differenti
express
nash
patient
re
iron
method
librari
construct
liver
tissu
librari
cluster
flowcel
use
truseq
cluster
kit
v
use
cbot
cluster
instrument
follow
sequenc
hiscansq
cycl
either
direct
run
complet
read
demultiplex
fastq
file
gener
use
casava
softwar
sampl
output
read
qualiti
analyz
gener
qc
plot
r
bioconductor
packag
edger
use
determin
differenti
express
re
iron
non
re
iron
samplesresult
transcriptom
analysi
reveal
gene
belong
pathway
extracellular
matrix
deposit
cellular
anchor
fibrogenesi
liver
develop
regener
show
significantli
increas
express
re
liver
gene
express
level
protein
aforement
pathway
collagen
type
iv
x
versican
lumican
laminin
fibulin
lectin
p
lysyl
oxidas
like
adam
metallopeptidas
thrombospondin
previous
demonstr
import
fibrogenesi
significantli
elev
re
liver
rel
group
addit
valid
find
gen
rna
sequenc
use
quantit
analysi
found
express
level
gene
significantli
augment
re
sampl
rel
group
conclus
util
sequenc
establish
direct
relationship
hepat
re
iron
fibrogen
extracellular
matrix
deposit
pathway
detail
analysi
pathway
specif
molecular
factor
therein
util
avail
gener
mous
model
andor
specif
inhibitor
mous
model
cell
line
vitro
clarifi
presenc
re
iron
lead
fibrosi
therebi
worsen
nash
disclosur
kri
v
kowdley
advisori
committe
review
panel
abbvi
enanta
gilead
intercept
merck
novarti
trio
health
verylx
grantresearch
support
abbvi
evidera
galectin
gilead
immuron
intercept
merck
ngm
biopharma
novarti
tobira
trio
health
speak
teach
gilead
intercept
follow
peopl
noth
disclos
priya
handa
vicki
jame
e
nelson
laura
wilson
katherin
p
yate
matthew
yeh
background
young
hyperandrogen
women
high
risk
metabol
syndrom
includ
increas
risk
nafld
whether
testosteron
predomin
androgen
associ
nafld
risk
independ
metabol
clear
also
unknown
whether
normal
rang
testosteron
level
women
confer
increas
risk
nafld
method
among
women
follow
prospect
multicent
coronari
arteri
risk
develop
young
adult
cardia
studi
assess
associ
testosteron
level
year
preval
nafld
year
nafld
defin
noncontrast
ct
scan
liver
attenu
hounsfield
unit
exclus
caus
hepat
steatosi
primari
predictor
free
testosteron
secondari
predictor
total
testosteron
adjust
sex
hormon
bind
globulin
shbg
logist
regress
perform
includ
subgroup
analysi
among
women
result
women
black
white
mean
age
entri
year
nafld
present
women
year
increas
quintil
free
testosteron
associ
increas
odd
preval
nafld
adjust
analys
tabl
importantli
free
testosteron
remain
strongli
associ
preval
nafld
even
women
normal
rang
testosteron
level
ci
estim
similar
use
total
testosteron
adjust
shbg
aor
entir
cohort
ci
includ
subgroup
women
aor
ci
conclus
increas
level
free
testosteron
even
within
normal
rang
independ
associ
preval
nafld
middl
age
androgen
may
import
role
develop
nafld
women
provid
potenti
novel
target
nafld
therapeut
disclosur
mari
e
rinella
advisori
committe
review
panel
abbvi
intercept
consult
fibrogen
ngm
shire
beth
lewi
grantresearch
support
novo
nordisk
nih
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
follow
peopl
noth
disclos
monika
sarkar
lisa
b
vanwagn
melissa
wellon
john
j
carr
jame
terri
erica
gunderson
laura
torchen
marcel
cedar
acut
alcohol
hepat
aah
seriou
clinic
present
associ
high
mortal
thu
acut
natur
aah
necessit
reliabl
predict
prognost
measur
pathophysiolog
event
aah
lead
increas
hepatocyt
death
may
reflect
prognosi
liver
injuri
studi
aim
identifi
alter
level
marker
hepatocyt
death
defin
clinic
relev
marker
aah
hypothes
replac
total
bilirubin
necrot
marker
meld
score
could
increas
predict
relev
clinic
laboratori
marker
aah
male
femal
patient
age
year
aah
classifi
sever
moder
sever
base
meld
score
data
demograph
drink
histori
audit
meld
maddrey
df
liver
injuri
marker
collect
addit
healthi
volunt
also
enrol
comparison
group
serum
protein
analyz
use
elisa
apoptosens
kit
fragment
level
healthi
control
aah
patient
sever
compar
use
anova
fragment
assess
within
sever
group
expect
sever
aah
patient
significantli
higher
meld
maddrey
df
ast
alt
score
compar
moder
aah
patient
fragment
show
clinic
relev
level
aah
patient
ratio
indic
highli
increas
hepatocyt
necrosi
moder
sever
aah
patient
sever
arm
patient
significantli
higher
compar
moder
arm
patient
wherea
statist
differ
two
arm
show
signific
associ
ast
alt
ratio
moder
sever
arm
meld
show
associ
ast
alt
ratio
either
moder
sever
arm
howev
modifi
meld
score
substitut
total
bilirubin
found
strong
signific
associ
ast
alt
ratio
sever
arm
patient
also
show
trend
toward
signific
associ
audit
score
sever
aah
patient
meld
highli
signific
effect
adjust
p
also
observ
df
maddrey
moder
sever
arm
patient
studi
support
import
assess
liver
injuri
sever
aah
provid
altern
benchmark
incorpor
mode
hepatocyt
death
assess
sever
provid
effect
prognost
marker
sever
aah
disclosur
follow
peopl
noth
disclos
vatsalya
vatsalya
matthew
cave
heather
b
clair
tom
burk
keith
c
falkner
craig
mcclain
background
aim
japan
societi
diabet
mellitu
dm
report
lead
caus
death
dm
patient
hepatocellular
carcinoma
hcc
among
malign
wherea
lung
cancer
lead
caus
death
gener
popul
japan
previous
report
result
studi
caus
liver
injuri
dm
patient
j
gastroenterol
although
posit
rate
hbsag
ab
high
japanes
dm
patient
major
liver
injuri
consid
due
nafldnash
aim
clarifi
overal
mortal
patient
patient
method
dm
patient
visit
dm
clinic
hospit
belong
japan
studi
group
nash
origin
studi
patient
male
femal
mean
age
follow
averag
durat
evalu
year
mortal
japanes
age
year
shown
databas
japanes
ministri
health
labor
welfar
defin
mortal
gener
popul
control
mortal
calcul
method
compar
dm
patient
gener
popul
result
among
dm
patient
total
patient
male
femal
f
die
period
mortal
dm
patient
control
follow
vs
p
vs
f
vs
mortal
caus
malign
dm
patient
control
follow
total
vs
p
vs
f
vs
mortal
diseas
total
vs
vs
f
vs
mortal
pneumonia
total
vs
p
vs
f
vs
mortal
caus
malign
dm
patient
control
male
follow
lung
cancer
vs
gastric
cancer
vs
colon
cancer
vs
pancrea
cancer
vs
hcc
vs
mortal
femal
follow
lung
cancer
vs
gastric
cancer
vs
p
colon
cancer
vs
pancrea
cancer
vs
hcc
vs
p
conclus
mortal
japanes
dm
patient
caus
malign
pneumonia
higher
control
wherea
mortal
caus
cardiovascular
diseas
dm
patient
compar
control
hcc
colon
cancer
reveal
significantli
higher
mortal
dm
patient
control
gender
disclosur
yutaka
kohgo
consult
pharmacosmo
grantresearch
support
asahikasei
medic
follow
peopl
noth
disclos
toshihid
shima
hirofumi
uto
kohjiro
ueki
toshinari
takamura
sumio
kawata
kohichiroh
yasui
naoto
nakamura
kazuo
notsumata
tatsuaki
nakat
kyoko
sakai
takeshi
okanou
background
aim
fibrosi
import
predictor
outcom
patient
nonalcohol
fatti
liver
diseas
nafld
quantit
risk
fibrosi
stage
systemat
assess
publish
unpublish
data
aim
quantifi
fibrosi
risk
mortal
among
nafld
cohort
method
systemat
search
multipl
databas
author
contact
februari
identifi
adult
nafld
cohort
studi
report
mortal
accord
fibrosi
stage
studi
use
nonalcohol
steatohepat
clinic
research
network
nash
crn
histolog
score
system
grade
blind
liver
pathologist
use
fibrosi
stage
refer
popul
fibrosi
risk
ratio
rr
mortal
estim
account
variabl
among
cohort
fibrosi
mortal
rate
ratio
mrr
also
calcul
result
nafld
patient
mean
age
year
men
includ
distribut
fibrosi
stage
baselin
respect
compar
nafld
patient
fibrosi
stage
fibrosi
increas
risk
mortal
risk
increment
accord
fibrosi
stage
fig
similar
trend
seen
increment
increas
incid
mortal
stage
mrr
ci
stage
mrr
ci
stage
mrr
ci
stage
mrr
ci
conclus
nafld
patient
fibrosi
increas
risk
mortal
risk
increment
accord
fibrosi
stage
furthermor
nafld
patient
increas
risk
mortal
earli
stage
fibrosi
earli
treatment
intervent
may
consid
popul
disclosur
giada
sebastiani
advisori
committe
review
panel
merck
grant
research
support
echosen
viiv
speak
teach
bm
gilead
abbvi
rohit
loomba
advisori
committe
review
panel
galm
inc
tobira
inc
arrowhead
research
inc
consult
gilead
inc
corgenix
inc
janssen
janssen
inc
zafgen
inc
celgen
inc
alnylam
inc
inanta
inc
deutrx
inc
grant
research
support
daiichi
sankyo
inc
aga
merck
inc
promedior
inc
kinem
inc
immuron
inc
adheron
inc
follow
peopl
noth
disclos
janki
r
patel
parambir
dulai
zobair
younossi
mattia
ekstedt
hann
hagstrom
patrik
nasr
per
stdl
stergio
kechagia
rolf
w
hultcrantz
siddharth
singh
purpos
hepat
fibrosi
nash
consequ
chronic
injuri
potenti
lead
cirrhosi
patient
nash
hepat
fibrosi
increas
risk
mortal
aim
use
revers
phase
protein
microarray
rppa
base
pathway
activ
map
hepat
tissu
uncov
potenti
mechan
may
involv
hepat
fibrosi
nash
method
snap
frozen
hepat
tissu
use
fatti
liver
diseas
nafld
patient
nash
nafld
stage
fibrosi
protein
extract
hepat
tissu
previous
describ
quantit
analysi
activationphosphoryl
state
key
signal
protein
perform
rppa
liver
biopsi
h
e
trichrom
stain
read
singl
hepatopathologist
accord
nash
protocol
imag
analysi
algorithm
use
quantifi
percentag
collagen
deposit
collagen
use
comput
assist
morphometri
cam
phosphoprotein
independ
associ
fibrosi
nash
assess
use
multipl
logist
regress
stepwis
select
consid
signific
pathway
analysi
perform
use
kegg
pathway
mappingresult
multivari
analysi
show
phosphoryl
growth
factor
activ
ephrin
intracellular
signal
pathway
ephrin
independ
associ
histolog
nash
phosphoryl
death
receptor
faad
protein
bim
posporyl
neg
associ
histolog
nash
presenc
stage
fibrosi
addit
phosphoryl
protein
cofilin
posit
associ
stage
fibrosi
total
level
chromatin
regul
neg
associ
addit
phosphoryl
mek
involv
focal
adhes
gap
junction
regul
actin
cytoskeleton
pathway
neg
associ
presenc
hepat
fibrosi
focal
adhes
adher
junction
pathway
posit
associ
collagen
quantit
final
phosphoryl
total
activ
mitogen
activ
protein
kinas
mapk
p
also
independ
associ
collagen
deposit
cam
conclus
strong
associ
signal
pathway
involv
apoptosi
quantit
collagen
deposit
histolog
nash
data
may
suggest
potenti
mechanist
pathway
treatment
target
nash
disclosur
mariaelena
pierobon
consult
perthera
inc
stock
sharehold
theranost
health
zachari
goodman
grantresearch
support
gilead
scienc
galectin
therapeut
intercept
alexion
conatu
cempra
nitto
denko
tobira
exalenz
emanuel
f
petricoin
advisori
committe
review
panel
theranost
health
inc
board
membership
cere
nanosci
inc
perthera
inc
consult
cere
nanosci
inc
perthera
inc
grantresearch
support
cere
nanosci
inc
patent
heldfil
theranost
health
inc
cere
nanosci
inc
stock
sharehold
theranost
health
inc
cere
nanosci
inc
perthera
inc
follow
peopl
noth
disclos
zobair
younossi
azza
karrar
maria
stepanova
kianoush
jeiran
alex
hodg
fanni
mong
lakshmi
alaparthi
dinan
abdelatif
aybik
birerdinc
vika
chandhok
background
nonalcohol
fatti
liver
diseas
associ
excess
fat
accumul
liver
progress
steatohepat
nash
defin
histolog
hallmark
inflamm
cell
death
fibrosi
histolog
nash
rather
similar
steatohepat
liver
biopsi
consid
necessari
diagnos
nash
presenc
fibrosi
typic
predict
patient
outcom
us
popul
nash
approxim
advanc
liver
fibrosi
due
diseas
thu
earli
diagnosi
crucial
method
result
liver
microenviron
chemic
morpholog
modifi
diseas
progress
depend
diseas
etiolog
biochem
chang
within
liver
milieu
cell
due
liver
injuri
nash
progress
rel
poorli
defin
fourier
transform
infrar
spectroscop
imag
emerg
approach
obtain
detail
imag
associ
biochem
inform
imag
tissu
base
principl
differ
region
absorb
differ
chemic
bond
e
g
co
within
cell
tissu
relat
presenc
composit
biomolecul
eg
lipid
dna
glycogen
protein
collagen
imag
everi
pixel
within
imag
compris
entir
ir
spectrum
give
inform
biochem
statu
cell
exploit
classif
studi
use
spectroscop
imag
examin
earli
transform
well
biochem
chang
patient
nash
progress
stage
iv
find
indic
biochemistri
stage
ii
distinctli
differ
could
classifi
perfectli
base
ir
signatur
use
multivari
analysi
sampl
patient
stage
iii
iv
also
found
biochem
differ
patient
stage
ii
current
focus
refin
classif
extract
biochemistri
region
fibrosi
steatosi
inflamm
improv
classif
among
four
stage
determin
precis
biomolecular
chang
occur
could
occur
conclus
imag
hold
excit
applic
novel
way
obtain
biochem
inform
cell
tissu
entir
rout
toward
give
new
insight
biomolecular
chang
take
place
part
nash
progress
biochem
inform
potenti
allow
object
autom
analysi
certain
aspect
nash
diagnosi
prognosi
disclosur
follow
peopl
noth
disclos
christin
massi
vishal
varma
hari
sreedhar
grace
guzman
michael
j
walsh
natalia
nieto
studi
purpos
primari
aim
studi
investig
effect
dapagliflozin
dapa
free
fatti
acid
carboxyl
acid
ca
alon
combin
liver
fat
content
overweight
type
diabet
patient
fatti
liver
diseas
nafld
method
patient
bmi
liver
fat
stabl
metformin
andor
sulfonylurea
treatment
random
placebo
mg
dapa
od
g
ca
od
combin
dapa
ca
week
parallel
group
doubl
blind
studi
patient
complet
studi
investig
baselin
week
includ
abdomin
mri
liver
adipos
tissu
fat
content
assess
g
oral
glucos
toler
test
ogtt
full
analysi
set
use
statist
rel
chang
calcul
geometr
mean
ratio
result
full
analysi
set
mean
sd
age
year
bmi
male
mean
liver
fat
activ
treatment
significantli
reduc
liver
fat
baselin
rel
reduct
liver
fat
combin
ca
signific
adjust
signific
dapa
ca
alon
compar
placebo
total
liver
fat
volum
l
chang
similarli
liver
fat
suggest
chang
liver
fat
secondari
chang
hepat
water
volum
dapa
ca
significantli
reduc
bodi
weight
abdomin
subcutan
viscer
fat
volum
well
improv
glucos
control
includ
fast
glucos
glucos
ogtt
hepatocyt
damag
biomark
ast
alt
ggt
reduc
dapa
ca
ca
advers
event
mild
moder
intens
expect
previou
studi
treatment
two
patient
one
dapa
group
one
placebo
group
experienc
sever
advers
event
assess
investig
unlik
caus
investig
drug
conclus
combin
dapa
ca
result
signific
reduct
percentag
total
liver
fat
monotherapi
result
numer
smaller
reduct
dapa
uniqu
effect
measur
hepatocyt
injuri
evid
combin
group
indic
effect
liver
fat
reduct
hepatocyt
damag
biomark
necessarili
associ
studi
suggest
benefici
effect
inhibit
alon
combin
ca
nafld
type
diabet
disclosur
jan
oscarsson
employ
astrazeneca
per
lundkvist
consult
merck
sharp
dohm
grantresearch
support
astra
zeneca
lar
johansson
employ
antaro
medic
mat
employ
astrazeneca
ulf
consult
astra
zeneca
lar
lind
consult
astrazeneca
jan
w
eriksson
advisori
committe
review
panel
novonordisk
consult
merck
sharp
dohm
sanofi
grantresearch
support
bristol
myer
squibb
astrazeneca
speak
teach
novonordisk
astrazeneca
follow
peopl
noth
disclos
e
jansson
linda
mori
background
although
grow
evid
patient
nonalcohol
fatti
liver
diseas
nafld
steatohepat
nash
increas
prevalenceincid
chronic
kidney
diseas
ckd
relationship
reduc
kidney
function
histolog
featur
patient
nafld
fulli
elucid
method
total
adult
patient
nafld
center
countri
spain
patient
australia
patient
cuba
patient
consecut
enrol
biopsi
review
local
pathologist
score
use
score
system
fibrosi
f
stage
subsequ
classifi
nafl
nash
combin
presenc
steatosi
balloon
lobular
inflamm
studi
includ
patient
decompens
cirrhosi
kidney
function
assess
estim
glomerular
filtrat
rate
egfr
formula
ckd
defin
egfr
less
result
kidney
function
assess
egfr
significantli
differ
among
patient
nafl
ml
howev
egfr
lower
nash
patient
advanc
fibrosi
p
anova
bonferroni
adjust
likewis
higher
proport
subject
advanc
fibrosi
egfr
compar
patient
without
advanc
fibrosi
p
adjust
confound
factor
bmi
diabet
smoke
age
gender
insulin
resist
compon
metabol
syndrom
concomit
medic
comorbid
presenc
advanc
fibrosi
remain
independ
predictor
decreas
egfr
p
egfr
ci
p
biomark
fibrosi
includ
nafld
fibrosi
score
nf
r
p
score
r
p
strongli
relat
egfr
patient
nf
lower
egfr
ml
compar
nf
ml
p
similarli
egfr
decreas
patient
ml
compar
ml
p
conclus
nafld
patient
advanc
fibrosi
strongli
associ
either
decreas
egfr
presenc
ckd
determin
egfr
ml
irrespect
risk
factor
obes
diabet
compon
metabol
syndrom
disclosur
jose
l
calleja
advisori
committe
review
panel
gilead
abbvi
speak
teach
abbvi
gilead
janssen
bm
agustin
albillo
advisori
committe
review
panel
griffol
abbvi
gilead
msd
grantresearch
support
gilead
javier
consult
gilead
janssen
abbvi
juan
turn
advisori
committe
review
panel
gilead
abbvi
janssen
bm
speak
teach
msd
gilead
janssen
bm
abbvi
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
eduardo
rocio
aller
rocio
helena
ramirez
jesu
banal
maria
teresa
carmelo
maria
luisa
victor
javier
salmeron
jose
l
judith
javier
abad
orest
lo
iacono
ruben
franc
mois
diago
conrado
juan
caballeria
salvador
benlloch
raul
j
andrad
lui
c
bertot
javier
ampuero
manuel
background
nonalcohol
fatti
liver
diseas
nafld
increas
preval
may
soon
major
caus
end
stage
liver
diseas
nonivas
strategi
defin
fibrosi
stage
import
diseas
manag
aim
studi
determin
util
transient
elastographi
te
either
alon
combin
clinic
marker
assess
fibrosi
stage
method
electron
medic
record
patient
diagnosi
nafldnash
undergo
te
may
decemb
singl
institut
review
patient
includ
reliabl
liver
stiff
measur
lsm
adequ
liver
biopsi
sampl
within
year
te
lsm
use
divid
patient
two
group
advanc
fibrosi
absenc
advanc
fibrosi
clinic
marker
bard
score
nf
calcul
combin
lsm
compar
liver
biopsi
determin
fibrosi
stage
result
patient
diagnosi
nashnafld
reliabl
lsm
liver
biopsi
includ
studi
lsm
consist
fibrosi
fibroscan
use
alon
accur
predict
fibrosi
stage
patient
differ
predict
valu
individu
marker
fibrosi
marker
increas
posit
predict
valu
neg
predict
valu
lsm
three
clinic
marker
correl
fibrosi
stage
liver
fibrosi
accur
predict
case
presenc
marker
correl
te
led
accur
predicit
patient
lost
liver
biopsi
fibrosi
addit
clinic
marker
improv
accur
te
conclus
te
valuabl
tool
detect
exclud
presenc
advanc
fibrosi
nafldnash
patient
addit
calcul
clinic
marker
increas
accuraci
te
discrep
te
clinic
marker
fibrosi
liver
biopsi
consid
prospect
larger
studi
util
te
clinic
marker
liver
biopsi
requir
confirm
result
disclosur
rolland
c
dickson
advisori
committe
review
panel
gilead
bm
follow
peopl
noth
disclos
amreen
dinani
rachel
jeffer
arifa
toor
background
fatti
live
diseas
nafld
becom
lead
caus
chronic
liver
diseas
de
western
world
liver
play
crucial
role
metabol
cholesterol
triglycerid
thyroid
hormon
interact
hepat
lipid
homeostasi
given
import
variat
thyroid
function
within
euthyroid
rang
consider
number
health
issu
includ
subclin
atherosclerosi
biochem
marker
increas
cardiovascular
risk
relev
examin
relationship
nafld
thyroid
function
paramet
euthyroid
popul
method
studi
conduct
lifelin
cohort
studi
n
cohort
studi
examin
health
behavior
particip
live
north
netherland
euthyroid
subject
tsh
mul
pmoll
pmoll
older
year
includ
exclus
criteria
particip
miss
data
excess
alcohol
use
known
hepat
cirrhosi
liver
function
three
time
upper
limit
current
cancer
ancestri
previou
current
use
thyroid
medic
current
use
lipid
glucos
lower
medic
priori
defin
liver
biochemistri
thyroid
function
paramet
metabol
syndrom
met
studi
nafld
defin
use
valid
fatti
liver
index
fli
fli
categor
nafld
p
consid
signific
result
particip
fli
found
individu
men
median
age
year
particip
fli
higher
alt
ast
alp
ggt
valu
higher
preval
met
vs
p
analysi
fli
independ
predict
higher
ci
per
sd
increment
p
lower
ci
p
tsh
strongest
associ
found
ratio
ci
p
associ
remain
similar
addit
adjust
presenc
met
ci
p
subject
enlarg
waist
circumfer
tsh
lower
higher
result
higher
ratio
p
conclus
larg
studi
particip
discov
euthyroid
peopl
suspect
nafld
character
higher
ratio
probabl
secondari
central
obes
disclosur
follow
peopl
noth
disclos
elin
van
den
berg
lynnda
van
marzyeh
amini
behrooz
z
alizadeh
tim
c
schreuder
klaa
nico
faber
h
blokzijl
robin
p
f
dullaart
background
aim
determin
presenc
cirrhosi
fatti
liver
diseas
nafld
import
alter
prognosi
mandat
screen
hepatocellular
carcinoma
hcc
sought
determin
cohort
patient
nafld
relat
cirrhosi
whether
cirrhosi
discov
incident
diagnos
intent
whether
patient
screen
hcc
method
patient
nafld
cirrhosi
seen
tertiari
academ
centr
medic
record
review
determin
mode
cirrhosi
diagnosi
incident
intent
specialti
diagnostician
evid
previou
clinic
imag
laboratori
featur
unrecogn
cirrhosi
result
nafld
relat
cirrhosi
patient
mean
age
year
male
major
discov
incident
major
nafld
diagnos
time
cirrhosi
diagnosi
incident
diagnosi
commonli
made
imag
perform
reason
unrel
liver
diseas
follow
liver
test
perform
reason
unrel
nafld
liver
diseas
follow
incident
find
varic
endoscopi
unexpect
find
surgeri
intent
diagnosi
predominantli
made
gastroenterologistshepatologist
patient
wherea
gener
practition
surgeon
physician
like
diagnos
cirrhosi
incident
p
high
proport
patient
diagnos
incident
previou
evid
cirrhosi
unexplain
thrombocytopenia
splenomegali
previou
outpati
clinic
review
hospit
although
patient
undergon
fibrosi
test
calcul
retrospect
major
high
score
prior
diagnosi
hepascor
nafld
fibrosi
score
total
cohort
diagnos
hcc
half
receiv
previou
screen
patient
hcc
screen
program
like
higher
bclc
stage
screen
program
stage
c
vs
conclus
major
nafld
cirrhosi
patient
diagnos
incident
despit
prior
clinic
biochem
evid
screen
fibrosi
marker
done
outsid
specialti
clinic
would
detect
patient
screen
hcc
nafld
cirrhot
associ
lower
bclc
stage
time
diagnosi
increas
awar
screen
cirrhosi
hcc
need
patient
nafld
disclosur
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
lui
c
bertot
gari
p
jeffrey
gerri
c
macquillan
georg
gara
michael
c
wallac
background
aim
nonalcohol
fatti
liver
diseas
nafld
nonalcohol
steatohepat
nash
manifest
metabol
syndrom
associ
arteriosclerosi
increas
risk
vascular
diseas
stroke
cardiovascular
diseas
chronic
kidney
diseas
ckd
howev
impact
liver
fibrosi
ckd
nafldnash
wholli
understood
aim
clarifi
relationship
progress
liver
fibrosi
ckd
nafld
method
total
nafld
patient
male
n
year
femal
n
year
diagnos
ultrasonographi
enrol
studi
ckd
evalu
bapwv
puls
wave
veloc
egfr
estim
glomerular
filtrat
rate
liver
fibrosi
estim
index
low
index
categol
group
l
nafl
group
h
nash
possibl
progress
fibrosi
accordingli
effect
liver
fibrosi
bapwv
egfr
examin
multipl
logist
regress
analysi
result
index
posit
correl
bapwv
r
p
neg
correl
egfr
r
p
bapwv
group
h
n
significantli
higher
egfr
significantli
lower
group
l
n
bapwv
cmsec
cmsec
p
egfr
p
multivari
analysi
indic
group
h
signific
risk
increas
bapwv
decreas
egfr
independ
age
diabet
dm
obes
bapwv
odd
ratio
p
egfr
odd
ratio
p
furthermor
dm
liver
fibrosi
addit
increas
risk
group
ldm
odd
ratio
p
group
odd
ratio
p
group
hdm
odd
ratio
p
conclus
progress
liver
fibrosi
nafld
signific
risk
ckd
affect
sever
ckd
ckd
care
monitor
nafld
regardless
comorbid
diabet
disclosur
follow
peopl
noth
disclos
yoshihito
kubotsu
hirokazu
takahashi
yoichiro
kitajima
satoshi
oeda
keizo
anzai
yuichiro
eguchi
introduct
fatti
liver
diseas
nafld
type
diabet
common
condit
regularli
coexist
act
synergist
drive
advers
outcom
preval
nafld
evid
advanc
hepat
fibrosi
accumul
evid
role
screen
nafld
fibrosi
diabet
popul
aim
studi
therefor
aim
firstli
defin
attitud
current
clinic
practic
diabet
specialist
toward
nafld
across
uk
secondli
implement
pathway
assess
nafld
patient
attend
diabet
outpati
clinic
final
assess
impact
multidisciplinari
approach
combin
hepatolog
diabet
input
clinic
manag
materi
method
onlin
survey
dissemin
diabetologist
across
uk
base
find
survey
diabet
patient
attend
outpati
clinic
oxford
univers
hospit
screen
advanc
fibrosi
use
score
elev
score
may
benefit
referr
multidisciplinari
metabol
hepatolog
clinic
result
diabet
specialist
respond
survey
respond
correctli
judg
preval
nafld
diabet
patient
even
fewer
correctli
judg
preval
advanc
fibrot
diseas
whilst
diabetologist
perform
liver
function
test
vast
major
use
score
system
assess
risk
advanc
diseas
within
last
month
respond
diagnosi
nafld
affect
approach
manag
light
find
local
think
nafld
campaign
launch
educ
diabetologist
assess
risk
impact
nafld
patient
diabet
subsequ
month
patient
attend
diabet
clinic
screen
advanc
fibrosi
use
screen
elev
data
analyz
patient
attend
multidisciplinari
clinic
month
follow
weight
reduc
alt
conclus
amongst
diabetologist
remain
limit
awar
preval
sever
nafld
patient
treat
score
easili
use
clinic
practic
identifi
patient
risk
advanc
fibrosi
like
benefit
dedic
multidisciplinari
approach
manag
disclosur
follow
peopl
noth
disclos
thoma
marjot
emilia
sbardella
jonathan
hazlehurst
ahmad
moolla
jeremi
cobbold
jeremi
tomlinson
nonalcohol
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
western
countri
may
progress
cirrhosi
liver
failur
complic
hepatocellular
carcinoma
recent
nonsurg
bariatr
techniqu
endobarri
gi
dynam
devic
mimic
gastric
bypass
surgeri
shield
duodenum
upper
jejunum
contact
chyme
report
lead
signific
weight
loss
rapid
improv
type
diabet
condit
import
risk
factor
nafld
therefor
investig
effect
endobarri
treatment
hepat
paramet
obes
uncontrol
patient
nafld
endobarri
devic
implant
month
duodenum
via
endoscop
procedur
uncontrol
diabet
obes
nafld
subject
age
male
bmi
bmi
waist
circumfer
serum
liver
enzym
level
glucos
hbalc
lipid
profil
perform
well
shear
wave
elastographi
swe
aixplor
superson
imagin
franc
fibromax
fibrotest
actitest
steatotest
nashtest
biopredict
franc
noninvas
evalu
hepat
injuri
month
follow
endobarri
implant
bmi
waist
circumfer
serum
liver
enzym
level
glucos
hbalc
lipid
profil
fibrosi
stage
swe
fibromax
decreas
significantli
baselin
addit
activitytest
steatotest
fat
liver
content
nashtest
steatohepat
score
fibromax
improv
significantli
baselin
month
endobarri
remov
subject
endobarri
endoscop
explant
earlier
due
side
effect
conclus
endobarri
minim
invas
bariatr
techniqu
achiev
signific
improv
hepat
fat
liver
content
steatohepat
score
fibrosi
stage
uncontrol
obes
diabet
nafld
patient
devic
may
suitabl
treatment
morbid
obes
relat
comorbid
includ
nafld
disclosur
follow
peopl
noth
disclos
oranit
gabriella
alon
lang
yeroham
kleinbaum
yael
inbar
sima
katsherginski
keren
tsaraf
ziv
ben
ari
background
aim
fibrosi
occur
differ
organ
associ
damag
fatti
liver
diseas
nafld
liver
fibrosi
also
sign
progress
adipos
tissu
seem
play
import
role
progress
nafld
contribut
adipos
tissu
fibrosi
unclear
aim
studi
check
adipos
tissu
obes
exhibit
fibrosi
ii
fibrosi
adipos
tissu
correl
liver
damag
fibrosi
iii
autophagi
adipos
tissu
associ
fibrosi
adipos
tissu
method
blood
viscer
adipos
liver
tissu
sampl
obtain
mean
age
morbidli
obes
patient
undergo
bariatr
surgeri
fibrosi
assess
siriu
red
stain
adipos
liver
tissu
mrna
express
gene
relat
fibrosi
collagen
autophagi
beclin
measur
adipos
liver
tissu
atg
stain
adipos
tissu
perform
immunohistochemistri
quantit
analyz
blood
sampl
analyz
routin
paramet
surrog
marker
apoptosi
cell
death
elisa
result
increas
fibrosi
observ
siriu
red
collagen
express
significantli
upregul
p
adipos
tissu
morbidli
obes
patient
compar
control
mrna
level
beclin
significantli
increas
adipos
tissu
obes
patient
compar
control
p
beclin
p
addit
amount
cell
adipos
tissu
significantli
correl
fibrosi
adipos
tissu
signific
correl
also
found
adipos
tissu
fibrosi
serum
well
express
autophagi
relat
gene
adipos
tissu
autophagi
relat
gene
express
liver
adipos
tissu
also
correl
conclus
morbid
obes
lead
fibrosi
adipos
tissu
associ
elev
express
autophagi
relat
gene
moreov
autophagi
adipos
tissu
liver
tissu
correl
implic
possibl
common
signal
axi
lead
increas
autophag
process
differ
tissu
underli
mechan
need
character
disclosur
follow
peopl
noth
disclos
leven
martin
schlattjan
sowa
till
hasenberg
lar
bechmann
guido
gerken
ali
canbay
farnesoid
x
receptor
fxr
nuclear
receptor
activ
directli
bile
acid
fxr
express
high
level
liver
intestin
play
central
role
regul
bile
lipid
homeostasi
obetichol
acid
oca
system
bile
acid
fxr
agonist
recent
approv
fda
treatment
primari
biliari
cirrhosi
demonstr
benefici
effect
patient
nonalcohol
steatohepat
nash
howev
treatment
associ
advers
effect
particularli
pruritu
elev
fxr
agonist
potenti
offer
therapeut
efficaci
improv
safeti
profil
test
recent
discov
novel
oral
activ
acid
fxr
agonist
pharmacokinet
studi
peripher
circul
portal
vein
bile
gut
tissu
fece
support
profil
activ
fxr
target
gene
express
intestin
includ
minim
effect
fxr
target
gene
express
liver
includ
ostbeta
contrast
system
fxr
agonist
oca
global
activ
fxr
target
gene
includ
intestin
liver
evalu
effect
hepat
steatosi
mice
per
group
fed
western
diet
wd
week
treat
vehicl
mgkg
qd
mgkg
qd
bid
week
wd
feed
significantli
increas
serum
liver
cholesterol
p
liver
triglycerid
p
compar
mice
fed
standard
chow
qd
bid
qd
normal
serum
cholesterol
liver
triglycerid
liver
cholesterol
content
level
compar
observ
mice
fed
standard
chow
consist
biochem
chang
histopatholog
analysi
show
improv
macrovesicular
steatosi
score
vehicl
treatment
p
bid
p
qd
efficaci
appear
mediat
primarili
intestin
indic
minim
increas
serum
alp
fxr
target
gene
product
wherea
markedli
increas
serum
alp
level
treatment
qd
bid
qd
lower
serum
bile
acid
level
result
suggest
fxr
agonist
could
use
treatment
hepatosteatosi
nash
patient
disclosur
helen
baribault
employ
ardelyx
stock
sharehold
ardelyx
matthew
siegel
employ
ardelyx
christoph
carrera
employ
ardelyx
stock
sharehold
ardelyx
qumber
jafri
employ
ardelyx
inc
christin
dowd
employ
ardelyx
jason
lewi
employ
ardelyx
manag
posit
ardelyx
stock
sharehold
ardelyx
andrew
king
employ
ardelyx
jeremi
caldwel
employ
ardelyx
inc
follow
peopl
noth
disclos
jianhua
chao
kenji
kozuka
hsu
limin
padmapriya
kumaraswami
ying
baom
nie
samantha
patricia
finn
rakesh
jain
background
nonalcohol
fatti
liver
diseas
nafld
includ
spectrum
histolog
phenotyp
includ
steatosi
steatohepat
nash
fibrosi
liver
biopsi
refer
diagnosi
invas
associ
procedur
risk
sampl
variabl
thu
urgent
need
noninvas
robust
diagnost
procedur
recent
describ
lipidom
signatur
associ
nafld
abl
fulfil
unmet
clinic
diagnost
need
differenti
nafld
healthi
cohort
discrimin
steatosi
nash
aim
valid
assay
nafld
diagnosi
use
refer
standard
appli
test
patient
method
thirti
patient
enrol
blind
nafld
cohort
collect
serum
sampl
time
liver
biopsi
metabol
syndrom
assess
base
presenc
least
three
condit
list
ncep
atpiii
patient
prescrib
hypocalor
diet
aerob
exercis
monitor
year
point
new
serum
sampl
collect
lipidom
test
establish
basi
patient
two
logist
regress
algorithm
discrimin
nafld
healthi
liver
assay
name
owliv
care
nash
steatosi
owliv
diagnost
perform
assay
assess
area
roc
curv
posit
neg
predict
valu
respect
result
appli
independ
cohort
femal
test
diagnos
correctli
patient
classifi
one
patient
nash
na
present
metabol
syndrom
one
patient
steatosi
na
although
without
balloon
valid
test
appli
patient
patient
lose
least
baselin
bodi
weight
among
respond
improv
diagnosi
present
posit
shift
nash
steatosi
steatosi
healthi
liver
interestingli
origin
diagnosi
remain
unchang
patient
conclus
result
obtain
independ
cohort
support
feasibl
lipidom
test
noninvas
tool
nafld
diagnosi
monitor
diseas
progress
regress
circumv
need
repeat
liver
biopsi
disclosur
follow
peopl
noth
disclos
miriam
concepcion
garcia
beatriz
antolin
natalia
mora
ibon
de
lui
roman
cristina
alonso
rocio
aller
background
chang
liver
histolog
current
standard
nafld
treatment
respons
liver
histolog
limit
includ
risk
high
cost
imprecis
alt
commonli
use
surrog
marker
relationship
alt
histolog
chang
adequ
defin
particularli
children
hypothes
combin
alt
measur
time
durat
alt
chang
would
predict
histolog
chang
better
reduct
ratio
current
use
method
retrospect
analysi
random
control
tonic
trial
publish
nash
clinic
research
network
compar
placebo
metformin
vitamin
e
along
lifestyl
advic
particip
liver
biopsi
screen
week
includ
analysi
alt
standard
time
averag
alt
sta
combin
level
alt
time
durat
level
calcul
use
area
curv
percent
chang
alt
plot
time
patient
three
method
assess
alt
compar
alt
reduct
ratio
baselin
compar
final
mean
alt
alt
sta
result
averag
fibrosi
score
baselin
na
possibl
alt
significantli
differ
improv
progress
fibrosi
separ
greatest
week
figur
improv
na
also
associ
significantli
improv
alt
howev
separ
seen
week
alt
sta
superior
alt
reduct
ratio
mean
alt
predict
fibrosi
na
improv
auc
fibrosi
na
respect
p
except
alt
reduct
ratio
fibrosi
conclus
alt
sta
best
predictor
histolog
improv
short
term
alt
less
week
fibrosi
week
na
differenti
well
improv
versu
progress
alt
sta
may
use
surrog
marker
fibrosi
chang
na
improv
clinic
trial
pediatr
nafld
alt
trend
fibrosi
progress
versu
improv
disclosur
sarah
e
barlow
stock
sharehold
dyax
corpor
joel
e
lavin
advisori
committe
review
panel
janssen
consult
prestig
brand
pfizer
merck
miriam
b
vo
advisori
committe
review
panel
aegerion
immuron
consult
shire
grantresearch
support
reson
health
mri
analyt
ab
follow
peopl
noth
disclos
damon
frezza
wen
chen
pinar
keskinocak
turgay
ayer
ran
jin
stavra
xanthako
background
nonalcohol
fatti
liver
diseas
nafld
global
health
concern
increas
preval
nafld
associ
increas
cardiovascular
diseas
relationship
evalu
limit
observ
studi
prospect
data
associ
nafld
coronari
arteri
diseas
cad
lack
purpos
ongo
studi
defin
preval
sever
cad
among
patient
nonalcohol
steatohepat
nash
nafld
method
adult
patient
prospect
enrol
predominantli
time
referr
routin
colon
cancer
screen
screen
evid
nafld
fibroscan
scan
lm
mr
elastographi
mre
prior
histori
liver
diseas
alcohol
ingest
greater
accept
rang
nafld
consid
exclusionari
patient
exceed
cutoff
valu
imag
test
offer
liver
biopsi
coronari
ct
angiographycoronari
arteri
calcium
cctacac
screen
presenc
sever
cad
cad
determin
basi
use
segment
model
sever
defin
obstruct
stenosi
stenosi
cad
vessel
free
plaqu
segment
involv
score
si
defin
atherosclerot
plaqu
coronari
segment
diffus
cad
defin
si
cac
quantifi
accord
agatston
method
result
date
particip
enrol
complet
biopsi
patient
complet
ccta
liver
biopsi
among
patient
evid
nafld
biopsi
cad
found
patient
diffus
cad
present
patient
obstruct
cad
patient
median
coronari
arteri
calcium
cac
score
iqr
patient
nafld
cad
detect
patient
diffus
cad
present
patient
found
obstruct
cad
median
cac
score
patient
nash
cad
present
diffus
cad
present
median
cac
score
iqr
differ
found
rate
cad
diffus
cad
median
cac
score
patient
nafld
compar
nash
patient
conclus
preval
cad
particularli
diffus
cad
high
among
patient
nafld
nash
median
cac
score
observ
nash
patient
may
portend
increas
risk
cardiovascular
event
disclosur
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
follow
peopl
noth
disclos
kelvin
n
bush
ryan
prentic
emilio
fentan
richard
w
hilliard
christoph
j
lisanti
ryan
schwope
katherin
cebe
pedro
manibusan
angelo
h
pared
jame
k
aden
jame
watt
dustin
thoma
background
aim
obes
becom
widespread
nation
epidem
preval
steatohepat
nash
liver
transplant
risen
substanti
aim
evalu
tempor
trend
within
unit
network
organ
share
uno
region
method
conduct
cohort
studi
util
uno
data
stratifi
uno
region
evalu
frequenc
adult
within
unit
state
us
determin
etiolog
queri
primari
secondari
diagnosi
code
nash
along
alcohol
liver
diseas
ald
chronic
hepat
c
hcv
result
annual
percentag
chang
apc
compar
hcv
ald
nash
group
lower
male
hispan
ethnic
distribut
howev
nash
group
higher
mean
age
bmi
caucasian
distribut
diabet
highest
number
within
uno
region
region
region
region
region
constitut
annual
number
region
region
increas
respect
region
region
region
highest
percent
perform
region
apc
region
apc
highest
annual
rise
proport
figur
percentag
reach
region
region
region
conclus
southeast
region
region
portion
midwest
region
obes
preval
account
major
rise
studi
need
clearli
establish
relationship
geograph
trend
preval
obes
disclosur
stevan
gonzalez
speak
teach
gilead
salix
abbvi
merck
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
aijaz
ahm
consult
squibb
gilead
scienc
inc
roch
abbvi
shire
janssen
pharmaceut
grantresearch
support
gilead
scienc
inc
follow
peopl
noth
disclos
georg
cholankeril
ryan
b
perumpail
menghan
hu
channa
r
jayasekera
edward
w
holt
zobair
younossi
background
cenicriviroc
cvc
oral
antagonist
current
evalu
phase
studi
adult
steatohepat
nash
liver
fibrosi
centaur
cvc
substrat
cvc
weak
inhibitor
vivo
effect
breast
cancer
resist
protein
bcrp
substrat
unknown
statin
wide
use
treat
dyslipidemia
patient
nash
type
diabet
metabol
syndrom
atorvastatin
simvastatin
substrat
rosuvastatin
bcrp
digoxin
caffein
method
phase
studi
healthi
subject
evalu
effect
cvc
mg
qd
day
pk
safeti
toler
test
drug
atorvastatin
mg
simvastatin
mg
rosuvastatin
mg
administ
caffein
mg
digoxin
mg
three
group
subject
receiv
test
drug
alon
day
cvc
alon
day
start
day
depend
test
drug
cvc
test
drug
last
studi
day
plasma
sampl
collect
hour
atorvastatin
simvastatin
rosuvastatin
without
cvc
administr
cmax
cmin
tau
determin
use
method
least
squar
geometr
mean
geometr
mean
ratio
gmr
confid
interv
ci
calcul
result
cvc
atorvastatin
cmax
u
increas
respect
simvastatin
cmax
u
increas
respect
rosuvastatin
cmax
u
increas
respect
cvc
effect
caffein
digoxin
pk
clinic
signific
increas
cmax
u
well
toler
ae
mild
seriou
ae
ae
lead
discontinu
conclus
cvc
atorvastatin
result
modest
interact
consid
clinic
signific
interact
cvc
simvastatin
rosuvastatin
suggest
dose
adjust
may
warrant
meaning
effect
cvc
substrat
observ
disclosur
eric
lefebvr
employ
tobira
therapeut
inc
san
francisco
ca
usa
stuart
harri
grantresearch
support
tobira
inc
michael
willett
employ
readi
clinic
llc
independ
contractor
tobira
therapeut
inc
star
seyedkazemi
employ
tobira
therapeut
stock
sharehold
tobira
therapeut
chang
consult
incarda
therapeut
inc
employ
tobira
therapeut
inc
patrick
smith
consult
tobira
mildr
gottwald
employ
tobira
therapeut
stock
sharehold
tobira
therapeut
gilead
scienc
tobira
therapeut
alexza
pharmaceut
inc
background
aim
peripher
blood
level
aspart
aminotransferas
astgot
transaminas
alanin
transaminas
altgpt
transaminas
frequent
reliabl
biomark
liver
injuri
although
ast
alt
play
central
role
glutam
product
transaminas
peripher
blood
level
ast
alt
regard
liver
injuri
biomark
ast
alt
catalyz
transamin
aspart
alanin
glutam
import
posit
regul
tissu
glutam
level
glutam
princip
excitatori
neurotransmitt
affect
memori
function
brain
blood
glutam
level
report
alter
mani
cognit
function
disord
studi
investig
impact
blood
transaminas
level
blood
glutam
concentr
memori
method
psychiatr
medic
neurolog
healthi
subject
femal
male
enrol
studi
local
advertis
plasma
ast
alt
level
measur
convent
autom
analyz
plasma
amino
acid
glutam
glutamin
glycin
measur
use
high
perform
liquid
chromatographi
hplc
system
five
indic
verbal
memori
visual
memori
gener
memori
attentionconcentr
delay
recal
wechsler
memori
use
measur
memori
function
result
plasma
ast
alt
signific
posit
correl
plasma
glutam
level
ast
alt
plasma
ast
alt
level
significantli
neg
correl
four
five
memori
function
verbal
memori
ast
alt
visual
memori
ast
alt
gener
memori
ast
alt
delay
recal
ast
alt
correl
attentionconcentr
plasma
glutam
significantli
neg
correl
three
five
memori
function
multivari
analys
demonstr
plasma
ast
alt
glutam
level
significantli
correl
memori
function
even
adjust
gender
educ
conclus
far
know
first
report
could
demonstr
impact
blood
transaminas
level
blood
glutam
concentr
memori
function
human
find
import
interpret
metabol
syndrom
elev
transaminas
cognit
dysfunct
disclosur
tetsuo
takehara
grantresearch
support
chugai
pharmceut
co
msd
k
k
squibb
mitsubishi
tanab
pharma
corpar
toray
industri
inc
janssen
pharmaceut
co
abbvi
speak
teach
msd
k
k
squibb
gilead
scienc
abbvi
follow
peopl
noth
disclos
yoshihiro
kamada
ryota
hashimoto
hidenaga
yamamori
yuka
yasuda
yuko
fujita
kenji
hashimoto
eiji
miyoshi
background
aim
current
knowledg
genet
basi
nonalcohol
fatti
liver
diseas
nafld
demonstr
variant
contribut
diseas
suscept
sever
locat
gene
regul
lipid
metabol
specif
consist
associ
nafld
sever
fibrosi
stage
across
differ
popul
adult
children
howev
associ
discov
variant
locat
loci
includ
recent
identifi
p
membran
bound
domain
contain
consist
replic
across
ethnic
group
encod
member
famili
specif
acyl
donor
notabl
report
result
show
genotyp
frequenc
deviat
equilibrium
hwe
explor
whether
associ
genet
risk
nafld
diseas
sever
studi
patient
nafld
proven
liver
biopsi
method
studi
includ
individu
patient
nafld
healthi
control
genotyp
perform
taqman
assay
sampl
power
addit
genet
model
account
possibl
popul
stratif
use
collect
snp
differ
loci
analyz
structur
program
show
similar
cluster
case
control
result
popul
genotyp
frequenc
control
n
cc
ct
tt
patient
cc
ct
tt
hwe
minor
allel
frequenc
variant
neither
associ
increas
suscept
nafld
test
trend
p
diseas
sever
p
howev
univari
analysi
observ
signific
associ
circul
triglycerid
tg
associ
either
glucos
metabol
total
hdl
met
compon
conclus
role
nafld
seem
conclus
variant
may
associ
tg
level
might
indirectli
regul
intermedi
step
fatti
acid
polyunsatur
fatti
tg
biosynthesi
still
unexplor
interact
may
explain
disproportion
impact
variant
nafld
among
differ
ethnic
group
replic
observ
among
differ
popul
inde
may
result
dispar
dietari
composit
disclosur
follow
peopl
noth
disclos
silvia
sookoian
diego
flichman
martin
garaycoechea
carla
gazzi
gustavo
castano
carlo
j
pirola
chronic
liver
diseas
cirrhosi
lead
caus
death
us
use
nation
databas
updat
estim
liver
diseas
burden
u
method
nation
ambulatori
hospit
ambulatori
medic
care
survey
nationwid
inpati
sampl
vital
statist
us
databas
use
estim
medic
care
mortal
primari
diagnosi
liver
diseas
exclud
viral
hepat
hepatocellular
carcinoma
rate
shown
per
popul
recent
year
avail
result
liver
diseas
contribut
million
ambulatori
visit
million
hospit
discharg
death
ambulatori
visit
rate
liver
diseas
diagnosi
higher
among
women
compar
men
vs
white
compar
african
american
vs
hispan
compar
vs
hospit
discharg
rate
also
increas
among
hispan
compar
vs
higher
among
men
compar
women
vs
similar
among
white
african
american
vs
ambulatori
visit
rate
rose
hospit
discharg
rate
doubl
mortal
rate
higher
among
men
compar
women
vs
hispan
compar
vs
slightli
higher
among
white
compar
african
american
vs
mortal
rate
declin
slowli
increas
slowli
declin
steepest
among
african
american
recent
revers
among
subgroup
figur
conclus
burden
liver
diseas
us
substanti
increas
revers
declin
mortal
trend
concern
deserv
popul
monitor
outcom
disclosur
follow
peopl
noth
disclos
aynur
constanc
e
ruhl
background
aim
remain
unknown
inflamm
promot
liver
fibrosi
earli
stage
steatohepat
nash
previous
found
use
microscopi
iem
express
apj
angiotensin
receptor
relat
angiogenesi
human
liver
cirrhosi
apelin
select
endogen
ligand
apj
receptor
recent
report
liver
fibrosi
marker
present
studi
examin
serum
apelin
level
hepat
express
apj
earli
advanc
stage
nash
patient
materi
method
studi
enrol
histolog
proven
nash
patient
healthi
control
serum
level
measur
elisa
compar
histopatholog
find
estim
brunt
fibrosi
stage
local
apj
receptor
examin
ihc
iem
use
liver
sampl
nash
patient
normal
liver
specimen
express
apj
receptor
also
examin
western
blot
analysi
result
serum
level
earli
stage
pgml
advanc
stage
nash
pgml
significantli
higher
control
pg
ml
p
p
respect
serum
level
increas
parallel
fibrosi
stage
western
blot
analysi
confirm
increas
express
apj
receptor
earli
nash
liver
compar
control
liver
p
interestingli
advanc
stage
nash
liver
exhibit
lower
express
apj
receptor
compar
earli
nash
liver
p
ihc
reveal
apj
receptor
local
mainli
arteri
capillari
lesser
extent
sinusoid
control
liver
earli
stage
nash
apj
receptor
show
strong
posit
stain
hepat
sinusoid
line
cell
inflammatori
cell
pericentr
area
weakli
hepat
sinusoid
line
cell
periport
area
advanc
nash
apj
observ
mainli
sinusoid
line
cell
region
portal
fibrosi
arteri
capillari
fibrot
septum
howev
apj
express
weaker
earli
nash
liver
iem
examin
reveal
aberr
express
apj
receptor
prolifer
arteri
capillari
open
sinusoid
apj
receptor
also
found
caveola
prolifer
capillari
endotheli
cell
pericyt
conclus
local
apj
receptor
shown
iem
suggest
associ
angiogenesi
even
earli
stage
nash
apelin
apj
receptor
close
relat
fibrosi
angiogenesi
nash
disclosur
wataru
ando
grantresearch
support
tosoh
corpor
follow
peopl
noth
disclos
hiroaki
yokomori
yutaka
inagaki
rie
kubota
katsuya
otori
isao
okazaki
background
select
potent
small
molecul
inhibitor
clinic
develop
treatment
nonalcohol
steatohepat
nash
sever
alcohol
hepat
studi
evalu
safeti
pk
subject
mild
moder
sever
hepat
impair
hi
subject
normal
hepat
function
support
develop
dose
recommend
patient
cirrhosi
method
subject
stabl
mild
moder
sever
hi
b
c
respect
per
group
healthi
control
normal
hepat
function
match
age
year
gender
bmi
per
hi
group
receiv
singl
mg
oral
dose
follow
intens
pk
sampl
hour
safeti
monitor
parametr
analysi
varianc
use
mix
effect
model
use
fit
pk
paramet
auc
c
confid
interv
ci
construct
geometr
mean
ratio
gmr
paramet
hi
group
match
control
subject
sinc
hi
may
alter
protein
bind
free
fraction
plasma
also
determin
summar
hepat
function
result
subject
complet
studi
advers
event
ae
mild
grade
moder
grade
one
ae
grade
headach
occur
one
subject
total
plasma
exposur
cmax
auc
similar
subject
mild
moder
hi
compar
healthi
control
tabl
modest
increas
auc
subject
sever
hi
versu
control
subject
compar
control
subject
free
fraction
increas
subject
sever
hi
mild
moder
hi
compar
control
unbound
vs
unbound
conclus
safeti
result
studi
consist
overal
safeti
profil
exposur
similar
subject
mild
moder
hi
compar
normal
hepat
function
subject
sever
hi
modestli
higher
exposur
result
studi
support
continu
clinic
develop
patient
liver
dysfunct
due
nash
alcohol
hepat
without
dose
adjust
regardless
presenc
hi
tabl
summari
pk
result
subject
hepat
impair
vs
normal
hepat
function
control
disclosur
cara
h
nelson
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
srini
ramanathan
employ
gilead
scienc
lu
wang
employ
gilead
scienc
thoma
oriordan
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
robert
p
myer
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
constantin
djedjo
employ
gilead
scienc
thoma
tarnowski
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
eric
lawitz
advisori
committe
review
panel
abbvi
achillion
pharmaceut
regulu
therav
enanta
idenix
pharmaceut
janssen
merck
co
novarti
gilead
grantresearch
support
abbvi
achillion
pharmaceut
boehring
ingelheim
squibb
gilead
scienc
glaxosmithklin
idenix
pharmaceut
intercept
pharmaceut
janssen
merck
co
novarti
nitto
denko
therav
salix
enanta
speak
teach
gilead
janssen
abbvi
bristol
meyer
squibb
merck
intercept
thoma
c
marburi
employ
orlando
clinic
research
center
follow
peopl
noth
disclos
ellen
kwan
jolen
berg
kenneth
lasset
background
fibroblast
growth
factor
hormon
import
regul
glucos
lipid
metabol
analog
improv
insulin
sensit
lipid
profil
contribut
nash
pathogenesi
preclin
model
well
obes
human
type
diabet
first
gener
pegyl
human
variant
extend
elimin
compar
endogen
human
enabl
daili
weekli
regimen
studi
pegyl
variant
modifi
decreas
proteolysi
extend
support
least
dose
method
random
singl
ascend
dose
studi
obes
bmi
healthi
subject
conduct
cohort
subject
random
subcutan
sc
mg
mg
mg
mg
mg
vs
placebo
serum
concentr
vs
time
data
use
deriv
cmax
tmax
auc
inf
total
clearanc
cltf
compartment
pk
model
develop
simul
concentr
vs
time
profil
weekli
dose
regimen
result
baselin
mean
age
male
hispan
death
sae
discontinu
due
ae
ae
mild
intens
pk
result
tabl
averag
termin
h
cmax
observ
h
dose
cmax
auc
inf
consist
across
dose
indic
pk
linear
pk
project
achiev
within
wk
accumul
index
weekli
dose
conclus
singl
dose
mg
compar
show
improv
pk
exposur
due
prolong
termin
pk
safeti
data
support
continu
clinic
develop
weekli
dose
nash
tabl
mean
standard
deviat
median
rang
disclosur
edgar
charl
employ
bm
rose
christian
employ
squibb
malaz
abu
tarif
employ
squibb
stock
sharehold
squibb
follow
peopl
noth
disclos
chunyu
kate
wu
anh
bui
background
aim
exercis
therapi
patient
fatti
liver
diseas
nafld
aerob
resist
exercis
improv
nafld
howev
effect
exercis
protocol
remain
unclear
moreov
given
high
preval
cardiovascular
diseas
nafld
choic
exercis
type
relat
exercis
energi
consumpt
compar
sought
assess
requir
frequenc
intens
durat
aerob
resist
exercis
requir
improv
hepat
steatosi
compar
exercis
regimen
regard
energi
consumpt
patient
nafld
method
literatur
search
perform
use
pubm
web
scienc
scopa
januari
articl
assess
effect
aerob
resist
hepat
steatosi
total
articl
studi
includ
aerob
resist
exercis
protocol
select
systemat
review
result
aerob
exercis
decreas
hepat
steatosi
seen
protocol
n
median
effect
protocol
metabol
equival
met
minsess
timesweek
week
resist
exercis
reduct
hepat
steatosi
seen
protocol
n
median
effect
protocol
met
min
session
timesweek
week
aerob
resist
exercis
reduc
intrahepat
lipid
respect
signific
differ
seen
durat
frequenc
period
exercis
two
exercis
regimen
energi
consumpt
significantli
lower
resist
aerob
exercis
group
vs
kcaltot
period
p
conclus
resist
exercis
improv
nafld
less
energi
consumpt
resist
exercis
may
feasibl
benefici
aerob
regimen
nafld
patient
poor
cardiorespiratori
fit
toler
particip
aerob
exercis
data
also
suggest
possibl
link
mode
exercis
hepat
lipid
metabol
disclosur
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
follow
peopl
noth
disclos
takumi
kawaguchi
ryuki
hashida
takato
ueno
hironori
koga
naoto
shiba
takuji
torimura
probabl
role
gut
nonalcohol
steatohepat
nash
progress
still
elucid
although
evid
anim
human
studi
suggest
increas
gut
permeabl
could
allow
passag
endotoxin
liver
enhanc
inflamm
aim
investig
preval
increas
intestin
permeabl
subject
nash
synbiot
supplement
contain
coloni
form
unit
cfu
lreuteri
plu
partial
hydrolyz
guar
gum
inulin
twice
daili
could
improv
paramet
includ
nash
patient
random
control
clinic
trial
subject
receiv
synbiot
supplement
healthi
nutrit
counsel
three
month
individu
receiv
healthi
nutrit
counsel
period
time
clinic
appoint
schedul
everi
month
provid
synbiot
gut
permeabl
evalu
baselin
intervent
lactulosemannitol
urinari
excret
test
urin
sampl
taken
patient
drunk
isosolar
solut
contain
lactulos
mannitol
measur
perform
high
perform
liquid
chromatographi
hplc
result
report
percentag
urinari
excret
probe
relat
amount
ingest
final
result
test
ratio
excret
percentag
lactulos
mannitol
result
test
compar
refer
valu
establish
healthi
popul
baselin
median
age
ys
patient
femal
patient
obes
hypertens
dyslipidem
sedentari
present
alter
glucos
metabol
classifi
metabol
syndrom
difer
clinic
histolog
paramet
group
patient
nash
present
high
preval
increas
gut
permeabl
baselin
differ
frequenc
increas
gut
permeabl
group
studi
group
control
group
three
month
synbiot
supplement
differ
percentag
lactulos
mannitol
excret
neither
lactulosemannitol
excret
ratio
intervent
group
respect
well
control
group
respect
patient
nash
present
high
frequenc
increas
gut
permeabl
improv
withl
reuteri
plu
partial
hydrolyz
guar
gum
inulin
supplement
disclosur
follow
peopl
noth
disclos
silvia
ferolla
claudia
couto
geyza
n
armiliato
paula
v
vidig
gabriela
ataliba
maria
de
lourd
ferrari
eduardo
g
vilela
henriqu
g
torr
aloisio
cunha
teresa
c
ferrari
background
extracellular
vesicl
ev
particl
releas
die
activ
cell
experiment
model
ev
releas
hepatocyt
lipotox
intern
neighbor
cell
contribut
liver
fibrosi
angiogenesi
object
studi
quantifi
character
ev
serum
patient
nonalcohol
steatohepat
nash
method
ev
isol
use
sequenti
centrifug
process
serum
healthi
control
nash
patient
advanc
fibrosi
ishak
dynam
light
scatter
analysi
zetas
malvern
worcestershir
uk
electron
microscopi
determin
size
morpholog
ev
flow
cytometri
quantifi
total
number
ev
ev
asialoglycoprotein
receptor
ev
number
compar
nash
patient
control
associ
ev
number
nash
characterist
includ
liver
biochemistri
nafld
activ
score
compon
fibrosi
stage
hepat
collagen
content
muscl
actin
express
morphometri
serum
fibrosi
marker
hepat
venou
pressur
gradient
hvpg
cirrhot
subject
determin
result
nash
patient
median
age
yr
femal
cirrhot
control
yr
femal
includ
ev
detect
subject
exosom
microparticl
identifi
compar
control
nash
patient
greater
median
iqr
number
total
ev
vs
per
l
serum
ev
vs
per
l
p
number
total
ev
correl
demograph
liver
biochemistri
histolog
fibrosi
marker
hvpg
meld
howev
number
ev
correl
fibrosi
stage
fibrotest
elf
test
nafld
fibrosi
score
bilirubin
platelet
hvpg
moreov
patient
clinic
signific
portal
hypertens
hvpg
mmhg
ev
patient
hvpg
mmhg
median
vs
per
l
conclus
patient
nash
number
circul
ev
correl
fibrosi
stage
serum
fibrosi
marker
hvpg
character
content
ev
may
help
elucid
pathogenesi
fibrosi
portal
hypertens
disclosur
robert
p
myer
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
constantin
djedjo
employ
gilead
scienc
zachari
goodman
grantresearch
support
gilead
scienc
galectin
therapeut
intercept
alexion
conatu
cempra
nitto
denko
tobira
exalenz
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
david
povero
casey
johnson
hirokazu
yamashita
mani
subramanian
jaim
bosch
ariel
e
feldstein
background
aim
patient
cirrhosi
due
fatti
liver
diseas
nafld
risk
liver
cardiac
relat
morbid
mortal
lifestyl
chang
incorpor
exercis
recommend
may
improv
fit
peak
predict
mortal
cirrhosi
patient
efficaci
safeti
patient
popul
well
establish
aim
determin
impact
exercis
train
aerob
fit
secondari
outcom
includ
hepat
steatosi
liver
injuri
insulin
resist
bodi
composit
muscl
strength
safeti
qualiti
life
measur
method
patient
histolog
confirm
nafld
cirrhosi
low
baselin
physic
activ
level
underw
week
progress
aerob
resist
exercis
min
thrice
weekli
supervis
exercis
physiologist
aerob
capac
assess
use
grade
cardiopulmonari
exercis
test
strength
via
repetit
maximum
test
liver
steatosi
magnet
reson
spectroscopi
bodi
composit
dexa
qualiti
life
use
valid
questionnair
cldq
result
eight
patient
approach
consent
studi
lack
interest
avail
main
reason
refus
subject
femal
mean
age
year
bmi
child
portal
hypertens
baselin
week
exercis
intervent
produc
signific
improv
peak
mlkgmin
mlkgmin
respect
maxim
strength
leg
press
kg
kg
seat
row
kg
kg
function
capac
improv
occur
improv
six
minut
walk
test
distanc
time
go
lean
muscl
mass
increas
overal
fat
mass
fell
trend
toward
signific
seen
reduct
waist
circumfer
total
fat
mass
p
signific
effect
note
hepat
steatosi
liver
enzym
insulin
resist
lipid
profil
qualiti
life
improv
chang
chronic
liver
diseas
questionnair
score
physic
domain
advers
event
note
conclus
uptak
exercis
poor
among
nafld
cirrhot
patient
howev
appropri
exercis
lead
clinic
signific
improv
aerob
fit
strength
function
capac
associ
reduct
fat
mass
improv
qualiti
life
strategi
increas
patient
particip
requir
disclosur
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
paul
crabtre
helena
ching
gari
p
jeffrey
jonathan
tibbal
gerri
c
macquillan
georg
gara
robert
u
newton
background
aim
probiot
commonli
use
bariatr
surgeri
howev
uncertainti
remain
regard
efficaci
aim
compar
effect
probiot
vs
placebo
hepat
inflammatori
clinic
outcom
post
laparoscop
sleev
gastrectomi
lsg
method
random
trial
treatment
probiot
supherb
vs
placebo
addit
conduct
among
morbidli
obes
fatti
liver
diseas
nafld
patient
underw
lsg
surgeri
primari
outcom
reduct
liver
fat
content
measur
secondari
outcom
improv
fibrosi
measur
elastographi
metabol
inflammatori
paramet
anthropometr
qualiti
life
qol
fecal
sampl
collect
analyz
microbi
composit
result
one
hundr
patient
women
mean
age
year
bmi
random
attend
visit
complet
index
hri
nafld
remiss
rate
similarli
reduc
probiot
placebo
group
vs
score
vs
respect
fibrosi
alt
protein
crp
leptin
level
significantli
reduc
qol
significantli
improv
differ
note
p
rel
abund
main
phyla
increas
firmicut
proteobacteria
actinobacteria
verrucomicrobia
one
main
phylum
decreas
bacteroidet
similar
extent
arm
conclus
probiot
administr
improv
hepat
inflammatori
clinic
outcom
post
lsg
disclosur
niv
zmora
grantresearch
support
gilead
intern
research
scholar
program
liver
diseas
follow
peopl
noth
disclos
shiri
sherf
dagan
shira
gili
muriel
webb
assaf
buch
andrei
keidar
asnat
raziel
nasser
sakran
david
goitein
natalia
goldenberg
jemal
mahdi
meirav
malli
eran
segal
eran
elinav
oren
shibolet
background
aim
exercis
therapi
effect
recommend
fatti
liver
diseas
nafld
report
examin
whether
signific
reduct
serum
level
alanin
aminotransferas
alt
achiev
exercis
therapi
patient
nafld
aim
studi
assess
effect
simpl
resist
exercis
week
nafld
method
fifti
nine
patient
nafld
assign
resist
exercis
group
n
control
group
n
resist
exercis
group
perform
exercis
squat
time
week
nonconsecut
day
trial
period
week
patient
control
group
proceed
regular
physic
activ
restrict
diet
throughout
studi
effect
exercis
compar
group
week
biochem
blood
paramet
hepat
steatosi
bodi
composit
assess
hepat
steatosi
bodi
composit
evalu
ultrasound
bioelectr
imped
analysi
respect
result
signific
interact
seen
alt
level
alt
level
vs
iul
p
vs
p
significantli
decreas
exercis
control
group
also
found
signific
interact
hepat
steatosi
grade
p
moreov
hepat
steatosi
grade
vs
p
significantli
decreas
exercis
control
group
chang
alt
level
correl
neg
chang
muscl
bodi
weight
ratio
exercis
group
conclus
data
demonstr
week
simpl
resist
exercis
compris
squat
repres
effect
treatment
nafld
disclosur
follow
peopl
noth
disclos
manabu
hayashi
atsushi
takahashi
hiromichi
imaizumi
masashi
fujita
ken
okai
kazumichi
abe
hiromasa
ohira
background
aim
incid
nafld
continu
parallel
rise
obes
rate
bariatr
surgeri
provid
effect
tool
weight
loss
feasibl
option
endobariatr
devic
includ
balloon
igb
may
provid
altern
option
weight
control
report
outcom
igb
treatment
obes
nafld
singl
centr
method
outcom
follow
igb
placement
obes
patient
insulin
till
tertiari
hospit
central
london
unit
kingdom
retrospect
examin
clinic
anthropometr
biochem
data
routin
record
examin
baselin
igb
remov
monthsresult
data
patient
avail
analysi
women
caucasian
background
mean
age
year
diabet
present
baselin
featur
metabol
syndrom
also
appar
patient
mean
baselin
weight
kg
bmi
waist
circumfer
cm
median
baselin
follow
month
igb
placement
signific
chang
seen
weight
mean
loss
bmi
mean
reduct
p
signific
improv
also
seen
alt
ggt
chang
correspond
weight
loss
p
commonli
report
side
effect
includ
nausea
vomit
abdomin
discomfort
prematur
igb
remov
requir
case
conclus
igb
provid
effect
altern
mean
induc
weight
loss
manag
obes
liver
dysfunct
short
term
improv
insulin
resist
hepat
transaminas
correl
greater
degre
weight
chang
disclosur
follow
peopl
noth
disclos
vi
nguyen
jiawei
li
paul
cordero
gilberto
alejandro
cueva
mai
khatib
jude
oben
background
purpos
proteas
activ
cell
surfac
coupl
receptor
gpcr
highli
express
multipl
cell
type
liver
includ
hepatocyt
stellat
cell
inflammatori
macrophag
activ
proteolyt
cleavag
exodomain
serin
proteas
recent
propos
import
regul
obes
metabol
syndrom
howev
connect
signal
metabol
liver
understood
aim
studi
evalu
role
signal
liver
metabol
lead
pathogenesi
fatti
liver
diseas
nash
method
use
methionin
cholin
defici
mcd
mous
model
nash
week
time
period
analyz
system
hepat
metabolit
nuclear
magnet
reson
nmr
liver
metabolit
extract
liver
extract
method
quantifi
enhanc
nmr
metabolom
compar
individu
metabolit
wild
type
versu
mice
mice
treat
pepducin
system
metabolit
extract
plasma
methanol
denatur
method
express
regulatori
enzym
critic
metabol
pathway
also
measur
result
found
defici
inhibit
provid
strike
protect
hepat
steatosi
inflamm
defici
well
treatment
significantli
decreas
hepat
triglycerid
p
plasma
level
liver
enzym
altp
ast
reduc
nafld
activ
score
na
nash
model
metabolom
gene
express
experi
show
inhibit
enhanc
fatti
acid
suppress
metabol
pathway
lead
speci
ro
product
conclus
signal
play
critic
role
regul
hepat
steatosi
inflamm
ro
gener
nash
condit
lead
cirrhosi
hepatocellular
carcinoma
current
approv
mean
pharmacolog
intervent
develop
novel
inhibitor
exemplifi
pepducin
may
provid
blueprint
develop
efficaci
agent
suppress
nash
disclosur
lidija
covic
grantresearch
support
oasi
pharmaceut
llc
athan
kuliopulo
manag
posit
oasi
pharmaceut
follow
peopl
noth
disclos
rajashre
rana
andrew
shearer
conor
calnan
nga
nguyen
laura
fynn
tianfang
huang
jame
baleja
background
abnorm
liver
function
test
lft
frequent
observ
human
immunodefici
viru
hiv
monoinfect
individu
absenc
alcohol
excess
evid
emerg
fatti
liver
diseas
nafld
may
import
caus
howev
aetiolog
nafld
hiv
infect
remain
unclear
aim
identifi
preval
risk
factor
nafld
patient
hiv
abnorm
lft
method
retrospect
studi
conduct
hiv
outpati
persist
abnorm
liver
function
alanin
aminotransferas
alt
upper
limit
normal
occas
month
apart
identifi
clinic
record
examin
assess
demograph
clinic
biochem
hiv
characterist
nafld
case
defin
patient
radiolog
evid
hepat
steatosi
absenc
viral
hepat
b
c
excess
alcohol
intak
caus
secondari
steatosi
control
defin
patient
evid
hepat
steatosi
ultrasound
identifi
caus
liver
diseas
result
among
hiv
cohort
patient
patient
persist
elev
alt
identifi
caus
elev
alt
hepat
c
viru
hepat
b
viru
alcohol
excess
nafld
drug
induc
hepat
liver
diseas
identifi
caus
patient
case
earli
stage
diseas
median
interquartil
rang
score
exclus
criteria
appli
nafld
case
compar
control
use
binari
logist
regress
bodi
mass
index
bmi
odd
ratio
confid
interv
ci
histori
hyperlipidaemia
ci
lipoprotein
hdl
cholesterol
ci
hdl
cholesterol
ratio
ci
significantli
associ
nafld
univari
analysi
multivari
analysi
bmi
adjust
ci
hyperlipidaemia
adjust
ci
independ
associ
nafld
factor
significantli
associ
nafld
univari
multivari
analysi
conclus
nafld
import
caus
persist
rais
alt
larg
cohort
patient
associ
metabol
rather
factor
manag
metabol
risk
factor
prioriti
patient
group
disclosur
mark
nelson
advisori
committe
review
panel
janssen
msd
bm
abbvi
viiv
gilead
consult
janssen
msd
bm
abbvi
viiv
gilead
grantresearch
support
boehring
ingelheim
janssen
msd
bm
abbvi
viiv
gilead
roch
speak
teach
gsk
janssen
msd
bm
abbott
viiv
gilead
mark
r
thursz
advisori
committe
review
panel
gilead
bm
abbott
laboratori
altimmun
follow
peopl
noth
disclos
rebekah
g
judg
jame
b
mauric
recent
easl
intern
guidelin
suggest
combin
blood
test
liver
stiff
measur
lsm
stage
liver
fibrosi
nafld
howev
whether
combin
provid
gain
accuraci
compar
two
constitut
test
demonstr
statist
therefor
sought
firstli
compar
accuraci
three
test
categori
nafld
secondli
compar
accuraci
test
nafld
refer
etiolog
chronic
hepat
c
chc
test
develop
valid
method
popul
includ
patient
nafld
chc
total
sixteen
test
blood
test
lsm
fibroscan
combin
lsm
blood
marker
uniqu
score
fibrometersvct
evalu
nafld
chc
refer
metavir
fibrosi
stage
liver
biopsi
chc
etiolog
accuraci
evalu
mainli
obuchowski
index
oi
target
fibrosi
stage
secondarili
auroc
binari
diagnost
target
result
combin
fibrometersvct
significantli
higher
oi
auroc
signific
sever
fibrosi
two
constitut
test
thu
oi
vs
vs
lsm
test
less
accur
test
e
g
oi
vs
fibrometernafld
vs
nafld
fibrosi
score
nafld
vs
chc
popul
oi
respect
nafld
vs
chc
decreas
order
accuraci
nafld
vs
lsm
vs
fibrometerald
vs
zeng
score
vs
hepascor
vs
vs
vs
apri
vs
fibrotest
vs
conclus
nafld
singl
accur
test
develop
chc
perform
better
test
develop
specif
nafld
test
combin
blood
marker
lsm
outperform
constitut
test
valid
recent
easl
guidelin
nafld
fibrosi
evalu
thu
simplifi
nafld
use
singl
test
lsm
one
blood
test
develop
chc
either
alon
prefer
combin
blood
marker
e
test
develop
chc
disclosur
paul
cale
consult
echosen
victor
de
ledinghen
board
membership
janssen
gilead
bm
abbvi
intercept
pharma
superson
imagin
grantresearch
support
superson
imagin
speak
teach
abbvi
merck
bm
gilead
jerom
boursier
consult
echosen
follow
peopl
noth
disclos
alexandra
ducancel
julien
vergniol
brigitt
le
bail
background
aim
hepat
fibrosi
major
determin
clinic
outcom
fatti
liver
diseas
nafld
remain
clear
need
establish
accuraci
marker
fibrosi
studi
aim
prospect
compar
diagnost
perform
abil
exclud
advanc
fibrosi
follow
test
nafld
fibroscan
fibromet
v
fibromet
nafld
fibromet
vcte
nafld
fibrosi
score
nf
apri
bard
astalt
ratio
method
patient
suspect
nafld
prospect
underw
fibroscan
examin
blood
sampl
within
week
standard
care
liver
biopsi
lb
march
januari
seven
uk
centr
lb
stage
blind
manner
two
expert
pathologist
accord
nash
crn
system
diagnost
perform
assess
term
area
roc
curv
auc
abil
exclud
advanc
fibrosi
assess
use
publish
except
fibromet
fm
yet
publish
fm
determin
maxim
youden
index
result
patient
male
median
age
iqr
year
median
bmi
complet
dataset
analysi
fibrosi
distribut
patient
na
score
perform
summari
test
present
tabl
conclus
fibromet
vcte
combin
biochem
paramet
liver
stiff
measur
fibroscan
highest
perform
characterist
posit
neg
predict
valu
respect
confirm
exclud
fibrosi
perform
fibrosi
score
auc
significantli
inferior
fm
vcte
delong
test
cutoff
either
publish
establish
maxim
youden
index
f
disclosur
quentin
anste
advisori
committe
review
panel
intercept
consult
genfit
eli
lilli
pfizer
inventiva
imperi
innov
grantresearch
support
abbvi
gsk
follow
peopl
noth
disclos
peter
j
eddow
indra
neil
guha
david
sheridan
emmanouil
tsochatzi
jeremi
cobbold
michael
e
allison
valeri
paradi
pierr
bedossa
philip
n
newsom
lower
socioeconom
statu
associ
wors
outcom
mani
chronic
medic
diseas
like
diabet
hypertens
howev
data
describ
impact
socioeconom
statu
patient
nonalcohol
fatti
liver
diseas
nafld
associ
metabol
diseas
therefor
aim
current
studi
evalu
diseas
sever
preval
metabol
syndrom
compon
patient
nafld
base
combin
household
incom
method
retrospect
analysi
nonalcohol
steatohepat
clinic
research
network
nash
crn
databas
includ
adult
patient
age
year
histolog
confirm
nafld
baselin
combin
household
incom
collect
cohort
divid
household
incom
low
household
incom
lhi
high
household
incom
hhi
histolog
paramet
diseas
sever
medic
compar
across
two
group
result
total
patient
lhi
hhi
includ
current
analysi
femal
gender
vs
p
race
vs
lhi
group
lhi
cohort
higher
bmi
vs
p
like
diabet
vs
p
metabol
syndrom
vs
p
compar
hhi
group
serum
alanin
aminotransferas
level
ul
iqr
ul
hhi
significantli
higher
ul
iqr
ul
observ
lhi
cohort
differ
distribut
steatosi
grade
lobular
inflamm
observ
two
cohort
howev
lhi
cohort
like
hepatocellular
balloon
vs
p
higher
percentag
lhi
vs
mild
portal
inflamm
histolog
marker
diseas
progress
nafld
final
subject
lhi
cohort
like
nash
vs
advanc
fibrosi
vs
p
hhi
cohort
conclus
patient
nafld
lower
household
incom
associ
histolog
advanc
diseas
higher
preval
metabol
syndrom
disclosur
rohit
kohli
consult
synageva
biopharma
grantresearch
support
raptor
independ
contractor
galectin
therapeut
speak
teach
alexion
pharmaceut
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
mohammad
siddiqui
patricia
h
belt
jame
tonascia
laura
wilson
jeann
clark
melissa
conto
daniel
brandman
factor
drive
progress
liver
diseas
nash
versu
simpl
hepat
steatosi
well
understood
rapidli
rise
rate
nash
seriou
complic
e
g
cirrhosi
hcc
requir
pathophysiolog
mechan
identifi
peopl
may
segreg
earli
suitabl
intervent
dna
damag
respons
ddr
associ
persist
oxid
stress
serv
major
role
hepatotox
cancer
examin
atm
relat
perturb
human
liver
nash
method
result
tissu
sampl
human
liver
explant
categor
histolog
normal
group
fatti
liver
group
nash
group
ea
total
rna
extract
multipl
sampl
per
group
probe
array
gene
pathway
ddr
normal
gene
express
level
compar
method
annot
gene
variou
group
ingenu
pathway
analysi
note
signific
differ
comparison
group
healthi
group
nash
sampl
represent
ddr
pathway
includ
atm
brca
multipl
regul
cell
cycl
checkpoint
control
dna
damagerepair
mechan
pathway
includ
key
downstream
regul
ddr
e
well
gene
pathway
relat
cancer
highli
promin
group
indic
diseas
progress
tissu
sampl
studi
substanti
rna
level
find
tissu
immunostain
liver
section
earli
marker
dna
break
found
hepatocyt
express
group
nash
wherea
rare
hepatocyt
group
p
next
verifi
whether
gene
express
chang
also
present
protein
level
studi
tissu
lysat
spot
array
phosphoprotein
repres
major
signal
pathway
identifi
greater
differ
express
analysi
confirm
preval
group
sampl
numer
activ
phosphoprotein
member
greater
express
atm
brca
relat
dna
damagerepair
pathway
along
pathway
cancer
oxid
stress
inflamm
cell
cycl
checkpoint
control
etc
conclus
ddr
relat
atm
pathway
separ
nash
fatti
liver
normal
liver
substanti
increas
ddr
like
pathophysiolog
prognost
signific
liver
injuri
remodel
oncogenesi
nash
appropri
develop
marker
identifi
character
nash
earli
stage
disclosur
follow
peopl
noth
disclos
preeti
viswanathan
priya
gupta
yogeshwar
sharma
sanjeev
gupta
background
aim
role
internet
ever
increas
present
era
first
sourc
medic
inform
imprecis
partial
comprehens
textual
inform
limit
efficaci
commun
diseas
process
patient
initi
appli
militari
readabl
test
sinc
util
varieti
field
adjudg
comprehens
level
document
report
compar
readabl
analysi
onlin
text
pertain
alcohol
hepat
ah
steatohepat
nash
method
inform
websit
acg
american
liver
foundat
alf
healthlin
com
institut
human
virolog
ihv
mayo
clinic
medlin
medicinenet
com
nation
institut
health
nih
patient
info
uptod
webmd
download
process
microsoft
word
data
format
categor
subsect
proprieti
inform
medic
term
expung
limit
bia
text
analyz
specif
level
readabl
use
six
valid
readabl
metric
result
modifi
document
nash
mean
grade
lower
origin
counterpart
lower
ah
highest
mean
readabl
grade
level
ah
record
ihv
grade
level
nash
acg
level
least
read
grade
level
ah
record
nih
webmd
nash
treatment
subsect
highest
mean
grade
level
ah
nash
anova
analysi
show
signific
differ
read
grade
level
depend
sourc
websit
p
subsect
compar
readabl
test
treatment
section
usual
difficult
section
written
compar
subsect
p
conclus
patient
educ
materi
except
webmd
recommend
grade
level
treatment
section
often
difficult
section
comprehend
greater
emphasi
clear
simpl
languag
warrant
increas
qualiti
comprehens
onlin
patient
educ
resourc
disclosur
nikolao
pyrsopoulo
advisori
committe
review
panel
vital
therapi
consult
merck
bm
gilead
intercept
grantresearch
support
merck
intercept
conatu
vital
therapi
abbvi
holog
roch
follow
peopl
noth
disclos
rishabh
gulati
mohammad
nawaz
laura
rotundo
introduct
aim
vitamin
e
vite
effect
treatment
steatohepat
nash
vite
associ
hemorrhag
stroke
platelet
dysfunct
similar
event
report
studi
vite
nash
encount
patient
gastrointestin
gi
bleed
vite
therapi
aim
determin
risk
iron
fe
defici
fatti
liver
diseas
nafld
patient
treat
vite
method
hemoglobin
hb
mcv
rdw
ferritin
monitor
prospect
frequent
patient
nafld
ongo
random
trial
differ
dose
natur
vite
iud
mean
treatment
durat
week
subject
decompens
cirrhosi
coagulopathi
thrombocytopenia
exclud
determin
specif
vite
treatment
compar
rate
fe
defici
histor
data
similar
trial
center
week
metformin
loomba
ap
well
avail
data
piven
trial
sanyal
nejm
result
subject
exhibit
worsen
preexist
fe
defici
median
vite
treatment
week
anemia
hb
gdl
seen
patient
median
week
subject
fe
defici
without
anemia
patient
complet
workup
gi
sourc
found
includ
colon
diverticulosi
gastric
ulcer
gastric
hyperplast
polyp
hemorrhoid
one
subject
aspirin
past
histori
fe
defici
notabl
fe
defici
spontan
resolv
without
vite
cessat
subject
bleed
anemia
occur
week
liver
biopsi
fe
defici
occur
diabet
compar
p
age
sex
nash
activ
score
cirrhosi
vite
dose
associ
fe
loss
comparison
patient
develop
mild
fe
defici
without
anemia
significantli
lower
rate
vite
piven
trial
exclud
diabet
anemia
hb
declin
differ
vite
placebo
arm
week
red
cell
indic
avail
conclus
occult
gi
bleed
fe
defici
common
vite
treatment
nafld
like
reflect
effect
platelet
function
turn
may
increas
risk
bleed
preexist
gi
lesion
close
monitor
iron
statu
warrant
first
month
treatment
especi
diabet
subject
past
histori
fe
defici
disclosur
follow
peopl
noth
disclos
yaron
rotman
shilpa
lingala
nevitt
morri
background
aim
clinic
determin
fibrosi
progress
nonalcohol
fatti
liver
diseas
nafld
still
definit
aim
studi
assess
clinic
determin
fibrosi
progress
rate
fpr
nafld
patient
baselin
histolog
evalu
special
focu
impact
pharmacolog
therapi
method
observ
cohort
italian
patient
tertiari
referr
center
liver
histolog
evalu
accord
kleiner
independ
predictor
fpr
select
stepwis
regress
approach
result
median
month
iqr
patient
show
amelior
stabil
progress
fibrosi
patient
nonalcohol
steatohepat
nash
similar
demograph
anthropometr
featur
higher
preval
type
diabet
use
axi
system
ra
inhibitor
fibrosi
progress
depend
length
associ
requir
presenc
nash
p
fibrosi
progress
faster
fpr
independ
associ
higher
apri
score
absenc
treatment
ra
inhibitor
diagnosi
baselin
signific
interact
use
ra
inhibitor
fpr
ra
inhibitor
associ
slower
fpr
patient
without
pn
conclus
nash
requir
fibrosi
progress
nafld
wherea
seem
drive
fibrogenesi
independ
hepat
inflamm
use
ra
inhibitor
may
contrast
fibrosi
progress
especi
patient
affect
disclosur
follow
peopl
noth
disclos
serena
pelusi
salvator
petta
chiara
rosso
vittorio
borroni
anna
ludovica
fracanzani
paola
dongiovanni
antonio
craxi
elisabetta
bugianesi
silvia
fargion
luca
valenti
background
nonalcohol
steatohepat
nash
current
second
lead
indic
liver
transplant
lt
unit
state
sever
studi
predict
nash
becom
lead
indic
liver
transplant
none
focus
whether
increas
trend
nash
continu
come
decad
aim
studi
predict
futur
trend
nash
among
adult
await
liver
transplant
unit
state
use
data
organ
procur
transplant
network
optn
well
nation
health
nutrit
examin
survey
nhane
method
extract
data
avail
nhane
round
preval
secular
trend
metabol
risk
factor
name
bmi
fast
plasma
glucos
dm
systol
blood
pressur
total
cholesterol
triglycerid
also
extract
data
optn
dataset
frequenc
secular
trend
primari
diagnos
time
liver
transplant
use
lag
time
use
preval
metabol
risk
factor
predict
futur
preval
nash
main
diagnosi
time
liver
transplant
result
nash
show
signific
increas
trend
main
diagnosi
time
liver
transplant
go
less
p
univari
analysi
popul
preval
metabol
risk
factor
name
bmi
p
fast
plasma
glucos
systol
blood
pressur
p
total
cholesterol
show
statist
signific
associ
frequenc
nash
main
diagnosi
time
liver
transplant
assum
observ
trend
continu
univari
model
base
calendar
year
predict
nash
main
diagnosi
liver
transplant
ci
best
multivari
model
includ
bmi
systol
blood
pressur
addit
calendar
year
decreas
predict
ci
conclus
previou
decad
preval
nash
main
caus
liver
diseas
increas
among
transplant
patient
observ
slow
increas
trend
obes
hypertens
predict
subsequ
slow
increas
trend
nash
next
decad
disclosur
ibrahim
hanouneh
advisori
committe
review
panel
gilead
speak
teach
merck
follow
peopl
noth
disclos
kaveh
hajifathalian
arthur
j
mccullough
aim
measur
hepat
magnet
reson
imag
mri
shown
correl
fibrosi
steatosi
inflamm
studi
aim
prospect
evalu
mri
patient
undergo
investig
fatti
liver
diseas
nafld
secondari
care
method
consecut
patient
centr
underw
mri
blood
sampl
scan
week
prior
standard
care
liver
biopsi
lb
mri
sequenc
gener
fat
fraction
pdff
map
hepat
iron
excess
shorten
independ
fibrosi
iron
correct
calcul
measur
use
liver
multiscan
softwar
perspectum
diagnost
oxford
uk
histolog
featur
nafld
score
accord
system
pathologist
blind
mri
find
result
patient
steatohepat
nash
simpl
steatosi
ss
similar
patient
demograph
two
group
overal
median
age
rang
year
mean
bmi
male
caucasian
mri
high
accuraci
assess
sever
steatosi
mean
pdff
grade
steatosi
respect
spearman
rho
p
overal
diseas
activ
defin
nafld
activ
score
na
show
signific
correl
p
enhanc
liver
fibrosi
elf
test
liver
stiff
ls
separ
nash
ss
auroc
ci
elf
ls
respect
significantli
associ
kleiner
fibrosi
stage
although
ls
p
elf
p
exclud
without
clinic
signific
diseas
nash
fibrosi
show
greater
neg
predict
valu
npv
either
elf
ls
auroc
ci
posit
predict
valu
npv
sensit
specif
publish
exclus
signific
diseas
outlin
tabl
conclus
nafld
mri
accur
assess
steatosi
grade
diseas
activ
defin
na
suggest
role
diseas
monitor
high
npv
exclud
signific
diseas
also
suggest
role
initi
assess
patient
suspect
nafld
thu
potenti
avoid
liver
biopsi
tabl
disclosur
catherin
kelli
employ
perspectum
diagnost
ltd
stock
sharehold
pespectum
diagnost
ltd
ami
h
herlihi
employ
perspectum
diagnost
matthew
kelli
manag
posit
perspectum
diagnost
ltd
gideon
hirschfield
advisori
committe
review
panel
intercept
pharma
gsk
consult
cymabay
novarti
grantresearch
support
falk
pharma
bioti
takeda
follow
peopl
noth
disclos
peter
j
eddow
natasha
mcdonald
nigel
p
davi
scott
sempl
stefan
g
hubscher
timothi
j
kendal
jame
hodson
philip
n
newsom
jonathan
fallowfield
background
accultur
associ
increas
risk
obes
possibl
diabet
among
associ
fatti
liver
diseas
nafld
unknown
evalu
associ
accultur
nafld
risk
among
use
data
nation
health
nutrit
examin
survey
nhane
method
use
two
separ
aggreg
dataset
nhane
iii
ii
pool
data
three
continu
cycl
nhane
year
nhane
two
nafld
definit
use
nhane
iii
one
base
ultrasound
second
elev
aminotransferas
one
nafld
definit
use
nhane
elev
aminotransferas
accultur
defin
three
way
place
birth
u
vs
mexico
languag
prefer
gener
statu
calcul
adjust
odd
ratio
confid
interv
ci
use
multivari
logist
regress
result
compar
higher
preval
obes
hypertens
hypercholesterolemia
higher
incom
high
school
educ
health
insur
access
medic
care
nhane
iii
birthplac
associ
risk
nafld
defin
ultrasound
unadjust
ci
adjust
ci
elev
aminotransferas
unadjust
ci
adjust
ci
likewis
associ
accultur
defin
birthplac
languag
prefer
gener
statu
risk
nafld
elev
aminotransferas
nhane
conclus
despit
greater
preval
nafld
risk
factor
among
highli
accultur
associ
accultur
risk
nafld
nhane
disclosur
hashem
b
consult
gilead
wako
follow
peopl
noth
disclos
maya
balakrishnan
fasiha
kanwal
aaron
p
thrift
posttranspl
liver
steatosi
occur
frequent
could
affect
patient
outcom
studi
aim
clarifi
risk
factor
steatosi
steatohepat
nash
live
liver
donor
transplant
retrospect
examin
live
liver
transplant
recipi
donor
identifi
risk
factor
steatosi
nash
patient
underw
liver
biopsi
year
liver
transplant
yearli
thereaft
abnorm
liver
enzym
level
detect
liver
steatosi
found
case
nash
diagnos
patient
averag
time
steatosi
liver
transplant
year
patient
liver
steatosi
group
younger
without
liver
steatosi
steatosi
preval
steatosi
significantli
higher
donor
steatosi
without
steatosi
steatosi
p
likewis
donor
steatosi
found
significantli
associ
nash
nash
nafl
multivari
analysi
also
show
recipi
age
p
donor
steatosi
p
risk
factor
liver
steatosi
forti
recipi
donor
examin
polymorph
snp
phospholipas
gene
identifi
predictor
sever
fatti
liver
diseas
signific
differ
preval
liver
steatosi
among
recipi
snp
hand
liver
steatosi
seen
significantli
higher
number
donor
gg
allel
cc
cg
cc
cg
p
patient
nash
show
gg
allel
conclus
donor
factor
donor
steatosi
genotyp
affect
risk
liver
steatosi
nash
live
liver
transplant
disclosur
follow
peopl
noth
disclos
hisamistu
miyaaki
satoshi
miuma
naota
taura
hidetaka
shibata
kazuhiko
nakao
background
abnorm
cholesterol
metabol
accumul
toxic
free
cholesterol
hepatocyt
may
result
hepat
inflamm
fibrosi
potenti
factor
contribut
pathogenesi
nash
accordingli
remov
cholesterol
liver
treatment
approach
could
decreas
possibl
revers
damag
volixibat
formerli
block
bile
acid
ba
reabsorpt
inhibit
asbt
termin
ileum
consequ
ba
excret
fece
forc
liver
synthes
new
ba
cholesterol
liver
serum
hypothes
inhibit
ba
reuptak
could
lead
therapeut
benefici
metabol
effect
nash
aim
assess
safeti
toler
pharmacodynam
pd
pharmacokinet
pk
volixibat
administ
day
method
random
placebo
pbo
phase
studi
overweight
obes
men
women
year
old
random
cohort
vari
volixibat
dose
regimen
daili
qd
twice
daili
bid
titrat
evalu
includ
pd
assess
fecal
ba
serum
concentr
marker
synthesi
ba
cholesterol
pk
stool
hard
bristol
stool
chart
bsc
safeti
toler
result
subject
random
volixibat
pbo
consist
minim
absorpt
volixibat
pk
could
calcul
mean
daili
fecal
ba
excret
higher
subject
receiv
volixibat
pmol
receiv
pbo
pmol
maxim
inhibit
ba
reabsorpt
occur
volixibat
dose
qd
mg
qd
two
third
maxim
effect
mg
bid
one
third
greater
mg
qd
compar
mg
qd
final
day
dose
day
mean
serum
concentr
higher
volixibat
pbo
median
rang
reduct
mmoll
total
cholesterol
mmoll
ldl
cholesterol
observ
volixibat
overal
volixibat
consid
safe
frequenc
bowel
movement
increas
overal
median
daili
evacu
rang
predos
evacu
rang
treatment
proportion
stool
sampl
rate
type
bsc
volixibat
pbo
seriou
advers
event
subject
complet
trial
conclus
studi
support
investig
volixibat
patient
nash
disclosur
melissa
palmer
employ
shire
manag
posit
shire
stock
sharehold
sh
ire
lee
jen
independ
contractor
shire
debra
silberg
employ
shire
caleb
bliss
employ
shire
stock
sharehold
shire
patrick
martin
employ
shire
manag
posit
shire
stock
sharehold
shire
brian
kirbi
c
stephen
djedjo
joann
birkebak
qinghua
song
krysia
grycz
jonna
weston
g
mani
subramanian
william
watkin
robert
p
myer
anita
mathia
gilead
scienc
inc
foster
citi
ca
usa
background
select
agonist
farnesoid
x
receptor
fxr
develop
treatment
nonalcohol
steatohepat
nash
cholestat
liver
disord
highli
select
fxr
drug
metabol
transport
regul
nuclear
hormon
receptor
e
g
pxr
car
ahr
highli
protein
bound
low
potenti
system
inhibitori
base
interact
undergo
oxid
metabol
studi
evalu
afeti
pharmacokinet
pk
pharmacodynam
pd
effect
healthi
volunt
safeti
pk
data
present
herein
method
random
studi
subject
receiv
singl
multipl
dose
qd
day
mg
fast
match
placebo
cohort
washout
singl
multipl
dose
period
safeti
pk
paramet
major
circul
metabolit
fold
less
potenc
fxr
compar
summar
treatment
group
data
pharmacodynam
effect
present
elsewher
result
enrol
subject
complet
studi
rate
advers
event
similar
placebo
activ
treat
subject
mg
cohort
respect
advers
event
grade
sever
consid
unrel
rapidli
absorb
maximum
plasma
concentr
cmax
occur
hour
across
dose
test
exhibit
median
hour
gener
auc
cmax
increas
less
upon
singl
multipl
dose
expect
due
short
daili
dose
minim
accumul
observ
auc
cmax
singl
multipl
dose
administr
similar
mg
dose
auc
c
respect
valu
observ
conclus
singl
multipl
daili
dose
fxr
agonist
well
toler
healthi
subject
safeti
pk
profil
biolog
activ
support
evalu
subject
nash
cholestat
liver
disord
disclosur
brian
kirbi
employ
gilead
scienc
constantin
djedjo
employ
gilead
scienc
joann
birkebak
employ
gilead
krystyna
grycz
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
william
watkin
employ
gilead
scienc
robert
p
myer
employ
gilead
scienc
inc
stock
sharehold
gilead
scienc
inc
anita
mathia
employ
gilead
scienc
inc
follow
peopl
noth
disclos
qinghua
song
jonna
weston
mani
subramanian
background
modifi
dixon
mdixon
sequenc
safe
altern
quantif
hepat
fat
content
accept
reason
method
assess
chang
hepat
fat
amount
phase
ii
studi
recent
control
attenu
paramet
cap
show
good
correl
intrahepat
fat
amount
compar
liver
biopsi
well
mr
data
larg
cross
section
cohort
howev
littl
known
whether
chang
cap
score
use
clinic
trial
investig
correl
cap
mr
serial
examin
clinic
trial
set
method
nafld
patient
evalu
mr
transient
elastographi
includ
cap
clinic
studi
mr
cap
evalu
three
month
probiot
clinic
trial
patient
nafld
result
baselin
cap
show
good
correl
assess
hepat
steatosi
p
also
chang
cap
valu
also
correl
chang
fat
use
clinic
trial
set
concord
rate
improv
aggrav
compar
two
method
howev
less
chang
amount
small
cap
valu
less
concord
rate
show
weak
chang
cap
valu
treatment
less
concord
rate
decreas
conclus
cap
mr
compar
diagnost
valu
hepat
steatosi
quantif
well
assess
chang
hepat
fat
amount
clinic
trial
howev
care
interpret
steatosi
chang
use
cap
score
given
absolut
chang
valu
less
clinic
trial
set
disclosur
follow
peopl
noth
disclos
sang
bong
ahn
dae
jun
jae
yoon
jeong
joo
hyun
sohn
backgroundaim
worldwid
spread
obes
diabet
lead
drastic
increas
nonalcohol
fatti
liver
diseas
nafld
complic
aim
assess
preval
nafld
sever
among
gener
mediterranean
popul
method
consid
consecut
individu
includ
abcd
studi
longitudin
observ
studi
cohort
repres
gener
popul
sicili
patient
neg
hcv
hbv
hiv
infect
alcohol
intak
gday
femal
gday
male
hepat
ultrasound
us
use
diagnos
steatosi
fibroscan
xl
probe
measur
liver
stiff
control
attenu
paramet
cap
liver
stiff
kpa
consid
suggest
signific
liver
fibrosi
petta
et
al
hepatolog
cap
db
consid
suggest
steatosi
de
ledinghen
v
et
al
jhep
result
steatosi
us
diagnos
individu
significantli
associ
male
gender
type
diabet
low
hdl
viscer
obes
split
analysi
accord
gender
steatosi
independ
link
viscer
obes
p
low
hdl
male
viscer
obes
p
type
diabet
femal
rate
us
steatosi
stiff
kpa
cap
progress
increas
male
without
obes
low
hdl
steatosi
among
theme
cap
stiff
one
risk
factor
steatosi
among
cap
stiff
risk
factor
steatosi
among
cap
stiff
similarli
femal
rate
us
steatosi
stiff
kpa
cap
progress
increas
patient
without
obes
diabet
steatosi
among
cap
stiff
one
risk
factor
steatosi
among
cap
stiff
risk
factor
steatosi
among
cap
stiff
conclus
nafld
present
gener
popul
preval
well
preval
liver
damag
increas
accord
presenc
obes
low
hdl
male
obes
diabet
femal
impact
variant
gene
steatosi
liver
damag
popul
investig
disclosur
follow
peopl
noth
disclos
salvator
petta
carola
buscemi
silvio
buscemi
david
corleo
vito
di
marco
purpos
preval
fatti
liver
diseas
nafld
may
correl
defici
acid
excess
fatti
acid
refin
carbohydr
western
diet
associ
coronari
arteri
diseas
metabol
syndrom
collat
effect
supplement
hepat
steatosi
method
search
medlin
embas
ovid
databas
review
titlesabstract
full
text
data
extract
perform
studi
includ
hepat
steatosi
present
defin
mri
ultrasound
histolog
data
pool
conduct
use
random
effect
model
data
present
standard
mean
differ
smd
mean
differ
md
result
total
studi
identifi
studi
includ
final
analysi
total
patient
pool
cohort
administ
dose
rang
gramsday
durat
treatment
week
month
decreas
hepat
fat
observ
arm
smd
ci
pool
analysi
also
reveal
decreas
alt
arm
md
ci
improv
md
ci
triglycerid
md
ci
sensit
analysi
exclud
observ
studi
also
demonstr
reduct
liver
fat
smd
ci
discuss
treatment
associ
reduct
liver
fat
patient
hepat
steatosi
conflict
data
regard
reduct
hepat
fibrosi
inflamm
balloon
degener
possibl
varianc
dosag
level
durat
treatment
subgroup
analys
demonstr
reduct
alt
decreas
triglycerid
insulin
resist
known
safeti
profil
supplement
may
benefici
reduc
hepat
steatosi
alt
improv
dyslipidemia
insulin
resist
decreas
cardiovascular
risk
forest
plot
show
associ
acid
liver
fat
disclosur
jame
h
okeef
board
membership
cardiotab
background
endogen
sex
hormon
associ
risk
diabet
metabol
syndrom
recent
studi
suggest
role
hormon
nonalcohol
fatti
liver
diseas
nafld
conduct
systemat
review
observ
studi
investig
associ
sex
hormon
nafld
method
comprehens
search
databas
medlin
embas
perform
incept
april
inclus
criterion
observ
studi
assess
associ
serum
total
testosteron
tt
bind
globulin
shbg
nafld
calcul
pool
mena
differ
md
odd
ratio
tt
shbg
confid
interv
ci
compar
subject
without
nafld
use
model
result
sixteen
trial
compris
men
women
met
inclus
criteria
tt
level
lower
men
nafld
md
nmoll
ci
without
men
higher
tt
level
lower
odd
nafld
ci
wherea
higher
tt
level
increas
odd
nafld
women
ci
sex
shbg
level
lower
patient
nafld
control
men
md
nmoll
ci
women
md
higher
shbg
level
associ
reduc
odd
nafld
men
ci
women
ci
conclus
demonstr
associ
tt
nafld
lower
tt
level
associ
men
nafld
invers
associ
women
nafld
wherea
higher
shbg
level
associ
lower
nafld
odd
men
women
random
effect
pool
mean
differ
tt
subject
without
nafld
men
women
disclosur
follow
peopl
noth
disclos
veeravich
jaruvongvanich
anawin
sanguankeo
sikarin
upala
background
recent
gene
express
gex
profil
differenti
mild
sever
nonalcohol
fatti
liver
diseas
nafld
fibrosi
independ
clinic
factor
evalu
whether
gex
profil
associ
clinic
decompens
death
aim
identifi
molecular
pathway
link
morbid
mortal
nafld
method
perform
retrospect
analysi
patient
nafld
whose
liver
tissu
previous
evalu
gex
via
microarray
patient
assess
liver
biopsi
death
liver
transplant
studi
end
outcom
includ
decompens
ascit
hepat
encephalopathi
hepatocellular
carcinoma
varic
bleed
composit
incorpor
stroke
myocardi
infarct
death
associ
composit
outcom
gex
quantifi
use
gener
linear
model
control
age
bodi
mass
index
diabet
mellitu
fibrosi
stage
result
patient
includ
femal
white
median
age
studi
entri
year
rang
median
follow
day
rang
four
patient
white
women
experienc
clinic
outcom
two
hepat
decompens
two
stroke
fibrosi
studi
entri
rang
stage
gene
show
signific
differenti
express
p
chang
express
patient
without
composit
outcom
two
probe
branch
chain
transaminas
upregul
fold
chang
princip
compon
analysi
hierarch
cluster
confirm
gex
aid
differenti
patient
outcom
without
conclus
initi
catabol
essenti
branch
chain
amino
acid
found
upregul
nafld
patient
clinic
decompens
upregul
previous
associ
high
liver
fat
content
poor
prognosi
hepatocellular
carcinoma
result
suggest
perturb
hepat
metabol
associ
poor
outcom
nafld
patient
point
toward
need
investig
target
tabl
select
differenti
express
gene
p
patient
without
outcom
disclosur
manal
f
abdelmalek
consult
bhv
pharma
taiwanj
pharma
grant
research
support
tobira
gilead
scienc
nihniddk
genfit
pharmaceut
immuron
galm
taiwanj
pharma
intercept
ngm
pharmaceut
bm
pharma
arisaph
speak
teach
alexion
follow
peopl
noth
disclos
kara
wegermann
ricardo
henao
yipe
pan
anna
mae
diehl
cynthia
moylan
introduct
vitamin
vd
defici
associ
obes
insulin
resist
howev
role
vd
defici
nafld
well
understood
aim
determin
relationship
serum
level
hepat
express
vd
metabol
gene
clinic
histolog
featur
nafld
method
adult
duke
nafld
clinic
databas
vd
level
within
month
liver
biopsi
includ
nafld
histolog
featur
control
patholog
diagnosi
clinic
characterist
vd
level
nafld
histolog
featur
summar
compar
group
gener
linear
model
use
analyz
associ
vd
level
metabol
gene
includ
vd
receptor
vdr
vd
bind
protein
encod
group
specif
compon
gc
cytochrom
complex
parathyroid
hormon
receptor
retino
x
receptor
rxr
nuclear
receptor
coactiv
ncoa
smad
peroxisom
receptor
ppar
nafld
histolog
sever
adjust
confound
correct
multipl
comparison
result
differ
age
gender
bmi
hypertens
htn
hyperlipidemia
hld
hypercholesterolemia
hcl
hypertriglyceridemia
htg
vd
level
ngml
vs
ngml
note
group
nafld
patient
like
higher
vs
light
skin
vs
vd
level
associ
sever
steatosi
lobular
inflamm
balloon
hepatocyt
fibrosi
univari
analysi
candid
gene
gene
probe
mild
stage
vs
advanc
stage
fibrosi
gene
gene
probe
signific
multipl
comparison
control
confound
associ
decreas
tabl
conclus
pilot
studi
vd
level
hepat
express
candid
gene
involv
vd
metabol
associ
nafld
histolog
sever
gene
interest
warrant
investig
larger
studi
hepat
gene
express
vd
pathway
gene
adjust
multipl
comparison
adjust
age
gender
bmi
race
hbalc
diabet
mellitu
htn
hld
hcl
htg
disclosur
dawn
l
pierci
grantresearch
support
gilead
niddk
speak
teach
alexion
manal
f
abdelmalek
consult
bhv
pharma
taiwanj
pharma
grant
research
support
tobira
gilead
scienc
nihniddk
genfit
pharmaceut
immuron
galm
taiwanj
pharma
intercept
ngm
pharmaceut
bm
pharma
arisaph
speak
teach
alexion
follow
peopl
noth
disclos
yuval
patel
ricardo
henao
cynthia
moylan
cynthia
guy
anna
mae
diehl
background
aim
current
three
million
peopl
undergo
comprehens
health
prevent
medicin
call
ningen
dock
annual
japan
control
attenu
paramet
cap
evalu
transient
elastographi
fibroscan
recent
method
assess
steatosi
use
clinic
practic
unknown
especi
relationship
cap
metabol
syndrom
reveal
health
introduc
cap
first
time
prospect
investig
relationship
cap
clinic
biolog
paramet
patient
method
cap
examin
perform
particip
without
suspect
chronic
liver
diseas
liver
stiff
cap
measur
perform
fibroscan
touch
mhz
standard
probe
experienc
oper
follow
factor
analyz
influenc
cap
valu
relationship
cap
paramet
age
gender
bodi
mass
index
bmi
waist
circumfer
hypertens
diabet
metabol
syndrom
alcohol
use
liver
stiff
measur
differ
biolog
paramet
result
characterist
particip
follow
male
median
age
year
mean
bmi
particip
overweight
bmi
waist
circumfer
cm
cap
measur
unreli
case
cap
measur
failur
independ
associ
fb
steatosi
detect
us
liverkidney
contrast
ct
liver
spleen
ratio
wherea
detect
cap
dbm
number
subject
dbm
dbm
dbm
dbm
steatosi
accord
cap
valu
respect
simpl
regress
analys
indic
cap
valu
significantli
correl
bmi
waist
circumfer
viscer
fat
area
ls
ratio
alt
triglycerid
high
densiti
lipoprotein
p
ci
multivari
analysi
factor
associ
cap
bmi
alt
triglycerid
conclus
cap
seem
use
immedi
detect
hepat
steatosi
comprehens
health
associ
cap
metabol
syndrom
could
interest
prevent
medicin
disclosur
norifumi
kawada
grantresearch
support
chugai
speak
teach
msd
bm
gilead
abbvi
follow
peopl
noth
disclos
hiroyasu
morikawa
sawako
k
uchida
background
aim
screen
steatohepat
nash
subject
fatti
liver
diseas
nafld
hamper
uncertainti
around
tool
liver
damag
studi
aim
valid
recent
develop
ion
index
nash
assess
diagnost
perform
singl
combin
noninvas
tool
liver
damag
larg
cohort
patient
nafld
materi
method
analys
data
italian
patient
southern
itali
northern
itali
consecut
enrol
biopsi
follow
score
liver
fibrosi
calcul
accord
publish
algorithm
ion
nf
apoptot
fragment
measur
elisa
immunoassorb
assay
liver
stiff
ls
evalu
fibroscan
liver
histolog
score
accord
kleiner
nash
diagnos
local
pathologist
accord
join
presenc
steatosi
inflamm
balloon
without
fibrosi
sever
fibrosi
defin
fibrosi
point
fibrosi
calcul
youden
index
result
whole
cohort
auc
ion
diagnosi
nash
npv
ppv
npv
ppv
respect
confirm
poor
perform
test
noninvas
diagnosi
nash
test
perform
better
diagnosi
sever
fibrosi
auc
ion
npv
ppv
npv
ppv
popul
auc
nf
ls
diagnosi
sever
fibrosi
npv
ppv
npv
ppv
npv
ppv
respect
next
test
sever
combin
noninvas
tool
order
improv
diagnost
perform
risk
sever
fibrosi
combin
ion
plu
ls
nf
plu
ls
plu
ls
similarli
improv
perform
singl
test
provid
correct
classif
case
respect
conclus
combin
ls
either
ion
nf
better
singl
noninvas
test
accur
exclud
sever
liver
fibrosi
disclosur
follow
peopl
noth
disclos
rami
ibrahim
kamal
jouness
chiara
rosso
salvator
petta
monica
cucco
milena
marietti
gian
paolo
caviglia
maria
lorena
abat
calogero
camma
antonina
smedil
antonio
craxi
giorgio
maria
saracco
elisabetta
bugianesi
object
weight
loss
diet
exercis
current
recommend
treatment
nafld
howev
efficaci
treatment
improv
nafld
reduc
steatosi
patient
type
diabet
unproven
method
evalu
particip
enrol
fatti
liver
ancillari
studi
look
ahead
action
health
diabet
trial
clinic
trial
design
assess
effect
intens
lifestyl
intervent
ili
compar
diabet
support
educ
dse
seriou
cardiovascular
event
overweight
obes
adult
type
diabet
particip
known
chronic
viral
hepat
cirrhosi
use
system
corticosteroid
habitu
consumpt
alcohol
drink
per
week
exclud
ancillari
studi
use
store
serum
sampl
measur
fibromax
fibrotest
steatotest
nashtest
baselin
year
studi
use
recommend
lab
cutoff
steatosi
nash
fibrosi
analys
analyz
outcom
treatment
arm
amount
weight
loss
across
treatment
arm
result
particip
random
ili
dse
store
specimen
includ
analys
baselin
women
mean
age
year
mean
bmi
base
recommend
cutoff
signific
steatosi
steatotest
nash
nashtest
signific
fibrosi
fibrotest
median
percentil
ul
month
particip
assign
ili
compar
dse
lost
weight
vs
p
greater
declin
vs
month
percentag
signific
steatosi
decreas
among
ili
dse
vs
similarli
percentag
particip
nash
decreas
among
ili
compar
dse
vs
compar
littl
weight
chang
weight
loss
significantli
greater
declin
improv
steatotest
signific
chang
fibrotest
intervent
group
degre
weight
loss
conclus
intens
lifestyl
intervent
patient
may
benefici
reduc
hepat
steatosi
inflamm
serum
biomark
nash
appear
sensit
chang
may
use
monitor
treatment
respons
disclosur
follow
peopl
noth
disclos
mariana
lazo
menglu
liang
jame
j
potter
jeann
clark
introduct
studi
suggest
circadian
rhythm
disrupt
result
liver
milieu
promot
steatosi
steatohepat
sinc
cycl
arguabl
bodi
import
circadian
rhythm
sleep
pattern
may
affect
natur
histori
fatti
liver
diseas
nafld
studi
aim
determin
sleep
durat
particular
associ
nafld
methodolog
data
obtain
combin
nation
health
nutrit
examin
survey
nhane
subject
incomplet
data
hepat
b
c
infect
signific
alcohol
intak
hepatotox
medic
use
exclud
subject
divid
priori
group
base
sleep
durat
hour
hour
hour
multivari
regress
use
estim
effect
sleep
durat
nafld
fibrosi
score
nf
fatti
liver
index
fli
alt
adjust
age
sex
ethnic
smoke
alcohol
use
calor
intak
high
alt
defin
ul
men
ul
women
base
previou
nhane
analys
result
total
adult
fast
lab
includ
mean
sleep
durat
hour
total
hour
sleep
hour
hour
peopl
slept
hour
younger
black
obes
higher
triglycerid
slept
hour
older
femal
mexican
white
peopl
slept
hour
smoke
less
less
like
diabet
hypertens
drinker
multivari
regress
sleep
hour
increas
odd
high
probabl
fli
high
alt
respect
sleep
hour
decreas
odd
high
probabl
fli
high
alt
respect
although
differ
statist
signific
mean
alt
hour
group
ul
higher
hour
group
odd
high
probabl
nf
increas
sleep
hour
univari
multivari
analysi
conclus
sleep
least
hour
per
night
may
protect
steatosi
steatohepat
sleep
durat
howev
appear
affect
fibrosi
risk
studi
suggest
sleep
may
modifi
risk
factor
nafld
research
warrant
use
biopsi
defin
nafld
phenotyp
morbid
mortal
endpoint
multivari
odd
ratio
fatti
liver
fibrosi
high
alt
disclosur
follow
peopl
noth
disclos
jame
philip
g
esteban
lisa
e
rein
aniko
szabo
samer
gawrieh
kia
saeian
introduct
approach
assess
steatohepat
nash
variou
degre
fibrosi
context
clinic
trial
import
goal
drug
develop
three
lead
candid
monitor
includ
magnet
reson
imag
livermultiscan
lm
liver
stiff
measur
use
vibrat
control
transient
elastographi
fibroscan
fs
liver
stiff
measur
use
magnet
reson
elastographi
mre
aim
examin
baselin
patient
characterist
relationship
lm
fs
mre
ongo
singl
site
trial
antifibrot
nash
patient
stage
three
fibrosi
http
clinicaltri
gov
method
patient
biopsi
confirm
nash
stage
fibrosi
enrol
clinic
trial
compar
placebo
patient
mgkg
patient
enrol
patient
baselin
assess
within
one
month
random
lm
perspectum
diagnost
mre
siemen
fs
echosen
result
mean
age
bmi
enrol
patient
year
respect
cohort
includ
men
women
white
hispan
one
asian
diabet
median
iqr
percentil
valu
lm
fs
mre
valu
millisecond
kpa
kpa
respect
signific
correl
fs
mre
measur
liver
stiff
r
p
two
fs
outlier
remov
correl
improv
r
p
contrast
signific
correl
lm
either
liver
stiff
measur
fs
mre
conclus
liver
stiff
measur
fs
mre
shown
relat
degre
liver
fibrosi
well
correl
cohort
nash
patient
biopsi
proven
stage
fibrosi
lm
lif
composit
steatosi
inflamm
fibrosi
well
correl
either
measur
liver
stiff
possibl
evalu
combin
fibrosi
necroinflamm
disclosur
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
adam
e
allgood
employ
galectin
therapeut
peter
g
traber
manag
posit
galectin
therapeut
follow
peopl
noth
disclos
karol
barstow
aim
bioelectr
imped
analysi
bia
safe
inexpens
simpl
reproduc
method
use
clinic
set
assess
bodi
composit
includ
total
bodi
fat
studi
sought
determin
whether
associ
total
bodi
fat
measur
bia
risk
nonalcohol
fatti
liver
diseas
nafld
whether
ad
benefit
bia
convent
bodi
fat
measur
bodi
mass
index
bmi
waist
circumfer
wc
determin
nafld
risk
method
conduct
cross
section
studi
among
subject
underw
bia
measur
bmi
wc
liver
imag
defin
nafld
presenc
hepat
steatosi
abdomin
imag
ultrasound
ct
scan
mri
absenc
viral
hepat
excess
alcohol
intak
distribut
convent
measur
bia
measur
bodi
fat
compar
case
nafld
control
without
nafld
use
logist
regress
model
adjust
age
sex
race
ethnic
addit
adjust
model
includ
bia
measur
convent
measur
bmi
wc
examin
whether
associ
bia
deriv
total
fat
nafld
risk
independ
bmi
wc
result
case
control
group
differ
age
sex
raceethn
model
adjust
age
sex
raceethn
bmi
higher
total
bodi
fat
weight
trunk
fat
weight
larger
weight
circumfer
statist
significantli
associ
increas
risk
nafld
increas
total
bodi
fat
trunk
fat
weight
statist
increas
risk
nafld
total
bodi
fat
weight
ci
fat
trunk
weight
ci
increas
waist
circumfer
increas
risk
risk
nafld
ci
howev
multivari
model
total
bodi
fat
weight
trunk
fat
weight
adjust
bmi
wc
stepwis
manner
associ
attenu
long
statist
significantli
associ
risk
nafld
wc
strongest
predictor
nafld
risk
even
presenc
bia
measur
highest
vs
lowest
tertil
adjust
total
bodi
fat
percent
ci
conclus
bia
provid
reliabl
measur
bodi
fat
associ
strongli
increas
risk
nafld
howev
seem
addit
predict
valu
bia
measur
bmi
wc
clinic
practic
disclosur
hashem
b
consult
gilead
wako
follow
peopl
noth
disclos
maya
balakrishnan
theresa
nguyen
wenker
fasiha
kanwal
aaron
p
thrift
cannabinoid
cb
receptor
g
receptor
gpcr
abundantli
express
gpcr
central
nervou
system
cn
low
express
level
peripher
tissu
howev
upregul
adipos
tissu
liver
kidney
diseas
implic
human
diseas
includ
obes
nash
diabet
diabet
nephropathi
fibrosi
previous
target
small
molecul
antagonist
treatment
obes
well
steatohepat
nash
efficaci
clinic
trial
drug
ultim
discontinu
due
undesir
central
nervou
system
cn
side
effect
hypothes
monoclon
antibodi
similar
efficaci
nash
metabol
diseas
devoid
cn
liabil
due
restrict
access
antibodi
cn
import
peripher
tissu
drive
diseas
demonstr
includ
adipocyt
macrophag
hepatocyt
hepat
stellat
cell
play
import
role
lipid
synthesi
fatti
acid
oxid
adiponectin
product
insulin
sensit
product
factor
condit
data
macrophag
hepatocyt
mous
model
metabol
diseas
demonstr
role
peripher
strengthen
data
new
gener
small
molecul
antagonist
remain
potent
anim
model
despit
limit
cn
penetr
howev
cn
drug
level
peripher
restrict
molecul
might
still
concern
monoclon
antibodi
might
suitabl
therapeut
modal
avoid
cn
effect
util
icap
technolog
stabil
gpcr
nativ
conform
select
monoclon
antibodi
receptor
identifi
panel
highli
select
binder
lead
demonstr
vitro
use
cell
line
human
hepat
stellat
cell
similar
rimonab
invers
agonist
antagon
receptor
compar
potenc
studi
rhesu
cynomolgu
monkey
show
less
found
cerebrospin
fluid
csf
label
pet
imag
demonstr
lack
cn
penetr
confirm
increas
express
increas
diseas
sever
nash
demonstr
activ
nash
model
stam
model
use
surrog
molecul
henc
believ
excit
potenti
therapeut
treatment
nash
metabol
diseas
benefit
previous
observ
small
molecul
lack
cn
liabil
commenc
clinic
trial
disclosur
ank
employ
bird
rock
bio
roger
ferrini
employ
bird
rock
bio
lei
shi
stock
sharehold
bird
rock
bio
teddi
yang
stock
sharehold
ruiyi
alan
glicklich
employ
bird
rockbio
inc
stock
sharehold
bird
roc
bio
paul
grayson
employ
bird
rock
bio
follow
peopl
noth
disclos
derek
mann
background
aim
alt
imperfectli
predict
histolog
sever
relat
alt
chang
histolog
respons
hr
treat
nash
patient
pt
suggest
confirm
help
predict
treatment
efficaci
without
need
control
liver
biopsi
assess
alt
histolog
chang
random
trial
elafibranor
ela
method
pt
treat
placebo
pbo
ela
includ
hr
defin
resolut
nash
without
fibrosi
worsen
complet
n
na
nafld
activ
score
complet
n
high
baselin
alt
althh
alt
uln
low
baselin
alt
altlow
alt
uln
analyz
effect
alt
hr
hr
also
assess
pt
alt
decreas
stabl
increas
alt
result
baselin
median
alt
higher
increas
na
iu
ml
luml
p
althigh
sever
histolog
lesion
altllow
vs
p
consid
baselin
alt
hr
rate
higher
ela
pbo
althhigh
pt
vs
respect
p
altlow
pt
differ
lower
vs
confirm
na
pt
althigh
ela
vs
pbo
p
altlow
ela
vs
pbo
compar
pbo
ela
reduc
alt
althhighh
altlow
respect
consid
alt
chang
treatment
hr
rate
higher
pt
alt
declin
stabl
increas
alt
vs
p
also
alt
chang
larger
hr
non
respond
vs
p
ela
pbo
progress
decreas
alt
observ
hr
ela
alt
reduct
higher
hr
vs
p
similarli
pbo
alt
reduct
higher
hr
vs
p
pt
declin
alt
ela
higher
hr
rate
pbo
vs
p
stronger
differ
vs
p
conclus
declin
alt
associ
histolog
improv
particularli
activ
pharmacotherapi
pt
resolv
nash
strongest
reduct
alt
higher
baselin
alt
associ
activ
diseas
better
respons
hr
ela
pbo
although
alt
reduct
absolut
predictor
hr
may
provid
import
insight
treatment
effect
disclosur
vlad
ratziu
advisori
committe
review
panel
galm
abbott
genfit
enterom
gilead
consult
tobira
intercept
exalenz
stephen
harrison
advisori
committe
review
panel
merck
nimbu
discoveri
fibrogen
intercept
cldf
zafgen
pfizer
consult
ngm
biopharmaceut
mediv
grantresearch
support
genfit
speak
teach
gilead
abbvi
cldf
merck
quentin
anste
grantresearch
support
vertex
pharmaceut
vertex
pharmaceut
vertex
pharmaceut
vertex
pharmaceut
alic
roudot
employ
genfit
sophi
megnien
employ
genfit
dean
w
hum
manag
posit
genfit
hanf
manag
posit
genfit
bart
stael
advisori
committe
review
panel
msd
consult
genfit
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
follow
peopl
noth
disclos
sven
francqu
pierr
bedossa
fouad
ben
sudrik
background
still
unknown
whether
genet
epigenet
factor
might
affect
pathogenesi
nonalcohol
fatti
liver
diseas
nafld
especi
clinic
util
genotyp
circul
histolog
featur
nafld
still
unclear
method
rate
surviv
hepatocellular
carcinoma
hcc
develop
year
investig
japanes
patient
nafld
patient
hcc
time
diagnosi
nafld
patient
develop
hcc
impact
serum
level
histolog
featur
hcc
evalu
rel
express
serum
calcul
use
compar
cycl
threshold
ct
method
spike
normal
intern
control
result
cumul
surviv
rate
end
year
respect
cumul
hcc
rate
end
year
respect
cumul
surviv
hcc
rate
vari
significantli
accord
sever
fibrosi
stage
genotyp
fibrosi
stage
gg
type
significantli
progress
cg
type
multipl
comparison
multivari
analysi
identifi
genotyp
predictor
fibrosi
stage
impact
tend
decreas
fibrosi
stage
serum
level
partli
affect
sever
steatosi
balloon
lobular
inflamm
fibrosi
stage
tend
decreas
fibrosi
stage
compar
fibrosi
stage
multivari
analysi
identifi
hcc
andor
histolog
compon
nash
morpholog
factor
independ
influenc
serum
level
diagnosi
nafld
evalu
serum
level
patient
without
hcc
significantli
higher
hcc
patient
fibrosi
stage
fibrosi
stage
longitudin
evalu
one
patient
time
year
diagnosi
nafld
hcc
serum
level
alreadi
tend
decreas
progress
fibrosi
stage
conclus
genotyp
partli
affect
histolog
featur
includ
fibrosi
stage
hcc
andor
histolog
compon
nash
affect
serum
level
independ
impact
genotyp
level
serum
tend
decreas
fibrosi
stage
prospect
studi
need
investig
impact
genotyp
serum
histolog
featur
hepatocarcinogenesi
nafld
disclosur
fumitaka
suzuki
speak
teach
bm
kenji
ikeda
speak
teach
eisai
compani
dainippon
sumitomo
pharmaceut
compani
hiromitsu
kumada
speak
teach
squibb
pharma
intern
msd
abbvi
glaxosmithklin
gilead
scienc
diainippon
sumitomo
pharma
yoshiyuki
suzuki
speak
teach
squibb
follow
peopl
noth
disclos
norio
akuta
yusuk
kawamura
satoshi
saitoh
yasuji
aras
shunichiro
fujiyama
hitomi
sezaki
tetsuya
hosaka
masahiro
kobayashi
mariko
kobayashi
background
inhibitor
newest
class
oral
diabet
agent
avail
market
import
advantag
inhibitor
favor
effect
reduct
bodi
weight
aim
aim
studi
elucid
effect
inhibitor
treatment
nafld
patient
method
retrospect
enrol
consecut
japanes
nafld
patient
treat
inhibitor
compar
chang
liver
inflamm
fibrosi
bodi
weight
end
also
assess
factor
contribut
normal
alt
level
result
mean
age
year
old
patient
male
gender
mean
bmi
patient
administ
mg
ipragliflozin
daili
mean
dose
period
day
end
bodi
weight
significantli
decreas
kg
kg
p
amelior
level
p
serum
alt
level
also
significantli
decreas
iul
iul
p
improv
index
p
final
patient
achiev
normal
alt
level
mean
reduct
weight
patient
achiev
normal
alt
level
kg
kg
patient
achiev
normal
alt
level
p
univari
logist
regress
analysi
indic
reduct
bodi
weight
per
kg
p
improv
level
per
p
factor
contribut
normal
alt
level
conclus
administr
inhibitor
led
good
glycaem
control
also
normal
alt
level
alter
index
favor
effect
bodi
weigh
reduct
disclosur
isogawa
akihiro
speak
teach
astella
pharma
inc
follow
peopl
noth
disclos
takamasa
ohki
mayuko
kondo
shigeyuki
kurosaki
kazuyoshi
funato
satoshi
kawamura
shuya
maeshima
yuki
karasawa
kentaro
kojima
michiharu
seki
nobuo
toda
kazumi
tagawa
introduct
healthi
volunt
subject
crucial
biomed
research
inadvert
inclus
subject
chronic
liver
diseas
healthi
control
compromis
studi
valid
subject
safeti
nafld
often
overlook
chronic
liver
diseas
despit
increas
preval
aim
identifi
preval
potenti
impact
nafld
presum
healthi
volunt
clinic
trial
nih
clinic
center
method
studi
subject
diagnosi
healthi
volunt
subject
studi
data
retriev
electron
databas
subject
viral
hepat
alcohol
abus
exclud
analysi
limit
subject
concomit
alt
weight
measur
subject
divid
group
healthi
alt
women
men
bmi
presum
nafld
elev
alt
bmi
indetermin
elev
alt
increas
bmi
comparison
limit
presum
nafld
healthi
subject
report
comparison
signific
p
studi
level
data
includ
trial
type
inclusionexclus
criteria
potenti
impact
recruit
nafld
subject
studi
valid
assess
protocol
result
subject
particip
healthi
volunt
clinic
trial
trial
per
subject
median
bmi
median
alt
ul
abnorm
alt
present
abnorm
weight
subject
presum
nafld
healthi
indetermin
nafld
subject
older
vs
year
higher
triglycerid
vs
mgdl
vs
mg
dl
vs
lower
vs
mgdl
trial
includ
intervent
vaccin
studi
subject
respect
nafld
impact
nafld
studi
valid
assess
high
low
none
studi
proport
nafld
subject
differ
impact
level
liver
enzym
bmi
use
screen
studi
respect
use
differ
impact
conclus
nafld
common
often
overlook
subject
enrol
healthi
volunt
clinic
trial
despit
potenti
impact
subject
safeti
valid
studi
find
disclosur
follow
peopl
noth
disclos
varun
k
takyar
anand
nath
andrea
beri
yaron
rotman
background
nonalcohol
steatohepat
nash
repres
one
common
caus
chronic
liver
diseas
associ
increas
risk
cirrhosi
hepatocellular
carcinoma
nash
one
lead
indic
liver
transplant
us
sever
observ
suggest
role
neutrophil
activ
expans
pathogenesi
nash
aim
present
studi
character
peripher
neutrophil
popul
subject
nash
method
flow
cytometr
analysi
whole
blood
use
identifi
phenotyp
convent
low
densiti
neutrophil
popul
ldg
freshli
isol
cell
intracellular
stain
assess
level
neutrophil
elastas
ne
myeloperoxidas
mpo
neutrophil
puriti
isol
whole
blood
use
platform
miltenyi
biotec
examin
direct
neutrophil
hepat
stellat
cell
hsc
hsc
line
cultur
supernat
isol
neutrophil
puriti
cultur
hour
absenc
exogen
stimul
serum
elisa
neutrophil
activ
marker
mpone
also
perform
result
thirteen
nash
subject
femal
male
recruit
major
advanc
diseas
na
subject
serv
control
ldg
level
increas
nash
subject
low
forward
side
scatter
fsc
ssc
leukocyt
compar
control
p
wilcoxin
sign
rank
ldg
popul
display
sever
phenotyp
differ
compar
convent
neutrophil
includ
decreas
express
p
case
addit
observ
differ
express
chemokinecytokin
receptor
involv
mobil
activ
neutrophil
ldg
increas
p
receptor
decreas
signific
decreas
receptor
express
nash
subject
control
also
note
p
increas
intens
intracellular
mpo
observ
convent
neutrophil
nash
subject
mfi
compar
control
mfi
p
circul
mpo
level
increas
nash
subject
vs
p
differ
seen
circul
ne
level
supernat
isol
neutrophil
enhanc
inhibit
express
hsc
stimul
conclus
taken
togeth
find
support
previous
unidentifi
role
neutrophil
pathogenesi
nash
suggest
neutrophil
may
repres
potenti
therapeut
target
amelior
diseas
disclosur
follow
peopl
noth
disclos
luci
silvia
giugliano
eric
l
campbel
linl
cheng
christin
collin
hugo
r
rosen
background
aim
nash
difficult
diagnos
stage
accept
method
liver
biopsi
patchi
natur
nash
fibrosi
caus
biopsi
sampl
error
variabl
stage
ratziu
et
al
hq
test
gener
diseas
sever
index
dsi
global
measur
liver
function
goal
pilot
studi
determin
dsi
could
diagnos
nash
assess
nash
diseas
sever
method
healthi
control
includ
normal
weight
bmi
overweight
bmi
obes
bmi
patient
center
univers
colorado
denver
baylor
univers
medic
center
dalla
nash
cryptogen
cirrhosi
concurr
obes
presum
late
stage
nash
patient
fibrosi
stage
cirrhosi
clinic
manifest
nash
diseas
sever
captur
patient
histori
includ
mediumlarg
varic
decompens
event
ascit
encephalopathi
varic
bleed
jaundic
test
involv
serum
sampl
prior
minut
simultan
administr
iv
acid
ca
oral
clearanc
ca
measur
dsi
calcul
clearanc
abil
dsi
diagnos
nash
assess
nash
diseas
sever
evalu
auroc
analys
diagnost
perform
sensit
specif
ppv
npv
optimum
cutoff
defin
maximum
youden
index
j
result
dsi
could
differenti
nash
patient
healthi
control
subject
even
overweight
obes
control
high
specif
ppv
youden
index
j
tabl
section
biopsi
diagnosi
cirrhosi
could
identifi
nash
patient
risk
mediumlarg
varic
risk
decompens
dsi
could
identifi
group
higher
much
better
specif
ppv
youden
index
j
tabl
section
b
c
conclus
test
could
altern
biopsi
diagnosi
nash
test
dsi
could
outperform
fibrosi
stage
assess
nash
diseas
sever
diagnost
perform
biopsi
disclosur
steve
helmk
patent
heldfil
univers
colorado
gregori
everson
advisori
committe
review
panel
rochegenentech
abbvi
galectin
squibb
hepc
connect
biotest
gilead
merck
board
membership
hepquant
llc
psc
partner
hepquant
llc
consult
abbvi
bm
gilead
squibb
grantresearch
support
rochegenentech
abbvi
squibb
merck
psc
partner
gilead
manag
posit
hepquant
llc
hepquant
llc
patent
heldfil
univ
colorado
speak
teach
abbvi
follow
peopl
noth
disclos
john
marr
michael
w
cookson
jennif
desanto
shannon
lauriski
jame
f
trotter
natur
killer
nkt
cell
invari
mait
cell
cell
evolutionarili
conserv
cell
receptor
enrich
liver
respond
inflammatori
cytokin
nkt
cell
also
recogn
lipid
antigen
mait
cell
also
recogn
riboflavin
metabolit
produc
bacteria
aim
examin
role
nkt
mait
cell
nonalcolhol
fatti
liver
diseas
nafld
method
multicolor
flow
cytometri
perform
pair
blood
liver
sampl
clinic
well
character
nafld
patient
comparison
use
blood
sampl
healthi
volunt
pair
blood
liver
biopsi
patient
chronic
hepat
c
viral
clearanc
result
correl
bmi
liver
fat
mri
spectroscopi
alt
result
nafld
patient
lower
frequenc
mait
cell
blood
healthi
control
nkt
mait
cell
activ
healthi
control
hcv
patient
evidenc
increas
express
fasl
nkt
cell
increas
express
mait
cell
nkt
mait
cell
nafld
patient
express
increas
level
degranul
cytotox
marker
ifni
tnfa
product
nkt
cell
impair
upon
vitro
stimul
cytokin
cell
receptor
ligand
agalc
nafld
patient
nkt
mait
cell
frequent
activ
liver
peripher
blood
nkt
cell
express
correl
alt
level
liver
fat
content
respect
similarli
liver
mait
cell
frequenc
correl
liver
fat
express
molecul
mait
cell
correl
alt
level
bmi
respect
cytokin
within
normal
limit
plasma
nafld
patient
except
increas
level
cytokin
produc
activ
monocytesmacrophag
known
activ
nkt
mait
cell
increas
monocyt
activ
confirm
express
increas
macrophag
activ
level
plasma
conclus
nkt
mait
cell
share
activ
cytotox
phenotyp
nafld
patient
may
driven
activ
monocytesmacrophag
frequenc
activ
statu
liver
nkt
mait
cell
correl
clinic
diseas
paramet
nash
suggest
role
cell
diseas
pathogenesi
disclosur
follow
peopl
noth
disclos
elisavet
serti
jen
werner
meghan
kean
fabian
j
bolt
shilpa
lingala
nevitt
morri
jake
liang
yaron
rotman
barbara
rehermann
background
aim
liver
stiff
measur
lsm
frequent
overestim
sever
liver
fibrosi
nonalcohol
fatti
liver
diseas
nafld
control
attenu
paramet
cap
new
paramet
provid
machin
use
lsm
associ
steatosi
bmi
two
factor
mostli
affect
lsm
peform
nafld
aim
determin
wheter
predict
liver
fibrosi
lsm
nafld
patient
affect
cap
valu
method
patient
assess
clinic
histolog
kleiner
score
featur
lsm
cap
perform
use
probe
cap
valu
group
tertil
lower
middl
higher
form
dbm
result
among
patient
fibrosi
mean
lsm
express
increas
accord
cap
tertil
vs
vs
along
line
auc
lsm
diagnosi
fibrosi
progress
reduc
lower
middl
higher
cap
tertil
consequ
subject
fibrosi
rate
lsm
result
fibrosi
increas
accord
cap
tertil
lower
vs
middl
vs
higher
consist
decision
predicit
fibrosi
suggest
combin
lsm
cap
valu
conclus
patient
nafld
cap
valu
alway
taken
account
order
avoid
overestim
liver
fibrosi
assess
te
disclosur
vincent
w
wong
advisori
committe
review
panel
abbvi
gilead
janssen
tobira
consult
merck
novamedica
speak
teach
gilead
echosen
grace
l
h
wong
speak
teach
echosen
echosen
echosen
echosen
fabio
marra
consult
bayer
healthcar
abbvi
astrazeneca
grant
research
support
viiv
speak
teach
gilead
henri
chan
advisori
committe
review
panel
gilead
janssen
squibb
roch
novarti
pharmaceut
abbvi
speak
teach
echosen
victor
de
ledinghen
board
membership
janssen
gilead
bm
abbvi
intercept
pharma
superson
imagin
grantresearch
support
superson
imagin
speak
teach
abbvi
merck
bm
gilead
follow
peopl
noth
disclos
salvator
petta
calogero
hiriart
julien
vergniol
anthoni
w
chan
vito
di
marco
wassil
merrouch
marco
barbara
brigitt
le
bail
umberto
arena
antonio
craxi
background
blood
test
liver
injuri
less
well
valid
nafld
patient
chronic
viral
hepat
aim
improv
valid
three
blood
test
use
nafld
patient
fibrotest
fibrosi
stage
steatotest
steatosi
grade
actitest
inflamm
activ
grade
method
new
nafld
patient
biopsi
blood
test
cohort
fibrofr
multicent
flip
consortium
contemporan
biopsi
blindli
assess
use
new
saf
score
provid
reliabl
reproduc
diagnosi
grade
stage
three
elementari
featur
nafld
steatosi
inflammatori
activ
fibrosi
reduc
interobserv
variabl
use
nonbinroc
main
endpoint
prevent
spectrum
effect
multipl
test
result
total
patient
reliabl
test
biopsi
includ
steatosi
sever
sever
activ
bridg
cirrhosi
median
nonbinroc
ci
test
signific
p
fibrotest
fibrosi
stage
actitest
activ
grade
steatotest
steatosi
grade
signific
result
persist
sensit
analys
stratifi
cohort
popul
gender
biopsi
length
time
interv
diabet
sever
obes
median
fibrotest
valu
increas
p
steadili
fibrosi
stage
rang
cirrhosi
none
fibrosi
test
nafld
fibrosi
score
bard
score
score
signific
increas
fibrosi
stage
actitest
median
valu
increas
p
two
featur
saf
activ
score
balloon
lobular
inflamm
balloon
valu
absenc
moder
sever
signific
differ
grade
lobular
inflamm
valu
absenc
moder
sever
signific
differ
adjac
stage
p
conclus
patient
nafld
steatotest
actitest
fibrotest
test
limit
may
offer
altern
biopsi
correl
simpl
gradingstag
saf
score
system
across
three
elementari
featur
nafld
steatosi
inflammatori
activ
fibrosi
disclosur
mona
munteanu
employ
biopredict
quentin
anste
advisori
committe
review
panel
intercept
consult
genfit
eli
lilli
pfizer
inventiva
imperi
innov
grantresearch
support
abbvi
gsk
giulio
marchesini
advisori
committe
review
panel
board
membership
genfit
gilead
glaxo
novarti
grantresearch
support
merck
sharp
dome
speak
teach
novo
nordisk
merck
sharp
dome
boerhing
ingelheim
eli
lilli
michael
h
trauner
consult
albireo
falk
phenex
gilead
novarti
msd
grantresearch
support
falk
albireo
intercept
dufour
advisori
committe
review
panel
bayer
bm
gilead
abbvi
novarti
sillagen
genfit
intercept
yen
ngo
employ
biopredict
stefan
traussnigg
grantresearch
support
phenex
pharmaceut
vlad
ratziu
advisori
committe
review
panel
galm
abbott
genfit
enterom
gilead
consult
tobira
intercept
exalenz
thierri
poynard
advisori
committe
review
panel
merk
grantresearch
support
gilead
stock
sharehold
biopredict
follow
peopl
noth
disclos
dina
tiniako
freder
charlott
elisabetta
bugianesi
claudia
p
oliveira
christof
day
stefano
bellentani
pierr
bedossa
background
hepat
steatosi
hs
common
person
hepat
c
viru
hcv
human
immunodefici
viru
hiv
infect
independ
contribut
hcv
hiv
hs
unclear
method
magnet
reson
imag
spectroscopi
use
measur
viscer
adipos
tissu
vat
hs
adult
hiv
uninfect
control
subject
genotyp
hcv
exclud
due
genotyp
report
steatogen
effect
preval
estim
hs
defin
mr
triglycerid
content
total
lipid
total
lipid
water
multivari
linear
regress
model
use
determin
associ
hiv
hcv
statu
hs
level
result
preval
hs
highest
control
follow
fect
across
group
compar
control
adjust
demograph
lifestyl
metabol
factor
hcv
monoinfect
hivhcv
coinfect
associ
ci
ci
less
hs
respect
hiv
monoinfect
significantli
differ
adjust
apri
hcv
monoinfect
hivhcv
coinfect
remain
associ
ci
ci
less
hs
respect
exclud
subject
suspect
cirrhosi
chang
result
hispan
ethnic
male
sex
vat
independ
associ
greater
hs
conclus
contrari
expect
adult
less
hs
control
even
adjust
demograph
lifestyl
metabol
factor
fibrosi
exclud
cirrhot
find
suggest
hcv
infect
may
protect
hs
mechan
occur
impact
hcv
treatment
hs
need
investig
disclosur
jennif
c
price
grantresearch
support
gilead
stock
sharehold
bm
johnson
johnson
abbvi
merck
marion
g
peter
advisori
committe
review
panel
j
j
gilead
roch
abbott
consult
merck
employ
hoffman
la
roch
follow
peopl
noth
disclos
yifei
rebecca
scherzer
natali
korn
kyle
tillinghast
susan
noworolski
phylli
tien
backgroundaim
nonalcohol
fatti
liver
diseas
nafld
associ
increas
risk
coronari
arteri
diseas
addit
advanc
fibrosi
nafld
patient
associ
cardiovascular
diseas
overal
mortal
therefor
investig
associ
coronari
atherosclerosi
noninvas
fibrosi
marker
detect
high
risk
popul
coronari
arteri
diseas
method
januari
decemb
total
subject
nafld
analyz
nafld
diagnos
ultrasonographi
st
vincent
hospit
heath
promot
center
coronari
atherosclerosi
repres
coronari
arteri
calcif
score
cac
assess
cardiac
comput
tomographi
nafld
fibrosi
score
nf
score
aspart
aminotransferas
ast
platelet
ratio
index
apri
score
forn
index
use
noninvas
fibrosi
marker
result
mean
age
studi
popul
year
subject
male
univari
analysi
high
cac
significantli
associ
old
age
year
diabet
mellitu
serum
glucos
estim
glomerular
filtrat
rate
gfr
ps
seem
associ
hypertens
bodi
mass
index
ps
multivari
analysi
old
age
male
gender
signific
risk
factor
p
p
nf
forn
index
significantli
associ
high
cac
ps
nf
score
significantli
factor
even
adjust
tradit
risk
factor
p
p
auroc
nf
predict
high
cac
valu
respect
conclus
hepat
fibrosi
assess
noninvas
fibrosi
marker
nf
independ
associ
high
cac
therefor
noninvas
fibrosi
marker
help
detect
high
risk
popul
coronari
arteri
diseas
disclosur
jinmo
yang
employ
cathol
univers
follow
peopl
noth
disclos
seon
song
u
im
chang
jeong
jang
si
hyun
bae
seung
kew
yoon
se
hyun
cho
background
aim
augment
patient
nonalcohol
fatti
liver
diseas
nafld
becom
big
problem
industri
countri
present
hepatocarcinogenesi
relat
nafld
addit
critic
issu
solv
urgent
despit
mani
energet
investig
detail
patholog
mechan
hepatocarcinogenesi
patient
nafld
obscur
cours
hepatocellular
carcinoma
hcc
develop
liver
even
though
steatot
patient
posit
serum
hepat
virus
recogn
one
hand
occult
hepat
b
viru
hbv
infect
consid
one
potenti
factor
hepatocarcinogenesi
especi
area
hypothes
occult
hbv
may
contribut
hepatocarcinogenesi
carri
follow
molecular
patholog
studi
method
nine
nafld
patient
men
women
yr
diagnos
patholog
hcc
subject
studi
besid
clinic
laboratori
data
analyz
liver
tissu
specimen
portion
histolog
polymeras
chain
reaction
pcr
hbv
genom
studi
dna
extract
five
section
tissu
pcr
perform
use
hbv
x
primer
sampl
shown
posit
result
examin
direct
sequenc
result
patient
case
metabol
factor
diabet
dyslipidemia
obes
hypertens
factor
one
posit
hepat
b
surfac
antigen
patient
posit
hepat
b
core
antibodi
collect
everi
patient
either
diabet
posit
histolog
portion
show
cirrhosi
case
mild
perivenular
fibrosi
case
dna
sampl
case
pcr
amplicon
expect
size
gener
one
prove
target
hbv
x
gene
segment
direct
sequenc
case
simpl
steatosi
without
fibrosi
metabol
factor
conclus
present
studi
reveal
japan
hepatocarcinogenesi
least
part
associ
occult
hbv
infect
addit
result
suggest
diabet
liver
histolog
might
use
predictor
hepatocarcinogenesi
disclosur
follow
peopl
noth
disclos
yoshihiro
ikura
kenichi
harada
tatsuya
osuga
backgroundaim
predictor
mortal
liver
decompens
help
determin
prognosi
thu
influenc
manag
patient
fatti
liver
diseas
nafld
examin
accuraci
four
clinic
model
predict
mortal
liver
relat
event
nafld
method
hepascor
nafld
fibrosi
score
nf
apri
fib
score
calcul
time
biopsi
patient
nafld
tertiari
centr
patient
follow
outcom
overal
mortalityliv
transplant
occurr
first
event
hepat
decompens
analysi
includ
multivari
cox
proport
hazard
model
c
statist
test
model
calibr
result
total
patient
mean
age
year
women
bmi
type
diabet
follow
mean
year
rang
patient
die
underw
liver
transplant
develop
liver
relat
event
hepascor
hazard
ratio
hr
confid
interv
ci
nf
hr
ci
apri
hr
ci
hr
ci
associ
overal
mortal
hr
liver
relat
event
ci
ci
ci
ci
hepascor
nf
apri
fib
respect
nf
hepascor
similar
predict
accuraci
overal
mortalityliv
transplant
liver
relat
event
outcom
tabl
model
calibr
well
differ
observ
predict
risk
overal
mortalityliv
transplant
conclus
score
system
use
tool
predict
overal
mortal
liver
relat
event
nafld
patient
accord
predefin
risk
group
c
index
four
score
system
predict
outcom
valu
repres
c
statist
standard
error
ci
disclosur
leon
adam
patent
heldfil
quest
diagnost
follow
peopl
noth
disclos
lui
c
bertot
gari
p
jeffrey
gerri
c
macquillan
georg
gara
yi
huang
recent
studi
indic
increas
preval
hepat
steatosi
steatohepat
nash
sever
alimentari
tract
diseas
includ
inflammatori
bowel
diseas
ibd
other
shown
nash
ibd
patient
associ
increas
suscept
liver
failur
date
littl
known
mechan
lead
hepat
steatosi
ibd
studi
aim
analyz
compar
predictor
liver
injuri
patient
nash
individu
crohn
diseas
cd
therefor
includ
patient
establish
nash
patient
establish
cd
without
histori
liver
diseas
analyz
serum
marker
liver
injuri
breath
test
small
intestin
bacteri
overgrowth
sibo
transient
elastographi
well
control
attenu
paramet
cap
assess
hepat
steatosi
expect
patient
nash
significantli
higher
bmi
compar
cd
accordingli
alt
ast
level
significantli
higher
nash
vs
cd
sibo
occur
two
individu
associ
steatosi
interestingli
transient
elastographi
reveal
increas
liver
stiff
nash
vs
cd
signific
differ
cap
measur
hepat
steatosi
group
fact
cd
patient
cap
previous
establish
cutoff
valu
signific
hepat
steatosi
maximum
cap
one
patient
although
patient
remain
within
normal
limit
ast
alt
significantli
higher
cd
patient
cap
compar
cd
patient
lower
cap
result
order
identifi
condit
associ
higher
cap
result
review
patient
drug
regimen
surpris
steroid
therapi
associ
cap
cohort
howev
individu
cap
like
treat
biolog
fact
cap
significantli
lower
patient
biolog
compar
treatment
strategi
vs
dbm
p
thu
cohort
nash
associ
higher
bmi
transaminas
level
liver
stiff
hepat
steatosi
assess
cap
pronounc
compar
cd
cd
patient
signific
steatosi
higher
transaminas
level
indic
sublimin
hepat
inflamm
despit
within
normal
level
treatment
biolog
seem
protect
cd
patient
hepat
steatosi
conlus
identifi
high
rate
hepat
steatosi
cd
alter
transaminas
level
potenti
associ
biolog
disclosur
follow
peopl
noth
disclos
katharina
willuweit
malt
brandenburg
svenja
sydor
sophia
assmuth
annemari
wegehaupt
sonja
kinner
alisan
kahraman
guido
gerken
ali
canbay
lar
bechmann
background
approxim
western
popul
suffer
nafld
rise
obes
peopl
complic
nafld
includ
non
alcohol
steatohepat
nash
liver
cirrhosi
hepatocellular
carcinoma
well
aggrav
diabet
cardiovascular
diseas
import
genet
factor
associ
nafld
aim
studi
analyz
efficaci
standard
low
calori
liver
diet
hepafast
bodym
kirkel
germani
especi
compound
nafld
patient
pt
influenc
genotyp
treatment
outcom
method
studi
non
cirrhot
patient
stratifi
accord
genotyp
patient
per
group
cc
cg
gg
patient
receiv
protein
shake
therapi
hepafast
week
instruct
follow
low
glycem
insulinem
logi
diet
anoth
week
eot
patient
seen
longitudin
four
time
point
baselin
week
month
time
point
liver
fat
content
assess
independentblind
investig
fibroscan
cap
addit
fatti
liver
index
fli
waist
circumfer
wc
bmi
hbalc
triglycerid
tg
ggt
analyz
result
date
patient
includ
studi
pt
age
genotyp
finish
hepafast
shake
therapi
baselin
week
outcom
variabl
decreas
till
week
second
time
point
fibroscan
cap
p
fli
p
wc
p
bmi
p
tg
p
ggt
p
evalu
accord
genotyp
reveal
higher
fibroscan
cap
drop
carrier
cc
vs
carrier
patient
finish
month
treatment
period
includ
logi
diet
fibroscan
cap
decreas
baselin
month
p
conclus
low
calori
diet
hepafast
shake
effect
strategi
significantli
lower
liver
fat
nafld
patient
effect
seem
pronounc
patient
carri
disclosur
manuela
teufelhart
grantresearch
support
bodym
harald
hofer
advisori
committe
review
panel
gilead
abbvi
speak
teach
janssen
bm
gilead
abbvi
peter
ferenc
advisori
committe
review
panel
idenix
gilead
msd
janssen
salix
abbvi
bm
wilson
therapeut
patent
heldfil
madau
rottapharm
speak
teach
gilead
roch
michael
h
trauner
consult
albireo
falk
phenex
gilead
novarti
msd
grantresearch
support
falk
albireo
intercept
follow
peopl
noth
disclos
helmuth
haslach
robert
winker
bernhard
meyer
benedikt
mehl
christian
rabitsch
sonja
nistler
scherzer
background
liver
biopsi
lb
gold
standard
tool
evalu
fibrosi
nafld
patient
five
simpl
noninvas
serum
test
use
routin
evalu
laboratori
valu
use
evalu
fibrosi
nafld
score
nafld
fibrosi
score
nf
aspart
aminotransferas
ast
platelet
ratio
index
apri
ast
alanin
transaminas
astalt
ratio
bard
bmi
astalt
ratio
diabet
score
data
compar
accuraci
score
scanti
aim
compar
diagnost
util
score
among
nafld
patient
seen
tertiari
academ
center
method
medic
chart
well
defin
nafld
patient
lb
review
collect
data
demograph
laboratori
valu
need
comput
five
score
compar
fibrosi
stage
lb
patient
concomit
hepat
c
alcohol
use
gd
liver
diseas
exclud
fibrosi
stage
liver
biopsi
stage
stratifi
minim
fibrosi
advanc
fibrosi
cirrhosi
accuraci
score
area
receiv
oper
characterist
auroc
curv
deriv
score
system
result
nafld
patient
mean
age
year
male
white
diabet
hypertens
dyslipidemia
gastric
bypass
cut
valu
use
predict
fib
nf
apri
ast
alt
ratio
bard
score
respect
valu
predict
accuraci
auroc
score
depict
tabl
overal
combin
use
five
simpl
score
order
auroc
accur
predict
fibrosi
stage
potenti
avoid
lb
nafld
patient
conclus
avail
fibrosi
score
nafld
patient
accur
combin
use
fibrosi
score
simpl
noninvas
tool
accur
predict
fibrosi
reduc
need
lb
prospect
studi
need
incorpor
liver
stiff
measur
serum
fibrosi
score
improv
accuraci
assess
fibrosi
nafld
patient
tabl
predict
accuraci
fibrosi
score
nafld
disclosur
follow
peopl
noth
disclos
sumant
arora
steven
young
ashwani
singal
background
nonalcohol
fatti
liver
nafld
usual
diagnos
context
metabol
syndrom
howev
uncommon
caus
nafld
lysosom
acid
lipas
lal
defici
lal
rare
autosom
recess
disord
caus
decreas
absenc
lal
enzym
respons
break
fat
lysosom
two
major
phenotyp
lal
defici
identifi
earli
onset
also
known
wolman
diseas
occur
infant
ii
late
onset
also
known
cholesteryl
ester
storag
diseas
cesd
occur
children
adult
aim
studi
evalu
possibl
cesd
caus
nafld
adult
patient
lack
typic
predispos
featur
nafld
hepatolog
practic
method
consecut
patient
diagnos
nafld
liver
associ
texa
hepatolog
clinic
june
march
screen
risk
factor
nafld
screen
criteria
favor
possibl
lal
defici
atyp
nafld
patient
use
patient
select
ldl
defici
test
dyslipidemia
low
level
dl
male
femal
andor
low
triglycerid
level
andor
persist
elev
despit
statin
therapi
eleven
patient
nafld
met
criteria
identifi
studi
patient
offer
consent
particip
lal
defici
diagnost
test
base
lal
enzym
activ
test
acid
lipas
blood
spot
statist
analysi
analys
perform
use
spss
result
studi
group
includ
six
male
five
femal
mean
age
patient
year
sd
mean
bodi
mass
index
bmi
sd
mean
alt
ul
sd
mean
ast
ul
sd
mean
nafld
fibrosi
score
sd
patient
liver
cirrhosi
mean
lal
blood
spot
patient
pmolehrspt
sd
mean
within
normal
refer
rang
lal
enzym
pmole
hrspt
conclus
studi
suggest
lal
defici
common
caus
atyp
nafld
subset
nafld
patient
need
studi
clarifi
risk
factor
better
defin
phenotyp
disclosur
scott
zela
advisori
committe
review
panel
gilead
speak
teach
merck
vertex
victor
advisori
committe
review
panel
genentech
grant
research
support
gilead
scienc
novarti
johnson
johnson
salix
genentech
bm
abbvi
speak
teach
merck
vertex
bm
abbvi
follow
peopl
noth
disclos
khalid
abdullah
robind
abrol
herman
ortiz
maria
welsh
chukwuma
egwim
insulin
resist
associ
nonalcohol
fatti
liver
diseas
nafld
lactat
lower
blood
glucos
triglycerid
increas
insulin
sensit
hypothes
longer
durat
lactat
would
associ
lower
preval
nafld
particip
multicent
coronari
arteri
risk
develop
young
adult
cardia
prospect
cohort
studi
deliv
birth
underw
ct
quantif
hepat
steatosi
year
follow
cohort
entri
includ
n
durat
lactat
defin
birth
nafld
assess
central
review
ct
imag
defin
liver
attenu
hounsfield
unit
exclus
caus
hepat
steatosi
unadjust
multivari
logist
regress
analys
perform
use
priori
set
confound
variabl
age
race
educ
bodi
mass
index
bmi
birth
vs
confound
variabl
backward
stepwis
elimin
includ
final
multivari
model
parou
women
black
white
mean
age
year
exam
report
lactat
report
month
report
month
report
month
nafld
longer
lactat
durat
associ
white
race
lower
bmi
baselin
visit
p
longer
lactat
durat
invers
associ
nafld
unadjust
logist
regress
per
increas
ci
associ
strengthen
aor
per
increas
ci
adjust
potenti
confound
tabl
conclus
longer
durat
lactat
associ
lower
odd
nafld
adjust
confound
lactat
modifi
risk
factor
may
reduc
nafld
parou
women
associ
characterist
women
nafld
year
multivari
model
determin
backward
stepwis
elimin
race
bmi
lactat
durat
final
model
disclosur
norah
terrault
advisori
committe
review
panel
eisai
biotest
consult
bm
merck
achillion
cocryst
grantresearch
support
eisai
biotest
vertex
gilead
abbvi
novarti
merck
cora
e
lewi
grantresearch
support
nih
novo
nordisk
follow
peopl
noth
disclos
veeral
h
ajmera
lisa
b
vanwagn
monika
sarkar
john
j
carr
erica
gunderson
background
elev
liver
chemistri
ultrasound
diagnos
fatti
liver
associ
atrial
fibril
af
independ
tradit
af
risk
factor
af
potent
risk
factor
stroke
associ
poor
outcom
transplant
nonalcohol
steatohepat
nash
cirrhosi
preval
af
patient
nash
nash
cirrhosi
unknown
purpos
assess
preval
impact
af
healthcar
util
patient
nash
nash
cirrhosi
method
patient
nash
nash
cirrhosi
identifi
use
bill
code
tertiari
care
center
electron
databas
nashcirrhosi
confirm
independ
review
liver
biopsi
report
center
code
identifi
presenc
comorbid
af
preval
squar
fisher
exact
test
use
compar
medic
usag
comorbid
well
hospit
length
stay
patient
nash
af
versu
patient
nash
without
af
result
patient
diagnosi
nashcirrhosi
patient
coexist
diagnosi
af
nashcirrhosi
mean
age
nashcirrhosi
patient
year
male
preval
af
nash
nash
cirrhosi
patient
patient
nashcirrhosi
af
older
vs
year
higher
preval
hypertens
vs
heart
failur
vs
cerebrovascular
vs
vascular
diseas
vs
compar
without
af
among
nash
cirrhosi
patient
score
indic
high
stroke
risk
need
anticoagul
patient
anticoagul
patient
agent
patient
receiv
cardiovers
ablat
patient
nash
af
hospit
visit
vs
longer
hospit
stay
compar
without
af
vs
day
conclus
af
preval
higher
patient
nash
nash
cirrhosi
compar
gener
popul
estim
patient
concurr
nashcirrhosi
af
high
burden
stroke
heart
failur
healthcar
util
howev
nashaf
patient
receiv
anticoagul
despit
indic
base
score
futur
studi
need
identifi
risk
nash
patient
af
encourag
manag
may
improv
af
outcom
impact
cardiovascular
outcom
burgeon
nash
popul
disclosur
mari
e
rinella
advisori
committe
review
panel
abbvi
intercept
consult
fibrogen
ngm
shire
follow
peopl
noth
disclos
maureen
p
whitsett
ami
yang
lisa
b
vanwagn
backgroundobject
nonalcohol
fatti
liver
diseas
nafld
worldwid
public
health
concern
coffe
might
protect
effect
nafld
howev
result
previou
report
conflict
therefor
conduct
summar
avail
data
method
studi
consist
two
first
includ
observ
studi
compar
risk
nafld
drink
coffe
second
analysi
includ
studi
compar
risk
liver
fibrosi
nafld
patient
drink
coffe
pool
odd
ratio
confid
interv
ci
calcul
result
articl
five
studi
met
elig
criteria
includ
analysi
risk
nafld
subject
drank
coffe
significantli
lower
subject
pool
ci
also
found
significantli
decreas
risk
liver
fibrosi
among
nafld
patient
drank
coffe
compar
pool
ci
conclus
studi
demonstr
significantli
decreas
risk
nafld
among
coffe
drinker
significantli
decreas
risk
liver
fibrosi
among
patient
nafld
drank
coffe
regular
basi
whether
consumpt
coffe
could
consid
prevent
measur
nafld
need
investig
forest
plot
includ
studi
impact
coffe
presenc
nafld
liver
fibrosi
nafld
disclosur
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
patompong
ungprasert
purpos
nash
liver
inflamm
balloon
degener
condit
caus
accumul
fat
deposit
liver
lead
fibrosi
symptom
typic
emerg
later
diseas
approv
therapi
exist
current
guidelin
recommend
lifestyl
chang
treat
associ
condit
advanc
stage
may
requir
liver
transplant
systemat
literatur
review
perform
defin
knowledg
base
relat
treatment
nash
method
literatur
databas
search
supplement
confer
abstract
identifi
studi
report
treatment
pattern
guidelin
outcom
nash
result
last
year
articl
examin
treatment
nash
major
trial
assess
pharmacolog
treatment
supplement
observ
studi
evalu
surgic
intervent
mainli
liver
transplant
nash
therapi
option
differ
around
world
diet
lifestyl
chang
studi
worldwid
shown
improv
liver
enzym
histolog
measur
altern
therapi
demonstr
benefit
wide
studi
pioglitazon
studi
europ
us
india
consist
reduc
liver
enzym
also
significantli
improv
histolog
measur
steatosi
lobular
inflamm
effect
balloon
fibrosi
vari
us
india
rosiglitazon
significantli
improv
liver
enzym
compar
baselin
level
well
score
evalu
histolog
measur
studi
howev
compar
placebo
european
trial
show
effect
histolog
measur
vitamin
e
demonstr
benefit
us
european
studi
vitamin
e
statist
improv
na
score
liver
enzym
level
rel
baselin
valu
placebo
significantli
improv
fibrosi
score
combin
ursodeoxychol
acid
significantli
decreas
hepat
steatosi
evid
treatment
pattern
nash
limit
vitamin
e
pioglitazon
prescrib
nash
patient
gastroenterologist
survey
hepatologist
conclus
pharmacolog
treatment
glitazon
vitamin
e
demonstr
variabl
perform
trial
commonli
led
histolog
improv
reduct
liver
enzym
nash
patient
whether
treatment
effect
halt
diseas
progress
cirrhosi
unknown
world
studi
larger
sampl
size
need
document
treatment
use
outcom
clinic
practic
approv
treatment
remain
unmet
need
manag
nash
disclosur
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
uptod
elsevi
manag
posit
sanyal
biotechnolog
amber
l
martin
consult
astrazeneca
karin
henriksson
employ
astrazeneca
r
bernt
kartman
employ
astrazeneca
stock
sharehold
astrazeneca
follow
peopl
noth
disclos
sarah
cadarett
mark
berner
hansen
background
non
alcohol
steatohepat
nash
present
show
signific
ethnic
divers
us
popul
aim
understand
differ
area
high
endem
obes
metabol
syndrom
use
databas
tertiari
referr
center
method
conduct
retrospect
analysi
patient
seen
follow
liver
institut
one
satellit
clinic
diagnosi
nash
base
icd
code
januari
jan
exclud
patient
incomplet
data
lost
follow
data
liver
biopsi
imag
lab
demograph
comorbid
link
metabol
syndrom
collect
irb
exempt
obtain
retrospect
analysi
data
result
analyz
chart
patient
complet
inform
patient
present
abnorm
lft
alt
uln
patient
present
fatti
liver
imag
entir
cohort
femal
self
report
race
distribut
caucasian
other
median
age
present
cohort
year
vari
differ
ethnic
group
hispan
asian
present
younger
age
other
differ
bmi
present
minor
racial
group
except
asian
patient
cirrhosi
present
either
biopsi
imag
characterist
sign
portal
hypertens
imag
endoscopi
term
metabol
syndrom
patient
diabet
patient
hypertens
patient
hyperlipidemia
present
patient
ethnic
distribut
bridg
fibrosi
cirrhosi
present
caucasian
hispan
differ
characterist
diseas
sever
present
tabl
conclus
present
analysi
larg
singl
center
tertiari
referr
center
databas
patient
nash
repres
cohort
southwest
region
us
term
ethnic
mix
asian
hispan
american
tend
present
younger
age
patient
present
cirrhosi
highlight
need
earli
referr
fibrosi
assess
patient
ethnic
divers
nash
present
disclosur
parvez
mantri
consult
salix
gilead
janssen
abbvi
bm
grant
research
support
salix
merck
gilead
mass
biolog
vital
therapi
santari
mass
biolog
squibb
abbiv
shinogi
tacer
intercept
speak
teach
gilead
janssen
salix
jeffrey
weinstein
speak
teach
merck
hector
e
nazario
speak
teach
merck
gilead
abbvi
janssen
follow
peopl
noth
disclos
ashwini
p
mehta
paul
hess
anup
kumar
maisha
barn
mangesh
pagadala
adil
habib
purpos
nafld
associ
higher
risk
complic
mortal
natur
histori
data
remain
limit
aim
examin
diseas
present
natur
histori
nafld
ethnic
divers
cohort
method
analys
retrospect
cohort
consecut
nafld
patient
asian
caucasian
hispan
seen
medic
center
ethnic
nafld
diagnos
imaginghistolog
evalu
exclus
criteria
hepat
heavi
alcohol
use
inflammatorygenet
liver
diseas
studi
endpoint
develop
nash
cirrhosi
decompens
liver
cancer
death
result
asian
like
male
lower
mean
bmi
vs
p
major
hispan
femal
present
younger
age
vs
year
p
asian
hyperlipidemia
vs
hypercholesterolemia
vs
howev
three
group
similar
rate
hypertens
diabet
coronari
arteri
diseas
three
group
similar
lowintermediatehigh
probabl
fibrosi
per
ast
platelet
ratio
score
asian
less
like
high
probabl
fibrosi
per
nafld
fibrosi
score
vs
p
multivari
analysi
demonstr
older
age
higher
bmi
diabet
hispan
ethnic
significantli
associ
nashhigh
probabl
fibrosi
baselin
median
month
three
group
similar
cumul
incid
rate
nash
cirrhosi
decompens
mortal
multivari
cox
proport
hazard
model
also
inclus
age
sex
bmi
diabet
ethnic
nashhigh
probabl
fibrosi
baselin
significantli
associ
develop
cirrhosi
mortal
ci
mortal
among
patient
nashhigh
probabl
fibrosi
estim
compar
patient
nafldlow
probabl
fibrosi
conclus
despit
differ
diseas
present
diseas
sequela
nafld
nash
cirrhosi
decompens
mortal
similar
among
asian
caucasian
hispan
patient
nashhigh
probabl
fibrosi
diseas
present
may
benefit
closer
diseas
monitor
reduc
mortal
disclosur
mindi
h
nguyen
advisori
committe
review
panel
squibb
gilead
consult
gilead
scienc
inc
grantresearch
support
gilead
scienc
inc
squibb
follow
peopl
noth
disclos
nghiem
b
ha
richard
h
le
sam
trinh
michael
nguyen
benjamin
yip
joseph
k
hoang
background
aim
nonalcohol
fatti
liver
diseas
nafld
one
common
liver
diseas
western
asian
countri
liver
biopsi
gold
standard
definit
diagnosi
steatohepat
nash
howev
liver
biopsi
pain
costli
risk
bleed
sever
laboratori
marker
includ
protein
crp
ponectin
cytokeratin
hyaluron
acid
ha
reportedli
use
differenti
nash
fatti
liver
nafl
howev
report
compar
marker
ident
patient
investig
util
marker
diagnosi
nash
method
total
nafld
patient
underw
liver
biopsi
investig
nash
nafl
diagnos
matteoni
classif
type
classifi
nafl
type
classifi
nash
measur
follow
marker
addit
routin
laboratori
examin
patient
ha
type
iv
total
ck
fragment
adiponectin
human
tissu
inhibitor
matrix
metallopeptidas
branch
chain
amino
acidtyrosin
molar
ratio
btr
astalt
apri
forn
index
nafld
fibrosi
score
investig
abil
marker
predict
nash
nafld
result
patient
diagnos
nash
histolog
nash
patient
degre
fibrosi
patient
degre
fibrosi
accord
brunt
classif
multipl
logist
regress
analysi
identifi
ha
odd
ratio
ci
ci
fck
ci
p
factor
independ
associ
diagnosi
nash
auroc
ha
diagnosi
nash
ci
ci
ci
respect
ci
ci
p
could
differenti
nash
nafl
even
exclud
patient
nash
advanc
fibrosi
auroc
diagnosi
nash
mild
fibrosi
nafld
ci
ci
respect
conclus
sever
laboratori
marker
use
predict
nash
patient
nafld
abil
predict
nash
even
focus
nash
mild
fibrosi
disclosur
follow
peopl
noth
disclos
natsuko
kobayashi
takashi
kumada
hidenori
toyoda
toshifumi
tada
background
person
live
hiv
high
risk
nonalcohol
steatohepat
nash
howev
data
nash
hiv
scarc
method
conduct
prospect
screen
studi
preval
predictor
nash
unselect
hiv
patient
serum
biomark
cytokeratin
transient
elastographi
te
associ
control
attenu
paramet
cap
patient
signific
alcohol
intak
coinfect
hepat
b
c
exclud
nash
defin
presenc
fatti
liver
cap
dbm
ul
case
defin
nash
offer
liver
biopsi
signific
liver
fibrosi
cirrhosi
stage
respect
defin
te
measur
kpa
respect
predictor
nash
determin
use
multivari
logist
regress
analysi
result
consecut
hiv
patient
median
age
iqr
year
men
median
count
iqr
cellul
antiretrovir
includ
fatti
liver
nash
diagnos
case
respect
signific
liver
fibrosi
cirrhosi
frequent
patient
nash
without
nash
see
figur
p
adjust
age
bmi
elev
alt
ci
te
measur
ci
independ
predictor
nash
patient
diagnosi
nash
agre
undergo
liver
biopsi
histolog
confirm
nash
case
conclus
nash
diagnos
te
cap
frequent
hiv
person
particularli
case
elev
alt
te
measur
diagnost
strategi
employ
tool
help
earli
identif
nash
initi
intervent
reduc
need
liver
biopsi
person
live
hiv
disclosur
marc
deschen
advisori
committe
review
panel
merk
gilead
abbvi
lupin
intercept
philip
wong
advisori
committe
review
panel
gilead
consult
lupin
grantresearch
support
gilead
marina
b
klein
consult
viiv
healthcar
merck
squibb
abbvi
gilead
grantresearch
support
viiv
healthcar
merck
nih
cihr
frq
clhr
canadian
hiv
trial
network
giada
sebastiani
advisori
committe
review
panel
merck
grant
research
support
echosen
viiv
speak
teach
bm
gilead
abbvi
follow
peopl
noth
disclos
amin
benmassaoud
peter
ghali
lynda
lennox
object
avail
data
preval
hepat
steatosi
hs
popul
scarc
discrep
control
attenu
paramet
cap
determin
accur
identifi
signific
hepat
steatosi
fat
accumul
hepatocyt
aim
studi
assess
preval
factor
associ
signific
hepat
steatosi
patient
method
patient
includ
prospect
studi
patient
underw
control
attenu
paramet
cap
determin
steatosi
classifi
signific
steatosi
cap
dbm
cap
dbm
cap
dbm
logist
regress
multivari
analys
perform
analyz
associ
hs
demograph
metabol
data
virolog
factor
antiretrovir
therapi
result
hiv
achiev
sustain
virolog
respons
svr
signific
hepat
steatosi
detect
patient
interestingli
less
sever
steatosi
observ
patient
longer
durat
known
vs
yr
p
longer
cart
naiv
period
vs
yr
p
expect
patient
signific
steatosi
show
higher
mean
level
vs
p
higher
mean
bmi
vs
p
higher
triglycerid
vs
mgdl
p
lower
hdl
cholesterol
vs
mgdl
p
compar
patient
without
steatosi
interestingli
multivari
analysi
reveal
bmi
independ
associ
steatosi
ci
p
longer
period
hr
ci
p
associ
less
hepat
steatosi
develop
impact
sever
steatosi
identifi
antiretrovir
drug
class
conclus
hepat
steatosi
highli
preval
among
patient
obes
independ
predictor
steatosi
develop
suppress
viral
replic
might
contribut
hepat
steatosi
howev
relat
antiretrovir
drug
known
caus
metabol
chang
disclosur
christoph
boeseck
consult
abbvi
viiv
speak
teach
msd
gilead
bm
k
rockstroh
advisori
committe
review
panel
abbvi
cipla
bm
merck
roch
tibotec
abbvi
bionor
tobira
viiv
abbott
gilead
janssen
consult
novarti
grantresearch
support
gilead
merck
speak
teach
bm
merck
siemen
tibotec
gilead
janssen
viiv
follow
peopl
noth
disclos
raphael
mohr
robert
schierwagen
carolynn
wasmuth
jonel
trebicka
background
among
ethnic
group
unit
state
highest
estim
preval
fatti
liver
diseas
observ
among
latino
nafld
fibrosi
score
nf
wide
use
tool
predict
fibrosi
among
patient
nafld
howev
nf
valid
predominantli
caucasian
studi
popul
accuraci
predict
advanc
fibrosi
among
latino
uncertain
therefor
undertook
studi
determin
diagnost
accuraci
nf
advanc
fibrosi
among
popul
compris
predominantli
latino
adult
nafld
method
retrospect
studi
among
adult
nafld
underw
liver
biopsi
ben
taub
gener
hospit
houston
tx
exclus
criteria
evid
heavi
alcohol
use
gday
men
gday
women
secondari
liver
diseas
drug
induc
liver
injuri
hiv
infect
nf
calcul
lab
obtain
within
three
month
liver
biopsi
compar
histolog
stage
fibrosi
statist
analysi
softwar
microsoft
excel
use
calcul
descript
statist
area
curv
auroc
sensit
specif
neg
predict
valu
npv
posit
predict
valu
ppv
result
overal
mean
age
bmi
year
respect
latino
women
diabet
forti
percent
advanc
fibrosi
patient
advanc
fibrosi
older
lower
platelet
p
albumin
p
higher
nf
p
compar
patient
mild
fibrosi
use
low
nf
cutoff
npv
ppv
latino
vs
overal
group
use
high
nf
cutoff
npv
ppv
latino
vs
overal
group
diagnost
accuraci
nf
advanc
fibrosi
ci
latino
vs
auroc
overal
group
use
nf
liver
biopsi
could
avoid
patient
overal
latino
subgroup
conclus
nafld
fibrosi
score
reliabl
exclud
advanc
fibrosi
high
proport
latino
patient
nafld
allow
liver
biopsi
use
direct
manner
disclosur
follow
peopl
noth
disclos
aradhna
seth
maya
balakrishnan
shilpa
jain
gagan
k
sood
background
whether
nonalcohol
fatti
liver
diseas
nafld
relat
subclin
artherosclerosi
unclear
coronari
arteri
calcium
scan
cac
robust
predictor
coronari
event
asymptomat
individu
sever
recent
studi
investig
associ
nafld
surrog
marker
thu
conduct
systemat
review
better
character
associ
nafld
cac
method
comprehens
search
databas
medlin
embas
perform
incept
may
inclus
criterion
observ
studi
assess
associ
nafld
cac
adult
subject
pool
odd
ratio
confid
interv
ci
multivari
model
confound
adjust
calcul
use
gener
invers
varianc
method
studi
heterogen
quantifi
use
q
statist
result
data
extract
studi
studi
involv
subject
nafld
significantli
associ
cac
figur
cac
pool
ci
pheterogen
ci
phetrogen
associ
nafld
cac
stronger
women
men
p
sex
conclus
nafld
also
associ
coronari
calcif
independ
tradit
risk
factor
obes
metabol
syndrom
asymptomat
individu
associ
appear
stronger
women
nafld
coronari
arteri
calcium
disclosur
follow
peopl
noth
disclos
veeravich
jaruvongvanich
anawin
sanguankeo
kamonkiat
wirunsawanya
sikarin
upala
background
aim
physic
exercis
benefici
effect
metabol
homeostasi
exercis
train
increas
skelet
muscl
mass
decreas
lipid
infiltr
skelet
muscl
contribut
improv
insulin
resist
nafld
aim
analyz
actual
impact
chang
skelet
muscl
exercis
train
nafld
method
longitudin
studi
perform
patient
male
diagnos
fatti
liver
diseas
abdomin
ultrasound
saga
univers
hospit
affili
facil
patient
drink
histori
gday
alcohol
viral
hepat
autoimmun
liver
diseas
malign
diseas
exclud
patient
perform
exercis
metabol
equival
task
met
week
month
food
intak
adjust
kcalkg
bodyweight
evalu
abdomin
lumbar
muscl
area
ct
imag
obtain
skelet
muscl
area
index
sai
lumbar
muscl
area
height
cm
lipid
infiltr
skelet
muscl
intramuscular
adipos
tissu
content
imac
liver
ratio
ls
ratio
also
measur
ct
techniqu
factor
contribut
improv
ls
ratio
alt
identifi
multipl
regress
model
result
exercis
train
decreas
imac
patient
decreas
bmi
decreas
fast
plasma
glucos
decreas
alt
improv
ls
ratio
p
respect
patient
without
decreas
imac
fail
improv
paramet
exercis
train
increas
sai
patient
decreas
bmi
decreas
alt
improv
ls
ratio
howev
interestingli
sai
also
show
signific
improv
paramet
decreas
imac
valu
p
increas
sai
valu
p
significantli
correl
improv
alt
level
decreas
imac
independ
factor
improv
ls
ratio
valu
p
signific
correl
increas
sai
improv
ls
ratio
conclus
although
increas
skelet
muscl
mass
factor
improv
liver
steatosi
nafld
decreas
lipid
infiltr
skelet
muscl
contribut
improv
liver
steatosi
well
alt
level
exercis
train
program
nafld
lipid
infiltr
skelet
muscl
could
indic
exercis
train
effect
nafld
possibl
therapeut
target
nafld
disclosur
follow
peopl
noth
disclos
hirokazu
takahashi
yoichiro
kitajima
yoshihito
kubotsu
satoshi
oeda
keizo
anzai
yuichiro
eguchi
background
aim
mechan
control
progress
simpl
steatosi
fibrosi
patient
fatti
liver
diseas
nafld
still
matter
investig
sparc
secret
matricellular
protein
liver
chronic
injuri
contribut
sparc
accumul
diseas
sever
mechan
involv
larg
unknown
nafld
assess
hypothesi
sparc
increas
liver
necrosi
inflamm
therefor
high
risk
fibrosi
method
immunohistochemistri
elisa
employ
local
quantifi
chang
sparc
morbidli
obes
patient
nafld
mous
model
result
correl
sever
liver
diseas
progress
simpl
steatosi
nash
result
obes
patient
subgroup
identifi
either
high
sparc
express
low
sparc
express
liver
tissu
high
express
sparc
parallel
extens
hepatocellular
necrosi
necroptosi
increas
factor
line
find
nash
anim
model
sparc
knockout
mice
protect
inflammatori
injuri
show
less
inflamm
fibrosi
conclus
sparc
accumul
associ
sever
liver
injuri
fibrogen
process
nafld
sparc
may
promis
diagnost
therapeut
target
monitor
progress
nafld
patient
disclosur
follow
peopl
noth
disclos
guillermo
mazzolini
catalina
atorrasagasti
agostina
onorato
estanislao
peixoto
martin
schlattjan
svenja
sydor
sowa
guido
gerken
ali
canbay
backgroundaim
patient
normal
bodi
mass
index
bmi
present
fatti
liver
diseas
nafld
design
lean
nafld
aim
present
studi
investig
role
genet
variabl
phospholipas
predisposit
nafld
diseas
sever
lean
nafld
patient
materi
method
total
consecut
nafld
patient
healthi
control
assess
dna
extract
peripher
blood
singl
nucleotid
polymorph
assess
sequenc
result
time
diagnosi
median
bmi
kg
obes
lean
median
na
avail
liver
biopsi
histolog
diagnosi
nash
obtain
frequenc
distribut
gg
genotyp
significantli
higher
nafld
patient
healthi
control
patient
nafld
gg
genotyp
associ
lower
platelet
count
p
presenc
steatohepat
p
hepat
fibrosi
p
compar
cc
cg
genotyp
subgroup
analysi
nafld
patient
patient
presenc
diabet
mellitu
insulin
resist
hypertens
hyperlipidemia
slightli
higher
obes
patient
compar
lean
patient
p
howev
serum
aminotransferas
level
slightli
higher
lean
patient
median
serum
ast
ggt
level
ul
rang
ul
vs
ul
rang
ul
ul
rang
ul
vs
ul
rang
ul
respect
presenc
liver
fibrosi
slightli
common
lean
nafld
obes
nafld
patient
vs
gg
genotyp
slightli
preval
lean
nafld
patient
compar
obes
nafld
patient
vs
compar
lean
obes
nafld
patient
gg
genotyp
serum
aminotransferas
level
slightli
higher
lean
patient
gg
genotyp
compar
obes
patient
gg
genotyp
median
serum
ast
ggt
level
ul
rang
ul
vs
ul
rang
ul
ul
rang
ul
vs
ul
rang
ul
respect
lean
nafld
patient
gg
genotyp
slightli
fibrot
liver
obes
nafld
patient
vs
conclus
patient
gg
genotyp
polymorph
like
develop
nafld
lean
patient
well
obes
patient
gg
genotyp
associ
sever
liver
diseas
obes
also
lean
nafld
patient
disclosur
cihan
yurdaydin
advisori
committe
review
panel
janssen
roch
merck
gilead
abbvi
speak
teach
bm
follow
peopl
noth
disclos
ramazan
idilman
senem
c
karatayli
fatih
karakaya
onur
keskin
bilg
gozukara
berna
sava
mithat
bozdayi
atilla
halil
elhan
introduct
pharmacolog
treatment
nonalcohol
fatti
liver
diseas
nafld
still
evolv
randomis
human
studi
histolog
end
point
adult
use
probiot
vsl
de
simon
formul
mix
lactic
acid
bacteria
bifidobacteria
patient
nafld
aim
present
studi
evalu
efficaci
probiot
vsl
adult
patient
nafld
methodolog
prospect
doubl
blind
placebo
control
randomis
proof
concept
studi
patient
liver
biopsi
proven
nafld
random
two
group
clinic
trial
registri
india
patient
gave
written
inform
consent
studi
approv
respect
institut
ethic
committe
group
mean
yr
receiv
standard
medic
treatment
smt
life
style
modif
oral
probiot
vsl
cap
billion
cfuday
one
year
group
mean
yr
receiv
smt
ident
placebo
cap
one
year
primari
object
studi
histolog
improv
nafld
activ
score
na
compon
hepat
fibrosi
secondari
object
improv
serum
alt
cytokin
profil
result
ten
patient
vsl
group
placebo
group
underw
repeat
liver
biopsi
one
year
comparison
baselin
even
though
signific
improv
hepat
steatosi
hepatocyt
balloon
lobular
inflamm
na
score
improv
significantli
year
vsl
group
compar
placebo
improv
na
score
significantli
higher
vsl
group
vs
signific
differ
improv
individu
compon
hepatocy
balloon
hepat
fibrosi
addit
histolog
improv
signific
improv
serum
alt
vs
iul
leptin
vs
vs
vsl
group
comparison
placebo
year
conclus
proof
concept
studi
patient
nafld
manag
lifestyl
modif
probiot
vsl
show
signific
improv
liver
histolog
vsl
also
improv
serum
alt
cytokin
profil
patient
nafld
disclosur
follow
peopl
noth
disclos
ajay
k
duseja
subrat
k
acharya
manu
mehta
shruti
chhabra
shalimar
satyavati
rana
ashim
da
siddhartha
datta
gupta
radha
k
dhiman
yogesh
k
chawla
backgroundaim
preval
fatti
liver
diseas
nafld
increas
worldwid
investig
whether
liver
stiff
ls
control
attenu
paramet
cap
assess
use
transient
elastographi
te
could
assess
liver
steatosi
fibrosi
accur
method
total
patient
underw
liver
biopsi
concomit
te
recruit
tertiari
hospit
korea
analyz
novemb
decemb
liver
fibrosi
assess
use
ast
platelet
ratio
index
apri
nafld
fibrosi
score
result
studi
popul
separ
control
group
n
nafld
group
n
base
liver
biopsi
result
patient
nafld
mean
age
year
male
predomin
n
accuraci
cap
detect
steatosi
grade
assess
area
receiv
oper
curv
auroc
respect
optim
valu
steatosi
dbm
dbm
dbm
moreov
auroc
ls
detect
fibrosi
grade
respect
optim
valu
fibrosi
patient
nafld
dbm
dbm
dbm
sensit
specif
optim
valu
detect
good
respect
respect
better
noninvas
marker
includ
apri
nafld
fibrosi
score
approxim
patient
nafld
show
discord
te
histolog
predict
factor
discord
age
bodi
mass
index
bmi
grade
steatosi
conclus
te
result
accur
detect
steatosi
also
fibrosi
patient
nafld
addit
te
better
sensit
specif
detect
advanc
fibrosi
cirrhosi
noninvas
marker
disclosur
follow
peopl
noth
disclos
hye
lee
beom
kyung
kim
seung
kim
young
kim
sang
hoon
ahn
han
jun
yong
park
background
treatment
bile
duct
disord
biliari
atresia
primari
scleros
cholang
biliari
strictur
limit
liver
transplant
hepatojejunostomi
due
lack
healthi
tissu
suitabl
biliari
reconstruct
object
develop
platform
vitro
expans
nativ
cholangiocyt
use
cell
gener
bioengin
biliari
tissu
perform
biliari
reconstruct
vivo
method
primari
human
cholangiocyt
isol
deceas
organ
donor
cultur
cell
base
establish
protocol
matur
mainten
stem
cell
deriv
cholangiocyt
extrahepat
cholangiocyt
organoid
eco
seed
bioengin
polyglycol
acid
pga
scaffold
gener
biliari
tissu
model
extrahepat
biliari
injuri
ehbi
gener
compromis
integr
biliari
tree
immunodefici
nsg
mice
longitudin
incis
gallbladd
wall
pga
scaffold
sutur
place
repair
wall
defect
acellular
scaffold
fibroblast
popul
scaffold
use
neg
control
result
eco
express
key
biliari
marker
ggt
cftr
maintain
function
properti
vitro
includ
alp
ggt
cftr
activ
transcriptom
analys
reveal
close
correl
eco
primari
cholangiocyt
eco
seed
pga
scaffold
form
structur
resembl
biliari
tissu
maintain
function
properti
marker
express
anim
undergo
biliari
reconstruct
scaffold
surviv
month
integr
cell
biliari
epithelium
anim
transplant
acellular
pga
scaffold
die
within
h
test
anim
receiv
scaffold
surviv
none
transplant
gallbladd
success
reconstruct
biliari
epithelium
replac
fibrotictissu
patenc
reconstruct
biliari
tree
confirm
use
magnet
reson
cholangiopancreatographi
mrcp
conclus
biliari
epitheli
cell
deriv
extrahepat
biliari
tree
effect
propag
vitro
maintain
transcript
function
ident
regen
potenti
eco
illustr
capac
organ
bioengin
function
biliari
epithelium
rescu
ehbi
murin
model
knowledg
first
report
organ
reconstruct
use
human
primari
cell
expand
vitro
disclosur
ludov
vallier
stock
sharehold
definigen
follow
peopl
noth
disclos
fotio
sampazioti
miguel
cardoso
de
brito
steve
sawiak
maria
j
natali
l
berntsen
olivia
c
tyso
daniel
ortmann
alessandro
bertero
johann
bargehr
mariel
c
zonneveld
mariann
pedersen
matthia
pawlowski
nikita
georgakopoulo
loukia
yiangou
edmund
godfrey
sara
upponi
richard
gieseck
casey
rimland
ingrid
simon
susan
davi
kim
b
jensen
sanjay
sinha
william
gelson
graem
j
alexand
espen
melum
nichola
r
hannan
kourosh
background
aim
liver
well
known
possess
high
regen
capac
howev
regener
often
impair
patient
liver
cirrhosi
although
progenitor
cell
recruit
implic
regener
fibrot
liver
origin
natur
hepat
progenitor
cell
hpc
fulli
understood
hand
recent
studi
use
genet
lineag
trace
analysi
indic
dedifferenti
matur
hepatocyt
play
import
role
injuredfibrot
liver
regener
present
studi
show
jaggedlnotch
signal
acceler
dedifferenti
process
contribut
regener
fibrot
liver
materi
method
liver
fibrosi
induc
wild
type
jaggedl
condit
knockout
jagl
cko
mice
repeat
carbon
tetrachlorid
inject
excis
liver
specimen
subject
immunohistochem
stain
quantit
gene
express
analys
molecul
hpc
marker
surviv
rate
extent
cell
prolifer
compar
wild
type
jagl
cko
mice
regen
process
alter
partial
hepatectomi
fibrot
liver
primari
matur
hepatocyt
quiescent
activ
hepat
stellat
cell
hsc
dedifferenti
afp
press
hpc
evalu
use
notch
inhibitor
hsc
obtain
jagl
cko
mice
result
signific
number
cell
featur
hpc
high
prolif
abil
detect
along
fibrou
septa
repeat
inject
wild
type
mice
septal
myofibroblast
highli
express
notch
ligand
jaggedl
notch
signal
activ
adjac
hpc
studi
jagl
cko
mice
demonstr
jaggedl
delet
suppress
mobil
prolifer
hpc
fibrot
liver
tissu
decreas
surviv
rate
treat
fibrot
mice
untreat
normal
anim
partial
hepatectomi
consist
vivo
result
cell
cultur
experi
indic
increas
jaggedl
express
activ
hsc
afp
express
hepatocyt
dedifferenti
hepatocyt
suppress
ad
notch
inhibitor
cultur
media
use
hsc
obtain
jagl
cko
mice
conclus
result
indic
jaggedlnotch
signal
contribut
regener
fibrot
liver
possibl
dedifferenti
matur
hepatocyt
provid
insight
novel
import
role
jaggedlnotch
signal
liver
pathophysiolog
disclosur
follow
peopl
noth
disclos
yasuhiro
nakano
sachi
nakao
hideaki
sumiyoshi
kenichiro
mikami
yuri
tanno
daigo
kasahara
hiroshi
kimura
tadashi
moro
akihid
kamiya
katsuto
hozumi
yutaka
inagaki
aim
deal
liver
failur
end
stage
liver
transplant
ultim
treatment
termin
stage
diseas
howev
demand
liver
transplant
number
provis
cadaver
liver
liver
tissu
live
donor
henc
develop
way
acquir
hepatocyt
consid
import
research
issu
decad
recent
direct
convers
technolog
develop
gener
induc
cell
ihep
ectop
express
transcript
factor
hand
includ
bioprint
technolog
advanc
structur
therebi
captur
complex
vivo
environ
therefor
herein
report
reconstruct
bioprint
hepat
architectur
recapitul
microenviron
liver
use
ihep
sourc
hepatocyt
method
gener
ihep
mous
embryon
fibroblast
cell
transduc
pmx
retrovirus
express
individu
hepat
transcript
factor
h
cell
cultur
hepatocyt
cultur
medium
hcm
type
dish
induc
lineag
transit
toward
ihep
bioprint
ihep
encapsul
algin
hydrogel
extrud
nozzl
pressur
crosslink
calcium
chlorid
hepat
structur
form
mm
mm
result
day
transduct
observ
epitheli
ihep
coloni
high
prolifer
rate
upon
sever
passag
number
fibroblast
reduc
ihep
grew
domin
dish
qpcr
immunofluoresc
analys
reveal
ihep
share
typic
hepat
gene
protein
express
profil
liver
tissu
moreov
ihep
also
function
characterist
hepatocyt
glycogen
storag
xenobiot
activ
bioprint
method
effici
construct
multipl
hepat
structur
interestingli
found
mimick
hepat
structur
assist
ihep
stabli
repopul
also
enhanc
hepat
gene
express
profil
ihep
conclus
combin
bioprint
technolog
ihep
gener
protocol
may
realist
option
overcom
problem
includ
donor
shortag
surgic
complic
liver
transplant
therebi
offer
new
paradigm
field
liver
regen
medicin
disclosur
follow
peopl
noth
disclos
jinhyouk
lim
kyo
jin
kang
dongho
choi
su
park
heung
mo
yang
dongwook
han
jaemin
jeong
hyeryeon
jeon
introduct
intraperiton
transplant
encapsul
primari
human
hepatocyt
emerg
therapi
children
acut
liver
failur
howev
sustain
function
cryopreserv
hepatocyt
isol
margin
graft
remain
challeng
mesenchym
stromal
cell
msc
enhanc
hepatocyt
viabil
metabol
mechan
yet
fulli
understood
msc
report
rescu
differ
type
injur
cell
transfer
function
mitochondria
nanostructur
call
tunnel
nanotub
tnt
therefor
hypothes
msc
rescu
hepatocyt
function
via
mitochondria
transfer
object
assess
transfer
mitochondria
occur
msc
hepatocyt
ii
studi
tnt
composit
iii
determin
tnt
inhibit
stop
mitochondria
transfer
affect
msc
trophic
effect
hepatocyt
materi
method
mitochondri
transfer
msc
hepatocyt
follow
use
fac
well
microscopi
stain
msc
mitochondria
red
fluoresc
die
mitotrack
red
tnt
presenc
studi
fluoresc
microscopi
character
tnt
perform
immunofluoresc
detect
actin
tubulin
express
test
dose
actin
polymer
inhibitor
latrunculin
lata
cytochalasin
cytd
mtt
annexin
vpi
assay
use
assess
latacytd
cytotox
mitochondri
transfer
tnt
inhibit
quantifi
fac
result
hepatocyt
contain
red
fluoresc
mitochondria
detect
earli
onset
use
live
microscopi
confirm
fac
statist
signific
p
vs
monocultur
tnt
contain
msc
mitochondria
observ
msc
hepatocyt
actin
identifi
main
tnt
structur
compon
lata
achiev
tnt
inhibit
without
cytotox
effect
cell
lead
decreas
number
hepatocyt
msc
mitochondria
conclus
preliminari
studi
show
msc
abl
transfer
mitochondria
primari
hepatocyt
tnt
might
respons
mechan
benefici
effect
msc
hepatocyt
function
data
help
advanc
knowledg
use
msc
hepatocyt
treatment
liver
diseas
transfect
msc
red
fluoresc
protein
dsred
current
perform
confirm
infirm
result
disclosur
anil
dhawan
advisori
committe
review
panel
promethera
consult
alexion
grantresearch
support
astella
speak
teach
ctr
follow
peopl
noth
disclos
raquel
charlott
lee
valeria
lansant
simon
walker
sharon
lehec
emer
fitzpatrick
celin
filippi
background
mesenchym
stem
cell
msc
prolifer
differenti
hepatocyt
potenti
cell
sourc
cirrhosi
treatment
studi
show
platelet
rich
plasma
prp
may
enhanc
liver
regener
test
hypothesi
prp
enhanc
msc
treatment
mous
cirrhosi
method
male
swiss
mice
treat
oral
oliv
oil
week
prp
obtain
healthi
mice
mous
stem
cell
madsc
week
mice
cultur
passag
prior
transfer
tail
vein
inject
without
prp
week
mice
liver
serum
harvest
day
transplant
marker
ecm
gene
express
character
use
msc
marker
protein
fibrosi
evalu
flow
cytometri
andor
immunohistochemistri
mice
divid
group
group
normal
cirrhot
cirrhot
pb
cirrhoticprp
ml
mice
prp
healthi
mice
cirrhoticmadsc
x
cellsmic
result
sc
highli
posit
rel
normal
liver
cell
highli
express
alb
tnf
afp
ldl
receptor
strongli
posit
hgf
moder
posit
aat
alb
transplant
transplant
cell
treat
mice
found
day
liver
compar
madsc
madsc
prp
cotreat
effect
improv
serum
astaltbilirubin
albumin
level
day
cirrhot
mice
p
significantli
procollagen
less
less
day
cirrhot
liver
histolog
index
collagen
deposit
improv
cirrhot
mice
compar
cirrhot
liver
p
conclus
cultur
madsc
express
hepatocyt
marker
inject
madsc
home
cirrhot
liver
prp
coadministr
enhanc
madsc
effect
improv
liver
function
reduc
fibrosi
disclosur
follow
peopl
noth
disclos
nhung
h
truong
nam
h
nguyen
trinh
v
le
huy
le
nghia
huynh
dat
q
ngo
thanh
v
nguyen
aixuan
holterman
ngoc
k
phan
phuc
v
pham
background
aim
label
retain
cell
assay
acetaminophen
injuri
model
previous
identifi
proxim
portion
biliari
tree
canal
here
coh
addit
peribiliari
hepatocyt
pbh
neighbor
coh
locat
potenti
function
stem
cell
nich
kuwahara
et
al
hepatolog
aim
studi
investig
possibl
role
coh
pbh
normal
liver
develop
absenc
injuri
method
label
divid
cell
fetal
liver
brdu
inject
intraperiton
pregnant
mice
time
point
postnat
mice
receiv
intraperiton
inject
brdu
age
day
confirm
brdu
label
fetal
postnat
liver
mice
sacrif
hour
label
pregnant
mice
allow
give
birth
newborn
mice
rais
week
old
growth
matur
liver
provid
chase
brdu
label
washout
follow
brdu
label
sacrif
likewis
postnat
label
mice
sacrif
age
week
pbh
biliari
cell
coh
analyz
doubl
chemistri
ihc
biliari
keratin
pank
brdu
cell
divis
prolifer
ratio
liver
weight
bodi
weight
analyz
everi
week
old
mice
result
stabil
brdu
label
liver
confirm
ihc
brdu
index
postnat
mice
liver
show
frequenc
cell
prolifer
hepatocyt
biliari
cell
coh
highest
age
day
diminish
steadili
peak
age
week
male
femal
mice
respect
week
post
chase
distribut
tain
pbh
biliari
cell
coh
total
brdu
posit
cell
lobular
peribiliari
hepatocyt
biliari
cell
coh
significantli
higher
prenat
label
liver
postnat
label
liver
postnat
label
liver
distribut
significantli
higher
liver
label
age
day
liver
label
age
day
respect
conclus
data
support
pbh
coh
cell
serv
resid
stem
cell
function
includ
contribut
parenchym
mass
organogenesi
earli
postnat
develop
also
suggest
stem
cell
nich
adult
may
quiescent
activ
kind
injuri
continu
activ
contribut
cell
lineag
develop
fetal
postnat
period
disclosur
follow
peopl
noth
disclos
reiichiro
kuwahara
tatsuya
ide
hironori
koga
neil
theis
takuji
torimura
human
embryon
stem
hepatocyt
heh
could
provid
power
tool
enabl
therapi
clinic
studi
mechan
underli
human
liver
develop
diseas
test
efficaci
safeti
pharmaceut
howev
current
vitro
protocol
yield
heh
low
level
liver
function
rel
adult
primari
human
hepatocyt
investig
potenti
salvianol
acid
b
sal
b
activ
pharmaceut
compound
present
salvia
miltiorrhiza
exert
antifibrot
effect
previou
research
enhanc
hepatocyt
differenti
human
embryon
stem
cell
hesc
hesc
line
use
standard
differenti
protocol
treatment
sal
b
albumin
express
consist
increas
determin
qpcr
elisa
indic
sal
b
might
promot
hepatocyt
differenti
process
express
larg
number
import
phase
ii
metabol
enzym
phase
iii
transport
also
increas
treat
cell
indic
biotransform
function
would
like
increas
addit
found
express
cholangiocyt
marker
significantli
reduc
treatment
sal
b
suggest
one
possibl
mechan
sal
b
may
promot
hepatocyt
differenti
inhibit
format
cholangiocyt
investig
reveal
activ
wnt
pathway
sal
cell
determin
wnt
result
increas
amount
nuclear
lead
increas
downstream
target
cyclin
notch
receptor
notch
ligand
jag
notch
receptor
target
treat
cell
suggest
notch
pathway
inhibit
numb
direct
transcript
target
wnt
signal
pathway
neg
regul
notch
pathway
indic
consist
activ
wnt
signal
suppress
notch
signal
thu
studi
demonstr
enhanc
hepatocyt
differenti
mediat
activ
wnt
signal
pathway
inhibit
notch
pathway
sal
b
conclus
sal
b
promot
hepatocyt
differenti
hesc
demonstr
sal
b
treatment
appear
enhanc
effort
gener
matur
hepatocyt
therapeut
pharmacolog
toxicolog
studi
disclosur
follow
peopl
noth
disclos
jiamei
chen
mark
zern
ping
liu
yuyou
duan
adipos
tissu
enrich
mesenchym
stromalstem
cell
conduct
clinic
studi
liver
regen
therapi
cirrhosi
intrahepat
arteri
administr
freshli
isol
autolog
adipos
tissu
deriv
stromalstem
regen
cell
adrc
also
character
obtain
fresh
cell
adrc
well
cultur
expand
stromal
cell
adsc
method
object
cirrhosi
patient
provid
written
inform
consent
patient
underw
liposuct
subcutan
adipos
tissu
abdomen
buttock
obtain
adipos
tissu
immedi
process
use
dissoci
equip
cytori
therapeut
inc
obtain
autolog
adrc
design
number
cell
infus
cathet
posit
hepat
arteri
safeti
evalu
assess
month
treatment
surfac
antigen
adrc
cultur
cell
adsc
assess
fac
serum
cytokinechemokin
concentr
measur
also
analyz
gene
express
freshli
isol
adrc
compar
cultur
adsc
dna
microarray
result
four
liver
cirrhosi
patient
enrol
type
c
type
c
nash
type
b
number
infus
adrc
among
adrc
adsc
cell
respect
express
mesenchym
stem
cell
surfac
marker
sever
advers
event
occur
three
among
treat
patient
improv
serum
albumin
concentr
month
treatment
serum
hgf
mif
elev
patient
one
day
treatment
surplu
adrc
treatment
success
expand
shape
mesenchym
stem
cell
observ
gene
express
profil
analysi
use
cluster
analysi
show
two
distinct
cluster
discern
adrc
adsc
complet
regardless
patient
etiolog
cirrhosi
freshli
isol
adrc
shown
involv
inflammatori
featur
suggest
relat
immunomodulatori
biolog
effect
conclus
intrahepat
arteri
administr
autolog
freshli
isol
adrc
immunomodulatori
biolog
effect
confirm
safe
conduct
without
seriou
advers
event
disclosur
shuichi
kaneko
grantresearch
support
md
co
inc
chugai
pharma
co
inc
toray
co
inc
daiichi
sankyo
co
inc
dainippon
sumitomo
co
inc
ajinomoto
co
inc
bristol
myer
squibb
inc
pfizer
co
inc
astella
inc
takeda
co
inc
otsuka
aapharmaceut
co
inc
eizai
co
inc
bayer
japan
eli
lilli
japan
follow
peopl
noth
disclos
yoshio
sakai
akihiro
seki
hajim
sunagozaka
takeshi
terashima
kazunori
kawaguchi
hatsun
mochida
alessandro
nasti
geraldin
b
buffa
masatoshi
yamato
kosuk
ishida
masaaki
takamura
soichiro
usui
takashi
wada
masao
honda
